<SEC-DOCUMENT>0001280776-23-000004.txt : 20230223
<SEC-HEADER>0001280776-23-000004.hdr.sgml : 20230223
<ACCEPTANCE-DATETIME>20230223070045
ACCESSION NUMBER:		0001280776-23-000004
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230223
DATE AS OF CHANGE:		20230223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNIC, INC.
		CENTRAL INDEX KEY:			0001280776
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562358443
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36201
		FILM NUMBER:		23655865

	BUSINESS ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036
		BUSINESS PHONE:		(332) 255-9818

	MAIL ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VITAL THERAPIES INC
		DATE OF NAME CHANGE:	20040219
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>imux-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:19abff6b-9d36-40e5-80a6-5fea77828601,g:313a8e66-68ba-4247-b883-d20269f0dca0,d:dff78559567c4173b665e875d419cf41--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:imux="http://imux.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>imux-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV80L2ZyYWc6YTNmMTc3NzAxOTAzNDY1MmIwNzA1MzBlYmFlNjlhMjIvdGFibGU6MmI0MGI2Yzc5ZWEyNDJjNDllNjhhODBhYzRhMWYyYWUvdGFibGVyYW5nZToyYjQwYjZjNzllYTI0MmM0OWU2OGE4MGFjNGExZjJhZV8zLTEtMS0xLTM0ODYy_07b077b7-df8a-4b86-9009-8b6452acd3f7">0001280776</ix:nonNumeric><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV80L2ZyYWc6YTNmMTc3NzAxOTAzNDY1MmIwNzA1MzBlYmFlNjlhMjIvdGFibGU6MmI0MGI2Yzc5ZWEyNDJjNDllNjhhODBhYzRhMWYyYWUvdGFibGVyYW5nZToyYjQwYjZjNzllYTI0MmM0OWU2OGE4MGFjNGExZjJhZV80LTEtMS0xLTM0ODYy_3763920b-e939-4feb-87fb-e1456672f420">2022</ix:nonNumeric><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV80L2ZyYWc6YTNmMTc3NzAxOTAzNDY1MmIwNzA1MzBlYmFlNjlhMjIvdGFibGU6MmI0MGI2Yzc5ZWEyNDJjNDllNjhhODBhYzRhMWYyYWUvdGFibGVyYW5nZToyYjQwYjZjNzllYTI0MmM0OWU2OGE4MGFjNGExZjJhZV81LTEtMS0xLTM0ODYy_e5d2f21b-7cbe-440a-ab46-a67bc6bb1827">FY</ix:nonNumeric><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV80L2ZyYWc6YTNmMTc3NzAxOTAzNDY1MmIwNzA1MzBlYmFlNjlhMjIvdGFibGU6MmI0MGI2Yzc5ZWEyNDJjNDllNjhhODBhYzRhMWYyYWUvdGFibGVyYW5nZToyYjQwYjZjNzllYTI0MmM0OWU2OGE4MGFjNGExZjJhZV82LTEtMS0xLTM0ODYy_c179667f-d064-4488-8e29-45162724f5a4">false</ix:nonNumeric><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3221b224-b06b-4599-934b-4790913ca766">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3cdcee94-7c82-4bf3-999e-30ecd1c05a92">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_4a1a30a6-155d-4e96-9d47-e78ee944ec76">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_58a0a228-b7d2-495a-8002-5c76ada4c7a6">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i4c6904d8a9104fa49767d8541244097e_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzkwMzI_3b155f68-f249-4b5a-829c-f22ff2797b9c">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="imux-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43e0b65cbd3346aeb1f08c2809f43307_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i019b6a9949464c96b393742d493e84c2_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b28bf41d41a44729bb53cadae860beb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic389dfc27c9a4f599aa3e1e541429096_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbaa6c3142f843bd9914319d7c76fd83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01764048ea4440fdbba38575095ead15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4273fe852996496a9bf00e5bd9ca421e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife1cbb9302f3417394aee800539a7c78_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7134d7b7af464feaa82036ca57d1ca9c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8350e86a9cac4049bf5f8412ebbbc922_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia88c39fd3b36467dbf626e7ce52cd7df_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42cae9630d124c15823d3c9c381fc07a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2021PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5184b8a176204d52b8ec471db493c60c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2021PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2df795cc621b4f6e870a724ef84c27b1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2021PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i398768618fec47a5abec4be325449aae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0638ec649d204c94997a5155ac425b91_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00de82f73e494662bbcb2347d6aa2a68_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b16c5e8d554ecfb4804e40b1137a63_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69622c2fdecf4530a84d6ff11b19e1a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:A4SCRoyaltySettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4ef0cd612dd459b89f27fa032430ea8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:A4SCRoyaltySettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b01402daaa6442ea66a3fe6b2b2dae4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:A4SCRoyaltySettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c967dfd128445f9a1b3ec335c1bb34f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i821d3d85d32247aba8a2d73345eaafda_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie05ff69c61e740ba9e894b118d4ead6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6af8e102c5642eb926a526cbf7478d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38ccd4cb28be412ab9d49ec84d752b6a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1316860810fd4869b98945ba64d7b8a9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc4516e5f23b4243bab5c3a7ad76b8b0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i629c982d47b84bd39b19868854e07c81_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:October2022PIPETransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5338bc359fb346e48caffc7500eefca1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:October2022PIPETransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1fd6056fc8f469aa10b7e33b55ac2f5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:October2022PIPETransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4645613f6b04714ad4c10813a979031_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56f6368984944c099b13638b641e4e99_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8049d7b76a47447681fe40c4a72397ed_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74203948938643e89bafdad4538d7216_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b9266faad484741a6ceae1bdc3f0eb6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e8bb23d203841bfa3a428096aca8874_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f1f7503d0874f6ab90216689469562d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10e76b47a8364dbb8b7aa258206cfd04_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic79be0a87a2d43ae992ef8e7625d53e2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ceb990338fd46f69ef655c24c8d15d0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90a687fe86e640878d4f8d1ab66c683b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:October2022PIPETransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d3cdfb91b17451989132881fd694dac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2021PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>imux:employee</xbrli:measure></xbrli:unit><xbrli:unit id="lease"><xbrli:measure>imux:lease</xbrli:measure></xbrli:unit><xbrli:context id="i40702a7fad274b3590022abc86d2a149_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3028499b4524a48a11940db473e95c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9487ab845434e10aca875ca321f6e67_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="financialinstitution"><xbrli:measure>imux:financialInstitution</xbrli:measure></xbrli:unit><xbrli:context id="id15e6eed9a474921925790496d9be215_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6f6dda26ad1f41d48bc084b4d8b166fd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:AustraliaAndGermanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24f459a16c08494da1b7e65020dc4fa7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:AustraliaAndGermanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29c8be7c0e67485390b3fa4ca6373ec9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c7189562e3a451ea2101622fe50411a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02a6493060a2472cb585f29aefea30e5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i576a1a2a1e6f40819d31ad6cc0c9d135_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4ebe77f21364c02a3042c9e9e034e31_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i824c6b2c61e244609c3ec75bfe251d84_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie62fec553f0c4425b46293481930bbc7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff9b0c581c08407a9041a6bb9632fa7e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bc235beae3e46b392aa9ef77f9e52a6_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ea7cf83aad5416b96424f40bc7375a9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1949ba12c82474aad6afbbd5c131134_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia76019b0488442de98cccc646c64f255_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i296998374f2942bf8199382e045c0c53_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42582e672b9a458a8f771feaaf27fdb0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49102a4b3a124b109aaa078cfdd43203_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ddd5b53cb394a72b342f64f7724bee5_I20200407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:GrafelfingGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d811dce20e94755bbed81698a836062_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc3845c2b8324eb192b6c5463738b9a4_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:GrafelfingGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i790f3d1e376c426a93f31d939f0cc7d9_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:GrafelfingGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24562792a7ba48619d879bb127f6e25a_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7723388552347f4a59e2d9f09a39771_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1220fdabe2ee4fb28d42b5efca4ed2e5_D20160501-20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-01</xbrli:startDate><xbrli:endDate>2016-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6d27db753c54b8eaeaf90c7573257b1_I20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6672b35cda564e6499bcb6f461f08725_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia12960a663974117bd81295909c9cc3a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42c64b30b3db47e08679854bf2c78b08_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff060470870f4782ab057c9bc17e5799_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief2a67c94b5d4e07875b949f040c609f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e11d04f3b714f7aa69b06869cf2dd60_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4387fb9fcb644cbfa9f299c3c426b334_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c272f1e1b9c4a5ab2d79ed4552a88ca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8682b8fb49274d31915223706871afca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice854542a5dd4a53ba69994da59a8099_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e7a9a04d1f5475985dad2756a363f66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b15df3b298345d2a6a8dd573021c03b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45b06aedd33f4a19969cd8bcfc7ae2ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92ef303dbac04f97b77afccd76a0ee69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d7c512c8dad49688494a40ed9a84a26_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia45eb959635c4618a8e96c1da9b0ea55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6499a7329114832bcca11b186e9322c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e590388cdee4815b9794125e1f4fc52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89236a268ded4c38beb10ce49d29d398_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1903fef7aaee4f7aaa653511f97e3f03_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43a90b71f4874951ab64ba8e4d321ed5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i441cf983bb6b42c1bfc3a145240c4326_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="i67bc3dd545e748af9503605c6cf6ad15_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:December2020ATMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia92a9ae619944848ae66ab4dd8a63242_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21732f0264304e5fb28318d6dc2b7ecb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i936d8c3c556941e4a8c00636316ee92c_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7649036809b74b5683c233704941dc74_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20ece55753144123bea427d4b5da5edd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88aea673e8c04440a92d7eb913623ddd_D20221010-20221010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-10</xbrli:startDate><xbrli:endDate>2022-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib94fad9370444fab84415ff498015dc8_I20221010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida3ab5946fc24e23800223feb5a9d8ab_D20221010-20221010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-10</xbrli:startDate><xbrli:endDate>2022-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c0142cb42641dcb4f087976d7a8e60_I20221010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i444f4698aac042ccbe20eda2d1da8d8b_D20221012-20221012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-12</xbrli:startDate><xbrli:endDate>2022-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eac70ade3724a7c9d3a5db3107626ea_D20210715-20210715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2021PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-15</xbrli:startDate><xbrli:endDate>2021-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifce58657f57045a8a9d5fdddad892a48_I20210715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2021PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f1ba5cf7cba4f8c9251c46ff206c135_D20210719-20210719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2021PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-19</xbrli:startDate><xbrli:endDate>2021-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1faf1225c920491e8209c19e9f4b2f1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a320bf359b749c7a617f5394f9b3c83_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a7cbfffc237456380acaaec206786ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11965a3f2e9c4db38fbab16426b46799_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i857f39ef5fe54694b80c6fbe030a98d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4677eaef5e04113aaa9e6c7d5aa9c4f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9caf2243577b40c7b672a10e37d9512e_D20210425-20210425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-25</xbrli:startDate><xbrli:endDate>2021-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35242908a173404d86425605eca4a779_I20210425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8554c441f8d04f83811d7362580665a3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i392c13496de949c3bd9f8fba9ec64518_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d5cdeb5b7e43c1b31aa26556827c45_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb3045344074d578abb47cff790ebe3_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i175d1c7c30d04a678f2f280df3ebfdc5_D20200101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia137d2b6cec944f3a9a6132548a13e6e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b246b23033045b2b45563237e60fb03_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c6904d8a9104fa49767d8541244097e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a978fed247440098141566fbf4052d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0414aabe31c45cfb03ec35d6944f613_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46791b70b39149f995d04e9d61847f37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7338620b6330458489fcef670be67b56_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5621a4c9af0345529c9a631b26c01878_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id677ffe69ecb43f09a9efd781f682fd3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3da78567fb1749fca30fc791bedfd050_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i427aa8bde64a40738335743ec62dbe35_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia250755510204b7fb17b62e711d72da6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida3606afb67f4fd6b20f8cb83d82b570_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f8826a093524faab9e1c7138d3c7734_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16b6edf94a0a462ab55397b394789287_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f9bdb96b5174dbb8d3bd65a0524bed5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ca30a45a6194bfe96a0c64a563c77ba_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib771df66db154a9d836d085b5ebc58d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifabfaf9983d146db9bfff97adf3e07b1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i484c36bf82584e408934987b8269bc9a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i348724b28ae74d24885e46926e9b5cf1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cac2d95041a44d49c19e83ff8a94426_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:FederalMinistryOfFinanceGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3329f0d0a5a47fd8a67187745e514d4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:FederalMinistryOfFinanceGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i717b3c5bcd7648beb9aad1d139fdc6dc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">imux:ForeignExcludingGermanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6278909cd154de6bd0d29a81c57b4ec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">imux:ForeignExcludingGermanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52447e4dbf09445884a309828fb3a7f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbbf0f771acf458ab6e0e6253ecd4de4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">imux:TaxYearsPriorTo2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c0bbccc8e094072b09a4b7d1aafb3c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">imux:TaxYearsPost2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id31cbe772be540f6ae60d3269ef43568_D20210101-20210514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imux:ExecutiveChairmanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic97bdf6441d44e2b83eaf02fe42ee442_D20201115-20201115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imux:ExecutiveChairmanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-15</xbrli:startDate><xbrli:endDate>2020-11-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4965c60a3c264702a9ac179a8a4a899a_D20210415-20210415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imux:ExecutiveChairmanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-15</xbrli:startDate><xbrli:endDate>2021-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55271ce968e14d408bd351945f042b13_D20210515-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imux:ExecutiveChairmanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-15</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id672e13b1b3b42b79a062e019e44f37d_D20220315-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imux:ExecutiveChairmanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-15</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa6db4839145429ebadca83963b31d82_D20220315-20220315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imux:ExecutiveChairmanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-15</xbrli:startDate><xbrli:endDate>2022-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i268e6ad4baa74fa6836147f78ab7c782_D20221228-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imux:ExecutiveChairmanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idff78559567c4173b665e875d419cf41_1"></div><div style="min-height:33.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.785%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDcx_408871f3-e5a5-4554-90eb-f0f76a4fc928"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDgz_f27ba1fd-3069-4340-b60c-72dfbb3cf374">10-K</ix:nonNumeric></ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.785%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.468%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6NjYxZjJhZGM4OGM1NDUyOGJjMTZmZmRhMGQ2YjMwNzUvdGFibGVyYW5nZTo2NjFmMmFkYzg4YzU0NTI4YmMxNmZmZGEwZDZiMzA3NV8wLTAtMS0xLTM0ODYy_c951417e-c4df-40b4-9c90-d1e43ac46266">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8xMjg_71ca21a6-ec87-4a40-b0a5-ed20faca74ec"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8xMjg_4dbc0414-9558-4f6f-8385-9f2ba62cb930">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.468%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6OTlhYjIyOTc5ZTUzNGRiZGI3ZGQ3ZWQ0NGRkOTJmMmIvdGFibGVyYW5nZTo5OWFiMjI5NzllNTM0ZGJkYjdkZDdlZDQ0ZGQ5MmYyYl8wLTAtMS0xLTM0ODYy_7bf02ca8-ef6a-4dab-afb4-4ba6309780b2">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDg0_448d5727-3ced-407e-870d-81589c135696">001-36201</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDc3_3eb6a804-c113-4757-be0b-5863d5170206">Immunic, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.785%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.497%"><tr><td style="width:1.0%"></td><td style="width:43.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6N2Y0ZDk4ODYxMzA0NDcyOWJmMzdhMzAwYThlYmVkMzkvdGFibGVyYW5nZTo3ZjRkOTg4NjEzMDQ0NzI5YmYzN2EzMDBhOGViZWQzOV8wLTAtMS0xLTM0ODYy_9d00c138-4d3f-430a-a14a-8be3da00102e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6N2Y0ZDk4ODYxMzA0NDcyOWJmMzdhMzAwYThlYmVkMzkvdGFibGVyYW5nZTo3ZjRkOTg4NjEzMDQ0NzI5YmYzN2EzMDBhOGViZWQzOV8wLTItMS0xLTM0ODYy_bbac2f1e-7268-4577-ae00-2d8d9461e009">56-2358443</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6N2Y0ZDk4ODYxMzA0NDcyOWJmMzdhMzAwYThlYmVkMzkvdGFibGVyYW5nZTo3ZjRkOTg4NjEzMDQ0NzI5YmYzN2EzMDBhOGViZWQzOV8yLTAtMS0xLTM0ODYy_961a1dc0-a234-41d6-a5aa-359cd2ae957f">1200 Avenue of the Americas,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6N2Y0ZDk4ODYxMzA0NDcyOWJmMzdhMzAwYThlYmVkMzkvdGFibGVyYW5nZTo3ZjRkOTg4NjEzMDQ0NzI5YmYzN2EzMDBhOGViZWQzOV8yLTEtMS0xLTM0ODYy_e94e93a5-de9d-4b20-a41a-a98060777584">Suite 200</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6N2Y0ZDk4ODYxMzA0NDcyOWJmMzdhMzAwYThlYmVkMzkvdGFibGVyYW5nZTo3ZjRkOTg4NjEzMDQ0NzI5YmYzN2EzMDBhOGViZWQzOV8zLTAtMS0xLTM0ODYy_92d76f31-38b3-4c78-8715-1ed5c50426f6">New York,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6N2Y0ZDk4ODYxMzA0NDcyOWJmMzdhMzAwYThlYmVkMzkvdGFibGVyYW5nZTo3ZjRkOTg4NjEzMDQ0NzI5YmYzN2EzMDBhOGViZWQzOV8zLTEtMS0xLTM0ODYy_d69ef3fc-bf71-4d38-b2bc-e8bc4ba14327">NY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6N2Y0ZDk4ODYxMzA0NDcyOWJmMzdhMzAwYThlYmVkMzkvdGFibGVyYW5nZTo3ZjRkOTg4NjEzMDQ0NzI5YmYzN2EzMDBhOGViZWQzOV8zLTItMS0xLTM0ODYy_27fce440-538f-4beb-95fd-613d412fc7cc">10036</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDg1_148a2425-bded-4c07-90a8-45c72af787c5">332</ix:nonNumeric>) <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDc0_ef18292f-fa33-4e7e-9445-e848f2b92209">255-9818</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.468%"><tr><td style="width:1.0%"></td><td style="width:35.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:83%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6ZTVhZDhlZmNlYzMxNDRlYzg3OWRmYmFhYjNmODcyNmQvdGFibGVyYW5nZTplNWFkOGVmY2VjMzE0NGVjODc5ZGZiYWFiM2Y4NzI2ZF8xLTAtMS0xLTM0ODYy_09409769-e853-420e-a66c-5161b557d430">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:83%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6ZTVhZDhlZmNlYzMxNDRlYzg3OWRmYmFhYjNmODcyNmQvdGFibGVyYW5nZTplNWFkOGVmY2VjMzE0NGVjODc5ZGZiYWFiM2Y4NzI2ZF8xLTEtMS0xLTM0ODYy_7e1c1144-451c-4695-b90a-b5647038059e">IMUX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:83%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6ZTVhZDhlZmNlYzMxNDRlYzg3OWRmYmFhYjNmODcyNmQvdGFibGVyYW5nZTplNWFkOGVmY2VjMzE0NGVjODc5ZGZiYWFiM2Y4NzI2ZF8xLTItMS0xLTM0ODYy_1a882214-d563-4044-91f3-bfe3dd1d14a9">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDY5_3fbb81b2-873b-49cb-8c70-2470757f2c01">No</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes  <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDgw_b977f05b-a364-4f8b-a878-925bcc8dede0">No</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8xMTI0_1cdb4f6b-22d6-4dee-b4cf-e93835e768b4">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8xNDYx_28a2e28e-4820-415c-b27c-c49389d71839">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.949%"><tr><td style="width:1.0%"></td><td style="width:18.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6YTNiYzUyYmI5ZGFkNGFjMmJhNDY0MTIyZmQxMTMzMTIvdGFibGVyYW5nZTphM2JjNTJiYjlkYWQ0YWMyYmE0NjQxMjJmZDExMzMxMl8xLTAtMS0xLTM0ODYy_c0916ebe-1c17-4677-9946-2ba973e2b8ab">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6YTNiYzUyYmI5ZGFkNGFjMmJhNDY0MTIyZmQxMTMzMTIvdGFibGVyYW5nZTphM2JjNTJiYjlkYWQ0YWMyYmE0NjQxMjJmZDExMzMxMl8xLTMtMS0xLTM0ODYy_8528df3f-87b1-4b0c-80b4-8c417a8a60dc">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6YTNiYzUyYmI5ZGFkNGFjMmJhNDY0MTIyZmQxMTMzMTIvdGFibGVyYW5nZTphM2JjNTJiYjlkYWQ0YWMyYmE0NjQxMjJmZDExMzMxMl8yLTMtMS0xLTM0ODYy_308c387f-d168-4a66-ab4b-38da5bc5a2eb">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDgx_064adf8a-1855-4ef2-9f55-2c48f83ec058">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b)&#9744; </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;Yes  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDgy_3fedc438-5543-4188-95d7-11715c2b855a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   No  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the common equity held by non-affiliates of the Registrant, based on the closing price of the common stock on The Nasdaq Stock Market on June 30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i43e0b65cbd3346aeb1f08c2809f43307_I20220630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8yNzIy_e0149111-15a6-4e96-ad8c-52b65eeb297a">106.1</ix:nonFraction>&#160;million.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 17, 2023, <ix:nonFraction unitRef="shares" contextRef="i019b6a9949464c96b393742d493e84c2_I20230217" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8yNzQ4_d73f7bf8-7e43-4935-ad84-06722e659f65">44,403,838</ix:nonFraction> shares of common stock, $0.0001 par value, were outstanding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Documents Incorporated by Reference: <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDcw_0476b4bf-6ca7-41df-8ef3-eb63086146c3" escape="true">Certain portions of the registrant&#8217;s definitive Proxy Statement for its 2023 Annual Meeting of Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.</ix:nonNumeric></span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idff78559567c4173b665e875d419cf41_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunic, Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Fiscal Year Ended December&#160;31, 2022 </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_19">PART I</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_22">Business.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_22">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_25">Risk Factors.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_25">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_28">Unresolved Staff Comments.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_28">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_31">Properties.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_31">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_34">Legal Proceedings.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_34">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_37">Mine Safety Disclosures.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_37">62</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_40">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_40">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_43">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_43">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_46">Selected Financial Data.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_46">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_49">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_49">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_67">Quantitative and Qualitative Disclosures About Market Risk.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_67">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_70">Financial Statements and Supplementary Data.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_70">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_73">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_73">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_76">Controls and Procedures.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_76">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_79">Other Information.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_79">81</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_82">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_82">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_85">Directors, Executive Officers and Corporate Governance.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_85">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_88">Executive Compensation.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_88">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_91">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_91">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_94">Certain Relationships and Related Transactions, and Director Independence.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_94">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_97">Principal Accountant Fees and Services.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_97">82</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_100">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_100">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_103">Exhibits and Financial Statement Schedules.&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_103">83</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_169">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="idff78559567c4173b665e875d419cf41_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Special Note Regarding Forward-Looking Statements</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K (&#8220;Annual Report&#8221;) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These forward-looking statements are based on our management&#8217;s current beliefs and assumptions and on information currently available to our management, and are contained principally in the sections entitled &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Forward-looking statements include all statements that are not historical facts and can be identified by terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;best in class,&#8221; &#8220;could,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;first-in-class,&#8221; &#8220;focused,&#8221; &#8220;goal,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;opportunity,&#8221; &#8220;pipeline,&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;pursuing,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;treatment option,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;might,&#8221; &#8220;can,&#8221; &#8220;continue&#8221; or similar expressions and the negatives of those terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements include, among other things, statements about:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the strategies, prospects, plans, expectations and objectives of management;</span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to maintain compliance with Nasdaq listing standards;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.3pt">strategies with respect to our development programs,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including our ability to develop and commercialize our product candidates and the timing and expected data of clinical trials and preclinical studies;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:28pt">our estimates regarding revenues, expenses, capital requirements, projected cash requirements and needs for additional financing</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">possible sources of funding for future operations;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to protect intellectual property rights and our intellectual property position;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">future economic conditions or performance;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">proposed products or product candidates;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to retain key personnel;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to maintain effective internal control over financial reporting; and</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">beliefs and assumptions underlying any of the foregoing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements including those described in &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Annual Report, unless an earlier date is specified. You should read this Annual Report and the documents that we reference in this Annual Report and have filed with the Securities and Exchange Commission ("SEC") as exhibits hereto completely and with the understanding that our actual future results may be materially different from what we expect.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="idff78559567c4173b665e875d419cf41_22"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;Business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:93%">Immunic, Inc. ("Immunic," &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. We are headquartered in New York City with our main operations in Gr&#228;felfing near Munich, Germany. We currently have approximately 66 employees.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently pursuing clinical development of three orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;); the izumerogant (proposed International Nonproprietary Name (&#8220;INN&#8221;) for IMU-935) program, which is an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (&#8220;ROR&#947;t&#8221;) that inhibits the interleukin-17 (&#8220;IL-17&#8221;) pathway in diseases such as psoriasis; and the IMU-856 program, which is targeted to restore intestinal barrier function and regenerate bowel epithelium.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the potential indications, clinical targets and clinical development status of our three product candidates:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><img src="imux-20221231_g1.jpg" alt="imux-20221231_g1.jpg" style="height:213px;margin-bottom:5pt;vertical-align:text-bottom;width:654px"/></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our most advanced drug candidate, vidofludimus calcium (IMU-838), is being tested in several ongoing MS trials as part of its overall clinical program in order to support a potential approval for patients with MS in major markets. The Phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis (&#8220;RMS&#8221;), comprising twin studies evaluating efficacy, safety, and tolerability of vidofludimus calcium versus placebo, and the supportive Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (&#8220;PMS&#8221;) are ongoing and actively enrolling patients. Our current expectation is to report data from the interim analysis of the CALLIPER trial in the second half of 2023 and to read-out top-line data at the end of 2024. Moreover, we currently expect to report data from the interim analysis of the ENSURE program in late 2024 and to read-out the first of the ENSURE trials end of 2025. Although we currently believe that each of these goals is achievable, they are each dependent on numerous factors, most of which are not under our direct control and can be difficult to predict. We plan to periodically review this assessment and provide updates of material changes as appropriate.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If approved, we believe that vidofludimus calcium, with combined anti-inflammatory, anti-viral, and neuroprotective effects, has the potential to be a unique treatment option targeted to the complex pathophysiology of MS. Multiple publications from 2022 have highlighted the enhanced understanding of the triggers and ongoing neuronal destruction of MS, namely, that MS is triggered by infection from Epstein-Barr virus (&#8220;EBV&#8221;) followed by cross-reactive antibody production and associated auto-inflammation and neuronal damage. Vidofludimus calcium is a known inhibitor of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;), which is a key enzyme in the metabolism of overactive immune cells and virus-infected cells. This mechanism is associated with the anti-inflammatory and anti-viral effects of vidofludimus calcium. Additionally, recent evidence indicates that vidofludimus calcium activates a yet-to-be-disclosed target with direct neuroprotective properties, which may enhance its potential benefit for patients.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that the combined mechanisms of vidofludimus calcium are unique in the MS space and support the therapeutic performance shown in our Phase 2 EMPhASIS trial in relapsing-remitting multiple sclerosis (&#8220;RRMS&#8221;) patients, in particular, via data illustrating the potential to reduce magnetic resonance imaging (&#8220;MRI&#8221;) lesions, prevent relapses, reduce the rate of disability progression, and reduce levels of serum neurofilament light chain (&#8220;NfL&#8221;), an important biomarker of neuronal death. Vidofludimus calcium has a consistent pharmacokinetic (&#8220;PK&#8221;), safety and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">tolerability profile and has already been exposed to more than 1,400 human subjects and patients in either of the drug&#8217;s formulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our second drug candidate, izumerogant (proposed INN for IMU-935), is a highly potent and selective inverse agonist of a transcription factor called ROR&#947;/ROR&#947;t. The nuclear receptor ROR&#947;t is believed to be the main driver for the differentiation of T helper 17 (&#8220;Th17&#8221;) cells and the release of cytokines involved in various inflammatory and autoimmune diseases. We believe this target is an attractive potential alternative to approaches acting on IL-23, the IL-17 receptor and directly on IL-17. We have observed strong cytokine inhibition targeting both Th1 and Th17 responses in preclinical testing, as well as indications of activity in animal models for psoriasis, graft versus host disease, MS and inflammatory bowel disease ("IBD"). Preclinical experiments indicated that izumerogant leads to a potent inhibition of Th17 differentiation, inhibition of cytokine secretion, and induction of regulatory T cells. Importantly, izumerogant did not affect thymocyte maturation, one of the important physiological functions of ROR&#947;t that should be maintained. Based on these preclinical data and the selectivity of the effect maintaining important physiological functions while providing the desired anti-Th17 effect, we believe that izumerogant has potential to be a first-and-best-in-class therapy for various autoimmune diseases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A Phase 1 clinical trial exploring safety, tolerability, pharmacodynamics (&#8220;PD&#8221;), PK and exploratory efficacy of izumerogant in moderate-to-severe psoriasis patients is currently ongoing. A pre-planned group-level interim analysis revealed on October 20, 2022 noted that the initial two active dose cohorts did not separate from placebo at four weeks. The overall trial is ongoing. Administration of izumerogant and placebo in this trial were demonstrated to be safe and well-tolerated, and no new safety signals were observed. We plan to provide further updates and guidance on potential next steps for this development program towards the end of the first quarter of 2023. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, izumerogant has been shown in preclinical models to target a mutated androgen receptor (&#8220;AR&#8221;), an established mechanism of treatment resistance to AR therapy, making it a potential treatment option for patients with metastatic castration-resistant prostate cancer (&#8220;mCRPC&#8221;). A Phase 1 clinical trial exploring safety and tolerability of increasing doses of izumerogant to establish the maximum tolerated dose and the recommended Phase 2 dose is currently ongoing in patients with mCRPC.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our third program, IMU-856, is an orally available small molecule modulator that targets a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. We have not yet disclosed the molecular target for IMU-856 to the public. Based on preclinical data, we believe this compound may represent a unique treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function and bowel wall architecture in patients suffering from gastrointestinal diseases such as celiac disease, IBD, irritable bowel syndrome with diarrhea (&#8220;IBS-D&#8221;) and other intestinal barrier function associated diseases. We believe that, because IMU-856 has been shown in preclinical investigations to avoid suppression of immune cells, it may therefore have the potential to maintain immune surveillance for patients during therapy, which would be an important advantage versus immunosuppressive medications. The final portion of a Phase 1 clinical trial exploring the safety and tolerability of IMU-856 in celiac disease patients during periods of gluten-free diet and gluten challenge is currently ongoing, and we expect initial results to be available in mid-2023.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additional antiviral-directed development activities remain ongoing through preclinical research examining the potential to treat a broad set of viral indications with new antiviral molecules. We have begun exploring several options to possibly support further development of our antiviral portfolio, including a potential spin-off into a new or existing company and potential licensing transactions.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We expect to continue to lead most of our research and development activities from our Gr&#228;felfing, Germany location, where dedicated scientific, regulatory, clinical and medical teams conduct their activities. Due to these teams' key relationships with local and international service providers, we anticipate that this will result in timely, cost-effective execution of our development programs. In addition, we are using our subsidiary in Melbourne, Australia to expedite the early clinical trials for izumerogant and IMU-856. We also conduct preclinical work in Halle/Saale, Germany through a collaboration with the Fraunhofer Institute.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of our clinical trials to meet their endpoints, failure to obtain regulatory approval and failure to obtain needed additional funding on acceptable terms, if at all, to complete the development and commercialization of our three development programs.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategy </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on the development of new molecules that maximize the therapeutic benefits for patients by uniquely addressing biologically relevant immunological targets. We take advantage of our established research and development infrastructure and operations in Germany and Australia to more efficiently develop our product candidates in indications of high unmet need and where the product candidates have the potential to elevate the standard of care for the benefit of patients. Given the mechanisms of action and the data generated for our product candidates, to date, we continue to execute on the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical development of our programs for established indications as well as explore additional indications where patients could potentially benefit from the unique profiles of each product candidate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently focused on maximizing the potential of our development programs through the following strategic initiatives:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Executing the ongoing Phase 3 ENSURE and Phase 2 CALLIPER clinical trial programs of vidofludimus calcium in MS.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Executing the ongoing clinical trials of izumerogant in patients with psoriasis and in patients with mCRPC, with the path for future development to be assessed following analysis of the results.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Executing the ongoing Phase 1 clinical trial of IMU-856 in patients with celiac disease.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued preclinical research to complement the existing clinical activities, explore additional indications for future development, and where appropriate, generate additional molecules for future development.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Facilitating readiness for potential commercial launch of our product candidates through targeted and stage-appropriate pre-commercial activities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evaluating potential strategic collaborations for each product candidate in order to complement our existing research and development capabilities and to facilitate potential commercialization of these product candidates by taking advantage of the resources and capabilities of strategic collaborators in order to enhance the potential and value of each product candidate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Liquidity and Financial Condition </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since our inception in 2016. We have an accumulated deficit of approximately $317.3&#160;million and $196.9 million as of December 31, 2022 and December 31, 2021, respectively. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the development of our product candidates and add personnel necessary to advance our pipeline of product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December 31, 2022, we have raised net cash of approximately $355.5 million from private and public offerings of preferred and common stock. As of December 31, 2022, the Company had cash and cash equivalents of approximately $106.7&#160;million and investments - other of $9.6&#160;million.  With these funds, we expect to be able to fund our operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Key Status Updates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Vidofludimus Calcium (IMU-838)</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 3 Program of Vidofludimus Calcium in RMS (ENSURE-1 and ENSURE-2 Trials) </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing ENSURE program comprises two identical multicenter, randomized, double-blind Phase 3 clinical trials designed to evaluate the efficacy, safety, and tolerability of vidofludimus calcium versus placebo in RMS patients. Based on vidofludimus calcium&#8217;s highly significant activity in preventing lesion formation in our Phase 2 EMPhASIS trial in RMS, the strong and consistent correlation observed between lesion formation and clinical relapse in third-party clinical trials, and the drug&#8217;s robust safety profile, to date, we believe that this Phase 3 program should provide a straightforward path towards potential regulatory approval of vidofludimus calcium in RMS.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the identical twin Phase 3 clinical trials, titled ENSURE-1 and ENSURE-2, is expected to enroll approximately 1,050 adult patients with active RMS at more than 100 sites in more than 15 countries, including the United States, India and countries in Latin America, Central and Eastern Europe. Patients will be randomized in a double-blinded fashion to either 30 mg daily doses of vidofludimus calcium or placebo and the primary endpoint for both clinical trials is time to first relapse up to 72 weeks. Key secondary endpoints include volume of new T2-lesions, time to confirmed disability progression, time to sustained clinically relevant changes in cognition, and percentage of whole brain volume change. With regard to the disability </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progression endpoint, the ENSURE program will apply a pooled analysis of confirmed disability worsening across both clinical trials.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ENSURE trials are being run concurrently. The first patient in ENSURE-1 was enrolled in November 2021. The first patient in ENSURE-2 was enrolled in January 2022. An interim analysis to assess event rates is planned to occur after approximately half of the relapse events have occurred in the double-blind treatment periods. This analysis is intended to inform potential sample size adjustment and help ensure that final study readout is not planned to occur before sufficient events have been achieved. This interim analysis will also allow for a non-binding futility analysis. We currently expect to report data from the interim analysis of the ENSURE program in late 2024 and to read-out the first of the ENSURE trials end of 2025.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Phase 2 Clinical Trial of Vidofludimus Calcium in PMS (CALLIPER Trial) </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2 CALLIPER trial of vidofludimus calcium is expected to enroll approximately 450 patients with PMS at more than 70 sites in North America, Western, Central and Eastern Europe with patients randomized to either 45 mg daily doses of vidofludimus calcium or placebo in a double-blinded fashion. The trial&#8217;s primary endpoint is the annualized rate of percent brain volume change up to 120 weeks. Key secondary endpoints include the annualized rate of change in whole brain atrophy and time to 24-week confirmed disability progression based on the Expanded Disability Status Scale (&#8220;EDSS&#8221;) which may further support disability data from the ENSURE trials. The first patient was enrolled in September 2021. Our current expectation is to report data from the interim analysis of the CALLIPER trial in the second half of 2023 and to read-out top-line data at the end of 2024.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An interim analysis comprising an unblinded analysis of serum NfL and glial fibrillary acidic protein (&#8220;GFAP&#8221;) is planned to occur once approximately half of the enrolled patients have completed 24 weeks of treatment. NfL and GFAP have been shown in third-party research to consistently correlate with disease activity in neurodegenerative disorders and have become two of the most important serum biomarkers for axonal damage over the past few years. As previously reported, results of the Phase 2 EMPhASIS trial of vidofludimus calcium in RRMS showed a robust decrease in serum NfL at 24 weeks (-17.0% for 30 mg and -20.5% for 45 mg), as compared to baseline values, while the patients on placebo experienced a 6.5% increase in serum NfL over the same period.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Phase 2 CALLIPER trial is intended to run concurrently with and to complement the Phase 3 program in RMS. In particular, CALLIPER is focused on progressive forms of MS and is designed to corroborate vidofludimus calcium&#8217;s neuroprotective potential, as exemplified by slowing of brain atrophy and delay in disability worsening. Neurodegeneration is a key concern in both PMS and RMS, since axonal and neural damage is responsible for the increasing and often severe disability experienced by patients. We believe that, if the CALLIPER trial is successful in showing a beneficial effect of vidofludimus calcium, this data, along with the ENSURE program and vidofludimus calcium&#8217;s strong safety and tolerability profile, may allow for a meaningful clinical differentiation of vidofludimus calcium from other oral MS medications and a potentially attractive commercial positioning. Although a supportive trial, we do not believe that data from the CALLIPER trial are a pre-condition for filing a New Drug Application (&#8220;NDA&#8221;) in RMS. Additional clinical studies and the potential regulatory path forward specific to the treatment of PMS will be informed by the results of the CALLIPER trial and will be further assessed accordingly. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 Clinical Trial of Vidofludimus Calcium in RRMS (EMPhASIS Trial) &#8211; Open-Label Portion</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2022, we reported newly available data from the Phase 2 EMPhASIS trial of vidofludimus calcium in RRMS. The trial includes an optional long-term open-label extension (&#8220;OLE&#8221;) phase running up to 9.5 years. An interim analysis was performed with data extraction in October 2022, when 209 patients remained on treatment in the OLE phase, some of whom have already received more than 180 continuous weeks (approximately four years) of active treatment with vidofludimus calcium. Long-term open-label treatment with vidofludimus calcium was associated with a low rate of confirmed disability worsening over time, comparing favorably to historical trial data for currently available MS medications. During the 24-week double-blind main treatment period, 12-week and 24-week Confirmed Disability Worsening (&#8220;12w/24wCDW&#8221;) events occurred in 1.6% of subjects in the combined vidofludimus calcium treatment arms as compared to 3.7% in the placebo group. In the OLE phase, the proportion of patients free from 12wCDW was 97.6% after 48 weeks and 94.5% after 96 weeks of vidofludimus calcium treatment as compared to the start of the OLE phase. Similar results were observed for 24wCDW and sustained CDW. The OLE phase also showed low relapse activity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Phase 2 Clinical Trial of Vidofludimus Calcium in Ulcerative Colitis (CALDOSE-1 Trial)</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 2, 2022, we reported top-line data from our Phase 2 CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe ulcerative colitis (&#8220;UC&#8221;). The trial did not achieve the primary endpoint of clinical remission for the pooled 30 and 45 mg/day active dose groups of vidofludimus calcium versus placebo at week 10. In addition, no meaningful </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">differences were observed between the three active dose groups for the overall intent-to-treat patient population (10 mg/day: 14.9%, 30 mg/day: 10.6%, 45 mg/day: 13.6%, placebo: 12.5%) or for the trial&#8217;s other secondary endpoints, including symptomatic remission, or endoscopic healing.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in this clinical trial was observed to be safe and well-tolerated. No new safety signals were observed. As compared to placebo, there were no increased rates of infections and infestations, no elevated rates of liver events or liver enzyme elevations, and no elevated rates for changes in hematology-related laboratory variables. The most common adverse events in this clinical trial were anemia (15/263 patients, 5.7%), headache (9/263 patients, 3.4%) and coronavirus disease 2019 (&#8220;COVID-19&#8221;) (7/263 patients, 2.7%). Most adverse events were generally mild in severity.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As is common for the design of clinical trials in UC, the use of oral systemic corticosteroids (&#8804;20 mg/day prednisolone equivalent) was allowed in CALDOSE-1 in patients who had been treated with corticosteroids for at least four weeks before randomization. Doses of corticosteroids were required to be kept constant throughout the induction phase (weaning was not allowed in this phase of the clinical trial), and the distribution of patients using corticosteroids was equal throughout all treatment groups. Surprisingly, CALDOSE-1 data suggest a previously unknown treatment interference between the efficacy of vidofludimus calcium and the concurrent use of corticosteroids in the UC patient population. More specifically, the non-steroid patient population showed an 11.4% advantage in clinical remission for vidofludimus calcium over placebo (pooled vidofludimus calcium treatment groups at week 10: 14.7%, placebo: 3.3%). Such a difference in clinical remission between active treatment and placebo would traditionally be considered as confirming therapeutic activity. In contrast, patients concomitantly taking vidofludimus calcium and corticosteroids during induction treatment had a lower rate of clinical remission at week 10 (11.5%) than placebo patients (20.6%) and also lower than the group of vidofludimus calcium monotherapy without concurrent use of steroids (14.7%). This treatment interference between vidofludimus calcium and corticosteroids was not expected based on our analysis of currently available preclinical or clinical data.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on these results, we announced that our development programs in the IBD indications will not be continued without a partner.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Izumerogant (IMU-935)</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:102%">Phase 1 Clinical Trial of Izumerogant in Moderate-to-Severe Psoriasis Patients</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 20, 2022, we announced the outcome of a pre-planned interim group-level data analysis of our Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis. The pre-planned interim analysis revealed that the group averages for Psoriasis Area and Severity Index ("PASI&#8221;) reductions in the two active arms did not separate from placebo at four weeks. Although the active arms performed in line with expectations, based on similarly designed trials, the trial experienced a greater decrease than expected in PASI in the placebo arm. Administration of izumerogant and placebo in this trial were demonstrated to be safe and well-tolerated, and no new safety signals were observed. We plan to provide further updates and guidance on potential next steps for this development program towards the end of the first quarter of 2023.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Following the announcement of our interim group-level data on October 20, 2022, our stock price experienced a significant decline from the prices preceding the announcement and the recent prices raised in our October 10, 2022 Private Placement. We considered these to be triggering events indicating that it is more likely than not that goodwill is impaired. As a result, we recorded a full impairment of our goodwill of approximately $33.0 million in the quarter ended December 31, 2022. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Phase 1 Clinical Trial of Izumerogant in mCRPC</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on strong preclinical results, we have initiated an open-label Phase 1 dose-escalation trial in mCRPC designed to evaluate the safety and tolerability of increasing doses of izumerogant to establish the maximum tolerated dose and the recommended phase 2 dose. The trial&#8217;s Principal Investigator is Johann Sebastian de Bono, MD, PhD, Regius Professor of Cancer Research and Professor in Experimental Cancer Medicine, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, London, United Kingdom. The trial was approved by the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;), the Research Ethics Committee (&#8220;REC&#8221;) and the Health Research Authority (&#8220;HRA&#8221;) in the United Kingdom. The first patient was enrolled in December 2021.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The pre-planned dose escalation in the trial with dosing of up to 900 mg daily of izumerogant has been completed. Initial safety data available, to date, show a promising safety profile, with only benign adverse events and no dose limiting toxicities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">IMU-856</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 20, 2022, we announced positive unblinded safety, tolerability and PK results from Part A (single ascending doses) and Part B (multiple ascending doses) of our Phase 1 clinical trial of IMU-856 in healthy human subjects.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the single ascending doses part, healthy human subjects were randomized in a double-blinded manner to either placebo or active treatment with single ascending doses of IMU-856 at 10 mg, 20 mg, 40 mg, 80 mg, 120 mg and 160 mg. Single ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached. No serious adverse events occurred. Moreover, a dose-linear PK profile was observed across the investigated dose range.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the multiple ascending doses part, healthy human subjects were dosed for 14 consecutive days with 40 mg, 80 mg or 160 mg once-daily of IMU-856 or placebo in a double-blinded manner. Multiple ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached. Treatment emergent adverse events were mostly mild in severity. No Investigational Medicinal Product-related serious adverse events were reported. No dose-dependent changes in laboratory parameters (including no effects on liver enzymes or in hematological parameters), vital signs, physical examination or electrocardiographic evaluations were found. PK analysis showed a quick achievement of stable steady-state plasma concentrations within the first week and stable steady-state trough levels over the 14-day treatment period with a low accumulation factor for IMU-856, allowing predictable trough levels during daily dosing. PK parameters in steady-state revealed a Tmax (time to reach maximum plasma concentration) of 2 to 3 hours post-dose, a plasma half-life of 17.4 to 21.5 hours and dose proportional increases in Cmax (maximum plasma drug concentration) and AUC (area under the concentration-time curve).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Phase 1 Clinical Trial of IMU-856 in Celiac Disease</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 5, 2022, we announced the start of the patient cohorts in our ongoing Phase 1 clinical trial of IMU-856 in patients with celiac disease. Part C is structured as a 28-day, double-blind, placebo-controlled trial designed to assess the safety, tolerability, PK, PD and biomarker responses of IMU-856 in patients with celiac disease during periods of gluten-free diet and gluten challenge. Approximately 42 patients were planned to be enrolled in two consecutive cohorts with IMU-856 given once-daily over 28 days. Secondary objectives include PK and disease markers, including those evaluating gastrointestinal architecture and inflammation. Sites in Australia and New Zealand are participating in Part C. Initial results are expected to be available in mid-2023.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product Acquisition History</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our wholly-owned subsidiary Immunic AG acquired vidofludimus calcium and izumerogant in September 2016 through asset acquisitions from 4SC AG (hereinafter, &#8220;4SC&#8221;), a publicly traded company based in Planegg-Martinsried, Germany. On March 31, 2021, Immunic AG and 4SC entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of a 4.4% royalty on net sales for $17.25 million. The payment was made 50% in cash and 50% in shares of Immunic&#8217;s common stock.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our rights to IMU-856 are secured pursuant to an option and license agreement (the &#8220;Daiichi Sankyo Option&#8221;) with Daiichi Sankyo Co., Ltd. (hereinafter, "Daiichi Sankyo") in Tokyo, Japan. On January 5, 2020, Immunic AG exercised its option under the Daiichi Sankyo Option to acquire the exclusive global rights to commercialize IMU-856. The license also grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856. Concurrent with the option exercise, Immunic AG paid to Daiichi Sankyo a one-time upfront licensing fee. Going forward, Daiichi Sankyo is eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Leadership</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are led by a team of dedicated and committed experienced professionals with an entrepreneurial spirit and track record of successful licensing transactions in the healthcare industry, worldwide. The team brings together several decades of leadership experience in the pharmaceutical industry with a strong scientific background and sound knowledge in drug discovery, product development, chemistry, manufacturing and controls processes, intellectual property, clinical trial design, health economics and market access, merger and acquisitions, capital markets, corporate finance, business development, regulatory affairs and project valuation. Our team members are inventors on project-related patents and have successfully published project-related scientific publications.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product Candidates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Vidofludimus Calcium (IMU-838)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vidofludimus calcium is a small molecule investigational drug in development as an oral next-generation treatment option for patients with MS and other chronic inflammatory and autoimmune diseases. By inhibiting DHODH, a key enzyme of pyrimidine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> biosynthesis, highly metabolically activated T and B immune cells experience metabolic stress, which leads to a modulation of their activity and function. Thereby, pro-inflammatory cytokines, such as interferon gamma (&#8220;IFN&#947;&#8221;), tumor necrosis factor alpha (&#8220;TNF&#945;&#8221;), IL-17A and IL-17F, produced by activated Th1 and Th17 cells, which represent subtypes of so-called T helper cells, are repressed and thereby reduce the inflammation associated with MS and other chronic inflammatory diseases.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In preclinical studies of vidofludimus, the active moiety and free acid form of vidofludimus calcium, apoptosis (or programmed cell death) was induced in activated T cells, which we believe may also play a crucial role in the activity of the drug by further dampening the inflammatory response. We believe that a key advantage of DHODH inhibition, in general, is that the sensitivity of specific immune cells to DHODH inhibition correlates with their intracellular metabolic activation state, and therefore may not negatively impact &#8220;normal&#8221; immune and bone marrow cells. In animal studies of vidofludimus calcium, animals treated with large doses of the active moiety of vidofludimus calcium were shown to lack detrimental effects on bone marrow, supporting the lack of an unspecific anti-proliferative effect regularly seen with many traditional immunomodulators.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the selectivity toward metabolically activated cells (with a high need for ribonucleic acid and deoxyribonucleic acid production), DHODH inhibition also leads to a direct antiviral effect, which has been observed in various virus infected cells, such as EBV infections, hepatitis C virus infections, severe acute respiratory syndrome coronavirus 2 (&#8220;SARS-CoV-2&#8221;) infections, cytomegalovirus infections and even hemorrhagic fever-causing viruses, such as Arena virus infections. Treatment with vidofludimus calcium may avoid virus infections and reactivations, one of the major drawbacks of the long-term use of traditional immunomodulators. We previously presented preclinical data demonstrating the activity of vidofludimus calcium to prevent the reactivation of latent EBV infection into lytic infection (Marschall et al., 2021). This mechanism may lead to reduce the regular cycle of reactivations and reinfections in the medium term, and thus the latent persistent EBV infection in patients in the long term.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Efficacy of vidofludimus has been observed in several animal disease models for IBD, MS, as well as systemic lupus erythematosus and transplant rejection. Previous filings by us with the SEC have summarized the development history of vidofludimus and the previous amorphous formulation of the free acid form of vidofludimus. After the consummation of the asset acquisition from 4SC, we developed and filed a patent application for a new specific polymorph of the calcium salt formulation of vidofludimus, vidofludimus calcium, which we believe exhibits improved physicochemical and PK properties. In 2017, we completed two Phase 1 studies of single or repeated once-daily doses of vidofludimus calcium in healthy volunteers, where we observed results supporting tolerability of repeated daily dosing of up to 50 mg of vidofludimus calcium.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also completed a Phase 1 trial in a total of 24 patients with either no liver function impairment or liver disease of Child-Pugh A Child-Pugh B grade which was designed to explore dose optimization of vidofludimus calcium. The study showed little influence on the PK of vidofludimus calcium in patients with Child-Pugh A Child-Pugh B liver impairment.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Indication: Multiple Sclerosis</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diagnosis and Prevalence</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MS is an autoimmune disease that affects the brain, spinal cord and optic nerve. In MS, myelin, the coating that protects the nerves, is attacked and damaged by the immune system. Thus, MS is considered an immune-mediated demyelinating disease of the central nervous system ("CNS"). MS is a progressive disease which, without effective treatment, leads to severe disability. We are developing vidofludimus calcium for the treatment of RMS, the most common form of MS. Approximately 85% of patients with MS are expected to develop RMS, with some patients developing more progressive forms of the disease. RMS is characterized by clearly defined attacks of new or increasing neurologic symptoms. These relapses are followed by periods of remissions, or partial or complete recovery. During remissions, all symptoms may disappear, or some symptoms may continue and become permanent.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MS is a disease with unpredictable symptoms that can vary widely. Common early signs of MS include vision problems, tingling and numbness or other unspecific neurological symptoms. Diagnosis of MS is confirmed via blood tests and a spinal tap, in which a small sample of fluid is removed from the spinal cord. However, most important for diagnosis are characteristic CNS lesions found using MRI.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">According to the National Multiple Sclerosis Society (2019), there are nearly one million patients in the United States living with MS. The MS International Federation (2021) indicates there are more than one million patients with MS in Europe as well. The disease has a large economic impact as it affects mainly young adults in the prime working age, peaking around 30 years old, although MS can occur in children and in adults. MS is up to three times more common in women than in men. MS affects twice as many women and men in certain age cohorts and is more common in areas inhabited by people of northern European ancestry, such as Europe, the United States, Canada, New Zealand and parts of Australia.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Evolution in Understanding of Disease Drivers of MS  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A recent publication shed new light on the role of infection with the EBV previously postulated to trigger MS. Bjornevik et al. (2022) analyzed EBV antibodies in serum from 801 individuals who developed MS among a cohort of more than 10 million people active in the US military over a 20-year period (1993 to 2013). Risk of MS increased 32-fold after infection with EBV but was not increased after infection with other viruses, including the similarly transmitted cytomegalovirus. Serum levels of NfL, a biomarker of axonal damage, increased only after EBV seroconversion. These findings cannot be explained by any known risk factor for MS and suggest EBV as the leading cause of MS. In addition, antibody producing cells directed against the latent EBV protein EBNA1 were found in the CSF of MS patients. Cross reactivity of anti-EBNA1 antibodies against GlialCAM, a protein that is predominantly expressed in glial cells in the CNS and potentially important in the myelination process of axons, further corroborates the connection between EBV infections and pathologic processes in MS (Lanz et al., 2022). Schneider-Hohendorf et al. (2022) investigated the T cell repertoire in MS patients and control populations, basically highlighting the top antigens that are seen by T cells on an ongoing basis. The study found that EBV-related antigens were on top of the list of antigens seen by T cells in MS patients but not in other EBV-infected populations. These results suggest that ongoing EBV reactivation seems to be an ongoing trigger for the immune system in MS patients and may be the trigger for disease progression and ongoing neurogenerative processes. The presence of a &#8220;smoldering disease&#8221; in the background that leads to progression independent of relapse activity (&#8220;PIRA&#8221;) was suggested by another large meta-analysis of clinical data in more than 35,000 MS patients (Lublin et al., 2022). PIRA was traditionally believed to be dominant driver of disease worsening in PMS and this was confirmed by this study as well. However, the study also found that approximately half of the disability accumulating in RMS patients were not related to relapse activity. This suggests that PIRA contributes half of the disability to disease progression in RMS in a mechanism other than relapse. In addition, this investigation found that many currently available drugs were able to delay or avoid disability associated with relapse activity but was unable to diminish the impact of PIRA. This confirms that PIRA presumably is caused by a process that is not addressed by currently used anti-inflammatory medications remains a high medical need. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Current Treatment Options</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are currently two main approaches to treating RMS. Some therapies, such as short-term corticosteroid medications, are used for treating relapses of MS symptoms. Other approaches are used as long-term treatments to reduce the number of relapses and prevent or slow down disability progression. The latter are referred to as disease-modifying therapies. We intend to develop vidofludimus calcium as a disease-modifying therapy for RMS.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial treatment options for RMS patients are often beta interferons (either as interferon beta-1a or interferon beta-1b) or glatiramer acetate, all of which are given by injection. For patients requiring more advanced treatment options, there are several oral medications, such as dimethyl fumarate, fingolimod, siponimod, teriflunomide, ozanimod or cladribine, and biologics, such as natalizumab, ocrelizumab, ublituximab, ofatumumab or alemtuzumab, approved for commercial use in MS in various countries. In addition, some of these drugs already have generic versions available in some countries and other drugs will become generic in the next years.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no specific guidance on which therapies or medications are used in which sequence of the MS disease course. Typically, treatments are escalated over time, considering:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">Level and progression of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">MS disease activity (relapse(s), disability worsening, MRI lesions),</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:14.5pt">Risks of long-term immunosuppression,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:14.5pt">Patient preferences or risks perceptions, and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:14.5pt">Safety/tolerability aspects.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many drugs approved for patients with RMS work through anti-inflammatory mechanisms by suppressing the immune system, either broadly or by targeting classes of immune cells, altering how the immune system functions and fights certain infections. As a result, people who take these therapies are at higher risk for John Cunningham virus infection or re-activation, which is believed to be the cause of a rare and often lethal viral disease of the brain called progressive multifocal </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">leukoencephalopathy ("PML"). To date, occurrences of PML have been reported in individuals with RMS treated with natalizumab, ocrelizumab, dimethyl fumarate and fingolimod. No case of PML has yet been reported for the DHODH inhibitor teriflunomide, which has been one of the key differentiators of teriflunomide from other disease-modifying therapies in RMS. The active moiety of vidofludimus calcium has also shown direct antiviral effects in several models of virus-infected cells, which we believe is caused by DHODH inhibition. Subject to further clinical trials, we believe that could be an important potential differentiator against other drug classes in RMS.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Current Development Plan and Clinical Studies</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the results of our ongoing clinical trials, we believe that vidofludimus calcium has the potential to demonstrate medically important advantages versus other treatments, due to its safety profile and its anti-inflammatory, anti-viral and neuroprotective properties observed-to-date. Vidofludimus calcium could provide MS patients with a distinctive therapy that is uniquely matched to the biological drivers of MS. In clinical trials, to date, it has shown data indicating:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A targeted effect on hyperactive immune cells without suppression of normal immune function.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Robust MRI lesion suppression by vidofludimus calcium, comparing favorably to other medications commercially available for RMS.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Improved rates of confirmed disability worsening.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A robust decrease in serum NfL, a biomarker for axonal damage, providing evidence of vidofludimus calcium&#8217;s potential neuroprotective activity.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A potent interaction with a yet-to-be-disclosed protein target, which is involved in protection of relevant neurons from cell death.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A very low discontinuation rate for vidofludimus calcium-treated RMS patients, substantially below placebo, which indicates an encouraging combination of tolerability and efficacy as well as maintenance of normal quality-of-life.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Absence of hepatotoxicity signals and other relevant adverse events leading to discontinuations, which distinguishes vidofludimus calcium from other oral RMS treatments.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The broad spectrum antiviral effect of vidofludimus calcium may support lowering the rate of viral infections and reactivations, including EBV reactivation, potentially resulting in slowing potential EBV-related neurodegenerative processes.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 Clinical Trial of Vidofludimus Calcium in RRMS (EMPhASIS Trial)</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Phase 2 EMPhASIS trial of vidofludimus calcium in RRMS consisted of two cohorts: The full data set of Cohort 1, which evaluated efficacy and safety of 30 mg or 45 mg once daily vidofludimus calcium compared to placebo, was published by us in August and September 2020, respectively. The Cohort 1 results were subsequently published in the peer reviewed journal, Annals of Clinical and Translational Neurology (Fox et al., 2022). Cohort 2, which evaluated efficacy and safety of 10 mg once daily vidofludimus calcium compared to placebo, was also published by us.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2020, we announced positive top-line data from our Phase 2 EMPhASIS trial of vidofludimus calcium in patients with RRMS. The trial achieved statistical significance on all primary and key secondary endpoints, indicating activity in RRMS patients. In particular, the trial met its primary endpoint, demonstrating a statistically significant reduction in the cumulative number of combined unique active (&#8220;CUA&#8221;) MRI lesions up to week 24 in patients receiving 45 mg of vidofludimus calcium once daily, by 62% (p=0.0002), as compared to placebo. The trial also met its key secondary endpoint, showing a statistically significant reduction in the cumulative number of CUA MRI lesions for the 30 mg once daily dose by 70% (p&lt;0.0001), as compared to placebo. On September 11, 2020, we published the full unblinded clinical data set from our Phase 2 EMPhASIS trial of vidofludimus calcium in patients with RRMS. The data confirmed and expanded on the previously announced top-line results.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2021, we announced interim data from Cohort 2 after 59 randomized patients completed week 12 MRI assessments. We concluded from this data, along with previously published data from Cohort 1, that 30 mg once daily vidofludimus calcium is the most appropriate anti-inflammatory dose for Phase 3 clinical trials in patients with RMS.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final data from Cohort 2 showed that the anti-inflammatory effects of vidofludimus calcium at the 10 mg dose were observed to be lower (13% reduction of gadolinium-enhancing MRI lesions up to 24 weeks, as compared to placebo) than those found with the 30 mg vidofludimus calcium dose in the pooled Cohort 1 and 2 data (78% reduction), providing further support </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the selection of 30 mg dosing in the ongoing ENSURE trials in RMS. Final Cohort 2 data also provided evidence of dose-proportional neuroprotective activity. For instance, the highest decrease of the biomarker serum NfL was observed with the 45 mg dose of vidofludimus calcium versus placebo (-26.0% median of differences between percentage change of serum neurofilament, Hodges-Lehmann estimation), a substantial decrease was seen with the 30 mg dose (-18.0%), while the smallest decrease was observed with the 10 mg dose of Cohort 2 (-9.0%). The 10 mg group in Cohort 2 also showed a signal with respect to improvement in EDSS, consistent with those signals seen with the higher doses in Cohort 1, although all of these early signals need to be confirmed in a larger patient population with longer follow-up periods. Taken together, these last two observations suggest that higher doses, such as 45 mg vidofludimus calcium, may be preferred doses for clinical trials in which neuroprotective effects are the main mechanism for improvement, such as in PMS.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While Cohort 1 blinded treatment was completed right before the COVID-19 pandemic started, final Cohort 2 data provide additional evidence that ongoing vidofludimus calcium treatment may reduce the risk of COVID-19 infections, presumably related to its known antiviral activity. In the entire Cohort 2 population of 59 patients, who were enrolled during pandemic conditions, incidental COVID-19 infections in the active treatment group were less frequent (8.5%, n=4/47) than in the placebo group (25.0%, n=3/12). Additionally, we obtained preclinical data underlining that vidofludimus calcium shows potent anti-EBV activity. We also confirmed that vidofludimus calcium can be detected to a noteworthy degree in the cerebrospinal fluid of animals, after oral dosing. We believe that this finding suggests that vidofludimus calcium may be able to act directly within the CNS.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2022, we reported newly available data from the EMPhASIS trial. The trial includes an optional long-term OLE phase running up to 9.5 years. An interim analysis was performed with data extraction in October 2022, when 209 patients remained on treatment in the OLE phase, some of whom have already received more than 180 continuous weeks (approximately four years) of active treatment with vidofludimus calcium. Long-term open-label treatment with vidofludimus calcium was associated with a low rate of confirmed disability worsening over time, comparing favorably to historical trial data for currently available MS medications. During the 24-week double-blind main treatment period, 12-week and 24-week Confirmed Disability Worsening (&#8220;12w/24wCDW&#8221;) events occurred in 1.6% of subjects in the combined vidofludimus calcium treatment arms as compared to 3.7% in the placebo group. In the OLE phase, the proportion of patients free from 12wCDW was 97.6% after 48 weeks and 94.5% after 96 weeks of vidofludimus calcium treatment as compared to the start of the OLE phase. Similar results were observed for 24wCDW and sustained CDW. The OLE phase also showed low relapse activity.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further information regarding our EMPhASIS trial in RRMS can be found on ClinicalTrials.gov under the identifier NCT03846219.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 3 Program of Vidofludimus Calcium in RMS (ENSURE-1 and ENSURE-2 Trials)</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, we announced U.S. Food and Drug Administration (&#8220;FDA&#8221;) clearance of our Investigational New Drug (&#8220;IND&#8221;) application for the Phase 3 ENSURE program of vidofludimus calcium in patients with RMS. The ENSURE program comprises two identical multicenter, randomized, double-blind Phase 3 clinical trials designed to evaluate the efficacy, safety, and tolerability of vidofludimus calcium versus placebo in RMS patients. Based on vidofludimus calcium&#8217;s highly significant activity in preventing lesion formation in our Phase 2 EMPhASIS trial in RMS, the strong and consistent correlation observed between lesion formation and clinical relapse in third-party clinical trials, and the drug&#8217;s robust safety profile, to date, we believe that this Phase 3 program should provide a straightforward path towards potential regulatory approval of vidofludimus calcium in RMS.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the identical twin Phase 3 clinical trials, titled ENSURE-1 and ENSURE-2, is expected to enroll approximately 1,050 adult patients with active RMS at more than 100 sites in more than 15 countries, including the United States, India and countries in Latin America, Central and Eastern Europe. Patients will be randomized in a double-blinded fashion to either 30 mg daily doses of vidofludimus calcium or placebo and the primary endpoint for both clinical trials is time to first relapse up to 72 weeks. Key secondary endpoints include volume of new T2-lesions, time to confirmed disability progression, time to sustained clinically relevant changes in cognition, and percentage of whole brain volume change. With regard to the disability progression endpoint, the ENSURE program will apply a pooled analysis of confirmed disability worsening across both clinical trials.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ENSURE trials are being run concurrently. The first patient in ENSURE-1 was enrolled in November 2021. The first patient in ENSURE-2 was enrolled in January 2022. An interim analysis to assess event rates is planned to occur after approximately half of the relapse events have occurred in the double-blind treatment periods. This analysis is intended to inform potential sample size adjustment and help ensure that final study readout is not planned to occur before sufficient events </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been achieved. This interim analysis will also allow for a non-binding futility analysis. We currently expect to report data from the interim analysis of the ENSURE program in late 2024 and to read-out the first of the ENSURE trials end of 2025.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further information regarding our ENSURE program in RMS can be found on ClinicalTrials.gov under the identifiers NCT05134441 (ENSURE-1) and NCT05201638 (ENSURE-2), respectively.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The execution of clinical Phase 3 clinical trials usually requires the use of a commercial formulation of the investigational drug manufactured at commercially usable quantities. Manufactures under contract with us have developed and produced a formulation of vidofludimus calcium which would allow commercially usable production batches. A Phase 1 bioequivalence study between the previous and the new formulation of vidofludimus calcium was completed and showed bioequivalence regarding drug exposure curve in blood plasma (area under the curve). A confirmatory relative bioavailability and food effect study demonstrated a high bioavailability of tablets as compared to a drinking solution and confirmed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finding of a complete and fast dissolution profile in human subjects. No food effect on the uptake or elimination of vidofludimus calcium after administration of the tablets was observed.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional investigations regarding metabolite characterization, metabolic modeling and potential drug-drug interactions, as well as other activities relating to clinical pharmacology are either ongoing or planned in anticipation for presentation to regulatory authorities.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discussions on a pediatric development plan in pediatric-onset MS have been initiated with the FDA , based on a proposal developed with clinical and regulatory advisors.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Phase 2 Clinical Trial of Vidofludimus Calcium in PMS (CALLIPER Trial) </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 1, 2021, we announced that the FDA also cleared our separate IND application for the supportive Phase 2 CALLIPER trial of vidofludimus calcium in patients with PMS. The first patient was enrolled in September 2021. Our current expectation is to report data from the interim analysis of the CALLIPER trial in the second half of 2023 and to read-out top-line data at the end of 2024.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The multicenter, randomized, double-blind, placebo-controlled Phase 2 CALLIPER trial of vidofludimus calcium is expected to enroll approximately 450 patients with PMS at more than 70 sites in North America, Western, Central and Eastern Europe with patients randomized to either 45 mg daily doses of vidofludimus calcium or placebo in a double-blinded fashion. The trial&#8217;s primary endpoint is the annualized rate of percent brain volume change up to 120 weeks. Key secondary endpoints include the annualized rate of change in whole brain atrophy and time to 24-week confirmed disability progression based on EDSS which may further support disability data from the ENSURE trials.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An interim analysis comprising an unblinded analysis of serum NfL </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and GFAP is planned to occur once approximately half of the enrolled patients have completed 24 weeks of treatment. NfL and GFAP have been shown in third-party research to consistently correlate with disease activity in neurodegenerative disorders and have become two of the most important serum biomarkers for axonal damage over the past few years. As previously reported, results of the Phase 2 EMPhASIS trial of vidofludimus calcium in RRMS showed a robust decrease in serum NfL at 24 weeks (-17.0% for 30 mg and -20.5% for 45 mg), as compared to baseline values, while the patients on placebo experienced a 6.5% increase in serum NfL over the same period.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Phase 2 CALLIPER trial is intended to run concurrently with and to complement the Phase 3 program in RMS. In particular, CALLIPER is focused on progressive forms of MS and is designed to corroborate vidofludimus calcium&#8217;s neuroprotective potential, as exemplified by slowing of brain atrophy and delay in disability worsening. Neurodegeneration is a key concern in both PMS and RMS, since axonal and neural damage is responsible for the increasing and often severe disability experienced by patients. We believe that, if the CALLIPER trial is successful in showing a beneficial effect of vidofludimus calcium, this data, along with the ENSURE program and vidofludimus calcium&#8217;s strong safety and tolerability profile, may allow for a meaningful clinical differentiation of vidofludimus calcium from other MS medications and potentially attractive commercial positioning. Although a supportive trial, we do not believe that data from the CALLIPER trial are a pre-condition for filing an NDA in RMS. Additional clinical studies and the potential regulatory path forward specific to the treatment of PMS will be informed by the results of the CALLIPER trial and will be further assessed accordingly.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further information regarding our CALLIPER trial in PMS can be found on ClinicalTrials.gov under the identifier NCT05054140.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Indication: Ulcerative Colitis</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 Clinical Trial of Vidofludimus Calcium in UC (CALDOSE-1 Trial)</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CALDOSE-1 trial of vidofludimus calcium in moderate-to-severe UC was a Phase 2b, dose-finding, multicenter, double-blind, placebo-controlled study including a blinded induction and maintenance phase, with double randomization (initial randomization for induction and second randomization for maintenance). CALDOSE-1 was conducted at more than 100 sites in 19 countries, including the United States and Western, Central and Eastern Europe. The primary endpoint comprised a composite of patient-reported outcome and endoscopy-assessed outcome, both evaluated following ten weeks of induction treatment with vidofludimus calcium or placebo. We have an active IND application for vidofludimus calcium in UC with the FDA.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 2, 2022, we reported top-line data from our Phase 2 CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe UC. The trial did not achieve the primary endpoint of clinical remission for the pooled 30 and 45 mg/day active dose groups of vidofludimus calcium versus placebo at week 10. In addition, no meaningful differences were observed between the three active dose groups for the overall intent-to-treat patient population (10 mg/day: 14.9%, 30 mg/day: 10.6%, 45 mg/day: 13.6%, placebo: 12.5%) or for the trial&#8217;s other secondary endpoints, including symptomatic remission, or endoscopic healing.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in this clinical trial was observed to be safe and well-tolerated. No new safety signals were observed. As compared to placebo, there were no increased rates of infections and infestations, no elevated rates of liver events or liver enzyme elevations, and no elevated rates for changes in hematology-related laboratory variables. The most common adverse events in this clinical trial were anemia (15/263 patients, 5.7%), headache (9/263 patients, 3.4%) and COVID-19 (7/263 patients, 2.7%). Most adverse events were generally mild in severity.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As is common for the design of clinical trials in UC, the use of oral systemic corticosteroids (&#8804;20 mg/day prednisolone equivalent) was allowed in CALDOSE-1 in patients who had been treated with corticosteroids for at least four weeks before randomization. Doses of corticosteroids were required to be kept constant throughout the induction phase (weaning was not allowed in this phase of the clinical trial), and the distribution of patients using corticosteroids was equal throughout all treatment groups. Surprisingly, CALDOSE-1 data suggest a previously unknown treatment interference between the efficacy of vidofludimus calcium and the concurrent use of corticosteroids in the UC patient population. More specifically, the non-steroid patient population showed an 11.4% advantage in clinical remission for vidofludimus calcium over placebo (pooled vidofludimus calcium treatment groups at week 10: 14.7%, placebo: 3.3%). Such a difference in clinical remission between active treatment and placebo would traditionally be considered as confirming therapeutic activity. In contrast, patients concomitantly taking vidofludimus calcium and corticosteroids during induction treatment had a lower rate of clinical remission at week 10 (11.5%) than placebo patients (20.6%) and also lower than the group of vidofludimus calcium monotherapy without concurrent use of steroids (14.7%). This treatment interference between vidofludimus calcium and corticosteroids was not expected based on our analysis of currently available preclinical or clinical data.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on these results, we announced that our development programs in the IBD indications will not be continued without a partner.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further information regarding our CALDOSE-1 trial in UC can be found on ClinicalTrials.gov under the identifier NCT03341962.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Indication: Crohn&#8217;s Disease</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on the results of the Phase 2 CALDOSE-1 trial in UC, we announced that our development programs in the IBD indications will not be continued without a partner.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Indication: Primary Sclerosing Cholangitis</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Phase 2 Clinical Trial of Vidofludimus Calcium in Primary Sclerosing Cholangitis</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We had previously entered into a collaboration with investigators at the Mayo Clinic to explore the use of vidofludimus calcium in Primary Sclerosing Cholangitis (&#8220;PSC&#8221;).  An investigator-sponsored proof-of-concept clinical trial of vidofludimus calcium in PSC, for which we provided the study medication, was conducted at the Mayo Clinic in Arizona and Minnesota, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">both of which are tertiary referral centers for PSC patients. The study was led by Elizabeth Carey, M.D., Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, who had received Investigator IND approval from the FDA and had been granted Institutional Review Board ("IRB") approval to conduct the study. The study was supported by a grant from the National Institutes of Health (&#8220;NIH&#8221;).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study planned to enroll 30 patients with PSC, aged 18 to 75 years, who received 30 mg of vidofludimus calcium once daily for a period of 24 weeks. Enrollment for the study took place between July 2019 and September 2020, but almost all enrollment occurred in 2019 and early 2020. During the COVID-19 pandemic, which began in early 2020, recruitment for this study was hampered, as patients with PSC are at a high risk of COVID-19 infections and were advised to avoid travel and unnecessary social contacts such as those required to participate in a clinical trial. Together with the investigators, we determined to readout data of the 18 patients who were enrolled prior to the COVID-19 pandemic. The ongoing pandemic situation also triggered the principal investigator&#8217;s decision to terminate the study in late 2020, before the intended recruitment goal of 30 patients was reached.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 18, 2021, we announced positive top-line data from the study which was designed to investigate vidofludimus calcium's potential to improve various biochemical parameters in PSC patients and help determine whether any such activity warrants further investigation randomized PSC trials. 18 of the targeted 30 patients were enrolled in the study (intent-to-treat population, &#8220;ITT&#8221;), of whom only 11 patients completed the full vidofludimus calcium treatment course and were evaluable over the 24-week treatment period (per-protocol population, &#8220;PP&#8221;).</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The primary objective of this study was to determine whether vidofludimus calcium reduces serum alkaline phosphatase (&#8220;ALP&#8221;) in adult patients diagnosed with PSC. The main analysis for the primary objective was whether patients could achieve a reduction of ALP at week 24 which is greater or equal to 25%, as compared to baseline, with an aspartate aminotransferase (&#8220;AST&#8221;) increase at week 24 of no more than 33%, as compared to baseline. This positive primary outcome was achieved by 3 of 11 patients in the PP population (27.3%, 95% CI: 6-61%). By virtue of inclusion criteria, patients at baseline had to have an elevated ALP value of at least 1.5 times the upper limit of normal. In addition, time from baseline was calculated as a continuous variable and treated as the primary predictor using a random intercept model which was adjusted for age at baseline and gender. For this longitudinal analysis of ALP from baseline to week 24 in the PP population, the ALP value statistically significantly (p=0.041) decreased by an average of 5.76 IU/L every 30 days (95% CI: -11.29, -0.23; statistical model). The time trend was not statistically significant in the ITT analysis (p=0.578) due to missing data following the high rate of treatment discontinuations during the COVID-19 pandemic. A consistent individual pattern of a stable decrease in ALP values was observed in the PP population between baseline and week 24, without any single patient showing an increase of more than 20% of ALP.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Secondary objectives were to investigate the liver biochemistry parameters, levels of AST and ALT, and total/direct/indirect bilirubin, as well as the concentrations of proinflammatory cytokines, as compared to baseline. The longitudinal analysis of both AST and ALT as well as total, direct and indirect bilirubin values showed a stable pattern in the PP population with no statistically significant change over time and the confidence interval to include the no-change scenario (AST: average 30 day change 1.22 IU/L, 95% CI: -0.53, 2.97, p=0.170; ALT: average 30 day change 0.85 IU/L, 95% CI -1.46, 3.15, p=0.467, total bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.02, p=0.561, direct bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.01, p=0.861, indirect bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.01, p=0.556). Similar results were found in the ITT population. In addition, a decrease in the Ulcerative Colitis Clinical Score was observed in evaluated patients, although the number of assessed patients was limited. The study also found that vidofludimus calcium is a safe and well-tolerated oral drug for PSC patients and treatment-emergent adverse events were rare and generally mild.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We decided not to continue the development of vidofludimus calcium in PSC.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further information regarding the investigator-sponsored PSC study can be found on ClinicalTrials.gov under the identifier NCT03722576.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Indication: COVID-19</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A publication from scientists in Wuhan, China (Xiong et al., 2020) had shown promising activity of DHODH inhibitors against SARS-CoV-2 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cellular studies. On April 21, 2020, we announced that vidofludimus calcium had successfully demonstrated preclinical activity against SARS-CoV-2. Specifically, vidofludimus calcium was observed to inhibit replication of clinical isolates of SARS-CoV-2 associated with COVID-19. In cellular assays, vidofludimus calcium demonstrated this antiviral activity at concentrations which are well below the blood concentrations associated with vidofludimus calcium dosing regimens studied in ongoing and previous clinical trials.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 Clinical Trial of Vidofludimus Calcium in Moderate COVID-19 (CALVID-1 Trial)</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CALVID-1 trial was a prospective, multicenter, randomized, placebo-controlled, double-blind clinical trial in hospitalized patients with moderate COVID-19, designed to evaluate efficacy, safety and tolerability of vidofludimus calcium. The aim of the CALVID-1 trial was to investigate vidofludimus calcium as an oral treatment option for COVID-19 and to support potential use of vidofludimus calcium as a treatment for current and potential future viral pandemic threats. Patients were enrolled at 20 sites in eleven countries, including the United States, Germany, and a range of other European countries. Patients were randomized to receive either 22.5 mg of vidofludimus calcium twice daily (45 mg/day), or placebo twice daily, for 14 consecutive days. Patients in both arms were also eligible to receive investigator&#8217;s choice of standard-of-care therapy throughout the duration of the study. Inclusion criteria called for hospitalized adult patients with a confirmed SARS-CoV-2 infection fulfilling clinical status category 3 or 4, as assessed with the nine-category ordinal scale proposed by the World Health Organization (&#8220;WHO&#8221;) COVID-19 Therapeutic Trial Synopsis, as well as certain additional clinical and laboratory criteria.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2021, we announced that vidofludimus calcium has shown evidence of clinical activity in hospitalized patients with moderate COVID-19. This planned main analysis of the CALVID-1 trial was based on data from 204 randomized patients and included top-line clinical efficacy, safety, disease marker, and virology data. Although the trial found very low rates of serious complications (e.g., mortality, rate of intensive care unit submissions and rate of invasive ventilations) in the population of hospitalized patients with moderate COVID-19, the data did show clinical activity of vidofludimus calcium based on multiple secondary endpoints, including clinically meaningful improvements in time to clinical recovery, time to clinical improvement, and disease markers. In addition, high-risk patients and patients over 65 years of age experienced a more substantial treatment effect of vidofludimus calcium. Vidofludimus calcium also prevented many COVID-19-related adverse events of higher severity. Finally, vidofludimus calcium was found to be safe and well-tolerated in this patient population.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full analysis of all 223 randomized patients supports the conclusions made for the main analysis. However, the full analysis also provided data on a few additional endpoints that were not assessed in the main analysis. The rate and timing of anti-SARS-CoV-2 antibodies patients are developing in response to the infection was found to be identical between the vidofludimus calcium and placebo treatment arms. We believe that this is an important confirmation of the mechanism of action of vidofludimus calcium that selectively targets highly metabolically activated cells involved in the disease process, but leaves antibody production relatively unaffected. Although no specific data are available at this point, we also believe that these data may support that vaccinations, including those for SARS-CoV-2, may be effectively given during vidofludimus calcium therapy. Many immunomodulatory therapies are known to interfere with vaccinations, however several studies with another DHODH inhibitor (teriflunomide) had shown that this is not the case for these class of drugs. The CALVID-1 SARS-CoV-2 antibody data are supportive of this finding as well. The full analysis was also able to detect a relationship between drug trough levels in blood plasma and the clinical recovery endpoint. Higher drug levels correlate with shorter clinical recovery periods. We believe that this is another important finding to provide evidence of clinical activity in moderate COVID-19 patients.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The results of the CALVID-1 trial have been published in the peer reviewed journal, Infectious Diseases and Therapy (Vehreschild et al., 2022). The paper, authored by the principal investigator of one of the clinical sites participating in the study, Prof. Maria Vehreschild, M.D., Head of Infectious Diseases at University Hospital Frankfurt, is entitled, &#8220;Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.&#8221;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further information regarding our CALVID-1 trial in COVID-19 can be found on ClinicalTrials.gov under the identifier NCT04379271.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CALVID-1 trial was able to highlight important differentiators of vidofludimus calcium as compared to existing medications in MS. Many other immunomodulatory drugs commercially used provide a beneficial effect on the disease but are also known to have a higher rate of virus reactivations as adverse drug reactions. For example, drugs approved for MS have shown the rare but clinically very important side effect of PML which is highly lethal and caused by a virus reactivation and infection of the brain tissue. Vidofludimus calcium has not shown an increased rate of infections and infestations, as compared to placebo, in the CALVID-1 trial. The same finding was already observed in other controlled clinical trials of vidofludimus calcium. We believe that both the underlying selectivity of DHODH inhibition on the immune system and the broad antiviral properties of vidofludimus calcium contribute to these findings.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the CALVID-1 trial also corroborate the broad antiviral activity of vidofludimus calcium, already known from previous </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing in a range of different virus families. We believe that these results support the ability of a host-cell directed antiviral mechanism of vidofludimus calcium to provide antiviral activities largely independent of mutational variants. We will continue to explore the broad antiviral properties of vidofludimus calcium, including testing its combination potential </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with other drugs in further </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preclinical studies. In other clinically important virus diseases, such as hepatitis or acquired immunodeficiency syndrome (&#8220;AIDS&#8221;), combination treatments are already the mainstay of therapy, whereas monotherapy was found to be inferior to such combinations. This additional research will enable us to explore the potential of vidofludimus calcium to target preparedness for potential future pandemics and for clinically important and underserved viral diseases.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investigator-Sponsored Phase 2 Trial of Vidofludimus Calcium in Combination with Oseltamivir in Moderate-to- Severe COVID-19 (IONIC Trial)</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, we announced enrollment of the first patients in an investigator-sponsored Phase 2 trial of vidofludimus calcium for the treatment of patients with moderate-to-severe COVID-19. On June 23, 2022, sponsor and lead site, University Hospitals Coventry and Warwickshire NHS Trust, London, United Kingdom, informed us that the IONIC trial is being closed down. Recruitment for the trial ended on May 20, 2022 and the last patient follow-up occurred in September 2022. On September 29, 2022, we were informed that the sponsor submitted the end of trial declaration. The trial was a prospective, randomized, parallel-group, open-label Phase 2b trial, designed to evaluate efficacy and safety of vidofludimus calcium in combination with the neuraminidase inhibitor, Oseltamivir (Tamiflu</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#9415;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), in approximately 120 adult patients with moderate to severe COVID-19.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further information regarding the IONIC trial in COVID-19 can be found on ClinicalTrials.gov under the identifier NCT04516915.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Vidofludimus Calcium Registration Plan</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All of our drug development candidates require approval from the FDA (for the United States), European Medicines Agency (&#8220;EMA&#8221;, for the European Union) and other national competent authorities (for any other territory) before they can be marketed for sale in the applicable jurisdiction. The activities required before drugs or biologics may be marketed in the United States include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">preclinical laboratory tests, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">vitro </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> preclinical studies and formulation and stability studies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">the submission to the FDA of an investigational new drug application for human clinical testing, which is known as an IND;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">adequate and well-controlled human clinical trials to demonstrate the safety and effectiveness of the drug;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practice (&#8220;cGMP&#8221;), requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the submission to the FDA of a new drug application, which is known as an NDA, for a drug; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">the approval by the FDA of an NDA.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA reviews all available data relating to safety, efficacy and quality and assesses the risk/benefit profile of a product candidate before granting approval. The data assessed by the FDA in reviewing an NDA includes preclinical testing data, including animal data, chemistry manufacturing and controls (&#8220;CMC&#8221;) data, PK, PD and drug-drug interaction data, and human clinical safety and efficacy data. Moreover, an agreement for a pediatric development plan (&#8220;PSP&#8221;) is required to be achieved with the FDA prior to NDA submission.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future human clinical testing and marketing outside the United States will be subject to foreign regulatory requirements. These requirements vary by jurisdiction, may differ from those in the United States and may require us to perform additional preclinical or clinical testing regardless of whether FDA approval has been obtained. The amount of time required to obtain necessary approvals from foreign regulatory agencies may be longer or shorter than that required for FDA approval. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ongoing Phase 3 program for vidofludimus calcium in RMS and an ongoing Phase 2 clinical trial for vidofludimus calcium in PMS. For our lead indication RMS, marketing approval would require completion of two successful, well-controlled Phase 3 clinical trials. Completing such clinical trials would require substantial financial and resource investments and may take several years to complete. In parallel, additional preclinical and clinical investigations need to be conducted in preparation for filing applications for regulatory approval, including additional pharmacological studies in special populations or drug-drug interaction studies. There are also additional steps required to develop and validate large-scale manufacturing capabilities as well as manufacturing controls.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Vidofludimus Calcium Manufacturing and Formulation</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vidofludimus calcium is provided as a white, uncoated immediate release tablet. Dose strengths for clinical trials are 5 mg, 15 mg, 22.5 mg, 30 mg and 45 mg, compared with placebo. The tablets are packaged in polyethylene bottles. Vidofludimus calcium has been synthesized in several batches of approximately 80 kg each of active pharmaceutical ingredient (&#8220;API&#8221;) and a drug product batch size of 500,000 tablets has been produced by manufacturers under contract with us. Our existing manufacturers have the capacity for manufacturing of up to several million units annually.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Vidofludimus Calcium Intellectual Property, Licenses and Royalties</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vidofludimus calcium is covered by several layers of patents and applications, all either granted or filed in the United States, the European Union and other territories. One layer of applications was filed to cover vidofludimus calcium&#8217;s active ingredient, the calcium salt of vidofludimus. These applications are granted in some jurisdictions and cover vidofludimus calcium until 2031, and U.S. Patent Term Extension (&#8220;PTE&#8221;) and/or European Supplementary Protection Certificates (&#8220;SPC&#8221;) could provide prolonged protection from generic entry up to 2036, depending on NDA submission time and IND filing in the United States and analogous filings in the European Union. Another layer consists of patent applications filed in early 2018 and directed to composition of matter of a newly-identified, specific polymorph of vidofludimus calcium and a related method of production of the clinical material for vidofludimus calcium, which is now the active ingredient of the currently used vidofludimus calcium formulation. This patent would offer exclusivity until 2039. In addition, a patent application covering the dosing scheme currently used with vidofludimus calcium was filed in 2017. This patent would cover all salt and free acid forms and offers the link between the expected label and respective patent claims. If issued, this patent could extend patent protection for vidofludimus calcium to 2038. Finally, an MS-specific patent application was filed in 2021 which would protect the dose strengths used for RMS and PMS until 2042. On top of the patent exclusivity, vidofludimus calcium as a new chemical entity will receive regulatory protection, which likely leads to five years plus a potential 30 months extension protection in the United States and eight plus two years protection in Europe. Further undisclosed patents dedicated to strengthen the exclusivity period for vidofludimus calcium and other forms of vidofludimus have been submitted or are planned to be submitted.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vidofludimus calcium and izumerogant were acquired in a transaction with 4SC in September 2016. We have subsequently submitted additional patent applications for independently developed intellectual property relating to each of vidofludimus calcium and izumerogant. On March 31, 2021, our German subsidiary, Immunic AG, and 4SC entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of a 4.4% royalty on net sales for $17.25 million. The payment was made 50% in cash and 50% in shares of our common stock.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Izumerogant (IMU-935): Targeting ROR&#947;t and Th17</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Izumerogant is a highly potent and selective inverse agonist of a transcription factor called ROR&#947;/ROR&#947;t. The nuclear receptor ROR&#947;t is believed to be the main driver for the differentiation of Th17 cells and the release of cytokines involved in various inflammatory and autoimmune diseases. The target ROR&#947;t (RORC) has three known main functions in T cells: (i) it is a key regulator of Th17 cell differentiation, (ii) it</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">is the crucial transcription factor for the genes encoding IL-17A and IL-17F, and (iii) it drives normal thymocyte maturation. We believe this target is an attractive potential alternative to approaches acting on IL-23, the IL-17 receptor and directly on IL-17.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Preclinical results confirm that izumerogant is a highly potent and selective inverse agonist of ROR&#947;t with an IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (the concentration of drug that inhibits 50% of the activity of the target) of around 24 nM in reporter assays and 20 nM in a microscale thermophoresis (&#8220;MST&#8221;) binding assay to the protein. The resulting effect of ROR&#947;t inhibition by izumerogant </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on IL-17A, IL-17F and IFN&#947; cytokine release from stimulated human lymphocytes is in the low single-digit nanomolar range, showing IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:1.4pt;vertical-align:baseline">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> levels of 5-6 nM. Furthermore, izumerogant potently inhibits Th17 differentiation and has demonstrated dose dependent activity in several cellular test systems and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in psoriasis/IL-17, graft versus host disease, experimental autoimmune encephalomyelitis (&#8220;EAE&#8221;) and IBD animal models.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">One of the potential risks of drugs targeting ROR&#947;t was identified in prior research suggesting that ROR&#947;t knockout or inhibition impacts Th17 differentiation, IL-17 transcription and thymocyte maturation to the same extent. More recent research published in Nature Immunology (He et al., 2017) suggests that these functions are differentially mediated by small structural changes of the ROR&#947;t protein impacting the interaction with co-factors and other proteins.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Preclinical experiments indicated that izumerogant leads to a potent inhibition of Th17 differentiation, inhibition of cytokine secretion, and induction of regulatory T cells. Importantly, izumerogant did not affect thymocyte maturation, one of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the important physiological functions that should be maintained. Based on these preclinical data and the selectivity of the effect maintaining important physiological functions while providing the desired anti-Th17 effect, we believe that izumerogant has potential to be a first-and-best-in-class therapy for various autoimmune diseases. Newly obtained data from acute and chronic treatment of mice corroborated in vivo that izumerogant is the first molecule observed to impact neither thymus size, thymocyte numbers, nor the maturation status of thymocytes, in contrast to two other known inhibitors of ROR&#947;t.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preclinical effect of targeting ROR&#947;t has been demonstrated in several preclinical experiments of competing ROR&#947;t modulators. Some molecules progressed to clinical stage. However, to our knowledge, izumerogant is currently the only product candidate in active clinical development.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IMU-935 recently received the proposed International Nonproprietary Name (&#8220;INN&#8221;), izumerogant, from the WHO.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Indication: Psoriasis</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diagnosis and Prevalence</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Psoriasis is a chronic inflammatory disease of the skin with unknown etiology that leads to hyperproliferation of keratinocytes and endothelial cells. Most mechanistic data support the hypothesis that psoriasis is an autoimmune disease driven by activated T-lymphocytes which then release cytokines, chemokines and pro-inflammatory molecules into the dermis and epidermis.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Psoriasis is characterized clinically by development of red, scaly, itchy, symmetrical, dry plaques typically located on skin overlying the elbows, knees, lumbar area and scalp. Plaques vary from a few millimeters in diameter to several centimeters and can be localized to a specific area or extend over most of the body surface.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:21.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Psoriasis is one of the most common chronic inflammatory skin diseases affecting 2% to 4% of the population in Western countries (Di Meglio et al., 2014; Armstrong et al., 2022). The prevalence rates are influenced by age, geographic location, and genetic background (Chandran and Raychaudhuri, 2010). Psoriasis is considered equally prevalent between genders and can occur at any age. However, there seems to be a bimodal distribution of the age of disease onset, with a first peak occurring during the teen years. Approximately 40% of patients first experience the disease before the age of 20, and approximately 10% of cases occur before the age of ten. A second peak has been reported in patients who are in their mid-50s (DRG, Psoriasis: Disease Landscape &amp; Forecast 2022).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Current Treatment Options</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current treatments for patients with psoriasis include topical therapies, oral therapies and biologics. Topical therapies, such as corticosteroids and vitamin D3 analogues, reduce inflammation, which slows the proliferation of keratinocytes and reduces itching. Oral therapies, such as methotrexate, cyclosporine, apremilast and deucravacitinib, target anti-inflammatory processes. Biologics block proteins produced by keratinocytes, dendritic cells, Th17 lymphocytes or other immune cells. Examples of biologics include anti-TNF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies, such as infliximab, etanercept and adalimumab. Monoclonal antibodies, such as secukinumab, ixekizumab and brodalumab, have been developed to target the pro-inflammatory cytokine IL-17. Anti-IL-23 agents, such as risankizumab, guselkumab and tildrakizumab, are further treatment options. Of note, therapies targeting the IL-17/IL-23 axis have largely revolutionized the treatment of patients with moderate to severe psoriasis as they have achieved highly successful skin clearance rates.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to develop izumerogant as an oral and more convenient treatment option for patients with moderate to severe psoriasis with a mechanism of action and efficacy that more broadly addresses the pathophysiology of psoriasis as compared to IL-17 antibodies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Indication: Castration-Resistant Prostate Cancer</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diagnosis and Prevalence</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Castration-resistant prostate cancer (&#8220;CRPC&#8221;) is a form of advanced prostate cancer and defined by disease progression despite androgen depletion therapy and may present as either a continuous rise in serum prostate-specific antigen (&#8220;PSA&#8221;) levels, the progression of pre-existing disease, and/or the appearance of new metastases (Saad et al., 2010). With an estimated almost 1.4 million new cases and 375,000 deaths worldwide, prostate cancer was the second most frequent cancer and the fifth leading cause of cancer death among men in 2020 (Sung H et al., 2021).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among patients whose prostate cancer is metastatic at the time of diagnosis, bone pain may be the leading symptom. Bone is the predominant site of disseminated prostate cancer, and pain is the most common manifestation of bone metastases. Other symptoms with metastatic disease may include hematuria, inability to void, incontinence, erectile dysfunction, weight loss, weakness or pain due to spinal cord compression, pain due to pathologic fractures, fatigue caused by anemia, or symptoms associated with chronic renal failure. Clinical signs associated with prostate cancer include an elevated PSA on laboratory testing and an abnormal prostate finding on digital rectal examination.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Current Treatment Options and Unmet Need</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While docetaxel is still considered a reference chemotherapy for patients with CRPC, cabazitaxel, abiraterone acetate and enzalutamide are commonly prescribed for the majority of patients with CRPC based on the ability to improve overall survival in men who progress after docetaxel. However, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and acquired resistance to these therapies seem to be inevitable, meaning that almost all show disease progression despite treatment with these agents (Chopra S and Rashid P, 2015). </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, we presented new preclinical data highlighting izumerogant's therapeutic potential in CRPC. Third-party studies have shown that ROR&#947; plays an important pro-tumor role by driving expression of the AR, leading to tumor growth. AR has been shown to be mutated in a constitutively active form called AR-V7 in 18% of untreated patients and up to 95% of patients treated with abiraterone acetate and enzalutamide. This mutation leads to resistance of AR-axis-targeted therapies and is associated with poor outcomes of progression free survival and overall survival for patients on AR-axis-targeted therapies (Sciarra et al., 2019). In preclinical studies, izumerogant was observed to inhibit the expression of mutated AR-V7, and the tumor growth of prostate cancer cell lines </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe izumerogant's potency in inhibiting tumorigenesis-promoting IL-17 and Th17 cells </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may result in further antitumoral activity in humans.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Current Development Plan and Clinical Studies</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are currently performing a Phase 1 clinical trial with izumerogant through our Australian subsidiary. We believe that this development approach could accelerate the program due to certain unique regulatory requirements and processes in Australia. In the third quarter of 2019, our Australian subsidiary received clearance from the Bellberry Human Research Ethics Committee in Australia to begin Phase 1 clinical trials of izumerogant under the Clinical Trial Notification scheme of the Australian Therapeutic Goods Administration.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 1 clinical trial of izumerogant is comprised of three parts:</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Part A: Single Ascending Dose Part</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first part of the Phase 1 clinical trial was a single ascending dose, double-blind, placebo-controlled study of izumerogant in healthy human subjects. This part was designed to evaluate the drug&#8217;s safety and PK profile and also included the evaluation of food effects.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, we announced that unblinded data from the single ascending dose part of the ongoing Phase 1 clinical trial of a new powder-in-capsule formulation of izumerogant, in which healthy human subjects were treated with 100 mg, 200 mg, 300 mg and 400 mg of this new formulation or placebo, found these single ascending daily doses of izumerogant to be safe and well-tolerated, and no maximum tolerated dose was reached. No serious adverse events occurred. A dose-proportional PK profile was observed across the investigated dose range.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Part B: Multiple Ascending Dose Part</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the single ascending dose part, we initiated a second portion of the Phase 1 clinical trial which was a multiple ascending dose, double-blind, placebo-controlled study in healthy human subjects with izumerogant given daily for 14 consecutive days. This part assessed the safety and PK properties of izumerogant.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, we also announced unblinded data from the multiple ascending dose part of the ongoing Phase 1 clinical trial, in which healthy human subjects were dosed for 14 days with 150 mg either once or twice daily doses of izumerogant or placebo, found these multiple ascending doses of izumerogant to be safe and well-tolerated, and no maximum tolerated dose was reached. Treatment emergent adverse events were generally mild in severity, with moderate treatment emergent adverse events reported in one of eleven izumerogant treated subjects, compared with one of four subjects on placebo. No serious adverse events were reported. No dose-dependent changes in laboratory values (including no effects on liver </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enzymes or in hematological parameters), vital signs or in electrocardiographic evaluations were found. PK analysis showed that stable steady-state plasma concentrations were achieved within the first week of dosing with an accumulation factor for izumerogant allowing predictable trough levels during daily dosing.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Part C: Psoriasis Patients</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of the favorable safety and tolerability data observed in healthy human subjects, we announced on October 27, 2021 that we have initiated part C of the ongoing Phase 1 clinical trial, where moderate-to-severe psoriasis patients are randomized to 28-day treatment with izumerogant or placebo. Assessments include safety, tolerability, PK and PD markers, as well as skin evaluations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2022, we announced the outcome of a pre-planned interim group-level data analysis of our Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis. The pre-planned interim analysis revealed that the group averages for PASI reductions in the two active arms did not separate from placebo at four weeks. Although the active arms performed in line with expectations, based on similarly designed trials, the trial experienced a greater decrease than expected in PASI in the placebo arm. Administration of izumerogant and placebo in this trial were demonstrated to be safe and well-tolerated, and no new safety signals were observed. We plan to provide further updates and guidance on potential next steps for this development program towards the end of the first quarter of 2023.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further information regarding our Phase 1 clinical trial can be found on anzctr.org.au under the registration number ACTRN12619001544167.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Phase 1 Clinical Trial of Izumerogant in mCRPC</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on strong preclinical results, we have initiated an open-label Phase 1 dose-escalation trial in mCRPC designed to evaluate the safety and tolerability of increasing doses of izumerogant to establish the maximum tolerated dose and the recommended phase 2 dose. The trial&#8217;s Principal Investigator is Johann Sebastian de Bono, MD, PhD, Regius Professor of Cancer Research and Professor in Experimental Cancer Medicine, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, London, United Kingdom. The trial was approved by the Medicines and Healthcare products Regulatory Agency ("MHRA"), the Research Ethics Committee ("REC") and the Health Research Authority ("HRA") in the United Kingdom. The first patient was enrolled in December 2021.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-planned dose escalation in the trial with dosing of up to 900 mg daily of izumerogant has been completed. Initial safety data available, to date, show a promising safety profile, with only benign adverse events and no dose limiting toxicities.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further information regarding Immunic&#8217;s Phase 1 clinical trial in mCRPC can be found on ClinicalTrials.gov under the identifier NCT05124795.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Izumerogant (IMU-935) Manufacturing and Formulation</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IM105935, the API of the izumerogant drug product, is a small molecule compound and is currently synthesized at up to 30 kg scale. Clinical trials are supplied with a powder-in-capsule formulation produced by manufacturers under contract with us.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Izumerogant (IMU-935) Intellectual Property, Licenses and Royalties</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022 the Company announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) for patent application 16/644581, entitled, &#8220;IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation&#8221;. The company also received notice of allowance of patent application EP18762111.5 in Europe, and notice of grant of patent application 2018330633 in Australia. All three patents cover composition of matter of izumerogant and related formulations, and are expected to provide protection into at least 2038, without accounting for potential PTE in the United States or SPC in Europe, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vidofludimus calcium and izumerogant were acquired in a transaction with 4SC in September 2016. We have subsequently submitted additional patent applications for independently developed intellectual property relating to each of vidofludimus calcium and izumerogant. On March 31, 2021, our German subsidiary, Immunic AG, and 4SC entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of a 4.4% royalty on net sales for $17.25 million. The payment was made 50% in cash and 50% in shares of our common stock.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">IMU-856: Targeting Intestinal Barrier Function</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMU-856 is an orally available small molecule modulator that targets a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. We have not yet disclosed the molecular target for IMU-856 to the public. Based on preclinical data, we believe this compound may represent a unique treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function and bowel wall architecture in patients suffering from gastrointestinal diseases such as celiac disease, IBD, IBS-D and other intestinal barrier function associated diseases. We believe that, because IMU-856 has been shown in preclinical investigations to avoid suppression of immune cells, it may therefore have the potential to maintain immune surveillance for patients during therapy, which would be an important advantage versus immunosuppressive medications.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bowel permeability is suspected to be involved in the initiation of many chronic inflammatory or autoimmune conditions, as the impaired intestinal barrier function may be one of the preconditions for antigens of the microbiome to be recognized by the body&#8217;s immune system. This is not only true for diseases of the bowel; the interaction of the immune system with components of the microbiome is suspected for many diseases throughout the body. To date, there are no good treatment strategies to ameliorate impaired bowel permeability.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Indication: Celiac Disease</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diagnosis and Prevalence</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Celiac disease is a multifactorial, complex autoimmune disease caused by an inappropriate immune reaction against a degradation product of gluten in genetically susceptible individuals. It is characterized by small intestinal epithelial injury, elevated intestinal permeability, and nutrient malabsorption. Celiac disease is estimated to affect 1 in 100 people, worldwide (Celiac Disease Foundation, 2022). In the United States, alone, it is estimated that 2.5 million people are undiagnosed and are, therefore, at risk for long-term health complications.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Celiac disease causes debilitating symptoms and serious medical complications. Many patients suffer from gastrointestinal symptoms such as diarrhea and have abnormal bowel epithelial lining (mucosal atrophy and crypt enlargement). Small bowel damage often leads to nutrient malabsorption that can result in a range of further clinical manifestations such as fatigue, anemia, osteopenia, weight loss, failure to thrive in children. In addition, extra-intestinal symptoms and systemic manifestations are often present, such as dermatitis, infertility, or neurological and skeletal disorders. Patients with persistent villous atrophy show an increased risk of lymphoproliferative malignancy. The intestinal epithelia barrier, physiologically impermeable to macromolecules such as gliadin, is recognized to play an important role in the pathogenesis of celiac disease.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Current Treatment Options</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is currently no known cure or treatment for celiac disease and patients must adhere to a strict, life-long gluten-free diet which can help manage symptoms and avoid disease flareups. However, a significant number of patients continue to experience disease activity and persistent symptoms despite a gluten-free diet as gluten is present in numerous food products, medications, household products and cosmetics as impurity. Thus, there is an increasing number of different treatment options in clinical development to reduce the burden of living with celiac disease and improve long-term health outcomes.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Current Development Plan and Clinical Studies </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current treatments of many conditions of the bowel are aimed at inhibiting inflammation, but they do not target the impaired bowel wall barrier function. IMU-856 is designed to target pathways impacting the bowel wall barrier function and is aimed to normalize such function. We believe that normalized bowel wall barrier function may avoid bacterial triggers, which may lead to the achievement and maintenance of remission without significantly influencing the immune competency of the patient.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently performing a Phase 1 clinical trial of IMU-856 through our Australian subsidiary. We believe that this development approach could accelerate the studies due to certain unique regulatory requirements and processes in Australia. The development activities for IMU-856 are intended to largely follow established processes and service provider relationships established for the izumerogant development program. This may lead to operational and financial synergies in study preparation </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and execution. In the third quarter of 2020, our Australian subsidiary received clearance from the Bellberry Human Research Ethics Committee in Australia to begin Phase 1 clinical trials of IMU-856 under the Clinical Trial Notification scheme of the Australian Therapeutic Goods Administration.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 1 clinical trial of IMU-856 is comprised of three parts:</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Part A: Single Ascending Dose Part</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first part of the Phase 1 clinical trial was a single ascending dose, double-blind, placebo-controlled study in healthy human subjects designed to assess safety, PD and PK properties of IMU-856. Healthy human subjects were randomized in a double-blinded manner to either placebo or active treatment with single ascending doses of IMU-856 at 10 mg, 20 mg, 40 mg, 80 mg, 120 mg and 160 mg. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2022, we announced unblinded safety, tolerability and PK results from the single ascending dose part of the Phase 1 clinical trial of IMU-856 in healthy human subjects. Single ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached. No serious adverse events occurred. Moreover, a dose-linear PK profile was observed across the investigated dose range.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Part B: Multiple Ascending Dose Part</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second portion of the Phase 1 clinical trial was a multiple ascending dose, double-blind, placebo-controlled study of IMU-856 in healthy human subjects. Healthy human subjects were dosed for 14 consecutive days with 40 mg, 80 mg or 160 mg once-daily of IMU-856 or placebo in a double-blinded manner. This part was designed to assess safety, PD and PK properties of IMU-856.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2022, we also announced unblinded results from the multiple ascending dose part of the ongoing Phase 1 clinical trial. Multiple ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached. Treatment emergent adverse events were mostly mild in severity. No Investigational Medicinal Product-related serious adverse events were reported. No dose-dependent changes in laboratory parameters (including no effects on liver enzymes or in hematological parameters), vital signs, physical examination or electrocardiographic evaluations were found. PK analysis showed a quick achievement of stable steady-state plasma concentrations within the first week and stable steady-state trough levels over the 14-day treatment period with a low accumulation factor for IMU-856, allowing predictable trough levels during daily dosing. PK parameters in steady-state revealed a Tmax (time to reach maximum plasma concentration) of 2 to 3 hours post-dose, a plasma half-life of 17.4 to 21.5 hours and dose proportional increases in Cmax (maximum plasma drug concentration) and AUC (area under the concentration-time curve).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Part C: Celiac Disease Patients</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2022, we announced the start of the patient cohorts in our ongoing Phase 1 clinical trial of IMU-856 in patients with celiac disease. Part C is structured as a 28-day, double-blind, placebo-controlled trial designed to assess the safety, tolerability, PK, PD and biomarker responses of IMU-856 in patients with celiac disease during periods of gluten-free diet and gluten challenge. Approximately 42 patients were planned to be enrolled in two consecutive cohorts with IMU-856 given once-daily over 28 days. Secondary objectives include PK and disease markers, including those evaluating gastrointestinal architecture and inflammation. Sites in Australia and New Zealand are participating in Part C. Initial results are expected to be available in mid-2023.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">IMU-856 Manufacturing and Formulation</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The API of the IMU-856 drug product is a small molecule compound and is currently synthesized at up to 8 kg scale. It is formulated as a tablet. Although the IMU-856 tablets are produced in different countries by manufacturers under contract with us, the final release for clinical trials is done by a vendor in Australia.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">IMU-856 Intellectual Property, Licenses and Royalties</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our rights to IMU-856 are secured pursuant to an option and license agreement (the &#8220;Daiichi Sankyo Option&#8221;) with Daiichi Sankyo Co., Ltd. (hereinafter, "Daiichi Sankyo") in Tokyo, Japan. On January 5, 2020, Immunic AG exercised its option under the Daiichi Sankyo Option to acquire the exclusive global rights to commercialize IMU-856. The license also grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856. Concurrent with the option exercise, Immunic AG paid to Daiichi Sankyo a one-time upfront licensing fee. Going forward, Daiichi Sankyo is eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, we announced that we have received a Notice of Allowance from the USPTO for patent application 16/646130, entitled, &#8220;Compound Having Cyclic Structure.&#8221; The patent covers composition-of-matter of IMU-856 and related pharmaceutical compositions and is expected to provide protection into at least 2038, without accounting for potential PTE.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Government Regulation - All Products</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), and its implementing regulations. All of Immunic&#8217;s drug development candidates require approval from the FDA (for the United States), EMA (for the European Union) and other national competent authorities (for any other territory) before they can be marketed for sale in the applicable jurisdiction. The activities required before drugs or biologics may be marketed in the United States include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">preclinical laboratory tests, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preclinical studies and formulation and stability studies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the submission to the FDA of an application for human clinical testing, which is known as an IND application;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">adequate and well-controlled human clinical trials to demonstrate the safety and effectiveness of the drug;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practice (&#8220;cGMP&#8221;), requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the submission to the FDA of an NDA for a drug; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the approval by the FDA of an NDA.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA reviews all available data relating to safety, efficacy and quality and assesses the risk/benefit profile of a product candidate before granting approval. The data assessed by the FDA in reviewing an NDA includes animal or preclinical testing data, chemistry, drug-drug interaction data, manufacturing controls data and clinical safety and efficacy data.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. Preclinical trials must also be conducted in accordance with FDA, EMA, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (&#8220;ICH&#8221;) and other  foreign authorities&#8217; legal requirements, regulations or guidelines, including Good Laboratory Practice (&#8220;GLP&#8221;), an international standard meant to harmonize the conduct and quality of non-clinical studies and the archiving and reporting of findings. Before human clinical testing can begin in the US, a sponsor must submit the results of the preclinical tests and, where applicable, human clinical data obtained in trials outside of the US, together with manufacturing information and analytical data, to the FDA as part of the IND, which is a request for authorization from the FDA to administer an IND product candidate to humans in clinical trials. An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding safety concerns before the clinical trial can begin. The FDA may impose a clinical hold at any time before or during clinical trials due to safety concerns about proposed or ongoing clinical trials or non-compliance with FDA requirements, and the trials may not commence or continue until the FDA notifies the sponsor that the hold has been lifted.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All clinical trials must be conducted under the supervision of one or more qualified investigators pursuant to protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection, inclusion/exclusion criteria and the safety and effectiveness criteria to be evaluated. The trial sponsor submits the protocol, as well as any subsequent protocol amendments, to the FDA as part of the IND. Sponsors must also provide all participating investigators and FDA safety reports of any serious and unexpected adverse events and any findings from laboratory tests in animals that suggest a significant risk for human subjects. For each institution where a clinical trial will be conducted, an IRB must review and approve the clinical trial protocol and informed consent form required to be provided to each trial subject or his or her legal representative prior to a clinical trial commencing, and conduct ongoing monitoring of the study until completed or termination to assure that appropriate steps are taken to protect the human subjects participating in the research.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase 1: In Phase 1 studies, the product candidate is initially introduced into healthy human subjects and tested for safety, dosage and tolerability, absorption, distribution, metabolism, excretion, and effect on the body.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase 2: Phase 2 studies are conducted in a limited patient population. These studies continue to evaluate safety while gathering preliminary data on effectiveness in patients with the targeted disease or condition, especially studying the potentially therapeutically effective dose.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase 3: Phase 3 trials further evaluate efficacy and safety in an expanded patient population, generally at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval studies, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval from the FDA. These studies are used to gather additional information about a product&#8217;s safety and/or efficacy in patients affected by the therapeutic indication. The FDA may require Phase 4 studies as a condition of approval of an NDA.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials must also be conducted in accordance with legal requirements, regulations or guidelines of the FDA and comparable foreign authorities, including human subject protection requirements and current good clinical practice (&#8220;cGCP&#8221; or &#8220;GCP&#8221;). In addition, clinical trials must be conducted using product candidates produced under cGMP requirements. The FDA or the sponsor may suspend a clinical trial at any time for various reasons, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB may suspend or terminate approval of a clinical trial at an institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts, known as a data safety monitoring board or committee, which monitors data from the trial to ensure patient safety and data integrity and may also make recommendations to alter or terminate a trial based on concerns for patient safety.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval for the commercial sale of any drug product, a sponsor must demonstrate in preclinical studies and well-controlled clinical trials that the product is safe and effective for its intended use and that the manufacturing facilities, processes and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity. The results of these preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information such as an agreed pediatric development plan (agreed &#8220;PSP&#8221;) are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees ($3,242,026 for 2023); under certain limited circumstances, a waiver of such fees may be obtained. After the submission of an NDA, but before approval of the NDA, the manufacturing facilities used to manufacture a product candidate must be inspected by the FDA to ensure compliance with the applicable cGMP requirements. The FDA may also inspect clinical trial sites and audit clinical study data to ensure that the sponsor&#8217;s studies were properly conducted in accordance with the IND regulations, human subject protection regulations, and cGCP.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the current Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines, the FDA goal for acting on the submission of an NDA for a new molecular entity is ten months from the date of &#8220;filing.&#8221; The FDA conducts a preliminary review of an NDA within 60 days after submission to determine whether it is sufficiently complete to permit substantive review, before accepting the NDA for filing. This two month preliminary review effectively extends the typical NDA review period to twelve months.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the FDA&#8217;s evaluation of an NDA, it will issue an approval letter or a complete response letter (&#8220;CRL&#8221;). An approval letter authorizes the sponsor to begin commercial marketing of the drug for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL describes the specific deficiencies in the NDA identified by the FDA. When possible, a CRL will recommend actions that the applicant might take, including providing additional clinical data, such as an additional Phase 3 clinical trial or other significant and time consuming requirements related to clinical trials, nonclinical studies or manufacturing, to place the application in condition for approval. If a CRL is issued, the sponsor must resubmit the NDA addressing all of the deficiencies identified in the letter, or withdraw the application. Even if the sponsor submits the recommended data and information, the FDA may decide that the resubmitted NDA does not satisfy the criteria for approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As condition to a product&#8217;s regulatory approval, the FDA may require a sponsor to conduct Phase 4 studies designed to further assess the drug&#8217;s safety and effectiveness after NDA approval, or may require other testing and surveillance programs to monitor the safety of the approved product. The FDA may also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) to assure the safe use of the drug. A REMS could include medication guides, communication plans to healthcare professionals or other activities to assure safe use, such as provider certification or training, restricted distribution methods, and patient registries.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $71.3 million and $61.1 million in research and development expenses in the years ended December 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our long-lived assets were located within both the United States and Germany in 2022 and 2021.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 23, 2023, we had 66 employees, nine of whom held M.D. degrees. Of the employees, 50 were engaged in research and development and 16 in administration. We consider our employee relations to be good.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We emphasize several measures and objectives in managing our human capital assets, including, among others, (i) employee safety and wellness, (ii) talent acquisition and retention, (iii) employee engagement, development and training, (iv) diversity and inclusion and (v) compensation. These targeted ideals may include annual bonuses, stock-based compensation awards, a 401(k) plan, healthcare, and insurance benefits, paid time-off, family leave, employee assistance programs. We also provide our employees with access to various innovative, flexible, and convenient health and wellness programs. We designed these programs to support employees&#8217; physical and mental health by providing tools and resources to improve or maintain their health status and encourage engagement in healthy behaviors.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information and Website</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to April 12, 2019, we were a clinical-stage biotherapeutic company known as Vital Therapies, Inc. that had historically been focused on the development of a cell-based therapy targeting the treatment of acute forms of liver failure. Vital Therapies, Inc. was originally incorporated in the State of California in May of 2003 as Vitagen Acquisition Corp., subsequently changed its name to Vital Therapies, Inc. in June 2003, and reincorporated in Delaware in January 2004. In April 2019, we completed an exchange transaction with Immunic AG pursuant to which holders of ordinary shares of Immunic AG exchanged all of their shares for shares of our common stock, resulting in Immunic AG becoming our wholly owned subsidiary. Following the exchange, we changed our name to Immunic, Inc. and we became a clinical-stage biopharmaceutical company focused on the development of selective oral therapies in immunology with the goal of becoming a leader in treatments for chronic inflammatory and autoimmune diseases.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located at 1200 Avenue of the Americas, Suite 200, New York, New York 10036. We also have an office at Lochhamer Schlag 21, 82166 Grafelfing, Germany. Our telephone number is (332) 255-9818. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a website at www.imux.com. The information contained on, or that can be accessed through, the website is not a part of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge through the investor relations page of our internet website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.</span></div><div><span><br/></span></div><div id="idff78559567c4173b665e875d419cf41_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. Before deciding to invest in our company or deciding to maintain or increase your investment, you should consider carefully the risks and uncertainties described below. The risks and uncertainties described below and in our other filings with the SEC are not the only risks we face. If one or more of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the market price for our common stock could decline, and you may lose your entire investment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risk Factor Summary</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of certain important factors that may make an investment in our Company speculative or risky. You should carefully consider the fuller risk factor disclosure set forth in this Annual Report, in addition to the other information herein, including the section of this report titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">The coronavirus pandemic has caused interruptions or delays of our business plan and may continue to have a significant adverse effect on our business. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Continued inflation and uncertainty in global economic conditions could negatively affect our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Our clinical trials have been delayed as a result of the ongoing military action by Russia in Ukraine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the continuation of this conflict could have further adverse effects on our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We have a limited operating history with our current business plan, have incurred significant losses since 2016, anticipate that we will continue to incur significant and increasing losses for the foreseeable future and may never achieve or maintain profitability. The absence of any commercial sales and our limited operating history make it difficult to assess our future viability.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We currently have no source of product sales revenue and may never earn product revenue or be profitable. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We will require substantial additional funding, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or future commercialization efforts.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">The marketing approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Clinical drug development involves a lengthy and expensive process with an uncertain outcome. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Clinical failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any product candidate we advance through clinical trials may not have favorable results in later clinical trials or receive marketing approval.  The effect of failure or results different than expectations can result in significant market value decline and possible negative financial results or asset related impairment.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Our product candidates may cause undesirable adverse effects or have other properties that could delay or prevent their marketing approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if obtained. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We are heavily dependent on the success of our product candidates, which are in the early stages of clinical development. We may not be able to  generate data for any of our product candidates sufficient to receive regulatory approval in our planned indications, which will be required before they can be commercialized. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Due to our limited resources and access to capital, we must decide to prioritize development of our current product candidates for certain indications and at certain doses. These decisions may prove to have been wrong and may materially adversely affect our business, financial condition, results of operations and prospects. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If we fail to attract and retain key management and scientific personnel,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">we may be unable to successfully develop or commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our product candidates. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Even if we obtain the required regulatory approvals in the United States and other territories, the commercial success of our product candidates will depend on market awareness and acceptance of our product candidates. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We currently have limited marketing and sales experience. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, if and when regulatory approval is received, we may be unable to generate any revenue. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If we fail to enter into strategic relationships or collaborations, our business, financial condition, commercialization prospects and results of operations may be materially adversely affected. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our products profitably.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully than, we do. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">The size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We may be unable to realize the potential benefits of any collaboration. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Our proprietary rights may not adequately protect our technologies and product candidates. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We may not be able to protect our intellectual property rights throughout the world. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Intellectual property rights do not protect against all potential threats to our competitive advantage. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We incur significant costs and demands upon management as a result of complying with the laws and regulations affecting public companies. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">The market price of our common stock has been and is expected to continue to be volatile.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We do not anticipate that we will pay any cash dividends in the foreseeable future. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Macroeconomic Risks</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The coronavirus pandemic has caused interruptions or delays of our business plan and may continue to have a significant adverse effect on our business. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 has had and continues to have a significant impact around the world.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to contain and mitigate the spread of COVID-19, many countries imposed unprecedented restrictions on travel, quarantines, vaccine mandates and other public health safety measures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although some of these restrictions have been loosened or lifted in the United States and other countries, new variants continue to emerge, new outbreaks are periodically reported and significant uncertainty and concern remain. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The extent to which the pandemic may continue to impact our business will depend on future developments, which are highly uncertain and cannot be predicted, but the development of clinical supply materials could be delayed and enrollment of patients in our ongoing studies may be delayed or suspended, if hospitals and clinics in areas where we are conducting trials have to shift resources to cope with the COVID-19 pandemic and may limit access or close clinical facilities due to the COVID-19 pandemic. Additionally, if our trial participants are unable to travel to our clinical study sites as a result of quarantines, vaccine mandates, travel bans or other restrictions resulting from the COVID-19 pandemic, we may experience higher discontinuation rates or delays in our clinical studies, as occurred in our investigator-sponsored trial of vidofludimus calcium in PSC that was conducted at the Mayo Clinic. Government-imposed quarantines and restrictions may also require us to temporarily terminate our clinical sites. Furthermore, if we determine that our trial participants may suffer from exposure to COVID-19 as a result of their participation in our clinical trials, we may voluntarily terminate certain clinical sites as a safety measure until we reasonably believe that the likelihood of exposure has subsided. As a result, our expected development timelines for our product candidates may be negatively impacted. We cannot predict the continuing impact of the COVID-19 pandemic, as consequences of such an event are highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts that have affected and may continue to affect our business, or our clinical studies in general. The COVID-19 pandemic has already adversely affected our operations and may further</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">materially disrupt or delay our business operations, further divert the attention and efforts of the medical community to coping with COVID-19, disrupt the marketplace in which we operate, and/or have continuing material adverse effects on our operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic could further disrupt our business and operations, interrupt our sources of supply, hamper our ability to raise additional funds or sell our securities, continue to slow down the overall economy or curtail consumer spending.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Continued inflation and uncertainty in global economic conditions could negatively affect our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse macroeconomic conditions, including inflation, slower growth or recession, higher interest rates, currency fluctuations, supply chain delays or shortages, high unemployment or personnel shortages could hurt our business. We have already seen a general increase in many of our costs as a result of inflation, although inflation has not yet had a material impact on our results of operations. However, the economies of Germany, the United States, Australia and other countries in which we do business have experienced high rates of inflation during 2022 and, if inflation were to continue for a prolonged period of time or the rate of inflation in our markets were to increase, or if a global recession were to occur, our expenses could increase substantially, resulting in increased losses from operations and net loss. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A downturn in the economic environment can also lead to limitations on our ability to obtain financing, reduced liquidity and declines in our stock price.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our clinical trials have been delayed as a result of the ongoing military action by Russia in Ukraine and the continuation of this conflict could have further adverse effects on our business.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Our clinical trials of vidofludimus calcium were originally planned to be conducted at more than</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">60 sites in Ukraine and Russia, but most had to be relocated to other countries because of the invasion of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ukraine by Russia in February 2022 and resulting sanctions imposed on Russia by the United States and other countries. These disruptions delayed our clinical development program, increased our costs and may disrupt future planned clinical development activities in these two countries. This military action has continued for more than a year and its future course and effects on our Company are highly unpredictable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently have 19 active sites in western Ukraine and the ongoing conflict could put the data associated with these patients in jeopardy as well as extend patient recruitment timelines. We anticipate that Ukraine will make up approximately 15%-20% of our ENSURE- 1 and ENSURE-2 phase 3 patient population.  In addition, no clinical sites in Russia have been activated or are intended to be used in the future.  Alternative sites to fully and timely compensate for our clinical trial activities in Ukraine may not continue to be available.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If our clinical trials are further interrupted, our clinical development program could experience further delays and increased costs and we may have insufficient data to support regulatory approvals of vidofludimus calcium, and any commercialization may be delayed or not approved, which could limit our potential revenue and hurt the competitive position of our potential products. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Financial Condition </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history with our current business plan, have incurred significant losses since 2016, anticipate that we will continue to incur significant and increasing losses for the foreseeable future and may never achieve or maintain profitability. The absence of any commercial sales and our limited operating history make it difficult to assess our future viability.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development-stage pharmaceutical company with a limited operating history with our current business plan. Our net losses were $120.4 million and $92.9 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $317.3 million and to date and have not generated any revenue from our current product candidates. Moreover, Immunic AG, the company&#8217;s operating subsidiary, has only a limited operating history upon which stockholders can evaluate our business and prospects, is not profitable and has incurred losses in each year since its inception in 2016. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biotechnology industry. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have devoted substantially all of our financial resources to identify, acquire and develop our product candidates, including providing general and administrative support for our operations. We expect our losses to increase as we continue to conduct clinical trials and continue to develop our lead product candidates. We expect to invest significant funds into the research and development of our current product candidates to determine the potential to advance these product candidates to seek regulatory approval. To date, we have financed our operations primarily through the sale of equity securities. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations or grants. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate significant revenue unless and until we are able to obtain marketing approval for, and successfully commercialize, any current or future product candidate. However pharmaceutical product development is an extremely costly and highly speculative undertaking and involves a substantial degree of risk. In addition, if we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive regulatory approval, and our ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors, and adequate market share for our product candidates. Even if we eventually obtain adequate market share for our product candidates, to the extent they receive regulatory and market approval, the potential markets for our product candidates may not be large enough for us to become profitable.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, and our expenses will increase substantially if and as we: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">continue the clinical development of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">continue efforts to discover, develop and/or acquire new product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">undertake the manufacturing of our product candidates for clinical development and, potentially, commercialization, or increase volumes manufactured by third parties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">advance our programs into larger, more expensive clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">initiate additional preclinical, clinical, or other trials or studies for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">seek regulatory and marketing approvals and reimbursement for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">experience any delays or encounter issues with the development and process for regulatory approval of our product candidates such as safety issues, clinical trial accrual delays, longer follow-up for planned studies, additional major studies or supportive studies necessary to support marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval and market for our self;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">make milestone, royalty or other payments under any third-party license agreements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">seek to maintain, protect and expand our intellectual property portfolio;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">seek to retain current skilled personnel and attract additional personnel; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">add operational, financial and management, and information systems personnel, including personnel to support our product development and commercialization efforts.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. Failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, expand our pipeline of product candidates or continue our operations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no source of product sales revenue and may never earn product revenue or be profitable. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated any revenues from commercial sales of any of our current product candidates. Our ability to generate product revenue depends upon our ability to successfully commercialize these product candidates or other product candidates that we may develop, in-license or acquire in the future. We do not anticipate generating revenue from the sale of products for the foreseeable future. Our ability to generate revenue from our current or future product candidates also depends on a number of additional factors, including our ability to: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">successfully complete research and clinical development of current and future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">establish and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">obtain regulatory approval from relevant regulatory authorities in jurisdictions where we intend to market our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">launch and commercialize any product candidates for which we obtain marketing approval, and if launched independently, successfully establish a sales force and marketing and distribution infrastructure;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">obtain coverage and adequate product reimbursement from insurance companies and other third-party payors, including government payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">achieve market acceptance for any approved products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">establish, maintain and protect our intellectual property rights; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">attract, hire and retain qualified personnel.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because of the numerous risks and uncertainties associated with clinical product development, including that our product candidates may not advance through development or achieve regulatory approval, we are unable to predict the timing or amount of any potential future product sale revenues. Our expenses also could increase beyond expectations if we decide to, or are required by the FDA or comparable foreign regulatory authorities to, perform studies or trials in addition to those that we currently anticipate. Even if we complete the development and regulatory processes described above, we anticipate incurring significant costs associated with launching and commercializing any product candidates that may be approved. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional funding, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or future commercialization efforts.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the inception of Immunic AG, substantially all of our resources have been dedicated to the clinical development of our product candidates. Developing pharmaceutical products, including conducting preclinical and non-clinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. We have consumed substantial amounts of cash since our inception. For example, in the years ended December 31, 2022 and December 31, 2021, we used net cash of $65.1 million and $83.8 million, respectively, in our operating activities, substantially all of which related to development of our current product candidates. We believe that we will continue to expend substantial resources for the foreseeable future toward the completion of clinical development and regulatory preparedness of our product candidates, preparations for a commercial launch of any approved product candidates, and development of any other current or future product candidates we may choose to further develop. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, seeking marketing approvals, and manufacturing and supply as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any drug development process is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any current or future product candidates that may be approved for marketing. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating plan may change as a result of factors currently unknown to us, and we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. Such financing may result in dilution to our stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may adversely affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2024. Our estimate as to how long we expect our existing cash and cash </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equivalents to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume cash and cash equivalents significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future capital requirements depend on many factors, including: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the scope, progress, results and costs of researching and developing our current product candidates, future product candidates and related preclinical and clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the cost of commercialization activities if our current product candidates and future product candidates are approved for sale, including marketing, sales and distribution costs and preparedness of our corporate infrastructure;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the cost of manufacturing current product candidates and future product candidates that we may obtain approval for and successfully commercialize;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the number and characteristics of any additional product candidates we may develop or acquire;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">any product liability or other lawsuits related to our products or otherwise commenced against us;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the expenses needed to attract and retain skilled personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs associated with being a public company;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property rights, including litigation costs and the outcome of any such litigation; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing, receipt and amount of sales of, or royalties on, any future approved products.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">preclinical studies, clinical trials or other development activities for our current product candidates or any future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our research and development activities; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our future product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic collaborations and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of such equity or convertible debt securities may include liquidation or other preferences that adversely affect the rights of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, acquire or license intellectual property rights, redeem stock or declare dividends, and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic collaborations and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Clinical Development and Marketing Approval of Our Product Candidates </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The marketing approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our current product candidates have gained marketing approval for sale in the United States or any other country, and we cannot guarantee that we will ever have marketable products. Our business is substantially dependent on our ability to complete the development of, obtain marketing approval for, and successfully commercialize, our product candidates in a timely manner. We cannot commercialize our product candidates in the United States without first obtaining approval from the FDA to market each product candidate. Similarly, we cannot commercialize our product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Our product candidates could fail to receive marketing approval for many reasons, including the following: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities may find the human subject protections for our clinical trials inadequate and place a clinical hold on (i) an investigational new drug (&#8220;IND&#8221;) application at the time of its submission, precluding commencement of any trials, or (ii) one or more clinical trials at any time during the conduct of such trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a new drug application &#8220;NDA&#8221;) to obtain marketing approval in the United States or elsewhere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities may find inadequate the manufacturing processes or facilities of manufacturers with which we contract for clinical and commercial supplies of our product candidates; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner that would delay marketing approval.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining approval of an NDA is a lengthy, expensive and uncertain process, and approval may not be obtained. We cannot be certain that any NDA submissions we may make will be accepted for filing and reviewed by the FDA, or ultimately be approved. If an application is not accepted for review, the FDA may require that we conduct additional clinical studies or preclinical testing, or take other actions before it will reconsider our application. If the FDA requires additional studies or data, we would incur increased costs and delays in the marketing approval process, which may require us to expend more resources than we have available. In addition, the FDA may not consider any additional information to be complete or sufficient to support the filing or approval of the NDA. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities outside of the United States, such as in Europe and Japan and in emerging markets, also have requirements for approval of drugs for commercial sale with which we must comply prior to marketing in those jurisdictions. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates into the relevant markets. Clinical trials conducted in one country may not be accepted or the results may not be found adequate by regulatory authorities in other countries, and obtaining regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. However, the failure to obtain regulatory approval in one jurisdiction could have a negative impact on our ability to obtain approval in a different jurisdiction. Approval processes vary among countries and can involve additional product candidate testing and validation and additional administrative review periods. Seeking foreign regulatory approval could require additional non-clinical studies or clinical trials, which could be costly and time-consuming. Foreign regulatory approval may be subject to all of the risks associated with obtaining FDA approval. For all of these reasons, we may not obtain foreign regulatory approvals on a timely basis, if at all. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process to develop, obtain marketing approval for, and commercialize product candidates both inside and outside of the United States is long, complex and costly, and approval is never guaranteed. The time required to obtain approval by the FDA and comparable foreign regulatory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary between jurisdictions. Even if our product candidates were to successfully obtain approval from regulatory authorities, any such approval might significantly limit the approved indications for use, including conditioning approval on the requirement of (i) more limited patient populations, (ii) precautions, warnings or contraindications on the product labeling, including &#8220;black box&#8221; warnings of serious risks, (iii) expensive and time-consuming post-approval clinical studies, risk evaluation and mitigation strategies ("REMS"), or surveillance, or (iv) limiting the claims that the product label may make, any of which may impede the successful commercialization of our product candidates. Following any approval for commercial sale of our product candidates, certain changes to the product, such as changes in manufacturing processes and additional labeling claims, as well as new safety information, may require costly new studies and will be subject to additional FDA notification, or review and approval. Also, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing approval for any of our product candidates may be withdrawn. If we are unable to obtain and maintain marketing approval for our product candidates in one or more jurisdictions, or any approval contains significant limitations, our ability to market our product candidates to our full target market will be reduced and our ability to realize the full market potential of our product candidates will be impaired. Furthermore, we may not be able to obtain sufficient funding or generate sufficient revenue and cash flows to continue or complete the development of any of our current or future product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process with an uncertain outcome. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. The FDA and comparable foreign regulatory authorities have substantial discretion when and if to grant approval to our product candidates. Even if we believe the data collected from clinical trials of our current product candidates are promising, such data may not be sufficient to support approval by the FDA or comparable foreign regulatory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorities. Our future clinical trial results also may not be successful. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is impossible to predict the extent to which the clinical trial process may be affected by existing or prospective legislative and regulatory developments. Due to these and other factors, our current or future product candidates could take significantly longer than expected to gain marketing approval, if at all. This could delay or eliminate any potential product revenue by delaying or terminating the potential commercialization of our current product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials are conducted at multiple sites, including some sites in countries outside the United States and the European Union, which may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of foreign and non-European Union contract research organizations ("CROs"), as well as expose us to risks associated with clinical investigators who are unknown to the FDA or European regulatory authorities, and with different standards of diagnosis, screening and medical care. Most of our clinical trials of vidofludimus calcium planned at sites in Ukraine and Russia had to be delayed, suspended or relocated because of the invasion of  Ukraine by Russia in February 2022, which caused disruptions to our clinical development program and increased our costs.   </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not completed all clinical trials required for the approval of any of our current product candidates. The commencement and completion of clinical trials for our current product candidates may be delayed, suspended or terminated as a result of many factors, including but not limited to: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the delay or refusal of regulators or institutional review boards (&#8220;IRBs&#8221;) at the medical institutions where the clinical trials are conducted. to authorize us to commence a clinical trial at a prospective trial site;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in regulatory requirements, policies and guidelines;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to reach agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in patient enrollment and variability in the number and types of patients available for clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the inability to enroll a sufficient number of patients in trials to ensure adequate statistical power to detect statistically significant treatment effects;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">lower than anticipated retention rates of patients and volunteers in clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">clinical sites deviating from trial protocols or dropping out of a trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">adding new clinical trial sites or relocating planned or existing clinical trial sites;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">negative or inconclusive results, which may require us to conduct additional preclinical or clinical trials or to abandon projects that we expect to be promising;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">safety or tolerability concerns, which could cause us to suspend or terminate a trial if we find that participants are exposed to unacceptable health risks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulators or IRBs requiring that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our third-party research and manufacturing contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">third-party researchers becoming debarred or otherwise penalized by the FDA or other regulatory authorities for violations of regulatory requirements, which could call into question data collected by such researcher and potentially affecting our ability rely on some or all of the data in support of our marketing applications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">difficulty in maintaining contact with patients after treatment, resulting in incomplete data;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in establishing the appropriate dosage levels;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the quality or stability of our current product candidates falling below acceptable standards;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the inability to produce or obtain sufficient quantities of our current product candidates to complete clinical trials; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">exceeding budgeted costs due to difficulty in accurately predicting the costs associated with clinical trials.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is a significant factor in the timing of clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, the design of the clinical trial, and competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are significant requirements imposed on us and on clinical investigators who conduct clinical trials that we sponsor. Although we are responsible for selecting qualified clinical investigators, providing them with the information they need to conduct the clinical trial properly, ensuring proper monitoring of the clinical trial, and ensuring that the clinical trial is conducted in accordance with the general investigational plan and protocols contained in the IND, we cannot ensure that clinical investigators will maintain compliance with all regulatory requirements at all times. The pharmaceutical industry has experienced cases where clinical investigators have been found to incorrectly record, omit, or even falsify data. We cannot ensure that the clinical investigators in our trials will not make mistakes or otherwise compromise the integrity or validity of data, any of which would have a significant negative effect on our ability to obtain marketing approval, our business, and our financial condition. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could encounter delays if a clinical trial is suspended or terminated by us, the IRBs or ethics committees of the institutions in which such trial is being conducted, the independent steering committee, the data safety monitoring board for such trial, or the FDA or comparable foreign regulatory authorities. We or such authorities may impose a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, safety issues or adverse side effects, failure to demonstrate a benefit from using the drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Delay or termination of clinical trials of our current product candidates will harm their commercial prospects and impair our ability to potentially generate revenues from such product candidates. In addition, any delays in completion of our clinical trials will increase our costs, slow our development and approval process and jeopardize our ability to commence product sales and generate revenues. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, clinical investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. We are required to report certain financial relationships with clinical investigators to the FDA and, where applicable, take steps to minimize the potential for bias resulting from such financial relationships. The FDA may evaluate the reported information and conclude that a financial relationship between us and a clinical investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. The FDA may refuse to accept our marketing applications, and other delays or even denial of marketing approval could result.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical testing or clinical trials of any development candidate may also show new and unexpected findings regarding safety and tolerability. Such findings may harm the ability to conduct further development of product candidates, delay such development, require additional expensive tests, harm our ability to partner these development candidates, or delay or prevent marketing approval by regulatory agencies. Such findings may also harm the ability to compete in the market with other products or to achieve certain pricing thresholds. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these occurrences could materially adversely affect our business, financial condition, results of operations, and prospects. In addition, many of the factors that could cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval of our product candidates. Significant clinical trial delays could also allow our competitors to bring products to market before we can, shorten any periods during which we may have the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exclusive right to commercialize any approved product candidates, and impair our ability to commercialize any approved product candidates, which may harm our business, financial condition, results of operations and prospects. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of patient-reported outcomes in our clinical trials may delay the development of our product candidates or increase development costs. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In recent years, due to regulatory changes, patient-reported outcomes ("PROs"), may have an important role in the development and regulatory approval of any of our product candidates. PROs involve patients&#8217; subjective assessments of efficacy, and this subjectivity increases the uncertainty in determining achievement of clinical endpoints. Such assessments can be influenced by factors outside of our control, and can vary widely from day-to-day for a particular patient, and from patient-to-patient and site-to-site within a clinical trial. Use of PROs may make the outcome of trials more uncertain and may increase our costs and time to finish regulatory approval trials.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any product candidate we advance through clinical trials may not have favorable results in later clinical trials or receive marketing approval. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical failure can occur at any stage of clinical development. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of pharmaceutical companies have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical or preclinical testing. For example, we announced in October 2022 the analysis of interim group-level data of our Phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis did not separate from placebo. Following this announcement, our stock price declined significantly, which caused us to record a full impairment of our goodwill in the quarter ended December 31, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data obtained from trials are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent marketing approval of our product candidates. In addition, the design of a clinical trial can determine whether its results will support approval of a product, or approval of a product for desired indications, and flaws or shortcomings in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to properly design and execute a clinical trial to support marketing approval for our desired indications. Further, clinical trials of product candidates often reveal that it is not practical or feasible to continue development efforts. If one of our product candidates is found to be unsafe or lack efficacy, we will not be able to obtain marketing approval for such product candidate and our business would be harmed. If the results of our clinical trials of our product candidates do not achieve pre-specified endpoints, we are unable to provide primary or secondary endpoint measurements deemed acceptable by the FDA or comparable foreign regulators, or we are unable to demonstrate an acceptable level of safety relative to the efficacy associated with our proposed indications, the prospects for approval of our product candidates would be materially and adversely affected.  For example, we announced in June 2022 that a phase 2 clinical trial of our most advanced drug candidate, vidofludimus calcium, did not achieve its primary endpoint in patients with moderate-to-severe ulcerative colitis. As a result, we do not plan any further drug development activities in ulcerative colitis without a partner.  A number of companies in the pharmaceutical industry, including those with greater resources and experience than we, have suffered significant setbacks in Phase 2 and Phase 3 clinical trials, even after seeing promising results in earlier clinical trials. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including differences in trial protocols and design, the size and type of the patient population, adherence to the dosing regimen and the rate of dropout among clinical trial participants. We do not know whether any clinical trials we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may conduct will demonstrate consistent and/or adequate efficacy and safety to obtain marketing approval for our product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable adverse effects or have other properties that could delay or prevent their marketing approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if obtained. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive &#8220;approved use&#8221; label or the delay or denial of marketing approval by the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA or other comparable foreign regulatory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorities. If any of our current or future product candidates is associated with serious adverse, undesirable or unacceptable side effects, we may need to abandon such candidate&#8217;s development or limit development to certain uses or sub-populations in which such side effects are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many drug candidates that initially showed promise in early-stage or clinical testing have later been found to cause side effects that prevented their further development. Results of our trials could reveal a high and unacceptable prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Drug-related side effects could also adversely affect patient recruitment or the ability of enrolled patients to complete the trial, or could result in potential product liability claims. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates receive marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory authorities may withdraw approvals of such products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be required to recall a product or change the way such product is administered to patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing process for the product or any component thereof;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory authorities may require the addition of labeling statements, such as a precaution, &#8220;black box&#8221; warning of serious risks or other warnings or a contraindication;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we or our collaborators may be required to implement a REMS or create a medication guide outlining the risks of such side effect for distribution to patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we or our collaborators could be sued and held liable for harm caused to patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the product may become less competitive and revenues could decline substantially; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our reputation would suffer.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of any approved product candidates, and could materially adversely affect our business, financial condition, results of operations and prospects. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are heavily dependent on the success of our product candidates, most of which are in the early stages of clinical development. We may not be able to generate data for any product candidates sufficient to receive regulatory approval in its planned indications, which will be required before it can be commercialized. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested substantially all of our efforts and financial resources to identify, acquire and develop our portfolio of product candidates. Our future success is dependent on our ability to successfully further develop, obtain regulatory approval for, and commercialize one or more product candidates. We currently generate no revenue from sales of any products, and we may never be able to develop or commercialize a product candidate. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our most advanced product candidate, vidofludimus calcium, had the first patient enrolled in a Phase 3 program for relapsing multiple sclerosis (&#8220;RMS&#8221;) in November 2021 and we do not expect the readout of topline data from this trial until the end of 2025.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. We cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may use our limited financial and operational resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and operational</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources, we may forego or delay pursuit of opportunities in some programs, product candidates or indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or more profitable market opportunities. Our spending on current and future research and development programs and future product candidates for specific indications may not yield any commercially viable products. We may also enter into strategic collaboration agreements to develop and commercialize some of our programs and potential product candidates in indications with potentially large commercial markets. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not accurately evaluate and predict the commercial potential or target market for a particular product candidate, we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may (i) relinquish valuable rights to that product candidate through strategic collaborations, licensing or other royalty arrangements when it would have been more advantageous to retain sole development and commercialization rights to such product candidate, or (ii) allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaborative arrangement. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being studied. Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying sufficient numbers of eligible patients to participate in clinical trials of our product candidates is essential to our success. The timing of our clinical trials depends in part on the rate at which we can recruit eligible patients to participate in clinical trials of our product candidates, and we may experience delays in our clinical trials if we encounter difficulties in enrollment. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The specific eligibility criteria of our planned clinical trials may further limit the population of available eligible trial participants. We may not be able to identify, recruit, and enroll a sufficient number of eligible patients to initiate or complete our clinical trials in a timely manner because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical trials, and the willingness of physicians to participate in our planned clinical trials. If patients are unwilling to participate in our clinical trials for any reason, the timeline for conducting trials and obtaining regulatory approval of our product candidates may be delayed. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in the completion of, or experiences termination of, any clinical trials of our product candidates, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from product candidates could be delayed or impaired. We have recently experienced delays in our planned clinical trials of vidofludimus calcium at sites in Ukraine and Russia because of the invasion of Ukraine by Russia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delays we may encounter in initiating or completing clinical trials would likely increase our overall costs, impair product candidate development and impair our ability to obtain regulatory approval. Any of these occurrences may harm our business, financial condition, and prospects significantly. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive marketing approval for any of our product candidates, such approved products will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, any approved product candidates could be subject to labeling and other restrictions, and we may be subject to penalties and legal sanctions if we fail to comply with regulatory requirements or experience unanticipated problems with any of our approved products. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, packaging, distribution, adverse event reporting, storage, labeling, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP regulations and GCP for any clinical trials that we conduct post-approval. Any marketing approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or subject to conditions of approval, or contain requirements for potentially costly post-approval studies, including Phase 4 clinical trials, and surveillance to monitor safety and efficacy. The FDA may also require us to implement a Risk Evaluation and Mitigation Strategy drug safety program as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Later discovery of previously unknown problems with an approved product, including adverse events of unanticipated severity or frequency, or problems with manufacturing operations or processes, or failure to comply with regulatory requirements, or evidence of acts that raise questions about the integrity of data supporting the product approval, may result in, among other things: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">fines, warning letters, untitled letters, or holds on clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">product seizure or detention, or refusal to permit the import or export of products; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">injunctions or the imposition of civil or criminal penalties.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval, manufacturing or commercialization of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or other jurisdictions. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or not able to maintain regulatory compliance, we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event described above may limit our ability to commercialize any approved product candidates and harm our business, financial condition, and prospects significantly.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain regulatory approval in jurisdictions outside the United States, we will not be able to market our products in those jurisdictions. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to market any approved product candidates in international markets, either ourselves or in conjunction with collaborators. Such marketing will require separate regulatory approvals in each market and compliance with numerous and varying regulatory requirements. The approval procedures vary from country to country and may require testing in addition to what is required for a marketing application in the United States. Moreover, the time required to obtain approval in other countries may be different than in the United States. In addition, in many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval in another jurisdiction. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval and additional or different risks. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in some or all of the international markets in which we intend to market any approved product candidates, which would significantly harm our business, results of operations and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agencies like the FDA and national competition regulators in European countries strictly regulate the marketing and promotion of drugs. If we are found to have improperly promoted any of our product candidates for uses beyond those that are approved, we may become subject to significant liability. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities like the FDA and national competition laws in Europe strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA or comparable foreign regulatory authorities as reflected in the product&#8217;s approved labeling, known as &#8220;off-label&#8221; use, nor may a product be promoted prior to marketing approval. If we receive marketing approval for a product candidate for its proposed indication(s), physicians may nevertheless prescribe the product for their patients in a manner that is inconsistent with the approved label if the physicians personally believe in their professional medical judgment it could be used in such manner. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such off-label uses. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA requires that promotional claims not be &#8220;false or misleading&#8221; as such terms are interpreted by the FDA. For example, the FDA requires substantial evidence, which generally consists of two adequate and well-controlled head-to-head clinical trials, for a company to make a claim that its product is superior to another product in terms of safety or effectiveness. Generally, unless we perform clinical trials meeting that standard comparing our product candidates to competing products and these claims are approved for our product labeling, we will not be able promote our product candidates as superior to competing products. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to have improperly promoted our product, including for an off-label use, we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may become subject to significant liability. Numerous drug manufacturers have been the subject of investigations related to off-label promotion resulting in multi-billion dollar settlements, consent decrees, and on-going monitoring under corporate integrity agreements or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deferred prosecution agreements. In addition, the FDA could also seek permanent injunctions under which specified promotional conduct is monitored, changed or curtailed. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current and future relationships with healthcare professionals, investigators, consultants, collaborators, actual customers, potential customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to sanctions. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which we may obtain marketing approval. Our current and future arrangements with healthcare professionals, investigators, consultants, collaborators, actual customers, potential customers and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act ("FCA"), which may constrain the business or financial arrangements and relationships through which we sell, market and distribute any drug candidates for which we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtain marketing approval. In addition, we may be subject to physician payment transparency laws and patient privacy and security regulation by the federal government and by the U.S. states and foreign jurisdictions in which we conduct business. The applicable federal, state and foreign healthcare laws that may affect our ability to operate include the following: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">The federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal and state healthcare programs such as Medicare and Medicaid. Remuneration has been interpreted broadly to include anything of value. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and those activities may be subject to scrutiny or penalty if they do not qualify for an exemption or safe harbor. A conviction for violation of the Anti-Kickback Statute results in mandatory exclusion from participation in federal healthcare programs. This statute has been applied to arrangements between pharmaceutical manufacturers and those in a position to purchase products or refer others including prescribers, patients, purchasers and formulary managers. In addition, the Affordable Care Act amended the Social Security Act to provide that the U.S. government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute also</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act, the penalties for which are described below. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or for making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties (tied to inflation) of $12,537 to $25,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(after May 9, 2022) per false claim or statement.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA") imposes criminal and civil penalties for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations impose obligations on covered entities, including healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The federal Open Payments program, created under the Physician Payment Sunshine Act, also known as Section 6002 of the Patient Protection and Affordable Care Act (the &#8220;Affordable Care Act&#8221;), and its implementing regulations, impose annual reporting requirements for certain manufacturers of drugs, devices, biologicals and medical supplies for payments and &#8220;transfers of value&#8221; provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. The SUPPORT for Patients and Communities Act expanded the scope of reporting such that companies must also report payments and transfers of value provided to other types of healthcare professionals. Failure to submit timely, accurately and completely the required information for all covered payments, transfers of value and ownership or investment interests may result in civil monetary penalties.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">There are many analogous state and foreign laws, such as: state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal statutes governing healthcare fraud. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our future business arrangements with third parties comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which could significantly harm our business. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including current and any future collaborators, are found not to be in compliance with applicable laws, those persons or entities may be subject to criminal, civil or administrative sanctions, including exclusion from participation in government healthcare programs, which could also negatively affect our business. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as import and export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties and other remedial measures, and incur legal expenses, which could adversely affect our business, financial condition, results of operations, stock price and prospects. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act ("FCPA"), and other anti-corruption laws that apply in countries where we do, or may in the future do, business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We also may participate in collaborations and relationships with third parties whose actions, if non-compliant, could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing or future laws might be administered or interpreted. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States and authorities in the European Union, including applicable import and export control regulations, economic sanctions on countries and persons, anti-money laundering laws, customs requirements and currency exchange regulations, collectively referred to as trade control laws. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be effective in ensuring our compliance with all applicable anti-corruption laws or other legal requirements, including trade control laws. If we are not in compliance with applicable anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and incur substantial legal expenses, which could have an adverse impact on our business, financial condition, results of operations, stock price and prospects. Likewise, any investigation of any potential violations of these anti-corruption laws or trade control laws by U.S. or other authorities could also have an adverse impact on our reputation, business, financial condition, results of operations, stock price and prospects. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The impact on us of recent and future healthcare reform legislation and other changes in the healthcare industry and healthcare spending is currently unknown, and may adversely affect our business model. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, legislative and regulatory changes and proposed changes regarding the healthcare system could prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any drug candidates for which we obtain marketing approval. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and other jurisdictions. We operate in a highly regulated industry and new laws, regulations, judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery of, or payment for, healthcare products and services could negatively impact our business, financial condition, results of operations and prospects. There continues to be significant interest in promoting healthcare reform, as evidenced by the enactment in the United States of the Affordable Care Act and efforts to repeal, invalidate or modify portions of the act. Among other things, the Affordable Care Act contains provisions that may reduce the profitability of drug products, including, for example, revising the methodology by which rebates owed by manufacturers for covered outpatient drugs under the Medicaid Drug Rebate Program are calculated, extending Medicaid rebates to individuals enrolled in Medicaid managed care plans, imposing mandatory discounts for certain Medicare Part D beneficiaries who fall into a coverage gap, and subjecting drug manufacturers to payment of an annual fee based on its market share of prior year total sales of branded programs to certain federal healthcare programs. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been judicial and congressional challenges to the Affordable Care Act, some of which have been successful, as well as efforts to repeal or replace certain aspects of the Affordable Care Act. If a new law is enacted, or if the Affordable Care Act is overturned, repealed or modified, in whole or in part, by judicial or legislative action, many if not all of the provisions of the Affordable Care Act may no longer apply to prescription drugs. While we are unable to predict what changes may ultimately be enacted, to the extent that future changes affect how any future prescription drug products are paid for and reimbursed by government and private payors, our business could be adversely impacted. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. On August 2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of 2% per fiscal year, which started in April 2013, and, due to subsequent legislative amendments, will remain in effect through 2027 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, also reduced Medicare payments to several categories of healthcare providers. The Biden administration and Congress may announce initiatives intended to result in lower drug prices. We are not in a position to know at this time whether such initiatives will become law or what impact they may potentially have on our business. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional healthcare reform measures and drug pricing regulations that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the revenue that we may potentially receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue or commercialize our drug candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is likely that federal and state legislatures within the United States and foreign governments will continue to consider changes to existing healthcare legislation. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the demand for any drug products for which we may obtain marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to set a price for our products that we believe is fair;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain coverage and reimbursement approval for a product approved for marketing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to generate revenues and achieve or maintain profitability; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the level of taxes that we are required to pay.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial condition or results of operations. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities and the activities of our contract manufacturers and suppliers involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at facilities of ours and our manufacturers, pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, or the risk of environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our contract manufacturers and suppliers for handling and disposing of these materials generally comply with the current standards prescribed by applicable laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In the event of contamination of injury, we may be held liable for any resulting damages, which could exceed our resources or result in government-imposed restrictions on our use of specified materials or interruptions of our business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have generally tended to become more stringent over time. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Risks Related to Our Business </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to our limited resources and access to capital, we must decide to prioritize development of our current product candidates for certain indications and at certain doses. These decisions may prove to have been wrong and may materially adversely affect our business, financial condition, results of operations and prospects. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited resources and access to capital to fund our operations, we must decide which dosages and indications to pursue for the clinical development of our current product candidates and the amount of resources to allocate to each. Our decisions concerning the allocation of research, collaboration, management and financial resources toward dosages or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. If we make incorrect determinations regarding the market potential of our current product candidates or if we misread trends in the pharmaceutical industry, our business, financial condition, results of operations and prospects could be materially adversely affected. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to win contracts or grants from governments, academic institutions or non-profits. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may apply for contracts or grants from government agencies, non-profit entities and academic institutions. Such contracts or grants can be highly attractive because they provide capital to fund the ongoing development of our product candidates without diluting our stockholders. However, there is often significant competition for these contracts or grants. Entities offering contracts or grants may have requirements to apply for, or to otherwise be eligible for, certain contracts or grants that our competitors may be able to satisfy that we cannot satisfy. In addition, such entities may make arbitrary decisions as to whether to offer contracts or make grants, to whom the contracts or grants may or will be awarded and the conditions and size of the contracts or grants to each awardee. Even if we are able to satisfy the award requirements, we may not be able to win any contracts or grants in a timely manner, if at all. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we enter into contracts with or receives grants from government agencies, non-profit entities or academic institutions, we may lose such contracts or grants due to failure to comply with applicable terms, limitations, or government regulations. As a result, our business, results of operations, financial condition and prospects could be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract and retain key management and scientific personnel, we may be unable to successfully develop or commercialize our product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success as a biotechnology company depends on our continued ability to attract, retain and motivate highly qualified management and scientific and clinical personnel. The loss of the services of any such personnel could delay or prevent obtaining marketing approval or commercialization of our product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may not be able to attract or retain qualified management and scientific personnel in the future due to the intense competition for a limited number of qualified personnel among biotechnology, pharmaceutical and other companies. Our failure to attract, hire, integrate and retain qualified personnel could impair our ability to achieve our business objectives. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of applicable insurance coverage, we could be forced to pay substantial damage awards. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of any of our product candidates in clinical trials and the sale of any approved products may expose us to product liability claims. We currently maintain a limited amount of product liability insurance. We intend to monitor the amount of coverage we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintain as the size and design of our clinical trials evolve and seek to adjust the amount of coverage we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintain accordingly. However, we may not maintain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance coverage that adequately protects us against some or all of the claims to which we might become subject. We might not be able to maintain adequate insurance coverage at a reasonable cost or in sufficient amounts or scope to protect us</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">against potential losses. In the event a claim is brought against us, we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">might be required to pay legal and other expenses to defend the claim, as well as uncovered damages awards resulting from a claim brought against us. Furthermore, whether or not we are ultimately successful in defending any such claims, we might be required to divert substantial financial and managerial resources to such defense, and adverse publicity could result, all of which could harm our business. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could have liability if our employees, independent contractors, investigators, CROs, consultants, collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees and other parties with which we do business may engage in fraudulent conduct or other illegal activity. Misconduct by employees and other parties could include intentional, reckless and/or negligent conduct or violation of FDA regulations and laws that require reporting true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare fraud and abuse laws and regulations, or laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commissions, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee and other third-party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate. Even if we are ultimately successful in defending any such actions, we could be required to divert financial and managerial resources to such action and adverse publicity could result, all of which could harm our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have approximately 66 employees. As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales, marketing, financial, legal and other resources. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing our growth. As we advance our product candidates through clinical trials, we will need to expand our development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities. As our operations expand, we expect that we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will need to manage additional relationships with such third parties, as well as additional collaborators and suppliers. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure and internal controls, operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of our development collaborators, third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our internal computer systems and those of our current and any future strategic collaborators, vendors, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, cybersecurity threats, war and telecommunication and electrical failures. We may experience cyber-attacks on our information technology systems by threat actors of all types (including but not limited to nation states, organized crime, other criminal enterprises, individual actors and/or advanced persistent threat groups). In addition, we may experience intrusions on our physical premises by any of these threat actors. If any such cyber-attack or physical intrusion were to cause interruptions in our operations, such as a material disruption of our development programs or our manufacturing operations, whether due to a loss of our trade secrets or other proprietary information, it would have a material and adverse effect on us. For example, the loss of clinical trial data from one or more ongoing or completed or future clinical trials could result in delays in our regulatory approval efforts, significantly increase our costs to recover or reproduce the data and expose us to liability. In addition, any breach of our computer systems or physical premises could result in a loss of data or compromised data integrity across more than one of our programs in different stages of development. Any such breach, loss, or compromise of clinical trial participant personal data may also subject us to civil fines and penalties or claims for damages, either under the General Data Protection Regulation and relevant member state law in the European Union, other foreign laws, and HIPAA, and other relevant state and federal privacy laws in the United States including the California Consumer Privacy Act. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, including but not limited to information related to our vidofludimus calcium product candidate, we could incur liability, our competitive and reputational position could be harmed, and the further development and commercialization of our investigational medicines could be delayed. On July 31, 2020 we discovered that an email account at the Company was subject to attempted unauthorized access for a period of up to 24 hours and we hired an investigator to ascertain what, if any, Company or patient information was impacted.  We do not believe any confidential or proprietary information was compromised and have taken steps to prevent unauthorized action in the future such as implementing two factor authentication for our email accounts. While we believe that our insurance policies include liability coverage for security breaches, we could be subject to indemnity claims or other damages that exceed, or are outside the scope of, our insurance coverage. As a result, the ramifications of a potential security breach could have a material adverse effect on our business, financial condition, results of operations and prospects, as well as cause a decline in the trading price of our common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain the required regulatory approvals in the United States and other territories, the commercial success of our product candidates will depend on market awareness and acceptance of our product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain marketing approval for our current product candidates or any other product candidates that we may develop or acquire in the future, our products may not gain market acceptance among physicians, key opinion leaders, healthcare payors, patients and the medical community. Market acceptance of any approved products depends on a number of factors, including: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing of market introduction;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the efficacy and safety of the product, as demonstrated in clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the clinical indications for which the product is approved and the label approved by regulatory authorities for use with the product, including any precautions, warnings or contraindications that may be required on the label;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">acceptance by physicians, key opinion leaders and patients of the product as a safe and effective treatment;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the cost, safety and efficacy of treatment in relation to alternative treatments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the number, cost and clinical profile of competing products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the growth of drug markets in our various indications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">relative convenience and ease of administration;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">marketing and distribution support;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the prevalence and severity of adverse side effects; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the effectiveness of our sales and marketing efforts.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance is critical to our ability to generate revenue. Any approved and commercialized product candidate may be accepted in only limited capacities or not at all. If any approved products are not accepted by the market to the extent that we expect, we may not be able to generate sufficient revenue and our business would suffer. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing and sales experience. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, if and when regulatory approval is received, we may be unable to generate any revenue. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never commercialized a product candidate, and we currently have no marketing and sales organization. To the extent our product candidates are approved for marketing, if we are unable to establish marketing and sales capabilities or enter into agreements with third parties to effectively market and sell our product candidates, we may not be able to successfully market and sell our product candidates or generate product revenue. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we currently do not have marketing, sales or distribution capabilities for our product candidates. In order to commercialize any of our products that receive marketing approval, we would have to build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. In the event of successful development of our product candidates, if we elect to build a targeted specialty sales force, such an effort would be expensive and time consuming. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have their own sales forces and established distribution systems, in lieu of or to augment any sales force and distribution systems we may create. If we are unable to enter into collaborations with third parties for the commercialization of any approved products on acceptable terms or at all, or if any such collaborator does not devote sufficient resources to the commercialization of our product or otherwise fails in commercialization efforts, we may not be able to successfully commercialize our product candidates even if we receive marketing approval. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future revenue will be materially and adversely impacted. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to enter into strategic relationships or collaborations, our business, financial condition, commercialization prospects and results of operations may be materially adversely affected. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our product development programs and the potential commercialization of our current product candidates will require substantial additional cash to fund expenses. Therefore, in addition to financing the development of our product candidates through additional equity financings or through debt financings, we may decide to enter into collaborations with pharmaceutical or biopharmaceutical companies for the development and potential commercialization of our product candidates in the United States or foreign markets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We announced in June 2022 that we do not plan further drug development activities in ulcerative colitis without a partner, following the failure of our phase 2 clinical trial to achieve its primary endpoint.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document. We may also be restricted under existing and future collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on acceptable terms, or at all. Any of these contingencies may require us to curtail the development of a particular product, reduce or delay one or more of our development programs, delay our potential commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring any approved product candidates to market and generate product revenue. If we do enter into a new collaboration agreement, we could be subject to the following risks, each of which may materially harm our business, commercialization prospects and financial condition: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may not be able to control the amount or timing of resources that the collaborator devotes to the product development program;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the collaborator may experience financial difficulties and thus not commit sufficient financial resources or personnel to the product development program;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be required to relinquish important rights such as marketing, distribution and intellectual property rights;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a collaborator could move forward with a competing product developed either independently or in collaboration with third parties, including our competitors; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect our or the collaborator&#8217;s willingness to complete our respective obligations under any arrangement.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our products profitably. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing, coverage, and reimbursement of any of our approved products must be sufficient to support our commercial efforts and other development programs, and the availability and adequacy of coverage and reimbursement by third-party payors, including governmental and private insurers, are essential for most patients to be able to afford expensive treatments. Sales of any of our approved product candidates will depend substantially, both domestically and in other jurisdictions, on the extent to which the costs of any of our approved products will be paid for or reimbursed by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or government payors and private payors. If coverage and reimbursement are not available, or are available only in limited amounts, we may have to subsidize or provide products for free, which would harm our potential revenues and profits, or we may not be able to successfully commercialize our products. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there is significant uncertainty related to the insurance coverage and reimbursement for newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services ("CMS"), an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for our novel product candidates and what reimbursement codes our product candidates may receive if approved. There also may be delays in obtaining coverage for newly-approved drugs. Obtaining coverage and reimbursement approval is time-consuming and costly, requiring us to provide payors with scientific, clinical, and cost-effectiveness data. Further, eligibility for coverage does not necessarily signify that a drug will be reimbursed in all cases or at a rate that covers our costs. Thus, even if we succeed in bringing a product to market, it may not be considered medically necessary or cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other price-restrictive regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of products. In many countries, the prices of products are subject to varying price control mechanisms as part of national health systems. Price controls or other changes in pricing regulation could restrict the amount that we may be able to charge for any of our products. Accordingly, the potential revenue and profits from markets outside the United States may be commercially inadequate. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and private payors in the United States and other jurisdictions to limit or reduce healthcare costs may result in restrictions on coverage and the level of reimbursement for new products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with products due to the increasing trend toward managed healthcare, including the increasing influence of health maintenance organizations, pharmacy benefit management organizations and additional legislative changes. The downward pressure on healthcare costs in general, and prescription drugs in particular, has and is expected to continue to increase in the future. For instance, government and private payors who reimburse patients or healthcare providers are increasingly seeking greater upfront discounts, additional rebates and other concessions to reduce prices for pharmaceutical products. As a result, it may be difficult for any of our products to achieve profitability, even if they receive regulatory approval. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully than, we do. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, universities and other research institutions worldwide with respect to our product candidates that we may seek to develop or commercialize in the future. Many of our competitors have materially greater name recognition and financial, manufacturing, marketing, research and drug development resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaborative or licensing relationships with our competitors. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In particular, the field of inflammatory bowel disease, including ulcerative colitis and Crohn&#8217;s disease, are highly competitive. Our competitors in the United States and elsewhere include major pharmaceutical, biotechnology and biosimilar manufacturers. Some of these competitors may have more extensive research and development, regulatory compliance, manufacturing, marketing and sales capabilities than we have. Many competitors also have significantly greater financial resources. These companies may succeed in developing products that are more effective or more economical than any of our product candidates and may also be more successful than we in manufacturing, developing and obtaining regulatory approvals and reimbursement for products. In addition, technological advances or different approaches developed by one or more of our competitors may render our products obsolete, less effective or uneconomical.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our competitors obtain marketing approval from the FDA or comparable foreign regulatory authorities for their product candidates more rapidly than we do, they could establish a strong market position before we are able to enter the market. Third-party payors, including governmental and private insurers, also may encourage the use of less expensive generic products. Failure of any approved product candidates of ours to effectively compete against established treatment options or to compete in the future with new products currently in development would harm our business, financial condition, results of operations and prospects. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential market opportunities for our product candidates are difficult to estimate and will depend on a number of factors beyond our control. Our estimates of potential market opportunities are predicated on many assumptions, which may include industry knowledge and publications, third-party research reports, and other surveys. Although we believe that our internal assumptions are reasonable based on currently available information, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain, and their reasonableness has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual markets for our product candidates could be substantially smaller than our estimates.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative developments in the field of oral therapies for chronic inflammatory and autoimmune diseases could damage public perception of our product candidates and negatively affect our business. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our product candidates will depend in part on public acceptance of the use of oral therapies for the treatment of chronic inflammatory and autoimmune diseases. Adverse events in clinical trials of our product candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other negative developments that may occur in the future, including in connection with competitors&#8217; therapies, could result in a decrease in demand for our product candidates. These events could also result in the suspension, discontinuation, or clinical hold of, or modifications to, our clinical trials. Our product candidates may not be accepted by the general public or the medical community and potential clinical trial subjects may be discouraged from enrolling in our clinical trials. As a result, we may not be able to continue, or may be delayed in conducting, our development programs. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Price controls may be imposed in foreign markets, which may adversely affect our future profitability. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be adversely affected. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Third Parties </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party suppliers and other third parties for production of our product candidates, and our dependence on these third parties may impair the advancement of our research and development programs and the development of our product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own or operate manufacturing facilities for clinical or commercial production of our product candidates. We lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. Instead, we rely on, and expect to continue to rely on, third parties for the supply of raw materials and manufacture of drug supplies necessary to conduct our preclinical studies and clinical trials. Our reliance on third parties for manufacturing exposes us to additional risks. Delays in production by third parties could delay our clinical trials or have an adverse impact on any commercial activities. In addition, our dependence on third parties for the manufacture of and formulation of our product candidates subjects us to the risk that such product candidates may have manufacturing defects that we has limited ability to prevent or control. Although we oversee these activities to ensure compliance with our quality standards, budgets and timelines, we have, and will continue to have, less control over the manufacturing of our product candidates than if we were to manufacture our product candidates. Further, the third parties we contract with could have staffing difficulties, might undergo changes in priorities or may become financially distressed, any of which would adversely affect the manufacturing and production of our product candidates. In addition, a third party could be acquired by, or enter into an exclusive arrangement with, one of our competitors, which would adversely affect our ability to access the formulations we require for the manufacturing of our product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The facilities used by our current contract manufacturers and any future manufacturers to manufacture our product candidates must be inspected by the FDA after we submit our NDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturers for compliance with the regulatory requirements, known as cGMPs, for manufacture of both active drug substances and finished drug products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, the FDA may refuse to approve our NDA. If the FDA does not approve our NDA because of concerns about the manufacture of our product candidates, or if significant manufacturing issues arise in the future, we may need to find alternative manufacturing facilities, which would significantly delay and adversely impact our ability to develop our product candidates, obtain marketing approval of our NDA or to continue to market any approved product candidates. Although we are ultimately responsible for ensuring compliance with these regulatory requirements, we do not have day-to-day control over a contract manufacturing organization&#8217;s ("CMO"), or other third-party manufacturer&#8217;s compliance with applicable laws and regulations, including cGMPs and other laws and regulations, such as those related to environmental, health and safety matters. Any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our product candidates or that obtained approvals could be revoked, which would adversely affect our business and reputation. In addition, third-party contractors, such as our CMOs, may elect not to continue to work with us due to factors beyond our control. They may also refuse to work with us because of their own financial difficulties, business priorities or other reasons, at a time that is costly or otherwise inconvenient for us. If we was unable to find adequate replacement or another acceptable solution in time, our clinical trials could be delayed or our commercial activities could be harmed. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Problems with the quality of the work performed by third parties may lead us to seek to terminate our working relationships and seek alternative service providers. However, making this change may be costly and may substantially delay clinical trials. In addition, it may be very challenging, and in some cases impossible, to find replacement service providers that can develop and manufacture our drug candidates in an acceptable manner and at an acceptable cost and on a timely basis. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale of products containing any defects or any delays in the supply of necessary products or services could adversely affect our business, financial condition, results of operations, and prospects. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Growth in the costs and expenses of components or raw materials may also adversely affect our business, financial condition, results of operations, and prospects. Supply sources could be interrupted from time to time and, if interrupted, supplies may not be resumed (whether in part or in whole) within a reasonable timeframe and at an acceptable cost or at all. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely on and plan to continue to rely on third parties to conduct clinical trials for our product candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, it may cause delays in commencing and completing clinical trials of our product candidates or we may be unable to obtain marketing approval for or commercialize our product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials must meet applicable FDA and foreign regulatory requirements. We do not have the ability to independently conduct clinical trials for any of our product candidates. We rely and expect to continue relying on third parties, such as CROs, medical institutions, clinical investigators and contract laboratories, to conduct all of our clinical trials of our product candidates; however, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with our investigational plan and protocol. Moreover, the FDA and foreign regulatory authorities require us to comply with IND and human subject protection regulations and cGCPs for conducting, monitoring, recording, and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. Our reliance on third parties does not relieve us of these responsibilities and requirements. Regulatory authorities enforce eGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our third-party contractors fail to comply with applicable eGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Upon inspection by a given regulatory authority, such regulatory authority may determine that one or more of our clinical trials do not comply with eGCPs. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the marketing approval process and increase our expenses. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry has experienced cases where clinical investigators have been found to incorrectly record data, omit data, or even falsify data. We cannot ensure that the CROs or clinical investigators in our trials will not make mistakes or otherwise compromise the integrity or validity of data, any of which would have a significant negative effect on our ability to obtain marketing approval, our business, and our financial condition. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or the third parties we rely on may encounter problems in clinical trials that may cause us or the FDA or foreign regulatory agencies to delay, suspend or terminate our clinical trials at any phase. These problems could include the possibility that we may not be able to manufacture sufficient quantities of materials for use in our clinical trials, conduct clinical trials at our preferred sites, enroll a sufficient number of patients for our clinical trials at one or more sites, or begin or successfully complete clinical trials in a timely fashion, if at all. Furthermore, we, the FDA or foreign regulatory agencies may suspend clinical trials of our product candidates at any time if we or they believe the subjects participating in the trials are being exposed to unacceptable health risks, whether as a result of adverse events occurring in our trials or otherwise, or if we or they find deficiencies in the clinical trial process or conduct of the investigation. The FDA or foreign regulatory agencies could also require additional clinical trials before or after granting marketing approval for any products, which would result in increased costs and significant delays in the development and commercialization of such products and could result in the withdrawal of such products from the market even if marketing approval has already been obtained. Our failure to adequately demonstrate the safety and efficacy of a product candidate in clinical development could delay or prevent marketing approval of the product candidate. Even if market approval has already been obtained, adverse data from post-approval studies could result in the product being withdrawn from the market. Any of these occurrences would likely have a material adverse effect on our business. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to realize the potential benefits of any collaboration. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in entering into a collaboration with respect to the development and/or commercialization of one or more product candidates, the collaboration may not be successful. Collaborations pose a number of risks, including: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators often have significant discretion in determining the extent of efforts and resources that they will apply to the collaboration, and may not commit sufficient attention and financial or other resources to the development, marketing or commercialization of the product or products that are subject to the collaboration;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may not perform their obligations as expected;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">any such collaboration may significantly limit our share of potential future profits from the associated program, and may require us to relinquish potentially valuable rights to our current product candidates, potential product candidates or proprietary technologies, or to grant licenses on terms that are not favorable to us;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may cease to devote sufficient resources to the development or commercialization of our product candidates, especially if the collaborators view our product candidates as competitive with their own products or product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the course of development, might cause delays or termination of the development or commercialization of product candidates, and might result in legal proceedings, which would be time-consuming, distracting and expensive;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may be impacted by changes in their strategic focus or available funding, or business combinations involving them, which could cause them to divert resources away from our collaboration;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the collaborations may not result in our achieving revenues to justify such transactions; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborations may be terminated, which may require us to raise additional capital to pursue further development or commercialization of the applicable product candidate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of any of these factors, a collaboration may not result in the successful development or commercialization of our product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sublicensees&#8217; exercise of rights under the agreements. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator to indemnify us and the collaborator is denied insurance coverage or the indemnification obligation exceeds the applicable insurance coverage, and if the collaborator does not have other assets available to indemnify us, our business, financial condition and results of operations could be adversely affected. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our contract manufacturers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">fail to comply with continuing regulations, resulting enforcement action could adversely affect us. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our contract manufacturers fail to comply with regulatory requirements or if previously unknown problems with products, manufacturers or manufacturing processes are discovered, we or the manufacturer could be subject to administrative or judicially imposed sanctions, including restrictions on the products or the manufacturers or manufacturing processes we use, warning letters, untitled letters (which the FDA uses as an initial notification of violations), civil or criminal penalties, fines, injunctions, product seizures or detentions, import bans, voluntary or mandatory product recalls and publicity requirements, suspension or withdrawal of regulatory approvals, total or partial suspension of production, and refusal to approve pending applications for marketing approval of new products. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our proprietary rights may not adequately protect our technologies and product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial success will depend in part on our ability to obtain additional patents and protect our existing patent position as well as our ability to maintain adequate protection of other intellectual property for our technologies, product candidates, and any future products in the United States and other countries. If we do not adequately protect our intellectual </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. The laws of some foreign countries, in particular China and India, do not protect our proprietary rights to the same extent or in the same manner as U.S. laws, and we may encounter significant problems in protecting and defending our proprietary rights in these and other countries. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies, product candidates and any future products are covered by valid and enforceable patents or are effectively maintained as trade secrets. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply for patents covering both our technologies and product candidates as we deem appropriate. However, we may fail to apply for patents on important technologies or product candidates in a timely fashion, or at all. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technologies or developing competing products and technologies. We cannot be certain that our patent applications will be approved or that any patents issued will adequately protect our intellectual property. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the patent positions of pharmaceutical companies are highly uncertain and involve complex legal and factual questions for which important legal principles are evolving and remain unresolved. As a result, the validity and enforceability of patents cannot be predicted with certainty. In addition, we do not know whether: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we or our licensors were the first to make the inventions covered by each of our issued patents and pending patent applications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we or our licensors were the first to file patent applications for these inventions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">any of the patents that cover our product candidates will be eligible to be listed in the FDA&#8217;s compendium of &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; sometimes referred to as the FDA&#8217;s Orange Book;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">others will independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">any of our or our licensors&#8217; pending patent applications will result in issued patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">any of our or our licensors&#8217; patents will be valid or enforceable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">any patents issued to us or our licensors and collaborators will provide us with any competitive advantages, or will be challenged by third parties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we will develop additional proprietary technologies that are patentable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">governmental authorities will exercise any of their statutory rights to our intellectual property that was developed with government funding; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our business may infringe the patents or other proprietary rights of others.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actual protection afforded by a patent varies based on products or processes, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory related extensions, the availability of legal remedies in a particular country, the validity and enforceability of the patents and our financial ability to enforce our patents and other intellectual property rights. Our ability to maintain and solidify our proprietary rights to our product candidates and future products will depend on our success in obtaining effective claims and enforcing those claims once granted. Our issued patents and those that may issue in the future, or those licensed to us, may be challenged, narrowed, invalidated or circumvented, and the rights granted under any issued patents may not provide us with proprietary protection or competitive advantages against competitors with similar products. Due to the extensive amount of time required for the development, testing and regulatory review of a product candidate, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also rely on trade secrets to protect some of our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to maintain. While we use reasonable efforts to protect our trade secrets, our or any of our collaborators&#8217; employees, consultants, contractors or scientific and other advisors may unintentionally or willfully disclose our proprietary information to competitors or others and we may not have adequate remedies in respect of such disclosure. Enforcement of claims that a third party has illegally obtained and is using trade secrets is expensive, time consuming and uncertain. In addition, foreign courts are sometimes less willing than U.S. courts to protect trade secrets. If our competitors independently develop equivalent knowledge, methods or know-how, we would not be able to assert our rights to trade secrets and our business could be harmed. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a party to license agreements under which we license intellectual property and receive commercialization rights relating to certain of our product candidates. If we fail to comply with obligations in such agreements or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business; any termination of such agreements would adversely affect our business. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to license agreements that give us various commercialization rights, the loss of which (whether due to our actions or inactions or those of the respective counterparties) may adversely affect our business. For instance, in November 2018, Immunic AG and Daiichi Sankyo entered into a license and option agreement that grants us an exclusive global option to license IMU-856 and related molecules. In January 2020, we exercised this option and acquired the rights to commercialization of IMU-856 in all countries including the U.S., Europe and Japan. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of (i) the licenses granted to us under our agreements with Daiichi Sankyo and other licensors, or (ii) the rights provided under such agreements, would prevent us from developing, manufacturing or marketing products covered by the license or subject to supply commitments, and could materially harm our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our technologies in all countries outside the United States, or from selling or importing products made using our technologies in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection, to develop their own products and further, may export otherwise infringing products to territories where we have patent protection but enforcement rights are weaker than in the United States. These products may compete with our product candidates in jurisdictions where we do not have any issued patents and our patent claims or other intellectual rights may not be effective or sufficient to prevent such competition.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries do not favor the enforcement of patents and other intellectual property rights, which could make it difficult for us to stop the infringement of our patents generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights throughout the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, we may be unable to extend the term of marketing exclusivity for our product candidates and our business may be materially harmed. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the timing, duration and specifics of any FDA marketing approval of any of our product candidates, one of the U.S. patents covering each such approved product or the use thereof may be eligible for up to five years of patent term restoration under the Hatch-Waxman Act. The Hatch-Waxman Act allows extension of a maximum of one patent per FDA-approved product. Patent term extension or special protection certificates also may be available in certain foreign countries upon regulatory approval of our product candidates. Nevertheless, we may not be granted patent term extension either in the United States or in any foreign country because of, among other things, failing to apply prior to applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension afforded as well as the scope of patent protection during any such extension could be less than we request. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we or our collaborators request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following expiration of our patent, and our potential revenue could be materially reduced. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not identify relevant patents or may incorrectly interpret the relevance, scope or expiration of a patent issued to others, which could adversely affect our ability to develop and market our product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent searches or analyses (including, but not limited to, the identification of relevant patents, the scope of patent claims or the expiration of relevant patents) might not be accurate, complete or thorough, and could fail to identify each and every patent and pending application in the United States and other jurisdictions that is or may potentially be relevant to or necessary for the commercialization of our product candidates in any jurisdiction. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope of a patent claim is determined by legal interpretation, the written disclosure in a patent and the patent&#8217;s prosecution history. If our interpretation of the relevance or the scope of a patent or a pending application is not accurate and we incorrectly determine that our product candidates are not covered by a third-party patent, we could be potentially liable for infringement, prevented from marketing our product candidate, or required to seek costly licenses from patent holders. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many patents may cover a marketed product, including but not limited to patents covering the composition, methods of use, formulations, production processes and purification processes of or for the product. The identification of all patents and their expiration dates relevant to the production and sale of a therapeutic product is extraordinarily complex and requires sophisticated legal knowledge in the relevant jurisdiction. It may be impossible to identify all patents in all jurisdictions relevant to a marketed product. Our determination of the expiration date of any patent in the United States or other jurisdictions that we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consider relevant may be incorrect, which could negatively impact our ability to develop and market our product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Patent and Trademark Office ("USPTO"), and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent prosecution process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patent and/or pending patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent or patent application. We employ an outside firm and rely on outside counsel to pay these fees. While an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are many situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market sooner, which would have a material adverse effect on our business. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent protection for our product candidates may expire before we are able to maximize their commercial value, which may subject us to increased competition and reduce or eliminate our opportunity to generate product revenue. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patents for our product candidates have, and any patents issued in the future will have, varying expiration dates and, when these patents expire, we may be subject to increased competition and we may not be able to recover our development costs or market any of our approved products profitably. In some of the larger potential markets, such as the United States and Europe, patent term extension or restoration may be available to compensate for time taken during aspects of the product&#8217;s development and regulatory review. However, extensions might not be granted or, if granted, the applicable time period or the scope of patent protection afforded during any extension period could be inadequate. In addition, even though some regulatory authorities may provide some other exclusivity for a product under their own laws and regulations, we may not be able to qualify the product or obtain exclusivity. If we are unable to obtain patent term extension, restoration or some other exclusivity, we could be subject to increased competition and our opportunity to establish or maintain product revenue could be substantially reduced or eliminated. Furthermore, we may not have sufficient time to recover our development costs prior to the expiration of our U.S. and foreign patents. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits or interference proceedings to protect patents held by us or our licensors or other intellectual property rights, which could be expensive, time-consuming and ultimately unsuccessful. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or other intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims, directly or through our licensors, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of our licensor is not valid or is unenforceable, or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of the patents we own or license at risk of being invalidated or interpreted narrowly and could put our licensors&#8217; patent applications at risk of not issuing. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings brought by the USPTO may be necessary to determine the priority of inventions with respect to patents and patent applications of our licensors or those of our current or future collaborators. An unfavorable outcome could require us to cease using the technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if a prevailing party does not offer us a license on terms that are acceptable to us. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distraction of our management and other employees. We may not be able to prevent, alone or with our collaborators, misappropriation of our proprietary rights, particularly in countries whose laws do not grant the same protections to intellectual property as fully as the United States. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential and proprietary information could be compromised by disclosure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, this could have a substantial adverse effect on the price of our common stock. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement or misappropriation may adversely affect our business and could prevent us from developing or commercializing our product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation and other challenges, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, ex-parte review, inter party review and post-grant review proceedings before the USPTO and foreign patent offices. Numerous U.S. and foreign patents and patent applications exist in the fields in which we are developing and may develop our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to third-party claims of patent infringement. Third-party claims that we infringe on their products or technology could present a number of issues, including: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">infringement and other intellectual property claims, whether with or without merit, can be extremely expensive and time-consuming to litigate and can divert management&#8217;s attention from our core business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk of substantial court-imposed damages for past infringement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a court prohibiting us from selling or licensing our product unless the patent holder licenses the patent to us, which it would not be required to do;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">even if a license is available from the patent holder, we may have to pay substantial royalties or grant cross licenses to our patents; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may need to redesign our processes to avoid further infringement, which may not be possible or could require expenditure of substantial funds and time.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization. We may be unaware of third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. For example, applications filed before November 29, 2000, and certain applications filed after that date that will not be filed outside the United States, remain confidential until issued as patents. Except for the preceding exceptions, patent applications in the United States and elsewhere are generally published only after a waiting period of approximately 18 months after the earliest filing. Therefore, patent applications covering our product candidates may have been filed by others without the knowledge of us or our licensors. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use or manufacture of our product candidates. We may also face misappropriation claims if a third party believes that we inappropriately obtained and used its trade secrets. If the third-party prevails on such claims, we may be prevented from further using such trade secrets, limiting our ability to develop our product candidates, and may be required to pay damages. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a court of competent jurisdiction held that any third-party patents covers aspects of our materials, formulations, methods of manufacture or methods for treatment, the holders of any such patents would be able to block our ability to develop and commercialize the applicable product candidate until such patent expired or unless we obtain a license. A license may not be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available on acceptable terms, if at all. Even if we were able to obtain a license, the rights could be nonexclusive, which could result in our competitors having access to our licensed intellectual property. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms or at all. In addition, during the course of any patent or other intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our product candidates, programs, or intellectual property could be diminished. Accordingly, the market price of our common stock may decline. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defending against claims of patent infringement or misappropriation of trade secrets could be costly and time-consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle at an early stage, such litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible to obtain or require substantial expenditure of time and money. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into collaborative arrangements that would help us bring our product candidates to market. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents and patent rights. Obtaining and enforcing patents and patent rights in the biotechnology industry involves both technological and legal complexity and, therefore, is costly, time-consuming and inherently uncertain. In addition, some patent reform legislation and court rulings in the United States have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents and patent rights, once obtained. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our U.S. patent applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law. In September 2011, the Leahy-Smith America Invents Act ("the AIA"), was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and reviewed after issuance, and may also affect patent litigation. USPTO regulations and procedures govern administration of the AIA and many of the substantive changes to patent law associated with the AIA. It is not clear what other, if any, impact the AIA will have on the operation of our business. Moreover, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of patent rights, all of which could have a material adverse effect on our business and financial condition. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a &#8220;first-inventor-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date, but before we or our licensor files a patent application, could therefore be awarded a patent covering an invention of ours even if we or our licensor had made the invention before the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patent rights depends on whether the differences between the licensor&#8217;s or our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain if we (or our licensor) was the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other changes, the AIA limits where a patentee may file a patent infringement suit and provides opportunities for third parties to challenge any issued patent in the USPTO. This applies to all U.S. patents, even those issued before March 16, 2013. Because the evidentiary standard to invalidate a patent claim in USPTO proceedings is lower than for a procedure in U.S. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal court, a challenger may attempt to use the USPTO procedures to invalidate our patent rights that would not have been invalidated in federal court. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the expense and uncertainty of litigation, we may conclude that, even if a third party is infringing our patents or our licensors&#8217; patents or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of us or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not protect against all potential threats to our potential competitive advantage. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is highly uncertain because intellectual property rights have limitations and may not adequately protect our business, or permit us to maintain any competitive advantage we may gain. The following examples are illustrative: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Others may be able to make products that are similar to our product candidates but that are not covered by the claims of the patents that we license from others or may license or own in the future.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Any of our collaborators might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we license or may, in the future, own or license.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Any of our collaborators might not have been the first to file patent applications covering certain of the patents or patent applications that we license or may, in the future, license.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Issued patents that have been licensed to us may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our competitors might conduct research and development activities in countries where we do not have license rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Ownership of patents or patent applications licensed to us may be challenged by third parties.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Confidentiality agreements with employees, consultants and others may not adequately prevent disclosure of trade secrets and protect other proprietary information. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets and/or confidential know-how can be difficult to maintain as confidential. In an effort to protect this type of information against disclosure or appropriation by competitors, we require our employees, consultants, contractors and advisors to enter into confidentiality agreements with us. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is challenging, expensive, time-consuming and unpredictable. The extent to which confidentiality agreements may be enforced does vary from jurisdiction to jurisdiction. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain or maintain trade secrets and/or trade protection of our confidential know-how could adversely affect our competitive position. Moreover, our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection of that information. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets and/or confidential know-how. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to license certain intellectual property from third parties, and such licenses may not be available on commercially reasonable terms, or at all. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold intellectual property, including patent rights that are important or necessary to the development or commercialization of our product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from such third parties. Such a license may not be available on commercially reasonable terms, or at all, which could prevent us from commercializing our product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed to us or others confidential information of their former employers or other owners of confidential information.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we may be subject to ownership disputes in the future arising from, among other things, consultants or third-parties who are involved in developing our product candidates. We may also be subject to claims that former employees, consultants, independent contractors, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to, and use of, confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights to certain intellectual property. Such an outcome could have a material adverse effect on our business. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents and other intellectual property. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who have been involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could be extremely costly and distract our management and other employees. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on third parties to assist with research and development and to manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements are intended to limit the rights of the third parties to use, disclose or publish our confidential information, including our trade secrets. Despite these contractual restrictions, the need to share trade secrets and other confidential information increases the risk that such trade secrets could become known to our competitors, could be inadvertently incorporated into the technology of others, or could be disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future we may also conduct joint research and development programs that may require us</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development, or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. If we cannot adequately protect our trademarks and trade names, then we may not be able to build name recognition in our markets of interest and our business would be harmed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trademarks or trade names. Over the long term, if we are unable to successfully register and protect our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Being a Public Company </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We incur significant costs and demands upon management as a result of complying with the laws and regulations affecting public companies. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur significant legal, accounting and other expenses that we would not incur as a private company, including costs associated with public company reporting requirements. We also incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act of 2002 (the "Sarbanes-Oxley Act"), as well as existing and new rules implemented by the SEC and The Nasdaq Stock Market ("Nasdaq"). These rules and regulations increase the company&#8217;s legal and financial compliance costs and make some activities more time-consuming and costly. Not all members of our management have previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations. These rules and regulations may also make it difficult and expensive for us to obtain directors&#8217; and officers&#8217; liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers of our company, which may adversely affect investor confidence in us and could cause our business and stock price to suffer. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective December 31, 2019, we are no longer an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements applicable to &#8220;emerging growth companies&#8221; no longer apply, and we are required to report on internal control over financial reporting, which will increase our costs as a public company and increase the demands on management.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective December 31, 2019, the fiscal year-end following the fifth anniversary of the completion of our initial public offering, we are no longer an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act. As a result, we are incurring significant additional expenses in complying with certain provisions of the Sarbanes-Oxley Act and rules implemented by the SEC. Moreover, if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline, and we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources. Furthermore, investor perceptions of us may suffer if, in the future, material weaknesses are found, and this could cause a decline in the market price of our stock. Any failure of our internal control over financial reporting could have a material adverse effect on the company&#8217;s stated operating results and harm our reputation. If we are unable to implement these changes effectively or efficiently, it could harm our operations, financial reporting and financial results and could result in an adverse opinion on internal control from our independent registered public accounting firm.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are no longer eligible for reduced disclosure requirements applicable to emerging growth companies regarding executive compensation and exemptions from the requirements of holding advisory say-on-pay votes on executive compensation. These increased disclosure requirements require additional attention from management and increased costs to the company, including higher legal fees, accounting fees and fees associated with investor relations activities, among others.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been and is expected to continue to be volatile.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been, and is expected to continue to be, subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">reports on or the perception of clinical trial progress, or the lack thereof, which we experienced in October 2022 when our stock price and market capitalization decreased significantly after announcing Phase 1b interim analysis of IMU-935 for the first two dose patient cohorts with moderate-to-severe psoriasis;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain regulatory approvals for our product candidates, and delays or failures to obtain such approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure of any of our approved product candidates to achieve commercial success;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to maintain our existing third-party license, supply and manufacturing agreements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure by us or our licensors to prosecute, maintain, or enforce our intellectual property rights;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in laws or regulations (or their interpretation) applicable to our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">any inability to obtain adequate supply of our product candidates or the inability to do so at acceptable prices;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">adverse regulatory authority decisions or delays;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">introduction of new products, services, or technologies by our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to meet or exceed financial and development projections that we may provide to the public;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to meet or exceed the financial and development projections of the investment community;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the perception of the pharmaceutical industry in general, and companies addressing our disease indications in particular, by the public, legislatures, regulators and the investment community;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">announcements of significant acquisitions, strategic collaborations, joint ventures, or capital commitments by us or our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">additions or departures of key personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant lawsuits, including patent, product liability or stockholder litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">if securities or industry analysts do not publish research or reports about our business, or if they issue negative or misleading opinions regarding our business and stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in the market valuations of similar companies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">general market or macroeconomic conditions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">sales of common stock by the company or our stockholders in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">trading volume of our common stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships or capital commitments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">adverse publicity relating to the markets in which we operate, including with respect to other products and product candidates in such markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the introduction of technological innovations or new therapies that compete or might compete with our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in the structure of healthcare payment systems; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">period-to-period fluctuations in our financial results.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations have had, and can be expected to continue to have, adverse effects on the trading price of our common stock. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, a decrease in our stock price may cause our common stock to no longer satisfy the continued listing standards of The Nasdaq Global Select Market. If we are not able to maintain the requirements for listing on The Nasdaq Global Select Market, we could be delisted, which would likely result in an immediate and significant decline in the trading price and liquidity of our stock, and would have a materially adverse effect on our ability to raise additional funds. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our organizational documents and Delaware law might discourage or delay acquisition attempts for the company that stockholders might consider favorable. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended and Restated Certificate of Incorporation, and Amended and Restated Bylaws, contain provisions that may delay or prevent an acquisition or change in control of the company. Our certificate of incorporation and bylaws include provisions that: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">authorize our board of directors to issue without further action by the stockholders, up to 20,000,000 shares of undesignated preferred stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, as a Delaware corporation, we are subject to provisions of Delaware corporations law, which may impair a takeover attempt that our stockholders may find beneficial. These anti-takeover provisions and other provisions under Delaware law could discourage, delay or prevent a transaction involving a change in control of our company, including actions that our stockholders may deem advantageous, or could negatively affect the trading price of our common stock. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing and to cause us to take other corporate actions they desire. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience adverse consequences because of required indemnification of officers and directors. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Provisions of our certificate of incorporation and bylaws provide that we will indemnify any director and officer as to liabilities incurred in their capacity as a director or officer and on those terms and conditions set forth therein to the fullest extent of Delaware law. Further, we have purchased directors and officers insurance on behalf of any such persons whether or not we would have the power to indemnify such person against the liability insured against. The foregoing could result in substantial expenditures by us and prevent any recovery from our officers, directors, agents and employees for losses incurred by the company as a result of their actions. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current expectation is that we will retain any future earnings to fund the development and growth of our business. As a result, any capital appreciation of the common stock of the company will be stockholders&#8217; sole source of any gain for the foreseeable future.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">statements on a timely basis could be impaired.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and Nasdaq rules and regulations. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. We must perform system and process evaluation and testing of our internal controls over financial reporting to allow </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K for each year, as required by Section 404 of the Sarbanes-Oxley Act ("Section 404").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This requires significant management efforts and requires us to incur substantial professional fees and internal costs to expand our accounting and finance functions. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us, as and when required, conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal controls over financial reporting that are deemed to be significant deficiencies or material weaknesses or that may require prospective or retroactive changes to our financial statements, or may identify other areas for further attention or improvement. Furthermore, we cannot be certain that our efforts will be sufficient to remediate or prevent future material weaknesses or significant deficiencies from occurring.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to comply with the requirements of Section 404, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our common stock would likely decline and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and stock price could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders may, from time to time, engage in proxy solicitations or put forth stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition and divert management&#8217;s attention. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or management team arising from a proxy contest or initiatives of activist stockholders could lead to the perception of a change in the direction of our business or instability, which may result in the loss of potential business opportunities, make it more difficult to pursue strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results and the trading price of our stock. If individuals are ultimately elected to our board of directors with a specific agenda, our ability to effectively implement our business strategy and create additional value for our stockholders may be adversely effected. We may choose to initiate, or may become subject to, litigation as a result of a proxy contest or matters arising from a proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant negative or other fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained and our stockholders may not be able to resell their shares of common stock for a profit, if at all. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An active trading market for our shares of common stock may not be sustained. If an active market for our common stock is not sustained, it may be difficult for stockholders to sell their shares at an attractive price or at all. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of shares by existing stockholders could cause</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">our stock price to decline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, whether after legal restrictions on resale lapse or at other times, the trading price of our common stock could decline. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. If we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could substantially decline immediately if one or more equity research analysts downgrade our stock or issue other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price and trading volume to decline.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we become profitable, our ability to use our net operating loss carryforwards and other tax attributes to offset future taxable income or taxes may be subject to limitations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred net losses since our inception, and expect to continue to incur operating losses for the foreseeable future. If we become profitable in the future, our ability to use net operating loss carryforwards, or NOLs, and other tax attributes to offset future taxable income or reduce taxes may be subject to limitations. In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50% cumulative change by value in its equity ownership of certain stockholders over a rolling three-year period) is subject to an annual limitation on its ability to utilize its pre-change NOLs and other tax attributes (including any research and development credit carryforwards). Similar provisions of state tax law may also apply to limit the use of our state NOLs and other tax attributes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have not performed an analysis to determine whether our past issuances of stock and other changes in our stock ownership may have resulted in one or more ownership changes within the meaning of Sections 382 and 383 of the Code. In addition, we may experience an ownership change in the future as a result of subsequent changes in our stock ownership, some of which are outside our control; and we are not intending to take any steps to prohibit any subsequent changes in our stock ownership in order to avoid such an ownership change. If an ownership change has occurred in the past or occurs in the future, we may not be able to use a material portion of our NOLs and other tax attributes to offset future taxable income or taxes if we attain profitability.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to any limitation imposed by Section 382 of Code, the use of NOLs arising after December 31, 2017 generally is limited to a deduction of 80% of taxable income for the corresponding taxable year. NOLs arising after December 31, 2017, with certain exceptions, may not be carried back to previous taxable years, but may be carried forward indefinitely.</span></div><div><span><br/></span></div><div id="idff78559567c4173b665e875d419cf41_28"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;Unresolved Staff Comments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="idff78559567c4173b665e875d419cf41_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;Properties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we lease approximately 24,300 square feet in Germany in Gr&#228;felfing and approximately 3,300 square feet of office space in the U.S. in New York City. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The New York City lease, which we entered into in November 2019, expires in July 2025 and provides the principal location for our U.S. operations. The Gr&#228;felfing, Germany lease, which was effective July 1, 2020 and then adjusted on March 1, 2021 and August 1, 2022 to add more square footage, expires in June 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="idff78559567c4173b665e875d419cf41_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;Legal Proceedings. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any litigation, nor are we aware of any pending or threatened litigation against us that we believe would materially affect our business, operating results, financial condition or cash flows. Our industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, we may be involved in various legal proceedings from time to time.</span></div><div id="idff78559567c4173b665e875d419cf41_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;Mine Safety Disclosures.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="idff78559567c4173b665e875d419cf41_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Select Market under the symbol "IMUX".</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 17, 2023, there were 42 holders of record of our common stock, which excludes stockholders whose shares were held in nominee or street name by brokers. The actual number of common stockholders is greater than the number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our equity compensation plans is incorporated herein by reference to Item&#160;12 of Part&#160;III of this Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;Selected Financial Data.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Annual Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in &#8220;Risk Factors&#8221; included elsewhere in this Annual Report. As used in this report, unless the context suggests otherwise, &#8220;we,&#8221; &#8220;us,&#8221; our&#8221; or &#8220;the Company&#8221; refer to Immunic, Inc. and its subsidiaries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:93%">We are a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. We are headquartered in New York City with our main operations in Gr&#228;felfing near Munich, Germany. We currently have approximately 66 employees.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently pursuing clinical development of three orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;); the izumerogant (proposed International Nonproprietary Name (&#8220;INN&#8221;) for IMU-935) program, which is an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (&#8220;ROR&#947;t&#8221;) that inhibits the interleukin-17 (&#8220;IL-17&#8221;) pathway in diseases such as psoriasis; and the IMU-856 program, which is targeted to restore intestinal barrier function and regenerate bowel epithelium.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since inception of $317.3 million through December&#160;31, 2022. We anticipate that we will continue to incur losses for at least the next several years. Due to the uncertainties involved with therapeutic product development and the clinical trial process, we cannot predict the timing or level of future expenses with certainty, when product approval might occur, if ever, or when profitability may be achieved or sustained.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div style="margin-top:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$60 Million Private Placement Equity Financing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2022, we entered into a Securities Purchase Agreement for a private placement with select accredited investors and certain existing investors. Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Shares&#8221;), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants to purchase Common Stock, at a purchase price of $4.34 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.01 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days&#8217; prior notice to the Company.  The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return.  All of the pre-funded warrants were exercised in January 2023.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Private Placement closed on October 12, 2022. The gross proceeds of the Private Placement were approximately $60.0 million, before deducting offering expenses payable by us of approximately $4.0 million. We intend to use the net proceeds from the Private Placement to fund the ongoing clinical development of our three lead product candidates, vidofludimus calcium (IMU-838), izumerogant (IMU-935) and IMU-856, and for other general corporate purposes.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug&#8217;s Neuroprotective Potential</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 17, 2022, we reported newly available data from the Phase 2 EMPhASIS trial of vidofludimus calcium in patients with relapsing-remitting multiple sclerosis (&#8220;RRMS&#8221;). The trial includes an optional long-term open-label extension (&#8220;OLE&#8221;) phase running up to 9.5 years. An interim analysis was performed with data extraction in October 2022, when 209 patients remained on treatment in the OLE phase, some of whom have already received more than 180 continuous weeks (approximately four years) of active treatment with vidofludimus calcium.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Long-term open-label treatment with vidofludimus calcium was associated with a low rate of confirmed disability worsening over time, comparing favorably to historical trial data for currently available MS medications. During the 24-week double-blind main treatment period, 12-week and 24-week Confirmed Disability Worsening (&#8220;12w/24wCDW&#8221;) events occurred in 1.6% of subjects in the combined vidofludimus calcium treatment arms as compared to 3.7% in the placebo group. In the OLE phase, the proportion of patients free from 12wCDW was 97.6% after 48 weeks and 94.5% after 96 weeks of vidofludimus calcium treatment as compared to the start of the OLE phase. Similar results were observed for 24wCDW and sustained CDW. The OLE phase also showed low relapse activity.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in RRMS at ACTRIMS Forum 2023</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 22, 2023, we announced that Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, will present data from the blinded and OLE parts of our phase 2 EMPhASIS trial of vidofludimus calcium in RRMS at the eighth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023, taking place February 23-25 in San Diego, California. The poster presentation includes our previously announced data from the trial showing that long-term open-label treatment with vidofludimus calcium was associated with a low rate of confirmed disability worsening over time, comparing favorably to historical trial data for currently available MS medications.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Publication of Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in RRMS in Peer Reviewed Journal</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2022, we announced that data from our Phase 2 EMPhASIS trial of vidofludimus calcium in patients with RRMS has been published in the peer reviewed journal, Annals of Clinical and Translational Neurology. The paper, authored by coordinating investigator, Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, is entitled, &#8220;Safety and efficacy of vidofludimus calcium, a selective dihydroorotate dehydrogenase inhibitor, in relapsing-remitting multiple sclerosis (EMPhASIS): a double-blind, randomized, placebo-controlled Phase 2 trial.&#8221;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Phase 1 Trial of Vidofludimus Calcium in Hepatic Impaired Patients</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed a Phase 1 trial in a total of 24 patients with either no liver function impairment or liver disease of Child-Pugh A Child-Pugh B grade which was designed to explore dose optimization of vidofludimus calcium. The study showed little influence on the PK of vidofludimus calcium in patients with Child-Pugh A Child-Pugh B liver impairmen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Update on the Use of Steroids in the Phase 2 EMPhASIS Trial in RRMS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on the observed interaction between vidofludimus calcium and chronic steroid use in the CALDOSE-1 trial in ulcerative colitis patients, we performed a post-hoc analysis of our Phase 2 EMPhASIS data in RRMS patients to explore the potential influence of steroids on these study results. As anticipated, steroid use was rare and among those RRMS patients who received any steroids, the majority received only short steroid courses following relapse events or acute neurological events. Only four patients received any steroids for reasons other than relapse (COVID-19 infection, eczema, acute bronchitis, and contact urticaria, one patient each). Most patients only had one single short course of steroids, and only nine patients had two or more steroid courses. The average duration of steroid treatment in this RRMS trial was 4.4 days with a maximum duration of 10 days. This indicates to us that steroids are rarely used in MS patients and mostly for a very short duration. In conclusion, comparing patients who received at least one dose of corticosteroids with those who did not, we do not see any difference in clinical parameters or any evidence that the rare, short-term use of steroids in RRMS patients has any influence on the effectiveness of vidofludimus calcium in this patient population.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Celiac Disease Research and Development Webcast</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2023, we hosted a celiac disease research and development webcast. Our management, including Daniel Vitt, Ph.D., Chief Executive Officer and President; Andreas Muehler, M.D., M.B.A., Chief Medical Officer; and Hella Kohlhof, Ph.D., Chief Scientific Officer, were joined by renowned key opinion leaders to discuss the dynamics of this multifactorial, complex autoimmune disease, immune stimulation and its connection to clinical symptoms, the role of the epithelial barrier in the pathogenesis of the disease, current and potential treatment options, and the continued unmet medical need for effective therapeutics, which is driving an increased focus within the industry.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:102%">Phase 1 Clinical Trial of IMU-856, Results of Parts A and B in Healthy Human Subjects</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 20, 2022, we announced positive unblinded safety, tolerability and pharmacokinetic (&#8220;PK&#8221;) results from Part A (single ascending doses) and Part B (multiple ascending doses) of our Phase 1 clinical trial of IMU-856 in healthy human subjects.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the single ascending doses part, healthy human subjects were randomized in a double-blinded manner to either placebo or active treatment with single ascending doses of IMU-856 at 10 mg, 20 mg, 40 mg, 80 mg, 120 mg and 160 mg. Single ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached. No serious adverse events occurred. Moreover, a dose-linear PK profile was observed across the investigated dose range.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the multiple ascending doses part, healthy human subjects were dosed for 14 consecutive days with 40 mg, 80 mg or 160 mg once-daily of IMU-856 or placebo in a double-blinded manner. Multiple ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached. Treatment emergent adverse events were mostly mild in severity. No Investigational Medicinal Product-related serious adverse events were reported. No dose-dependent changes in laboratory parameters (including no effects on liver enzymes or in hematological parameters), vital signs, physical examination or electrocardiographic evaluations were found. PK analysis showed a quick achievement of stable steady-state plasma concentrations within the first week and stable steady-state trough levels over the 14-day treatment period with a low accumulation factor for IMU-856, allowing predictable trough levels during daily dosing. PK parameters in steady-state revealed a Tmax (time to reach maximum plasma concentration) of 2 to 3 hours post-dose, a plasma half-life of 17.4 to 21.5 hours and dose proportional increases in Cmax (maximum plasma drug concentration) and AUC (area under the concentration-time curve).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMU-856 Composition-of-Matter Patent Granted</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 16, 2022, we announced that we have received a Notice of Allowance from the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) for patent application 16/646130, entitled, &#8220;Compound Having Cyclic Structure.&#8221; The patent covers composition-of-matter of IMU-856 and related pharmaceutical compositions and is expected to provide protection into at least 2038, without accounting for potential PTE.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Start of Patient Cohorts in Phase 1 Clinical Trial of IMU-856 in Celiac Disease</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:21.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 5, 2022, we announced the start of the patient cohorts in our ongoing Phase 1 clinical trial of IMU-856 in patients with celiac disease. Part C is structured as a 28-day, double-blind, placebo-controlled trial designed to assess the safety, tolerability, PK, pharmacodynamic (&#8220;PD&#8221;) and biomarker responses of IMU-856 in patients with celiac disease during periods of gluten-free diet and gluten challenge. Approximately 42 patients were planned to be enrolled in two consecutive cohorts with IMU-856 given once-daily over 28 days. Secondary objectives include PK and disease markers, including those evaluating gastrointestinal architecture and inflammation. Sites in Australia and New Zealand are participating in Part C. Initial results are expected to be available in mid-2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2022, we reported top-line data from our Phase 2 CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe ulcerative colitis (&#8220;UC&#8221;). The trial did not achieve the primary endpoint of clinical remission for the pooled 30 and 45 mg/day active dose groups of vidofludimus calcium versus placebo at week 10. In addition, no meaningful differences were observed between the three active dose groups for the overall intent-to-treat patient population (10 mg/day: 14.9%, 30 mg/day: 10.6%, 45 mg/day: 13.6%, placebo: 12.5%) or for the trial&#8217;s other secondary endpoints, including symptomatic remission, or endoscopic healing.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in this clinical trial was observed to be safe and well-tolerated. No new safety signals were observed. As compared to placebo, there were no increased rates of infections and infestations, no elevated rates of liver events or liver enzyme elevations, and no elevated rates for changes in hematology-related laboratory variables. The most common adverse events in this clinical trial were anemia (15/263 patients, 5.7%), headache (9/263 patients, 3.4%) and COVID-19 (7/263 patients, 2.7%). Most adverse events were generally mild in severity.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common for the design of clinical trials in UC, the use of oral systemic corticosteroids (&#8804;20 mg/day prednisolone equivalent) was allowed in CALDOSE-1 in patients who had been treated with corticosteroids for at least four weeks before </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">randomization. Doses of corticosteroids were required to be kept constant throughout the induction phase (weaning was not allowed in this phase of the clinical trial), and the distribution of patients using corticosteroids was equal throughout all treatment groups. Surprisingly, CALDOSE-1 data suggest a previously unknown treatment interference between the efficacy of vidofludimus calcium and the concurrent use of corticosteroids in the UC patient population. More specifically, the non-steroid patient population showed an 11.4% advantage in clinical remission for vidofludimus calcium over placebo (pooled vidofludimus calcium treatment groups at week 10: 14.7%, placebo: 3.3%). Such a difference in clinical remission between active treatment and placebo would traditionally be considered as confirming therapeutic activity. In contrast, patients concomitantly taking vidofludimus calcium and corticosteroids during induction treatment had a lower rate of clinical remission at week 10 (11.5%) than placebo patients (20.6%) and also lower than the group of vidofludimus calcium monotherapy without concurrent use of steroids (14.7%). This treatment interference between vidofludimus calcium and corticosteroids was not expected based on our analysis of currently available preclinical or clinical data.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on these results, we announced that our development programs in the IBD indications will not be continued without a partner.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investigator-Sponsored Phase 2 IONIC Trial in Moderate-to-Severe COVID-19 Closed Down</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 23, 2022, sponsor and lead site, University Hospitals Coventry and Warwickshire NHS Trust, London, United Kingdom, informed us that the investigator-sponsored Phase 2 IONIC trial for the treatment of patients with moderate-to-severe COVID-19 is being closed down. Recruitment for the trial ended on May 20, 2022 and the last patient follow-up occurred in  September 2022. On September 29, 2022, we were informed that the sponsor submitted the end of trial declaration. The trial was a prospective, randomized, parallel-group, open-label Phase 2b trial, designed to evaluate efficacy and safety of vidofludimus calcium in combination with the neuraminidase inhibitor, Oseltamivir (Tamiflu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#9415;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">), in approximately 120 adult patients with moderate-to-severe COVID-19.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-Planned Phase 1b Interim Analysis of Izumerogant in Moderate-to-Severe Psoriasis and Goodwill Impairment</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 20, 2022, we announced the outcome of a pre-planned interim group-level data analysis of our Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis. The overall trial is ongoing. The pre-planned interim analysis revealed that the group averages for Psoriasis Area and Severity Index ("PASI&#8221;) reductions in the two active arms did not separate from placebo at four weeks. Although the active arms performed in line with expectations, based on similarly designed trials, the trial experienced a greater decrease than expected in PASI in the placebo arm. Administration of izumerogant and placebo in this trial were demonstrated to be safe and well-tolerated, and no new safety signals were observed. We plan to provide further updates and guidance on potential next steps for this development program towards the end of the first quarter of 2023. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Following the announcement of our interim group level data on October 20, 2022, our stock price experienced a significant decline from the prices preceding the announcement and the recent prices raised in our October 10, 2022 Private Placement. We considered these to be triggering events indicating that it is more likely than not that goodwill is impaired. Upon further evaluation we incurred a non-cash full impairment of our goodwill of approximately $33.0 million in the quarter ended December 31, 2022.  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 1 Clinical Trial of Izumerogant in mCRPC</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The pre-planned dose escalation in the Phase 1 clinical trial of izumerogant in mCRPC with dosing of up to 900 mg daily has been completed. Initial safety data available, to date, show a promising safety profile, with only benign adverse events and no dose limiting toxicities.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Izumerogant Composition-of-Matter Patents Granted</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, we received a Notice of Allowance from the USPTO for patent application 16/644581, entitled, &#8220;IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation&#8221;. We also received notice of allowance of patent application EP18762111.5 in Europe, and notice of grant of patent application 2018330633 in Australia. All three patents cover composition-of-matter of izumerogant and related formulations, and are expected to provide protection into at least 2038, without accounting for potential Patent Term Extension ("PTE") in the United States or Supplementary Protection Certificates in Europe, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Exploratory Phase 1 Drug-Drug Interaction Study of Izumerogant</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">An exploratory Phase 1 study was completed in 15 evaluable healthy human subjects to assess the drug-drug interaction potential of izumerogant. No relevant signals for drug-drug interaction potential were observed and treatment was safe and well-tolerated.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:102%">Phase 1 Clinical Trial of Izumerogant, Results of Parts A and B in Healthy Human Subjects</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, we provided an update on our izumerogant program, including new preclinical and clinical data. The main result from preclinical investigations was that izumerogant inhibits cytokine production (thought to be a pre-condition for its use in immunological and autoimmune diseases) while maintaining the known and required physiological functions of maturing T lymphocytes. In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mouse cell differentiation and maturation assays, izumerogant was observed to selectively inhibit ROR&#947;t-dependent gene expression during Th17 differentiation without affecting either ROR&#947;t-dependent gene regulation relevant to thymocyte development, or the viability of these cells. In third-party research, impairment of thymocyte development has been shown to be associated with serious safety issues, including, among others, T cell malfunction and potential lymphoma formation. We believe that izumerogant's observed selectivity may enable it to inhibit both the generation of Th17 cells and the production of IL-17 cytokines that are responsible for the development of autoimmune diseases, without impairing thymocyte development, which is associated with the potential risk of lymphoma seen with other, third-party ROR&#947;t programs.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, we provided an update on the preclinical and clinical development of izumerogant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, announcing that:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unblinded data from the single ascending dose part of the ongoing Phase 1 clinical trial of a new powder-in-capsule formulation of izumerogant, in which healthy human subjects were treated with 100 mg, 200 mg, 300 mg and 400 mg of this new formulation or placebo, found these single ascending daily doses of izumerogant to be safe and well-tolerated, and no maximum tolerated dose was reached. No serious adverse events occurred. A dose-proportional PK profile was observed across the investigated dose range.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unblinded data from the multiple ascending dose part of the ongoing Phase 1 clinical trial, in which healthy human subjects were dosed for 14 days with 150 mg either once or twice daily doses of izumerogant or placebo, found these multiple ascending doses of izumerogant to be safe and well-tolerated, and no maximum tolerated dose was reached. Treatment emergent adverse events were generally mild in severity, with moderate treatment emergent adverse events reported in one of eleven izumerogant treated subjects, compared with one of four subjects on placebo. No serious adverse events were reported. No dose-dependent changes in laboratory values (including no effects on liver enzymes or in hematological parameters), vital signs or in electrocardiographic evaluations were found. PK analysis showed that stable steady-state plasma concentrations were achieved within the first week of dosing with an accumulation factor for izumerogant allowing predictable trough levels during daily dosing.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Based on the favorable safety and tolerability data observed in healthy human subjects, our Phase 1 clinical trial of izumerogant was expanded in October 2021 to include a third portion, part C, in which moderate-to-severe psoriasis patients are randomized to 28-day treatment of izumerogant or placebo. Assessments include safety, tolerability, PK and PD markers, as well as skin evaluations. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In previous preclinical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> data, it was shown that izumerogant selectively inhibits Th17 differentiation and IL-17 production, whereas ROR&#947;t was unaffected by izumerogant during thymocyte maturation and, therefore, does not harm normal thymocyte maturation. Data from acute and chronic treatment of mice corroborated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that izumerogant is the first molecule observed to impact neither thymus size, thymocyte numbers, nor the maturation status of thymocytes, in contrast to two other known inhibitors of ROR&#947;t. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Changes in Board of Directors</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 6, 2022, we announced the appointment of Monika Maria T&#246;rns&#233;n as a member of our Board of Directors, effective as of July 5, 2022. As a Class III director, Ms. T&#246;rns&#233;n&#8217;s term lasts until the Company&#8217;s 2023 annual meeting of stockholders. Concurrently, we also announced that current Class III director, Jan Van den Bossche, resigned from the Board. The Board accepted Mr. Van den Bossche&#8217;s resignation effective July 5, 2022. Mr. Van den Bossche&#8217;s decision to resign did not result from any disagreement with the Company on any matter relating to Company operations, policies or practices.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Executive Chairman Agreement with Duane Nash</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship with a base salary of $25,417 per month pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020. On October 15, 2020, the Company and Dr. Nash entered into an addendum (the &#8220;First Addendum&#8221;) to extend the term of the Executive Chairman Agreement to April 15, 2021.  In connection with the First Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 120,000 shares of Company common stock, which vests monthly over six months commencing on November 15, 2020.  On April 15, 2021, the Company and Dr. Nash entered into Addendum No. Two (the &#8220;Second Addendum&#8221;) to extend the term of the Executive Chairman Agreement to April 15, 2022.  In connection with the Second Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 90,000 shares of Company common stock, which vests monthly over 12 months commencing on May 15, 2021, and to increase Dr. Nash&#8217;s monthly base salary to $27,960 from $25,417. On March 15, 2022, the Company and Dr. Nash entered into Addendum No. Three (the &#8220;Third Addendum&#8221;), which extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $29,358 per month. In connection with the Third Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 75,000 shares of the Company&#8217;s common stock, which vests monthly over 12 months commencing on April 10, 2022.  On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="idff78559567c4173b665e875d419cf41_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles in the United States ("US"), or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an on-going basis, management makes its best estimate of the ultimate outcome for these items based on historical trends and other information available when the financial statements are prepared. Changes in estimates are typically recognized in the period when new information regarding estimates becomes available to management. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in more detail in Note 2, "Summary of Significant Accounting Policies," in the notes to the consolidated financial statements. See below for what we believe are our Critical Accounting Policies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reporting currency is US dollars. During the twelve months ended December&#160;31, 2022 and 2021, Immunic AG&#8217;s operations were located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the US dollar are translated into US dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into US dollars are recorded in stockholders&#8217; equity net of the anticipated income tax effects as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (loss). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry or market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 20, 2022, we announced the outcome of a  significant interim analysis of our Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis which was not deemed positive progress. On October 21, 2022, we experienced a significant decrease in our market capitalization.  We considered this to be a triggering event as the fair market value of the company was less than its book value indicating that it is more likely than not that goodwill is impaired.  Upon further evaluation, we recorded an approximately $33.0&#160;million goodwill impairment charge in the fourth quarter of 2022 which represents a full write down of our previous goodwill balance.  We did not have any goodwill impairment during the year ended December 31, 2021. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC, PMS and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board ("FASB") Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of December 31, 2022 and 2021, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. we recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  We are subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2017 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><div id="idff78559567c4173b665e875d419cf41_55"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates or achieving market acceptance and commercial success for any product that does receive regulatory approval.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with our research activities, including our product discovery efforts and the development of our product candidates. Our research and development expenses include: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses and milestone payments incurred under arrangements with third parties, such as CROs, contract manufacturing organizations, collaborations with partners, consultants, and our scientific advisors; and</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">internal personnel expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used in future research and development activities are capitalized as prepaid expenses and expensed when the service has been performed or when the goods have been received.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in March 2016, we have spent a total of approximately $214.8 million in research and development expenses through December 31, 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. We have spent the majority of our research and development resources on vidofludimus calcium, our lead development program, for clinical trials in MS, UC, COVID-19 and PSC.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Immunic AG received a grant of up to approximately $730,000 from the German Federal Ministry of Education and Research, in support of the InnoMuNiCH (Innovations through Munich-Nippon Cooperation in Healthcare) project.  The grant funds have been used to fund a three-year research project relating to autoimmune diseases by us and our three project partners.  Since the inception of the grant, we have recorded $611,000 of income in total of which $254,000 and $178,000 were recorded in 2022 and 2021, respectively, and were classified in Other Income in the accompanying consolidated statement of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our research and development expenses are expected to increase in the foreseeable future as we continue to conduct ongoing research and development activities, initiate new preclinical and clinical trials and build our pipeline of product candidates.   Our research and development expenses may also increase in the foreseeable future due to the current inflationary environment as well as supply chain shortages, which result in increased costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The process of conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving regulatory approval for any of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful development of product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to the development and regulatory success of each product candidate, and ongoing assessments as to each product candidate&#8217;s commercial potential.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel expenses, professional fees for legal, accounting, tax and business consulting services, insurance premiums and stock-based compensation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our money market funds and bank accounts which are a portion of our cash and cash equivalents balance. Our interest income has been increasing throughout 2022 as interest rates in the U.S.  have been increasing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of a research and development tax incentive related to clinical trials performed in Australia and foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreseeable future.  The intercompany loan between Immunic Inc. and Immunic AG was settled on September 28, 2022 through an equity infusion from Immunic Inc. to Immunic AG.  </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span><br/></span></div><div id="idff78559567c4173b665e875d419cf41_58"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Fiscal Years Ended December&#160;31, 2022 and 2021 </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses for the years ended December&#160;31, 2022 and 2021 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment (see Note 2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4SC royalty settlement (see note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,488&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,665&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,823&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,488)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,665)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,823)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(919)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,280)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,407)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,945)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,462)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses increased by $10.1 million during the twelve months ended December 31, 2022, as compared to the twelve months ended December 31, 2021. The increase reflects (i) a $9.2 million increase in external development costs related to the Phase 3 program of vidofludimus calcium in relapsing multiple sclerosis, (ii) a $3.9 million increase in external development costs related to the clinical trials of izumerogant, (iii) a $3.9 million increase in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in progressive multiple sclerosis, (iv) a $2.5 million increase in personnel expense in research and development, $1.5 million of which is related to non-cash stock compensation expense and the remainder of which is related to an increase in headcount, and (v) a $1.4 million increase in external development costs related to the Phase 1 clinical trial of IMU-856. The increases were partially offset by (i) a decrease of $5.8 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in ulcerative colitis, (ii) a $3.0 million decrease in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in COVID-19, (iii) a decrease of $1.3 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in relapsing-remitting multiple sclerosis, and (iv) a decrease of $0.7 million in external development costs across numerous categories.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative expenses increased by $2.0 million during the twelve months ended December 31, 2022, as compared to the twelve months ended December 31, 2021. The increase was primarily due to (i) a $1.6 million increase in personnel expense in general and administrative, $0.5 million of which is related to non-cash stock compensation expense and the remainder of which is related to an increase in headcount, (ii) a $0.3 million increase in travel expenses, and (iii) a $0.1 million net increase across numerous categories.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 20, 2022, we announced the outcome of a  significant interim analysis of our Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis, which was not deemed positive progress. On October 21, 2022, we experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill is impaired.  Upon further evaluation, we recorded an approximately $33.0&#160;million non-cash goodwill impairment charge in the fourth quarter of 2022 which represents a full write down of our previous goodwill balance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 31, 2021, Immunic AG and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.25 million (Tranche III of the Agreement). The payment was made 50% in cash and 50% in shares of Immunic&#8217;s common stock.  No further payment obligations remain between Immunic and 4SC AG.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other expense decreased by $0.4 million during the twelve months ended December 31, 2022, as compared to the twelve months ended December 31, 2021. The decrease was primarily attributable to (i) a $1.0 million increase in interest income as a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">result of higher interest rates, and (ii) a $0.5 million increase in research and development tax incentives for clinical trials in Australia as a result of increased spending on clinical trials in Australia. This was offset by a $1.1 million decrease in grants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity and Capital Resources </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since our inception in 2016. Our net losses were approximately $120.4&#160;million  and $92.9 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of approximately $317.3&#160;million. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the development of our product candidates and add personnel necessary to operate as a company with an advanced pipeline of product candidates. To the extent additional funds are necessary to meet long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of indebtedness, additional equity financings or a combination of these potential sources of funds, although we can provide no assurance that these sources of funding will be available on reasonable terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December&#160;31, 2022, we have raised net cash of approximately $355.5 million from private and public offerings of preferred and common stock. As of December 31, 2022, we had cash and cash equivalents of approximately $106.7&#160;million and investments - other of $9.6&#160;million. With these funds we expect to be able to fund our operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we filed a shelf registration statement on Form S-3 (the "2020 Shelf Registration Statement").   The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. As of February 17, 2023, there is $75.0&#160;million remaining on this shelf registration statement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0 million of common stock that may be issued and sold under an at-the-market sales agreement with SVB Leerink as agent ("December 2020 ATM"). We have used and intend to continue to use the net proceeds from the December 2020 ATM to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 17, 2023, $8.4 million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0 million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Securities LLC as agent. We intend to use the net proceeds from the offering to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Securities LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Securities LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 17, 2023, $80.0 million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, we raised gross proceeds of $40.9&#160;million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were  $39.6&#160;million after deducting underwriter commissions of $1.2&#160;million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Equity Offerings</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">$60 Million Private Placement Equity Financing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2022, we entered into a Securities Purchase Agreement for a private placement with select accredited investors and certain existing investors. Pursuant to the Securities Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Shares&#8221;), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants to purchase Common Stock, at a purchase price of $4.34 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.01 per share of Common Stock, are immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days&#8217; prior notice to the Company.  All of the Pre-Funded Warrants were exercised in January 2023.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Private Placement closed on October 12, 2022. The gross proceeds of the Private Placement were approximately $60.0 million, before deducting offering expenses payable by the Company. The Company intends to use the net proceeds from the Private Placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), izumerogant (IMU-935) and IMU-856, and for other general corporate purposes.</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%;text-decoration:underline">July 2021 Public Equity Offering</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 15, 2021, we entered into an underwriting agreement with Piper Sandler &amp; Co., as representative of the several underwriters listed on Schedule A thereto, in connection with our public offering of 4,500,000 shares of our common stock, $0.0001 par value per share, at a public offering price of $10.00 per share. Under the terms of the underwriting agreement, we granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 675,000 shares of common stock at the public offering price, less underwriting discounts and commissions.  This option was not exercised.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 19, 2021, we closed the offering. The net proceeds to us from the offering were approximately $42.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Capital Requirements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we have not generated any revenue from product sales and we do not know when, or if, we will generate any revenue from product sales. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize any of our product candidates. At the same time, we expect our expenses to increase as we continue the ongoing research, development, manufacture and clinical trials of, and seek regulatory approval for, our product candidates. We also incur additional costs associated with operating as a public company. In addition, subject to obtaining regulatory approval of any of our product candidates, we anticipate that we will need substantial additional funding in connection with our continuing operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future expenses and capital requirements are difficult to forecast and will depend on many factors, including, but not limited to:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and structure of any strategic options and transactions, if any;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and outcome of any future litigation;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expenses, including salaries, benefits, stock-based compensation expense and other compensation expenses related to retention and termination of personnel;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, duration, results and costs of research and development and ongoing clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of future regulatory submissions;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of developing and validating the manufacturing processes for any potential product candidates;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of any commercialization activities, including reimbursement, marketing, sales and distribution costs;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish new collaborations, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of any future product candidates we pursue;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved with being a public company;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents, including litigation costs and the outcome of such litigation; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount from the sales of, or royalties on, any future products.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of stock offerings, debt financings, strategic alliances, collaborations and licensing arrangements. Recent developments, however, will make it more difficult and costly for us to obtain funding for our cash needs. We do not expect to achieve revenue from product sales prior to the use of the net proceeds from our public and private offerings to date. We do not have any committed external source of funds. Additional funds may not be available on acceptable terms, if at all. To the extent that we raise additional capital through the sale of equity securities, the ownership interest of our stockholders will be diluted and it may be on terms that are not favorable to us or our stockholders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sales of equity securities will also be more difficult for at least the foreseeable future because of general volatility in the equity markets for companies like us, as well as the significant decline in the trading price of our stock following our announcement on October 21, 2022 of the Phase 1b interim analysis of izumerogant in moderate-to-severe psoriasis.  Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt or other terms that are not favorable to us or our stockholders. Also, the cost of debt financing has increased due to the rise in interest rates beginning in March 2022.  If we raise additional funds through collaborations and licensing arrangements with third parties, we would expect to relinquish substantial rights to our technologies or our future products, or grant licenses on terms that may not be favorable to us. If we were to complete a merger, we may relinquish all control over the organization and could experience detrimental tax effects.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to raise adequate funds, we may have to liquidate some or all of our assets. Any of these factors could harm our operating results and could result in substantial declines in the trading price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had cash and cash equivalents of approximately $106.7&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the years ended December&#160;31 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in operating activities </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, operating activities used $65.1 million of cash. The use of cash related to our net loss of $120.4 million adjusted for non-cash charges of $45.7 million related to $33.0 million of goodwill impairment, $7.9 million of stock-based compensation and a $4.8 million foreign currency loss as well as a $9.5 million net change in our operating assets and liabilities. Changes in our operating assets and liabilities consisted primarily of an decrease of $7.5 million in prepaid expenses and other current assets combined with a $2.0 million increase in other current liabilities, accrued expenses and accounts payable.  The decrease in prepaid expenses and other current assets is primarily due to lower prepaid clinical costs.  The increase in liabilities is primarily due to an increase in clinical costs as a result of the start of our Phase 3 clinical studies for RMS and Phase 2 clinical studies for PMS. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, operating activities used $83.2 million of cash. The use of cash related to our net loss of $92.9 million adjusted for non-cash charges of $8.6 million related to common stock issued for the 4SC AG transaction, $5.9 million related to stock-based compensation and a $4.3 million unrealized foreign currency loss as well as a $9.3 million net change in our operating assets and liabilities. Changes in our operating assets and liabilities consisted primarily of an increase of $12.8 million in prepaid expenses and other current assets partially offset by $3.5 million increase in other current liabilities, accrued expenses and accounts payable.  The increase in prepaid expenses and other current assets is primarily due to higher prepaid clinical costs and an increased receivable for the Australian research and development credit.  The increase in liabilities is primarily due to an increase in clinical costs as a result of the start of our Phase 3 clinical studies for RMS and Phase 2 clinical studies for PMS. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in investing activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, net investing activities used $9.7 million of cash, primarily due to purchase of 9.6 million of time deposits that had an original maturity of greater than three months and the purchase of equipment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, net investing activities used $0.1 million of cash, primarily due to purchase of equipment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by financing activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, financing activities provided $95.8&#160;million of cash of consisting of net cash proceeds from the sale of common stock under the $60 Million Private Placement Equity Financing and the December 2020 ATM.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, financing activities provided $42.8&#160;million of cash of consisting of net cash proceeds from the sale of common stock under the July 2021 equity offering and the December 2020 ATM.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2022, we have not entered into and did not have any relationships with unconsolidated entities or financial collaborations, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purpose.</span></div><div id="idff78559567c4173b665e875d419cf41_61"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, the Company entered into a purchase agreement with 4SC whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction was accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to 4.4% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing 120,070 shares of the Company&#8217;s common stock to 4SC at the time, while keeping the obligation to pay Tranche III in effect. Approximately $1.5 million of expense was recorded as a result of the issuance of these shares on April 12, 2019. On March 31, 2021, Immunic AG, a wholly-owned subsidiary of the Company, and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.3&#160;million (Tranche III of the purchase agreement). The payment was made 50% in cash and 50% in shares of Immunic&#8217;s common stock. Pursuant to the Agreement, the Company filed a resale shelf registration statement on Form S-3 covering the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resale of the Shares. With the execution of the Agreement, no further payment obligations remain between Immunic AG and 4SC AG.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 - Collaboration Arrangements of the Notes to the Financial Statements regarding the Company&#8217;s obligations under the option agreement with Daiichi Sankyo, which includes the potential payment of future development, regulatory and sales milestone payments, as well as royalties related to IMU-856</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Maturities of the operating lease obligation are as follows as of December&#160;31, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2022, the Company has non-cancelable contractual obligations under certain agreements related to its development programs for vidofludimus calcium, izumerogant and IMU-856 totaling approximately $4.5 million, all of which is expected to be paid in 2023.</span></div><div id="idff78559567c4173b665e875d419cf41_64"></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements. </span></div><div id="idff78559567c4173b665e875d419cf41_67"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Sensitivity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash and cash equivalents of $106.7 million as of December&#160;31, 2022, which were held for working capital purposes. We do not enter into investments for trading or speculative purposes. We do not believe that we have any material exposure to changes in the fair value of these investments as a result of changes in interest rates due to their short-term nature. However, $28.9 million of these funds are held in German bank accounts that were earning between 1%-2.5% interest as of December 31, 2022.  Decreases or increases in interest rates, however, will reduce or increase future investment income, respectively, to the extent we have funds available for investment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary research and development operations are conducted in our facilities in Germany. We have entered into and may continue to enter into international agreements, primarily related to our clinical studies. Accordingly, we have exposure to foreign currency exchange rates and fluctuations between the U.S. dollar and foreign currencies, primarily the euro and the Australian dollar, which could adversely affect our financial results, including income and losses as well as assets and liabilities. To date, we have not entered into, and do not have any current plans to enter into, any foreign currency hedging transactions or derivative financial transactions. Our exposure to foreign currency risk will fluctuate in future periods as our research and clinical development activities in Europe and Australia change. We currently maintain a significant amount of our assets outside of the U.S.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of our foreign subsidiaries are the applicable local currencies. Accordingly, the effects of exchange rate fluctuations on the net assets of these operations are accounted for as translation gains or losses in accumulated other comprehensive income (loss) within stockholders&#8217; equity.  Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). Our German subsidiary is currently a significant portion of our business and, accordingly, a change of 10% in the currency exchange rates, primarily the euro, could have a material impact on their financial position or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although operating in local currencies may limit the impact of currency rate fluctuations on the results of operations of our German and Australian subsidiaries, rate fluctuations may impact the consolidated financial position as the assets and liabilities of our foreign operations are translated into U.S. dollars in preparing our consolidated balance sheets. As of December 31, 2022, our German and Australian subsidiaries had net current assets (defined as current assets less current liabilities), subject to foreign currency translation risk, of $27.7 million. A decrease of approximately $2.8 million in net current assets would result as of December 31 2022, from a hypothetical 10% adverse change in quoted foreign currency exchange rates, primarily due to the euro.  In addition, a 10% change in the foreign currency exchange rates for the year ended December 31, 2022, would have impacted our net loss by approximately $7.3 million, primarily due to the euro.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced a general increase in costs as a result of global inflation, however, we do not believe that inflation and changing prices had a material impact on our results of operations for any periods presented herein.</span></div><div id="idff78559567c4173b665e875d419cf41_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.&#160;Financial Statements and Supplementary Data.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements required pursuant to this item are included in Part IV, Item&#160;15 of this Annual Report, and are presented beginning on page&#160;F-1.</span></div><div id="idff78559567c4173b665e875d419cf41_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;Controls and Procedures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, with the participation of our Chief Executive Officer and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2022. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rule 13a-15(e) of the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2022, our Chief Executive Officer and Principal Financial Officer have concluded that, as of December&#160;31, 2022, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) under the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial Officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance (a) that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, (b) that our receipts and expenditures are being made only in accordance with authorizations of our management and directors, and (c) regarding the prevention or timely detection of the unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our management conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control - Integrated Framework (2013). Based on this evaluation, our management concluded that, as of December&#160;31, 2022, our internal control over financial reporting was effective.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="idff78559567c4173b665e875d419cf41_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;Other Information.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="idff78559567c4173b665e875d419cf41_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.&#160;Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our definitive proxy statement (the &#8220;Definitive Proxy Statement&#8221;), to be filed with the SEC in connection with our 2023 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2022, under the headings &#8220;Election of Directors,&#8221; &#8220;Board of Directors and Corporate Governance,&#8221; &#8220;Executive Officers,&#8221; and &#8220;Section 16(a) Beneficial Ownership Reporting Compliance,&#8221; and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a written Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer and our principal accounting officer and every other director, officer and employee of Immunic. The Code of Business Conduct and Ethics is available on our Internet website at www.imux.com. A copy of the Code of Business Conduct and Ethics will be provided free of charge by making a written request and mailing it to our corporate headquarters offices to the attention of the Investor Relations Department. If any amendment to, or a waiver from, a provision of the Code of Business Conduct and Ethics that applies to the principal executive officer, principal financial officer and principal accounting officer is made, such information will be posted on our Internet website within four business days at www.imux.com.</span></div><div id="idff78559567c4173b665e875d419cf41_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11.&#160;Executive Compensation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be found in our Definitive Proxy Statement under the heading "Executive Compensation" and is incorporated herein by reference.</span></div><div id="idff78559567c4173b665e875d419cf41_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12.&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be found in our Definitive Proxy Statement under the heading "Security Ownership" and is incorporated herein by reference.</span></div><div id="idff78559567c4173b665e875d419cf41_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13.&#160;Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be found in our Definitive Proxy Statement under the headings "Board of Directors and Corporate Governance" and "Related Person Transactions" and is incorporated herein by reference.</span></div><div id="idff78559567c4173b665e875d419cf41_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14.&#160;Principal Accounting Fees and Services.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be found in our Definitive Proxy Statement under the heading "Ratification of Appointment of Independent Registered Public Accounting Firm" and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="idff78559567c4173b665e875d419cf41_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;Exhibits, Financial Statement Schedules.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:11.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">1. Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#160;We have filed the following documents as part of this Annual Report:</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Baker Tilly US,  LLP, Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idff78559567c4173b665e875d419cf41_112">F-2</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idff78559567c4173b665e875d419cf41_115">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idff78559567c4173b665e875d419cf41_115">4</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idff78559567c4173b665e875d419cf41_118">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idff78559567c4173b665e875d419cf41_118">5</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idff78559567c4173b665e875d419cf41_121">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idff78559567c4173b665e875d419cf41_121">6</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders&#8217; Equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idff78559567c4173b665e875d419cf41_124">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idff78559567c4173b665e875d419cf41_124">7</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idff78559567c4173b665e875d419cf41_127">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idff78559567c4173b665e875d419cf41_127">8</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idff78559567c4173b665e875d419cf41_130">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#idff78559567c4173b665e875d419cf41_130">9</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2. Financial Statement Schedules.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> None.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">3. Exhibits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The following exhibits are filed herewith or are incorporated by reference to exhibits previously </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">filed with the U.S. Securities and Exchange Commission.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBITS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-1.htm">Amended and Restated Articles of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-2.htm">Third Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000837/e618652_ex4-2.htm">2019 Omnibus Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 20, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit422022.htm">Description of Registrant's Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380522001344/e621975_ex4-1.htm">Form of Pre-Funded Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 11, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-1.htm">Sales Agreement, dated July 17, 2019, between Immunic, Inc. and SVB Leerink LLC.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-2.htm">Option and License Agreement, dated September 27, 2018, between Immunic AG and Daiichi Sankyo Company, Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-3.htm">Asset Purchase Agreement, dated May 13, 2016, between Immunic AG and 4SC AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-4.htm">Form of Indemnification Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-ex105dienstvertragand.htm">Service Agreement dated August 22, 2016 between Immunic AG and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-ex106dienstvertragdan.htm">Service Agreement dated September 29, 2016 between Immunic AG and Daniel Vitt</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-5.htm">Employment Agreement between Dr. Daniel Vitt and Immunic AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex10-1.htm">Addendum to Service Agreement between Immunic AG and Dr. Daniel Vitt.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex99-3.htm">Employment Agreement, dated September 4, 2019, between Immunic, Inc. and Dr. Andreas Muehler.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex99-2.htm">Addendum, dated September 4, 2019, to Service Agreement between Immunic AG and Dr. Andreas Muehler.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex99-4.htm">Addendum, dated September 4, 2019, to Service Agreement between Immunic AG and Dr. Hella Kohlhof.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000499/e619564_ex10-2.htm">Employment Agreement dated April 17, 2020, between Immunic, Inc. and Duane Nash.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380521000513/e620493_ex10-1.htm">Second Addendum to Employment Agreement dated October 15, 2020, between Immunic, Inc. and Duane Nash.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 19, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000519/e619576_ex10-1.htm">Placement Agency Agreement, dated April 23, 2020, between Immunic, Inc. and Roth Capital Partners, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000519/e619576_ex10-2.htm">Form of Securities Purchase Agreement, dated April 23, 2020, between Immunic, Inc. and the investors party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000688/e619697_ex10-1.htm">Placement Agency Agreement, dated June 10, 2020, between Immunic, Inc.  and the Roth Partners, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 12, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000688/e619697_ex10-2.htm">Form of Securities Purchase Agreement, dated June 10, 2020, between Immunic, Inc. and the investors party thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 12, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000975/e619841_ex1-1.htm">Underwriting Agreement, dated August 4, 2020, by and between Immunic, Inc. and SVB Leerink LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520001296/e620006_ex10-1.htm">Finance Contract, dated October 19, 2020, between Immunic, Inc., Immunic AG and European Investment Bank</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520001296/e620006_ex10-2.htm">Form of Guarantee Agreement between Immunic, Inc., Immunic AG and European Investment Bank.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000002/e620187_ex10-1.htm">Sales Agreement, dated December 29, 2020 between Immunic, Inc. and SVB Leerink LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 4, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520001425/e620080_ex10-1.htm">Amendment Letter, dated November 11, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 13, 2020</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380521000441/e620436_ex10-1.htm">Settlement Agreement, dated March 31, 2021, between Immunic AG and 4SC AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000513/e620493_ex10-1.htm">Addendum No. 2 to Employment Agreement dated April 15, 2021 between Immunic, Inc. and Duane Nash</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-1.htm">Second Addendum to Service Agreement between Immunic AG and Dr. Daniel Vitt</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-2.htm">Second Addendum, dated June 10, 2021 to Service Agreement between Immunic AG and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-3.htm">Employment Agreement, dated June 10, 2021 between Immunic, Inc. and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-4.htm">Employment Agreement, dated June 10, 2021 between Immunic, Inc. and Glenn Whaley</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex99-2.htm">Second Addendum, dated June 10, 2021, to Service Agreement between Immunic AG and Dr. Hella Kohlhof</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521001043/e620806_ex1-1.htm">Underwriting Agreement, dated July 15, 2021, by and between Immunic, Inc. and Piper Sandler &amp; Co</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521001455/e621010_ex10-1.htm">Employment Agreement, dated October 14, 2021, between Immunic, Inc. and Patrick Walsh</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 14, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380522000023/e621200_ex10-1.htm">Third Addendum, dated January 5, 2022, to Service Agreement between Immunic AG and Dr. Daniel Vitt</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 10, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380522000023/e621200_ex10-2.htm">Third Addendum, dated January 5, 2022, to Service Agreement between Immunic AG and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 10, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380522000023/e621200_ex10-3.htm">Third Addendum, dated January 5, 2022, to Service Agreement between Immunic AG and Dr. Hella Kohlhof</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 10, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380522000504/e621458_ex10-1.htm">Addendum No. 3 to Employment Agreement, dated March 15, 2022, between Immunic, Inc. and Duane Nash</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380522000711/e621604_ex10-1.htm">Sales Agreement dated as of May 2, 2022, between SVB Securities LLC and Immunic, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380522001344/e621975_ex10-1.htm">Securities Purchase Agreement, dated October 10, 2022, by and among the Company and the Purchasers</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 11, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380522001809/e618165_ex10-1.htm">Addendum No. 4 dated December 28, 2022 to Employment Agreement, between Immunic, Inc. and Duane Nash</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523000064/e618207_ex10-1.htm">Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Daniel Vitt</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523000064/e618207_ex10-2.htm">Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523000064/e618207_ex10-3.htm">Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Hella Kohlhof</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2023</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-123122xexhibit211.htm">List of subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit23111.htm">Consent of Baker Tilly U.S. LLP, Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_169">Power of Attorney (included on the signature page)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-123122xexhibit311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-123122xexhibit312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-123122xexhibit321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-123122xexhibit322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Database.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with Item&#160;601(b)(32)(ii) of Regulation S-K and SEC Release No.&#160;33-8238 and 34-47986, Final Rule: Management&#8217;s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:92.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_112">Report of Baker Tilly U</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_112">S</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_112"> LLP, Independent Registered Public Accounting Firm (PCAOB ID </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMDkvZnJhZzozNmMyYTEzYWEyZWE0NjJjYjYxYTA4MWY5ZmExYjBiMy90YWJsZTpkOTVhMzMyYmU0Njg0MGVmYjliNzc3Y2ZkODU1MGM4Mi90YWJsZXJhbmdlOmQ5NWEzMzJiZTQ2ODQwZWZiOWI3NzdjZmQ4NTUwYzgyXzEtMC0xLTEtMzQ4NjIvdGV4dHJlZ2lvbjo2ZmM2ODEwZTQ0YWM0Mzk1OGU4MzVlMjRhMjRkNjU4Ml85Mg_d284138a-d48f-4802-8aa1-efe131550eb2">23</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_112">)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_115">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_118">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_121">Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_124">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_127">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idff78559567c4173b665e875d419cf41_130">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-9</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 1</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To the shareholders and the board of directors of Immunic, Inc.:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have audited the accompanying consolidated balance sheets of Immunic, Inc. (the "Company") as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders' equity, and cash flows, for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Critical Audit Matter</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which it relates.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Assessment of accrual for research and development costs related to clinical trial activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Critical Audit Matter Description</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described in Note 2 and 3 to the consolidated financial statements, the Company records expenses and accruals for estimated costs of research and development activities, including third party contract services costs for clinical research. Clinical trial activities performed by third parties are expensed based upon estimates of work completed in accordance with agreements with the respective Clinical Research Organization. Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Auditing the accounting for accrued clinical trial expenses is complex because of the high volume of data used in management&#8217;s estimates, the assumptions used by management to develop their estimates and the procedures necessary to verify the cost and extent of unbilled work performed during the reporting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">How We Addressed the Matter in Our Audit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We obtained an understanding of the Company&#8217;s process and evaluated the design and implementation of internal controls related to the completeness and valuation of accrued clinical trial expenses.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To test the clinical trial accrual, our audit procedures included, among others, testing the accuracy and completeness of the underlying data used in the estimates and evaluating and testing the significant assumptions used by management to estimate the accruals. To test the significant assumptions, we corroborated the progress of clinical trials and other research and development projects with the Company&#8217;s research and development personnel that oversee the clinical trials, and obtained information received directly from third parties, which included the third parties&#8217; estimate of costs incurred to date. We also tested subsequent invoicing received from third parties.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTIvZnJhZzpjM2M3NDg4ZmM2M2M0NjBlOTlmM2JiNTM1NjgwMzE3My90ZXh0cmVnaW9uOmMzYzc0ODhmYzYzYzQ2MGU5OWYzYmI1MzU2ODAzMTczXzIxOTkwMjMyODk0ODY_d672eecb-e84d-4750-8744-8fd70ab4da74">Baker Tilly US, LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have served as the Company's auditor since 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTIvZnJhZzpjM2M3NDg4ZmM2M2M0NjBlOTlmM2JiNTM1NjgwMzE3My90ZXh0cmVnaW9uOmMzYzc0ODhmYzYzYzQ2MGU5OWYzYmI1MzU2ODAzMTczXzIxOTkwMjMyODk0ODc_df4bfa6c-27e0-4d3e-b1b4-b0f9350c710b">Minneapolis, MN</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">February 23, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 3</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzQtMS0xLTEtMzQ4NjI_f20af40b-6957-4ebc-99c6-51cb197659db">106,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzQtMy0xLTEtMzQ4NjI_2608f7aa-dbae-4e9c-8abd-19baf5969da1">86,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments - other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzUtMS0xLTEtMzk4NDc_1906042b-7c31-42b3-bb1a-d973fd4caf38">9,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzUtMy0xLTEtMzk4NDc_4ce0f728-321d-437d-83b7-1990a64b9db3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzUtMS0xLTEtMzQ4NjI_5032852d-74d8-4747-b507-d43bc1162337">9,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzUtMy0xLTEtMzQ4NjI_c33d9ada-250d-4427-9404-8ddbc7537f07">18,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzYtMS0xLTEtMzQ4NjI_10acf1de-7de8-430e-ab09-deb232e1c646">125,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzYtMy0xLTEtMzQ4NjI_433b02f7-3039-466a-8ec8-5da649e47326">104,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzctMS0xLTEtMzQ4NjI_2c5bb9a7-b248-4299-8af8-4e68825d0136">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzctMy0xLTEtMzQ4NjI_e96b174c-c795-4d8a-999d-ba0f3bd1c87c">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill (note 2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzgtMS0xLTEtMzQ4NjI_b092a53b-26a8-422f-9447-bb75d7bf4fb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzgtMy0xLTEtMzQ4NjI_8d71f11f-eee6-4604-ad01-885a8ba88dd5">32,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzktMS0xLTEtMzQ4NjI_5a96f241-b913-4c4a-ad84-41b80d2ad541">1,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzktMy0xLTEtMzQ4NjI_2ec1dd89-f3d4-4b24-8930-5fa1116ad0c9">948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzEwLTEtMS0xLTM0ODYy_f5bc927b-0ce5-498c-a99f-fd29dec7cb38">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzEwLTMtMS0xLTM0ODYy_9acccd27-5a10-4082-87f9-3342b15dcdc9">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzExLTEtMS0xLTM0ODYy_06e12a72-f302-48dd-be4b-a897f083beb3">127,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzExLTMtMS0xLTM0ODYy_fbd631ee-f8ef-4933-a964-70fe3594c5f2">139,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities  and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE0LTEtMS0xLTM0ODYy_f87c36c7-a048-496b-85ae-950892b7ed9b">4,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE0LTMtMS0xLTM0ODYy_d59fb7cf-31bb-4619-8365-ee88558bc061">3,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE1LTEtMS0xLTM0ODYy_d9dd73fc-b525-49c1-9256-994a47628161">7,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE1LTMtMS0xLTM0ODYy_f6bd9514-9049-467f-ab8e-62cd7441bd10">7,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE2LTEtMS0xLTM0ODYy_40f52c5e-50fa-4a85-b5ef-3758f46c80ba">810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE2LTMtMS0xLTM0ODYy_7271ebb3-1bc2-4424-aacf-b6c1ab057fd8">585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE3LTEtMS0xLTM0ODYy_7901b082-2ae0-488e-87c5-b59e04a3e76e">13,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE3LTMtMS0xLTM0ODYy_c2bf9a79-755d-4c1b-8225-e7b63ab53aa6">11,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE5LTEtMS0xLTM0ODYy_c8a61a27-3357-4f64-b180-b73db45d0002">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE5LTMtMS0xLTM0ODYy_7bae81cc-d0fb-4a85-babb-17b072190ff6">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzIwLTEtMS0xLTM0ODYy_f86219c5-f70c-42c9-8382-fe33e44cb702">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzIwLTMtMS0xLTM0ODYy_401dda25-01af-477f-b320-a5f662d7bc3b">584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzIxLTEtMS0xLTM0ODYy_35e9f2d6-7218-4b1d-a70a-5a4c013c5503">14,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzIxLTMtMS0xLTM0ODYy_4ffc4d3d-157d-46b9-a860-1c140c072918">11,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (note 4)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzIyLTEtMS0xLTM0ODYy_b4799c07-3aa9-4c87-b317-6976938fce49"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzIyLTMtMS0xLTM0ODYy_da71cc73-21ac-416c-842b-9f3fd222360c"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzkxMA_6ed7eb7e-0bd5-48dd-a5ee-36d02f38234b"><ix:nonFraction unitRef="usdPerShare" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzkxMA_e15ef16c-a56f-4442-ac0c-0769a16076c2">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzkzOQ_0fe29f1c-51ce-43fc-bd0b-abbd5a476513"><ix:nonFraction unitRef="shares" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzkzOQ_91a6c8d4-101e-4b8c-8578-d2566825e153">20,000,000</ix:nonFraction></ix:nonFraction> authorized and <ix:nonFraction unitRef="shares" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzk0NA_15131a19-0ba4-413f-a4ac-d5a69ae5cdf4"><ix:nonFraction unitRef="shares" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzk0NA_79690e61-f4b0-4cff-ba30-e875e90571d7"><ix:nonFraction unitRef="shares" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzk0NA_79cde244-5aa4-4d3a-ae01-85089ba5a9e3"><ix:nonFraction unitRef="shares" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzk0NA_92854a1e-fba0-4d48-a6d8-a23f9546ddae">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at December&#160;31, 2022 and 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTEtMS0xLTM0ODYy_cfd40eff-c974-4923-8c4b-18af173a683f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTMtMS0xLTM0ODYy_89df00a2-e35f-45d6-89bb-f9256a12175c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk1Mw_3c03cd9a-8090-4927-9bb2-370bb6582519"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk1Mw_3e812123-ebed-40fc-ba00-19624f46ed29">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk2Nw_17c8303a-56d3-47ac-906b-0cd43156b3c3"><ix:nonFraction unitRef="shares" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk2Nw_dd761b58-88e2-4731-9bf8-d0a009d770e9">130,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk4MA_6e7dc3d5-6f08-407c-9c22-af9826ef559f"><ix:nonFraction unitRef="shares" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk4MA_fd81ed9a-3452-4ed3-9968-56a4e06c9077">39,307,286</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk5Mw_a829b461-1ca6-4d3d-8c53-5a7041023fbf"><ix:nonFraction unitRef="shares" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk5Mw_ab2800ff-3eea-440e-a4f2-fc0b4f68feff">26,335,418</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTEtMS0xLTM0ODYy_0052f6fb-f565-42db-bd09-8d41cc14e5f7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTMtMS0xLTM0ODYy_237e3a08-cef4-4524-8277-28ceb9636e03">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI2LTEtMS0xLTM0ODYy_4c05eacf-6cff-403c-a7ad-729cf0c4a003">427,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI2LTMtMS0xLTM0ODYy_d3826cbc-7af3-4a64-9192-cbc6c8c09bb3">324,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI3LTEtMS0xLTM0ODYy_e21c4649-c799-4246-87b4-a3259c6fe9af">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI3LTMtMS0xLTM0ODYy_afe705f5-6822-4589-aee0-b7bdafd6ee63">252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI4LTEtMS0xLTM0ODYy_30150d12-8f6d-40e7-885d-f039b77627f5">317,280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI4LTMtMS0xLTM0ODYy_1dec4227-17aa-4d94-a6a3-8c3380fafaaa">196,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI5LTEtMS0xLTM0ODYy_fe02e00a-9b5d-4cdf-a12b-ee15a8da4026">113,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI5LTMtMS0xLTM0ODYy_eadd4fc8-aaa0-4b9f-b29a-9c76fb66ce99">127,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzMwLTEtMS0xLTM0ODYy_6f4b5a1a-6e5d-4458-9779-6a4b56215c17">127,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzMwLTMtMS0xLTM0ODYy_ad5ff95e-8b01-40f7-bc46-1f661ea43312">139,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 4</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"><tr><td style="width:1.0%"></td><td style="width:68.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzMtMS0xLTEtMzQ4NjI_1e0f06ea-e743-4845-ad27-b06a79547ed6">71,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzMtMy0xLTEtMzQ4NjI_5961905f-a816-4cbc-8d53-30d9e85c2396">61,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzQtMS0xLTEtMzQ4NjI_0a3a133c-7a67-488f-82da-13b18240e74f">15,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzQtMy0xLTEtMzQ4NjI_399ef72b-789b-4cf8-9009-24867262f997">13,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment (see Note 2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzUtMS0xLTEtMzU4MTM_f935fbac-520b-40b5-b511-95916593a926">32,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzUtMy0xLTEtMzU4MDE_f70453c0-9c14-42d2-9fdc-8e2c9f0c7708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4SC Royalty Settlement (See Note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="imux:RoyaltySettlementAgreementSalesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzUtMS0xLTEtMzQ4NjI_cb41e649-ce91-4535-bbe8-7be05727c015">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="imux:RoyaltySettlementAgreementSalesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzUtMy0xLTEtMzQ4NjI_6b2a567b-46fd-41eb-a3c7-94c2b7932b1b">17,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzYtMS0xLTEtMzQ4NjI_4082e27b-c4c3-41dd-8b87-58cb88f339a3">119,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzYtMy0xLTEtMzQ4NjI_856324b7-a606-44c3-9882-74f16a143503">91,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzctMS0xLTEtMzQ4NjI_883a958d-27a9-4e9a-b922-a4cbac8d03c0">119,488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzctMy0xLTEtMzQ4NjI_f994a485-3a6a-4d51-b585-8f41e5893dba">91,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzktMS0xLTEtMzQ4NjI_91cb7f87-969b-446a-bbd8-b0bc669d45d9">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzktMy0xLTEtMzQ4NjI_b0d855c1-49f7-4437-82b0-1bf40356c858">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzEwLTEtMS0xLTM0ODYy_2ee21f21-3559-406c-8edd-6457c624c81e">1,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzEwLTMtMS0xLTM0ODYy_7f76a42b-ac9d-47ad-b2e6-f138626c59a7">1,346</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzExLTEtMS0xLTM0ODYy_22eee007-335b-47d1-ae20-bff44004d689">919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzExLTMtMS0xLTM0ODYy_1665f106-e806-42b7-bc9d-788652fef3f6">1,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzEyLTEtMS0xLTM0ODYy_ac4d9de2-d3d0-40f4-812b-f38ca7b1dee8">120,407</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzEyLTMtMS0xLTM0ODYy_48778cbd-fbc5-47fb-8f14-457f266cac86">92,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE0LTEtMS0xLTM0ODYy_2f4f1aee-c802-4bc1-9cc0-5dd8c7b34a8c"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE0LTEtMS0xLTM0ODYy_d0cf27b9-fb20-49ac-bd05-4473101719ed">3.78</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE0LTMtMS0xLTM0ODYy_021937de-fa38-4d42-b95a-9b928cb6cdbe"><ix:nonFraction unitRef="usdPerShare" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE0LTMtMS0xLTM0ODYy_51f76ba2-dd30-49a5-8f14-d18e74907ad8">3.93</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE2LTEtMS0xLTM0ODYy_90dee67e-ba8f-4feb-b0e8-15a93d2b61bb"><ix:nonFraction unitRef="shares" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE2LTEtMS0xLTM0ODYy_c6e00cfe-0540-436b-a42d-c095516692e4">31,819,006</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE2LTMtMS0xLTM0ODYy_a8664581-6361-44f6-92a7-abac24683fb7"><ix:nonFraction unitRef="shares" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE2LTMtMS0xLTM0ODYy_d47f3004-9e9c-4958-9fd1-2c2cf10ccd5c">23,652,779</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 5</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"><tr><td style="width:1.0%"></td><td style="width:68.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjEvZnJhZzo0M2RmOTVjNzc1OTE0NTk5YTA4YjIxMWRiZDBlZjkxMy90YWJsZTpiM2RlNDFiMzEzZjE0OTViOGM2MGI4ZTFiOTI3MjM2NC90YWJsZXJhbmdlOmIzZGU0MWIzMTNmMTQ5NWI4YzYwYjhlMWI5MjcyMzY0XzItMS0xLTEtMzQ4NjI_ac4d9de2-d3d0-40f4-812b-f38ca7b1dee8">120,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjEvZnJhZzo0M2RmOTVjNzc1OTE0NTk5YTA4YjIxMWRiZDBlZjkxMy90YWJsZTpiM2RlNDFiMzEzZjE0OTViOGM2MGI4ZTFiOTI3MjM2NC90YWJsZXJhbmdlOmIzZGU0MWIzMTNmMTQ5NWI4YzYwYjhlMWI5MjcyMzY0XzItMy0xLTEtMzQ4NjI_48778cbd-fbc5-47fb-8f14-457f266cac86">92,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjEvZnJhZzo0M2RmOTVjNzc1OTE0NTk5YTA4YjIxMWRiZDBlZjkxMy90YWJsZTpiM2RlNDFiMzEzZjE0OTViOGM2MGI4ZTFiOTI3MjM2NC90YWJsZXJhbmdlOmIzZGU0MWIzMTNmMTQ5NWI4YzYwYjhlMWI5MjcyMzY0XzQtMS0xLTEtMzQ4NjI_e6598bb2-1900-430e-b9b5-173d4bae9abc">3,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjEvZnJhZzo0M2RmOTVjNzc1OTE0NTk5YTA4YjIxMWRiZDBlZjkxMy90YWJsZTpiM2RlNDFiMzEzZjE0OTViOGM2MGI4ZTFiOTI3MjM2NC90YWJsZXJhbmdlOmIzZGU0MWIzMTNmMTQ5NWI4YzYwYjhlMWI5MjcyMzY0XzQtMy0xLTEtMzQ4NjI_1f44807c-f397-4e40-ba26-aa5fc6c20415">3,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjEvZnJhZzo0M2RmOTVjNzc1OTE0NTk5YTA4YjIxMWRiZDBlZjkxMy90YWJsZTpiM2RlNDFiMzEzZjE0OTViOGM2MGI4ZTFiOTI3MjM2NC90YWJsZXJhbmdlOmIzZGU0MWIzMTNmMTQ5NWI4YzYwYjhlMWI5MjcyMzY0XzUtMS0xLTEtMzQ4NjI_1d53a1ea-73d4-4d00-a207-b3c65fa38e9a">117,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjEvZnJhZzo0M2RmOTVjNzc1OTE0NTk5YTA4YjIxMWRiZDBlZjkxMy90YWJsZTpiM2RlNDFiMzEzZjE0OTViOGM2MGI4ZTFiOTI3MjM2NC90YWJsZXJhbmdlOmIzZGU0MWIzMTNmMTQ5NWI4YzYwYjhlMWI5MjcyMzY0XzUtMy0xLTEtMzQ4NjI_2825d99d-944d-4e41-a05e-a9a985aefd24">89,085</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 6</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_124"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;shares)</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:36.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.676%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.319%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic389dfc27c9a4f599aa3e1e541429096_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzYtMi0xLTEtMzQ4NjI_96302624-9523-4e4e-be06-85dfc0837399">21,168,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic389dfc27c9a4f599aa3e1e541429096_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzYtNC0xLTEtMzQ4NjI_071cac23-83d9-4edc-b3aa-a4aacd52eebb">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbaa6c3142f843bd9914319d7c76fd83_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzYtNi0xLTEtMzQ4NjI_49d0fd37-69e6-4d0f-b811-f45786cf8a97">266,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01764048ea4440fdbba38575095ead15_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzYtOC0xLTEtMzQ4NjI_5b74286b-45aa-4389-af37-cc1fe5775aed">4,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4273fe852996496a9bf00e5bd9ca421e_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzYtMTAtMS0xLTM0ODYy_4dd28454-82a4-4591-847e-24dfcffc28a7">103,928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife1cbb9302f3417394aee800539a7c78_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzYtMTItMS0xLTM0ODYy_b9b27120-2586-4106-b9f5-43d587157a8c">158,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7134d7b7af464feaa82036ca57d1ca9c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzctMTAtMS0xLTM0ODYy_18dc2fdf-5f5d-4c37-9d1e-18d4ecdea906">92,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzctMTItMS0xLTM0ODYy_697bbcbe-fe41-468e-888f-1ee91b03f59b">92,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8350e86a9cac4049bf5f8412ebbbc922_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzgtOC0xLTEtMzQ4NjI_f24766f8-80ad-48b9-af73-e8ee95c9c009">3,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzgtMTItMS0xLTM0ODYy_73511656-da03-4c61-bab9-ccf1a5e796f3">3,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88c39fd3b36467dbf626e7ce52cd7df_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzktNi0xLTEtMzQ4NjI_cefcafeb-b775-4f29-aa03-5e23057570e2">5,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzktMTItMS0xLTM0ODYy_7c18a615-90b2-43b7-816c-e79fc454551b">5,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - July 2021 equity offering net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i42cae9630d124c15823d3c9c381fc07a_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEwLTAtMS0xLTM0ODYyL3RleHRyZWdpb246ZjhhNWNlZTk4NGYzNDNmY2I5NDVmMTMyNjI4NzgyNWRfMTA5OTUxMTYyNzg3NA_1d4716a1-8324-44dd-a94e-716e3adaa3a5">2,980</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5184b8a176204d52b8ec471db493c60c_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEwLTItMS0xLTM0ODYy_b3e3e092-c22c-4cd0-95ab-1a80c40a8657">4,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5184b8a176204d52b8ec471db493c60c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEwLTQtMS0xLTM0ODYy_fe29e72a-b61e-4084-a2eb-c94946fa8d65">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df795cc621b4f6e870a724ef84c27b1_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEwLTYtMS0xLTM0ODYy_92f82994-c76a-44d2-9138-ffbee4975700">42,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42cae9630d124c15823d3c9c381fc07a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEwLTEyLTEtMS0zNDg2Mg_17415cbd-470c-4930-9a05-d2d5fd6e6de5">42,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - At The Market Sales Agreement net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i398768618fec47a5abec4be325449aae_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzExLTAtMS0xLTM0ODYyL3RleHRyZWdpb246OTYzN2E5MTNlOGRiNDEwNGE3YjEwOWE5MzE4NzVlNzVfMTA5OTUxMTYyNzg2OA_ff617414-dad5-4e41-95dc-edc0159608e3">23</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0638ec649d204c94997a5155ac425b91_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzExLTItMS0xLTM0ODYy_4ab08944-3fce-400f-9c80-9b516e245f2e">73,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00de82f73e494662bbcb2347d6aa2a68_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzExLTYtMS0xLTM0ODYy_614de334-0a83-440c-9281-183dbd7bc87c">729</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i398768618fec47a5abec4be325449aae_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzExLTEyLTEtMS0zNDg2Mg_8760c53e-28b0-4e1a-a961-53566f61cdc8">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued in connection with the Company's employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52b16c5e8d554ecfb4804e40b1137a63_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEyLTItMS0xLTM0ODYy_12e42f0b-7041-4705-aed9-9ee8cd21be70">12,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88c39fd3b36467dbf626e7ce52cd7df_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEyLTYtMS0xLTM0ODYy_285b7163-95ab-4155-ad59-7bc96cc5625e">92</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEyLTEyLTEtMS0zNDg2Mg_a511ab4a-eb2d-49e3-9a7e-d50aa05eabde">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the 4SC royalty settlement (see note 4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69622c2fdecf4530a84d6ff11b19e1a6_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEzLTItMS0xLTM0ODYy_c5576b1f-22ea-4a69-9964-8c6ce992250c">581,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef0cd612dd459b89f27fa032430ea8_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEzLTYtMS0xLTM0ODYy_4c02e6b5-ed82-480e-a175-4d69c109fbb7">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b01402daaa6442ea66a3fe6b2b2dae4_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEzLTEyLTEtMS0zNDg2Mg_9d0474eb-d1ae-400e-9a59-5348c6d42b50">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c967dfd128445f9a1b3ec335c1bb34f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE0LTItMS0xLTM0ODYy_04e72a60-3ce0-496f-9fea-dd226c02fac8">26,335,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c967dfd128445f9a1b3ec335c1bb34f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE0LTQtMS0xLTM0ODYy_198c9b7e-3f28-4757-a583-b44d59b437b1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i821d3d85d32247aba8a2d73345eaafda_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE0LTYtMS0xLTM0ODYy_5b6a152e-c6fe-41f9-bcd3-44bcb6512045">324,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie05ff69c61e740ba9e894b118d4ead6c_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE0LTgtMS0xLTM0ODYy_b32ef51c-9181-4415-9936-531a9cf7ed12">252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6af8e102c5642eb926a526cbf7478d4_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE0LTEwLTEtMS0zNDg2Mg_bef118d4-0f6c-4c00-8e99-32cf66b9465e">196,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE0LTEyLTEtMS0zNDg2Mg_f82cf975-9461-4e57-b8fb-3735b4e8cde8">127,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ccd4cb28be412ab9d49ec84d752b6a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE1LTEwLTEtMS0zNDg2Mg_f918cbbf-c4e6-4a06-af7a-8c57e7977440">120,407</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE1LTEyLTEtMS0zNDg2Mg_7c45dc20-e99e-4ee9-a542-12cf3aee9c7e">120,407</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1316860810fd4869b98945ba64d7b8a9_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE2LTgtMS0xLTM0ODYy_305e2c15-5fda-4673-ab67-082d208bfe6b">3,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE2LTEyLTEtMS0zNDg2Mg_99033fec-db40-43d3-848a-bc0bf727c0aa">3,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc4516e5f23b4243bab5c3a7ad76b8b0_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE3LTYtMS0xLTM0ODYy_4ed2d30b-0e23-4370-bdef-4ceb3c6d09b6">7,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE3LTEyLTEtMS0zNDg2Mg_ab54a138-d125-4f5f-a9c7-9fbd1bdf23a0">7,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and Pre-funded Warrants  - October 2022 PIPE transaction, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i629c982d47b84bd39b19868854e07c81_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE4LTAtMS0xLTM0ODYyL3RleHRyZWdpb246YzUzZjY3NWViNWNhNGYxYzkzNGMwNGNmZTMwZGIwYmJfMTA5OTUxMTYyNzkwMA_ec2b8ac2-b300-4e64-800c-c61e0d75d25f">4,012</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5338bc359fb346e48caffc7500eefca1_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE4LTItMS0xLTM0ODYy_5ac75e3f-6ab7-4790-aa26-44da4d007464">8,696,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5338bc359fb346e48caffc7500eefca1_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE4LTQtMS0xLTM0ODYy_04ea2e2f-f1d7-4d73-8651-3c462f59080d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1fd6056fc8f469aa10b7e33b55ac2f5_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE4LTYtMS0xLTM0ODYy_cf45d566-be55-4a8f-b6c8-a88775842842">55,988</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629c982d47b84bd39b19868854e07c81_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE4LTEyLTEtMS0zNDg2Mg_a2148edf-fb28-423f-bf26-d27d38c87f7e">55,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - At The Market Sales Agreement net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="if4645613f6b04714ad4c10813a979031_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE5LTAtMS0xLTM0ODYyL3RleHRyZWdpb246YzliZGIzZTNiMDc3NDBjNjg4ODFkYjU5MjIyZWI2YzFfMTA5OTUxMTYyNzg3NA_f95c6681-b575-4fcc-bc99-f3cd98963049">1,226</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56f6368984944c099b13638b641e4e99_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE5LTItMS0xLTM0ODYy_c6e86b45-2209-40c3-b31e-1e116bfa85c2">4,204,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8049d7b76a47447681fe40c4a72397ed_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE5LTYtMS0xLTM0ODYy_516443d7-0ee9-4926-8bc1-a075ad88b6f1">39,584</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4645613f6b04714ad4c10813a979031_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE5LTEyLTEtMS0zNDg2Mg_d2c8f7ae-f303-4c46-a6b0-419fb1cf06b4">39,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued in connection with the Company's employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74203948938643e89bafdad4538d7216_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIwLTItMS0xLTM0ODYy_19206d1c-140c-4bf1-8b53-c65e646f2b5e">70,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc4516e5f23b4243bab5c3a7ad76b8b0_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIwLTYtMS0xLTM0ODYy_d49eb509-c2f1-42df-9fe7-341d6f849313">182</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIwLTEyLTEtMS0zNDg2Mg_05d2ce2a-ec4b-4c33-9418-e05c7e307d93">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued in connection with the Company's stock option plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74203948938643e89bafdad4538d7216_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIxLTItMS0xLTM0ODYy_05b0b7c5-fc25-4a51-b2e2-95dccd36ce32">852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc4516e5f23b4243bab5c3a7ad76b8b0_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIxLTYtMS0xLTM0ODYy_21aeb5b6-07bb-45b9-9e37-4ab89aa7c9fd">5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIxLTEyLTEtMS0zNDg2Mg_179a2c13-3c9f-40f1-8fdf-20439e7ec127">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b9266faad484741a6ceae1bdc3f0eb6_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIyLTItMS0xLTM0ODYy_cbaba892-0528-4111-be98-109609d7b1e7">39,307,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b9266faad484741a6ceae1bdc3f0eb6_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIyLTQtMS0xLTM0ODYy_d2d11cfa-f184-4886-b914-bcb10bbd7662">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e8bb23d203841bfa3a428096aca8874_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIyLTYtMS0xLTM0ODYy_4240f5fe-79a5-4d73-95dc-1d73a7254a31">427,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f1f7503d0874f6ab90216689469562d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIyLTgtMS0xLTM0ODYy_7c4e53f2-b1bd-4ab1-99cf-20352e80a559">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10e76b47a8364dbb8b7aa258206cfd04_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIyLTEwLTEtMS0zNDg2Mg_2c89cb11-1d2c-414c-98f5-f6c7bccfc864">317,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIyLTEyLTEtMS0zNDg2Mg_309670d2-ef86-4bde-8e2e-90c379e246e4">113,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 7</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"><tr><td style="width:1.0%"></td><td style="width:70.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.851%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMtMS0xLTEtMzQ4NjI_baddfecb-8d41-4d86-843f-c93b0cf93b42">120,407</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMtMy0xLTEtMzQ4NjI_99f0e3b5-7ffd-48fd-90e9-171643b50ded">92,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzUtMS0xLTEtMzQ4NjI_06dd07fe-f307-427b-ace3-0e75f0057dba">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzUtMy0xLTEtMzQ4NjI_6d955a49-b1d5-41b0-a01d-82b28dc03e73">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment (see Note 2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzYtMS0xLTEtMzQ4NjI_8d286097-8461-4bf3-89f4-b91d858de8a1">32,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzYtMy0xLTEtMzQ4NjI_58d9992d-b872-4b5f-b0bc-f1edcb2baa01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzgtMS0xLTEtMzQ4NjI_c5009cd7-8f80-4e78-bcd3-0cd7505ce48c">7,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzgtMy0xLTEtMzQ4NjI_fa3afd34-fd02-4f21-994a-e4c8169e183d">5,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzktMS0xLTEtMzQ4NjI_8e8ce2e6-abba-4f40-bd73-b9aed77e3fd0">4,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzktMy0xLTEtMzQ4NjI_85e62813-64df-48a3-98bb-640a518fc3ea">4,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued in connection with the 4SC royalty settlement (see Note 4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzEwLTEtMS0xLTM0ODYy_a9b51e2c-7dd7-43b2-890f-86b919533da4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzEwLTMtMS0xLTM0ODYy_f585c087-ffca-47a2-8187-6f2795bae60d">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzEzLTEtMS0xLTM0ODYy_4a49e548-ca42-437c-8670-c68cec0450a8">7,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzEzLTMtMS0xLTM0ODYy_90875958-1d79-4de4-83eb-fe75b099ac3e">12,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE0LTEtMS0xLTM0ODYy_7929a952-0c73-43a6-b4a5-825f2e77b1e2">799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE0LTMtMS0xLTM0ODYy_62648590-4075-43da-bbdc-e711c13ba123">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other  liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE1LTEtMS0xLTM0ODYy_81807691-d984-4f60-9cf3-205b0c846081">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE1LTMtMS0xLTM0ODYy_47a6d07b-8389-4066-8de9-9dd6efeb985a">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE2LTEtMS0xLTM0ODYy_d51901a6-d06c-40a2-aa0f-57e2e3e8f246">1,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE2LTMtMS0xLTM0ODYy_5030c771-f339-4ffb-a273-1005f0134ac4">3,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE3LTEtMS0xLTM0ODYy_7453a543-4ec7-45cc-ae0e-366658fcc2fc">65,144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE3LTMtMS0xLTM0ODYy_e56853ae-af47-49ca-b984-d8c5c6683cfa">83,233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of Investments-other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE5LTEtMS0xLTQwMDg3_52452f12-9901-49eb-abb9-a06ca78fd57c">9,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE5LTMtMS0xLTQwMDk3_c6dc948c-afbb-4971-9613-cde31cf9b15c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE5LTEtMS0xLTM0ODYy_c51f2e95-f8bf-4523-8f01-c0a2ceb1561e">112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE5LTMtMS0xLTM0ODYy_83e57b7d-aba3-46e7-bace-7416f032e8ad">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in  investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI0LTEtMS0xLTM0ODYy_d194632a-b67d-47f1-a145-f73ea2d656fe">9,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI0LTMtMS0xLTM0ODYy_0de57c7a-1e88-4527-8650-7524b9eb3826">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock through At The Market offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ic79be0a87a2d43ae992ef8e7625d53e2_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI4LTAtMS0xLTM0ODYyL3RleHRyZWdpb246ODUzYjNjZWU0OTc1NDY1YWJiZTI3YWY0NmMyNmQxN2NfMTA5OTUxMTYyNzkxNw_3db0081b-bbba-4734-8a27-c0b362d55360">1,226</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6ceb990338fd46f69ef655c24c8d15d0_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI4LTAtMS0xLTM0ODYyL3RleHRyZWdpb246ODUzYjNjZWU0OTc1NDY1YWJiZTI3YWY0NmMyNmQxN2NfMTA5OTUxMTYyNzkyMw_c3d293e9-3b71-4f37-9006-6adc89cb5815">23</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79be0a87a2d43ae992ef8e7625d53e2_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI4LTEtMS0xLTM0ODYy_97ba6b68-4d03-4428-9465-fa37d8e36560">39,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ceb990338fd46f69ef655c24c8d15d0_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI4LTMtMS0xLTM0ODYy_93d6696a-fba3-4976-999e-d9f158b5297d">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from shares issued in connection with the Company's employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI5LTEtMS0xLTM0ODYy_7a3771b1-9d35-4980-8838-c5695417f9d3">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI5LTMtMS0xLTM0ODYy_ff155833-1e4d-467e-80b7-023a79550ac5">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock and Pre-funded Warrants  - October 2022 PIPE transaction, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i629c982d47b84bd39b19868854e07c81_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMwLTAtMS0xLTM0ODYyL3RleHRyZWdpb246Zjk5MTJmYjRiNGJhNDk3ZGJmMzIyZWEwNmMxMTY5NDRfMTA5OTUxMTYyNzkyMQ_1ee95e80-97d2-4a6e-b6e6-16d0ff1b82d1">4,012</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i90a687fe86e640878d4f8d1ab66c683b_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMwLTAtMS0xLTM0ODYyL3RleHRyZWdpb246Zjk5MTJmYjRiNGJhNDk3ZGJmMzIyZWEwNmMxMTY5NDRfMTA5OTUxMTYyNzkyNg_eea7ea2e-edba-4977-adcc-065b8766f7c4">0</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629c982d47b84bd39b19868854e07c81_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMwLTEtMS0xLTM0ODYy_bbfb67ce-9225-4680-b7f0-8c2a5ed42dea">55,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a687fe86e640878d4f8d1ab66c683b_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMwLTMtMS0xLTM0ODYy_4db98a07-60bf-41bf-940a-ab588d75293c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMyLTEtMS0xLTM0ODYy_cb5e91f1-1bb3-4751-87ce-ae20ff30bf7d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMyLTMtMS0xLTM0ODYy_42c2aa72-1d0c-4edc-aa7b-9d226335e5f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from July 2021 public equity offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i42cae9630d124c15823d3c9c381fc07a_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMzLTAtMS0xLTM0ODYyL3RleHRyZWdpb246ODlkZTMxYjFjZGQ3NGJhZTlmOGYzNWNkYmE5NDBlMDlfNzc_fbf0a6c7-e553-4b67-85ee-0fb72169d364">2,980</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3cdfb91b17451989132881fd694dac_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMzLTEtMS0xLTM0ODYy_f5b6033f-59f8-4273-964b-6629a6889e0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42cae9630d124c15823d3c9c381fc07a_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMzLTMtMS0xLTM0ODYy_c70c17df-5553-4e96-8c84-cf1f5bcc6422">42,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM1LTEtMS0xLTM0ODYy_ac799743-49db-4b6b-8547-92acdae5673c">95,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM1LTMtMS0xLTM0ODYy_fc0556c2-d507-4928-856a-f1dcc4f09a53">42,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM2LTEtMS0xLTM0ODYy_55315484-ff66-4a46-bc4b-1aba2aa735a2">993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM2LTMtMS0xLTM0ODYy_7a6dfe37-374a-4873-8b9d-85f74c71c32d">130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM3LTEtMS0xLTM0ODYy_699c1e92-c3db-4d0d-bfdc-c428ae10aa3b">19,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM3LTMtMS0xLTM0ODYy_a7ce1b64-7eeb-4ecf-bfa2-aa4d04d57bb4">40,589</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM4LTEtMS0xLTM0ODYy_429c4811-5409-4a1e-8065-ec143b4975b5">86,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife1cbb9302f3417394aee800539a7c78_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM4LTMtMS0xLTM0ODYy_8acf393d-7ff1-45dd-9410-d757de8e2ed0">127,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM5LTEtMS0xLTM0ODYy_ad9e0d82-191f-411e-9f7b-138d3b9111ce">106,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM5LTMtMS0xLTM0ODYy_2bc9f04f-d34b-4f16-8acd-26d9b6b9926d">86,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued in connection with the 4SC royalty settlement (see Note 4)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzQzLTEtMS0xLTM0ODYy_613b4fb3-27e0-4de6-83f7-aae4fff19337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzQzLTMtMS0xLTM0ODYy_58c6ee2f-e150-43cd-92dc-955594d9d80c">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of use asset obtained in exchange for lease obligation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzQ0LTEtMS0xLTM0ODYy_03341312-7e6f-4188-a6d5-4f7a26d5c005">974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzQ0LTMtMS0xLTM0ODYy_13b2e71a-b1b9-4232-9e79-143ca21922a9">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 8</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="idff78559567c4173b665e875d419cf41_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzQ2Mjc_7f6d125f-a6d2-4d76-a653-166abf7fe010" continuedAt="i9d3fda00ccb24481a6373a06126bc58b" escape="true">Description of Business and Basis of Financial Statements</ix:nonNumeric></span></div><ix:continuation id="i9d3fda00ccb24481a6373a06126bc58b" continuedAt="i43edb7d11a8c46d8babdb68a70422744"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic, Inc. ("Immunic" or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#228;felfing near Munich, Germany. The Company currently has approximately <ix:nonFraction unitRef="employee" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="dei:EntityNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzIxOTkwMjMyNjM5NTQ_5d3a1dcb-fb9e-40ba-9964-2162238fc0e8">66</ix:nonFraction> employees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is currently pursuing clinical development of three orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;); the izumerogant (proposed International Nonproprietary Name (&#8220;INN&#8221;) for IMU-935) program, which is an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (&#8220;ROR&#947;t&#8221;) that inhibits the interleukin-17 (&#8220;IL-17&#8221;) pathway in diseases such as psoriasis; and the IMU-856 program, which is targeted to restore intestinal barrier function and regenerate bowel epithelium.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's <ix:nonFraction unitRef="lease" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="imux:NumberOfDevelopmentPrograms" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzIxOTkwMjMyNjg5Mzk_7de723dc-354b-427b-a3a6-9c9b6af2dfd3">three</ix:nonFraction> development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. Immunic has never been profitable and has incurred operating losses in each year since inception (2016). Immunic has an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzIyMDg_f0e1a91d-9e30-4a07-a727-d67210b7e17c">317.3</ix:nonFraction>&#160;million as of December&#160;31, 2022 and approximately $<ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzIyMzg_da8bb006-2fde-4a8e-a46f-ce776ca5a8dd">196.9</ix:nonFraction>&#160;million as of December&#160;31, 2021. Substantially all of Immunic&#8217;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December&#160;31, 2022, Immunic has raised net cash of approximately $<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzU0OTc1NTgyMzQ2Ng_d344acaa-e66c-4571-a5c1-141ef8b1dc6d">355.5</ix:nonFraction> million from private and public offerings of preferred and common stock. As of December 31, 2022, the Company had cash and cash equivalents of approximately $<ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzU0OTc1NTgyMzQ3NQ_be6a03bb-3625-432e-a321-caaedf132375">106.7</ix:nonFraction>&#160;million and investments - other of $<ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-5" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzU0OTc1NTgyNzMyNA_32f7d449-e10d-46bc-9ac7-a809015d8a40">9.6</ix:nonFraction>&#160;million. With these funds the Company expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i43edb7d11a8c46d8babdb68a70422744">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG (which began operations in 2016) and Immunic Australia Pty Ltd. (which began operations in 2018).  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.</ix:continuation> </span></div><div id="idff78559567c4173b665e875d419cf41_136"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3MzU3_0fd16432-8085-4e76-a13f-106a6c7d207a" continuedAt="i5a25e675631845f2aa901d59d2bd0796" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i5a25e675631845f2aa901d59d2bd0796" continuedAt="ib369f93de6694da385c1734fbab4098d"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzgy_e43924a8-766c-4b48-a121-1e0497cf4c90" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib369f93de6694da385c1734fbab4098d" continuedAt="ifd8efeb905ad4dfc85bd503759dad94d"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzgz_d846fa22-7fb3-4997-951c-1757120abd24" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="imux:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzcw_e7ec84b2-de59-43eb-9d16-1f4557519d0d" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments- other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments-other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S of approximately $<ix:nonFraction unitRef="usd" contextRef="i40702a7fad274b3590022abc86d2a149_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM1NDY_4021944e-7d91-4c79-8f67-255b5801f028">85.7</ix:nonFraction>&#160;million, Germany of approximately $<ix:nonFraction unitRef="usd" contextRef="ib3028499b4524a48a11940db473e95c4_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM1NjE_f8d018a7-9a9c-438c-8f99-224f68e520f8">19.1</ix:nonFraction>&#160;million and Australia of approximately $<ix:nonFraction unitRef="usd" contextRef="ic9487ab845434e10aca875ca321f6e67_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM1NzY_7500f3fc-3bd4-45e9-8a90-a310150ee241">1.9</ix:nonFraction>&#160;million. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with <ix:nonFraction unitRef="financialinstitution" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="imux:NumberOfFinancialInstitutionsUsedForCashDeposits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzU0OTc1NTgzNzQ1OA_2f71fd49-bc36-4911-8cf1-474c4da67888">two</ix:nonFraction> large financial institutions. Our Cash and Cash equivalents in the U.S. is primarily held in a U.S. Government money market fund account and was earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="id15e6eed9a474921925790496d9be215_I20221231" decimals="3" name="us-gaap:InvestmentInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzU0OTc1NTg3MzAwNQ_beecb6b9-b896-4141-9f5d-62d15734e131">4.3</ix:nonFraction>%. Our cash and cash equivalents in Germany and Australia were earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="i6f6dda26ad1f41d48bc084b4d8b166fd_I20221231" decimals="3" name="us-gaap:InvestmentInterestRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE2NDkyNjc1MDEwMDM_6e81c248-6a8c-4cf7-83b9-95c355750e43">&#8212;</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i24f459a16c08494da1b7e65020dc4fa7_I20221231" decimals="4" name="us-gaap:InvestmentInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE2NDkyNjc1MDEwMDk_d9ecef36-0089-40d4-abd6-33baeb5f32df">0.87</ix:nonFraction>%</span></div><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:InvestmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTQ4ODk_c7d100c1-2204-43b7-9f09-0b8cc911061a" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:22.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i29c8be7c0e67485390b3fa4ca6373ec9_I20221231" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTozMDU0NjlkZjhkYWQ0MzEwODI5NTE0OGU5MWM0MGFkYS90YWJsZXJhbmdlOjMwNTQ2OWRmOGRhZDQzMTA4Mjk1MTQ4ZTkxYzQwYWRhXzEtMi0xLTEtMzk5NDg_be04bc68-6e1f-4746-a412-cc6aa3f66b96">9,629</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i1c7189562e3a451ea2101622fe50411a_I20211231" decimals="-3" name="us-gaap:OtherShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTozMDU0NjlkZjhkYWQ0MzEwODI5NTE0OGU5MWM0MGFkYS90YWJsZXJhbmdlOjMwNTQ2OWRmOGRhZDQzMTA4Mjk1MTQ4ZTkxYzQwYWRhXzEtNC0xLTEtMzk5NDg_d4405bea-dbba-4b27-857c-41e5cd467ec1">0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTozMDU0NjlkZjhkYWQ0MzEwODI5NTE0OGU5MWM0MGFkYS90YWJsZXJhbmdlOjMwNTQ2OWRmOGRhZDQzMTA4Mjk1MTQ4ZTkxYzQwYWRhXzItMi0xLTEtMzk5Nzc_54adfa59-446d-4422-a19e-26d897ddf98a">9,629</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:OtherShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTozMDU0NjlkZjhkYWQ0MzEwODI5NTE0OGU5MWM0MGFkYS90YWJsZXJhbmdlOjMwNTQ2OWRmOGRhZDQzMTA4Mjk1MTQ4ZTkxYzQwYWRhXzItNC0xLTEtMzk5Nzc_f409ab9e-79ed-4ca5-b34e-cbeda51ec92b">0</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="i02a6493060a2472cb585f29aefea30e5_I20221231" decimals="4" name="us-gaap:InvestmentInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE2NDkyNjc1MDEwMzM_5079d2bf-6833-4932-b57b-101d283f29f4">0.61</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i576a1a2a1e6f40819d31ad6cc0c9d135_I20221231" decimals="4" name="us-gaap:InvestmentInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE2NDkyNjc1MDEwNDc_febd2309-ff44-4ff7-ab8e-0fda198b4b26">0.87</ix:nonFraction>% and have a remaining maturity <ix:nonNumeric contextRef="if4ebe77f21364c02a3042c9e9e034e31_D20220101-20221231" name="imux:InvestmentEarningInterestRateRemainingMaturityPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTQ5MDU_7bca7200-f559-41ce-9ce1-47af636f3262">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i824c6b2c61e244609c3ec75bfe251d84_D20220101-20221231" name="imux:InvestmentEarningInterestRateRemainingMaturityPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTQ5MDc_9a6d8953-7dee-4217-a3df-803ab65c9813">4</ix:nonNumeric> months.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3MzYz_163b22c7-0143-4367-9ea7-86c9a563a666" continuedAt="i6f3a66dfff0049fba6be7b3abe142558" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifd8efeb905ad4dfc85bd503759dad94d" continuedAt="i15ad86cebd004c84aca52f8d06890b07"><ix:continuation id="i6f3a66dfff0049fba6be7b3abe142558"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzcy_0e4fee78-0a7b-461b-a031-81af252367fe" continuedAt="i26c46350b76a4d829af4617396768941" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i26c46350b76a4d829af4617396768941">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from <ix:nonNumeric contextRef="ie62fec553f0c4425b46293481930bbc7_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzQ1NjE_13084210-a596-4f63-b29b-b4bce115b630">three years</ix:nonNumeric> to <ix:nonNumeric contextRef="iff9b0c581c08407a9041a6bb9632fa7e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzQ1Njc_d1f68051-67a4-4df5-aad9-8d392e46d11c">thirteen years</ix:nonNumeric>.</ix:continuation> Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzQ2MTM_0b0cc74c-c590-4677-a7f6-04c036c48ab5">77,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzQ2MjA_06fbf770-2088-48ff-bc21-2ea0d2d577bf">85,000</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzg2_0b3860b3-f930-44a3-acbc-e92acdc34439" continuedAt="i53e8cf2106d74dfe8b88dfa43d918159" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i53e8cf2106d74dfe8b88dfa43d918159">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzUwMTQ_6c2fd075-cddb-45ce-83fd-be2ede0c5108"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzUwMTQ_ca674eb3-16c8-4632-a585-bf1a0d0b24cf">no</ix:nonFraction></ix:nonFraction> impairment losses during the years ended December&#160;31, 2022 and 2021 other than goodwill which is described below.</span></div><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzkz_644f49c8-2509-411f-ad2f-2e2939d28c39" continuedAt="i937cc73cc4d24f92ad8989523dcf1441" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i937cc73cc4d24f92ad8989523dcf1441">On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired.</ix:continuation>  The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $<ix:nonFraction unitRef="usd" contextRef="i4bc235beae3e46b392aa9ef77f9e52a6_D20221001-20221231" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzU0OTc1NTg0OTU4Mg_dd4c6492-89d7-46ba-9260-221d445d188d">33.0</ix:nonFraction>&#160;million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance.  The Company did not have any goodwill impairment during the year ended December 31, 2021.  <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTIyNzI_dc55a02d-5f11-4ede-8748-05cd1a30ed5b" continuedAt="i2d1ec8d0f10045ca914461addd168ef8" escape="true">The changes in the carrying amount of goodwill for the years presented are as follows (amounts in thousands):</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="i2d1ec8d0f10045ca914461addd168ef8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"></td><td style="width:75.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.073%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount of goodwill at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZToxZDNhZWYyYjIxMDk0YzYyYjYyMDA0YmQ0NjNmM2IyZC90YWJsZXJhbmdlOjFkM2FlZjJiMjEwOTRjNjJiNjIwMDRiZDQ2M2YzYjJkXzAtMS0xLTEtMzgwNDA_feb18992-ae4b-47bc-8bf3-9bc72b81800a">32,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill during the year ended December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZToxZDNhZWYyYjIxMDk0YzYyYjYyMDA0YmQ0NjNmM2IyZC90YWJsZXJhbmdlOjFkM2FlZjJiMjEwOTRjNjJiNjIwMDRiZDQ2M2YzYjJkXzEtMS0xLTEtMzgwNDA_105e688e-289b-48d9-a06b-19a64f26a0b7">32,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount of goodwill at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZToxZDNhZWYyYjIxMDk0YzYyYjYyMDA0YmQ0NjNmM2IyZC90YWJsZXJhbmdlOjFkM2FlZjJiMjEwOTRjNjJiNjIwMDRiZDQ2M2YzYjJkXzItMS0xLTEtMzgwNDA_d9e21e11-ec33-41c5-b606-ce6d9e623c3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3MzYy_3a197aff-01f9-4298-b57e-1dda63e3df37" continuedAt="ic1a092482db645e0b42b3159bb7d06b0" escape="true"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzk0_4840f9c7-43f5-4484-a5bb-9c2f2022e88f" continuedAt="i9cb4a48c9a7042f3bfe4420a1213dc58" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i15ad86cebd004c84aca52f8d06890b07" continuedAt="i543d48454f2947a88feb66a072256d3c"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic1a092482db645e0b42b3159bb7d06b0"><ix:continuation id="i9cb4a48c9a7042f3bfe4420a1213dc58">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</ix:continuation></ix:continuation></span></div><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzk1_7c44aea3-40fb-440c-91ce-5fb75028ab31" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM1OTA_92bf989d-bf76-4034-ae4e-97505aa31e5b" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. Government assistance is recognized at a rate of <ix:nonFraction unitRef="number" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="3" name="imux:GovernmentAssistanceRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM1OTI_8a008099-d508-4a2f-b525-2d4789abdbf9">43.5</ix:nonFraction>% of the qualified research and development expenditures which are incurred.  We recognized $<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-5" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM1OTk_d078f1a3-9f43-422d-877d-14519f117ad8">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-5" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MTM_b6d49c6b-3001-4df2-b43e-96d96458eaa9">1.7</ix:nonFraction>&#160;million of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3221b224-b06b-4599-934b-4790913ca766"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3cdcee94-7c82-4bf3-999e-30ecd1c05a92">other income</span></span> related to research activities performed during the years ended December 31, 2022 and 2021, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzc4_8a554752-4b54-48a4-a3ef-333eaf4244cb" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzk2_361f7184-e81c-4410-be22-c4a6ae159d43" continuedAt="i71b15dc56dc049fd94007bb0748ae651" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i543d48454f2947a88feb66a072256d3c" continuedAt="i4390be9bad4b4f79992296078ae6960a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i71b15dc56dc049fd94007bb0748ae651">application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</ix:continuation></span></div><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzc5_5cbf0612-bdfe-45a9-b9b3-3d31b2dd318c" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than <ix:nonNumeric contextRef="i6ea7cf83aad5416b96424f40bc7375a9_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzU0OTc1NTg2Mzc1OQ_8516e884-7145-44f3-8fd7-bc4329b3c0d8">12</ix:nonNumeric> months and up to <ix:nonNumeric contextRef="ie1949ba12c82474aad6afbbd5c131134_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzU0OTc1NTg2Mzc3Mw_88bc6928-4d8a-464f-8415-cb0f86269222">60</ix:nonNumeric> months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="lease" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="imux:LesseeOperatingLeasesNumberOfExistingLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzU0OTc1NTg2MzkzNg_1ed94b6d-c4ce-4828-95c8-95fbe3a4a21e">two</ix:nonFraction> existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's <ix:nonFraction unitRef="lease" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="imux:LesseeOperatingLeasesNumberOfExistingLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzU0OTc1NTg2NDE5Ng_1ed94b6d-c4ce-4828-95c8-95fbe3a4a21e">two</ix:nonFraction> leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3MzY4_ccf71a69-f01d-48d4-81cd-10ad9f4f04d5" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzg3_d674e07b-6b50-408c-b3ba-23f5b41da592" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December&#160;31, 2022 and 2021, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:StockholdersEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTA3MTc_faedc1f3-23a6-4987-ab0d-7a43e3f607da" continuedAt="iea49414477664e7baece2c744fe3f4bf" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4390be9bad4b4f79992296078ae6960a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iea49414477664e7baece2c744fe3f4bf">for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</ix:continuation></span></div><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzg4_86c7e269-54ed-4f71-8f47-737915a59b43" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3MzY2_12ecd550-8bf3-415f-be78-5331964ae995" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia76019b0488442de98cccc646c64f255_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTpjYjFhNGIyZDQyMWQ0ZDYwYTUzZTdiYTRiZTg0N2MyMi90YWJsZXJhbmdlOmNiMWE0YjJkNDIxZDRkNjBhNTNlN2JhNGJlODQ3YzIyXzItMS0xLTEtMzQ4NjI_301db2fd-d31d-4940-a42b-931c9ba74228">3,791,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i296998374f2942bf8199382e045c0c53_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTpjYjFhNGIyZDQyMWQ0ZDYwYTUzZTdiYTRiZTg0N2MyMi90YWJsZXJhbmdlOmNiMWE0YjJkNDIxZDRkNjBhNTNlN2JhNGJlODQ3YzIyXzItMy0xLTEtMzQ4NjI_73f9fbb6-64db-4b69-b333-7fdd56e2463f">2,157,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prefunded stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42582e672b9a458a8f771feaaf27fdb0_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTpjYjFhNGIyZDQyMWQ0ZDYwYTUzZTdiYTRiZTg0N2MyMi90YWJsZXJhbmdlOmNiMWE0YjJkNDIxZDRkNjBhNTNlN2JhNGJlODQ3YzIyXzMtMS0xLTEtMzY2ODk_3db6892e-401c-4193-9eb7-55e04d8d017b">5,096,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49102a4b3a124b109aaa078cfdd43203_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTpjYjFhNGIyZDQyMWQ0ZDYwYTUzZTdiYTRiZTg0N2MyMi90YWJsZXJhbmdlOmNiMWE0YjJkNDIxZDRkNjBhNTNlN2JhNGJlODQ3YzIyXzMtMy0xLTEtMzY2ODk_4d624bbb-4c9a-47ff-88a7-552e9c0917ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTpjYjFhNGIyZDQyMWQ0ZDYwYTUzZTdiYTRiZTg0N2MyMi90YWJsZXJhbmdlOmNiMWE0YjJkNDIxZDRkNjBhNTNlN2JhNGJlODQ3YzIyXzQtMS0xLTEtMzY2ODk_9d67ef34-dc1a-4dea-84c8-f0656f105215">8,888,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTpjYjFhNGIyZDQyMWQ0ZDYwYTUzZTdiYTRiZTg0N2MyMi90YWJsZXJhbmdlOmNiMWE0YjJkNDIxZDRkNjBhNTNlN2JhNGJlODQ3YzIyXzQtMy0xLTEtMzY2ODk_f2bb75d5-123d-4f13-b61d-08e39ba2bdd8">2,157,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzgw_a6679989-21ef-4315-a7b6-b8773a6211cf" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 14</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90ZXh0cmVnaW9uOjRjZDIxNmE2OGRiODRlYjM4OTA0NjE4YWMyYTNjYmM5XzM1OA_ace21db9-458d-4128-8514-9c3839ce49c0" continuedAt="iba738c44021e4ca2b32c07524877027f" escape="true">Balance Sheet Details</ix:nonNumeric></span></div><ix:continuation id="iba738c44021e4ca2b32c07524877027f"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90ZXh0cmVnaW9uOjRjZDIxNmE2OGRiODRlYjM4OTA0NjE4YWMyYTNjYmM5XzM2MA_6a4a109c-81ce-406d-a99f-53dd3142ade0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid Expense and Other Current Assets consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="imux:PrepaidClinicalAndRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzItMS0xLTEtMzQ4NjI_59287825-8edb-4080-99f5-51f8ed903a95">5,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="imux:PrepaidClinicalAndRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzItMy0xLTEtMzQ4NjI_c476e206-be7a-41b2-ad6c-1fbc7b3cc259">14,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzMtMS0xLTEtMzQ4NjI_1d198cb2-3694-4888-812c-f1a75e1c2dc8">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzMtMy0xLTEtMzQ4NjI_8ba959c1-77d5-46e9-a799-5cc9d28893d6">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="imux:ResearchAndDevelopmentTaxIncentiveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzQtMS0xLTEtMzQ4NjI_06ae7a7e-0ba4-4959-96d1-93687d7aa4ef">2,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="imux:ResearchAndDevelopmentTaxIncentiveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzQtMy0xLTEtMzQ4NjI_c32db877-f9d8-4601-956c-687ad300d3c5">1,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzUtMS0xLTEtMzQ4NjI_56da47d8-662f-4e4f-8ff0-0f97632f5033">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzUtMy0xLTEtMzQ4NjI_acdc8ea5-f082-49ea-916f-f75fc348fbd8">1,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzYtMS0xLTEtMzQ4NjI_fab0acf1-3cfe-45dc-b6e2-5c36661ad625">9,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzYtMy0xLTEtMzQ4NjI_0e9852dd-5e28-4265-a78f-73586544b2b5">18,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90ZXh0cmVnaW9uOjRjZDIxNmE2OGRiODRlYjM4OTA0NjE4YWMyYTNjYmM5XzM1Mg_c0bb4f91-2ff0-441f-bcf5-9659bc5e4647" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="imux:ClinicalCostsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzItMS0xLTEtMzQ4NjI_4d9f64da-48b0-4a6e-9b70-2a39e0a1f35c">3,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="imux:ClinicalCostsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzItMy0xLTEtMzQ4NjI_f586d066-990c-433a-8a89-fa7e660ed5e1">3,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="imux:LegalAndAuditCostsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzMtMS0xLTEtMzQ4NjI_9c2f7574-467d-407e-ae0d-e1fe7eca06f2">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="imux:LegalAndAuditCostsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzMtMy0xLTEtMzQ4NjI_841b7c28-5f4e-4632-8a42-95f5e5beea94">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzQtMS0xLTEtMzQ4NjI_d34e6708-82ea-45c9-80db-9e7e795069f9">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzQtMy0xLTEtMzQ4NjI_d5eca9c3-0c0e-46ce-9958-f563815858de">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzUtMS0xLTEtMzQ4NjI_9a23dfbe-eb38-4851-b774-3b9b3c810a69">4,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzUtMy0xLTEtMzQ4NjI_5808211d-e43c-4459-b018-5ad714efb279">3,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="imux:AccruedClinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzItMS0xLTEtMzQ4NjI_f8a045b8-d63b-4444-86b8-780a77c72e4a">6,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="imux:AccruedClinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzItMy0xLTEtMzQ4NjI_6dd01e37-fd9a-4be2-83c7-191215f91575">6,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="imux:AccruedLegalAndAuditCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzMtMS0xLTEtMzQ4NjI_2558250b-6a8a-436f-a53d-12d03fe82337">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="imux:AccruedLegalAndAuditCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzMtMy0xLTEtMzQ4NjI_89abe7f5-44e9-43da-bf1e-4640b2b54de3">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="imux:AccruedCompensationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzQtMS0xLTEtMzQ4NjI_e5f90309-ca89-4a03-8b64-7eba73aeb5f1">890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="imux:AccruedCompensationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzQtMy0xLTEtMzQ4NjI_98b027ea-723f-41d4-9cb8-c280f7812ea3">674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzUtMS0xLTEtMzQ4NjI_db23afff-5b7e-42bb-885a-6b46fe49daee">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzUtMy0xLTEtMzQ4NjI_d12756ef-1d0d-4715-960f-78d99120df72">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzYtMS0xLTEtMzQ4NjI_3a66a3c0-4576-430d-8526-6659ad8dac74">7,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzYtMy0xLTEtMzQ4NjI_c09cd4f6-d6e3-4115-acd2-6c3e13a035ff">7,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90ZXh0cmVnaW9uOjRjZDIxNmE2OGRiODRlYjM4OTA0NjE4YWMyYTNjYmM5XzM1Nw_8a65534d-f231-4324-b35f-4eee37078257" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist  of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.296%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_4a1a30a6-155d-4e96-9d47-e78ee944ec76"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_58a0a228-b7d2-495a-8002-5c76ada4c7a6">Lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMS0xLTEtMzQ4NjI_4a0ed4d0-8ecc-4d6c-b9a7-9b21a550c6e3">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMy0xLTEtMzQ4NjI_27586c94-2f0a-4bf7-9f01-ce3de9843924">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzMtMS0xLTEtMzQ4NjI_0b8a73d5-3256-4d08-a4e2-1c783a325e24">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzMtMy0xLTEtMzQ4NjI_b12f47d0-81b6-4594-a4c2-8b5d1ecf89fd">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzQtMS0xLTEtMzQ4NjI_d416311d-aa00-49f8-bca4-bdffd98c2603">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzQtMy0xLTEtMzQ4NjI_ce88e936-1e5b-4d2c-8300-4e629bb2f82b">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="idff78559567c4173b665e875d419cf41_142"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzU2MjQ_810ddf9a-2d8d-46d4-9d60-db038cfafad1" continuedAt="i36a9c603e31a4c218f62858aed120578" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i36a9c603e31a4c218f62858aed120578" continuedAt="i3347f73727bb44f091fe9bad1bc1be7a"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office and June 30, 2025 for the Gr&#228;felfing, Germany office.  The Company formerly leased office space in </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3347f73727bb44f091fe9bad1bc1be7a" continuedAt="i0a9a55a83255468fb2545fa8e0b27c7e"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Planegg-Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025.  The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a <ix:nonNumeric contextRef="i4ddd5b53cb394a72b342f64f7724bee5_I20200407" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzU2MjY_cb2f1688-6c14-4383-8a45-0120ee88a9f6">five year</ix:nonNumeric> lease for its facility in Gr&#228;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#228;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a <ix:nonNumeric contextRef="i4d811dce20e94755bbed81698a836062_D20220101-20221231" name="imux:LesseeOperatingLeaseRentHolidayPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzU2MTk_9158de12-0d0c-472b-95c6-9e2fc36a8db4">six month</ix:nonNumeric> rent holiday at the beginning of the lease as well as a three month rent holiday upon the 27 month extension starting May 2023.  There were net additions to right of use assets of $<ix:nonFraction unitRef="usd" contextRef="icc3845c2b8324eb192b6c5463738b9a4_D20210301-20210331" decimals="-3" name="imux:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzIxOTkwMjMyNjM4NDE_cc6b06fc-c8c9-4345-acf0-bfcc9d8bd4d4">435,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i790f3d1e376c426a93f31d939f0cc7d9_D20220801-20220831" decimals="-3" name="imux:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzIxOTkwMjMyNjM4NTE_552934c3-0cef-428a-b9b8-3b9c9338e71e">642,000</ix:nonFraction> as a result of signing for additional lease space at the Gr&#228;felfing, Germany office in March 2021 and August 2022, respectively.  There were net additions to right of use assets of $<ix:nonFraction unitRef="usd" contextRef="i24562792a7ba48619d879bb127f6e25a_D20221201-20221231" decimals="-3" name="imux:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzIxOTkwMjMyNjMzOTU_9e77bd9b-04c5-4842-a25f-948b2bcf2e11">332,000</ix:nonFraction> as a result of extending the New York City lease in December 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be <ix:nonFraction unitRef="number" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="2" name="imux:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzE5NDM_91b69b12-1e74-48a1-8a33-2eea2b84f233">6</ix:nonFraction>% for the original leases and <ix:nonFraction unitRef="number" contextRef="ib7723388552347f4a59e2d9f09a39771_I20221231" decimals="2" name="imux:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzE2NDkyNjc0NDk5NzM_bf599df0-bd73-458d-b248-9d46cc2c7bb4">8</ix:nonFraction>% for the New York City extension, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" name="imux:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzIzMDk_1f9dd1e5-391c-48e5-8277-f867f63ed349">727,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" name="imux:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzIzMTY_4b1d1f24-30d8-42ee-b062-f90156f3aa89">503,000</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzU2MjA_66f11155-aa28-4d35-9847-1326ad4c19f4" continuedAt="idf9ede0c917a4bd1b408ca59425905a6" escape="true">Maturities of the operating lease obligation are as follows as of December&#160;31, 2022 (in thousands):</ix:nonNumeric></span><ix:continuation id="idf9ede0c917a4bd1b408ca59425905a6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzAtMi0xLTEtMzQ4NjI_80f100e0-e064-4da5-959a-e51f23cdae90">647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzEtMi0xLTEtMzQ4NjI_8edab702-9eac-41bb-b418-95f08cbd2c6e">680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzItMi0xLTEtMzQ4NjI_0a29eaa0-5322-465d-8513-9e958ceab444">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzMtMi0xLTEtMzQ4NjI_3fb85ea3-696b-4bf6-ba9e-07cbad2abe4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzQtMi0xLTEtMzQ4NjI_883f2bac-b925-4e07-9ec5-5760afb0e84d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzUtMi0xLTEtMzQ4NjI_a351293b-a82c-4361-b797-d526fbfbebe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzYtMi0xLTEtMzQ4NjI_24e544ae-711c-41f5-b6e3-1d1661c0cccf">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzctMi0xLTEtMzQ4NjI_1f01dd2f-348c-4369-b965-ffb42c6b0660">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzgtMi0xLTEtMzQ4NjI_6644feb2-4fa7-45dd-8a74-a0d50f9086f9">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2022, the Company has non-cancelable contractual obligations under certain agreements related to its development programs in vidofludimus calcium, izumerogant and IMU-856 totaling approximately $<ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-5" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzI4MjU_0c680218-7749-4f33-93b3-8b5faa83480e">4.5</ix:nonFraction> million, all of which is expected to be paid in 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, the Company entered into a purchase agreement (the &#8220;Agreement&#8221;) with 4SC AG, whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to <ix:nonFraction unitRef="number" contextRef="i1220fdabe2ee4fb28d42b5efca4ed2e5_D20160501-20160531" decimals="3" name="imux:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzM0NzQ_195779f9-3786-4ebd-a580-8e11843df90e">4.4</ix:nonFraction>% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing <ix:nonFraction unitRef="shares" contextRef="id6d27db753c54b8eaeaf90c7573257b1_I20190412" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzM2OTI_9b712470-4d6a-4042-858c-05d7f1da597d">120,070</ix:nonFraction> shares of the Company&#8217;s common stock, immediately following the Transaction, to 4SC AG while keeping Tranche III in effect. Approximately $<ix:nonFraction unitRef="usd" contextRef="id6d27db753c54b8eaeaf90c7573257b1_I20190412" decimals="-5" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzM4MzM_0da50a97-045c-431e-ab6d-b348a1e2be44">1.5</ix:nonFraction> million of expense was recorded as a result of the issuance of these shares on April 12, 2019. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, Immunic AG, a wholly-owned subsidiary of the Company, and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the <ix:nonFraction unitRef="number" contextRef="i6672b35cda564e6499bcb6f461f08725_D20210331-20210331" decimals="3" name="imux:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzQxMTQ_a6ee5282-831f-4d9f-80e2-ab4c117f6493">4.4</ix:nonFraction>% royalty on net sales for $<ix:nonFraction unitRef="usd" contextRef="i6672b35cda564e6499bcb6f461f08725_D20210331-20210331" decimals="-4" name="imux:RoyaltySettlementAgreementSalesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzQxNDI_d666dee2-5ae8-4f5b-b715-9d25ed6a2477">17.25</ix:nonFraction>&#160;million </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0a9a55a83255468fb2545fa8e0b27c7e"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Tranche III of the Agreement). The payment was made <ix:nonFraction unitRef="number" contextRef="ia12960a663974117bd81295909c9cc3a_I20210331" decimals="INF" name="imux:RoyaltySettlementAgreementCashPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzQxOTg_fb61a69d-ad23-4983-98ec-e4a2e9a42d03">50</ix:nonFraction>% in cash and <ix:nonFraction unitRef="number" contextRef="ia12960a663974117bd81295909c9cc3a_I20210331" decimals="INF" name="imux:RoyaltySettlementAgreementSharesPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzQyMTM_ec6dd04f-f5df-43ac-af69-a51e9dc30323">50</ix:nonFraction>% in shares of Immunic&#8217;s common stock (the &#8220;Shares&#8221;). Pursuant to the Agreement, the Company filed a resale shelf registration statement on Form S-3 covering the resale of the Shares. With the execution of the Agreement, no further payment obligations remain between Immunic AG and 4SC AG.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div></ix:continuation><div id="idff78559567c4173b665e875d419cf41_145"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90ZXh0cmVnaW9uOjJjMTM5MTkxOTcwMzQ0MGY4OWFlZmExZjkxZmY3Yjg1Xzg3MQ_0352dc84-9c39-4661-ba18-e4927a084b1f" continuedAt="i980b7fb68c674252a01f819a4854d718" escape="true">Fair Value </ix:nonNumeric></span></div><ix:continuation id="i980b7fb68c674252a01f819a4854d718"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90ZXh0cmVnaW9uOjJjMTM5MTkxOTcwMzQ0MGY4OWFlZmExZjkxZmY3Yjg1Xzg2OA_d772372e-de34-4d21-8be5-155639b90585" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c64b30b3db47e08679854bf2c78b08_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzMtMS0xLTEtMzQ4NjI_a10ce080-087c-4280-931f-b509930583a6">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff060470870f4782ab057c9bc17e5799_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzMtMy0xLTEtMzQ4NjI_6e7b17d0-d8e0-4df4-8526-eada176f082a">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2a67c94b5d4e07875b949f040c609f_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzMtNS0xLTEtMzQ4NjI_0b2c1cb2-4074-4005-8938-6e854ad06484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e11d04f3b714f7aa69b06869cf2dd60_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzMtNy0xLTEtMzQ4NjI_7c9b9faa-8d7f-4a6f-bf0b-34b4500b70b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4387fb9fcb644cbfa9f299c3c426b334_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzQtMS0xLTEtMzQ4NjI_5e66be56-7c42-4fdb-9104-5ad3a2a86840">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c272f1e1b9c4a5ab2d79ed4552a88ca_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzQtMy0xLTEtMzQ4NjI_8b4e948f-f287-451a-8993-946d70c8d768">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8682b8fb49274d31915223706871afca_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzQtNS0xLTEtMzQ4NjI_496ebafd-0250-4739-a4db-604af7464658">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice854542a5dd4a53ba69994da59a8099_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzQtNy0xLTEtMzQ4NjI_677a07a5-9b9d-4ddd-9be9-4f8f0d57099c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e7a9a04d1f5475985dad2756a363f66_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzktMS0xLTEtMzQ4NjI_d441d96b-f7d3-46bb-b087-b5f0104832a1">31,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b15df3b298345d2a6a8dd573021c03b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzktMy0xLTEtMzQ4NjI_77aa6555-4ba5-4f28-8d15-f821df1959e8">31,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b06aedd33f4a19969cd8bcfc7ae2ac_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzktNS0xLTEtMzQ4NjI_a1101fce-961f-4f94-9ae7-ebd5714a4482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ef303dbac04f97b77afccd76a0ee69_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzktNy0xLTEtMzQ4NjI_755d7ae3-5aa5-4498-bdd7-8e406a4ce008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7c512c8dad49688494a40ed9a84a26_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzEwLTEtMS0xLTM0ODYy_775e931f-1835-41c3-a255-ae7135f1db80">31,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45eb959635c4618a8e96c1da9b0ea55_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzEwLTMtMS0xLTM0ODYy_c8f283f1-2df1-4321-8857-a10f2ba77787">31,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6499a7329114832bcca11b186e9322c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzEwLTUtMS0xLTM0ODYy_33ed670c-0a87-4f09-a7ba-83221846dd2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e590388cdee4815b9794125e1f4fc52_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzEwLTctMS0xLTM0ODYy_3c7b559b-44a7-4292-b352-b5cf1e12aecb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="id15e6eed9a474921925790496d9be215_I20221231" decimals="3" name="us-gaap:InvestmentInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90ZXh0cmVnaW9uOjJjMTM5MTkxOTcwMzQ0MGY4OWFlZmExZjkxZmY3Yjg1XzIxOTkwMjMyNTc5NTA_beecb6b9-b896-4141-9f5d-62d15734e131">4.3</ix:nonFraction>% in a U.S. Government money market fund.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of December 31, 2022. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.  For the assessment of the fair value of goodwill and the related impairment of goodwill we used a level one assessment in our testing of goodwill.  See Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of significant accounting policies "Goodwill".</span></div></ix:continuation><div id="idff78559567c4173b665e875d419cf41_148"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzgxMjE_cde6d848-0d67-4436-bbfd-2462f451e387" continuedAt="ife7271fafe024eba81bcebcd2af93ee4" escape="true">Common Stock</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="ife7271fafe024eba81bcebcd2af93ee4" continuedAt="ibbaea8cbc4a446808a8529db821a8010">Shelf Registration Statements</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibbaea8cbc4a446808a8529db821a8010" continuedAt="ia8c0d62c6e234d2c898b51a6487394b0"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $<ix:nonFraction unitRef="usd" contextRef="i89236a268ded4c38beb10ce49d29d398_I20201130" decimals="-5" name="imux:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTQzOTA_34008d8b-65a3-4701-9fcc-a63b4f383144">250.0</ix:nonFraction>&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of February 17, 2023, there is $<ix:nonFraction unitRef="usd" contextRef="i1903fef7aaee4f7aaa653511f97e3f03_I20230217" decimals="-5" name="imux:ShelfRegistrationStatementAmountRemaining" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTQ1Njg_1452c974-2ac0-48a2-a878-55fcadebc7db">75.0</ix:nonFraction>&#160;million remaining on this shelf registration statement </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i43a90b71f4874951ab64ba8e4d321ed5_I20201231" decimals="-5" name="imux:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTQ3NjQ_23a4dd30-ed10-4c40-94c3-6960580c650c">50.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon <ix:nonFraction unitRef="d" contextRef="i441cf983bb6b42c1bfc3a145240c4326_I20221231" decimals="INF" name="imux:ShelfRegistrationTerminationPriorWrittenNotice" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTU1NDg_58268d20-d8f5-4903-b81a-e12488599be9">ten</ix:nonFraction> days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 17, 2023, $<ix:nonFraction unitRef="usd" contextRef="i67bc3dd545e748af9503605c6cf6ad15_I20230217" decimals="-5" name="imux:SaleOfStockRemainingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTU3MjM_4347cfd7-4e10-40cf-a163-873e0a612a73">8.4</ix:nonFraction>&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="ia92a9ae619944848ae66ab4dd8a63242_I20220510" decimals="-5" name="imux:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTU5MTc_e9a79331-94c8-4725-bd45-b89ad94d93a6">80.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon <ix:nonFraction unitRef="d" contextRef="i21732f0264304e5fb28318d6dc2b7ecb_I20221231" decimals="INF" name="imux:ShelfRegistrationTerminationPriorWrittenNotice" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTY2NTU_7b0a1212-b450-4f08-9aec-d3ae0eaea7b5">ten</ix:nonFraction> days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.  As of February 17, 2023, $<ix:nonFraction unitRef="usd" contextRef="i936d8c3c556941e4a8c00636316ee92c_I20230217" decimals="-5" name="imux:SaleOfStockRemainingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTY4MzA_2b7d2d5b-6dd0-4fe7-90bb-234d6c5b210a">80.0</ix:nonFraction>&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company has agreed to pay SVB Leerink a commission equal to <ix:nonFraction unitRef="number" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="3" name="imux:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTY5NDQ_e10d05e0-f440-44d6-a960-395da1495028">3.0</ix:nonFraction>% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, the Company raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7649036809b74b5683c233704941dc74_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTc3NzQ_999e23fc-6a7e-4fef-a866-65c6d249f2df">40.9</ix:nonFraction>&#160;million pursuant to the December 2020 ATM through the sale of <ix:nonFraction unitRef="shares" contextRef="i7649036809b74b5683c233704941dc74_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTc3Nzg_a8145de0-0662-447c-a129-71b922e3cea7">4,204,113</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7649036809b74b5683c233704941dc74_D20220101-20221231" decimals="2" name="imux:SharesIssuedWeightedAverageSharePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTc3ODI_40881c23-f7ef-407e-b076-0ae9ec9fb9ef">9.72</ix:nonFraction> per share. The net proceeds from the December 2020 ATM were  $<ix:nonFraction unitRef="usd" contextRef="i7649036809b74b5683c233704941dc74_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTc3ODY_001bf7e0-356b-4e43-b23b-85bb31dc60f5">39.6</ix:nonFraction>&#160;million after deducting underwriter commissions of $<ix:nonFraction unitRef="usd" contextRef="i7649036809b74b5683c233704941dc74_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTc3OTA_2de5e60c-5ace-4aa3-98c7-c238819ee184">1.2</ix:nonFraction>&#160;million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2021, the Company raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i20ece55753144123bea427d4b5da5edd_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTg0NDI_5cccba45-9020-4a58-82c9-2d65f346ae33">0.8</ix:nonFraction>&#160;million pursuant to the December 2020 ATM through the sale of <ix:nonFraction unitRef="shares" contextRef="i20ece55753144123bea427d4b5da5edd_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTg1MDA_32dbecd5-2daa-4a71-855f-7ba5276cac77">73,221</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i20ece55753144123bea427d4b5da5edd_D20210101-20211231" decimals="2" name="imux:SharesIssuedWeightedAverageSharePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTg1NTg_d93d4764-fe79-4604-b2a1-6f031526eae8">10.27</ix:nonFraction> per share. The net proceeds from the December 2020 ATM were  $<ix:nonFraction unitRef="usd" contextRef="i20ece55753144123bea427d4b5da5edd_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTg2MjM_fa43b463-0412-4ad8-a58e-ad54221b5b67">0.7</ix:nonFraction>&#160;million after deducting underwriter commissions of $<ix:nonFraction unitRef="usd" contextRef="i20ece55753144123bea427d4b5da5edd_D20210101-20211231" decimals="0" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTg2NzA_89798fbb-4088-4840-a35c-569d6231ac6c">22,555</ix:nonFraction>.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia8c0d62c6e234d2c898b51a6487394b0" continuedAt="i58298243bea349d9aba00d7e302a9048"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">$60 Million Private Placement Equity Financing</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) for a private placement (the &#8220;Private Placement&#8221;) with select accredited investors and certain existing investors (each, a &#8220;Purchaser&#8221; and collectively, the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) <ix:nonFraction unitRef="shares" contextRef="i88aea673e8c04440a92d7eb913623ddd_D20221010-20221010" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjIzMTY_ddddcf52-84a1-4a02-bb05-cd26c5c70d70">8,696,552</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ib94fad9370444fab84415ff498015dc8_I20221010" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjIzNjg_5fa964a8-189d-42ea-a0eb-c5e59474630e">0.0001</ix:nonFraction> per share (the &#8220;Shares&#8221;), at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib94fad9370444fab84415ff498015dc8_I20221010" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjI0MjE_233e73f4-6ba1-4551-9d40-585af02719a1">4.35</ix:nonFraction> per Share, and (ii) <ix:nonFraction unitRef="shares" contextRef="ida3ab5946fc24e23800223feb5a9d8ab_D20221010-20221010" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjI0NDU_ce8a9911-50fc-4f10-8acd-f3d34da95a1d">5,096,552</ix:nonFraction> pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase Common Stock (the &#8220;Warrant Shares&#8221; and together with the Shares and the Pre-Funded Warrants, the &#8220;Securities&#8221;), at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if8c0142cb42641dcb4f087976d7a8e60_I20221010" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjI2NDQ_291e989d-9923-41f4-bef1-3a7006eba048">4.34</ix:nonFraction> per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if8c0142cb42641dcb4f087976d7a8e60_I20221010" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjI3Mjc_66b8f6fe-afc9-45d0-8a6a-6c864eb91031">0.01</ix:nonFraction> per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than <ix:nonFraction unitRef="number" contextRef="ib94fad9370444fab84415ff498015dc8_I20221010" decimals="4" name="imux:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjI5ODQ_32d8da6a-e920-4b51-9fe7-bcd182297f61">9.99</ix:nonFraction>% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of <ix:nonFraction unitRef="number" contextRef="if8c0142cb42641dcb4f087976d7a8e60_I20221010" decimals="4" name="imux:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjMxODQ_9484d09e-d252-496d-91d6-7e4e37595fa5">19.99</ix:nonFraction>% by providing at least <ix:nonNumeric contextRef="if8c0142cb42641dcb4f087976d7a8e60_I20221010" name="imux:EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjMyMTA_21c212b0-cf93-4542-98a4-18e7071302fa">61</ix:nonNumeric> days&#8217; prior notice to the Company.  The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return.  All of the pre-funded warrants were exercised in January of 2023.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Private Placement closed on October 12, 2022. The gross proceeds of the Private Placement were approximately $<ix:nonFraction unitRef="usd" contextRef="i444f4698aac042ccbe20eda2d1da8d8b_D20221012-20221012" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjMzNTg_ef6ffbc9-9391-4eaa-8466-5ada5232d485">60.0</ix:nonFraction>&#160;million, before deducting offering expenses payable by the Company of approximately $4.0 million. The Company intends to use the net proceeds from the Private Placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), izumerogant (IMU-935) and IMU-856, and for other general corporate purposes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registration statement for these securities was deemed effective by Securities and Exchange Commission on December 20, 2022.   </span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">July 2021 Public Equity Offering</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 15, 2021, the Company entered into an underwriting agreement with Piper Sandler &amp; Co., in connection with the Company&#8217;s public offering of <ix:nonFraction unitRef="shares" contextRef="i2eac70ade3724a7c9d3a5db3107626ea_D20210715-20210715" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzM4NjI_3f25f5eb-3aa3-4002-945c-537926147cfc">4,500,000</ix:nonFraction> shares of the Company&#8217;s common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ifce58657f57045a8a9d5fdddad892a48_I20210715" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzM5MDM_5271e016-66ac-42d9-a98c-56e57bb1e044">0.0001</ix:nonFraction> par value per share, at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifce58657f57045a8a9d5fdddad892a48_I20210715" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzM5NTc_960cf6c0-b2ed-464c-b00c-5ab4560c710f">10.00</ix:nonFraction> per share. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 19, 2021, the Company closed the Offering. The net proceeds to the Company from the Offering was approximately $<ix:nonFraction unitRef="usd" contextRef="i9f1ba5cf7cba4f8c9251c46ff206c135_D20210719-20210719" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzQwOTI_61b847c9-345f-41ae-864a-b575af8b508c">42.0</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:113%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue <ix:nonFraction unitRef="shares" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzcyMjc_b0659579-216d-4f08-9773-2b627f672c8a">130,000,000</ix:nonFraction> shares of common stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzcyNjc_e60ef970-cbc1-4912-835e-c0d316f36d6b">0.0001</ix:nonFraction>. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through December&#160;31, 2022, <ix:nonFraction unitRef="usdPerShare" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2Xzc3MDg_718475c3-7836-40b8-a836-4f6ae814d1c1"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2Xzc3MDg_8a99a8af-5524-4e50-af53-7474406f929d">no</ix:nonFraction></ix:nonFraction> cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2Xzc4NzA_e595eb20-99bf-4d41-9a9a-42687fc91e3f">20,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2Xzc4ODM_6abc89ba-8f33-415e-b510-de197d36708d">0.0001</ix:nonFraction> par value preferred stock, rights and preferences to be set by the board of directors. <ix:nonFraction unitRef="shares" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2Xzc5NzM_9abd91ad-fe34-4372-979d-041c3ae14b19">No</ix:nonFraction> preferred shares were outstanding as of December&#160;31, 2022.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i58298243bea349d9aba00d7e302a9048"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzgxMjI_c6b1cf2c-d890-489b-bb28-6fa596399ace" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance as of December&#160;31, 2022 are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1faf1225c920491e8209c19e9f4b2f1d_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90YWJsZTo1MzE2MzI5Nzg1YmQ0NzZhYjE4YTg0NWM3ZGI5ZGU5Mi90YWJsZXJhbmdlOjUzMTYzMjk3ODViZDQ3NmFiMThhODQ1YzdkYjlkZTkyXzItMS0xLTEtMzQ4NjI_68868cfc-320a-4def-ada9-4962a29cfe4f">116,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prefunded stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a320bf359b749c7a617f5394f9b3c83_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90YWJsZTo1MzE2MzI5Nzg1YmQ0NzZhYjE4YTg0NWM3ZGI5ZGU5Mi90YWJsZXJhbmdlOjUzMTYzMjk3ODViZDQ3NmFiMThhODQ1YzdkYjlkZTkyXzMtMS0xLTEtMzY2NjU_ed6f9cf5-2c4e-415f-b9e8-af3e043890ec">5,096,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a7cbfffc237456380acaaec206786ea_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90YWJsZTo1MzE2MzI5Nzg1YmQ0NzZhYjE4YTg0NWM3ZGI5ZGU5Mi90YWJsZXJhbmdlOjUzMTYzMjk3ODViZDQ3NmFiMThhODQ1YzdkYjlkZTkyXzMtMS0xLTEtMzQ4NjI_25bfb3b3-29ee-4fcd-8a99-9903cbc82042">3,791,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11965a3f2e9c4db38fbab16426b46799_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90YWJsZTo1MzE2MzI5Nzg1YmQ0NzZhYjE4YTg0NWM3ZGI5ZGU5Mi90YWJsZXJhbmdlOjUzMTYzMjk3ODViZDQ3NmFiMThhODQ1YzdkYjlkZTkyXzUtMS0xLTEtMzQ4NjI_67bbbe7d-7d4c-4bcf-af33-81f32839366e">43,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i857f39ef5fe54694b80c6fbe030a98d5_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90YWJsZTo1MzE2MzI5Nzg1YmQ0NzZhYjE4YTg0NWM3ZGI5ZGU5Mi90YWJsZXJhbmdlOjUzMTYzMjk3ODViZDQ3NmFiMThhODQ1YzdkYjlkZTkyXzYtMS0xLTEtMzQ4NjI_d2a6f73e-70ec-423a-bd8d-4d56ea9fcc5d">46,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4677eaef5e04113aaa9e6c7d5aa9c4f_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90YWJsZTo1MzE2MzI5Nzg1YmQ0NzZhYjE4YTg0NWM3ZGI5ZGU5Mi90YWJsZXJhbmdlOjUzMTYzMjk3ODViZDQ3NmFiMThhODQ1YzdkYjlkZTkyXzctMS0xLTEtMzQ4NjI_f8b4abbe-08b9-4ae2-83f2-6698d3dc0806">188,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90YWJsZTo1MzE2MzI5Nzg1YmQ0NzZhYjE4YTg0NWM3ZGI5ZGU5Mi90YWJsZXJhbmdlOjUzMTYzMjk3ODViZDQ3NmFiMThhODQ1YzdkYjlkZTkyXzgtMS0xLTEtMzQ4NjI_38c3231d-da53-4209-b5f7-f62eb926e027">9,283,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="idff78559567c4173b665e875d419cf41_151"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzYxMDE_dd43ea9b-801e-48cf-b303-1a67818989e8" continuedAt="if07632ad149b465cb9a27618df8c7623" escape="true">Stock-based Compensation Plans</ix:nonNumeric></span></div><ix:continuation id="if07632ad149b465cb9a27618df8c7623" continuedAt="ibfcc4b55242f4b8cb0a0991ec68d7a67"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of <ix:nonFraction unitRef="number" contextRef="i9caf2243577b40c7b672a10e37d9512e_D20210425-20210425" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzU0MTc_82c008e2-38e9-41c0-9d0c-53d8457f7f2b">15</ix:nonFraction>% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#8217;s common stock. The purchase price of the stock is the lesser of (i) <ix:nonFraction unitRef="number" contextRef="i9caf2243577b40c7b672a10e37d9512e_D20210425-20210425" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzU2MzA_a6500521-1deb-41bf-b8d3-d0ecc8363388">85</ix:nonFraction>% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is <ix:nonFraction unitRef="shares" contextRef="i35242908a173404d86425605eca4a779_I20210425" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzU4NDA_38c18b79-c8bb-431f-9027-e8a1bc344e4b">200,000</ix:nonFraction> shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has issued <ix:nonFraction unitRef="shares" contextRef="i8554c441f8d04f83811d7362580665a3_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0NDc_d38d2ee5-73ef-4fb5-8a70-ebe4e9b16893">70,351</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i392c13496de949c3bd9f8fba9ec64518_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzYxODA_e8041366-b541-44df-92f8-0fd98f5a63e1">12,758</ix:nonFraction> shares under the ESPP for the twelve months ended December 31, 2022 and 2021, respectively. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i8554c441f8d04f83811d7362580665a3_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0NTU_1719dcd5-ef39-4b41-b369-157b2f778dd2">96,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i392c13496de949c3bd9f8fba9ec64518_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzExNTc_b4d0fc78-2942-4301-8720-52e584c72218">46,000</ix:nonFraction> of expense related to the plan in the twelve months ended December 31, 2022 and 2021, respectively.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of <ix:nonFraction unitRef="shares" contextRef="i00d5cdeb5b7e43c1b31aa26556827c45_I20190731" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2Mzc5NTY_e897025e-b1ad-4e05-8526-2ab78c99a476">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to <ix:nonFraction unitRef="number" contextRef="i5cb3045344074d578abb47cff790ebe3_D20190701-20190731" decimals="INF" name="imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzgxMzQ_4c22533d-3420-415a-8274-94271cbc36a4">4</ix:nonFraction>% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable increase of <ix:nonFraction unitRef="shares" contextRef="i5cb3045344074d578abb47cff790ebe3_D20190701-20190731" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzgyMjU_7dd169bd-91fe-451d-928c-e0509785387a">4,900,000</ix:nonFraction> shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of <ix:nonFraction unitRef="shares" contextRef="i175d1c7c30d04a678f2f280df3ebfdc5_D20200101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0NjQ_ae0f3d93-de2b-47cf-b553-29701e45d2dd">4,408,871</ix:nonFraction> shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than <ix:nonNumeric contextRef="ia137d2b6cec944f3a9a6132548a13e6e_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2Mzg4MjA_2f79d3fa-a57c-4d96-a73b-289f07158757">ten years</ix:nonNumeric>. Incentive stock options granted to employees typically vest over <ix:nonNumeric contextRef="i7b246b23033045b2b45563237e60fb03_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2Mzg4OTA_361befa0-b418-44aa-885a-04dba273c69d">four years</ix:nonNumeric>. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzkwMzI_3b155f68-f249-4b5a-829c-f22ff2797b9c">three</span> or <ix:nonNumeric contextRef="ib6a978fed247440098141566fbf4052d_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzkwMzk_a913ddfd-83c7-4c1d-9d43-cb29f52ad2a8">four years</ix:nonNumeric>.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibfcc4b55242f4b8cb0a0991ec68d7a67" continuedAt="ib048fc9fea4e427fbe15aac5cc713b23"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzYxMDI_69344539-cb93-46aa-9a25-29e56138cbbb" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the twelve months ended December 31, 2022 and 2021 under the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEtMS0xLTEtMzQ4NjI_2561c375-8526-421e-9e4a-435ecae59f43">2,157,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEtMy0xLTEtMzQ4NjI_4c3c2905-ac65-4fb7-be36-299044502395">13.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzItMS0xLTEtMzQ4NjI_3019a376-5a9b-4136-a8bb-d82349416815">1,886,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzItMy0xLTEtMzQ4NjI_35e80e14-97fe-4fb5-9d4d-32f0603aa9ca">8.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzMtMS0xLTEtMzQ4NjI_bc54e4bf-fd48-4aa6-9a4a-87b9f0015158">852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzMtMy0xLTEtMzQ4NjI_43c26702-92b9-4f50-a195-519376b1e79e">5.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzQtMS0xLTEtMzQ4NjI_96e95abc-c8df-41c6-8c32-c57d05f4d1e2">251,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzQtMy0xLTEtMzQ4NjI_0ae2f054-b202-4b05-8ba5-ec2804785b5a">10.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzUtMS0xLTEtMzQ4NjI_e0164e2a-1c79-4814-b183-974bd58ad1fb">3,791,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzUtMy0xLTEtMzQ4NjI_78142247-e30e-46dd-b0ed-4ef4d0ae3c19">11.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzUtNS0xLTEtMzQ4NjI_f5863c7f-3ddf-44bc-af97-222b73082ef0">8.35</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzUtNy0xLTEtMzQ4NjI_5b34737f-3d75-460f-9866-3a518679fe1e">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzYtMS0xLTEtMzQ4NjI_cb945030-8f04-4470-b8f3-02574f567751">3,791,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzYtMy0xLTEtMzQ4NjI_d494280d-1ad3-4ada-ab6d-147a5aae7927">11.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzYtNS0xLTEtMzQ4NjI_d98b9c0f-254f-4bf7-ace9-1c36fba89cd2">8.35</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzYtNy0xLTEtMzQ4NjI_0893fa6f-7508-485c-9723-8450f483413f">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzctMS0xLTEtMzQ4NjI_44ceef6a-1859-44bd-a5ca-632c3a706fce">1,398,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzctMy0xLTEtMzQ4NjI_4a57b8a0-8d4c-40ba-90bd-a73827014fcb">13.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzctNS0xLTEtMzQ4NjI_e8a95ab9-3b0c-4808-8c6d-da7c7da7d7e5">7.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzctNy0xLTEtMzQ4NjI_2c82603e-5cee-4447-8483-b60721e569c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46791b70b39149f995d04e9d61847f37_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEwLTEtMS0xLTM0ODYy_876be1ee-b2f0-49bb-92c9-bf02f89bddc0">1,117,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46791b70b39149f995d04e9d61847f37_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEwLTMtMS0xLTM0ODYy_62306dc4-f004-4b03-a49a-85c8093c3997">12.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzExLTEtMS0xLTM0ODYy_b88e390e-e0df-4c4f-aaa3-c8e5b37b691b">1,193,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzExLTMtMS0xLTM0ODYy_fbbbb54e-d08d-4af1-97f6-20954a50c806">14.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEyLTEtMS0xLTM0ODYy_84611b66-b22a-43bb-8d26-4fbcf1947ee9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEyLTMtMS0xLTM0ODYy_8c9296f7-f0df-44f6-af25-a73badf033aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEzLTEtMS0xLTM0ODYy_ef3fefb9-7617-4c80-97e6-023f5d77e56c">153,509</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEzLTMtMS0xLTM0ODYy_586c8e46-74b7-4a27-bf9c-83d699d240f2">13.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE0LTEtMS0xLTM0ODYy_a2f75a4b-4323-4c4b-b33d-69c168085b2d">2,157,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE0LTMtMS0xLTM0ODYy_3cd6ec17-7722-40d4-82d4-6dc2e920cb4b">13.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE0LTUtMS0xLTM0ODYy_7ebb03a3-127b-4723-b5c1-eee24c91a582">8.74</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE0LTctMS0xLTM0ODYy_75738fb5-f00f-4865-9fd4-0f1772aef0d4">302,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE1LTEtMS0xLTM0ODYy_0c2389dc-d604-4167-bb62-c31bdcca6fe4">2,157,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE1LTMtMS0xLTM0ODYy_359257f7-509b-4c7b-8fa6-6ed7224905b7">13.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE1LTUtMS0xLTM0ODYy_4603b727-8293-4875-808c-2ba251964562">8.74</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE1LTctMS0xLTM0ODYy_1ca5e1f6-972f-4786-9ad3-fcbc05cf3a0a">302,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE2LTEtMS0xLTM0ODYy_18b5918d-247f-4d68-a43c-dd0a97782246">752,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE2LTMtMS0xLTM0ODYy_4b85b700-673c-4518-987a-19c2292f28e1">13.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE2LTUtMS0xLTM0ODYy_099e61dc-d3c6-4b37-8afa-0a55b47038c8">8.15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE2LTctMS0xLTM0ODYy_69e61a89-cc43-4d30-94de-70b568919dc6">79,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be <ix:nonFraction unitRef="number" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2NDAxODk_c84602e4-c3c0-46ea-8041-8f59b1652b0b">zero</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib048fc9fea4e427fbe15aac5cc713b23"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i5621a4c9af0345529c9a631b26c01878_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzQ0NDM_2b501688-30c2-44af-a763-3c253e3ec6a6">6.81</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="id677ffe69ecb43f09a9efd781f682fd3_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0NzU_8cbf785e-4de3-4281-88ae-b41f20e42109">10.52</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzYxMDM_9b6554fd-0314-467a-b4d1-00485b8c9c5d" continuedAt="i6ad3aa1f5b5840b39759a17a27b34274" escape="true">The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="i6ad3aa1f5b5840b39759a17a27b34274"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.526%"><tr><td style="width:1.0%"></td><td style="width:57.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5621a4c9af0345529c9a631b26c01878_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzEtMS0xLTEtMzQ4NjI_c20d9460-8756-4ac8-83ba-d89119ae7fb9">2.09</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id677ffe69ecb43f09a9efd781f682fd3_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzEtMi0xLTEtMzQ4NjI_5052931b-6327-4726-9759-8f64461730c4">0.93</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5621a4c9af0345529c9a631b26c01878_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzItMS0xLTEtMzQ4NjI_94d19215-e5ee-42ef-a203-1973313aa92c">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id677ffe69ecb43f09a9efd781f682fd3_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzItMi0xLTEtMzQ4NjI_9c412ae6-f462-4440-9db5-432194c0d373">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5621a4c9af0345529c9a631b26c01878_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzMtMS0xLTEtMzQ4NjI_1e64127f-929d-4e7d-878b-baaa2d45918b">97.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id677ffe69ecb43f09a9efd781f682fd3_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzMtMi0xLTEtMzQ4NjI_33bcf31a-d329-4aa1-ad6a-6c248710cf4d">93.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5621a4c9af0345529c9a631b26c01878_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzQtMS0xLTEtMzQ4NjI_cc9bfe35-b299-442a-bea7-7df759b9ab6f">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id677ffe69ecb43f09a9efd781f682fd3_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzQtMi0xLTEtMzQ4NjI_368f9eaa-9f21-4488-9de4-1cff24a4de8d">6.0</ix:nonNumeric></span></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzYxMDg_653ea402-8806-4a28-a032-759bdb539e3a" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year<br/>&#160;Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3da78567fb1749fca30fc791bedfd050_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3ZGQzMjRhMzdjMDc0NmRiYTgyZjQxZDNjMGMyODgwMC90YWJsZXJhbmdlOjdkZDMyNGEzN2MwNzQ2ZGJhODJmNDFkM2MwYzI4ODAwXzItMS0xLTEtMzQ4NjI_c08a1b66-2e15-4368-b37a-7ce3a7289c5a">3,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i427aa8bde64a40738335743ec62dbe35_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3ZGQzMjRhMzdjMDc0NmRiYTgyZjQxZDNjMGMyODgwMC90YWJsZXJhbmdlOjdkZDMyNGEzN2MwNzQ2ZGJhODJmNDFkM2MwYzI4ODAwXzItMy0xLTEtMzQ4NjI_e1abadba-ceb1-4bd3-962e-ec61975a0f6c">1,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia250755510204b7fb17b62e711d72da6_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3ZGQzMjRhMzdjMDc0NmRiYTgyZjQxZDNjMGMyODgwMC90YWJsZXJhbmdlOjdkZDMyNGEzN2MwNzQ2ZGJhODJmNDFkM2MwYzI4ODAwXzMtMS0xLTEtMzQ4NjI_7dacd443-e41a-479d-a7c1-27f522002fb0">4,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3606afb67f4fd6b20f8cb83d82b570_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3ZGQzMjRhMzdjMDc0NmRiYTgyZjQxZDNjMGMyODgwMC90YWJsZXJhbmdlOjdkZDMyNGEzN2MwNzQ2ZGJhODJmNDFkM2MwYzI4ODAwXzMtMy0xLTEtMzQ4NjI_928918ad-ae97-4426-a064-e47d8e70faa7">4,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f8826a093524faab9e1c7138d3c7734_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3ZGQzMjRhMzdjMDc0NmRiYTgyZjQxZDNjMGMyODgwMC90YWJsZXJhbmdlOjdkZDMyNGEzN2MwNzQ2ZGJhODJmNDFkM2MwYzI4ODAwXzQtMS0xLTEtMzQ4NjI_fb0244d6-4500-4d4c-a077-22cebbb78f6c">7,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b6edf94a0a462ab55397b394789287_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3ZGQzMjRhMzdjMDc0NmRiYTgyZjQxZDNjMGMyODgwMC90YWJsZXJhbmdlOjdkZDMyNGEzN2MwNzQ2ZGJhODJmNDFkM2MwYzI4ODAwXzQtMy0xLTEtMzQ4NjI_b2642e44-7ee5-4833-9309-c149695d6365">5,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 there was $<ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0ODM_6bc3ff4d-6592-4f29-8334-b86c4e9e96fb">15.6</ix:nonFraction>&#160;million  in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0OTc_9acf8052-e8e0-413f-85aa-1aaaf94efbb0">2.74</ix:nonNumeric> years.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital&#8217;s 2012 Stock Option Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain <ix:nonFraction unitRef="shares" contextRef="i1f9bdb96b5174dbb8d3bd65a0524bed5_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzU0NTQ_edeab945-f958-4310-a059-b5db7853c19f">43,311</ix:nonFraction> shares available for grant under the 2014 Plan as of December 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Vital&#8217;s Board of Directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan <ix:nonFraction unitRef="shares" contextRef="i5ca30a45a6194bfe96a0c64a563c77ba_I20170930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzU2ODA_730ada02-a19f-4f6c-a784-1499f2aa9f34">46,250</ix:nonFraction> shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib771df66db154a9d836d085b5ebc58d3_D20210101-20211231" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0OTg_74b9c285-4bde-476a-aeeb-c0a6b8fecc18"><ix:nonFraction unitRef="usd" contextRef="ifabfaf9983d146db9bfff97adf3e07b1_D20220101-20221231" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0OTg_9150384d-d7c3-4936-b98a-3e431ec6267e">No</ix:nonFraction></ix:nonFraction> expense was recorded for the plans assumed from Vital during the twelve months ended December 31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="margin-top:17.6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 22</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzM4ODk_02d76128-29a4-40c4-a96f-edb0f4b77c51" continuedAt="ibb391b28702944f8bd8823d06545b758" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="ibb391b28702944f8bd8823d06545b758" continuedAt="i866fa5bb15664f4992fd784bd8fa18ce"><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzM4OTA_ef9238a6-5f67-47c1-8703-a0354d0a250b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i484c36bf82584e408934987b8269bc9a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzItMS0xLTEtMzQ4NjI_152cfff7-2f44-4bef-a8b7-134370082fcd">47,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i348724b28ae74d24885e46926e9b5cf1_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzItMy0xLTEtMzQ4NjI_2a957973-39f9-466e-91df-d9f20a8d0438">11,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cac2d95041a44d49c19e83ff8a94426_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzMtMS0xLTEtMzQ4NjI_b1ad1ca5-9f1d-4f21-8523-e58691cc94b6">67,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3329f0d0a5a47fd8a67187745e514d4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzMtMy0xLTEtMzQ4NjI_6b12f392-ab82-49d1-962f-c54e5139b45e">78,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i717b3c5bcd7648beb9aad1d139fdc6dc_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzQtMS0xLTEtMzQ4NjI_29e93f59-b76e-4101-80b7-c185a57efa24">5,911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6278909cd154de6bd0d29a81c57b4ec_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzQtMy0xLTEtMzQ4NjI_bbfe189e-dc74-48c5-84c3-3fb491889adf">2,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzUtMS0xLTEtMzQ4NjI_6bdca457-5c26-4a69-80dd-40cb47996c2c">120,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzUtMy0xLTEtMzQ4NjI_fd1f8008-c11f-4da9-9382-0501edd842b0">92,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzM4ODU_ea63ce25-dd47-43d2-8587-b7928be38842" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate reconciliation consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:72.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzItMS0xLTEtMzQ4NjI_2f3e4808-1359-46d3-8ff9-67411dbed4b4">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzItMy0xLTEtMzQ4NjI_5206c320-71c3-4201-8273-0959c05ed0ae">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzQtMS0xLTEtMzQ4NjI_59c46ff3-d6e6-4324-9602-620c55ad9d81">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzQtMy0xLTEtMzQ4NjI_788c2198-4df0-491f-81dd-a6cfc3e78599">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzUtMS0xLTEtMzQ4NjI_f365e781-dd6a-4795-9c30-acc1e2f561bc">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzUtMy0xLTEtMzQ4NjI_91011900-2dc7-4f90-ac26-c4c9ccb7f307">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effect of rate change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzctMS0xLTEtMzQ4NjI_e5e42cda-7746-4da5-978b-09056e83a324">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzctMy0xLTEtMzQ4NjI_0f6be20d-264b-414e-940f-29e98317214d">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzgtMS0xLTEtNDAyMDE_838b1dd6-6278-4329-a88a-86dd4cab43b5">5.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzgtMy0xLTEtNDAyMDE_aa97b5c9-c23e-4296-b972-f105eb5cf80a">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzgtMS0xLTEtMzQ4NjI_4250e6d2-9b23-4deb-8625-3570b721eb45">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzgtMy0xLTEtMzQ4NjI_50adb011-267e-4696-8288-7b3c8e4702b7">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzktMS0xLTEtMzQ4NjI_f650e3bb-1426-414a-83c3-99db5afd8c44">15.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzktMy0xLTEtMzQ4NjI_52cff9be-4bbc-4457-8b8a-a2d42dc168ef">22.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzEwLTEtMS0xLTM0ODYy_e9b5798d-ea1b-49d7-9388-15389502d5e1">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzEwLTMtMS0xLTM0ODYy_c3ae58e5-a477-41e9-a57f-29b292788e8d">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes result from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in years in which those temporary differences are expected to be recovered or settled. As tax laws and rates change, deferred tax assets and liabilities are adjusted through income tax expense. There is <ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="INF" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzczMg_59051c19-b0a7-42c7-9e70-4304447b660b"><ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="INF" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzczMg_eae1e6e1-8c74-4a73-a3df-4b5888d5ddff">no</ix:nonFraction></ix:nonFraction> current or deferred income tax expense in the years ended December 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's net deferred tax assets are shown below. A valuation allowance has been established as realization of such net deferred tax assets has not met the more likely-than-not threshold requirement. If the Company's judgment changes and it is determined that the Company will be able to realize these net deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on the net deferred tax assets will be accounted for as a reduction to income tax expense.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i866fa5bb15664f4992fd784bd8fa18ce" continuedAt="i702ab24d743c4113bddeb7ce5d6c9610"><div style="text-align:justify;text-indent:22.5pt"><ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzM4ODI_6037febd-bb1b-4b1a-a66f-a7e3f3ceed04" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzQtMS0xLTEtMzQ4NjI_12ec1776-38c2-406d-8d7d-31789b2b4afd">19,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzQtMy0xLTEtMzQ4NjI_666f0fb3-5f9a-4ce8-a3de-7d9cef706f7d">18,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzYtMS0xLTEtMzQ4NjI_f8c468a7-432a-445f-abdc-e030915a3a42">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzYtMy0xLTEtMzQ4NjI_a5cb601d-596f-4e41-9a40-ef117ed372a0">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzctMS0xLTEtMzQ4NjI_818e9f0d-8941-4cb0-980d-fc48e8ef3a96">2,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzctMy0xLTEtMzQ4NjI_dadd2f63-8097-4145-a06e-d1b09bc2a659">3,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzgtMS0xLTEtMzQ4NjI_c4ee84e1-dd61-4ee5-ac03-fc39ae828c20">47,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzgtMy0xLTEtMzQ4NjI_bd481452-1481-4b11-831e-75f83d953621">34,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain or loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzktMS0xLTEtMzQ4NjI_5019166d-0040-4ed1-91df-b8e2db021de5">1,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzktMy0xLTEtMzQ4NjI_289e9ad5-f3a5-4fa2-970e-7e58958fa354">1,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzEwLTEtMS0xLTM0ODYy_aa81fd9b-2f6c-45a0-933a-d9c6d758df7d">693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzEwLTMtMS0xLTM0ODYy_7ecf80d6-7da8-465f-8466-58f183befddd">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzExLTEtMS0xLTM0ODYy_a5fcc70f-4b63-4ac2-b09e-34bfbb9ae40e">73,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzExLTMtMS0xLTM0ODYy_87f63fa7-fae2-4eae-a313-0164f6c9b5cd">58,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzEzLTEtMS0xLTM0ODYy_c686e1a2-563e-4da1-86b3-0523e755e260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzEzLTMtMS0xLTM0ODYy_aeeb74e4-9d02-4fed-aa0f-c6a3fc4ba08a">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total deferred tax liability    </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE0LTEtMS0xLTM0ODYy_585707e5-8f34-4318-91d6-bb09f57bcae4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE0LTMtMS0xLTM0ODYy_61e244da-c098-4fe9-810b-fd515eefeff6">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="imux:DeferredTaxAssetsAndLiabilitiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE1LTEtMS0xLTM0ODYy_d4276784-89c9-455c-8e12-5d66245fb89d">73,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="imux:DeferredTaxAssetsAndLiabilitiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE1LTMtMS0xLTM0ODYy_264ca78b-e34c-4018-9abf-f06185890570">58,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE2LTEtMS0xLTM0ODYy_88cf6947-d2a4-4fcd-b182-16f233857d6b">73,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE2LTMtMS0xLTM0ODYy_68b8ce10-bd5f-4c1e-a83e-3c49e4c010b4">58,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE3LTEtMS0xLTM0ODYy_d793e47b-8527-4826-a3db-1e5f4ad947ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE3LTMtMS0xLTM0ODYy_ea4b7a45-41e7-4006-9dec-0e16562684a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net operating losses each year since inception due to its history as a development stage company with no realized revenues from its planned principal operations. These cumulative operating losses provide significant negative evidence in the determination of whether or not the Company will be able to realize deferred tax assets such as net operating losses and other favorable temporary differences. There can be no assurance that it will ever generate taxable income. As a result, the Company has maintained a full valuation allowance against the entire balance of its net deferred tax assets since the date of inception. The valuation allowance has increased by $<ix:nonFraction unitRef="usd" contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzIwNDg_6a8346a1-c5f8-493a-965e-9fbbe6f00c7f">14.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzIwNTU_c13f604f-ee6f-41fe-863b-f80b9a00adeb">22.3</ix:nonFraction>&#160;million and for the years ended December 31, 2021 and 20, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, Immunic had available NOLs of approximately $<ix:nonFraction unitRef="usd" contextRef="i52447e4dbf09445884a309828fb3a7f5_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzIxOTQ_772f5f7a-da75-4eaf-9430-9a88fed6cb54">190.2</ix:nonFraction>&#160;million in Germany and Australia. These NOLs do not expire.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ibbbf0f771acf458ab6e0e6253ecd4de4_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzIyODg_9b78a927-707d-485a-8b7e-29ae9d17f939">15.6</ix:nonFraction>&#160;million were generated prior to 2018 and expire over 20 years beginning in 2023. The $<ix:nonFraction unitRef="usd" contextRef="i0c0bbccc8e094072b09a4b7d1aafb3c3_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzIzNjg_2a7cbe45-1f90-41c5-81c4-b739f372488f">78.9</ix:nonFraction>&#160;million of post 2017 federal NOL carryforwards do not expire. Sections 382 of the Internal Revenue Code of 1986 subject the future utilization of net operating losses, to an annual limitation in the event of certain ownership changes, as defined. The Company may have undergone ownership changes and therefore may be limited in the amount of net operating losses available for utilization in the future.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzI3ODQ_759efde2-f0db-407c-9865-bebaa9e1b502"><ix:nonFraction unitRef="usd" contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzI3ODQ_96fb071f-00cd-4ffc-a10e-d9f7a3bf4598">no</ix:nonFraction></ix:nonFraction>t have any uncertain tax positions for the years ended December 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the full valuation allowance that the Company has on its net deferred tax asset balance, there are <ix:nonFraction unitRef="usd" contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzI5OTA_e7dd60fe-8030-4d39-9406-9962221a1b8e">no</ix:nonFraction> uncertain tax positions that would impact the effective tax rate if recognized.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2018 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i702ab24d743c4113bddeb7ce5d6c9610">Immunic, Inc. recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet. There were no such interest or penalties for any of the years presented.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div id="idff78559567c4173b665e875d419cf41_160"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzExMjk_020b7214-1b44-4680-a398-a2a620826093" continuedAt="if88414ae36c143f893cbd31f2e25980e" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span><br/></span></div><ix:continuation id="if88414ae36c143f893cbd31f2e25980e"><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship with a base salary of $<ix:nonFraction unitRef="usd" contextRef="id31cbe772be540f6ae60d3269ef43568_D20210101-20210514" decimals="0" name="imux:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1MjE_ad1ce67f-32cc-4a88-908a-3be76aa1bd80">25,417</ix:nonFraction> per month pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020. On October 15, 2020, the Company and Dr. Nash entered into an addendum (the &#8220;First Addendum&#8221;) to extend the term of the Executive Chairman Agreement to April 15, 2021.  In connection with the First Addendum, the Company made a one-time award to Dr. Nash of an option to purchase <ix:nonFraction unitRef="shares" contextRef="ic97bdf6441d44e2b83eaf02fe42ee442_D20201115-20201115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1MzA_a50ac272-3280-4c22-b608-2fa57aaf07ff">120,000</ix:nonFraction> shares of Company common stock, which vests monthly over six months commencing on November 15, 2020.  On April 15, 2021, the Company and Dr. Nash entered into Addendum No. Two (the &#8220;Second Addendum&#8221;) to extend the term of the Executive Chairman Agreement to April 15, 2022.  In connection with the Second Addendum, the Company made a one-time award to Dr. Nash of an option to purchase <ix:nonFraction unitRef="shares" contextRef="i4965c60a3c264702a9ac179a8a4a899a_D20210415-20210415" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1Mzk_f3ee90be-b452-484d-876f-f24ca0dc93c9">90,000</ix:nonFraction> shares of Company common stock, which vests monthly over 12 months commencing on May 15, 2021, and to increase Dr. Nash&#8217;s monthly base salary to $<ix:nonFraction unitRef="usd" contextRef="i55271ce968e14d408bd351945f042b13_D20210515-20211231" decimals="0" name="imux:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1NDc_5ad9c1e6-725f-4c80-883c-47105c11111b">27,960</ix:nonFraction> from $<ix:nonFraction unitRef="usd" contextRef="id31cbe772be540f6ae60d3269ef43568_D20210101-20210514" decimals="0" name="imux:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1NTY_4fdb0d8f-5844-4fdb-a4f9-5d022cd40032">25,417</ix:nonFraction>. On March 15, 2022, the Company and Dr. Nash entered into Addendum No. Three (the &#8220;Third Addendum&#8221;), which extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $<ix:nonFraction unitRef="usd" contextRef="id672e13b1b3b42b79a062e019e44f37d_D20220315-20221231" decimals="0" name="imux:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1NjU_a187e619-e878-4575-96ee-1345ad2d1132">29,358</ix:nonFraction> per month. In connection with the Third Addendum, the Company made a one-time award to Dr. Nash of an option to purchase <ix:nonFraction unitRef="shares" contextRef="ifa6db4839145429ebadca83963b31d82_D20220315-20220315" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1NzQ_3261b0fc-e7c9-4bd8-ae1e-0d1983696832">75,000</ix:nonFraction> shares of the Company&#8217;s common stock, which vests monthly over 12 months commencing on April 10, 2022.  On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $<ix:nonFraction unitRef="usd" contextRef="i268e6ad4baa74fa6836147f78ab7c782_D20221228-20231231" decimals="0" name="imux:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1ODI_157a392e-6f75-4475-98e0-027e17c4bd00">30,250</ix:nonFraction> per month (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 25</span></div></div></div><div id="idff78559567c4173b665e875d419cf41_169"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form&#160;10-K to be signed on its behalf by the undersigned, thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunic,&#160;Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 23, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ DANIEL VITT</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and President</span></td></tr></table></div><div><span><br/></span></div><div id="idff78559567c4173b665e875d419cf41_172"></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Daniel Vitt and Glenn Whaley, and each of them, his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form&#160;10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form&#160;10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ DANIEL VITT</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, Chief Executive Officer and President</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ GLENN WHALEY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ DUANE D. NASH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Chairman</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Duane D. Nash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ TAMAR HOWSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tamar Howson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JOERG NEERMANN</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joerg Neermann</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ VINCENT OSSIPOW</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vincent Ossipow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ BARCLAY A. PHILLIPS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barclay A. Phillips</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ MARIA TORNSEN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maria Tornsen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>exhibit422022.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if1deb9c108f143b28dbd15c8579e7a35_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DESCRIPTION OF CAPITAL STOCK </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our authorized capital stock consists of 130,000,000 shares of common stock, par value $0.0001 per share, and 20,000,000 shares of preferred stock, par value $0.0001 per share.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following description of our common stock summarizes its material terms and provisions, but it is not complete. For the complete terms of our common stock, please refer to our certificate of incorporation and our bylaws that are incorporated by reference into the Annual Report on Form 10-K of which this exhibit is a part.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Common Stock</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2020, there were 21,168,240 shares of common stock outstanding. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors, and as a consequence, minority stockholders will not be able to elect directors on the basis of their votes alone.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to preferences that may be applicable to any then outstanding shares of preferred stock, holders of common stock are entitled to receive ratably such dividends as may be declared by the board of directors out of funds legally available therefor. In the event of a liquidation, dissolution or winding up of us, holders of the common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any then outstanding shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to our common stock. All outstanding shares of common stock are fully paid and non-assessable. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any of our outstanding preferred stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Listing</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;IMUX.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Transfer Agent and Registrar</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transfer agent and registrar for our common stock is American Stock Transfer &#38; Trust Company, LLC (&#8220;AST&#8221;). The transfer agent and registrar&#8217;s address is 6201 15th Avenue, Brooklyn, New York 11219.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Dividends</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have not declared any cash dividends on our common stock since inception and we do not anticipate paying any cash dividends on our common stock in the foreseeable future.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Possible Anti-Takeover Effects of Delaware Law and our Charter Documents</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could make the following transactions more difficult&#58; an acquisition of us by means of a tender offer, an acquisition of us by means of a proxy contest or otherwise, or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interest, including transactions which provide for payment of a premium over the market price for our shares.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delaware Anti-Takeover Statute</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to Section 203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), an anti-takeover statute. In general, Section 203 of the DGCL prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the time the person became an interested stockholder, unless the business combination or the acquisition of shares that resulted in a stockholder becoming an interested stockholder is approved in a prescribed manner. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns (or within three years prior to the determination of interested stockholder status did own) 15% or more of a corporation&#8217;s voting stock. The existence of this provision would be expected to have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by our stockholders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Undesignated Preferred Stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ability of our board of directors, without action by the stockholders, to issue up to 20,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to effect a change in control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Requirements for Advance Notification of Stockholder Nominations and Proposals.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Elimination of Stockholder Action by Written Consent.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Staggered Board.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Removal of Directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote in the election of directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stockholders Not Entitled to Cumulative Voting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Authorized but Unissued Shares</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our authorized but unissued shares of common stock and preferred stock will be available for future issuance without stockholder approval. We may use additional shares for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions and as employee compensation. The existence of authorized but unissued shares of undesignated preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">obligations, our board of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer, stockholder or stockholder group. The rights of holders of our common stock described above will be subject to, and may be adversely affected by, the rights of any preferred stock that we may designate and issue in the future. The issuance of shares of undesignated preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Director Liability</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our bylaws limit the extent to which our directors are personally liable to us and our stockholders, to the fullest extent permitted by the DGCL. The inclusion of this provision in our bylaws may reduce the likelihood of derivative litigation against directors and may discourage or deter stockholders or management from bringing a lawsuit against directors for breach of their duty of care.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interest.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>imux-ex105dienstvertragand.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib762923063344b5aaf2b48973c43f0bf_1"></div><div style="min-height:70.56pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:1px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">DIENSTVERTRAG</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SERVICE AGREEMENT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">zwischen</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">between</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Immunic AG, <br>vertreten durch den Vorsitzenden des Aufsichtsrates</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Immunic AG, <br>represented by the Chairman of the Supervisory Board</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">- nachfolgend &#8222;Gesellschaft&#34; genannt -</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">- hereinafter referred to as the &#34;Company&#34; -</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">und</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Herrn Dr. med. Rolf Andreas M&#252;hler,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dr. med. Rolf Andreas M&#252;hler,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">- nachfolgend &#8222;Vorstand&#34; genannt -</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">- hereinafter referred to as the &#34;Board Member&#34; -</font></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Aufgabenbereich und Pflichten</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Responsibilities and Obligations</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.8pt;padding-right:2.75pt;text-align:justify;text-indent:-16.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.89pt">Herr Dr. Rolf Andreas M&#252;hler ist mit Beschluss des Aufsichtsrates der Gesellschaft vom 23.03.2016 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">(Anlage&#160;1) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">f&#252;r ein Jahr zum ordentlichen Mitglied des Vorstandes der Gesellschaft bestellt worden. Diese Bestellung soll bis zum Ablauf des 31.&#160;August 2019 verl&#228;ngert werden. Er wird als Vorstand f&#252;r den Bereich Medical (Chief Medical Officer, CMO) der Gesellschaft bestellt und vertritt die Gesellschaft gemeinsam mit einem Vorstand oder einem Prokuristen. Der Aufsichtsrat kann dem Vorstand Einzelvertretungsbefugnis erteilen sowie von den Beschr&#228;nkungen des &#167;&#160;181 Alt. 2 BGB befreien.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Dr. Rolf Andreas M&#252;hler was appointed a member of the Management Board of the Company for one year by resolution of the Supervisory Board of the Company dated 23 March 2016 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">(Annex 1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. This appointment is to be extended until the end of 31 August 2019. He is appointed as Chief Medical Officer (CMO) of the Company and represents the Company together with a member of the Management Board or an authorized signatory. The Supervisory Board may grant the Board Member sole power of representation as well as exemption from the restrictions of &#167; 181 Alt. 2 of the German Civil Code (BGB).</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 2 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.8pt;padding-right:2.75pt;text-align:justify;text-indent:-16.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.89pt">Der Vorstand f&#252;hrt die Gesch&#228;fte der Gesellschaft nach Ma&#223;gabe der Gesetze, der Satzung, der Gesch&#228;ftsordnung f&#252;r den Vorstand und dieses Dienstvertrages. Der Vorstand hat insbesondere f&#252;r die laut einer Gesch&#228;ftsordnung des Vorstands unter Zustimmungsvorbehalt stehenden Gesch&#228;fte und Ma&#223;nahmen die Zustimmung des Aufsichtsrats einzuholen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member shall conduct the business of the Company in accordance with the law, the Articles of Association, the rules of procedure for the Management Board and this Service Agreement. In particular, the Board Member shall obtain the approval of the Supervisory Board for transactions and measures subject to approval in accordance with the rules of procedure of the Management Board.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.8pt;padding-right:2.75pt;text-align:justify;text-indent:-16.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.89pt">Dem Vorstand obliegen insbesondere die Aufgaben, die im Sinne des jeweiligen Gesch&#228;ftsverteilungsplans zum Gesch&#228;ftsbereich des Medicalvorstands (CMO) geh&#246;ren.</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:38.75pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In particular, the Board Member is responsible for the tasks that belong to the business area of the Chief Medical Officer (CMO) within the meaning of the respective schedule of responsibilities.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.8pt;padding-right:2.75pt;text-align:justify;text-indent:-16.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.89pt">Dienstort ist M&#252;nchen&#47;Planegg-Martinsried. Sofern die Pflichten nach diesem Vertrag es zulassen, ist der Vorstand frei in der Wahl des Ortes der Aus&#252;bung seiner T&#228;tigkeit.</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:38.75pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The place of work is Munich&#47;Planegg-Martinsried. If the obligations according to this agreement allow it, the Board Member is free in the choice of the place of the exercise of its activity.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:38.75pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Nebent&#228;tigkeiten</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.18pt;text-align:center;vertical-align:top"><font style="font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ancillary Activities</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.8pt;padding-right:2.75pt;text-align:justify;text-indent:-16.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.89pt">Der Vorstand wird seine ganze Arbeitskraft und seine s&#228;mtlichen fachlichen Kenntnisse und Erfahrungen der Gesellschaft widmen. Die &#220;bernahme einer entgeltlichen Nebent&#228;tigkeit sowie von Aufsichtsrats-, Beirats- oder &#228;hnlichen Mandanten bedarf der vorherigen Zustimmung durch den Aufsichtsratsvorsitzenden.</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:38.75pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member will devote all its working capacity and all its professional knowledge and experience to the Company. The assumption of an ancillary commercial activity as well as mandates in a supervisory board or advisory board or similar mandates require the prior consent of the Chairman of the Supervisory Board.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.8pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Dem Aufsichtsratsgremium ist bekannt, dass der Vorstand zum Zeitpunkt der Unterzeichnung dieses Vertrages die in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Anlage 2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">aufgelisteten Mandate innehat und erteilt zu deren Fortf&#252;hrung seine Zustimmung.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The Supervisory Board is aware that the Board Member holds the mandates listed in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Annex 2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">at the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">time of signing of this agreement and grants its approval to their continuation.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 3 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.8pt;padding-right:2.75pt;text-align:justify;text-indent:-16.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.89pt">F&#252;r den Vorstand gilt das Wettbewerbsverbot des &#167;&#160;88 AktG. W&#228;hrend der Dauer dieses Vertrages wird sich der Vorstand auch nicht an Unternehmen beteiligen, die mit der Gesellschaft in Wettbewerb stehen oder mit denen die Gesellschaft Gesch&#228;ftsverbindungen unterh&#228;lt, es sei denn, der Aufsichtsrat hat vorher seine schriftliche Zustimmung erteilt.</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:38.75pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member is subject to the non-competition clause of Section 88 of the German Stock Corporations Act (AktG). During the term of this agreement, the Board Member will also not invest in companies that compete with the Company or with which the Company has business relationships, unless the Supervisory Board has given its prior written consent.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.8pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Das Wettbewerbsverbot gilt nicht f&#252;r Beteiligungen an Unternehmen in Gestalt von Wertpapieren, die an B&#246;rsen gehandelt und zum Zwecke der Kapitalanlage erworben werden. Dar&#252;ber hinaus sind etwaig bestehende, vorrangige Regelungen aus einem Investment Agreement und&#47;oder Shareholders' Agreement zu Wettbewerbsverboten bzw. erlaubten T&#228;tigkeiten des Vorstands zu beachten.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The non-competition clause does not apply to interests in companies in the form of bonds traded on the stock exchange and acquired for the purpose of capital investment. In addition, any existing overriding regulation from an Investment Agreement and&#47;or Shareholders' Agreement on restraints of competition or permitted activities of the Board Member must be observed.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Verg&#252;tung und Bonus</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Remuneration and bonus</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Der Vorstand erh&#228;lt f&#252;r seine T&#228;tigkeit</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member receives for its activities</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:38.75pt;padding-right:2.75pt;text-align:justify;text-indent:-20.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:9.39pt">ein festes Jahresgehalt </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">(&#8222;Grundverg&#252;tung&#34;) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">in H&#246;he von EUR 156.000,00 brutto, das in 12 gleichen Monatsraten jeweils nachtr&#228;glich am Monatsletzten ausbezahlt wird. Sofern dieser Vertrag nicht w&#228;hrend der Dauer eines gesamten Kalenderjahres besteht, wird das Jahresfestgehalt zeitanteilig gezahlt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:38.8pt;padding-right:2.75pt;text-align:justify;text-indent:-20.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:10.38pt">a fixed annual salary </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">(&#34;Basic Remuneration&#34;) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">in the amount of EUR&#160;156,000.00 gross, paid in 12 equal monthly instalments at the end of each month. If this agreement does not exist for the duration of an entire calendar year, the fixed annual salary shall be paid pro rata temporis.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 4 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:38.75pt;padding-right:2.75pt;text-align:justify;text-indent:-20.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:9.39pt">eine j&#228;hrliche variable Verg&#252;tung, die bei 100-prozentigem Erreichen der festgelegten Jahresziele maximal EUR 24.000,00 brutto betr&#228;gt. Die Einzelheiten, insbesondere zum Verfahren der Zielfestlegung, zur Feststellung der Zielerreichung und zur F&#228;lligkeit ergeben sich aus dem Rahmenvertrag zur Zielvereinbarung in seiner jeweils geltenden Fassung. Die Art der Ziele, die Voraussetzungen f&#252;r ihre Erreichung und ihre Gewichtung zueinander werden f&#252;r das jeweilige Gesch&#228;ftsjahr in einer gesonderten Zielfestlegung niedergelegt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:38.8pt;padding-right:2.75pt;text-align:justify;text-indent:-20.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:10.38pt">an annual variable remuneration of up to EUR&#160;24,000.00 gross if the defined annual targets are achieved 100 percent. The details, in particular with regard to the procedure for setting targets, determining the achievement of targets and the due date, are set out in the Framework Agreement regarding the targets (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Rahmenvertrag zur Zielvereinbarung</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">) in its current version. The nature of the objectives, the conditions for their achievement and their weighting in relation to each other are laid down for each financial year in a separate target setting.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Die Grundverg&#252;tung und die variable Verg&#252;tung werden j&#228;hrlich durch den Aufsichtsrat &#252;berpr&#252;ft. Dabei sind die wirtschaftliche Entwicklung der Gesellschaft sowie die pers&#246;nliche Leistung des Vorstandes zu ber&#252;cksichtigen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Basic Remuneration and the variable remuneration are reviewed annually by the Supervisory Board. The economic development of the Company and the personal performance of the Board Member must be taken into account.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Im &#220;brigen kann der Aufsichtsrat die Bez&#252;ge des Vorstands insgesamt auf die angemessene H&#246;he herabsetzen, wenn sich die Lage der Gesellschaft so verschlechtert, dass die Weitergew&#228;hrung der Bez&#252;ge unbillig f&#252;r die Gesellschaft w&#228;re&#59; Ruhegehalt, Hinterbliebenenbez&#252;ge und Leistungen verwandter Art k&#246;nnen dabei nur in den ersten drei Jahren nach Ausscheiden aus der Gesellschaft herabgesetzt werden (&#167; 87 (2) AktG). Der Vorstand kann in diesem Fall diesen Dienstvertrag au&#223;erordentlich mit einer Frist von sechs Wochen zum Schluss des n&#228;chsten Kalendervierteljahres nach Erkl&#228;rung der Herabsetzung k&#252;ndigen (&#167; 87 (2) Satz 3 AktG). Entf&#228;llt eine verschlechterte Lage der Gesellschaft, ist die Herabstufung wieder r&#252;ckg&#228;ngig zu machen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Otherwise, the Supervisory Board may reduce the total remuneration of the Board Member to the appropriate amount, if the situation of the Company deteriorates to such an extent that the continued granting of the remuneration would be inequitable for the Company&#59; retirement pension, survivors benefits and benefits of a related kind may only be reduced in the first three years after leaving the Company (Section 87 (2) AktG). In this case, the Board Member may terminate this Service Agreement extraordinarily with six weeks' notice to the end of the next calendar quarter after declaration of the reduction (Section 87 (2) sentence 3 AktG). If a deterioration in the situation of society does not apply, the downgrade shall be reversed.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Versicherungen und Nebenleistungen</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Insurance and Fringe Benefits</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 5 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Auch soweit keine gesetzliche Versicherungspflicht besteht, zahlt die Gesellschaft an das Vorstandsmitglied monatliche Zusch&#252;sse zur Kranken-und Pflegeversicherung des Vorstandsmitglieds. Die einzelnen Zusch&#252;sse entsprechen in ihrer H&#246;he der H&#228;lfte der vom Vorstandsmitglied gezahlten Beitr&#228;ge, h&#246;chstens jedoch dem jeweils unter Ber&#252;cksichtigung der jeweils geltenden Beitragsbemessungsgrenzen gesetzlich geschuldeten H&#246;chstbetrag des Arbeitgeberanteils der gesetzlichen Kranken- und Pflegeversicherung. Die von der Gesellschaft geschuldeten Zusch&#252;sse werden dem Vorstandsmitglied jeweils am Kalendermonatsende gezahlt. Die auf diese Zahlungen etwaig anfallende Einkommensteuer tr&#228;gt das Vorstandsmitglied.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Even if there is no statutory insurance obligation, the Company shall pay the Board Member monthly health and long-term care insurance contributions for the Board Member. The individual contributions are in their amount equivalent to the amount of the contributions paid by the Board Member, but limited to the amount of the employer's contribution to the statutory health and long-term care insurance legally owed in each case, taking into account the applicable contribution assessment thresholds. The contributions owed by the Company are paid to the Board Member at the end of each calendar month. Any income tax payable on these payments shall be borne by the Board Member.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Die Gesellschaft zahlt an das Vorstandsmitglied monatliche Zusch&#252;sse zur Bayerischen &#196;rzteversorgung des Vorstandsmitglieds. Die einzelnen Zusch&#252;sse entsprechen in ihrer H&#246;he der H&#228;lfte der vom Vorstandsmitglied gezahlten Beitr&#228;ge. Die von der Gesellschaft geschuldeten Zusch&#252;sse werden dem Vorstandsmitglied jeweils am Kalendermonatsende gezahlt. Die auf diese Zahlungen etwaig anfallende Einkommensteuer tr&#228;gt das Vorstandsmitglied.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Company pays the Board Member monthly contributions for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Bayerische &#196;rzteversorgung</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> of the Board Member. The individual contributions correspond in their amount to half of the contributions paid by the Board Member. The contributions owed by the Company are paid to the Board Member at the end of each calendar month. Any income tax payable on these payments shall be borne by the Board Member.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Der Vorstand erh&#228;lt in angemessenem Umfang f&#252;r die im Gesellschaftsinteresse erforderlichen Aufwendungen Ersatz. Erforderliche Reisekosten werden gegen Einzelnachweis erstattet. Die darin enthaltenen Tage- und &#220;bernachtungsgelder k&#246;nnen im Rahmen der steuerlich zul&#228;ssigen Betr&#228;ge auch pauschal abgerechnet werden.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member shall be reimbursed to an appropriate extent for the expenses required in the interest of the Company. Required travel expenses will be reimbursed against itemization. The daily and overnight allowances contained therein may also be settled as a lump sum within the limits of the amount permissible for tax purposes.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 6 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Die Gesellschaft kann den Vorstand nach ihrem Ermessen f&#252;r die Dauer dieses Dienstvertrages im Rahmen einer Risiko-Lebensversicherung in H&#246;he von EUR 500.000,00 f&#252;r den Todesfall und im Rahmen einer Unfallversicherung in H&#246;he von EUR&#160;700.000,00 f&#252;r den Invalidit&#228;tsfall versichern bzw. eine bereits bestehende Versicherung fortf&#252;hren. Der Vorstand hat das Recht, den&#47;die Bezugsberechtigten zu bestimmen.</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:6.35pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">At its discretion, the Company may insure the Board Member for the duration of this Service Agreement under a risk life insurance policy in the amount of EUR 500,000.00 in the event of death and under an accident insurance policy in the amount of EUR&#160;700,000.00 in the event of disability or continue an existing insurance policy. The Board Member is entitled to determine the beneficiary&#47;beneficaries.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Im Falle der &#220;bernahme einer bestehenden Direktversicherung kann diese gem&#228;&#223; &#167;&#160;40 b EStG in ihrer geltenden Fassung weiter gef&#252;hrt werden. Die pauschale Versteuerung &#252;bernimmt in diesem Fall die Gesellschaft.</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:6.35pt;padding-right:2.75pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In the event that an existing direct insurance policy is taken over, this insurance policy can be managed in its current version under Section 40 b German Income Tax Act (EStG). In this case, the lump sum taxation is paid by the Company.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 7 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Die Gesellschaft bietet dem Vorstand die M&#246;glichkeit zur Teilnahme an einer Pensionskasse, Unterst&#252;tzungskasse oder einer &#228;hnlichen betrieblichen Altersversorgung (BAV) bzw. zur &#220;bernahme einer bereits bestehenden BAV. In diesem Zusammenhang kann der Vorstand einen Teil seiner Gehaltsanspr&#252;che zugunsten einer betrieblichen Altersversorgungszusage umwandeln. Die dem Vorstand gem&#228;&#223; &#167;&#160;3 (1) lit. a) gew&#228;hrte Grundverg&#252;tung wird dabei mit Wirkung zum Beginn einer betrieblichen Altersversorgungszusage entsprechend um einen monatlichen Bruttobetrag gek&#252;rzt, um in eine wertgleiche Zusage auf betriebliche Versorgungsleistung umgewandelt zu werden. In H&#246;he dieses Betrags verringert sich der Anspruch des Vorstands auf Zahlung der Grundverg&#252;tung. Sollte der Vorstand die Versorgungszusage im weiteren Verlauf ganz oder teilweise wieder k&#252;ndigen oder ruhen lassen, so lebt der entsprechende Verg&#252;tungsanspruch wieder auf.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Company offers the Board Member the opportunity to participate in a pension fund, support fund or similar company pension scheme (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">betriebliche Altersvorsorge</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">, BAV) or to take over an existing BAV. In this context, the Board Member can convert part of its salary entitlements into a company pension commitment. The Basic Remuneration granted to the Board Member pursuant to &#167; 3 (1) lit. a) shall be reduced by a gross monthly amount with effect from the beginning of a company pension commitment to be converted into an equal-value commitment to company pension benefits. The Board Member's entitlement to payment of the Basic Remuneration is reduced by this amount. If the Board Member rescinds or suspends the pension commitment in whole or in part in the further course of the plan, the corresponding entitlement to compensation shall revive.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 8 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Die Gesellschaft schlie&#223;t f&#252;r den Vorstand eine Verm&#246;gensschaden-Haftpflichtversicherung (D&#38;O) f&#252;r den Fall ab, dass der Vorstand wegen einer in Aus&#252;bung seiner T&#228;tigkeit begangenen Pflichtverletzung von einem Dritten oder der Gesellschaft aufgrund gesetzlicher Haftpflichtbestimmungen privatrechtlichen Inhalts f&#252;r einen Verm&#246;gensschaden in Anspruch genommen wird. Der Vorstand tr&#228;gt dabei eine Selbstbeteiligung in H&#246;he des Mindestwerts gem&#228;&#223; &#167;&#160;93 (2) AktG (derzeit je Schadensfall 10% des Schadens, maximal aber das 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#47;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:1.55pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">-fache der Grundverg&#252;tung pro Jahr (j&#228;hrliche H&#246;chstgrenze). Kommt es zu mehreren Schadensf&#228;llen in einem Jahr, gilt die j&#228;hrliche H&#246;chstgrenze f&#252;r alle Schadensf&#228;lle zusammen. Der Selbstbehalt passt sich bei &#196;nderung der Grundverg&#252;tung (bzw. bei &#196;nderung von &#167;&#160;93 (2) AktG) automatisch an&#59; der Vorstand ist verpflichtet, die entsprechenden &#196;nderungen beim Selbstbehalt des D&#38;O Versicherungsvertrages zu veranlassen, und &#47; oder s&#228;mtliche in diesem Zusammenhang erforderlichen Erkl&#228;rungen abzugeben. Das Bezugsjahr f&#252;r den anzuwendenden Selbstbehalt ist das Jahr des Pflichtversto&#223;es.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Company enters into a directors' and officers' liability insurance policy (D&#38;O) for the Board Member for the event that a third party or the Company makes a claim against the Board Member for a loss of assets due to a breach of duty committed in the performance of its duties due to statutory liability provisions under private law. The Board Member bears a deductible in the amount of the minimum value pursuant to Section 93 (2) of the German Stock Corporation Act (AktG) (currently 10% of the damage per claim, but not more than one and a half times the basic annual remuneration (annual maximum limit). In case of several loss events in one year, the annual maximum limit applies to all loss events in combination. The deductible is automatically adjusted in the event of a change in the Basic Renumaration (or in the event of a change in Section 93 (2) AktG)&#59; the Board Member is obliged to arrange for the corresponding changes to the deductible in the D&#38;O insurance agreement and &#47; or to provide all declarations required in this regard. The reference year for the deductible to be applied is the year of the violation.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Urlaub</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Holiday</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Der Vorstand hat Anspruch auf einen Jahresurlaub von 30 Arbeitstagen. Arbeitstage sind alle Kalendertage mit Ausnahme von Samstagen, Sonntagen und gesetzlichen Feiertagen am Sitz der Gesellschaft. Bei unterj&#228;hrigem Besch&#228;ftigungsbeginn oder -ende wird der Jahresurlaub in diesem Kalenderjahr zeitanteilig gew&#228;hrt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member is entitled to an annual vacation of 30 working days. Working days are all calendar days except Saturdays, Sundays and public holidays at the registered office of the Company. If employment begins or ends during the course of the year, annual vacation in this calendar year will be granted pro rata temporis.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Die Urlaubszeit ist unter Ber&#252;cksichtigung der Gesch&#228;ftslage mit den anderen Vorstandsmitgliedern abzustimmen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The holiday period shall be coordinated with the other members of the Executive Board, taking into account the business situation.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 9 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1.18pt;text-align:center;vertical-align:top"><font style="font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Bez&#252;ge bei Krankheit, Arbeitsunf&#228;higkeit oder Tod</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.18pt;text-align:center;vertical-align:top"><font style="font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Beneficiaries in the event of illness, incapacity for work or death</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">lm Fall einer Dienstverhinderung (z.B. infolge Erkrankung) ist das Vorstandsmitglied verpflichtet, den Aufsichtsratsvorsitzenden der Gesellschaft unverz&#252;glich &#252;ber Grund und Dauer der Dienstverhinderung zu informieren und auf vordringlich zu erledigende Aufgaben hinzuweisen. Dauert die Dienstverhinderung l&#228;nger als eine Woche, hat das Vorstandsmitglied im Fall einer Erkrankung ein &#228;rztliches Attest oder im Fall einer sonstigen Dienstverhinderung eine schriftliche Erkl&#228;rung vorzulegen, woraus sich der Grund der Arbeitsunf&#228;higkeit sowie deren voraussichtliche Dauer ergeben.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In the event of an unforeseen absence (e.g. due to illness), the Board Member is obliged to inform the Chairman of the Supervisory Board of the Company without undue delay of the reason for and probable duration of the impediment to service and draw the attention on the tasks to be performed urgently. If the absence lasts longer than one week, the Board Member must submit a medical certificate or in the event of any other incapacity or a written declaration in the event of any other disability, stating the reason for the incapacity and its probable duration.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Das Vorstandsmitglied tritt bereits jetzt etwaige (Schadensersatz-)Anspr&#252;che in H&#246;he der nach dieser Regelung von der Gesellschaft geleisteten oder zu leistenden Zahlungen an die Gesellschaft ab, die ihm gegen&#252;ber Dritten wegen der Arbeitsverhinderung zustehen. Das Vorstandsmitglied ist verpflichtet, der Gesellschaft unverz&#252;glich s&#228;mtliche zur Geltendmachung derartiger (Schadensersatz-)Anspr&#252;che notwendigen Angaben zu machen sowie hierf&#252;r notwendige Unterlagen zu &#252;berlassen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The Board Member hereby assigns to the Company any (compensation) claims in the amount of the payments made or to be made by the Company in accordance with this provision to which he is entitled in respect of third parties due to the impediment to work. The Board Member is obligated to provide the Company with all information necessary for asserting such (compensation) claims and to provide the Company with the necessary documents without undue delay.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 10 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Bei einer vor&#252;bergehenden krankheitsbedingten oder sonstigen unverschuldeten Arbeitsunf&#228;higkeit des Vorstandes wird die Grundverg&#252;tung gem&#228;&#223; &#167; 3 (1) lit. a) w&#228;hrend der Zeit der Arbeitsunf&#228;higkeit bis zu einer Dauer von sechs Monaten, l&#228;ngstens jedoch bis zur Beendigung dieses Dienstvertrages weitergezahlt. Dauert die Arbeitsunf&#228;higkeit l&#228;nger als ununterbrochen 3 Monate an, kann der Aufsichtsrat die variable Verg&#252;tung nach Anlage 4 unter Ber&#252;cksichtigung der Dauer der Arbeitsunf&#228;higkeit angemessen reduzieren.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In the event of a temporary illness or other non-culpable incapacity to work, the basic remuneration pursuant to &#167; 3 (1) lit. a) shall continue to be paid during the period of the incapacity to work up to a period of six months, at the latest until the termination of this Service Agreement. If the incapacity to work lasts longer than three months without interruption, the Supervisory Board may reduce the variable remuneration in accordance with Annex 4 by a reasonable amount, taking into account the duration of the incapacity to work.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Bei einer dauernden Arbeitsunf&#228;higkeit des Vorstandes endet der Dienstvertrag mit dem Ende des Quartals, in dem die dauernde Arbeitsunf&#228;higkeit festgestellt worden ist.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In the event of permanent incapacity to work of the Board Member, the employment agreement ends at the end of the quarter in which the permanent incapacity to work was determined.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Ist der Vorstand l&#228;nger als sechs Monate au&#223;erstande, seiner T&#228;tigkeit nachzugehen, kann der Aufsichtsrat verlangen, dass das Vorliegen einer dauernden Arbeitsunf&#228;higkeit durch einen von ihm ausgew&#228;hlten Arzt auf Kosten der Gesellschaft nachgepr&#252;ft wird. Nimmt der Vorstand den Termin trotz zweimaliger Aufforderung durch den Aufsichtsrat nicht wahr, gilt der Vorstand als dauernd arbeitsunf&#228;hig. Die Aufforderungen haben mit einer Woche zeitlichen Abstands voneinander zu erfolgen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">If the Board Member is unable to carry out its duties for more than six months, the Supervisory Board may demand that the existence of a permanent incapacity to work be reviewed by a doctor of its choice at the Company's expense. If the Board Member fails to meet the demand despite two requests by the Supervisory Board, the Board Member shall be deemed permanently incapacitated for work. The requests shall be made at intervals of one week.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Eine Abfindung ist bei einer Beendigung des Dienstvertrags wegen dauernder Arbeitsunf&#228;higkeit nicht zu leisten.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">A severance payment shall not be made in the event of termination of the employment agreement due to permanent incapacity to work.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Stirbt der Vorstand w&#228;hrend der Dauer des Dienstvertrages, ist die Grundverg&#252;tung nach &#167; 3 (1) lit. a) noch f&#252;r den Sterbemonat und f&#252;r die zwei darauf folgenden Monate zu zahlen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">If the Board Member dies during the term of this Service Agreement, the Basic Remuneration according to &#167; 3 (1) lit. a) shall still be payable for the month of death and for the following two months.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 11 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Die Boni nach &#167; 3 (1) lit. b) werden entsprechend Anlage 4 Ziff. 3 durch den Aufsichtsrat festgelegt und an den Ehepartner, bei deren Fehlen an die unterhaltsberechtigten Kinder des Vorstands (letztere als Gesamtgl&#228;ubiger) oder seine Erben bezahlt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The bonuses pursuant to &#167; 3 (1) lit. b) are determined by the Supervisory Board in accordance with Annex 4 No. 3 and paid to the spouse, in the event of their absence to the dependent children of the Board Member (the latter as joint creditor) or his heirs.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.18pt;text-align:center;vertical-align:top"><font style="font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sonderleistungen und Sonderk&#252;ndigungsrecht bei Kontrollerwerb</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Special services and special right of termination in the event of acquisition of control</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 12 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Kommt es nach der Unterzeichnung dieses Vertrags zu einem Kontrollerwerb im Sinne eines Anteilserwerbs von mehr als 50% durch einen Aktion&#228;r, Dritten oder gemeinsam handelnde Personen oder zu einer wirtschaftlich vergleichbaren Transaktion (z.B. Verkauf des Gesch&#228;ftsbetriebs oder eines wesentlichen Teils davon durch die Gesellschaft, Verkauf von wesentlichen Beteiligungsgesellschaften der Gesellschaft, Verschmelzung auf ein anderes Unternehmen, Verkauf von mehr als 50% der Anteile der Gesellschaft nach einem &#8222;Delisting&#34; der Gesellschaft, etc.) und will sich die Gesellschaft in diesem Zusammenhang oder in dessen Folge von dem Vorstand durch vorzeitige Vertragsaufl&#246;sung trennen, ohne hierf&#252;r einen wichtigen Grund im Sinn des &#167; 626 BGB zu haben, so erh&#228;lt der Vorstand zus&#228;tzlich zu der Verg&#252;tung und allen Leistungen, die ihm bis zum Trennungszeitpunkt zustehen, eine Abfindung. Die H&#246;he der Abfindung entspricht der Summe der Gesamtverg&#252;tung (Grundverg&#252;tung, variable Verg&#252;tung sowie Nebenleistungen), die der Vorstand bis zum Ablauf der in &#167; 10 (1) definierten Dauer gem&#228;&#223; diesem Vertrag erhalten hatte, w&#228;re der Vertrag nicht vorzeitig beendet, sondern bis zum Ende der vollen Amtszeit erf&#252;llt worden. F&#252;r Zwecke der Berechnung der Abfindung nach diesem Absatz (1) wird davon ausgegangen, dass dem Vorstand jeweils der maximale Bonus gem&#228;&#223; Anlage 4 (ggf. pro rata temporis bis zum Ende der Vertragslaufzeit) gezahlt worden w&#228;re. Betr&#228;gt die ordentliche Laufzeit dieses Vertrages gem&#228;&#223; &#167;&#160;10 (1) zum Zeitpunkt des Wirksamwerdens der Trennung nach diesem Absatz (1) weniger als 15 Monate, berechnet sich die zu zahlende Abfindung auf Basis einer fiktiven Restlaufzeit von 15 Monaten, d.&#160;h. die Abfindung wird berechnet auf Basis einer angenommenen Restlaufzeit von mindestens 15 Monaten. </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">If, after the signing of this Agreement, control is acquired in the sense of a share acquisition of more than 50% by a shareholder, third party or persons acting jointly or in the sense of an economically comparable transaction (e.g. sale of the business operations or a substantial part thereof by the Company, sale of substantial associated companies of the Company, merger with another company, sale of more than 50% of the shares of the Company after a delisting of the Company, etc.) and if the Company wishes to terminate the agreement with the Board Member in this context or as a result thereof by early termination of the agreement without having an important reason within the meaning of Section 626 of the German Civil Code (BGB), the Board Member shall receive a severance payment in addition to the remuneration and all benefits to which it is entitled up to the time of termination. The amount of the severance payment corresponds to the sum of the total remuneration (basic remuneration, variable remuneration as well as fringe benefits)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">that the Board Member would have received until expiry of the term defined in &#167; 10 (1) of this agreement, if the agreement would not have been terminated prematurely, but would have been fulfilled up until the end of the full term of office. For the purpose of calculating the severance payment pursuant to this paragraph (1), it is assumed that the maximum bonus would have been paid to the Board Member in each case in accordance with Annex 4 (if applicable pro rata temporis until the end of the agreement term). If the ordinary term of this agreement pursuant to &#167; 10 (1) is less than 15 months at the time the separation pursuant to this paragraph (1) takes effect, the severance payment to be made shall be calculated on the basis of a fictitious remaining term of 15 months, i.e. the severance payment shall be calculated on the basis of an assumed remaining term of at least 15 months.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">W&#228;hrend der Vertragslaufzeit stattfindende Anhebungen der Verg&#252;tung gem&#228;&#223; &#167; 3 (1) werden bei den beschriebenen Berechnungen ber&#252;cksichtigt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Any increases in remuneration in accordance with &#167; 3 (1) that take place during the term of the agreement shall be taken into account in the calculations described.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Die Abfindung ist in voller H&#246;he zusammen mit dem Gehalt f&#252;r den Monat, zu dessen Ende die Trennung nach Absatz (1) wirksam wird, zur Zahlung f&#228;llig.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The severance payment shall be payable in full together with the salary for the month at the end of which the separation referred to in paragraph (1) takes effect.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 13 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Im Falle dieses Absatzes (1) wird dem Vorstand ein au&#223;erordentliches Sonderk&#252;ndigungsrecht zu diesem Dienstvertrag einger&#228;umt. Das Sonderk&#252;ndigungsrecht kann innerhalb von sechs Wochen ab Kenntnis des Vorstands &#252;ber den rechtskr&#228;ftigen Vollzug des Kontrollwechsels im Sinne des Absatzes (1) mit einer Frist von drei Monaten zum Monatsende ausge&#252;bt werden. Dar&#252;ber hinaus besteht ein Sonderk&#252;ndigungsrecht des Vorstands auch dann, wenn der Vorstand innerhalb von einem Jahr nach Vollzug des Kontrollwechsels abberufen wird. In diesem Fall betr&#228;gt die Sonderk&#252;ndigungsfrist zwei Wochen. Die K&#252;ndigung kann innerhalb von vier Wochen nach Abberufung durch den Vorstand erkl&#228;rt werden.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In the event of this paragraph (1), the Board Member shall be granted an extraordinary right of termination of this Service Agreement. The special right of termination may be exercised within six weeks of the knowledge of the Board Member of the legally binding execution of the change of control within the meaning of paragraph (1) with a notice period of three months to the end of the month. In addition, the Board Member has a special right of termination even if the Board Member is dismissed within one year of the completion of the change of control. In this case, the special notice period is two weeks. The termination may be declared by the Board Member within four weeks after dismissal.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Diensterfindungen und Schutzrechte</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Service inventions and industrial property rights</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 14 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Erfindungen des Vorstands sowie seine technischen oder organisatorischen Verbesserungsvorschl&#228;ge werden entsprechend den jeweils geltenden Bestimmungen des Gesetzes &#252;ber Arbeitnehmererfindungen vom 25.7.1957 mit folgender Ma&#223;gabe behandelt&#58; Der Vorstand wird der Gesellschaft Diensterfindungen, freie Erfindungen und technische wie organisatorische Verbesserungsvorschl&#228;ge unverz&#252;glich melden und der Gesellschaft zur ausschlie&#223;lichen, beschr&#228;nkten oder unbeschr&#228;nkten Inanspruchnahme anbieten. Die Erkl&#228;rung der Inanspruchnahme hat seitens der Gesellschaft innerhalb von vier Monaten nach der Meldung zu erfolgen. Die Gesellschaft hat das Recht, jedoch nicht die Verpflichtung, zur Anmeldung von Schutzrechten im In- und Ausland. Im Fall einer Diensterfindung oder eines technischen oder organisatorischen Verbesserungsvorschlags sind sich die Parteien darin einig, dass eine etwaige Verg&#252;tung f&#252;r eine von der Gesellschaft in Anspruch genommene Diensterfindung mit der Zahlung der Grundverg&#252;tung nach &#167; 3 (1) lit. a) dieses Vertrages vollst&#228;ndig abgegolten ist. Im Fall einer freien Erfindung ist dem Vorstandsmitglied eine markt&#252;bliche Verg&#252;tung zu zahlen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Inventions by the Board Member and its technical or suggestions for organizational improvements shall be treated in accordance with the applicable provisions of the Act on Employee Inventions of 25 July 1957, subject to the following provisions&#58; The Board Member will immediately notify the Company of job-related inventions, free inventions and technical and organizational suggestions for improvement and offer them to the Company for exclusive, limited or unlimited use. The Company must declare the claim within four months of notification. The Company is entitled, but not obliged, to register intellectual property rights in Germany and abroad. In the case of a job-related invention or a technical or organizational suggestion for improvement, the parties agree that any remuneration for a service invention claimed by the Company shall be paid in full upon payment of the basic remuneration pursuant to &#167; 3 (1) lit. a) of this Agreement. In the case of a free invention, the Board Member shall be paid remuneration in line with market-based conditions.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Der Vorstand &#252;bertr&#228;gt der Gesellschaft ausschlie&#223;liche, zeitlich, r&#228;umlich und inhaltlich unbeschr&#228;nkte Nutzungs- und Verwertungsrechte f&#252;r alle etwaigen nach dem Urhebergesetz schutzf&#228;higen T&#228;tigkeitsergebnisse, die das Vorstandsmitglied w&#228;hrend der Dauer seines Dienstvertrages w&#228;hrend seiner Arbeitszeit oder, sofern sie Bezug zu seinen dienstvertraglichen Aufgaben haben, auch au&#223;erhalb seiner Arbeitszeit erstellt. Die &#220;bertragung der urheberrechtlichen Nutzungs- und Verwertungsrechte umfasst auch etwaige bei Vertragsschluss noch unbekannte Nutzungsarten. Die &#220;bertragung der Nutzungs- und Verwertungsrechte umfasst insbesondere auch die Erlaubnis zur Bearbeitung und Lizenzvergabe an Dritte. Das Vorstandsmitglied verzichtet ausdr&#252;cklich auf sonstige ihm etwa als Urheber zustehende Rechte an den T&#228;tigkeitsergebnissen, insbesondere auf das Recht auf Namensnennung, auf Bearbeitung und auf Zug&#228;nglichmachung des Werkes.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member shall grant the Company exclusive rights of use and exploitation, unlimited in terms of time, space and content, for any works which may be protected under the Copyright Act and which the Board Member produces during the term of this Service Agreement during his working hours or, if they relate to his duties under the Service Agreement, also outside of his working hours. The transfer of the copyrighted rights of use and exploitation also includes any types of use still unknown at the time of conclusion of the agreement. The transfer of the rights of use and exploitation includes in particular the permission for processing and licensing to third parties. The Board Member expressly waives any other rights to the works, which he is entitled as the author, in particular the right to name, edit and make accessible the work.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 15 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Soweit T&#228;tigkeitsergebnisse, die der Vorstand w&#228;hrend der Dauer seines Dienstvertrages w&#228;hrend seiner Arbeitszeit oder, sofern sie Bezug zu seinen dienstvertraglichen Aufgaben haben, auch au&#223;erhalb seiner Arbeitszeit erstellt, nicht bereits nach Absatz (1) und (2) &#252;bertragen sind, &#252;bertr&#228;gt der Vorstand der Gesellschaft s&#228;mtliche Rechte an diesen T&#228;tigkeitsergebnissen, insbesondere Marken- und sonstige Kennzeichenrechte sowie eingetragene Designs.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Insofar as works which the Board Member produces during the term of its Service Agreement, during its working hours or, insofar as they relate to its duties under the Service Agreement, also outside its working hours, have not already been transferred in accordance with paragraphs (1) and (2), the Board Member shall transfer to the Company all rights to these works, in particular trademark and other distinctive rights as well as registered designs.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Die Parteien sind sich einig, dass die Einr&#228;umung dieser Rechte und der Verzicht auf Rechte nach dieser Regelung vollumf&#228;nglich mit der Zahlung der Grundverg&#252;tung nach &#167;&#160;3 (1) lit. a) dieses Vertrages abgegolten sind, soweit dem nicht zwingende gesetzliche Regelungen entgegenstehen. Der Vorstand ist verpflichtet, jedwedes seiner schutzrechtsf&#228;higen T&#228;tigkeitsergebnisse unverz&#252;glich der Gesellschaft, vertreten durch den Aufsichtsrat, zu meiden und die Gesellschaft im erforderlichen Umfang, auch nach Beendigung dieses Dienstvertrages, bei der Erlangung von Schutzrechten zu unterst&#252;tzen. Soweit der Vorstand seine Mitwirkungspflichten nach der Beendigung dieses Dienstvertrages erf&#252;llt, erh&#228;lt der Vorstand hierf&#252;r einen angemessenen Tagessatz sowie eine Erstattung aller Aufwendungen, die ihm durch seine Mitwirkung entstanden sind.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The parties agree that the granting of these rights and the waiver of rights under this provision are fully covered by the payment of the Basic Remuneration under &#167; 3 (1) lit. a) this agreement, unless otherwise provided for by mandatory legal provisions. The Board Member is obliged to notify any of the works that are capable of being protected by intellectual property rights without delay to the Company, represented by the Supervisory Board, and to support the Company to the necessary extent, even after termination of this Service Agreement, in obtaining intellectual property rights. To the extent that the Board Member fulfils its duties to cooperate after the termination of this Service Agreement, the Board Member shall receive an appropriate daily rate as well as a reimbursement of all expenses incurred by him resulting from his cooperation.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.18pt;text-align:center;vertical-align:top"><font style="font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Geheimhaltung und R&#252;ckgabe von Unterlagen, Interessenkonflikte</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Confidentiality and return of documents, conflicts of interest</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 16 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Der Vorstand verpflichtet sich, &#252;ber alle ihm im Rahmen seiner T&#228;tigkeit oder sonst zur Kenntnis gelangenden gesch&#228;ftlichen und betrieblichen Angelegenheiten der Gesellschaft und aller Verbundenen Unternehmen strengstes Stillschweigen zu bewahren, einschlie&#223;lich des Inhalts dieses Dienstvertrages sowie den Vertragsverhandlungen, die dem Abschluss dieses Dienstvertrages zugrunde liegen. Der Vorstand verpflichtet sich weiterhin, diese Informationen nicht f&#252;r den eigenen oder den Nutzen anderer zu verwenden und alle solche gesch&#228;ftlichen und betrieblichen Angelegenheiten betreffenden Gesch&#228;ftsunterlagen der Gesellschaft und der Verbundenen Unternehmen unter Verschluss zu halten. Unter gesch&#228;ftlichen und betrieblichen Angelegenheiten im Sinne dieser Regelung verstehen die Parteien insbesondere Gesch&#228;fts- und Betriebsgeheimnisse sowie alle Informationen und Daten mit Bezug zu vertraulichen Angelegenheiten und gesch&#228;ftsbezogenem Know-how, s&#228;mtliche Informationen &#252;ber alle mit dem existenten oder k&#252;nftigen Gesch&#228;ft der Gesellschaft und der Verbundenen Unternehmen in Zusammenhang stehenden Gesch&#228;ftspl&#228;ne und Gesch&#228;ftsstrategien, Verfahren, Preis- oder Marktstrategien und Produkt-, Dienstleistungs- oder Entwicklungsplanungen, geplante Unternehmenserwerbe oder -ver&#228;u&#223;erungen, s&#228;mtliche Gesch&#228;ftszahlen und Details der organisatorischen Strukturen sowie die wesentlichen Ideen und Prinzipien, welche diesen Strategien und Planungen zugrunde liegen, und alle Informationen, von denen vern&#252;nftigerweise erwartet werden kann, dass sie zu solchen Strategien oder Planungen f&#252;hren w&#252;rden und die von der Gesellschaft, von Verbundenen Unternehmen oder dem Vorstandsmitglied w&#228;hrend der Dauer dieses Dienstvertrages erdacht, erfunden, &#252;berarbeitet, entdeckt, entwickelt, erworben, beurteilt, getestet oder angewendet worden sind.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member undertakes to maintain the strictest secrecy with regard to all business and operational matters of the Company and old affiliated companies that come to its attention in the course of its activities or otherwise, including the contents of this Service Agreement and the negotiations on which the conclusion of this Service Agreement is based. The Board Member further undertakes not to use this information for its own benefit or for the benefit of others and to keep all business documents of the Company and its affiliates relating to such business and operational matters under lock and key. For the purposes of this provision, business and operational matters shall mean, in particular, business and trade secrets and all information and data relating to confidential matters and business-related know-how, all information, all business plans and strategies, procedures, price or market strategies and product, service or development plans relating to the existing or future business of the Company and its affiliates, planned corporate acquisitions or disposals, all business figures and details of the organizational structures and the principal ideas and principles underlying such strategies and plans, and all information that can reasonably be expected to result in such strategies or plans and that has been invented, redacted, discovered, developed, assessed, tested or applied by the Company, its affiliates or the Board Member during the term of this Service Agreement.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Die Geheimhaltungsverpflichtung nach vorstehendem Absatz (1) dauert auch nach Beendigung des Dienstverh&#228;ltnisses fort. Im Rahmen einer von dem Vorstand nach Beendigung dieses Dienstvertrages ausge&#252;bten beruflichen oder unternehmerischen T&#228;tigkeit kann er sein als Vorstandsmitglied erworbenes Wissen einsetzen, sofern dabei die gesetzlichen Beschr&#228;nkungen &#8211; insbesondere nach &#167;&#167; 3, 17 UWG, &#167;&#160;823 (1) und (2) BGB i.V.m. UWG, &#167;&#160;826 BGB und den datenschutzrechtlichen Regelungen &#8211; sowie die Beschr&#228;nkungen aus dem nachvertraglichen Wettbewerbsverbot nach &#167;&#160;16 dieses Vertrages strikt beachtet werden.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The obligation to maintain secrecy pursuant to paragraph (1) above shall continue even after the termination of the employment relationship. The Board Member may use the knowledge acquired as a Board Member within the scope of a professional or entrepreneurial activity carried out by the Board Member after termination of this Service Agreement, provided that he complies with the statutory restrictions - in particular Sections 3, 17 UWG, Section 823 (1) and (2) BGB in conjunction with Sections 3, 17 UWG, Section 823 (1) and (2) BGB associated with UWG, Section 826 BGB and the data protection regulations.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Der Vorstand ist verpflichtet, in Zweifelsf&#228;llen &#252;ber den Umfang der Geheimhaltungsverpflichtung nach vorstehenden Abs&#228;tzen (1) und (2) mit dem Aufsichtsrat der Gesellschaft eine Kl&#228;rung herbeizuf&#252;hren.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In cases of doubt, the Board Member is obliged to reach a clarification with the Supervisory Board of the Company regarding the scope of the confidentiality obligation pursuant to paragraphs (1) and (2) above.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 17 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Der Vorstand verpflichtet sich, auf Verlangen der Gesellschaft jederzeit und sp&#228;testens bei Ende seiner Bestellung zum Organ auch ohne gesonderte Aufforderung alle in seinem Besitz befindlichen Unterlagen der Gesellschaft oder Verbundener Unternehmen, insbesondere alle Notizen, Memoranden, Aufzeichnungen, Protokolle und Berichte, Akten sowie alle anderen &#228;hnlichen Dokumente (einschlie&#223;lich Abschriften, Ablichtungen, Kopien oder sonstiger Reproduktionen), die im Zusammenhang mit seiner T&#228;tigkeit stehen, unverz&#252;glich und vollst&#228;ndig an die Gesellschaft zur&#252;ckzugeben. Ein Zur&#252;ckbehaltungsrecht ist ausgeschlossen. Diese Regelung gilt sinngem&#228;&#223; f&#252;r elektronisch gespeicherte Daten sowie die jeweiligen Daten- oder Programmtr&#228;ger.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member undertakes, at the request of the Company at any time and at the latest at the end of its appointment to the board and without separate request, to return to the Company all documents of the Company or affiliated companies in its possession, in particular all notes, memoranda, records, minutes and reports, files as well as all other similar documents (including copies, photocopies or other reproductions) in connection with its activities without delay and in full. A right of retention is excluded. This provision applies to electronically stored data as well as to the respective data or program carriers.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Die Herausgabeverpflichtung bezieht sich auch auf sonstiges, im Besitz des Vorstands befindliches Eigentum der Gesellschaft oder Verbundener Unternehmen bzw. von der Gesellschaft oder von einem Verbundenen Unternehmen geleaste Gegenst&#228;nde. Diese Herausgabeverpflichtung erstreckt sich insbesondere auch auf ein dem Vorstand etwa &#252;berlassenes Mobiltelefon, Laptop oder sonstige Ger&#228;te der Datenverarbeitung, bei Ende seiner Bestellung zum Organ auch, wenn insoweit eine private Nutzung gestattet war.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The release obligation also applies to other property of the Company or affiliates or items leased by the Company or an affiliate that is in possession of the Board Member. This release obligation also extends in particular to a mobile phone, laptop or other data processing device left in the possession of the Board Member, at the end of its appointment to the Board even if private use was permitted in this respect.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.7pt;padding-right:2.75pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.79pt">Der Vorstand hat m&#246;gliche und tats&#228;chliche Interessenkonflikte unverz&#252;glich dem Aufsichtsrat gegen&#252;ber offenzulegen und die anderen Vorstandsmitglieder hier&#252;ber zu informieren.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member must immediately disclose possible and actual conflicts of interest to the Supervisory Board and inform the other members of the Management Board hereof.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Vertragsdauer</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.18pt;text-align:center;vertical-align:top"><font style="font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term of the Agreement</font></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 18 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.75pt;padding-right:2.75pt;text-align:justify;text-indent:-16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.84pt">Dieser Vertrag wird mit Wirkung zum 22.&#160;August 2016 abgeschlossen. Er endet mit Ablauf des 31. August 2019.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">This agreement will be concluded with effect as of 22 August 2016. It ends at the end of 31 August 2019.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.75pt;padding-right:2.75pt;text-align:justify;text-indent:-16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.84pt">Das Recht zur au&#223;erordentlichen K&#252;ndigung bleibt unber&#252;hrt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The right to extraordinary termination remains unaffected.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.75pt;padding-right:2.75pt;text-align:justify;text-indent:-16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.84pt">Im Fall eines Widerrufs der Bestellung, der Amtsniederlegung durch das Vorstandsmitglied oder bei einer sonstigen Beendigung der Organstellung endet dieser Dienstvertrag mit Ablauf eines Jahres nach dem Ende des Amtes, sp&#228;testens jedoch zum Ende der Laufzeit nach Absatz (1). Eine etwaige fr&#252;here Beendigung aufgrund Absatz (2) dieses Vertrages bleibt unber&#252;hrt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In the event of revocation of the appointment, demission by the Board Member or other termination of the position, this Service Agreement shall end at the end of one year after the end of the term of office, at the latest, however, at the end of the term pursuant to paragraph (1). A possible termination due to paragraph (2) of this agreement remains unaffected.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.75pt;padding-right:2.75pt;text-align:justify;text-indent:-16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.84pt">Der Vorsitzende des Aufsichtsrats wird dem Vorstand sp&#228;testens neun Monate vor Ablauf dieses Vertrages, also bis zum 30. November 2018, schriftlich mitteilen, ob und unter welchen Bedingungen der Aufsichtsrat den Vorstand erneut zum Vorstandsmitglied bestellen wird und ob er bereit ist, den Dienstvertrag entsprechend der Dauer der neuen Bestellung zu verl&#228;ngern oder einen neuen Dienstvertrag zu mindestens gleichen Bedingungen mit ihm abzuschlie&#223;en, Der Vorstand wird innerhalb von zwei Monaten ab Zugang des Angebots des Aufsichtsratsvorsitzenden erkl&#228;ren, ob er die erneute Bestellung annimmt und bereit ist, den f&#252;r die Fortsetzung oder Erneuerung des Dienstvertrages angebotenen Bedingungen zuzustimmen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Chairman of the Supervisory Board will inform the Board Member in writing no later than nine months before the expiry of this agreement, i.e. by 30 November 2018, whether and under what conditions the Supervisory Board will reappoint the Board Member and whether he is willing to extend the Service Agreement for the duration of the new appointment or to conclude a new Service Agreement on at least the same terms. Within two months of receipt of the Supervisory Board Chairman's offer, the Board Member will declare whether it accepts the reappointment and is prepared to agree to the terms and conditions offered for the continuation or renewal of the Service Agreement.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.75pt;padding-right:2.75pt;text-align:justify;text-indent:-16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.84pt">Die Gesellschaft ist berechtigt, den Vorstand nach dem Widerruf seiner Bestellung gem&#228;&#223; &#167; 84 (3) AktG oder im Zusammenhang mit einer Beendigung des Dienstvertrages, insbesondere nach einer K&#252;ndigung oder im Anschluss an den Abschluss eines Aufhebungsvertrages, ganz oder teilweise von seiner Pflicht zur Dienstleistung unter Fortzahlung der Grundverg&#252;tung gem&#228;&#223; &#167; 3 (1) lit. a) widerruflich oder unwiderruflich freizustellen. Im Fall der unwiderruflichen Freistellung werden offene Urlaubs- und sonstige Freizeitausgleichsanspr&#252;che angerechnet, die damit erledigt sind. Der Dienstvertrag im &#220;brigen wird von der Freistellung nicht ber&#252;hrt&#59; insoweit bestehen insbesondere die Verschwiegenheitspflicht und das vertragliche Wettbewerbsverbot bis zum Ende des Dienstvertrages fort. Anderweitiger Verdienst w&#228;hrend der Freistellungszeit wird gem&#228;&#223; &#167; 615 Satz 2 BGB angerechnet. Eine Anrechnung erfolgt nicht, wenn und soweit der anderweitige Verdienst aus einer genehmigten Nebent&#228;tigkeit (&#167; 2 (1) dieses Dienstvertrages) stammt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Company is entitled, after the revocation of its appointment pursuant to Section 84 (3) AktG or in connection with a termination of the Service Agreement, in particular following a termination or following the conclusion of a termination agreement, to release the Board Member in whole or in part from its obligation to provide services with continued payment of the Basic Remuneration pursuant to &#167; 3 (1) a) revocably or irrevocably. In the event of irrevocable release, receivable holiday and other time off compensation claims shall be credited and settled. The rest of the Service Agreement is not affected by the indemnification&#59; in this respect, the obligation to maintain secrecy and the contractual non-competition clause continue to apply until the end of the Service Agreement. Other earnings during the exemption period shall be credited in accordance with Section 615 sentence 2 BGB. Crediting does not take place if and as far as the other earnings originate from an approved secondary activity (&#167; 2 (1) of this Service Agreement).</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 19 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.75pt;padding-right:2.75pt;text-align:justify;text-indent:-16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.84pt">Der Dienstvertrag endet sp&#228;testens am Ende des Kalenderjahres, in dem das Vorstandsmitglied sein 65. Lebensjahr vollendet, sofern dieser Dienstvertrag nicht bereits nach Absatz (1) bis (2) dieses Vertrages vor diesem Zeitpunkt geendet hat.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Service Agreement shall end at the latest at the end of the calendar year in which the Board Member reaches the age of 65, unless this Service Agreement has not already ended before this date in accordance with paragraphs (1) to (2) of this agreement.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.75pt;padding-right:2.75pt;text-align:justify;text-indent:-16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.84pt">Bei vorzeitiger Beendigung der Vorstandst&#228;tigkeit ohne wichtigen Grund entsprechen die Zahlungen an den Vorstand einschlie&#223;lich Nebenleistungen maximal dem Wert von zwei Jahresverg&#252;tungen (Abfindungs-Cap) und &#252;berschreiten nicht die Gesamtverg&#252;tung (Grundverg&#252;tung, variable Verg&#252;tung sowie Nebenleistungen) f&#252;r die Restlaufzeit des Dienstvertrages. Bei einem Kontrollerwerb nach &#167; 7 gilt ein Abfindungs-Cap von maximal drei Jahresverg&#252;tungen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In the event of premature termination of the board activity without good cause, payments to the Board Member including fringe benefits shall not exceed the value of two years' remuneration (severance payment cap) and shall not exceed the total remuneration (Basic Remuneration, variable remuneration and fringe benefits) for the remaining term of the Service Agreement. In the case of an acquisition of control pursuant to &#167; 7, a severance payment cap of a maximum of three years' remuneration applies.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Ausschlussfristen</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Cut-off Periods</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 20 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.75pt;padding-right:2.75pt;text-align:justify;text-indent:-16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.84pt">Anspr&#252;che der Gesellschaft und des Vorstands aus dem Dienstverh&#228;ltnis oder im Zusammenhang mit diesem Dienstverh&#228;ltnis verfallen, ungeachtet ihres Rechtsgrundes, wenn die bzw. der Anspruchsberechtigte den Anspruch nicht innerhalb einer Frist von sechs Monaten, berechnet ab dem Zeitpunkt der F&#228;lligkeit und der Kenntnis oder grob fahrl&#228;ssigen Unkenntnis des Anspruchsberechtigten von den anspruchsbegr&#252;ndenden Umst&#228;nden, durch schriftliche Erkl&#228;rung gegen&#252;ber der jeweils anderen Vertragspartei geltend macht. F&#252;r die Beurteilung der Rechtzeitigkeit der Geltendmachung ist der Zugang der schriftlichen Erkl&#228;rung ma&#223;geblich. Dies gilt nicht f&#252;r die Geltendmachung von Anspr&#252;chen wegen Verletzung des Lebens, des K&#246;rpers oder der Gesundheit sowie bei vors&#228;tzlichen Pflichtverletzungen. Die Vers&#228;umung der Ausschlussfrist f&#252;hrt zum Verlust des Anspruchs.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Claims of the Company and the Board Member arising from or in connection with the employment relationship shall expire, irrespective of their legal basis, if the entitled person does not assert the claim within a period of six months, calculated from the due date and the knowledge or grossly negligent ignorance of the entitled person of the circumstances giving rise to the claim, by means of a written declaration to the respective other party. For the assessment of the timeliness of the assertion, the receipt of the written declaration is decisive. This does not apply to the assertion of claims due to injury to life, body or health as well as in the case of intentional breaches of duty. Failure to comply with the cut-off period will result in the loss of the claim.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.75pt;padding-right:2.75pt;text-align:justify;text-indent:-16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.84pt">Etwaige Anspr&#252;che der Gesellschaft nach &#167; 93 (2) und (3) AktG gegen das Vorstandsmitglied bleiben gem&#228;&#223; &#167; 93 (4) Satz 3 AktG von vorstehendem Absatz (1) unber&#252;hrt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Any claims of the Company pursuant to Section 93 (2) and (3) AktG against the Board Member shall remain unaffected by the above paragraph (1) pursuant to Section 93 (4) sentence 3 AktG.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Schlussbestimmungen</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Final Provisions</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.75pt;padding-right:2.75pt;text-align:justify;text-indent:-16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.84pt">Dieser Vertrag enth&#228;lt die gesamte Vereinbarung zwischen den Parteien. Bereits getroffene Vereinbarungen zwischen den Parteien werden hiermit ausdr&#252;cklich aufgehoben.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">This agreement contains the entire agreement between the parties. Prior agreements between the parties are hereby expressly cancelled.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.75pt;padding-right:2.75pt;text-align:justify;text-indent:-16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.84pt">&#196;nderungen oder Erg&#228;nzungen dieses Vertrages einschlie&#223;lich dieser Schriftformklausel bed&#252;rfen zu ihrer Wirksamkeit der Schriftform.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Changes or additions to this agreement, including this written form clause, must be made in writing to be effective.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.75pt;padding-right:2.75pt;text-align:justify;text-indent:-16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.84pt">Dieser Vertrag unterliegt dem Recht der Bundesrepublik Deutschland.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">This agreement is subject to the law of the Federal Republic of Germany.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 21 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.75pt;padding-right:2.75pt;text-align:justify;text-indent:-16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.84pt">Erf&#252;llungsort ist der Sitz der Gesellschaft, Gerichtsstand f&#252;r Streitigkeiten aus diesem Vertrag ist der Sitz der Gesellschaft.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Place of performance is the seat of the Company, place of jurisdiction for disputes from this agreement is the seat of the Company.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.75pt;padding-right:2.75pt;text-align:justify;text-indent:-16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.84pt">Sollte eine Bestimmung dieses Vertrages ganz oder teilweise rechtsunwirksam oder undurchf&#252;hrbar sein oder werden, so wird die G&#252;ltigkeit der &#252;brigen Bestimmungen dieses Vertrages nicht ber&#252;hrt. Vielmehr ist die ganz oder teilweise rechtsunwirksame oder undurchf&#252;hrbare Bestimmung durch eine Bestimmung zu ersetzen, die den mit der unwirksamen Bestimmung angestrebten wirtschaftlichen Erfolg soweit wie m&#246;glich erreicht. Das gleiche gilt im Fall von L&#252;cken dieses Vertrages.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Should any provision of this agreement be or become invalid or unenforceable in whole or in part, the validity of the remaining provisions of this agreement shall not be affected. Rather, the invalid or unenforceable provision, in whole or in part, shall be replaced by a provision that achieves as far as possible the economic purpose intended by the invalid provision. The same shall apply in the event of any gaps in this agreement.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Martinsried, den</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Martinsried, den</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Dr. J&#246;rg Neermann</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Dr. Andreas M&#252;hler</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Immunic AG,<br>vertreten durch den Aufsichtsratsvorsitzenden<br>Dr. J&#246;rg Neermann</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dr. Andreas M&#252;hler</font></td></tr></table></div><div><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 22 von 23</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Anlagenverzeichnis</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10.97pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule of Annexes</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anlage 1&#58;&#160;&#160;&#160;&#160;AR-Beschluss vom 23.03.2016</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10.97pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annex 1&#58;&#160;&#160;&#160;&#160;AR resolution of 23.03.2016</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anlage 2&#58;&#160;&#160;&#160;&#160;Genehmigte Nebent&#228;tigkeiten des Vorstands</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10.97pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annex 2&#58;&#160;&#160;&#160;&#160;Approved ancillary activity of the Board Member</font></td></tr></table></div><div style="margin-bottom:12pt;padding-left:7.2pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:7.2pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 23 von 23</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Anlage 1&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">  AR-Beschluss vom 23.03.2016 &#47; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Annex 1&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> AR resolution of 23.03.2016</font></div><div><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 24 von 23</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Anlage 2&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">  Genehmigte Nebent&#228;tigkeiten des Vorstands &#47; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Annex 2&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> Approved ancillary activity of the Board Member</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-7.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:3.25pt">Takeda Group, einschlie&#223;lich der 100%-igen Tochtergesellschaft Takeda Pharmaceuticals International, vormals Millennium Pharmaceuticals (durchschnittlicher Aufwand beschr&#228;nkt auf maximal 8 Stunden pro Woche)  &#47;  <br><br>Takeda Group, including its wholly owned subsidiary Takeda Pharmaceuticals International, formerly Millennium Pharmaceuticals (average effort limited to a maximum of 8 hours per week)</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363757.1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>4
<FILENAME>imux-ex106dienstvertragdan.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ied3b7e4c59f043258ecb241870577240_1"></div><div style="min-height:70.56pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">DIENSTVERTRAG</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">SERVICE AGREEMENT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">zwischen</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">between</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Immunic AG</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%"> <br>vertreten durch den Vorsitzenden des Aufsichtsrates</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Immunic AG, <br>represented by the Chairman of the Supervisory Board</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">- nachfolgend &#8222;Gesellschaft&#34; genannt -</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">- hereinafter referred to as the <br>&#34;Company&#34; -</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">und</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Herrn Daniel Vitt,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Mr. Daniel Vitt,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">- nachfolgend &#8222;Vorstand&#34; genannt -</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">- hereinafter referred to as the &#34;Board Member&#34; -</font></td></tr><tr style="height:25pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Aufgabenbereich und Pflichten</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Responsibilities and Obligations</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Herr Daniel Vitt soll zum ordentlichen Mitglied des Vorstandes der Gesellschaft bestellt werden. Er wird als gesch&#228;ftsf&#252;hrendes Vorstandsmitglied (CEO) der Gesellschaft bestellt und vertritt die Gesellschaft gemeinsam mit einem Vorstand oder einem Prokuristen. Der Aufsichtsrat kann dem Vorstand die Befreiung von &#167; 181 BGB erteilen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Mr. Daniel Vitt is to be appointed as a member of the Company's Management Board. He will be appointed as the managing director (CEO) of the Company and represents the Company together with a member of the Management Board or an authorized signatory. The Supervisory Board may grant the Board Member exemption from Section 181 of the German Civil Code (BGB).</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Der Vorstand f&#252;hrt die Gesch&#228;fte der Gesellschaft nach Ma&#223;gabe der Gesetze, der Satzung, der Gesch&#228;ftsordnung f&#252;r den Vorstand und dieses Dienstvertrages. Der Vorstand hat insbesondere f&#252;r die in &#167; 7 der Gesch&#228;ftsordnung des Vorstands genannten Gesch&#228;fte und Ma&#223;nahmen die Zustimmung des Aufsichtsrats einzuholen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member shall conduct the business of the Company in accordance with the law, the Articles of Association, the rules of procedure for the Management Board and this Service Agreement. In particular, the Board Member shall obtain the approval of the Supervisory Board for transactions and measures subject to approval in accordance with the rules of procedure of the Management Board.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 2 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Dem Vorstand obliegen insbesondere die Aufgaben, die im Sinne des jeweiligen Gesch&#228;ftsverteilungsplans (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Anlage 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">) zum Gesch&#228;ftsbereich des gesch&#228;ftsf&#252;hrenden Vorstandsmitglieds (CEO) geh&#246;ren.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In particular, the Board Member is responsible for those tasks which, within the meaning of the respective schedule of responsibilities (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Annex 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">), belong to the business area of the managing director of the Executive Board (CEO).</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Dienstort ist M&#252;nchen&#47;Planegg-Martinsried.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The place of work is Munich&#47;Planegg-Martinsried.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Nebent&#228;tigkeiten</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Ancillary Activities</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Der Vorstand wird seine ganze Arbeitskraft und seine s&#228;mtlichen fachlichen Kenntnisse und Erfahrungen der Gesellschaft widmen. Die &#220;bernahme einer entgeltlichen Nebent&#228;tigkeit sowie von Aufsichtsrats-, Beirats- oder &#228;hnlichen Mandanten bedarf der vorherigen Zustimmung durch den Aufsichtsratsvorsitzenden.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member will devote all its working capacity and all its professional knowledge and experience to the Company. The assumption of an ancillary commercial activity as well as mandates in a supervisory board or advisory board or similar mandates require the prior consent of the Chairman of the Supervisory Board.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Dem Aufsichtsratsgremium ist bekannt, dass der Vorstand zum Zeitpunkt der Unterzeichnung dieses Vertrages die in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Anlage 2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> aufgelisteten Mandate innehat und erteilt zu deren Fortf&#252;hrung seine Zustimmung.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The Supervisory Board is aware that the Board Member holds the mandates listed in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Annex 2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">at the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">time of signing of this agreement and grants its approval to their continuation.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">F&#252;r den Vorstand gilt das Wettbewerbsverbot des &#167; 88 AktG. W&#228;hrend der Dauer dieses Vertrages wird sich der Vorstand auch nicht an Unternehmen beteiligen, die mit der Gesellschaft in Wettbewerb stehen oder mit denen die Gesellschaft Gesch&#228;ftsverbindungen unterh&#228;lt, es sei denn, der Aufsichtsrat hat vorher seine schriftliche Zustimmung erteilt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member is subject to the non-competition clause of Section 88 of the German Stock Corporations Act (AktG). During the term of this agreement, the Board Member will also not invest in companies that compete with the Company or with which the Company has business relationships, unless the Supervisory Board has given its prior written consent.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Das Wettbewerbsverbot gilt nicht f&#252;r Beteiligungen an Unternehmen in Gestalt von Wertpapieren, die an B&#246;rsen gehandelt und zum Zwecke der Kapitalanlage erworben werden.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The non-competition clause does not apply to interests in companies in the form of bonds traded on stock exchanges and acquired for the purpose of capital investment.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Verg&#252;tung und Bonus</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Remuneration and Bonus</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 3 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Der Vorstand erh&#228;lt f&#252;r seine T&#228;tigkeit</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member receives for its activities</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:39.05pt;padding-right:2.75pt;text-align:justify;text-indent:-20.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:10.38pt">ein festes Jahresgehalt (&#8222;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Grundverg&#252;tung</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#34;) in H&#246;he von EUR&#160;215.000,00 brutto, das in 12 gleichen Monatsraten jeweils nachtr&#228;glich am Monatsletzten ausbezahlt wird. Sofern dieser Vertrag nicht w&#228;hrend der Dauer eines gesamten Kalenderjahres besteht, wird das Jahresfestgehalt zeitanteilig gezahlt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:39.05pt;padding-right:2.75pt;text-align:justify;text-indent:-20.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:10.38pt">a fixed annual salary </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">(&#34;Basic Remuneration&#34;) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">in the amount of EUR&#160;215,000.00 gross, paid in 12 equal monthly instalments at the end of each month. If this agreement does not exist for the duration of an entire calendar year, the fixed annual salary shall be paid pro rata temporis.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:39.05pt;padding-right:2.75pt;text-align:justify;text-indent:-20.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:10.38pt">eine j&#228;hrliche variable Verg&#252;tung, die bei 100-prozentigem Erreichen der festgelegten Jahresziele maximal EUR 30.000,00 brutto betr&#228;gt. Die Einzelheiten, insbesondere zum Verfahren der Zielfestlegung, zur Feststellung der Zielerreichung und zur F&#228;lligkeit ergeben sich aus dem Rahmenvertrag zur Zielvereinbarung in seiner jeweils geltenden Fassung. Die Art der Ziele, die Voraussetzungen f&#252;r ihre Erreichung und ihre Gewichtung zueinander werden f&#252;r das jeweilige Gesch&#228;ftsjahr in einer gesonderten Zielfestlegung niedergelegt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:39.05pt;padding-right:2.75pt;text-align:justify;text-indent:-20.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:10.38pt">an annual variable remuneration of up to EUR&#160;30,000.00 gross if the defined annual targets are achieved 100 percent. The details, in particular with regard to the procedure for setting targets, determining the achievement of targets and the due date, are set out in the Framework Agreement regarding the targets (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Rahmenvertrag zur Zielvereinbarung</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">) in its current version. The nature of the objectives, the conditions for their achievement and their weighting in relation to each other are laid down for each financial year in a separate target setting.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Die Grundverg&#252;tung und die variable Verg&#252;tung werden j&#228;hrlich durch den Aufsichtsrat &#252;berpr&#252;ft. Dabei sind die wirtschaftliche Entwicklung der Gesellschaft sowie die pers&#246;nliche Leistung des Vorstandes zu ber&#252;cksichtigen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">the Basic Remuneration and the variable remuneration are reviewed annually by the Supervisory Board. The economic development of the Company and the personal performance of the Board Member must be taken into account.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 4 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">lm &#220;brigen kann der Aufsichtsrat die Bez&#252;ge des Vorstands insgesamt auf die angemessene H&#246;he herabsetzen, wenn sich die Lage der Gesellschaft so verschlechtert, dass die Weitergew&#228;hrung der Bez&#252;ge unbillig f&#252;r die Gesellschaft w&#228;re&#59; Ruhegehalt, Hinterbliebenenbez&#252;ge und Leistungen verwandter Art k&#246;nnen dabei nur in den ersten drei Jahren nach Ausscheiden aus der Gesellschaft herabgesetzt werden (&#167; 87 (2) AktG). Der Vorstand kann in diesem Fall diesen Dienstvertrag au&#223;erordentlich mit einer Frist von sechs Wochen zum Schluss des n&#228;chsten Kalendervierteljahres nach Erkl&#228;rung der Herabsetzung k&#252;ndigen (&#167; 87 (2) Satz 3 AktG). Entf&#228;llt eine verschlechterte Lage der Gesellschaft, ist die Herabstufung wieder r&#252;ckg&#228;ngig zu machen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">otherwise, the Supervisory Board may reduce the total remuneration of the Board Member to the appropriate amount if the situation of the Company deteriorates to such an extent that the continued granting of the remuneration would be inequitable for the Company&#59; retirement pension, survivors' benefits and benefits of a related kind may only be reduced in the first three years after leaving the Company (Section 87 (2) AktG). In this case, the Board Member may terminate this Service Agreement extraordinarily with six weeks' notice to the end of the next calendar quarter after declaration of the reduction (Section 87 (2) sentence 3 AktG). If a deterioration in the situation of society does not apply, the downgrade shall be reversed.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Versicherungen und Nebenleistungen</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Insurance and Fringe Benefits</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 5 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Auch soweit keine gesetzliche Versicherungspflicht besteht, zahlt die Gesellschaft an das Vorstandsmitglied monatliche Zusch&#252;sse zur Kranken-und Pflegeversicherung des Vorstandsmitglieds. Die einzelnen Zusch&#252;sse entsprechen in ihrer H&#246;he der H&#228;lfte der vom Vorstandsmitglied gezahlten Beitr&#228;ge, h&#246;chstens jedoch dem jeweils unter Ber&#252;cksichtigung der jeweils geltenden Beitragsbemessungsgrenzen gesetzlich geschuldeten H&#246;chstbetrag des Arbeitgeberanteils der gesetzlichen Kranken- und Pflegeversicherung. Die von der Gesellschaft geschuldeten Zusch&#252;sse werden dem Vorstandsmitglied jeweils am Kalendermonatsende gezahlt. Die auf diese Zahlungen etwaig anfallende Einkommensteuer tr&#228;gt das Vorstandsmitglied.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Even if there is no statutory insurance obligation, the Company shall pay the Board Member monthly health and long-term care insurance contributions for the Board Member. The individual contributions are in their amount equivalent to the amount of the contributions paid by the Board Member, but at the most to the maximum amount of the employer's contribution to the statutory health and long-term care insurance legally owed in each case, taking into account the applicable contribution assessment thresholds. The contributions owed by the Company are paid to the Board Member at the end of each calendar month. Any income tax payable on these payments shall be borne by the Board Member.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Der Vorstand erh&#228;lt in angemessenem Umfang f&#252;r die im Gesellschaftsinteresse erforderlichen Aufwendungen Ersatz. Erforderliche Reisekosten werden gegen Einzelnachweis erstattet. Die darin enthaltenen Tage- und &#220;bernachtungsgelder k&#246;nnen im Rahmen der steuerlich zul&#228;ssigen Betr&#228;ge auch pauschal abgerechnet werden.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member shall be reimbursed to an appropriate extent for the expenses required in the interest of the Company. Required travel expenses will be reimbursed against itemization. The daily and overnight allowances contained therein may also be settled as a lump sum within the limits of the amount permissible for tax purposes.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Die Gesellschaft kann den Vorstand nach ihrem Ermessen f&#252;r die Dauer dieses Dienstvertrages im Rahmen einer Risiko-Lebensversicherung in H&#246;he von EUR 500.000,00 f&#252;r den Todesfall und im Rahmen einer Unfallversicherung in H&#246;he von EUR 700.000,00 f&#252;r den Invalidit&#228;tsfall versichern bzw. eine bereits bestehende Versicherung fortf&#252;hren. Der Vorstand hat das Recht, den&#47;die Bezugsberechtigten zu bestimmen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">At its discretion, the Company may insure the Board Member for the duration of this Service Agreement under a risk life insurance policy in the amount of EUR 500,000.00 in the event of death and under an accident insurance policy in the amount of EUR 700,000.00 in the event of disability or continue an existing insurance policy. The Board Member is entitled to determine the beneficiary&#47;beneficaries.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Im FaIle der &#220;bernahme einer bestehenden Direktversicherung kann diese gem&#228;&#223; &#167; 40 b EStG in ihrer geltenden Fassung weiter gef&#252;hrt werden. Die pauschale Versteuerung &#252;bernimmt in diesem Fall die Gesellschaft.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In the event that an existing direct insurance policy is taken over, this insurance policy can be managed in its current version under Section 40 b German Income Tax Act (EStG). In this case, the lump sum taxation is paid by the Company.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 6 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Die Gesellschaft bietet dem Vorstand die M&#246;glichkeit zur Teilnahme an einer Pensionskasse, Unterst&#252;tzungskasse oder einer &#228;hnlichen betrieblichen Altersversorgung (BAV) bzw. zur &#220;bernahme einer bereits bestehenden BAV. In diesem Zusammenhang kann der Vorstand einen Teil seiner Gehaltsanspr&#252;che zugunsten einer betrieblichen Altersversorgungszusage umwandeln. Die dem Vorstand gem&#228;&#223; &#167; 3 (1) lit. a) gew&#228;hrte Grundverg&#252;tung wird dabei mit Wirkung zum Beginn einer betrieblichen Altersversorgungszusage entsprechend um einen monatlichen Bruttobetrag gek&#252;rzt, um in eine wertgleiche Zusage auf betriebliche Versorgungsleistung umgewandelt zu werden. In H&#246;he dieses Betrags verringert sich der Anspruch des Vorstands auf Zahlung der Grundverg&#252;tung. Sollte der Vorstand die Versorgungszusage im weiteren Verlauf ganz oder teilweise wieder k&#252;ndigen oder ruhen lassen, so lebt der entsprechende Verg&#252;tungsanspruch wieder auf.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Company offers the Board Member the opportunity to participate in a pension fund, support fund or similar company pension scheme </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">(betriebliche Altersvorsorge</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">, BAV) or to take over an existing BAV. In this context, the Board Member can convert part of its salary entitlements into a company pension commitment. The Basic Remuneration granted to the Board Member pursuant to &#167; 3 (1) lit. a) shall be reduced by a gross monthly amount with effect from the beginning of a company pension commitment to be converted into an equal-value commitment to company pension benefits. The Board Member's entitlement to payment of the Basic Remuneration is reduced by this amount. If the Board Member rescinds or suspends the pension commitment in whole or in part in the further course of the plan, the corresponding entitlement to compensation shall revive.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 7 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Die Gesellschaft schlie&#223;t f&#252;r den Vorstand eine Verm&#246;gensschaden-Haftpflichtversicherung (D&#38;O) f&#252;r den Fall ab, dass der Vorstand wegen einer in Aus&#252;bung seiner T&#228;tigkeit begangenen Pflichtverletzung von einem Dritten oder der Gesellschaft aufgrund gesetzlicher Haftpflichtbestimmungen privatrechtlichen Inhalts f&#252;r einen Verm&#246;gensschaden in Anspruch genommen wird. Der Vorstand tr&#228;gt dabei eine Selbstbeteiligung in H&#246;he des Mindestwerts gem&#228;&#223; &#167; 93 (2) AktG (derzeit je Schadensfall 10% des Schadens, maximal aber das 1 &#189;-fache der Grundverg&#252;tung pro Jahr (j&#228;hrliche H&#246;chstgrenze). Kommt es zu mehreren Schadensf&#228;llen in einem Jahr, gilt die j&#228;hrliche H&#246;chstgrenze f&#252;r alle Schadensf&#228;lle zusammen. Der Selbstbehalt passt sich bei &#196;nderung der Grundverg&#252;tung (bzw. bei &#196;nderung von &#167; 93 (2) AktG) automatisch an&#59; der Vorstand ist verpflichtet, die entsprechenden &#196;nderungen beim Selbstbehalt des D&#38;O Versicherungsvertrages zu veranlassen, und&#47;oder s&#228;mtliche in diesem Zusammenhang erforderlichen Erkl&#228;rungen abzugeben. Das Bezugsjahr f&#252;r den anzuwendenden Selbstbehalt ist das Jahr des Pflichtversto&#223;es.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Company enters into a directors' and officers' liability insurance policy (D&#38;O) for the Board Member for the event that a third party or the Company makes a claim against the Board Member for a loss of assets due to a breach of duty committed in the performance of its duties due to statutory liability provisions under private law. The Board Member bears a deductible in the amount of the minimum value pursuant to Section 93 (2) of the German Stock Corporation Act (AktG) (currently 10% of the damage per claim, but not more than one and a half times the Basic Remuneration per year (annual maximum limit). In case of several loss events in one year, the annual maximum limit applies to all loss events in combination. The deductible is automatically adjusted in the event of a change in the Basic Renumaration (or in the event of a change in Section 93 (2) AktG)&#59; the Board Member is obliged to arrange for the corresponding changes to the deductible in the D&#38;O insurance agreement and &#47; or to provide all declarations required in this regard. The reference year for the deductible to be applied is the year of the violation.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Urlaub</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Holiday</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Der Vorstand hat Anspruch auf einen Jahresurlaub von 30 Arbeitstagen. Arbeitstage sind alle Kalendertage mit Ausnahme von Samstagen, Sonntagen und gesetzlichen Feiertagen am Sitz der Gesellschaft. Bei unterj&#228;hrigem Besch&#228;ftigungsbeginn oder -ende wird der Jahresurlaub in diesem Kalenderjahr zeitanteilig gew&#228;hrt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member is entitled to an annual vacation of 30 working days. Working days are all calendar days except Saturdays, Sundays and public holidays at the registered office of the Company. If employment begins or ends during the course of the year, annual vacation in this calendar year will be granted pro rata temporis.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 8 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Die Urlaubszeit ist unter Ber&#252;cksichtigung der Gesch&#228;ftslage mit den anderen Vorstandsmitgliedern abzustimmen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The holiday period shall be coordinated with the other members of the Executive Board, taking into account the business situation.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.18pt;text-align:center;vertical-align:top"><font style="font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Bez&#252;ge bei Krankheit, Arbeitsunf&#228;higkeit oder Tod</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Beneficiaries in the event of illness, incapacity for work or death</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Im Fall einer Dienstverhinderung (z.B. infolge Erkrankung) ist das Vorstandsmitglied verpflichtet, den Aufsichtsratsvorsitzenden der Gesellschaft unverz&#252;glich &#252;ber Grund und Dauer der Dienstverhinderung zu informieren und auf vordringlich zu erledigende Aufgaben hinzuweisen. Dauert die Dienstverhinderung l&#228;nger als eine Woche, hat das Vorstandsmitglied im Fall einer Erkrankung ein &#228;rztliches Attest oder im Fall einer sonstigen Dienstverhinderung eine schriftliche Erkl&#228;rung vorzulegen, woraus sich der Grund der Arbeitsunf&#228;higkeit sowie deren voraussichtliche Dauer ergeben. Das Vorstandsmitglied tritt bereits jetzt etwaige (Schadensersatz-)Anspr&#252;che in H&#246;he der nach dieser Regelung von der Gesellschaft geleisteten oder zu leistenden Zahlungen an die Gesellschaft ab, die ihm gegen&#252;ber Dritten wegen der Arbeitsverhinderung zustehen. Das Vorstandsmitglied ist verpflichtet, der Gesellschaft unverz&#252;glich s&#228;mtliche zur Geltendmachung derartiger (Schadensersatz-)Anspr&#252;che notwendigen Angaben zu machen sowie hierf&#252;r notwendige Unterlagen zu &#252;berlassen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In the event of an unforeseen absence (e.g. due to illness), the Board Member is obliged to inform the Chairman of the Supervisory Board of the Company without undue delay of the reason for and probable duration of the absence and draw the attention on the tasks to be performed urgently. If the absence lasts longer than one week, the Board Member must submit a medical certificate in the event of illness or a written declaration in the event of any other incapacity, stating the reason for the incapacity and its probable duration. The Board Member hereby assigns to the Company any (compensation) claims in the amount of the payments made or to be made by the Company in accordance with this provision to which he is entitled in respect of third parties due to the impediment to work. The Board Member is obligated to provide the Company with all information necessary for asserting such (compensation) claims and to provide the Company with the necessary documents without undue delay.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Bei einer vor&#252;bergehenden krankheitsbedingten oder sonstigen unverschuldeten Arbeitsunf&#228;higkeit des Vorstandes wird die Grundverg&#252;tung gem&#228;&#223; &#167;&#160;3 (1) lit. a) w&#228;hrend der Zeit der Arbeitsunf&#228;higkeit bis zu einer Dauer von sechs Monaten, l&#228;ngstens jedoch bis zur Beendigung dieses Dienstvertrages weitergezahlt. Dauert die Arbeitsunf&#228;higkeit l&#228;nger als ununterbrochen 3 Monate an, kann der Aufsichtsrat die variable Verg&#252;tung nach Anlage 4 unter Ber&#252;cksichtigung der Dauer der Arbeitsunf&#228;higkeit angemessen reduzieren.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In the event of a temporary illness or other non-culpable incapacity to work, the basic remuneration pursuant to &#167; 3 (1) lit. a) shall continue to be paid during the period of the incapacity to work up to a period of six months, at the latest until the termination of this Service Agreement. If the incapacity to work lasts longer than three months without interruption, the Supervisory Board may reduce the variable remuneration in accordance with Annex 4 by a reasonable amount, taking into account the duration of the incapacity to work.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Bei einer dauernden Arbeitsunf&#228;higkeit des Vorstandes endet der Dienstvertrag mit dem Ende des Quartals, in dem die dauernde Arbeitsunf&#228;higkeit festgestellt worden ist.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In the event of permanent incapacity to work of the Board Member, the employment agreement ends at the end of the quarter in which the permanent incapacity to work was determined.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Ist der Vorstand l&#228;nger als sechs Monate au&#223;erstande, seiner T&#228;tigkeit nachzugehen, kann der Aufsichtsrat verlangen, dass das Vorliegen einer dauernden Arbeitsunf&#228;higkeit durch einen von ihm ausgew&#228;hlten Arzt auf Kosten der Gesellschaft nachgepr&#252;ft wird. Nimmt der Vorstand den Termin trotz zweimaliger Aufforderung durch den Aufsichtsrat nicht wahr, gilt der Vorstand als dauernd arbeitsunf&#228;hig. Die Aufforderungen haben mit einer Woche zeitlichen Abstands voneinander zu erfolgen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">If the Board Member is unable to carry out its duties for more than six months, the Supervisory Board may demand that the existence of a permanent incapacity to work be reviewed by a doctor of its choice at the Company's expense. If the Board Member fails to meet the demand despite two requests by the Supervisory Board, the Board Member shall be deemed permanently incapacitated for work. The requests shall be made at intervals of one week.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 9 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Eine Abfindung ist bei einer Beendigung des Dienstvertrags wegen dauernder Arbeitsunf&#228;higkeit nicht zu leisten.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">A severance payment shall not be made in the event of termination of the employment agreement due to permanent incapacity to work.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Stirbt der Vorstand w&#228;hrend der Dauer des Dienstvertrages, ist die Grundverg&#252;tung nach &#167; 3 (1) lit. a) noch f&#252;r den Sterbemonat und f&#252;r die zwei darauf folgenden Monate zu zahlen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">If the Board Member dies during the term of this Service Agreement, the Basic Remuneration according to &#167; 3 (1) lit. a) shall still be payable for the month of death and for the following two months.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Die Boni nach &#167; 3 (1) lit. b) werden entsprechend Anlage 4 Ziff. 3 durch den Aufsichtsrat festgelegt und an den Ehepartner, bei deren Fehlen an die unterhaltsberechtigten Kinder des Vorstands (letztere als Gesamtgl&#228;ubiger) oder seine Erben bezahlt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The bonuses pursuant to &#167; 3 (1) lit. b) are determined by the Supervisory Board in accordance with Annex 4 No. 3 and paid to the spouse, in the event of their absence to the dependent children of the Board Member (the latter as joint creditor) or his heirs.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.18pt;text-align:center;vertical-align:top"><font style="font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Sonderleistungen und Sonderk&#252;ndigungsrecht bei Kontrollerwerb</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Special services and special right of termination in the event of acquisition of control</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Kommt es nach der Unterzeichnung dieses Vertrags zu einem Kontrollerwerb im Sinne eines Anteilserwerbs von mehr als 50% durch einen Aktion&#228;r, Dritten oder gemeinsam handelnde Personen oder zu einer wirtschaftlich vergleichbaren Transaktion (z.B. Verkauf des Gesch&#228;ftsbetriebs oder eines wesentlichen Teils davon durch die Gesellschaft, Verkauf von wesentlichen Beteiligungsgesellschaften der Gesellschaft, Verschmelzung auf ein anderes Unternehmen, Verkauf von mehr als 50% der Anteile der Gesellschaft nach einem &#8222;Delisting&#34; der Gesellschaft, etc.) und will sich die Gesellschaft in diesem Zusammenhang oder in dessen Folge von dem Vorstand durch vorzeitige Vertragsaufl&#246;sung trennen, ohne hierf&#252;r einen wichtigen Grund im Sinn des &#167; 626 BGB zu haben, so erh&#228;lt der Vorstand zus&#228;tzlich zu der Verg&#252;tung und allen Leistungen, die ihm bis zum Trennungszeitpunkt zustehen, eine Abfindung. Die H&#246;he der Abfindung entspricht der Summe der Gesamtverg&#252;tung (Grundverg&#252;tung, variable Verg&#252;tung sowie Nebenleistungen), die der Vorstand bis zum Ablauf der in &#167; 10 (1) definierten Dauer gem&#228;&#223; diesem Vertrag erhalten h&#228;tte, w&#228;re der Vertrag nicht vorzeitig beendet, sondern bis zum Ende der vollen Amtszeit erf&#252;llt worden. F&#252;r Zwecke der Berechnung der Abfindung nach diesem Absatz (1) wird davon ausgegangen, dass dem Vorstand jeweils der maximale Bonus gem&#228;&#223; Anlage 4 (ggf. pro rata temporis bis zum Ende der Vertragslaufzeit) gezahlt worden w&#228;re. Betr&#228;gt die ordentliche Laufzeit dieses Vertrages gem&#228;&#223; &#167; 10 (1) zum Zeitpunkt des Wirksamwerdens der Trennung nach diesem Absatz (1) weniger als 15 Monate, berechnet sich die zu zahlende Abfindung auf Basis einer fiktiven Restlaufzeit von 15 Monaten, d. h. die Abfindung wird berechnet auf Basis einer angenommenen Restlaufzeit von mindestens 15 Monaten. W&#228;hrend der Vertragslaufzeit stattfindende Anhebungen der Verg&#252;tung gem&#228;&#223; &#167; 3 (1) werden bei den beschriebenen Berechnungen ber&#252;cksichtigt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">If, after the signing of this agreement, control is acquired in the sense of a share acquisition of more than 50% by a shareholder, third party or persons acting jointly or in the sense of an economically comparable transaction (e.g. sale of the business operations or a substantial part thereof by the Company, sale of substantial associated companies of the Company, merger with another company, sale of more than 50% of the shares of the Company after a delisting of the Company, etc) and if the Company wishes to terminate the agreement with the Board Member in this context or as a result thereof by early termination of the agreement without having an important reason within the meaning of Section 626 of the German Civil Code (BGB), the Board Member shall receive a severance payment in addition to the remuneration and all benefits to which it is entitled up to the time of termination. The amount of the severance payment corresponds to the sum of the total remuneration (basic remuneration, variable remuneration as well as fringe benefits) that the Board Member would have received until expiry of the term defined in &#167; 10 (1) of this agreement, if the agreement would not have been terminated prematurely, but would have been fulfilled by the end of the full term of office. For the purpose of calculating the severance payment pursuant to this paragraph (1), it is assumed that the maximum bonus would have been paid to the Board Member in each case in accordance with Annex 4 (if applicable pro rata temporis until the end of the agreement term). If the ordinary term of this agreement pursuant to &#167; 10 (1) is less than 15 months at the time the separation pursuant to this paragraph (1) takes effect, the severance payment to be made shall be calculated on the basis of a fictitious remaining term of 15 months, i.e. the severance payment shall be calculated on the basis of an assumed remaining term of at least 15 months. Any increases in remuneration in accordance with &#167; 3 (1) that take place during the term of the agreement shall be taken into account in the calculations described.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:20.75pt;padding-right:2.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:8.84pt">Die Abfindung ist in voller H&#246;he zusammen mit dem Gehalt f&#252;r den Monat, zu dessen Ende die Trennung nach Absatz (1) wirksam wird, zur Zahlung f&#228;llig.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The severance payment shall be payable in full together with the salary for the month at the end of which the separation referred to in paragraph (1) takes effect.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 10 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:20.75pt;padding-right:2.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:8.84pt">Im Falle dieses Absatzes (1) wird dem Vorstand ein au&#223;erordentliches Sonderk&#252;ndigungsrecht zu diesem Dienstvertrag einger&#228;umt. Das Sonderk&#252;ndigungsrecht kann innerhalb von sechs Wochen ab Kenntnis des Vorstands &#252;ber den rechtskr&#228;ftigen Vollzug des Kontrollwechsels im Sinne des Absatzes (1) mit einer Frist von drei Monaten zum Monatsende ausge&#252;bt werden. Dar&#252;ber hinaus besteht ein Sonderk&#252;ndigungsrecht des Vorstands auch dann, wenn der Vorstand innerhalb von einem Jahr nach Vollzug des Kontrollwechsels abberufen wird. In diesem Fall betr&#228;gt die Sonderk&#252;ndigungsfrist zwei Wochen. Die K&#252;ndigung kann innerhalb von vier Wochen nach Abberufung durch den Vorstand erkl&#228;rt werden.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In the event of this paragraph (1), the Board Member shall be granted an extraordinary right of termination to this Service Agreement. The extraordinary right of termination may be exercised within six weeks of the knowledge of the Board Member of the legally binding execution of the change of control within the meaning of paragraph (1) with a notice period of three months to the end of the month. In addition, the Board Member has a special right of termination even if the Board Member is dismissed within one year of the completion of the change of control. In this case, the special notice period is two weeks. The termination may be declared by the Board Member within four weeks after dismissal.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Diensterfindungen und Schutzrechte</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Service inventions and industrial property rights</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 11 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Erfindungen des Vorstands sowie seine technischen oder organisatorischen Verbesserungsvorschl&#228;ge werden entsprechend den jeweils geltenden Bestimmungen des Gesetzes &#252;ber Arbeitnehmererfindungen vom 25.7.1957 mit folgender Ma&#223;gabe behandelt&#58; Der Vorstand wird der Gesellschaft Diensterfindungen, freie Erfindungen und technische wie organisatorische Verbesserungsvorschl&#228;ge unverz&#252;glich melden und der Gesellschaft zur ausschlie&#223;lichen, beschr&#228;nkten oder unbeschr&#228;nkten Inanspruchnahme anbieten. Die Erkl&#228;rung der Inanspruchnahme hat seitens der Gesellschaft innerhalb von vier Monaten nach der Meldung zu erfolgen. Die Gesellschaft hat das Recht, jedoch nicht die Verpflichtung, zur Anmeldung von Schutzrechten im In- und Ausland. Im Fall einer Diensterfindung oder eines technischen oder organisatorischen Verbesserungsvorschlags sind sich die Parteien darin einig, dass eine etwaige Verg&#252;tung f&#252;r eine von der Gesellschaft in Anspruch genommene Diensterfindung mit der Zahlung der Grundverg&#252;tung nach &#167; 3 (1) lit. a) dieses Vertrages vollst&#228;ndig abgegolten ist. Im Fall einer freien Erfindung ist dem Vorstandsmitglied eine markt&#252;bliche Verg&#252;tung zu zahlen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Inventions by the Board Member and its technical or organizational suggestions for improvement shall be treated in accordance with the applicable provisions of the Act on Employee Inventions of 25 July 1957, subject to the following provisions&#58; The Board Member will immediately notify the Company of job-related inventions, free inventions and technical and organizational suggestions for improvement and offer them to the Company for exclusive, limited or unlimited use. The Company must declare acceptance within four months of notification. The Company is entitled, but not obliged, to register intellectual property rights in Germany and abroad. In the case of a job-related invention or a technical or organizational suggestion for improvement, the parties agree that any remuneration for a service invention claimed by the Company shall be paid in full upon payment of the basic remuneration pursuant to &#167; 3 (1) lit. a) of this agreement. In the case of a free invention, the Board Member shall be paid a remuneration in line with market-based conditions.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 12 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Der Vorstand &#252;bertr&#228;gt der Gesellschaft ausschlie&#223;liche, zeitlich, r&#228;umlich und inhaltlich unbeschr&#228;nkte Nutzungs- und Verwertungsrechte f&#252;r alle etwaigen nach dem Urhebergesetz schutzf&#228;higen T&#228;tigkeitsergebnisse, die das Vorstandsmitglied w&#228;hrend der Dauer seines Dienstvertrages w&#228;hrend seiner Arbeitszeit oder, sofern sie Bezug zu seinen dienstvertraglichen Aufgaben haben, auch au&#223;erhalb seiner Arbeitszeit erstellt. Die &#220;bertragung der urheberrechtlichen Nutzungs- und Verwertungsrechte umfasst auch etwaige bei Vertragsschluss noch unbekannte Nutzungsarten. Die &#220;bertragung der Nutzungs- und Verwertungsrechte umfasst insbesondere auch die Erlaubnis zur Bearbeitung und Lizenzvergabe an Dritte. Das Vorstandsmitglied verzichtet ausdr&#252;cklich auf sonstige ihm etwa als Urheber zustehende Rechte an den T&#228;tigkeitsergebnissen, insbesondere auf das Recht auf Namensnennung, auf Bearbeitung und auf Zug&#228;nglichmachung des Werkes.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member shall grant the Company exclusive rights of use and exploitation, unlimited in terms of time, space and content, for any works which may be protected under the German Copyright Act and which the Board Member produces during the term of his Service Agreement during his working hours or, if they relate to his duties under the Service Agreement, also outside his working hours. The transfer of the rights of use and exploitation also includes any types of use still unknown at the time of conclusion of the agreement. The transfer of the rights of use and exploitation includes in particular the permission for processing and licensing to third parties. The Board Member expressly waives any other rights to the works to which he is entitled as the author, in particular the right to name, edit and make accessible the work.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Soweit T&#228;tigkeitsergebnisse, die der Vorstand w&#228;hrend der Dauer seines Dienstvertrages w&#228;hrend seiner Arbeitszeit oder, sofern sie Bezug zu seinen dienstvertraglichen Aufgaben haben, auch au&#223;erhalb seiner Arbeitszeit erstellt, nicht bereits nach Absatz (1) und (2) &#252;bertragen sind, &#252;bertr&#228;gt der Vorstand der Gesellschaft s&#228;mtliche Rechte an diesen T&#228;tigkeitsergebnissen, insbesondere Marken- und sonstige Kennzeichenrechte sowie eingetragene Designs.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Insofar as works which the Board Member produces during the term of its Service Agreement, during its working hours or, insofar as they relate to its duties under the Service Agreement, also outside its working hours, have not already been transferred in accordance with paragraphs (1) and (2), the Board Member shall transfer to the Company all rights to these works, in particular trademark and other distinctive rights as well as registered designs.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 13 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Die Parteien sind sich einig, dass die Einr&#228;umung dieser Rechte und der Verzicht auf Rechte nach dieser Regelung vollumf&#228;nglich mit der Zahlung der Grundverg&#252;tung nach &#167; 3 (1) lit. a) dieses Vertrages abgegolten sind, soweit dem nicht zwingende gesetzliche Regelungen entgegenstehen. Der Vorstand ist verpflichtet, jedwedes seiner schutzrechtsf&#228;higen T&#228;tigkeitsergebnisse unverz&#252;glich der Gesellschaft, vertreten durch den Aufsichtsrat, zu melden und die Gesellschaft im erforderlichen Umfang, auch nach Beendigung dieses Dienstvertrages, bei der Erlangung von Schutzrechten zu unterst&#252;tzen. Soweit der Vorstand seine Mitwirkungspflichten nach der Beendigung dieses Dienstvertrages erf&#252;llt, erh&#228;lt der Vorstand hierf&#252;r einen angemessenen Tagessatz sowie eine Erstattung aller Aufwendungen, die ihm durch seine Mitwirkung entstanden sind.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The parties agree that the granting of these rights and the waiver of rights under this provision are fully covered by the payment of the Basic Remuneration under &#167; 3 (1) lit. a) this agreement, otherwise provided for by mandatory legal provisions. The Board Member is obliged to notify any of the works that are capable of being protected by intellectual property rights without delay to the Company, represented by the Supervisory Board, and to support the Company to the necessary extent, even after termination of this Service Agreement, in obtaining intellectual property rights. To the extent that the Board Member fulfils its duties to cooperate after the termination of this Service Agreement, the Board Member shall receive an appropriate daily rate as well as a reimbursement of all expenses incurred by him resulting from his cooperation.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Geheimhaltung und R&#252;ckgabe von Unterlagen, Interessenkonflikte</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Confidentiality and return of documents, conflicts of interest</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 14 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Der Vorstand verpflichtet sich, &#252;ber alle ihm im Rahmen seiner T&#228;tigkeit oder sonst zur Kenntnis gelangenden gesch&#228;ftlichen und betrieblichen Angelegenheiten der Gesellschaft und aller Verbundenen Unternehmen strengstes Stillschweigen zu bewahren, einschlie&#223;lich des Inhalts dieses Dienstvertrages sowie den Vertragsverhandlungen, die dem Abschluss dieses Dienstvertrages zugrunde liegen. Der Vorstand verpflichtet sich weiterhin, diese Informationen nicht f&#252;r den eigenen oder den Nutzen anderer zu verwenden und alle solche gesch&#228;ftlichen und betrieblichen Angelegenheiten betreffenden Gesch&#228;ftsunterlagen der Gesellschaft und der Verbundenen Unternehmen unter Verschluss zu halten. Unter gesch&#228;ftlichen und betrieblichen Angelegenheiten im Sinne dieser Regelung verstehen die Parteien insbesondere Gesch&#228;fts- und Betriebsgeheimnisse sowie alle Informationen und Daten mit Bezug zu vertraulichen Angelegenheiten und gesch&#228;ftsbezogenem Know-how, s&#228;mtliche Informationen &#252;ber alle mit dem existenten oder k&#252;nftigen Gesch&#228;ft der Gesellschaft und der Verbundenen Unternehmen in Zusammenhang stehenden Gesch&#228;ftspl&#228;ne und Gesch&#228;ftsstrategien, Verfahren, Preis- oder Marktstrategien und Produkt-, Dienstleistungs- oder Entwicklungsplanungen, geplante Unternehmenserwerbe oder -ver&#228;u&#223;erungen, s&#228;mtliche Gesch&#228;ftszahlen und Details der organisatorischen Strukturen sowie die wesentlichen Ideen und Prinzipien, welche diesen Strategien und Planungen zugrunde liegen, und alle Informationen, von denen vern&#252;nftigerweise erwartet werden kann, dass sie zu solchen Strategien oder Planungen f&#252;hren werden und die von der Gesellschaft, von Verbundenen Unternehmen oder dem Vorstandsmitglied w&#228;hrend der Dauer dieses Dienstvertrages erdacht, erfunden, &#252;berarbeitet, entdeckt, entwickelt, erworben, beurteilt, getestet oder angewendet worden sind.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member undertakes to maintain the strictest secrecy with regard to all business and operational matters of the Company and old affiliated companies that come to its attention in the course of its activities or otherwise, including the contents of this Service Agreement and the negotiations on which the conclusion of this Service Agreement is based. The Board Member further undertakes not to use this information for its own benefit or for the benefit of others and to keep all business documents of the Company and its Affiliates relating to such business and operational matters under lock and key. For the purposes of this provision, business and operational matters shall mean, in particular, business and trade secrets and all information and data relating to confidential matters and business-related know-how, all information, all business plans and strategies, procedures, price or market strategies and product, service or development plans relating to the existing or future business of the Company and its Affiliates, planned corporate acquisitions or disposals, all business figures and details of the organizational structures and the principal ideas and principles underlying such strategies and plans, and all information that can reasonably be expected to result in such strategies or plans and that has been invented, redacted, discovered, developed, assessed, tested or applied by the Company, its affiliates or the Board Member during the term of this Service Agreement.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 15 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Die Geheimhaltungsverpflichtung nach vorstehendem Absatz (1) dauert auch nach Beendigung des Dienstverh&#228;ltnisses fort. Im Rahmen einer von dem Vorstand nach Beendigung dieses Dienstvertrages ausge&#252;bten beruflichen oder unternehmerischen T&#228;tigkeit kann er sein als Vorstandsmitglied erworbenes Wissen einsetzen, sofern dabei die gesetzlichen Beschr&#228;nkungen insbesondere nach &#167;&#167; 3, 17 UWG, &#167; 823 (1) und (2) BGB i.V. m. UWG, &#167;&#160;826 BGB und den datenschutzrechtlichen Regelungen sowie die Beschr&#228;nkungen aus dem nachvertraglichen Wettbewerbsverbot nach &#167; 16 dieses Vertrages strikt beachtet werden.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The obligation to maintain secrecy pursuant to the previous paragraph (1) shall continue even after the termination of the employment relationship. The Board Member may use his knowledge acquired as a Board Member within the scope of a professional or entrepreneurial activity carried out by the Board Member after termination of this Service Agreement, provided that the statutory restrictions - in particular pursuant to Sections 3, 17 UWG (German Act Against Unfair Competition), Section 823 (1) and (2) BGB associated with Sections 3, 17 UWG, Section 823 (1) and (2) BGB associated with the UWG, Section 826 BGB and the data protection regulations.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Der Vorstand ist verpflichtet, in Zweifelsf&#228;llen &#252;ber den Umfang der Geheimhaltungsverpflichtung nach vorstehenden Abs&#228;tzen (1) und (2) mit dem Aufsichtsrat der Gesellschaft eine Kl&#228;rung herbeizuf&#252;hren.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In cases of doubt, the Board Member is obliged to reach a clarification with the Supervisory Board of the Company regarding the scope of the confidentiality obligation pursuant to the previous paragraphs (1) and (2).</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Der Vorstand verpflichtet sich, auf Verlangen der Gesellschaft jederzeit und sp&#228;testens bei Ende seiner Bestellung zum Organ auch ohne gesonderte Aufforderung alle in seinem Besitz befindlichen Unterlagen der Gesellschaft oder Verbundener Unternehmen, insbesondere alle Notizen, Memoranden, Aufzeichnungen, Protokolle und Berichte, Akten sowie alle anderen &#228;hnlichen Dokumente (einschlie&#223;lich Abschriften, Ablichtungen, Kopien oder sonstiger Reproduktionen), die im Zusammenhang mit seiner T&#228;tigkeit stehen, unverz&#252;glich und vollst&#228;ndig an die Gesellschaft zur&#252;ckzugeben. Ein Zur&#252;ckbehaltungsrecht ist ausgeschlossen. Diese Regelung gilt sinngem&#228;&#223; f&#252;r elektronisch gespeicherte Daten sowie die jeweiligen Daten- oder Programmtr&#228;ger.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member undertakes, at the request of the Company at any time and at the latest at the end of its appointment to the Board and without separate request, to return to the Company all documents of the Company or affiliated companies in its possession, in particular all notes, memoranda, records, minutes and reports, files as well as all other similar documents (including copies, photocopies or other reproductions) in connection with its activities without delay and in full. A right of retention is excluded. This provision applies to electronically stored data as well as the respective data or program carriers.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Die Herausgabeverpflichtung bezieht sich auch auf sonstiges, im Besitz des Vorstands befindliches Eigentum der Gesellschaft oder Verbundener Unternehmen bzw. von der Gesellschaft oder von einem Verbundenen Unternehmen geleaste Gegenst&#228;nde. Diese Herausgabeverpflichtung erstreckt sich insbesondere auch auf ein dem Vorstand etwa &#252;berlassenes Mobiltelefon, Laptop oder sonstige Ger&#228;te der Datenverarbeitung, bei Ende seiner Bestellung zum Organ auch, wenn insoweit eine private Nutzung gestattet war.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The release obligation also applies to other property of the Company or affiliates or items leased by the Company or an affiliate that is in possession of  the Board Member. This release obligation also extends in particular to a mobile phone, laptop or other data processing device left in the possession of the Board Member, at the end of its appointment to the Board even if private use was permitted in this respect.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 16 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Der Vorstand hat m&#246;gliche und tats&#228;chliche Interessenkonflikte unverz&#252;glich dem Aufsichtsrat gegen&#252;ber offenzulegen und die anderen Vorstandsmitglieder hier&#252;ber zu informieren.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Board Member must immediately disclose possible and actual conflicts of interest to the Supervisory Board and inform the other members of the Management Board hereof.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Vertragsdauer</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Term of the Agreement</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Der Vertrag steht insgesamt unter der (A) aufschiebenden Bedingung, dass (i) der Vorstand zum Vorstand der Gesellschaft bestellt wird und (ii) dass die Tranche I gem. Sec. 4 Abs. 2 des Investment Agreements vom 10 August an die Gesellschaft vollst&#228;ndig gezahlt und (B) aufl&#246;senden Bedingung, dass die Option aus dem Asset Purchase Agreement zwischen der Gesellschaft und der 4SC AG nicht bis zum 30. September 2016 ausge&#252;bt wird.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The agreement is subject to (A) the condition precedent that (i) the Board Member is appointed to the Management Board of the Company and (ii) that Tranche I pursuant to Sec. 4 (2) of the Investment Agreement of 10 August is paid in full to the Company and (B) the condition precedent that the option under the Asset Purchase Agreement between the Company and 4SC AG is not exercised by 30 September 2016.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Dieser Vertrag wird mit Wirkung zum fr&#252;hestm&#246;glichen Termin, jedoch sp&#228;testens dem 1. April 2017, abgeschlossen. Er endet mit Ablauf von drei Jahren.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">This contract will be concluded with effect at the earliest possible date, but no later than 1 April 2017. It ends with the expiration of three years.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Das Recht zur au&#223;erordentlichen K&#252;ndigung bleibt unber&#252;hrt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The right to extraordinary termination remains unaffected.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Im Fall eines Widerrufs der Bestellung, der Amtsniederlegung durch das Vorstandsmitglied oder bei einer sonstigen Beendigung der Organstellung endet dieser Dienstvertrag mit Ablauf eines Jahres nach dem Ende des Amtes, sp&#228;testens jedoch zum Ende der Laufzeit nach Absatz (1). Eine etwaige fr&#252;here Beendigung aufgrund Absatz (2) dieses Vertrages bleibt unber&#252;hrt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In the event of revocation of the appointment, demission by the Board Member or other termination of the position, this Service Agreement shall end at the end of one year after the end of the term of office, at the latest, however, at the end of the term pursuant to paragraph (1). A possible termination due to paragraph (2) of this agreement remains unaffected.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 17 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Der Vorsitzende des Aufsichtsrats wird dem Vorstand sp&#228;testens neun Monate vor Ablauf dieses Vertrages schriftlich mitteilen, ob und unter welchen Bedingungen der Aufsichtsrat den Vorstand erneut zum Vorstandsmitglied bestellen wird und ob er bereit ist, den Dienstvertrag entsprechend der Dauer der neuen Bestellung zu verl&#228;ngern oder einen neuen Dienstvertrag zu mindestens gleichen Bedingungen mit ihm abzuschlie&#223;en. Der Vorstand wird innerhalb von zwei Monaten ab Zugang des Angebots des Aufsichtsratsvorsitzenden erkl&#228;ren, ob er die erneute Bestellung annimmt und bereit ist, den f&#252;r die Fortsetzung oder Erneuerung des Dienstvertrages angebotenen Bedingungen zuzustimmen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Chairman of the Supervisory Board will inform the Board Member in writing no later than nine months before the expiry of this agreement, whether and under which conditions the Supervisory Board will reappoint the Board Member and whether he is willing to extend the Service Agreement for the duration of the new appointment or to conclude a new Service Agreement on at least the same terms. Within two months of receipt of the Supervisory Board Chairman's offer, the Board Member will declare whether it accepts the reappointment and is prepared to agree to the terms and conditions offered for the continuation or renewal of the Service Agreement.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 18 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Die Gesellschaft ist berechtigt, den Vorstand nach dem Widerruf seiner Bestellung gem&#228;&#223; &#167; 84 (3) AktG oder im Zusammenhang mit einer Beendigung des Dienstvertrages, insbesondere nach einer K&#252;ndigung oder im Anschluss an den Abschluss eines Aufhebungsvertrages, ganz oder teilweise von seiner Pflicht zur Dienstleistung unter Fortzahlung der Grundverg&#252;tung gem&#228;&#223; &#167; 3 (1) lit. a) widerruflich oder unwiderruflich freizustellen. lm Fall der unwiderruflichen Freistellung werden offene Urlaubs- und sonstige Freizeitausgleichsanspruche angerechnet, die damit erledigt sind. Der Dienstvertrag im &#220;brigen wird von der Freistellung nicht ber&#252;hrt&#59; insoweit bestehen insbesondere die Verschwiegenheitspflicht und das vertragliche Wettbewerbsverbot bis zum Ende des Dienstvertrages fort. Anderweitiger Verdienst w&#228;hrend der Freistellungszeit wird gem&#228;&#223; &#167; 615 Satz 2 BGB angerechnet. Eine Anrechnung erfolgt nicht, wenn und soweit der anderweitige Verdienst aus einer genehmigten Nebent&#228;tigkeit (&#167; 2 (1) dieses Dienstvertrages) stammt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">The Company is entitled, after the revocation of its appointment pursuant to Section 84 (3) AktG or in connection with a termination of the Service Agreement, in particular following a termination or following the conclusion of a termination agreement, to release the Board Member in whole or in part from its obligation to provide services with continued payment of the Basic Remuneration pursuant to &#167; 3 (1) a) revocably or irrevocably. In the event of irrevocable release, receivable holiday and other time off compensation claims shall be credited and settled. The rest of the Service Agreement remains unaffected by the indemnification&#59; in this respect, the obligation to maintain secrecy and the contractual non-competition clause continue to apply until the end of the Service Agreement. Other earnings during the exemption period shall be deducted in accordance with Section 615 sentence 2 BGB. If and as far as the other earnings originate from an approved ancillary activity (&#167; 2 (1) of this Service Agreement) they are not subject to deduction.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Bei vorzeitiger Beendigung der Vorstandst&#228;tigkeit ohne wichtigen Grund entsprechen die Zahlungen an den Vorstand einschlie&#223;lich Nebenleistungen maximal dem Wert von zwei Jahresverg&#252;tungen (Abfindungs-Cap) und &#252;berschreiten nicht die Gesamtverg&#252;tung (Grundverg&#252;tung, variable Verg&#252;tung sowie Nebenleistungen) f&#252;r die Restlaufzeit des Dienstvertrages. Bei einem Kontrollerwerb nach &#167; 7 gilt ein Abfindungs-Cap von maximal drei Jahresverg&#252;tungen.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">In the event of premature termination of the board activity without good cause, payments to the Board Member including fringe benefits shall not exceed the value of two years' remuneration (severance payment cap) and shall not exceed the total remuneration (Basic Remuneration, variable remuneration and fringe benefits) for the remaining term of the Service Agreement. In the case of an acquisition of control pursuant to &#167; 7, a severance payment cap of a maximum of three years' remuneration applies.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Ausschlussfristen</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Preclusive Period</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 19 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Anspr&#252;che der Gesellschaft und des Vorstands aus dem Dienstverh&#228;ltnis oder im Zusammenhang mit diesem Dienstverh&#228;ltnis verfallen, ungeachtet ihres Rechtsgrundes, wenn die bzw. der Anspruchsberechtigte den Anspruch nicht innerhalb einer Frist von sechs Monaten, berechnet ab dem Zeitpunkt der F&#228;lligkeit und der Kenntnis oder grob fahrl&#228;ssigen Unkenntnis des Anspruchsberechtigten von den anspruchsbegr&#252;ndenden Umst&#228;nden, durch schriftliche Erkl&#228;rung gegen&#252;ber der jeweils anderen Vertragspartei geltend macht. F&#252;r die Beurteilung der Rechtzeitigkeit der Geltendmachung ist der Zugang der schriftlichen Erkl&#228;rung ma&#223;geblich. Dies gilt nicht f&#252;r die Geltendmachung von Anspr&#252;chen wegen Verletzung des Lebens, des K&#246;rpers oder der Gesundheit sowie bei vors&#228;tzlichen Pflichtverletzungen. Die Vers&#228;umung der Ausschlussfrist f&#252;hrt zum Verlust des Anspruchs.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Claims of the Company and the Board Member arising from or in connection with the employment relationship shall excluded, irrespective of their legal basis, if the entitled person does not assert the claim within a period of six months, calculated from the due date and the knowledge or grossly negligent ignorance of the entitled person of the circumstances giving rise to the claim, by means of a written declaration to the respective other party. For the assessment of the timeliness of the assertion, the receipt of the written declaration is decisive. This does not apply to the assertion of claims due to injury to life, body or health as well as in the case of intentional breaches of duty. Failure to comply with the preclusive period will result in the loss of the claim.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Etwaige Anspr&#252;che der Gesellschaft nach &#167; 93 (2) und (3) AktG gegen das Vorstandsmitglied bleiben gem&#228;&#223; &#167; 93 (4) Satz 3 AktG von vorstehendem Absatz (1) unber&#252;hrt.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Any claims of the Company pursuant to Section 93 (2) and (3) AktG against the Board Member shall remain unaffected by the above paragraph (1) pursuant to Section 93 (4) sentence 3 AktG.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#167; 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;padding-left:17.98pt"><br>Schlussbestimmungen</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.18pt;text-align:center;vertical-align:top"><font style="font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Final Provisions</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Dieser Vertrag enth&#228;lt die gesamte Vereinbarung zwischen den Parteien. Bereits getroffene Vereinbarungen zwischen den Parteien werden hiermit ausdr&#252;cklich aufgehoben.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">This agreement contains the entire agreement between the parties. Prior agreements between the parties are hereby expressly cancelled.</font></div></td></tr></table></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 20 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:47.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">&#196;nderungen oder Erg&#228;nzungen dieses Vertrages einschlie&#223;lich dieser Schriftformklausel bed&#252;rfen zu ihrer Wirksamkeit der Schriftform.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Changes or additions to this agreement, including this written form clause, must be made in writing to be effective.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Dieser Vertrag unterliegt dem Recht der Bundesrepublik Deutschland.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">This agreement is subject to the law of the Federal Republic of Germany.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Erf&#252;llungsort ist der Sitz der Gesellschaft. Gerichtsstand f&#252;r Streitigkeiten aus diesem Vertrag ist der Sitz der Gesellschaft.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Place of performance is the seat of the Company, place of jurisdiction for disputes from this agreement is the seat of the Company.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Sollte eine Bestimmung dieses Vertrages ganz oder teilweise rechtsunwirksam oder undurchf&#252;hrbar sein oder werden, so wird die G&#252;ltigkeit der &#252;brigen Bestimmungen dieses Vertrages nicht ber&#252;hrt. Vielmehr ist die ganz oder teilweise rechtsunwirksame oder undurchf&#252;hrbare Bestimmung durch eine Bestimmung zu ersetzen, die den mit der unwirksamen Bestimmung angestrebten wirtschaftlichen Erfolg soweit wie m&#246;glich erreicht. Das gleiche gilt im Fall von L&#252;cken dieses Vertrages.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:18.9pt;padding-right:2.75pt;text-align:justify;text-indent:-16.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:6.99pt">Should any provision of this agreement be or become invalid or unenforceable in whole or in part, the validity of the remaining provisions of this agreement shall not be affected. Rather, the invalid or unenforceable provision, in whole or in part, shall be replaced by a provision that achieves as far as possible the economic purpose intended by the invalid provision. The same shall apply in the event of any gaps in this agreement.</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Martinsried, den</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Martinsried, this</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">&#47;s&#47; Dr. Daniel Vitt</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">&#47;s&#47; Dr. J&#246;rg Neermann</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Dr. Daniel Vitt</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Dr. J&#246;rg Neermann<br>Aufsichtsratsvorsitzender</font></td></tr></table></div><div><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seite 21 von 19</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Anlagenverzeichnis</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Schedule of Annexes</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.36pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Anlage 1&#58; &#160;&#160;&#160;&#160;AR-Beschluss</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.36pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Annex 1&#58; &#160;&#160;&#160;&#160;Supervisory Board Resolution</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.36pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Anlage 2&#58; &#160;&#160;&#160;&#160;Gesch&#228;ftsverteilungsplan aktuell</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.36pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Annex 2&#58; &#160;&#160;&#160;&#160;Schedule of Responsibilities</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.36pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Anlage 3&#58; &#160;&#160;&#160;&#160;Genehmigte Nebent&#228;tigkeiten des Vorstands</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.36pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Annex 3&#58; &#160;&#160;&#160;&#160;Approved Ancillary Activities of the Board Member</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:145%">Germany 10363769.1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>imux-123122xexhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib289ca210c8d4fa0af223dea5fe1bba1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;21.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries of the Registrant</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is a list of subsidiaries of the Registrant. All of the subsidiaries listed below are wholly-owned subsidiaries of Immunic, Inc. and are owned directly by Immunic, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:77.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.642%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction&#160;of<br>Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunic AG</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>exhibit23111.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i34a279af42ef4caa922d1525dfb4d2c0_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 23.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the Registration Statements on Form S&#8209;3 (File No. 333&#8209;</font><font style="background-color:#ffffff;color:#373739;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">225230, 333-250083, 333-255303, and 333-268737), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Form S&#8209;4 (File No. 333&#8209;</font><font style="background-color:#ffffff;color:#373739;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">229510</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">), and Form S-8 (File No. 333&#8209;</font><font style="background-color:#ffffff;color:#373739;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">233864 and 333-258235</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">) of Immunic, Inc. of our report dated February 23, 2023, relating to the consolidated financial statements of Immunic, Inc., which appears in this annual report on Form 10-K for the year ended December 31, 2022. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">s&#47; Baker Tilly US, LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Minneapolis, Minnesota </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">February 23, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>imux-123122xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icbcc0af954af445099062a87be4b6630_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Vitt, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2022 of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 23, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>imux-123122xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8bab6de5b66e474ebe9505a41e5b94e2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Glenn Whaley, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.  I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2022 of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 23, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>imux-123122xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i51df9ea7bcee4836ad9d21ea998d5d95_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Daniel Vitt, as Chief Executive Officer and President of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 23, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>imux-123122xexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8bd700abeb7141409fcfe118f1725237_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Glenn Whaley as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge&#58;&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 23, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>imux-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:19abff6b-9d36-40e5-80a6-5fea77828601,g:313a8e66-68ba-4247-b883-d20269f0dca0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:imux="http://imux.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://imux.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="imux-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="imux-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="imux-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="imux-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://imux.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://imux.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://imux.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://imux.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://imux.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://imux.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>0000010 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatements" roleURI="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements">
        <link:definition>0000011 - Disclosure - Description of Business and Basis of Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://imux.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000012 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetails" roleURI="http://imux.com/role/BalanceSheetDetails">
        <link:definition>0000013 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://imux.com/role/CommitmentsandContingencies">
        <link:definition>0000014 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://imux.com/role/FairValue">
        <link:definition>0000015 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://imux.com/role/CommonStock">
        <link:definition>0000016 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationPlans" roleURI="http://imux.com/role/StockbasedCompensationPlans">
        <link:definition>0000017 - Disclosure - Stock-based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://imux.com/role/IncomeTaxes">
        <link:definition>0000018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://imux.com/role/RelatedPartyTransactions">
        <link:definition>0000019 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000021 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsTables" roleURI="http://imux.com/role/BalanceSheetDetailsTables">
        <link:definition>0000022 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://imux.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000023 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://imux.com/role/FairValueTables">
        <link:definition>0000024 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockTables" roleURI="http://imux.com/role/CommonStockTables">
        <link:definition>0000025 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationPlansTables" roleURI="http://imux.com/role/StockbasedCompensationPlansTables">
        <link:definition>0000026 - Disclosure - Stock-based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://imux.com/role/IncomeTaxesTables">
        <link:definition>0000027 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails" roleURI="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails">
        <link:definition>0000028 - Disclosure - Description of Business and Basis of Financial Statements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>0000029 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesInvestmentsDetails" roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails">
        <link:definition>0000030 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesGoodwillDetails" roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails">
        <link:definition>0000031 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails">
        <link:definition>0000032 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>0000033 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccountsPayableDetails" roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails">
        <link:definition>0000034 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccruedExpensesDetails" roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails">
        <link:definition>0000035 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails" roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails">
        <link:definition>0000036 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>0000037 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails" roleURI="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails">
        <link:definition>0000038 - Disclosure - Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails_1" roleURI="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails_1">
        <link:definition>0000038 - Disclosure - Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000039 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueAdditionalInformationDetail" roleURI="http://imux.com/role/FairValueAdditionalInformationDetail">
        <link:definition>0000040 - Disclosure - Fair Value - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockShelfRegistrationStatementDetails" roleURI="http://imux.com/role/CommonStockShelfRegistrationStatementDetails">
        <link:definition>0000041 - Disclosure - Common Stock - Shelf Registration Statement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityOfferingDetails" roleURI="http://imux.com/role/CommonStockEquityOfferingDetails">
        <link:definition>0000042 - Disclosure - Common Stock - Equity Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockCommonStockDetails" roleURI="http://imux.com/role/CommonStockCommonStockDetails">
        <link:definition>0000043 - Disclosure - Common Stock - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockPreferredStockDetails" roleURI="http://imux.com/role/CommonStockPreferredStockDetails">
        <link:definition>0000044 - Disclosure - Common Stock - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockSharesReservedforFutureIssuanceDetails" roleURI="http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails">
        <link:definition>0000045 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationPlansAdditionalInformationDetails" roleURI="http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails">
        <link:definition>0000046 - Disclosure - Stock-based Compensation Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationPlansSummaryofStockOptionActivityDetails" roleURI="http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails">
        <link:definition>0000047 - Disclosure - Stock-based Compensation Plans - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails" roleURI="http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails">
        <link:definition>0000048 - Disclosure - Stock-based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" roleURI="http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails">
        <link:definition>0000049 - Disclosure - Stock-based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" roleURI="http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails">
        <link:definition>0000050 - Disclosure - Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxRateReconciliationDetails" roleURI="http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails">
        <link:definition>0000051 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://imux.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>0000052 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000053 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>0000054 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="imux_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_ClinicalCostsPayableCurrent" abstract="false" name="ClinicalCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_AccruedClinicalCostsCurrent" abstract="false" name="AccruedClinicalCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" abstract="false" name="EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="imux_SaleOfStockRemainingCapacity" abstract="false" name="SaleOfStockRemainingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_EmployeeStockOptionsforFutureGrantMember" abstract="true" name="EmployeeStockOptionsforFutureGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_AccruedLegalAndAuditCostsCurrent" abstract="false" name="AccruedLegalAndAuditCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_OperatingAndVariableLeasesCost" abstract="false" name="OperatingAndVariableLeasesCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_SharesIssuedWeightedAverageSharePricePerShare" abstract="false" name="SharesIssuedWeightedAverageSharePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="imux_ShelfRegistrationTerminationPriorWrittenNotice" abstract="false" name="ShelfRegistrationTerminationPriorWrittenNotice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="imux_NonStatutoryEmployeeStockOptionMember" abstract="true" name="NonStatutoryEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_RoyaltySettlementAgreementCashPaymentPercent" abstract="false" name="RoyaltySettlementAgreementCashPaymentPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="imux_DuaneNashMDJDMBAMember" abstract="true" name="DuaneNashMDJDMBAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_DeferredTaxAssetsAndLiabilitiesGross" abstract="false" name="DeferredTaxAssetsAndLiabilitiesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" abstract="false" name="AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="imux_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="imux_TwoThousandFourteenEquityIncentivePlanMember" abstract="true" name="TwoThousandFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" abstract="false" name="EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="imux_GrafelfingGermanyMember" abstract="true" name="GrafelfingGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" abstract="false" name="CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="imux_A2019OmnibusEquityIncentivePlanMember" abstract="true" name="A2019OmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_LegalAndAuditCostsPayableCurrent" abstract="false" name="LegalAndAuditCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="imux_AccruedCompensationCurrent" abstract="false" name="AccruedCompensationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_NumberOfDevelopmentPrograms" abstract="false" name="NumberOfDevelopmentPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="imux_IncentiveEmployeeStockOptionMember" abstract="true" name="IncentiveEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_ForeignExcludingGermanyMember" abstract="true" name="ForeignExcludingGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_NumberOfFinancialInstitutionsUsedForCashDeposits" abstract="false" name="NumberOfFinancialInstitutionsUsedForCashDeposits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" abstract="false" name="MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_InvestmentEarningInterestRateRemainingMaturityPeriod" abstract="false" name="InvestmentEarningInterestRateRemainingMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" abstract="false" name="EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_A2021EmployeeStockPurchasePlanMember" abstract="true" name="A2021EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_May2022ATMMember" abstract="true" name="May2022ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_ImmunicAGMember" abstract="true" name="ImmunicAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_December2020ATMMember" abstract="true" name="December2020ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_ShelfRegistrationStatementAmountRemaining" abstract="false" name="ShelfRegistrationStatementAmountRemaining" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="imux_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_A4SCRoyaltySettlementMember" abstract="true" name="A4SCRoyaltySettlementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_TaxYearsPost2017Member" abstract="true" name="TaxYearsPost2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_TaxYearsPriorTo2018Member" abstract="true" name="TaxYearsPriorTo2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_RoyaltySettlementAgreementSalesNet" abstract="false" name="RoyaltySettlementAgreementSalesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_AtTheMarketSalesAgreementMember" abstract="true" name="AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" abstract="false" name="ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="imux_OperatingLeaseIncrementalBorrowingRate" abstract="false" name="OperatingLeaseIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_LesseeOperatingLeasesNumberOfExistingLeases" abstract="false" name="LesseeOperatingLeasesNumberOfExistingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="imux_RoyaltySettlementAgreementSharesPaymentPercent" abstract="false" name="RoyaltySettlementAgreementSharesPaymentPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="imux_LesseeOperatingLeaseRentHolidayPeriod" abstract="false" name="LesseeOperatingLeaseRentHolidayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="imux_NewYorkCityMember" abstract="true" name="NewYorkCityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_ResearchAndDevelopmentTaxIncentiveCurrent" abstract="false" name="ResearchAndDevelopmentTaxIncentiveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_ExecutiveChairmanAgreementMember" abstract="true" name="ExecutiveChairmanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_PrepaidClinicalAndRelatedCostsCurrent" abstract="false" name="PrepaidClinicalAndRelatedCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_October2022PIPETransactionMember" abstract="true" name="October2022PIPETransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_SalaryCostsMonthlyBaseSalary" abstract="false" name="SalaryCostsMonthlyBaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_July2021PublicEquityOfferingMember" abstract="true" name="July2021PublicEquityOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_AustraliaAndGermanyMember" abstract="true" name="AustraliaAndGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="imux_GovernmentAssistanceRate" abstract="false" name="GovernmentAssistanceRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="imux_A2017InducementEquityIncentivePlanMember" abstract="true" name="A2017InducementEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>imux-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:19abff6b-9d36-40e5-80a6-5fea77828601,g:313a8e66-68ba-4247-b883-d20269f0dca0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://imux.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_57b2318a-7260-42ed-aed5-2914bd0eb512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f87e4ba6-92fb-4f85-ab38-e2319749c6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_57b2318a-7260-42ed-aed5-2914bd0eb512" xlink:to="loc_us-gaap_AssetsCurrent_f87e4ba6-92fb-4f85-ab38-e2319749c6e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b1c43b21-99a5-412f-b6e6-c3468af06926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_57b2318a-7260-42ed-aed5-2914bd0eb512" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b1c43b21-99a5-412f-b6e6-c3468af06926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_afa18990-bfe3-49d8-8605-25c0217752f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_57b2318a-7260-42ed-aed5-2914bd0eb512" xlink:to="loc_us-gaap_Goodwill_afa18990-bfe3-49d8-8605-25c0217752f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bb2ba795-d233-4ea3-9107-7f982d143575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_57b2318a-7260-42ed-aed5-2914bd0eb512" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bb2ba795-d233-4ea3-9107-7f982d143575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_27654cff-7d0b-4ea2-897f-93c199190c28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_57b2318a-7260-42ed-aed5-2914bd0eb512" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_27654cff-7d0b-4ea2-897f-93c199190c28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b03366a0-644b-429c-8895-c19f43e9498f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_63f73d68-3134-47fa-be44-440bd322c011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b03366a0-644b-429c-8895-c19f43e9498f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_63f73d68-3134-47fa-be44-440bd322c011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d05f546-9c9b-4e4d-ad8b-2517fb35bae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b03366a0-644b-429c-8895-c19f43e9498f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d05f546-9c9b-4e4d-ad8b-2517fb35bae5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_1b6d927c-2912-4848-b25d-5eb6ff1119ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b03366a0-644b-429c-8895-c19f43e9498f" xlink:to="loc_us-gaap_OtherShortTermInvestments_1b6d927c-2912-4848-b25d-5eb6ff1119ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6667307e-8464-484e-8a22-f7bbd9199f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e2bbf718-5114-469b-82f3-7a413cd1a98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6667307e-8464-484e-8a22-f7bbd9199f50" xlink:to="loc_us-gaap_PreferredStockValue_e2bbf718-5114-469b-82f3-7a413cd1a98c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6d2d1a30-7065-4062-9856-3aec10b6a6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6667307e-8464-484e-8a22-f7bbd9199f50" xlink:to="loc_us-gaap_CommonStockValue_6d2d1a30-7065-4062-9856-3aec10b6a6cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_52ffea86-3129-473a-864b-87e9e84764b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6667307e-8464-484e-8a22-f7bbd9199f50" xlink:to="loc_us-gaap_AdditionalPaidInCapital_52ffea86-3129-473a-864b-87e9e84764b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_95599eca-e963-49d4-93be-9169db146ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6667307e-8464-484e-8a22-f7bbd9199f50" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_95599eca-e963-49d4-93be-9169db146ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a0304a1d-4748-4df2-9d42-3100a3ba1caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6667307e-8464-484e-8a22-f7bbd9199f50" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a0304a1d-4748-4df2-9d42-3100a3ba1caa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_6fdfde39-03d2-4bea-8f2b-ae915d9b467b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c6109d90-d2e1-48ef-848f-3db42dc8ad42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_6fdfde39-03d2-4bea-8f2b-ae915d9b467b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c6109d90-d2e1-48ef-848f-3db42dc8ad42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a1b45df8-67ab-482c-8029-7b348f11d60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_11b5eda5-dbff-4e82-9b37-7c91921497e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a1b45df8-67ab-482c-8029-7b348f11d60d" xlink:to="loc_us-gaap_LiabilitiesCurrent_11b5eda5-dbff-4e82-9b37-7c91921497e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_aeb2335e-5540-4837-b884-ab9c703e874b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a1b45df8-67ab-482c-8029-7b348f11d60d" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_aeb2335e-5540-4837-b884-ab9c703e874b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9ae61a9-b19c-46ed-a58b-72cdb27fcd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4831c85e-3b6e-4759-a074-1a354df28d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9ae61a9-b19c-46ed-a58b-72cdb27fcd61" xlink:to="loc_us-gaap_LiabilitiesCurrent_4831c85e-3b6e-4759-a074-1a354df28d7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_00a2f990-f808-4540-b40c-5227334ec3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9ae61a9-b19c-46ed-a58b-72cdb27fcd61" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_00a2f990-f808-4540-b40c-5227334ec3d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_83aea7fd-c858-47b5-911e-c2e54fdd30ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9ae61a9-b19c-46ed-a58b-72cdb27fcd61" xlink:to="loc_us-gaap_StockholdersEquity_83aea7fd-c858-47b5-911e-c2e54fdd30ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_04932a40-19e8-4765-b436-5750c7a4dfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9ae61a9-b19c-46ed-a58b-72cdb27fcd61" xlink:to="loc_us-gaap_CommitmentsAndContingencies_04932a40-19e8-4765-b436-5750c7a4dfb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_16a93ae6-ea09-4e01-be1e-2b87b30e86c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_08960a74-5787-4588-b287-a74c242dbf87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16a93ae6-ea09-4e01-be1e-2b87b30e86c7" xlink:to="loc_us-gaap_AccountsPayableCurrent_08960a74-5787-4588-b287-a74c242dbf87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_46b5064f-f1d5-4451-9301-ad1ce407e539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16a93ae6-ea09-4e01-be1e-2b87b30e86c7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_46b5064f-f1d5-4451-9301-ad1ce407e539" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_17aabe4b-9a57-466e-bb2e-6efa2c6f96c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16a93ae6-ea09-4e01-be1e-2b87b30e86c7" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_17aabe4b-9a57-466e-bb2e-6efa2c6f96c9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ca11df5a-2f3c-4e49-b81d-8d0d90722535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6155ba74-a957-4d56-85df-923d33af7876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ca11df5a-2f3c-4e49-b81d-8d0d90722535" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6155ba74-a957-4d56-85df-923d33af7876" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_11abac9f-9a22-462f-9b8f-76172493fd18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ca11df5a-2f3c-4e49-b81d-8d0d90722535" xlink:to="loc_us-gaap_InvestmentIncomeInterest_11abac9f-9a22-462f-9b8f-76172493fd18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f9995bc0-a55a-46f6-85f5-e5a04618b795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9c26643f-8833-46c6-a41c-fe092df4278d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f9995bc0-a55a-46f6-85f5-e5a04618b795" xlink:to="loc_us-gaap_OperatingIncomeLoss_9c26643f-8833-46c6-a41c-fe092df4278d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2b9389b2-cf8f-477a-8544-a205fdc278ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f9995bc0-a55a-46f6-85f5-e5a04618b795" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2b9389b2-cf8f-477a-8544-a205fdc278ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8908b3ea-7787-47cb-9119-aa7b70c412ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3a58e20f-184b-4df5-afca-1b2b7a687ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8908b3ea-7787-47cb-9119-aa7b70c412ed" xlink:to="loc_us-gaap_OperatingExpenses_3a58e20f-184b-4df5-afca-1b2b7a687ab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5ffccd1d-bdef-466a-8402-85cc361c647a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_854e9040-4d9f-4ef9-9c91-8b884d461214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5ffccd1d-bdef-466a-8402-85cc361c647a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_854e9040-4d9f-4ef9-9c91-8b884d461214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3c102d10-5f83-462f-9ae9-f8a31a4b4818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5ffccd1d-bdef-466a-8402-85cc361c647a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3c102d10-5f83-462f-9ae9-f8a31a4b4818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_64a644da-7910-4808-9cc5-7ade2a4531f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5ffccd1d-bdef-466a-8402-85cc361c647a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_64a644da-7910-4808-9cc5-7ade2a4531f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_RoyaltySettlementAgreementSalesNet_de844414-a8d8-49bd-a406-6cb898389861" xlink:href="imux-20221231.xsd#imux_RoyaltySettlementAgreementSalesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5ffccd1d-bdef-466a-8402-85cc361c647a" xlink:to="loc_imux_RoyaltySettlementAgreementSalesNet_de844414-a8d8-49bd-a406-6cb898389861" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_51abd128-6315-4b83-b682-07ef980d5ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_85941395-a5de-44a3-aaa3-a391c8c973f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_51abd128-6315-4b83-b682-07ef980d5ed6" xlink:to="loc_us-gaap_NetIncomeLoss_85941395-a5de-44a3-aaa3-a391c8c973f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_24c660b1-02cb-44f4-98df-8024c5da61bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_51abd128-6315-4b83-b682-07ef980d5ed6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_24c660b1-02cb-44f4-98df-8024c5da61bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62c98dc9-e703-4e95-aed6-6deb068e352d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0afd2c80-96a2-40cf-b7e3-637092cdff94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62c98dc9-e703-4e95-aed6-6deb068e352d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0afd2c80-96a2-40cf-b7e3-637092cdff94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e943fac4-bc60-4006-8397-a6a57bc7400f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62c98dc9-e703-4e95-aed6-6deb068e352d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e943fac4-bc60-4006-8397-a6a57bc7400f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_85b7a5ba-2e88-43fb-8c2d-61921a040f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62c98dc9-e703-4e95-aed6-6deb068e352d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_85b7a5ba-2e88-43fb-8c2d-61921a040f2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2aed9571-fcc0-4b1e-b96f-d3a6a1e25e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62c98dc9-e703-4e95-aed6-6deb068e352d" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2aed9571-fcc0-4b1e-b96f-d3a6a1e25e00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8009d703-7d92-48ad-9655-e995348699de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62c98dc9-e703-4e95-aed6-6deb068e352d" xlink:to="loc_us-gaap_ShareBasedCompensation_8009d703-7d92-48ad-9655-e995348699de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_21389895-12f1-4e4f-8eb5-499d055aa73e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62c98dc9-e703-4e95-aed6-6deb068e352d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_21389895-12f1-4e4f-8eb5-499d055aa73e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_68bac674-fbda-48a5-af20-20e8ff85b913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62c98dc9-e703-4e95-aed6-6deb068e352d" xlink:to="loc_us-gaap_NetIncomeLoss_68bac674-fbda-48a5-af20-20e8ff85b913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_639ab639-b714-44ad-bd28-bf13855a0872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62c98dc9-e703-4e95-aed6-6deb068e352d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_639ab639-b714-44ad-bd28-bf13855a0872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9fc032d2-d06a-4da3-b4c1-7c111b012e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62c98dc9-e703-4e95-aed6-6deb068e352d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9fc032d2-d06a-4da3-b4c1-7c111b012e5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_af563f93-0971-452b-bb15-b883a973de68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62c98dc9-e703-4e95-aed6-6deb068e352d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_af563f93-0971-452b-bb15-b883a973de68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c2c4c143-b211-4dba-b366-38021d884448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_368880ac-1999-4697-ba52-245ac42f99de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c2c4c143-b211-4dba-b366-38021d884448" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_368880ac-1999-4697-ba52-245ac42f99de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5163db9f-e037-47d4-bec2-6c2ac1fbee6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c2c4c143-b211-4dba-b366-38021d884448" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5163db9f-e037-47d4-bec2-6c2ac1fbee6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_625ed58e-76c5-4e55-8a2c-3491e091e581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c2c4c143-b211-4dba-b366-38021d884448" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_625ed58e-76c5-4e55-8a2c-3491e091e581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e4141d12-016d-4ae9-af1b-b51ee04b4648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c2c4c143-b211-4dba-b366-38021d884448" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e4141d12-016d-4ae9-af1b-b51ee04b4648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d86b8ba-520b-429c-a687-943ed1e5c6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5c1c68a7-cf8a-4655-a0a7-541dae334ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d86b8ba-520b-429c-a687-943ed1e5c6d2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5c1c68a7-cf8a-4655-a0a7-541dae334ac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f262be24-3346-47f3-b1a6-e65f8e37f474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d86b8ba-520b-429c-a687-943ed1e5c6d2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f262be24-3346-47f3-b1a6-e65f8e37f474" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_55e54d8a-cc79-4826-87ec-b22f6eeea3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d86b8ba-520b-429c-a687-943ed1e5c6d2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_55e54d8a-cc79-4826-87ec-b22f6eeea3bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a50af42e-2aee-4787-8d30-ab93d492bf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_009dead2-6f64-4475-92fc-7ace6f7ab25d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a50af42e-2aee-4787-8d30-ab93d492bf3b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_009dead2-6f64-4475-92fc-7ace6f7ab25d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_6f223249-7b1b-479c-83b2-77395e9be1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a50af42e-2aee-4787-8d30-ab93d492bf3b" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_6f223249-7b1b-479c-83b2-77395e9be1bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8b5b3210-c6a8-42a2-969d-224480ea3ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PrepaidClinicalAndRelatedCostsCurrent_a4ea3a7e-10b8-43fc-8977-6a0a8c217573" xlink:href="imux-20221231.xsd#imux_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8b5b3210-c6a8-42a2-969d-224480ea3ad4" xlink:to="loc_imux_PrepaidClinicalAndRelatedCostsCurrent_a4ea3a7e-10b8-43fc-8977-6a0a8c217573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ResearchAndDevelopmentTaxIncentiveCurrent_35687ac8-f914-4d1b-8e63-92f84b6ac63e" xlink:href="imux-20221231.xsd#imux_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8b5b3210-c6a8-42a2-969d-224480ea3ad4" xlink:to="loc_imux_ResearchAndDevelopmentTaxIncentiveCurrent_35687ac8-f914-4d1b-8e63-92f84b6ac63e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_73b2026e-e965-4706-8110-6fa397194c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8b5b3210-c6a8-42a2-969d-224480ea3ad4" xlink:to="loc_us-gaap_OtherAssetsCurrent_73b2026e-e965-4706-8110-6fa397194c57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_8d22639f-9d14-449f-baa4-5573ec07bdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8b5b3210-c6a8-42a2-969d-224480ea3ad4" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_8d22639f-9d14-449f-baa4-5573ec07bdfe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetails"/>
  <link:calculationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_699a6cd3-3de0-4153-b354-acd4e0b3d963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ClinicalCostsPayableCurrent_9454c34f-332e-44c2-b0d6-3e71a7798c64" xlink:href="imux-20221231.xsd#imux_ClinicalCostsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_699a6cd3-3de0-4153-b354-acd4e0b3d963" xlink:to="loc_imux_ClinicalCostsPayableCurrent_9454c34f-332e-44c2-b0d6-3e71a7798c64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LegalAndAuditCostsPayableCurrent_ceba5022-d20f-4774-b28d-139e1e824d49" xlink:href="imux-20221231.xsd#imux_LegalAndAuditCostsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_699a6cd3-3de0-4153-b354-acd4e0b3d963" xlink:to="loc_imux_LegalAndAuditCostsPayableCurrent_ceba5022-d20f-4774-b28d-139e1e824d49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_341a124d-101c-409e-bb52-8faa6e68c6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_699a6cd3-3de0-4153-b354-acd4e0b3d963" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_341a124d-101c-409e-bb52-8faa6e68c6c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_85f5732b-ddb6-48be-8b44-50581bc225d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1b42cd16-f7a5-43eb-a0d1-0225895e77dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_85f5732b-ddb6-48be-8b44-50581bc225d5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1b42cd16-f7a5-43eb-a0d1-0225895e77dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedClinicalCostsCurrent_c4ceadb9-1bca-4aa0-ac56-88872ad7c9f8" xlink:href="imux-20221231.xsd#imux_AccruedClinicalCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_85f5732b-ddb6-48be-8b44-50581bc225d5" xlink:to="loc_imux_AccruedClinicalCostsCurrent_c4ceadb9-1bca-4aa0-ac56-88872ad7c9f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedLegalAndAuditCostsCurrent_2be42156-e01b-429e-8506-a55317d2c476" xlink:href="imux-20221231.xsd#imux_AccruedLegalAndAuditCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_85f5732b-ddb6-48be-8b44-50581bc225d5" xlink:to="loc_imux_AccruedLegalAndAuditCostsCurrent_2be42156-e01b-429e-8506-a55317d2c476" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedCompensationCurrent_9005e345-fd69-47fd-b9c6-240d53317122" xlink:href="imux-20221231.xsd#imux_AccruedCompensationCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_85f5732b-ddb6-48be-8b44-50581bc225d5" xlink:to="loc_imux_AccruedCompensationCurrent_9005e345-fd69-47fd-b9c6-240d53317122" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1a8f2afc-e9d0-4fe7-9d0d-84e058511a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_cc56cc1c-7af4-481c-bd41-ad2c18732ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_1a8f2afc-e9d0-4fe7-9d0d-84e058511a2c" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_cc56cc1c-7af4-481c-bd41-ad2c18732ea7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e43caddc-8936-4df0-8c84-c84302eb6bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_1a8f2afc-e9d0-4fe7-9d0d-84e058511a2c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e43caddc-8936-4df0-8c84-c84302eb6bc4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_323f53ec-ff1e-4d01-ac80-23e05582c8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_32b06b2a-dfd0-43bf-8cc6-0f7293f32081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_323f53ec-ff1e-4d01-ac80-23e05582c8d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_32b06b2a-dfd0-43bf-8cc6-0f7293f32081" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c298a1f4-a7f4-4ad3-b0f0-eb2f58bfdc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_323f53ec-ff1e-4d01-ac80-23e05582c8d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c298a1f4-a7f4-4ad3-b0f0-eb2f58bfdc7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6b54e974-ed89-4211-9253-05835b66cf97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_323f53ec-ff1e-4d01-ac80-23e05582c8d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6b54e974-ed89-4211-9253-05835b66cf97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_25333a34-1c22-4862-a8e5-dfd434850b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_323f53ec-ff1e-4d01-ac80-23e05582c8d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_25333a34-1c22-4862-a8e5-dfd434850b6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a42cf958-19ee-4e85-9611-e48deb814d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_323f53ec-ff1e-4d01-ac80-23e05582c8d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a42cf958-19ee-4e85-9611-e48deb814d02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d14a334a-e79c-4031-954f-984e7542cfa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_323f53ec-ff1e-4d01-ac80-23e05582c8d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d14a334a-e79c-4031-954f-984e7542cfa7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="imux-20221231.xsd#CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b8c405f-f15a-46b5-8b62-55d057e5c200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6851f545-dbfb-40a7-b7ea-74ca3337af99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b8c405f-f15a-46b5-8b62-55d057e5c200" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6851f545-dbfb-40a7-b7ea-74ca3337af99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6e165984-57ec-4f5f-87e7-0bc61400cb04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b8c405f-f15a-46b5-8b62-55d057e5c200" xlink:to="loc_us-gaap_OperatingLeaseLiability_6e165984-57ec-4f5f-87e7-0bc61400cb04" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#IncomeTaxesIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ab91e158-a114-4bcc-ad49-5ede3f4ecf65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0205719a-60b9-44b5-a558-48c326726841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ab91e158-a114-4bcc-ad49-5ede3f4ecf65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0205719a-60b9-44b5-a558-48c326726841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_83d9be13-593d-46d8-a1c2-523cc13e712e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ab91e158-a114-4bcc-ad49-5ede3f4ecf65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_83d9be13-593d-46d8-a1c2-523cc13e712e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1dc7b2b5-de7b-4c76-bdfe-8ccc0aca66f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ab91e158-a114-4bcc-ad49-5ede3f4ecf65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1dc7b2b5-de7b-4c76-bdfe-8ccc0aca66f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2c1ebb3c-5801-4484-9895-e31e4ded67b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ab91e158-a114-4bcc-ad49-5ede3f4ecf65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2c1ebb3c-5801-4484-9895-e31e4ded67b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_6d1da9e8-836a-4d10-8145-bd26b8e050ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ab91e158-a114-4bcc-ad49-5ede3f4ecf65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_6d1da9e8-836a-4d10-8145-bd26b8e050ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_5582cc8c-4a0c-4026-9fd0-c9ffab770dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ab91e158-a114-4bcc-ad49-5ede3f4ecf65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_5582cc8c-4a0c-4026-9fd0-c9ffab770dda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1b143fb4-2b04-402a-8e8e-bb2710225568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ab91e158-a114-4bcc-ad49-5ede3f4ecf65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1b143fb4-2b04-402a-8e8e-bb2710225568" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_imux_DeferredTaxAssetsAndLiabilitiesGross_c4991245-2eaa-4f3a-9b37-c4867e80deb4" xlink:href="imux-20221231.xsd#imux_DeferredTaxAssetsAndLiabilitiesGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_9f6acd37-92cf-4481-8b22-effa23f69133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_imux_DeferredTaxAssetsAndLiabilitiesGross_c4991245-2eaa-4f3a-9b37-c4867e80deb4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_9f6acd37-92cf-4481-8b22-effa23f69133" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_93b86be8-ee21-4c49-a28c-dedd42c0ba0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_imux_DeferredTaxAssetsAndLiabilitiesGross_c4991245-2eaa-4f3a-9b37-c4867e80deb4" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_93b86be8-ee21-4c49-a28c-dedd42c0ba0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_88dc66aa-b8cc-45ec-b01b-c7179bf5435a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cadbd032-c98c-4c4e-acfa-d1c190d5d046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_88dc66aa-b8cc-45ec-b01b-c7179bf5435a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cadbd032-c98c-4c4e-acfa-d1c190d5d046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_16a088e0-9048-4ed6-889f-8b5849bcdc38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f86569c2-b021-4352-b3c4-7883fbe3a3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_16a088e0-9048-4ed6-889f-8b5849bcdc38" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f86569c2-b021-4352-b3c4-7883fbe3a3ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_511a5403-83fa-4c1a-8ee8-1eb2c543cf07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_16a088e0-9048-4ed6-889f-8b5849bcdc38" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_511a5403-83fa-4c1a-8ee8-1eb2c543cf07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_df913bd6-afc5-46e2-a758-0c1f8f8910c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_16a088e0-9048-4ed6-889f-8b5849bcdc38" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_df913bd6-afc5-46e2-a758-0c1f8f8910c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_f0ebfdac-c131-4a9a-846e-fdd531f99b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_16a088e0-9048-4ed6-889f-8b5849bcdc38" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_f0ebfdac-c131-4a9a-846e-fdd531f99b06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_aab16da3-3f95-45f7-80d1-a42575a34cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_16a088e0-9048-4ed6-889f-8b5849bcdc38" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_aab16da3-3f95-45f7-80d1-a42575a34cf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_9a9bab56-81dc-410b-9b55-ba714e874439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_16a088e0-9048-4ed6-889f-8b5849bcdc38" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_9a9bab56-81dc-410b-9b55-ba714e874439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6e5e0c4b-55a8-4b21-8702-d61638739df4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a320b73c-75b9-4ff6-9675-5fc0783cd967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6e5e0c4b-55a8-4b21-8702-d61638739df4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a320b73c-75b9-4ff6-9675-5fc0783cd967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DeferredTaxAssetsAndLiabilitiesGross_d2c48047-fdfb-4d75-b5db-519531173379" xlink:href="imux-20221231.xsd#imux_DeferredTaxAssetsAndLiabilitiesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6e5e0c4b-55a8-4b21-8702-d61638739df4" xlink:to="loc_imux_DeferredTaxAssetsAndLiabilitiesGross_d2c48047-fdfb-4d75-b5db-519531173379" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>imux-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:19abff6b-9d36-40e5-80a6-5fea77828601,g:313a8e66-68ba-4247-b883-d20269f0dca0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i0297236b1e0c47f1a9f55654d944c78a_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7a7d6170-6b38-4738-9b29-6de4496ae909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7a7d6170-6b38-4738-9b29-6de4496ae909" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c6482f23-6680-4722-baec-9ee237a1a2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c6482f23-6680-4722-baec-9ee237a1a2a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fa89bf65-e161-4ad6-aaac-efd6eafe91b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_StockholdersEquity_fa89bf65-e161-4ad6-aaac-efd6eafe91b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_740679ad-8709-4671-8f3e-41721379680e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_NetIncomeLoss_740679ad-8709-4671-8f3e-41721379680e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a53aafda-9924-4a13-afd2-315967f5ee79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a53aafda-9924-4a13-afd2-315967f5ee79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01b39173-3e70-4963-bed5-95a9a2092434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01b39173-3e70-4963-bed5-95a9a2092434" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb573cff-fed1-4c4a-975c-5570054e451e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb573cff-fed1-4c4a-975c-5570054e451e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f4d2967b-7698-47c9-a1f8-94ee4ecd2348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f4d2967b-7698-47c9-a1f8-94ee4ecd2348" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1678e985-d61f-44e4-95e9-9dcf5b6e4a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1678e985-d61f-44e4-95e9-9dcf5b6e4a70" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_af2225b7-8160-4c7b-a24f-174b17e01472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_af2225b7-8160-4c7b-a24f-174b17e01472" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0397856c-e356-4aaf-b1f6-e1f26e275f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_05878e4b-0c9f-400d-b76a-55cafa29feed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3e67b270-b41f-40f0-8e30-4fd74f30749d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7a7d6170-6b38-4738-9b29-6de4496ae909" xlink:to="loc_us-gaap_StatementTable_3e67b270-b41f-40f0-8e30-4fd74f30749d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_accb73f3-e7e4-423c-9ae7-d2617fad506f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3e67b270-b41f-40f0-8e30-4fd74f30749d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_accb73f3-e7e4-423c-9ae7-d2617fad506f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_accb73f3-e7e4-423c-9ae7-d2617fad506f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_accb73f3-e7e4-423c-9ae7-d2617fad506f" xlink:to="loc_us-gaap_EquityComponentDomain_accb73f3-e7e4-423c-9ae7-d2617fad506f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_852a7322-cacc-4f42-b88f-121fd75ea179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_accb73f3-e7e4-423c-9ae7-d2617fad506f" xlink:to="loc_us-gaap_EquityComponentDomain_852a7322-cacc-4f42-b88f-121fd75ea179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f90938dd-6d9d-4c67-809a-a3b5dda21871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_852a7322-cacc-4f42-b88f-121fd75ea179" xlink:to="loc_us-gaap_CommonStockMember_f90938dd-6d9d-4c67-809a-a3b5dda21871" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_14da6bfc-08b6-430b-a3fd-85fabda28aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_852a7322-cacc-4f42-b88f-121fd75ea179" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_14da6bfc-08b6-430b-a3fd-85fabda28aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb31e183-7109-413c-ab2d-168c107976f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_852a7322-cacc-4f42-b88f-121fd75ea179" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb31e183-7109-413c-ab2d-168c107976f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_02a17397-4c18-462f-bb86-6b8efcae8940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_852a7322-cacc-4f42-b88f-121fd75ea179" xlink:to="loc_us-gaap_RetainedEarningsMember_02a17397-4c18-462f-bb86-6b8efcae8940" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_18e57377-c454-4f6c-975b-0585a28fa7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3e67b270-b41f-40f0-8e30-4fd74f30749d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_18e57377-c454-4f6c-975b-0585a28fa7a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_18e57377-c454-4f6c-975b-0585a28fa7a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18e57377-c454-4f6c-975b-0585a28fa7a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_18e57377-c454-4f6c-975b-0585a28fa7a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_031e491d-3d9e-4a65-b6c5-55bdfe69ff64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18e57377-c454-4f6c-975b-0585a28fa7a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_031e491d-3d9e-4a65-b6c5-55bdfe69ff64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_July2021PublicEquityOfferingMember_da8a2d45-c34e-4019-9cab-9e5faf200850" xlink:href="imux-20221231.xsd#imux_July2021PublicEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_031e491d-3d9e-4a65-b6c5-55bdfe69ff64" xlink:to="loc_imux_July2021PublicEquityOfferingMember_da8a2d45-c34e-4019-9cab-9e5faf200850" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AtTheMarketSalesAgreementMember_fcd5cce0-0ad9-48fb-8050-999031cd295a" xlink:href="imux-20221231.xsd#imux_AtTheMarketSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_031e491d-3d9e-4a65-b6c5-55bdfe69ff64" xlink:to="loc_imux_AtTheMarketSalesAgreementMember_fcd5cce0-0ad9-48fb-8050-999031cd295a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A4SCRoyaltySettlementMember_8dc12d7c-9a0e-4b95-b911-0bc652e4bf65" xlink:href="imux-20221231.xsd#imux_A4SCRoyaltySettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_031e491d-3d9e-4a65-b6c5-55bdfe69ff64" xlink:to="loc_imux_A4SCRoyaltySettlementMember_8dc12d7c-9a0e-4b95-b911-0bc652e4bf65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_October2022PIPETransactionMember_07ffd661-b495-49a3-839d-9b02063f7ade" xlink:href="imux-20221231.xsd#imux_October2022PIPETransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_031e491d-3d9e-4a65-b6c5-55bdfe69ff64" xlink:to="loc_imux_October2022PIPETransactionMember_07ffd661-b495-49a3-839d-9b02063f7ade" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="i2da65775afdc4343ac4fc6cd72c51284_ConsolidatedStatementsofStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3a2509ab-1b18-4bf3-92b1-4f61d912262e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1c416e64-e4c0-48db-ae64-ba0a2587a597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3a2509ab-1b18-4bf3-92b1-4f61d912262e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1c416e64-e4c0-48db-ae64-ba0a2587a597" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_52079223-c3cd-4e88-8753-3e30aeb14c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3a2509ab-1b18-4bf3-92b1-4f61d912262e" xlink:to="loc_us-gaap_StatementTable_52079223-c3cd-4e88-8753-3e30aeb14c3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_241f3468-7263-4a2e-977f-e64b65a645a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_52079223-c3cd-4e88-8753-3e30aeb14c3d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_241f3468-7263-4a2e-977f-e64b65a645a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_241f3468-7263-4a2e-977f-e64b65a645a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_241f3468-7263-4a2e-977f-e64b65a645a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_241f3468-7263-4a2e-977f-e64b65a645a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c4f62e6-d8c2-48ff-b785-4a995b4ad641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_241f3468-7263-4a2e-977f-e64b65a645a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c4f62e6-d8c2-48ff-b785-4a995b4ad641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_July2021PublicEquityOfferingMember_02139ce0-0779-4e22-87eb-c59a84a487f1" xlink:href="imux-20221231.xsd#imux_July2021PublicEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c4f62e6-d8c2-48ff-b785-4a995b4ad641" xlink:to="loc_imux_July2021PublicEquityOfferingMember_02139ce0-0779-4e22-87eb-c59a84a487f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AtTheMarketSalesAgreementMember_50fbc125-21ca-4001-a3b3-2f3eafe79816" xlink:href="imux-20221231.xsd#imux_AtTheMarketSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c4f62e6-d8c2-48ff-b785-4a995b4ad641" xlink:to="loc_imux_AtTheMarketSalesAgreementMember_50fbc125-21ca-4001-a3b3-2f3eafe79816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_October2022PIPETransactionMember_21cb0d10-566b-4a28-bd04-08f39d62723f" xlink:href="imux-20221231.xsd#imux_October2022PIPETransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c4f62e6-d8c2-48ff-b785-4a995b4ad641" xlink:to="loc_imux_October2022PIPETransactionMember_21cb0d10-566b-4a28-bd04-08f39d62723f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://imux.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="iee949ebf9dba4af6b7acbc613c1bfdda_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cf2474f6-5cbe-4184-8135-17062c62c28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cf2474f6-5cbe-4184-8135-17062c62c28e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9f716ad6-d9bc-4df5-821a-fa84a55d5b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cf2474f6-5cbe-4184-8135-17062c62c28e" xlink:to="loc_us-gaap_NetIncomeLoss_9f716ad6-d9bc-4df5-821a-fa84a55d5b09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cda6dccf-e129-4c6a-8fe3-40cc33deb79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cf2474f6-5cbe-4184-8135-17062c62c28e" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cda6dccf-e129-4c6a-8fe3-40cc33deb79f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fa29d1c1-def9-4c6e-a585-a432373178e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cda6dccf-e129-4c6a-8fe3-40cc33deb79f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fa29d1c1-def9-4c6e-a585-a432373178e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ebc58e42-58c9-44ac-8565-9d9cf2565be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cda6dccf-e129-4c6a-8fe3-40cc33deb79f" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ebc58e42-58c9-44ac-8565-9d9cf2565be7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5867fc1f-12da-4242-8fec-80ee2d32307c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cda6dccf-e129-4c6a-8fe3-40cc33deb79f" xlink:to="loc_us-gaap_ShareBasedCompensation_5867fc1f-12da-4242-8fec-80ee2d32307c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c0a3611e-f88d-4636-9634-53a8d8419287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cda6dccf-e129-4c6a-8fe3-40cc33deb79f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c0a3611e-f88d-4636-9634-53a8d8419287" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_e07208d7-3dc7-4396-a67b-353f792f16e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cda6dccf-e129-4c6a-8fe3-40cc33deb79f" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_e07208d7-3dc7-4396-a67b-353f792f16e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a5de515-a9f9-4ea9-88fa-1d363fc06ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cf2474f6-5cbe-4184-8135-17062c62c28e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a5de515-a9f9-4ea9-88fa-1d363fc06ee5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fc392aeb-e321-4d2f-a8b5-7b7ddbb06f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a5de515-a9f9-4ea9-88fa-1d363fc06ee5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fc392aeb-e321-4d2f-a8b5-7b7ddbb06f03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7be26c49-a62e-4412-adbe-b039f34d5e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a5de515-a9f9-4ea9-88fa-1d363fc06ee5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7be26c49-a62e-4412-adbe-b039f34d5e89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_10c8541c-3fbf-4774-ae8e-1a1fa2e7a5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a5de515-a9f9-4ea9-88fa-1d363fc06ee5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_10c8541c-3fbf-4774-ae8e-1a1fa2e7a5b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8d031b5f-000a-41ad-86ed-d977949749cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a5de515-a9f9-4ea9-88fa-1d363fc06ee5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8d031b5f-000a-41ad-86ed-d977949749cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_372255d3-53b0-44a7-9470-9e637f905aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cf2474f6-5cbe-4184-8135-17062c62c28e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_372255d3-53b0-44a7-9470-9e637f905aef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cdb8fc1-72bb-45f6-abb7-df949ea73c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cdb8fc1-72bb-45f6-abb7-df949ea73c20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_a3f94ff2-aef4-4481-a88d-6d55bf8eb019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cdb8fc1-72bb-45f6-abb7-df949ea73c20" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_a3f94ff2-aef4-4481-a88d-6d55bf8eb019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2e574c5b-5a18-4284-9794-13327afa84a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cdb8fc1-72bb-45f6-abb7-df949ea73c20" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2e574c5b-5a18-4284-9794-13327afa84a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d96f6849-b8ba-4c38-9a52-dfc4d1539ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cdb8fc1-72bb-45f6-abb7-df949ea73c20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d96f6849-b8ba-4c38-9a52-dfc4d1539ee2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6877ba70-0e7e-4d55-9ec9-0c763b8f2afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6877ba70-0e7e-4d55-9ec9-0c763b8f2afe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ff42936a-e818-48a8-a9e5-fd9144a1e5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6877ba70-0e7e-4d55-9ec9-0c763b8f2afe" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ff42936a-e818-48a8-a9e5-fd9144a1e5d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ec212e2a-bd72-48ba-b94e-0d5ea108e1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6877ba70-0e7e-4d55-9ec9-0c763b8f2afe" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ec212e2a-bd72-48ba-b94e-0d5ea108e1b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_f44cfafd-bd83-4f1c-80ec-aaaf9cda869e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6877ba70-0e7e-4d55-9ec9-0c763b8f2afe" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_f44cfafd-bd83-4f1c-80ec-aaaf9cda869e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb6447f4-07e8-4034-ad57-aa015c3bd8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6877ba70-0e7e-4d55-9ec9-0c763b8f2afe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb6447f4-07e8-4034-ad57-aa015c3bd8bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78732313-70cc-4ace-8a25-c69caf032739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78732313-70cc-4ace-8a25-c69caf032739" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5cd2049b-8234-47ae-ba7f-82c9f4cce7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5cd2049b-8234-47ae-ba7f-82c9f4cce7e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6ea5b59-7fa9-48be-a344-3c31a4c34ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6ea5b59-7fa9-48be-a344-3c31a4c34ce7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_564d1e0c-84ad-416c-a25d-1152fa573bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ba2df784-b509-4b1e-a087-47b6a0dbf499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ba2df784-b509-4b1e-a087-47b6a0dbf499" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_fbb8f2b2-b977-47a5-a1bf-93f6e7892542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ba2df784-b509-4b1e-a087-47b6a0dbf499" xlink:to="loc_us-gaap_StockIssued1_fbb8f2b2-b977-47a5-a1bf-93f6e7892542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b962b996-8978-4c41-b889-60492fb5e961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ba2df784-b509-4b1e-a087-47b6a0dbf499" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b962b996-8978-4c41-b889-60492fb5e961" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_eb9d6928-4268-42eb-8dfb-44dc95c4c3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_StatementTable_eb9d6928-4268-42eb-8dfb-44dc95c4c3fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7090c97f-0ea5-4962-b00f-6ebfe0ea16c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_eb9d6928-4268-42eb-8dfb-44dc95c4c3fe" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7090c97f-0ea5-4962-b00f-6ebfe0ea16c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7090c97f-0ea5-4962-b00f-6ebfe0ea16c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7090c97f-0ea5-4962-b00f-6ebfe0ea16c3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7090c97f-0ea5-4962-b00f-6ebfe0ea16c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef83ef9b-b2ce-4273-8eee-b466689d1124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7090c97f-0ea5-4962-b00f-6ebfe0ea16c3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef83ef9b-b2ce-4273-8eee-b466689d1124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PublicOfferingMember_3b1add34-2bfa-47fc-b33a-55207084ba7c" xlink:href="imux-20221231.xsd#imux_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef83ef9b-b2ce-4273-8eee-b466689d1124" xlink:to="loc_imux_PublicOfferingMember_3b1add34-2bfa-47fc-b33a-55207084ba7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_October2022PIPETransactionMember_dff57758-5a02-4171-afc1-4b2620770f65" xlink:href="imux-20221231.xsd#imux_October2022PIPETransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef83ef9b-b2ce-4273-8eee-b466689d1124" xlink:to="loc_imux_October2022PIPETransactionMember_dff57758-5a02-4171-afc1-4b2620770f65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_July2021PublicEquityOfferingMember_edb015a0-8af4-4917-8b4c-d8ae05eb02c0" xlink:href="imux-20221231.xsd#imux_July2021PublicEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef83ef9b-b2ce-4273-8eee-b466689d1124" xlink:to="loc_imux_July2021PublicEquityOfferingMember_edb015a0-8af4-4917-8b4c-d8ae05eb02c0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended" id="ib20b34babe1b49ffba308ce90d12060c_ConsolidatedStatementsofCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_371fafad-b5b5-4ae0-8bfd-296033242dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c7f43295-a74a-4b59-bcf5-8b3c8cc9ff67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_371fafad-b5b5-4ae0-8bfd-296033242dde" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c7f43295-a74a-4b59-bcf5-8b3c8cc9ff67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_efdf7a5b-1163-4bae-b781-2ee72514e394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_371fafad-b5b5-4ae0-8bfd-296033242dde" xlink:to="loc_us-gaap_StatementTable_efdf7a5b-1163-4bae-b781-2ee72514e394" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_02ca7fbc-7a39-4c5c-8d1e-6f3f74df06df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_efdf7a5b-1163-4bae-b781-2ee72514e394" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_02ca7fbc-7a39-4c5c-8d1e-6f3f74df06df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02ca7fbc-7a39-4c5c-8d1e-6f3f74df06df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_02ca7fbc-7a39-4c5c-8d1e-6f3f74df06df" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02ca7fbc-7a39-4c5c-8d1e-6f3f74df06df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73ea99d9-ee95-4019-a5e3-a08b83e14f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_02ca7fbc-7a39-4c5c-8d1e-6f3f74df06df" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73ea99d9-ee95-4019-a5e3-a08b83e14f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PublicOfferingMember_58d4f433-1c44-497f-9e3b-3703accd134c" xlink:href="imux-20221231.xsd#imux_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73ea99d9-ee95-4019-a5e3-a08b83e14f88" xlink:to="loc_imux_PublicOfferingMember_58d4f433-1c44-497f-9e3b-3703accd134c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_October2022PIPETransactionMember_93234c19-7ec2-46f2-8bc5-43e6fd0649e2" xlink:href="imux-20221231.xsd#imux_October2022PIPETransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73ea99d9-ee95-4019-a5e3-a08b83e14f88" xlink:to="loc_imux_October2022PIPETransactionMember_93234c19-7ec2-46f2-8bc5-43e6fd0649e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_July2021PublicEquityOfferingMember_1f3ec74d-f1e1-442b-b0f1-8f392b3a50b9" xlink:href="imux-20221231.xsd#imux_July2021PublicEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73ea99d9-ee95-4019-a5e3-a08b83e14f88" xlink:to="loc_imux_July2021PublicEquityOfferingMember_1f3ec74d-f1e1-442b-b0f1-8f392b3a50b9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i2ea6e2db4f824794b104eaf2a61b0659_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48e5cd13-5e5d-4e4f-bd9c-9166294413e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48e5cd13-5e5d-4e4f-bd9c-9166294413e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_NumberOfFinancialInstitutionsUsedForCashDeposits_dfee4dbe-d86e-43df-b2f4-a4811eb5d74c" xlink:href="imux-20221231.xsd#imux_NumberOfFinancialInstitutionsUsedForCashDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_imux_NumberOfFinancialInstitutionsUsedForCashDeposits_dfee4dbe-d86e-43df-b2f4-a4811eb5d74c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_fa5f9604-9026-4a8e-8bff-15aadd3a2fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_InvestmentInterestRate_fa5f9604-9026-4a8e-8bff-15aadd3a2fdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_InvestmentEarningInterestRateRemainingMaturityPeriod_b28d1066-28a0-46c7-8c98-9bef24bbff1f" xlink:href="imux-20221231.xsd#imux_InvestmentEarningInterestRateRemainingMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_imux_InvestmentEarningInterestRateRemainingMaturityPeriod_b28d1066-28a0-46c7-8c98-9bef24bbff1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1a457dbf-9b7a-4719-b431-9e452dcab2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1a457dbf-9b7a-4719-b431-9e452dcab2ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_2a7f6274-6e12-45eb-9c05-6b171b14fb61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_DepreciationAndAmortization_2a7f6274-6e12-45eb-9c05-6b171b14fb61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_4a3339e2-e3a0-4776-8e68-267a49e3c424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_4a3339e2-e3a0-4776-8e68-267a49e3c424" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ba5bbb38-fca4-4d2c-a2ae-55b3e4e82dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ba5bbb38-fca4-4d2c-a2ae-55b3e4e82dda" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_GovernmentAssistanceRate_4d6619d3-818f-447c-b230-b8852dbdef5a" xlink:href="imux-20221231.xsd#imux_GovernmentAssistanceRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_imux_GovernmentAssistanceRate_4d6619d3-818f-447c-b230-b8852dbdef5a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_114e1665-3dd2-47d0-9898-665236a48a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_114e1665-3dd2-47d0-9898-665236a48a73" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_43fe02ec-a755-44b1-8ab4-1f2e8ad8d394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_43fe02ec-a755-44b1-8ab4-1f2e8ad8d394" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6c264fe7-7efb-40ee-a04d-385ed1b6fc60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6c264fe7-7efb-40ee-a04d-385ed1b6fc60" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LesseeOperatingLeasesNumberOfExistingLeases_13923b10-966f-436d-8249-35a93ae79898" xlink:href="imux-20221231.xsd#imux_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_imux_LesseeOperatingLeasesNumberOfExistingLeases_13923b10-966f-436d-8249-35a93ae79898" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c54bdb-8ac5-4087-a457-92679b7dd12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c54bdb-8ac5-4087-a457-92679b7dd12c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_073931ac-2b8b-4d5f-b1cd-142f513af409" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c54bdb-8ac5-4087-a457-92679b7dd12c" xlink:to="loc_srt_StatementGeographicalAxis_073931ac-2b8b-4d5f-b1cd-142f513af409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_073931ac-2b8b-4d5f-b1cd-142f513af409_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_073931ac-2b8b-4d5f-b1cd-142f513af409" xlink:to="loc_srt_SegmentGeographicalDomain_073931ac-2b8b-4d5f-b1cd-142f513af409_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_674805d4-d8c3-4aae-8a9d-ec291a1f8c52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_073931ac-2b8b-4d5f-b1cd-142f513af409" xlink:to="loc_srt_SegmentGeographicalDomain_674805d4-d8c3-4aae-8a9d-ec291a1f8c52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b81665dd-f0d0-4b3c-91c6-5643b6fe857a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_674805d4-d8c3-4aae-8a9d-ec291a1f8c52" xlink:to="loc_country_US_b81665dd-f0d0-4b3c-91c6-5643b6fe857a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AustraliaAndGermanyMember_6cb71caa-c1ef-4904-8c53-ee027e2eb3cb" xlink:href="imux-20221231.xsd#imux_AustraliaAndGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_674805d4-d8c3-4aae-8a9d-ec291a1f8c52" xlink:to="loc_imux_AustraliaAndGermanyMember_6cb71caa-c1ef-4904-8c53-ee027e2eb3cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_f2cca15a-2c66-4d50-bf6a-6546140b0e70" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imux_AustraliaAndGermanyMember_6cb71caa-c1ef-4904-8c53-ee027e2eb3cb" xlink:to="loc_country_DE_f2cca15a-2c66-4d50-bf6a-6546140b0e70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_d9d1e435-9536-4edd-a5e9-1f1eeabb0a90" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imux_AustraliaAndGermanyMember_6cb71caa-c1ef-4904-8c53-ee027e2eb3cb" xlink:to="loc_country_AU_d9d1e435-9536-4edd-a5e9-1f1eeabb0a90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdfb6faf-6b83-4531-b310-243808de151a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c54bdb-8ac5-4087-a457-92679b7dd12c" xlink:to="loc_srt_RangeAxis_fdfb6faf-6b83-4531-b310-243808de151a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fdfb6faf-6b83-4531-b310-243808de151a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fdfb6faf-6b83-4531-b310-243808de151a" xlink:to="loc_srt_RangeMember_fdfb6faf-6b83-4531-b310-243808de151a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae40ad5e-e73a-4de1-a067-cae248eee54f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fdfb6faf-6b83-4531-b310-243808de151a" xlink:to="loc_srt_RangeMember_ae40ad5e-e73a-4de1-a067-cae248eee54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8cbb0d0e-d5c4-4f85-b1d7-0f656f637f69" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ae40ad5e-e73a-4de1-a067-cae248eee54f" xlink:to="loc_srt_MinimumMember_8cbb0d0e-d5c4-4f85-b1d7-0f656f637f69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9e6c9e35-a683-4290-bd3b-da623ed7e13b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ae40ad5e-e73a-4de1-a067-cae248eee54f" xlink:to="loc_srt_MaximumMember_9e6c9e35-a683-4290-bd3b-da623ed7e13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_e82e6045-a821-462d-aebd-61784d35b0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c54bdb-8ac5-4087-a457-92679b7dd12c" xlink:to="loc_us-gaap_InvestmentTypeAxis_e82e6045-a821-462d-aebd-61784d35b0e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e82e6045-a821-462d-aebd-61784d35b0e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_e82e6045-a821-462d-aebd-61784d35b0e0" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e82e6045-a821-462d-aebd-61784d35b0e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2a91cd79-4b43-4b22-8058-67122b740f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_e82e6045-a821-462d-aebd-61784d35b0e0" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2a91cd79-4b43-4b22-8058-67122b740f50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ec4c77f6-58f2-4b68-8479-563b7ecf15c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2a91cd79-4b43-4b22-8058-67122b740f50" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ec4c77f6-58f2-4b68-8479-563b7ecf15c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_2e25e769-b67d-4d56-b835-9d686926c9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2a91cd79-4b43-4b22-8058-67122b740f50" xlink:to="loc_us-gaap_BankTimeDepositsMember_2e25e769-b67d-4d56-b835-9d686926c9bf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#SummaryofSignificantAccountingPoliciesInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="extended" id="i930ceaa1d2e44b46b77ae680233d6985_SummaryofSignificantAccountingPoliciesInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_bf6e7621-9498-4d62-8054-15234a862f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_5a7b8507-772b-4390-a96d-df61498bc52a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_bf6e7621-9498-4d62-8054-15234a862f79" xlink:to="loc_us-gaap_OtherShortTermInvestments_5a7b8507-772b-4390-a96d-df61498bc52a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d30759e4-bafd-4a30-82ce-c70c2dbf42de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_bf6e7621-9498-4d62-8054-15234a862f79" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d30759e4-bafd-4a30-82ce-c70c2dbf42de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_03b56c4b-1c7f-4535-8a4b-61a702391347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d30759e4-bafd-4a30-82ce-c70c2dbf42de" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_03b56c4b-1c7f-4535-8a4b-61a702391347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_03b56c4b-1c7f-4535-8a4b-61a702391347_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_03b56c4b-1c7f-4535-8a4b-61a702391347" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_03b56c4b-1c7f-4535-8a4b-61a702391347_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8081d39d-8f97-4470-9143-1daf89a797f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_03b56c4b-1c7f-4535-8a4b-61a702391347" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8081d39d-8f97-4470-9143-1daf89a797f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_8d02097a-e6f4-4ef3-b83e-3297e42c3802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8081d39d-8f97-4470-9143-1daf89a797f5" xlink:to="loc_us-gaap_BankTimeDepositsMember_8d02097a-e6f4-4ef3-b83e-3297e42c3802" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended" id="i6d3ad11faa2646b59dde26bf48887d05_SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_904489ec-a4d9-423a-8274-5fe5ba359dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_828bd878-3d64-44d5-be77-21ca333d4641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_904489ec-a4d9-423a-8274-5fe5ba359dd1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_828bd878-3d64-44d5-be77-21ca333d4641" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51646de7-7375-4764-8d83-baa7fd8acb57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_904489ec-a4d9-423a-8274-5fe5ba359dd1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51646de7-7375-4764-8d83-baa7fd8acb57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02f6382b-f1ce-44a4-b757-140897d971da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51646de7-7375-4764-8d83-baa7fd8acb57" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02f6382b-f1ce-44a4-b757-140897d971da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02f6382b-f1ce-44a4-b757-140897d971da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02f6382b-f1ce-44a4-b757-140897d971da" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02f6382b-f1ce-44a4-b757-140897d971da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2615d3e8-8684-42bc-a8b1-7606d751780d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02f6382b-f1ce-44a4-b757-140897d971da" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2615d3e8-8684-42bc-a8b1-7606d751780d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_65d274be-7b35-4b81-9b52-4154dbb58704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2615d3e8-8684-42bc-a8b1-7606d751780d" xlink:to="loc_us-gaap_StockOptionMember_65d274be-7b35-4b81-9b52-4154dbb58704" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_28fbaf5b-c18d-4cc1-95a9-5a18fbd63144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2615d3e8-8684-42bc-a8b1-7606d751780d" xlink:to="loc_us-gaap_WarrantMember_28fbaf5b-c18d-4cc1-95a9-5a18fbd63144" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i05419bee3d1042cf9b81bb486ee40876_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e2476729-70f0-4ed9-9720-da5ddc1ae48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e2476729-70f0-4ed9-9720-da5ddc1ae48b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LesseeOperatingLeaseRentHolidayPeriod_014d540c-062d-493d-b40a-a2e258507d5c" xlink:href="imux-20221231.xsd#imux_LesseeOperatingLeaseRentHolidayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_LesseeOperatingLeaseRentHolidayPeriod_014d540c-062d-493d-b40a-a2e258507d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_e01d8fbc-b87f-45f5-a1da-529fb44ddf58" xlink:href="imux-20221231.xsd#imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_e01d8fbc-b87f-45f5-a1da-529fb44ddf58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_OperatingLeaseIncrementalBorrowingRate_6a0c8f85-d704-411d-84fc-cee354c68407" xlink:href="imux-20221231.xsd#imux_OperatingLeaseIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_OperatingLeaseIncrementalBorrowingRate_6a0c8f85-d704-411d-84fc-cee354c68407" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_OperatingAndVariableLeasesCost_4a071e07-8282-48ac-9190-83c78d44b88f" xlink:href="imux-20221231.xsd#imux_OperatingAndVariableLeasesCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_OperatingAndVariableLeasesCost_4a071e07-8282-48ac-9190-83c78d44b88f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_73a96b82-cf44-4b56-945e-6fe0f6d19a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_us-gaap_ContractualObligation_73a96b82-cf44-4b56-945e-6fe0f6d19a51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_96fa1fef-6e7c-4f3a-8b73-63b07554a113" xlink:href="imux-20221231.xsd#imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_96fa1fef-6e7c-4f3a-8b73-63b07554a113" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d281efe7-2004-4a35-88c0-0542bb59910f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_us-gaap_CommonStockSharesIssued_d281efe7-2004-4a35-88c0-0542bb59910f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9ad99b4e-8369-40b3-82be-29b1d6637070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_us-gaap_CommonStockValue_9ad99b4e-8369-40b3-82be-29b1d6637070" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_RoyaltySettlementAgreementSalesNet_b4c64f5e-3906-4d3c-af5e-7f54205be0d0" xlink:href="imux-20221231.xsd#imux_RoyaltySettlementAgreementSalesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_RoyaltySettlementAgreementSalesNet_b4c64f5e-3906-4d3c-af5e-7f54205be0d0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_RoyaltySettlementAgreementCashPaymentPercent_a9345733-ce45-4a85-bbdb-8104aef744c7" xlink:href="imux-20221231.xsd#imux_RoyaltySettlementAgreementCashPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_RoyaltySettlementAgreementCashPaymentPercent_a9345733-ce45-4a85-bbdb-8104aef744c7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_RoyaltySettlementAgreementSharesPaymentPercent_76c74b93-ebff-4553-8c43-17fee59cbc68" xlink:href="imux-20221231.xsd#imux_RoyaltySettlementAgreementSharesPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_RoyaltySettlementAgreementSharesPaymentPercent_76c74b93-ebff-4553-8c43-17fee59cbc68" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_926e25cf-8381-40fd-a66a-1b8bf24ef410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_us-gaap_LossContingenciesTable_926e25cf-8381-40fd-a66a-1b8bf24ef410" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3f5cf1b3-8a63-4e20-85f9-1f39ca6ad0c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_926e25cf-8381-40fd-a66a-1b8bf24ef410" xlink:to="loc_srt_StatementGeographicalAxis_3f5cf1b3-8a63-4e20-85f9-1f39ca6ad0c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3f5cf1b3-8a63-4e20-85f9-1f39ca6ad0c9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3f5cf1b3-8a63-4e20-85f9-1f39ca6ad0c9" xlink:to="loc_srt_SegmentGeographicalDomain_3f5cf1b3-8a63-4e20-85f9-1f39ca6ad0c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e673516c-ec5d-465b-a70d-9178d74f3ac2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3f5cf1b3-8a63-4e20-85f9-1f39ca6ad0c9" xlink:to="loc_srt_SegmentGeographicalDomain_e673516c-ec5d-465b-a70d-9178d74f3ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_GrafelfingGermanyMember_ba9af99c-63fe-4eb6-8777-b470c9090620" xlink:href="imux-20221231.xsd#imux_GrafelfingGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e673516c-ec5d-465b-a70d-9178d74f3ac2" xlink:to="loc_imux_GrafelfingGermanyMember_ba9af99c-63fe-4eb6-8777-b470c9090620" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_NewYorkCityMember_b2d2beb9-7c34-49d8-811c-3ab843f695c5" xlink:href="imux-20221231.xsd#imux_NewYorkCityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e673516c-ec5d-465b-a70d-9178d74f3ac2" xlink:to="loc_imux_NewYorkCityMember_b2d2beb9-7c34-49d8-811c-3ab843f695c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2128f151-7a0a-41e3-b221-843daf761cf1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_926e25cf-8381-40fd-a66a-1b8bf24ef410" xlink:to="loc_dei_LegalEntityAxis_2128f151-7a0a-41e3-b221-843daf761cf1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2128f151-7a0a-41e3-b221-843daf761cf1_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2128f151-7a0a-41e3-b221-843daf761cf1" xlink:to="loc_dei_EntityDomain_2128f151-7a0a-41e3-b221-843daf761cf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_05311456-d796-40d7-acd2-466dd073eab5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2128f151-7a0a-41e3-b221-843daf761cf1" xlink:to="loc_dei_EntityDomain_05311456-d796-40d7-acd2-466dd073eab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicAGMember_ea6dcfb5-5954-417b-8460-ec90ec4d7c31" xlink:href="imux-20221231.xsd#imux_ImmunicAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_05311456-d796-40d7-acd2-466dd073eab5" xlink:to="loc_imux_ImmunicAGMember_ea6dcfb5-5954-417b-8460-ec90ec4d7c31" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i2e846bf03d294885a4541fc8def74fa6_FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b222ce28-1812-4563-8b3f-fb7cc398c350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_98634dd2-8e1d-442c-a0c4-cdd7c6ebf81a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b222ce28-1812-4563-8b3f-fb7cc398c350" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_98634dd2-8e1d-442c-a0c4-cdd7c6ebf81a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a5dec2e3-9811-473f-8a55-cd0c2d4c736c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_98634dd2-8e1d-442c-a0c4-cdd7c6ebf81a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a5dec2e3-9811-473f-8a55-cd0c2d4c736c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0dd41c7-396e-424b-846f-d75f11829a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b222ce28-1812-4563-8b3f-fb7cc398c350" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0dd41c7-396e-424b-846f-d75f11829a9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5dda88a-b69e-4b4c-ac7f-3cfc5a9ceb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0dd41c7-396e-424b-846f-d75f11829a9e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5dda88a-b69e-4b4c-ac7f-3cfc5a9ceb3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5dda88a-b69e-4b4c-ac7f-3cfc5a9ceb3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5dda88a-b69e-4b4c-ac7f-3cfc5a9ceb3d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5dda88a-b69e-4b4c-ac7f-3cfc5a9ceb3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06c446f6-fcb0-4652-923a-2a2dbc9f0016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5dda88a-b69e-4b4c-ac7f-3cfc5a9ceb3d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06c446f6-fcb0-4652-923a-2a2dbc9f0016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3d20dbcc-f154-4a66-b6d8-2808261208b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06c446f6-fcb0-4652-923a-2a2dbc9f0016" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3d20dbcc-f154-4a66-b6d8-2808261208b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_dfeeab51-4102-4965-b0f1-3a78bf2b9db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06c446f6-fcb0-4652-923a-2a2dbc9f0016" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_dfeeab51-4102-4965-b0f1-3a78bf2b9db7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fc343a87-c8df-4201-b8c7-96a4f6ee6e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06c446f6-fcb0-4652-923a-2a2dbc9f0016" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fc343a87-c8df-4201-b8c7-96a4f6ee6e37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a000c79d-9a78-4f5b-be65-0b8352348c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0dd41c7-396e-424b-846f-d75f11829a9e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a000c79d-9a78-4f5b-be65-0b8352348c75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a000c79d-9a78-4f5b-be65-0b8352348c75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a000c79d-9a78-4f5b-be65-0b8352348c75" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a000c79d-9a78-4f5b-be65-0b8352348c75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d98ccf5c-ec67-49a8-ba8a-42168a1ee77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a000c79d-9a78-4f5b-be65-0b8352348c75" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d98ccf5c-ec67-49a8-ba8a-42168a1ee77f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6b2e7dab-490f-4b67-b98b-01c571383aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d98ccf5c-ec67-49a8-ba8a-42168a1ee77f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6b2e7dab-490f-4b67-b98b-01c571383aaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_bacbd598-ec5f-4684-ba32-e8792765b9af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0dd41c7-396e-424b-846f-d75f11829a9e" xlink:to="loc_us-gaap_InvestmentTypeAxis_bacbd598-ec5f-4684-ba32-e8792765b9af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_bacbd598-ec5f-4684-ba32-e8792765b9af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_bacbd598-ec5f-4684-ba32-e8792765b9af" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_bacbd598-ec5f-4684-ba32-e8792765b9af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_bf26b184-ce4a-4082-bd9a-d0a0fcf712bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_bacbd598-ec5f-4684-ba32-e8792765b9af" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_bf26b184-ce4a-4082-bd9a-d0a0fcf712bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_fc7215cd-043e-4367-a0ec-607393bbf3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_bf26b184-ce4a-4082-bd9a-d0a0fcf712bd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_fc7215cd-043e-4367-a0ec-607393bbf3b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/FairValueAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20221231.xsd#FairValueAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/FairValueAdditionalInformationDetail" xlink:type="extended" id="idd96712228e043579f02e10672b88643_FairValueAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91596688-ec06-4176-94d6-936a4d8c0124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_d5775ba0-a5e5-4585-9e73-b6c2d4789c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91596688-ec06-4176-94d6-936a4d8c0124" xlink:to="loc_us-gaap_InvestmentInterestRate_d5775ba0-a5e5-4585-9e73-b6c2d4789c98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14188b08-f0c4-4884-9021-87407338dce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91596688-ec06-4176-94d6-936a4d8c0124" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14188b08-f0c4-4884-9021-87407338dce3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1d790397-209f-454b-ad05-2adffd66620a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14188b08-f0c4-4884-9021-87407338dce3" xlink:to="loc_srt_StatementGeographicalAxis_1d790397-209f-454b-ad05-2adffd66620a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1d790397-209f-454b-ad05-2adffd66620a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1d790397-209f-454b-ad05-2adffd66620a" xlink:to="loc_srt_SegmentGeographicalDomain_1d790397-209f-454b-ad05-2adffd66620a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_91085dd7-ed98-44f3-acb7-629d66417869" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1d790397-209f-454b-ad05-2adffd66620a" xlink:to="loc_srt_SegmentGeographicalDomain_91085dd7-ed98-44f3-acb7-629d66417869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9f7e80f4-f7b7-415a-bf92-f4d303560bb5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_91085dd7-ed98-44f3-acb7-629d66417869" xlink:to="loc_country_US_9f7e80f4-f7b7-415a-bf92-f4d303560bb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ff630ed9-3e2b-4c96-9e42-ba738e3f2e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14188b08-f0c4-4884-9021-87407338dce3" xlink:to="loc_us-gaap_InvestmentTypeAxis_ff630ed9-3e2b-4c96-9e42-ba738e3f2e02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ff630ed9-3e2b-4c96-9e42-ba738e3f2e02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_ff630ed9-3e2b-4c96-9e42-ba738e3f2e02" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ff630ed9-3e2b-4c96-9e42-ba738e3f2e02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6e76a89b-d9e0-4037-a0dc-c901189e829f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_ff630ed9-3e2b-4c96-9e42-ba738e3f2e02" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6e76a89b-d9e0-4037-a0dc-c901189e829f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4e3f88a8-b34e-4b56-8836-30eda05253d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6e76a89b-d9e0-4037-a0dc-c901189e829f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4e3f88a8-b34e-4b56-8836-30eda05253d5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#CommonStockShelfRegistrationStatementDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="extended" id="i5b1f722aa2724b0d86dc58c92026e694_CommonStockShelfRegistrationStatementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_f5718b4a-9ee0-4166-abe6-a3df3fd02d25" xlink:href="imux-20221231.xsd#imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_f5718b4a-9ee0-4166-abe6-a3df3fd02d25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShelfRegistrationStatementAmountRemaining_919c68c2-5f91-4ac3-ab3c-ee74878c9ae0" xlink:href="imux-20221231.xsd#imux_ShelfRegistrationStatementAmountRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_imux_ShelfRegistrationStatementAmountRemaining_919c68c2-5f91-4ac3-ab3c-ee74878c9ae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShelfRegistrationTerminationPriorWrittenNotice_90b101bf-5018-4934-ade4-eb5dc5116717" xlink:href="imux-20221231.xsd#imux_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_imux_ShelfRegistrationTerminationPriorWrittenNotice_90b101bf-5018-4934-ade4-eb5dc5116717" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SaleOfStockRemainingCapacity_a3756017-a12e-41d3-8594-dc7814ea2d81" xlink:href="imux-20221231.xsd#imux_SaleOfStockRemainingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_imux_SaleOfStockRemainingCapacity_a3756017-a12e-41d3-8594-dc7814ea2d81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_b17cc89c-af65-4a93-a208-27717e255888" xlink:href="imux-20221231.xsd#imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_b17cc89c-af65-4a93-a208-27717e255888" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d5111da3-d347-4726-ab1f-fa00168b4e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d5111da3-d347-4726-ab1f-fa00168b4e46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a8d97524-1d59-4f6f-a383-c682aa3dc802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a8d97524-1d59-4f6f-a383-c682aa3dc802" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SharesIssuedWeightedAverageSharePricePerShare_faa7395e-7a31-4ce9-ad6b-487873d89ecb" xlink:href="imux-20221231.xsd#imux_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_imux_SharesIssuedWeightedAverageSharePricePerShare_faa7395e-7a31-4ce9-ad6b-487873d89ecb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d1f98477-68f9-4d94-9cf0-7288127fe5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d1f98477-68f9-4d94-9cf0-7288127fe5ec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_57b38ca8-5d4e-4164-808c-4654b2c5535b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_us-gaap_PaymentsForCommissions_57b38ca8-5d4e-4164-808c-4654b2c5535b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_40572417-d8bd-4fb9-884c-5305507f4a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_40572417-d8bd-4fb9-884c-5305507f4a51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4f247f0b-7a1e-4e75-bf20-64b483722dff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40572417-d8bd-4fb9-884c-5305507f4a51" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4f247f0b-7a1e-4e75-bf20-64b483722dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4f247f0b-7a1e-4e75-bf20-64b483722dff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4f247f0b-7a1e-4e75-bf20-64b483722dff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4f247f0b-7a1e-4e75-bf20-64b483722dff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_131b6374-50e1-4561-ba8c-06aefbf6b1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4f247f0b-7a1e-4e75-bf20-64b483722dff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_131b6374-50e1-4561-ba8c-06aefbf6b1d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_024ca52e-dd13-4415-9d6f-9928b1c8ffc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_131b6374-50e1-4561-ba8c-06aefbf6b1d6" xlink:to="loc_us-gaap_SubsequentEventMember_024ca52e-dd13-4415-9d6f-9928b1c8ffc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2ebda75f-af38-412b-a294-b36a78fa4c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40572417-d8bd-4fb9-884c-5305507f4a51" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2ebda75f-af38-412b-a294-b36a78fa4c22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2ebda75f-af38-412b-a294-b36a78fa4c22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2ebda75f-af38-412b-a294-b36a78fa4c22" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2ebda75f-af38-412b-a294-b36a78fa4c22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_92e50ce6-3f7d-4db2-b3fa-915ba98b46d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2ebda75f-af38-412b-a294-b36a78fa4c22" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_92e50ce6-3f7d-4db2-b3fa-915ba98b46d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_December2020ATMMember_2ac28e11-bbc6-4f6c-b798-f28303be576b" xlink:href="imux-20221231.xsd#imux_December2020ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_92e50ce6-3f7d-4db2-b3fa-915ba98b46d4" xlink:to="loc_imux_December2020ATMMember_2ac28e11-bbc6-4f6c-b798-f28303be576b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_May2022ATMMember_0afedf7a-0908-46bb-a0a9-cb210534a58e" xlink:href="imux-20221231.xsd#imux_May2022ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_92e50ce6-3f7d-4db2-b3fa-915ba98b46d4" xlink:to="loc_imux_May2022ATMMember_0afedf7a-0908-46bb-a0a9-cb210534a58e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockEquityOfferingDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#CommonStockEquityOfferingDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommonStockEquityOfferingDetails" xlink:type="extended" id="i93635455391a48c3993da37fd019937c_CommonStockEquityOfferingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_97ae2483-756d-438f-aebf-040a5ded78ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_97ae2483-756d-438f-aebf-040a5ded78ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2b984c81-1eda-44ff-ab8c-41bf6603a4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2b984c81-1eda-44ff-ab8c-41bf6603a4f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_c8e8f239-f4ba-4b5f-b526-0ef8416ee7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_SharePrice_c8e8f239-f4ba-4b5f-b526-0ef8416ee7cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_6c60d1f3-005c-40b8-a8d1-cb36bb4930a1" xlink:href="imux-20221231.xsd#imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_6c60d1f3-005c-40b8-a8d1-cb36bb4930a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_090b2761-adbb-4b8c-9bfc-1e80caddf69d" xlink:href="imux-20221231.xsd#imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_090b2761-adbb-4b8c-9bfc-1e80caddf69d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_0ce5643d-f5ce-4741-a663-34e761a0ced3" xlink:href="imux-20221231.xsd#imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_0ce5643d-f5ce-4741-a663-34e761a0ced3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2075c732-73fc-4b40-8df9-9c5b94ac446d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2075c732-73fc-4b40-8df9-9c5b94ac446d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5c849c83-1676-465a-9031-06cf37d0868a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5c849c83-1676-465a-9031-06cf37d0868a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_40115dd8-e1f0-4d23-b3fe-2dc54be662cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_40115dd8-e1f0-4d23-b3fe-2dc54be662cf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_551f8d3d-6134-4337-ac3e-1aea9d8533e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_551f8d3d-6134-4337-ac3e-1aea9d8533e2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_cf9a0905-a28d-44c8-a07c-b0f45ea59967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_cf9a0905-a28d-44c8-a07c-b0f45ea59967" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_145c00ed-d1bc-4544-8b84-dabbf1202864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_145c00ed-d1bc-4544-8b84-dabbf1202864" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_612de7f9-3b5e-4c91-aa1e-43ab92dbda58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_612de7f9-3b5e-4c91-aa1e-43ab92dbda58" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5d20bff9-a676-4775-9657-300de2ab7b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5d20bff9-a676-4775-9657-300de2ab7b10" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ad3fe961-81c6-4063-890c-49d3682b838b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ad3fe961-81c6-4063-890c-49d3682b838b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_86fcbc68-016e-4c1a-81ed-e627e8c1d127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_86fcbc68-016e-4c1a-81ed-e627e8c1d127" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_503a8809-4f88-4a02-accc-5ab970595a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86fcbc68-016e-4c1a-81ed-e627e8c1d127" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_503a8809-4f88-4a02-accc-5ab970595a89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_503a8809-4f88-4a02-accc-5ab970595a89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_503a8809-4f88-4a02-accc-5ab970595a89" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_503a8809-4f88-4a02-accc-5ab970595a89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3d182a88-bb8c-402e-a6ee-7841e40a1324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_503a8809-4f88-4a02-accc-5ab970595a89" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3d182a88-bb8c-402e-a6ee-7841e40a1324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2be2a068-3866-4564-adde-5e8e1ebae259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3d182a88-bb8c-402e-a6ee-7841e40a1324" xlink:to="loc_us-gaap_SubsequentEventMember_2be2a068-3866-4564-adde-5e8e1ebae259" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_70c5dafe-d9bf-491f-a22a-dfa848d92a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86fcbc68-016e-4c1a-81ed-e627e8c1d127" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_70c5dafe-d9bf-491f-a22a-dfa848d92a07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70c5dafe-d9bf-491f-a22a-dfa848d92a07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_70c5dafe-d9bf-491f-a22a-dfa848d92a07" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70c5dafe-d9bf-491f-a22a-dfa848d92a07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe5dd10f-0d2f-4869-ad9c-9e9c859a2b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_70c5dafe-d9bf-491f-a22a-dfa848d92a07" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe5dd10f-0d2f-4869-ad9c-9e9c859a2b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_aab97694-0cc7-4a37-baa2-294964619f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe5dd10f-0d2f-4869-ad9c-9e9c859a2b24" xlink:to="loc_us-gaap_CommonStockMember_aab97694-0cc7-4a37-baa2-294964619f46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PreFundedWarrantsMember_76a25c02-d795-469a-9fdd-b2ba33faa77e" xlink:href="imux-20221231.xsd#imux_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe5dd10f-0d2f-4869-ad9c-9e9c859a2b24" xlink:to="loc_imux_PreFundedWarrantsMember_76a25c02-d795-469a-9fdd-b2ba33faa77e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_July2021PublicEquityOfferingMember_89f6e318-2da3-4e9a-89d1-825c72101fa0" xlink:href="imux-20221231.xsd#imux_July2021PublicEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe5dd10f-0d2f-4869-ad9c-9e9c859a2b24" xlink:to="loc_imux_July2021PublicEquityOfferingMember_89f6e318-2da3-4e9a-89d1-825c72101fa0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#CommonStockSharesReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="extended" id="i4fbf2a3b79d5404c9f5eea2f0a3d839d_CommonStockSharesReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_785aed5f-b702-49a0-9510-eb59ef68bd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7281dd7f-4851-4811-8511-2ffe464e4932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_785aed5f-b702-49a0-9510-eb59ef68bd2b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7281dd7f-4851-4811-8511-2ffe464e4932" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_16561d5e-fb6f-4e74-b721-eaa979eda659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_785aed5f-b702-49a0-9510-eb59ef68bd2b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_16561d5e-fb6f-4e74-b721-eaa979eda659" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7e268cbf-558d-45c7-aac2-2fc23a5a51d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_16561d5e-fb6f-4e74-b721-eaa979eda659" xlink:to="loc_us-gaap_AwardTypeAxis_7e268cbf-558d-45c7-aac2-2fc23a5a51d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e268cbf-558d-45c7-aac2-2fc23a5a51d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7e268cbf-558d-45c7-aac2-2fc23a5a51d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e268cbf-558d-45c7-aac2-2fc23a5a51d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00b78b1e-737e-43f4-8cb4-2aa4dda4139b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7e268cbf-558d-45c7-aac2-2fc23a5a51d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00b78b1e-737e-43f4-8cb4-2aa4dda4139b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4ddd5d91-33e7-4676-8517-9ea88fbaa84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00b78b1e-737e-43f4-8cb4-2aa4dda4139b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4ddd5d91-33e7-4676-8517-9ea88fbaa84a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PreFundedWarrantsMember_0c7eb696-fbed-4f4f-90b1-f5a652e52a86" xlink:href="imux-20221231.xsd#imux_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00b78b1e-737e-43f4-8cb4-2aa4dda4139b" xlink:to="loc_imux_PreFundedWarrantsMember_0c7eb696-fbed-4f4f-90b1-f5a652e52a86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeStockOptionsforFutureGrantMember_318e46d5-ed4f-4947-8da5-5eae5f936cd7" xlink:href="imux-20221231.xsd#imux_EmployeeStockOptionsforFutureGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00b78b1e-737e-43f4-8cb4-2aa4dda4139b" xlink:to="loc_imux_EmployeeStockOptionsforFutureGrantMember_318e46d5-ed4f-4947-8da5-5eae5f936cd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_caa61e3a-ba67-47ca-86ad-6f3a8b25b19d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_16561d5e-fb6f-4e74-b721-eaa979eda659" xlink:to="loc_us-gaap_PlanNameAxis_caa61e3a-ba67-47ca-86ad-6f3a8b25b19d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_caa61e3a-ba67-47ca-86ad-6f3a8b25b19d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_caa61e3a-ba67-47ca-86ad-6f3a8b25b19d" xlink:to="loc_us-gaap_PlanNameDomain_caa61e3a-ba67-47ca-86ad-6f3a8b25b19d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5e1ec449-9683-40d4-9ecf-e70ea8dc91da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_caa61e3a-ba67-47ca-86ad-6f3a8b25b19d" xlink:to="loc_us-gaap_PlanNameDomain_5e1ec449-9683-40d4-9ecf-e70ea8dc91da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2021EmployeeStockPurchasePlanMember_da6a8ac2-6bb2-4fb5-a299-c23c45192f65" xlink:href="imux-20221231.xsd#imux_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5e1ec449-9683-40d4-9ecf-e70ea8dc91da" xlink:to="loc_imux_A2021EmployeeStockPurchasePlanMember_da6a8ac2-6bb2-4fb5-a299-c23c45192f65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_cfd63aa4-67e6-4d0b-94f8-b92a024c586b" xlink:href="imux-20221231.xsd#imux_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5e1ec449-9683-40d4-9ecf-e70ea8dc91da" xlink:to="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_cfd63aa4-67e6-4d0b-94f8-b92a024c586b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2017InducementEquityIncentivePlanMember_ca9142d8-c0d7-40c6-bd94-87eba79042c6" xlink:href="imux-20221231.xsd#imux_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5e1ec449-9683-40d4-9ecf-e70ea8dc91da" xlink:to="loc_imux_A2017InducementEquityIncentivePlanMember_ca9142d8-c0d7-40c6-bd94-87eba79042c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a8fb2dff-4ed6-4159-be9d-d92363ac7cd4" xlink:href="imux-20221231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5e1ec449-9683-40d4-9ecf-e70ea8dc91da" xlink:to="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a8fb2dff-4ed6-4159-be9d-d92363ac7cd4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#StockbasedCompensationPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" xlink:type="extended" id="i073aa42c54414e79a95a858539d8f41a_StockbasedCompensationPlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_aaa8c17c-4225-4531-a8d1-3fe1662f2806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_aaa8c17c-4225-4531-a8d1-3fe1662f2806" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_86e6efe0-de81-425a-b5f3-10cd25bedde1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_86e6efe0-de81-425a-b5f3-10cd25bedde1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_08b5b127-b14b-4749-874f-8a86132ec08b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_08b5b127-b14b-4749-874f-8a86132ec08b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_72750108-460e-4570-bb94-e003cae996e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_72750108-460e-4570-bb94-e003cae996e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d169b9e1-89bc-4ff8-b420-aea71d0a626d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d169b9e1-89bc-4ff8-b420-aea71d0a626d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_34da1aeb-0873-4afd-804c-809a0368e3d6" xlink:href="imux-20221231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_34da1aeb-0873-4afd-804c-809a0368e3d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_da5a35cd-ca7b-4171-9a4f-d7216a563733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_da5a35cd-ca7b-4171-9a4f-d7216a563733" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c5c471db-e8dc-48df-b6d9-f5108894f3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c5c471db-e8dc-48df-b6d9-f5108894f3a6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8aff6099-f123-4eb9-a686-1451a9637898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8aff6099-f123-4eb9-a686-1451a9637898" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9c4d88f4-1221-48a2-9d73-76518252b129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9c4d88f4-1221-48a2-9d73-76518252b129" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_462b5154-3add-4d55-b513-7a9c9ee35a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_462b5154-3add-4d55-b513-7a9c9ee35a54" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_28d2689e-b848-4336-8b30-4b222e868437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_28d2689e-b848-4336-8b30-4b222e868437" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_abcb22d2-8dd1-4836-ab9a-c2eaecedeefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_abcb22d2-8dd1-4836-ab9a-c2eaecedeefd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d958c70-d74e-4dd3-9de0-56b918d0b413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d958c70-d74e-4dd3-9de0-56b918d0b413" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c3c5f351-d029-4d9c-af09-ec8a3b6aedc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d958c70-d74e-4dd3-9de0-56b918d0b413" xlink:to="loc_us-gaap_PlanNameAxis_c3c5f351-d029-4d9c-af09-ec8a3b6aedc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c3c5f351-d029-4d9c-af09-ec8a3b6aedc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c3c5f351-d029-4d9c-af09-ec8a3b6aedc3" xlink:to="loc_us-gaap_PlanNameDomain_c3c5f351-d029-4d9c-af09-ec8a3b6aedc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c7cc6de1-b8a6-46cf-b126-cd01b6aca287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c3c5f351-d029-4d9c-af09-ec8a3b6aedc3" xlink:to="loc_us-gaap_PlanNameDomain_c7cc6de1-b8a6-46cf-b126-cd01b6aca287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2021EmployeeStockPurchasePlanMember_a530e179-3763-45d6-aa1e-c4d27ea8c6ab" xlink:href="imux-20221231.xsd#imux_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c7cc6de1-b8a6-46cf-b126-cd01b6aca287" xlink:to="loc_imux_A2021EmployeeStockPurchasePlanMember_a530e179-3763-45d6-aa1e-c4d27ea8c6ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2019OmnibusEquityIncentivePlanMember_0eed378a-9735-4026-9439-f699b336e466" xlink:href="imux-20221231.xsd#imux_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c7cc6de1-b8a6-46cf-b126-cd01b6aca287" xlink:to="loc_imux_A2019OmnibusEquityIncentivePlanMember_0eed378a-9735-4026-9439-f699b336e466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_379201dd-5497-4030-8329-17c37ac21964" xlink:href="imux-20221231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imux_A2019OmnibusEquityIncentivePlanMember_0eed378a-9735-4026-9439-f699b336e466" xlink:to="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_379201dd-5497-4030-8329-17c37ac21964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_88a91493-b1bc-4b6f-b476-9f688526232e" xlink:href="imux-20221231.xsd#imux_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c7cc6de1-b8a6-46cf-b126-cd01b6aca287" xlink:to="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_88a91493-b1bc-4b6f-b476-9f688526232e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2017InducementEquityIncentivePlanMember_f1f98e62-cab9-4dc4-8905-0454921b1ae1" xlink:href="imux-20221231.xsd#imux_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c7cc6de1-b8a6-46cf-b126-cd01b6aca287" xlink:to="loc_imux_A2017InducementEquityIncentivePlanMember_f1f98e62-cab9-4dc4-8905-0454921b1ae1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b8ffb847-c28c-4c80-a31b-c0a3f8b8e631" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d958c70-d74e-4dd3-9de0-56b918d0b413" xlink:to="loc_srt_RangeAxis_b8ffb847-c28c-4c80-a31b-c0a3f8b8e631" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b8ffb847-c28c-4c80-a31b-c0a3f8b8e631_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b8ffb847-c28c-4c80-a31b-c0a3f8b8e631" xlink:to="loc_srt_RangeMember_b8ffb847-c28c-4c80-a31b-c0a3f8b8e631_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0e15c1dc-622f-4542-a6e7-ce4c18bc941d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b8ffb847-c28c-4c80-a31b-c0a3f8b8e631" xlink:to="loc_srt_RangeMember_0e15c1dc-622f-4542-a6e7-ce4c18bc941d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6d194041-0dbd-4899-871a-1c974bdf920e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0e15c1dc-622f-4542-a6e7-ce4c18bc941d" xlink:to="loc_srt_MinimumMember_6d194041-0dbd-4899-871a-1c974bdf920e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_df89a754-0b4b-4fbe-a005-1d21a5977603" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0e15c1dc-622f-4542-a6e7-ce4c18bc941d" xlink:to="loc_srt_MaximumMember_df89a754-0b4b-4fbe-a005-1d21a5977603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4c399da6-a31a-49c9-88ca-7f8df17600aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d958c70-d74e-4dd3-9de0-56b918d0b413" xlink:to="loc_us-gaap_AwardTypeAxis_4c399da6-a31a-49c9-88ca-7f8df17600aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c399da6-a31a-49c9-88ca-7f8df17600aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4c399da6-a31a-49c9-88ca-7f8df17600aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c399da6-a31a-49c9-88ca-7f8df17600aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_360cfcff-6b41-49cc-a949-e1323132511d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4c399da6-a31a-49c9-88ca-7f8df17600aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_360cfcff-6b41-49cc-a949-e1323132511d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_IncentiveEmployeeStockOptionMember_cac1686c-9af7-4b72-a12a-8a4e462574e4" xlink:href="imux-20221231.xsd#imux_IncentiveEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_360cfcff-6b41-49cc-a949-e1323132511d" xlink:to="loc_imux_IncentiveEmployeeStockOptionMember_cac1686c-9af7-4b72-a12a-8a4e462574e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_NonStatutoryEmployeeStockOptionMember_4c0f6ee3-9a02-4d0f-8057-63501d154998" xlink:href="imux-20221231.xsd#imux_NonStatutoryEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_360cfcff-6b41-49cc-a949-e1323132511d" xlink:to="loc_imux_NonStatutoryEmployeeStockOptionMember_4c0f6ee3-9a02-4d0f-8057-63501d154998" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#StockbasedCompensationPlansSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="extended" id="iee128509708a4cb49373e0a1dcbfa8d4_StockbasedCompensationPlansSummaryofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3744f2b-5dc7-4033-9f5c-f9fa4c91aee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3744f2b-5dc7-4033-9f5c-f9fa4c91aee2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_36293d72-c321-468e-a58e-e74703f273cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3744f2b-5dc7-4033-9f5c-f9fa4c91aee2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_36293d72-c321-468e-a58e-e74703f273cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ce4e3585-c86d-47c4-a1e6-d406f7e27060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3744f2b-5dc7-4033-9f5c-f9fa4c91aee2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ce4e3585-c86d-47c4-a1e6-d406f7e27060" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3d3ea76-db71-48e4-af2b-53896ada393e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3744f2b-5dc7-4033-9f5c-f9fa4c91aee2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3d3ea76-db71-48e4-af2b-53896ada393e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_305a3428-6fc9-41c5-9a49-53050f90d024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3744f2b-5dc7-4033-9f5c-f9fa4c91aee2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_305a3428-6fc9-41c5-9a49-53050f90d024" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_454f4645-b142-417b-9ce1-608afc76be7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fb690ee6-1ac9-47d4-88fb-9157eccfe512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fb690ee6-1ac9-47d4-88fb-9157eccfe512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7d326d2a-40a8-489f-96c8-864381d42478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7d326d2a-40a8-489f-96c8-864381d42478" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2dd359d2-8c46-43e4-bbc7-98aa4a54c13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2dd359d2-8c46-43e4-bbc7-98aa4a54c13a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3bad4393-06d1-43cb-8039-a8f9ddcb4462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2dd359d2-8c46-43e4-bbc7-98aa4a54c13a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3bad4393-06d1-43cb-8039-a8f9ddcb4462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ed0bef85-9278-48ba-9f1d-314fb53d1a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2dd359d2-8c46-43e4-bbc7-98aa4a54c13a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ed0bef85-9278-48ba-9f1d-314fb53d1a2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9d6d63db-9bdc-48c7-9f9a-b0185ce01e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2dd359d2-8c46-43e4-bbc7-98aa4a54c13a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9d6d63db-9bdc-48c7-9f9a-b0185ce01e68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2cbad858-f97d-423b-bb18-a0d7e8eee337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2dd359d2-8c46-43e4-bbc7-98aa4a54c13a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2cbad858-f97d-423b-bb18-a0d7e8eee337" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_29390fd6-73ff-411d-bcc4-9ee7b347ddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d277ea25-8f0f-44f5-b066-5d8cfe29fa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d277ea25-8f0f-44f5-b066-5d8cfe29fa6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_04de6cab-060a-48a2-9b9b-7d7eba7f238d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_04de6cab-060a-48a2-9b9b-7d7eba7f238d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_af36be18-dff4-4261-834c-069c3894dd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_af36be18-dff4-4261-834c-069c3894dd7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_cfcca0c4-e29c-4015-9fd4-a2090f722ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_cfcca0c4-e29c-4015-9fd4-a2090f722ecc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_01b8a5aa-cc76-4eeb-bb0f-268db950c61f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_01b8a5aa-cc76-4eeb-bb0f-268db950c61f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6d33fbcd-9f66-4775-8ef7-584d428aeac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6d33fbcd-9f66-4775-8ef7-584d428aeac5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_96759d04-0db9-4199-bf99-269d48085110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_96759d04-0db9-4199-bf99-269d48085110" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2b2472af-cae3-4663-a8d6-a806ed86e854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2b2472af-cae3-4663-a8d6-a806ed86e854" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce15b711-3327-4e77-ac60-8fb534616d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce15b711-3327-4e77-ac60-8fb534616d32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a2e71b38-c7e4-4d05-aee3-9b521a92e1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce15b711-3327-4e77-ac60-8fb534616d32" xlink:to="loc_us-gaap_AwardTypeAxis_a2e71b38-c7e4-4d05-aee3-9b521a92e1e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2e71b38-c7e4-4d05-aee3-9b521a92e1e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a2e71b38-c7e4-4d05-aee3-9b521a92e1e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2e71b38-c7e4-4d05-aee3-9b521a92e1e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4c19c63-a3ba-4951-8b49-da3dcc6180b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a2e71b38-c7e4-4d05-aee3-9b521a92e1e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4c19c63-a3ba-4951-8b49-da3dcc6180b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dc92dd7c-dbad-48ec-9da1-8591617a631a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4c19c63-a3ba-4951-8b49-da3dcc6180b5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dc92dd7c-dbad-48ec-9da1-8591617a631a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4e768463-95f4-41c2-adfa-254f03bf2815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce15b711-3327-4e77-ac60-8fb534616d32" xlink:to="loc_us-gaap_PlanNameAxis_4e768463-95f4-41c2-adfa-254f03bf2815" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4e768463-95f4-41c2-adfa-254f03bf2815_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4e768463-95f4-41c2-adfa-254f03bf2815" xlink:to="loc_us-gaap_PlanNameDomain_4e768463-95f4-41c2-adfa-254f03bf2815_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e2e07b3f-f830-4fd3-a329-4dc1aa405ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4e768463-95f4-41c2-adfa-254f03bf2815" xlink:to="loc_us-gaap_PlanNameDomain_e2e07b3f-f830-4fd3-a329-4dc1aa405ad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_dacfa579-22ce-4bdb-858c-53a1f7a80077" xlink:href="imux-20221231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e2e07b3f-f830-4fd3-a329-4dc1aa405ad7" xlink:to="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_dacfa579-22ce-4bdb-858c-53a1f7a80077" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails" xlink:type="extended" id="i6e3a81531d3348c1bddb1a6b98428cc8_StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33da093f-dcfb-4005-8f49-8163d33a253d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5bf0d714-fdfb-4492-be06-bc2b08cf613d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33da093f-dcfb-4005-8f49-8163d33a253d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5bf0d714-fdfb-4492-be06-bc2b08cf613d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d45e71f8-f521-40db-bc1d-2830b6ed9f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33da093f-dcfb-4005-8f49-8163d33a253d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d45e71f8-f521-40db-bc1d-2830b6ed9f4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c75671fe-d965-49df-b7a1-ac5ba27f26c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33da093f-dcfb-4005-8f49-8163d33a253d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c75671fe-d965-49df-b7a1-ac5ba27f26c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0da9e783-73fe-415a-8a93-23cc54e4aa0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33da093f-dcfb-4005-8f49-8163d33a253d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0da9e783-73fe-415a-8a93-23cc54e4aa0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5890d3e-5b5c-4ae2-81de-257e2386632d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33da093f-dcfb-4005-8f49-8163d33a253d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5890d3e-5b5c-4ae2-81de-257e2386632d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a12fc74b-4245-4fef-9da3-cc7ce0c66ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5890d3e-5b5c-4ae2-81de-257e2386632d" xlink:to="loc_us-gaap_PlanNameAxis_a12fc74b-4245-4fef-9da3-cc7ce0c66ff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a12fc74b-4245-4fef-9da3-cc7ce0c66ff7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a12fc74b-4245-4fef-9da3-cc7ce0c66ff7" xlink:to="loc_us-gaap_PlanNameDomain_a12fc74b-4245-4fef-9da3-cc7ce0c66ff7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aa1ce657-793e-485a-9c44-529043246b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a12fc74b-4245-4fef-9da3-cc7ce0c66ff7" xlink:to="loc_us-gaap_PlanNameDomain_aa1ce657-793e-485a-9c44-529043246b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2019OmnibusEquityIncentivePlanMember_948cbcf0-ee27-4cda-9f71-35fe4a4d4ab2" xlink:href="imux-20221231.xsd#imux_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_aa1ce657-793e-485a-9c44-529043246b25" xlink:to="loc_imux_A2019OmnibusEquityIncentivePlanMember_948cbcf0-ee27-4cda-9f71-35fe4a4d4ab2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="extended" id="i1c1719badf054fb0ba67f4226d055fe5_StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_817ffc72-f4e4-4cfb-b05c-bce13a0b1de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6c8fe0f8-6e43-4792-a1ab-8bfa63b89092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_817ffc72-f4e4-4cfb-b05c-bce13a0b1de0" xlink:to="loc_us-gaap_ShareBasedCompensation_6c8fe0f8-6e43-4792-a1ab-8bfa63b89092" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9eb9c358-aa4d-453f-9bc5-361d44b17675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_817ffc72-f4e4-4cfb-b05c-bce13a0b1de0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9eb9c358-aa4d-453f-9bc5-361d44b17675" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d51084da-a49a-45f3-b029-bd9b484a247a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9eb9c358-aa4d-453f-9bc5-361d44b17675" xlink:to="loc_srt_TitleOfIndividualAxis_d51084da-a49a-45f3-b029-bd9b484a247a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d51084da-a49a-45f3-b029-bd9b484a247a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_d51084da-a49a-45f3-b029-bd9b484a247a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d51084da-a49a-45f3-b029-bd9b484a247a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_217d10bc-bc8d-4461-ba7f-d3dbbd3cdf0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_d51084da-a49a-45f3-b029-bd9b484a247a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_217d10bc-bc8d-4461-ba7f-d3dbbd3cdf0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeMember_f4b5f48c-dc9c-44a5-b9db-0b054fcda22e" xlink:href="imux-20221231.xsd#imux_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_217d10bc-bc8d-4461-ba7f-d3dbbd3cdf0f" xlink:to="loc_imux_EmployeeMember_f4b5f48c-dc9c-44a5-b9db-0b054fcda22e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_65f7f2fd-7418-4059-8504-aa9723a367ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9eb9c358-aa4d-453f-9bc5-361d44b17675" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_65f7f2fd-7418-4059-8504-aa9723a367ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_65f7f2fd-7418-4059-8504-aa9723a367ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_65f7f2fd-7418-4059-8504-aa9723a367ff" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_65f7f2fd-7418-4059-8504-aa9723a367ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e485d87c-59e4-4147-abbc-449cae758325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_65f7f2fd-7418-4059-8504-aa9723a367ff" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e485d87c-59e4-4147-abbc-449cae758325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_908c4365-daa6-4a7c-aa81-2cc2f0505a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e485d87c-59e4-4147-abbc-449cae758325" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_908c4365-daa6-4a7c-aa81-2cc2f0505a19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0e955b14-b1fc-453b-82c9-c51f699f9ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e485d87c-59e4-4147-abbc-449cae758325" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0e955b14-b1fc-453b-82c9-c51f699f9ea3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" xlink:type="extended" id="id7dd470e472d431ba2d85a974d7472a0_IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_d9f03414-d74f-4793-9388-45f8187eba51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_34ded21d-af63-487f-9c35-f92d82e4fcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d9f03414-d74f-4793-9388-45f8187eba51" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_34ded21d-af63-487f-9c35-f92d82e4fcfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_0472b01b-1f84-4b2a-81b3-2bc300b1c5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d9f03414-d74f-4793-9388-45f8187eba51" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_0472b01b-1f84-4b2a-81b3-2bc300b1c5b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_83c002d1-7876-40db-ac4b-b87dca5b11c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_0472b01b-1f84-4b2a-81b3-2bc300b1c5b9" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_83c002d1-7876-40db-ac4b-b87dca5b11c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_83c002d1-7876-40db-ac4b-b87dca5b11c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_83c002d1-7876-40db-ac4b-b87dca5b11c8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_83c002d1-7876-40db-ac4b-b87dca5b11c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ff6ed75c-79c4-4b47-8d90-e1452aa0c828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_83c002d1-7876-40db-ac4b-b87dca5b11c8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ff6ed75c-79c4-4b47-8d90-e1452aa0c828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_61d2744a-099c-4b3f-8993-35f96b91dab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ff6ed75c-79c4-4b47-8d90-e1452aa0c828" xlink:to="loc_us-gaap_DomesticCountryMember_61d2744a-099c-4b3f-8993-35f96b91dab6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_91d89a4c-cc7d-40cb-8d29-557e82379bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ff6ed75c-79c4-4b47-8d90-e1452aa0c828" xlink:to="loc_us-gaap_ForeignCountryMember_91d89a4c-cc7d-40cb-8d29-557e82379bd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_75459e17-0ea3-4aa5-b819-a3c43291bea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_0472b01b-1f84-4b2a-81b3-2bc300b1c5b9" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_75459e17-0ea3-4aa5-b819-a3c43291bea2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_75459e17-0ea3-4aa5-b819-a3c43291bea2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_75459e17-0ea3-4aa5-b819-a3c43291bea2" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_75459e17-0ea3-4aa5-b819-a3c43291bea2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_18c6f368-19e9-4038-9d8a-c58a803c110a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_75459e17-0ea3-4aa5-b819-a3c43291bea2" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_18c6f368-19e9-4038-9d8a-c58a803c110a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_8bdaf490-4718-47de-814b-3f856792f513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_18c6f368-19e9-4038-9d8a-c58a803c110a" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_8bdaf490-4718-47de-814b-3f856792f513" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalMinistryOfFinanceGermanyMember_91e65408-0d8c-4203-851a-b11df0510654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalMinistryOfFinanceGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_18c6f368-19e9-4038-9d8a-c58a803c110a" xlink:to="loc_us-gaap_FederalMinistryOfFinanceGermanyMember_91e65408-0d8c-4203-851a-b11df0510654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ForeignExcludingGermanyMember_bf348dcf-f551-4131-bdef-a75f2e2462e1" xlink:href="imux-20221231.xsd#imux_ForeignExcludingGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_18c6f368-19e9-4038-9d8a-c58a803c110a" xlink:to="loc_imux_ForeignExcludingGermanyMember_bf348dcf-f551-4131-bdef-a75f2e2462e1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i9817d3ac8fcd495cba1d96d1d7adbd4f_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_b01dde29-9604-4dc3-a22b-40266211bcff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_25879fde-945e-41d5-9fdc-c35d26ce4d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b01dde29-9604-4dc3-a22b-40266211bcff" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_25879fde-945e-41d5-9fdc-c35d26ce4d16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_09900a05-5fd1-4814-80fd-423825197d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b01dde29-9604-4dc3-a22b-40266211bcff" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_09900a05-5fd1-4814-80fd-423825197d67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_9b76f095-0d07-4144-baea-26d9e1d7f1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b01dde29-9604-4dc3-a22b-40266211bcff" xlink:to="loc_us-gaap_OperatingLossCarryforwards_9b76f095-0d07-4144-baea-26d9e1d7f1b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6db28ecc-cb3d-4bae-b874-2f167ab014e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b01dde29-9604-4dc3-a22b-40266211bcff" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6db28ecc-cb3d-4bae-b874-2f167ab014e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_df04bb13-063f-4195-8deb-fca291e182c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b01dde29-9604-4dc3-a22b-40266211bcff" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_df04bb13-063f-4195-8deb-fca291e182c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_562dd7f8-8e6e-416a-a16d-8ebbd6b6ccec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b01dde29-9604-4dc3-a22b-40266211bcff" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_562dd7f8-8e6e-416a-a16d-8ebbd6b6ccec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ef7da105-6028-4832-9af6-6741398708ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_562dd7f8-8e6e-416a-a16d-8ebbd6b6ccec" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ef7da105-6028-4832-9af6-6741398708ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ef7da105-6028-4832-9af6-6741398708ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ef7da105-6028-4832-9af6-6741398708ff" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ef7da105-6028-4832-9af6-6741398708ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d3b0b67c-96c3-4c23-9273-9d3d049f4051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ef7da105-6028-4832-9af6-6741398708ff" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d3b0b67c-96c3-4c23-9273-9d3d049f4051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_cc161db8-aa24-400c-ad95-2a9da37dbffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d3b0b67c-96c3-4c23-9273-9d3d049f4051" xlink:to="loc_us-gaap_ForeignCountryMember_cc161db8-aa24-400c-ad95-2a9da37dbffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_8a48772b-80bc-42fa-866b-687eeda2d7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d3b0b67c-96c3-4c23-9273-9d3d049f4051" xlink:to="loc_us-gaap_DomesticCountryMember_8a48772b-80bc-42fa-866b-687eeda2d7e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_1630a5c7-d252-46be-bc69-8ba15b02d19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_562dd7f8-8e6e-416a-a16d-8ebbd6b6ccec" xlink:to="loc_us-gaap_TaxPeriodAxis_1630a5c7-d252-46be-bc69-8ba15b02d19b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_1630a5c7-d252-46be-bc69-8ba15b02d19b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_1630a5c7-d252-46be-bc69-8ba15b02d19b" xlink:to="loc_us-gaap_TaxPeriodDomain_1630a5c7-d252-46be-bc69-8ba15b02d19b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_100428e1-814f-4645-ab1d-56fad634b399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_1630a5c7-d252-46be-bc69-8ba15b02d19b" xlink:to="loc_us-gaap_TaxPeriodDomain_100428e1-814f-4645-ab1d-56fad634b399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TaxYearsPriorTo2018Member_11bdb290-3367-4949-b09f-06147fbdc219" xlink:href="imux-20221231.xsd#imux_TaxYearsPriorTo2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_100428e1-814f-4645-ab1d-56fad634b399" xlink:to="loc_imux_TaxYearsPriorTo2018Member_11bdb290-3367-4949-b09f-06147fbdc219" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TaxYearsPost2017Member_28edb879-ff1e-4e1f-b9bb-adaa4cf91ab2" xlink:href="imux-20221231.xsd#imux_TaxYearsPost2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_100428e1-814f-4645-ab1d-56fad634b399" xlink:to="loc_imux_TaxYearsPost2017Member_28edb879-ff1e-4e1f-b9bb-adaa4cf91ab2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="i1e50b3aeb04440d8bcf745f932b9682f_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_26ae8d8a-1e3e-415a-8049-b7c0419fa85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SalaryCostsMonthlyBaseSalary_a18cce7c-235b-4c12-96c3-c7489ddd93c9" xlink:href="imux-20221231.xsd#imux_SalaryCostsMonthlyBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26ae8d8a-1e3e-415a-8049-b7c0419fa85d" xlink:to="loc_imux_SalaryCostsMonthlyBaseSalary_a18cce7c-235b-4c12-96c3-c7489ddd93c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_781d2f4f-f0bf-46fc-a3c6-ce325ea0fba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26ae8d8a-1e3e-415a-8049-b7c0419fa85d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_781d2f4f-f0bf-46fc-a3c6-ce325ea0fba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26ae8d8a-1e3e-415a-8049-b7c0419fa85d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4f46b425-24ce-435d-9035-f1d569435d0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:to="loc_srt_CounterpartyNameAxis_4f46b425-24ce-435d-9035-f1d569435d0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f46b425-24ce-435d-9035-f1d569435d0d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4f46b425-24ce-435d-9035-f1d569435d0d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f46b425-24ce-435d-9035-f1d569435d0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6c2c0264-ef3b-4720-8212-0a9768aa559d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4f46b425-24ce-435d-9035-f1d569435d0d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6c2c0264-ef3b-4720-8212-0a9768aa559d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DuaneNashMDJDMBAMember_e4215808-ff01-4469-a6c0-0aedb80b04eb" xlink:href="imux-20221231.xsd#imux_DuaneNashMDJDMBAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6c2c0264-ef3b-4720-8212-0a9768aa559d" xlink:to="loc_imux_DuaneNashMDJDMBAMember_e4215808-ff01-4469-a6c0-0aedb80b04eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_4711fba0-1730-414b-b4f2-e33598e8bf06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:to="loc_srt_TitleOfIndividualAxis_4711fba0-1730-414b-b4f2-e33598e8bf06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4711fba0-1730-414b-b4f2-e33598e8bf06_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_4711fba0-1730-414b-b4f2-e33598e8bf06" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4711fba0-1730-414b-b4f2-e33598e8bf06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_19b6163e-474b-4861-bd60-dd67ea39da8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_4711fba0-1730-414b-b4f2-e33598e8bf06" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_19b6163e-474b-4861-bd60-dd67ea39da8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_32d3594e-47d0-428e-b533-eb93ec415c62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_19b6163e-474b-4861-bd60-dd67ea39da8f" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_32d3594e-47d0-428e-b533-eb93ec415c62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5d379f2e-005a-406a-93b6-6d25eba48962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5d379f2e-005a-406a-93b6-6d25eba48962" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5d379f2e-005a-406a-93b6-6d25eba48962_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5d379f2e-005a-406a-93b6-6d25eba48962" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5d379f2e-005a-406a-93b6-6d25eba48962_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2f722dc7-2c0d-4db7-b6ff-b4a32ae3b9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5d379f2e-005a-406a-93b6-6d25eba48962" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2f722dc7-2c0d-4db7-b6ff-b4a32ae3b9c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ExecutiveChairmanAgreementMember_555833f7-f641-4e03-a8cd-3edad33ce422" xlink:href="imux-20221231.xsd#imux_ExecutiveChairmanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2f722dc7-2c0d-4db7-b6ff-b4a32ae3b9c5" xlink:to="loc_imux_ExecutiveChairmanAgreementMember_555833f7-f641-4e03-a8cd-3edad33ce422" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ede0d070-b499-4765-a8f3-4f7685344282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ede0d070-b499-4765-a8f3-4f7685344282" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ede0d070-b499-4765-a8f3-4f7685344282_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ede0d070-b499-4765-a8f3-4f7685344282" xlink:to="loc_us-gaap_RelatedPartyDomain_ede0d070-b499-4765-a8f3-4f7685344282_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_182916d7-dc47-4d75-b5ff-dbc044d9416e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ede0d070-b499-4765-a8f3-4f7685344282" xlink:to="loc_us-gaap_RelatedPartyDomain_182916d7-dc47-4d75-b5ff-dbc044d9416e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_de255c00-e2dd-4ecd-b19e-78562b4d2edb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_182916d7-dc47-4d75-b5ff-dbc044d9416e" xlink:to="loc_srt_AffiliatedEntityMember_de255c00-e2dd-4ecd-b19e-78562b4d2edb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_033d36d0-cbcd-40f4-9581-0801425895f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:to="loc_srt_StatementScenarioAxis_033d36d0-cbcd-40f4-9581-0801425895f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_033d36d0-cbcd-40f4-9581-0801425895f7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_033d36d0-cbcd-40f4-9581-0801425895f7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_033d36d0-cbcd-40f4-9581-0801425895f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_78e1e742-aeee-4575-a20a-a803c7d9f590" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_033d36d0-cbcd-40f4-9581-0801425895f7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_78e1e742-aeee-4575-a20a-a803c7d9f590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_6d1e8e13-fca9-48a5-bb8e-6610c1e3a9e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_78e1e742-aeee-4575-a20a-a803c7d9f590" xlink:to="loc_srt_ScenarioForecastMember_6d1e8e13-fca9-48a5-bb8e-6610c1e3a9e3" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>imux-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:19abff6b-9d36-40e5-80a6-5fea77828601,g:313a8e66-68ba-4247-b883-d20269f0dca0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_7752e0ab-3fac-4037-a57d-f4eac4f83e69_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da57603e-4137-4337-b8a7-af4f3db3744e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_AuditInformationAbstract_label_en-US" xlink:label="lab_imux_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_imux_AuditInformationAbstract_documentation_en-US" xlink:label="lab_imux_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AuditInformationAbstract" xlink:href="imux-20221231.xsd#imux_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_AuditInformationAbstract" xlink:to="lab_imux_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_49e10194-502d-46ee-9b70-9f3bb493b5dc_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2e59a50e-9edd-4e66-b208-77515a84e303_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation and Presentation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_a77eee7b-3fe3-4c33-a61e-19446ca34fa2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b1009871-ba7c-4515-8cb6-9e7dba9ac801_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ClinicalCostsPayableCurrent_29e66790-5fba-4135-81e9-6f4c306f059b_terseLabel_en-US" xlink:label="lab_imux_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and related costs</link:label>
    <link:label id="lab_imux_ClinicalCostsPayableCurrent_label_en-US" xlink:label="lab_imux_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:label id="lab_imux_ClinicalCostsPayableCurrent_documentation_en-US" xlink:label="lab_imux_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ClinicalCostsPayableCurrent" xlink:href="imux-20221231.xsd#imux_ClinicalCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ClinicalCostsPayableCurrent" xlink:to="lab_imux_ClinicalCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_42662cf1-b95f-403c-bbf0-6749fcc3adc4_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_2cedcf4b-dd10-4283-a274-1584a989e90f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_bf3c33c5-b380-403a-a7fa-56a6ae1d4d47_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9ba85403-6e15-4570-b65a-dd5564fdd864_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_EmployeeStockOptionsforFutureGrantMember_162fd5a7-a1f4-403d-a680-b082e49d2260_terseLabel_en-US" xlink:label="lab_imux_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options available for future grant:</link:label>
    <link:label id="lab_imux_EmployeeStockOptionsforFutureGrantMember_label_en-US" xlink:label="lab_imux_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:label id="lab_imux_EmployeeStockOptionsforFutureGrantMember_documentation_en-US" xlink:label="lab_imux_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeStockOptionsforFutureGrantMember" xlink:href="imux-20221231.xsd#imux_EmployeeStockOptionsforFutureGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_EmployeeStockOptionsforFutureGrantMember" xlink:to="lab_imux_EmployeeStockOptionsforFutureGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0d3f66dc-f991-4ed5-b1af-5cb8b1391e87_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_83ddcf50-192d-40b0-880a-4c1ce17b631c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_30c5dd08-69a9-444d-8489-ebdc5cbaa8e1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_da53f3c2-f6ee-48bb-b94f-00f7e8f8ec23_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_4d4577ae-5377-43e7-9746-3485e0a524ec_terseLabel_en-US" xlink:label="lab_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase or decrease not in excess of percentage</link:label>
    <link:label id="lab_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_label_en-US" xlink:label="lab_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent</link:label>
    <link:label id="lab_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_documentation_en-US" xlink:label="lab_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:href="imux-20221231.xsd#imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:to="lab_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ed48ec0e-9518-4a84-bb77-e6e12440a965_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentInterestRate_5530ce63-d049-4636-b400-b021e87c30be_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment interest rate</link:label>
    <link:label id="lab_us-gaap_InvestmentInterestRate_label_en-US" xlink:label="lab_us-gaap_InvestmentInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentInterestRate" xlink:to="lab_us-gaap_InvestmentInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_17886487-1bf6-47ab-9365-d4bbebe8b23d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_39e5364b-c8c0-47ca-a0c7-2049966c6c56_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets, valuation allowance total</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_798ddf05-4276-4b1c-a8db-fa227d7f9f10_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_8032774b-c53c-4b87-baf8-5559c2700ce0_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_077630e0-6860-4205-89be-1fabffac94dd_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_38eb42cc-1496-4b12-ba5a-bb1ad7cbd896_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_640401ae-737c-4d3e-a69e-76413ba3bdc7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ResearchAndDevelopmentTaxIncentiveCurrent_0acc0a19-6209-44ec-b62c-b6073b3be478_terseLabel_en-US" xlink:label="lab_imux_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian research and development tax incentive</link:label>
    <link:label id="lab_imux_ResearchAndDevelopmentTaxIncentiveCurrent_label_en-US" xlink:label="lab_imux_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive, Current</link:label>
    <link:label id="lab_imux_ResearchAndDevelopmentTaxIncentiveCurrent_documentation_en-US" xlink:label="lab_imux_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:href="imux-20221231.xsd#imux_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:to="lab_imux_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1e23bf2c-e809-40b6-b242-a412fada4579_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0ad06c0f-74da-49bb-9588-92f6fda44fed_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_InvestmentEarningInterestRateRemainingMaturityPeriod_9b6966ff-79d8-48fd-ab36-ff773ea17f1d_terseLabel_en-US" xlink:label="lab_imux_InvestmentEarningInterestRateRemainingMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earning interest at a rate maturity (in months)</link:label>
    <link:label id="lab_imux_InvestmentEarningInterestRateRemainingMaturityPeriod_label_en-US" xlink:label="lab_imux_InvestmentEarningInterestRateRemainingMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Earning Interest Rate, Remaining Maturity Period</link:label>
    <link:label id="lab_imux_InvestmentEarningInterestRateRemainingMaturityPeriod_documentation_en-US" xlink:label="lab_imux_InvestmentEarningInterestRateRemainingMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Earning Interest Rate, Remaining Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_InvestmentEarningInterestRateRemainingMaturityPeriod" xlink:href="imux-20221231.xsd#imux_InvestmentEarningInterestRateRemainingMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_InvestmentEarningInterestRateRemainingMaturityPeriod" xlink:to="lab_imux_InvestmentEarningInterestRateRemainingMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_56c336c3-278e-425a-87d0-3e80f8b2f71d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c7e48fb1-7553-4ed9-89d8-a54c22bd9c7c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3caa3e2c-5e90-459f-905c-2aa080fdf1ce_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5bbd9369-9421-4c73-8b34-7ec874d446e7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_47a44c41-bd98-41ea-9123-aab92ea88fe8_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_e9f87874-8962-46e2-97a8-5d8b3d9b29ff_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_PreFundedWarrantsMember_d73212bd-480e-4b4a-8351-565f1ac4a67c_terseLabel_en-US" xlink:label="lab_imux_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded stock warrants</link:label>
    <link:label id="lab_imux_PreFundedWarrantsMember_label_en-US" xlink:label="lab_imux_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_imux_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_imux_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PreFundedWarrantsMember" xlink:href="imux-20221231.xsd#imux_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_PreFundedWarrantsMember" xlink:to="lab_imux_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_49307b30-d400-47bf-a8c5-c5f0a9d69106_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_0821b890-4064-4303-85a8-7a5291b6beda_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a69fa209-357b-4be1-9ed4-3e0b3e66659c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_f564d243-1b5d-4afa-9352-75c184d969c9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_c96621d7-2670-4109-bf21-0b301e9c282d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_98469497-1df6-4c20-87d4-884329865fca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_e34ca86e-4d14-47b5-baaf-03593b1f2f11_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b28251f1-1ea9-4046-9f20-dd3f54108c50_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_28856b8c-014f-426e-aced-51544004ec00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_e453993f-37f0-48dc-a6c3-5f5bb0096ee2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_NumberOfFinancialInstitutionsUsedForCashDeposits_a190ac88-7e4b-4980-b717-b076614b551f_terseLabel_en-US" xlink:label="lab_imux_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of financial institutions used for cash deposits</link:label>
    <link:label id="lab_imux_NumberOfFinancialInstitutionsUsedForCashDeposits_label_en-US" xlink:label="lab_imux_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Financial Institutions Used For Cash Deposits</link:label>
    <link:label id="lab_imux_NumberOfFinancialInstitutionsUsedForCashDeposits_documentation_en-US" xlink:label="lab_imux_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Financial Institutions Used For Cash Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:href="imux-20221231.xsd#imux_NumberOfFinancialInstitutionsUsedForCashDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:to="lab_imux_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5f6e111f-8ae4-4785-bd2f-1834323ac6d3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, weighted-average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_979f8e9e-c282-4557-92d6-af2c04dbda48_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_68a8ed33-4a00-45c3-b36f-804b574cf562_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_575c6121-b61b-4c26-948c-ce82f520ffa8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c8d56e98-5760-4a45-b041-348750ff21f9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7362c877-bcdb-4879-a01c-5bdef1415b53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_b1f1fd85-f907-46e7-8535-f830f0f26522_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b681ad3-7bc0-4838-af27-5ddc06c52602_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_35e0b63b-133d-496a-b047-7bb43217cce0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_67e42d97-c95e-493b-94a0-a286e006a3e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_09dd3436-f34b-4ac8-9746-bb2ac2d64f8e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contributions per employee (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_d787253f-02f1-410e-beeb-41e8985dcb3d_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_4bbb5c18-bc21-4672-8cd4-4694dd24f3b4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments - other</link:label>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments" xlink:to="lab_us-gaap_OtherShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_bd159a18-73f8-4de5-956b-b71af0bace50_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a238ac9a-bbed-4dc4-a2bb-11c469b5a001_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2ea3b86e-2f16-405c-87e5-00ace35ee473_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_908e748a-7e9f-46a3-b19d-8165134fa0cf_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_df6d7113-3792-48db-b08e-680e537a6e78_verboseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_770c1b56-ec2c-4b6d-a871-ce5dc80212ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_64423a4e-ed4c-49f4-a1d7-7922e3e5af65_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_db3a664b-bf71-4546-a87a-ac168b50d421_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b0507568-3aa9-4c13-b6b8-38790568e4f2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f083d9e-abb9-44f8-ab3d-beb30bda9f94_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_c0cbacd6-2deb-4617-a119-e0f9e1a0d0e0_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2fd93a66-248f-4b8f-86f5-1cf45ae89925_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fba3b33a-a251-4cb8-84df-7407d0e9c4b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_894c82fa-1d02-4148-a7b0-ee2da2b94adc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3007f6d0-b846-484b-8d79-3127a9272934_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited and expired (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_7137adda-4506-4490-b548-10bfa80d438d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b318b853-71c4-4c87-a3f5-f2cc8e2dbd44_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_97259258-edbb-45e7-adcc-6c6317b458b7_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e0d5725d-8916-4635-a7e4-eb82827f070f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_6526a809-35d0-4a16-ae52-7676e5b33cb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0809ee39-9fbc-4ccc-a7f6-f3d780f091f8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_LesseeOperatingLeaseRentHolidayPeriod_a9e73a3e-0872-42be-baed-c34157600fb6_terseLabel_en-US" xlink:label="lab_imux_LesseeOperatingLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent holiday period</link:label>
    <link:label id="lab_imux_LesseeOperatingLeaseRentHolidayPeriod_label_en-US" xlink:label="lab_imux_LesseeOperatingLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Holiday Period</link:label>
    <link:label id="lab_imux_LesseeOperatingLeaseRentHolidayPeriod_documentation_en-US" xlink:label="lab_imux_LesseeOperatingLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Holiday Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LesseeOperatingLeaseRentHolidayPeriod" xlink:href="imux-20221231.xsd#imux_LesseeOperatingLeaseRentHolidayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_LesseeOperatingLeaseRentHolidayPeriod" xlink:to="lab_imux_LesseeOperatingLeaseRentHolidayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_July2021PublicEquityOfferingMember_986f66fd-bf81-4a8a-b6d4-6bf16e6bf2d3_terseLabel_en-US" xlink:label="lab_imux_July2021PublicEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2021 Public Equity Offering</link:label>
    <link:label id="lab_imux_July2021PublicEquityOfferingMember_label_en-US" xlink:label="lab_imux_July2021PublicEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2021 Public Equity Offering [Member]</link:label>
    <link:label id="lab_imux_July2021PublicEquityOfferingMember_documentation_en-US" xlink:label="lab_imux_July2021PublicEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2021 Public Equity Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_July2021PublicEquityOfferingMember" xlink:href="imux-20221231.xsd#imux_July2021PublicEquityOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_July2021PublicEquityOfferingMember" xlink:to="lab_imux_July2021PublicEquityOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_8c03329f-1611-4cbb-b6f2-1e10bc05b8a5_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_645bbbfe-37e0-4829-9916-ad64f7dd2353_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_TwoThousandFourteenEquityIncentivePlanMember_8dd6a14a-9633-4971-ad2e-720d1cc3912f_terseLabel_en-US" xlink:label="lab_imux_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Equity Incentive Plan</link:label>
    <link:label id="lab_imux_TwoThousandFourteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_imux_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_imux_TwoThousandFourteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_imux_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandFourteenEquityIncentivePlanMember" xlink:href="imux-20221231.xsd#imux_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="lab_imux_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5cd006f6-d81b-4b76-a5e3-9f4380a71516_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_22b1bba7-0f0f-4c14-b2c0-214e65e42e4e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2e2c6383-47e7-4a55-afe5-b79d703c842d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_OperatingLeaseIncrementalBorrowingRate_12aa8aac-1a0e-4036-8058-7041d131fc8b_terseLabel_en-US" xlink:label="lab_imux_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate on operating leases</link:label>
    <link:label id="lab_imux_OperatingLeaseIncrementalBorrowingRate_label_en-US" xlink:label="lab_imux_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:label id="lab_imux_OperatingLeaseIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_imux_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_OperatingLeaseIncrementalBorrowingRate" xlink:href="imux-20221231.xsd#imux_OperatingLeaseIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_OperatingLeaseIncrementalBorrowingRate" xlink:to="lab_imux_OperatingLeaseIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_50e0cb2e-72a1-4726-9341-ba59467378a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6c833719-4492-4424-8898-6fb9a38d8719_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_8a7324b8-b869-4be3-8f93-ae18a4f5bb78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ff7dd938-ed2f-4db3-abde-0827f21d9f1d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1dd61049-7c86-4242-a48f-0c485cf87159_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1c8f19c4-a6fe-41c4-b3cd-3299539737fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_607b5d92-4eea-49b5-ba9b-ef61e210e3c1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_610bd736-ffde-4b43-8116-a181b92c6040_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_85432f36-3b9c-4785-9c98-24177613864d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c23f6ea5-b937-4022-a361-a9da8e6ed027_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b44bfafa-8522-42f3-a319-79fa8d0cfaf9_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cabb5c4c-7790-42c5-8dfb-da9b50d64704_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_44bef164-e650-4ea8-803e-f7138cb4f3b9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ExecutiveChairmanAgreementMember_eee25887-856b-403e-914a-1e212506fe16_terseLabel_en-US" xlink:label="lab_imux_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement</link:label>
    <link:label id="lab_imux_ExecutiveChairmanAgreementMember_label_en-US" xlink:label="lab_imux_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement [Member]</link:label>
    <link:label id="lab_imux_ExecutiveChairmanAgreementMember_documentation_en-US" xlink:label="lab_imux_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ExecutiveChairmanAgreementMember" xlink:href="imux-20221231.xsd#imux_ExecutiveChairmanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ExecutiveChairmanAgreementMember" xlink:to="lab_imux_ExecutiveChairmanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_SharesIssuedWeightedAverageSharePricePerShare_b090077a-fbe2-4712-afe4-1048b10de5fb_terseLabel_en-US" xlink:label="lab_imux_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Weighted Average Share Price Per Share</link:label>
    <link:label id="lab_imux_SharesIssuedWeightedAverageSharePricePerShare_label_en-US" xlink:label="lab_imux_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Weighted Average Share Price Per Share</link:label>
    <link:label id="lab_imux_SharesIssuedWeightedAverageSharePricePerShare_documentation_en-US" xlink:label="lab_imux_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Weighted Average Share Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SharesIssuedWeightedAverageSharePricePerShare" xlink:href="imux-20221231.xsd#imux_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_SharesIssuedWeightedAverageSharePricePerShare" xlink:to="lab_imux_SharesIssuedWeightedAverageSharePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_dd707892-8971-4cdc-af5c-0f4f5fcbab83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_AustraliaAndGermanyMember_4802addc-429f-4c77-b1b6-9facf6756cbe_terseLabel_en-US" xlink:label="lab_imux_AustraliaAndGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia and Germany</link:label>
    <link:label id="lab_imux_AustraliaAndGermanyMember_label_en-US" xlink:label="lab_imux_AustraliaAndGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia and Germany [Member]</link:label>
    <link:label id="lab_imux_AustraliaAndGermanyMember_documentation_en-US" xlink:label="lab_imux_AustraliaAndGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia and Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AustraliaAndGermanyMember" xlink:href="imux-20221231.xsd#imux_AustraliaAndGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_AustraliaAndGermanyMember" xlink:to="lab_imux_AustraliaAndGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_b1802a6b-c02b-4d77-a972-d0963fa3b04d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_d671e55a-2bc4-4c67-a754-ecbe0d1748a8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8904a9d0-5a8e-4649-abd2-f336e945257f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e8f95b23-d136-4ce4-8fd9-6eebb9eb39c9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e02b86e4-45dd-4fb3-ac1a-be3a508a4135_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which compensation cost will be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21c385a5-1678-4ee2-b4ca-0ed850f5de21_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, weighted-average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_08237b75-6f9d-404a-833c-002670bc7a28_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_52d63799-53b5-4ad5-9fc8-273e6378fc49_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of Investments-other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_33a2a47d-db56-4769-b53a-51388890911b_terseLabel_en-US" xlink:label="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:href="imux-20221231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:to="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_873f2861-ce97-4485-ab0b-e8ecf409e694_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_dba445c6-941e-4d19-ae3e-2462c6906559_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7a58d119-670b-47c3-acec-8fdccf052548_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_da4c2c06-4142-4106-a792-987301a6344f_terseLabel_en-US" xlink:label="lab_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:label id="lab_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_label_en-US" xlink:label="lab_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:label id="lab_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_documentation_en-US" xlink:label="lab_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:href="imux-20221231.xsd#imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:to="lab_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_AccruedLegalAndAuditCostsCurrent_c34b3d16-afb2-41ba-b003-c78e1ba23c02_terseLabel_en-US" xlink:label="lab_imux_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal and audit costs</link:label>
    <link:label id="lab_imux_AccruedLegalAndAuditCostsCurrent_label_en-US" xlink:label="lab_imux_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:label id="lab_imux_AccruedLegalAndAuditCostsCurrent_documentation_en-US" xlink:label="lab_imux_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedLegalAndAuditCostsCurrent" xlink:href="imux-20221231.xsd#imux_AccruedLegalAndAuditCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_AccruedLegalAndAuditCostsCurrent" xlink:to="lab_imux_AccruedLegalAndAuditCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_b089808b-3926-459e-8df6-d723a96b26d8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f62d72b1-f924-42d0-9c90-2b0282a16e8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmount_31ab21ab-60fc-4902-855a-c68244968d7e_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government assistance, amount</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmount_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceAmount" xlink:to="lab_us-gaap_GovernmentAssistanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_075bef7f-62cd-4571-9ecd-37acc72b92cc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_90c477f6-5cae-433e-8255-643fe13eca1e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_DeferredTaxAssetsAndLiabilitiesGross_71a92c10-cc4d-49a1-a04e-0ee31f2eadbb_totalLabel_en-US" xlink:label="lab_imux_DeferredTaxAssetsAndLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_imux_DeferredTaxAssetsAndLiabilitiesGross_label_en-US" xlink:label="lab_imux_DeferredTaxAssetsAndLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets and Liabilities, Gross</link:label>
    <link:label id="lab_imux_DeferredTaxAssetsAndLiabilitiesGross_documentation_en-US" xlink:label="lab_imux_DeferredTaxAssetsAndLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets and Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DeferredTaxAssetsAndLiabilitiesGross" xlink:href="imux-20221231.xsd#imux_DeferredTaxAssetsAndLiabilitiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_DeferredTaxAssetsAndLiabilitiesGross" xlink:to="lab_imux_DeferredTaxAssetsAndLiabilitiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_4e16c875-ad77-4737-aa9c-0942ac7fcc32_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3b0a96a0-99a3-4fc9-834f-4c2f8721cbe3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistancePolicyTextBlock_968711b3-f002-4a4b-9cfe-c807fdd925bb_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government assistance</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistancePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e839c132-33b1-4421-bd5d-d2fde855abc3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_039fa4e1-d389-4cef-8e65-bf8e383384a5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f019ebfa-b85b-46f3-b3e6-fdc288263685_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_67016004-cbc0-4eb0-8dda-34b8dcf37552_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a7da77e1-9452-443e-83b3-caa8984f09af_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_a6d5346b-7174-4d9d-9fa4-3ddf4739d2e8_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_856929b9-ee56-4f51-88af-b1048082119f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_e599e0db-14d5-4fd4-84df-f6549bab60ad_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_226308af-a977-4cb8-8c17-d0e1b8f979ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_174ec53c-b85a-48ce-886a-071a31f338b4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_38490af7-afb8-4406-89de-97052dc1aefb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a10f95e4-599a-488e-ac3a-1b1f9975b7dd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_3be18c4c-35b8-44ac-9787-5752c5970126_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest , weighted-average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_248e0a83-ec5b-4be8-a7b2-bb2a9ece6a9b_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ec5e589d-170c-4c27-8357-eab7911bdf35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under the ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_74fade3b-072a-47de-b97a-f186bc734d32_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_GrafelfingGermanyMember_7a564775-9e8c-4959-aa2f-8d894c75bfec_terseLabel_en-US" xlink:label="lab_imux_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany</link:label>
    <link:label id="lab_imux_GrafelfingGermanyMember_label_en-US" xlink:label="lab_imux_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany [Member]</link:label>
    <link:label id="lab_imux_GrafelfingGermanyMember_documentation_en-US" xlink:label="lab_imux_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_GrafelfingGermanyMember" xlink:href="imux-20221231.xsd#imux_GrafelfingGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_GrafelfingGermanyMember" xlink:to="lab_imux_GrafelfingGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c1d468a1-847c-45b2-93a4-08f4450380c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_663e2e09-4964-4b9d-9ff1-9ceb8f2c55a6_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a1834e47-c9b7-4c06-8498-14472a7e8115_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_e7755701-e6e4-4d74-a53e-d6e66cd3d557_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2f315a30-a46d-42b1-88de-1b71f9164f35_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_AU_057f6892-5c7e-462d-a16c-022b6ac2ec15_terseLabel_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia</link:label>
    <link:label id="lab_country_AU_label_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AUSTRALIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4a37bafc-393c-4fc5-9bf1-0760b28811df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_fa6d2989-f4dc-440c-ba17-b7274c470410_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_c2d813e3-7b51-4f27-91dd-c1a2f5a137f5_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VAT receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_0b5fd59f-a5ba-4a5e-b91a-8130b2a4d20a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_43765293-3976-4258-90b5-988d0ab7874c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_GovernmentAssistanceRate_d0dd3227-867f-4aac-b1ac-5aa7c4dbb754_terseLabel_en-US" xlink:label="lab_imux_GovernmentAssistanceRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government assistance rate</link:label>
    <link:label id="lab_imux_GovernmentAssistanceRate_label_en-US" xlink:label="lab_imux_GovernmentAssistanceRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance Rate</link:label>
    <link:label id="lab_imux_GovernmentAssistanceRate_documentation_en-US" xlink:label="lab_imux_GovernmentAssistanceRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_GovernmentAssistanceRate" xlink:href="imux-20221231.xsd#imux_GovernmentAssistanceRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_GovernmentAssistanceRate" xlink:to="lab_imux_GovernmentAssistanceRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8a6d8d2d-dc7a-49b8-aff8-32ed17845c19_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_PrepaidClinicalAndRelatedCostsCurrent_1e0fc6cb-1173-46f5-b94c-3a34c6d53803_terseLabel_en-US" xlink:label="lab_imux_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical and related costs</link:label>
    <link:label id="lab_imux_PrepaidClinicalAndRelatedCostsCurrent_label_en-US" xlink:label="lab_imux_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:label id="lab_imux_PrepaidClinicalAndRelatedCostsCurrent_documentation_en-US" xlink:label="lab_imux_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PrepaidClinicalAndRelatedCostsCurrent" xlink:href="imux-20221231.xsd#imux_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_PrepaidClinicalAndRelatedCostsCurrent" xlink:to="lab_imux_PrepaidClinicalAndRelatedCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_7d1b5bb9-0dff-465c-828b-67c18ab8a221_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_60f19c01-8a59-480e-b934-629735fac9dd_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3abe27c7-fbdd-4342-bbae-e89fad6c03ce_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_88328d22-3399-4120-8dad-48afb52405a2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_A2017InducementEquityIncentivePlanMember_49df2c3d-1ab8-4538-8972-2654175a5cab_terseLabel_en-US" xlink:label="lab_imux_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan</link:label>
    <link:label id="lab_imux_A2017InducementEquityIncentivePlanMember_label_en-US" xlink:label="lab_imux_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_imux_A2017InducementEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_imux_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2017InducementEquityIncentivePlanMember" xlink:href="imux-20221231.xsd#imux_A2017InducementEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_A2017InducementEquityIncentivePlanMember" xlink:to="lab_imux_A2017InducementEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_b7ec018d-1520-4580-bb55-7bb731749866_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e88d1654-10d7-4a8a-941e-5156ed1befa1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6587efca-37cb-4bf4-8c21-efe9b43af09b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issues in private placement transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_98c8d770-c26d-4acc-9995-be5b70868451_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3bd71a7b-b96e-4467-9bb3-ff73e5c66f43_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_bf544d5a-3711-4f8a-9b00-0c62b234e41f_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_759fbdbf-e3b4-41bd-b3be-53cf46e2c556_terseLabel_en-US" xlink:label="lab_imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Other Investments</link:label>
    <link:label id="lab_imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_label_en-US" xlink:label="lab_imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Other Investments [Policy Text Block]</link:label>
    <link:label id="lab_imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_documentation_en-US" xlink:label="lab_imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:href="imux-20221231.xsd#imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:to="lab_imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c79df740-daf9-4583-867b-198dd2793971_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_db44f493-8ec6-42fd-a104-c591575f18f1_terseLabel_en-US" xlink:label="lab_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May not exercise of percentage</link:label>
    <link:label id="lab_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_label_en-US" xlink:label="lab_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage</link:label>
    <link:label id="lab_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_documentation_en-US" xlink:label="lab_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:href="imux-20221231.xsd#imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:to="lab_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_574d78c7-2a6b-4666-a3e0-4ef534172b73_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c12b6f3b-99d6-40eb-bdd6-13810444133e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f1bc5582-818f-4417-9805-6c767070355a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_36e211dc-4b71-431f-bc12-90f951bb02af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_416838bf-e3d2-43a2-8359-275b767a50ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_2bb95c7f-b101-46c9-a660-93a6679714b9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_0d0bacae-cbab-4bb4-8a56-676c5a6f902f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a3396f36-e04c-4144-97c1-e22a36e60eee_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c870129c-6823-4482-b998-48b6953722a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_fd0e5616-20fe-444c-ac8d-0862669b1f5e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investment</link:label>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTableTextBlock" xlink:to="lab_us-gaap_InvestmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_NonStatutoryEmployeeStockOptionMember_aba0b6de-bba4-4ce8-beeb-c5fd708c4a70_terseLabel_en-US" xlink:label="lab_imux_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option</link:label>
    <link:label id="lab_imux_NonStatutoryEmployeeStockOptionMember_label_en-US" xlink:label="lab_imux_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:label id="lab_imux_NonStatutoryEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_imux_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_NonStatutoryEmployeeStockOptionMember" xlink:href="imux-20221231.xsd#imux_NonStatutoryEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_NonStatutoryEmployeeStockOptionMember" xlink:to="lab_imux_NonStatutoryEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_1fc56c33-b220-4377-ab44-4697d8a7ab24_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_fc0eb413-9218-4b87-ab64-f631a5ab3fed_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2a9ff2ae-f16b-482b-8d80-e50d497e3c58_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_473457cf-f892-42db-814c-989fc590f7d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_AccruedCompensationCurrent_e280edc7-e39c-4d2e-a203-164666998383_terseLabel_en-US" xlink:label="lab_imux_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_imux_AccruedCompensationCurrent_label_en-US" xlink:label="lab_imux_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:label id="lab_imux_AccruedCompensationCurrent_documentation_en-US" xlink:label="lab_imux_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedCompensationCurrent" xlink:href="imux-20221231.xsd#imux_AccruedCompensationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_AccruedCompensationCurrent" xlink:to="lab_imux_AccruedCompensationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7380d770-1caf-4dc3-9b9b-bdb15e301478_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_da57eb4a-345b-4ca6-b734-9b40ffff8510_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_780c005b-a830-407a-87ac-a477f8b7cd3d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_e7aeb677-7c7a-4c52-914d-ba4ef4ea5f15_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f3c3a22e-ea05-4342-96ec-e8bbb4d88a87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted-Average Exercise Price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a5255463-b7ab-4a46-9aa6-d9c01365a174_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_a2599018-b48c-4c37-a963-f0d3c346e7f6_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b8c733fd-fe79-400a-9a2e-02bf87f73a30_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_55bfa5ea-9457-4e5d-a092-3a98fd4000b5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ImmunicAGMember_48e7d39c-81ed-4c98-9a7f-49b173a7d2ca_terseLabel_en-US" xlink:label="lab_imux_ImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic AG</link:label>
    <link:label id="lab_imux_ImmunicAGMember_label_en-US" xlink:label="lab_imux_ImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic AG [Member]</link:label>
    <link:label id="lab_imux_ImmunicAGMember_documentation_en-US" xlink:label="lab_imux_ImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic AG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicAGMember" xlink:href="imux-20221231.xsd#imux_ImmunicAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ImmunicAGMember" xlink:to="lab_imux_ImmunicAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_99d9972f-e3c1-4a78-8682-7d2e8d2c5e1a_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_98813ab4-6a6f-4745-abac-12eb4025ad1d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_991018d7-b51b-4957-a3ad-7af7bf994f9d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_19461cba-ce5f-47eb-8f72-a7357d77b381_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_440120f4-b975-4d10-8324-fbbf0c5af7f7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d71954e5-7330-4412-9a83-fadaa19dc961_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_15a327ef-d57c-4df6-8d9e-9d448dc3f2aa_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_bdebff22-20af-4393-bcc0-4173414fefde_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_83117a9f-2dc1-48b3-9cc4-80acdcbeaf27_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Weighted-Average Exercise Price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_80e3373d-f4f7-4904-be35-82641d5e2c30_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_c220cdf5-970b-4820-9244-d64b305de322_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e37ee590-4365-4471-b0e0-9ad35a1b9d9d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_42008c0b-4e15-4197-9a10-cdb34a2e07f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c3b5efcf-03ba-4836-8fec-6a397f2d9511_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b08065b0-34fe-46b8-8c9f-05b3be214ee8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalMinistryOfFinanceGermanyMember_2113215e-d124-4dab-b82e-f7aca6ed9254_terseLabel_en-US" xlink:label="lab_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_us-gaap_FederalMinistryOfFinanceGermanyMember_label_en-US" xlink:label="lab_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Ministry of Finance, Germany [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalMinistryOfFinanceGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:to="lab_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a5931528-b696-4249-8d4d-9ce91d41bc3e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_77ead1eb-56c5-48df-8b98-f32372ac5adf_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7c2bf918-388a-4977-9ea7-2365276a5a69_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c2122a0d-e928-42ff-923d-fbbee72fc88b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_185d2975-a67a-4bc1-9814-804b8b36a24d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_31e8a46f-2fca-46fd-b8e0-27350e6d0c0f_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (note 2)</link:label>
    <link:label id="lab_us-gaap_Goodwill_2bb24bb6-3655-42b1-ae6c-522bd3146165_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of goodwill at December 31, 2021</link:label>
    <link:label id="lab_us-gaap_Goodwill_c4398c27-20b9-41f9-865a-d3ce1e21cd2b_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of goodwill at December 31, 2022</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_5d96cb31-1090-4a1e-a6f2-4a93c7d1c1be_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_cac139d9-52da-4023-b185-5b8d90242878_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_725b1a51-ecd4-435d-8cd7-89b3046f7c5c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d8c5b75e-d6f4-400f-9b39-383740cf4f12_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2c5eafe4-a5cc-4dfa-849e-c16b145377fe_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_d3808811-b5ca-41e9-bf5a-6ec65187d4b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b1a57a3b-9abf-49dd-b002-55d755627d4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_b97d3fc5-357b-451f-afd9-35438c14ebe9_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_93bdb020-dc82-4eef-aff2-9c0b9d4dee6c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c220549d-21f5-4a93-9d45-951a0b914852_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_EmployeeMember_6370b0dc-e6f0-4598-8a4a-8f3328bd286f_terseLabel_en-US" xlink:label="lab_imux_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_imux_EmployeeMember_label_en-US" xlink:label="lab_imux_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_imux_EmployeeMember_documentation_en-US" xlink:label="lab_imux_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeMember" xlink:href="imux-20221231.xsd#imux_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_EmployeeMember" xlink:to="lab_imux_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e01e917b-04ce-489c-ba52-aa30bce4b1f5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_98e90ba3-8c26-419a-892b-16cc54b531ea_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_486ca63e-1d23-4f8b-b458-93951dcbd6dd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_TaxYearsPriorTo2018Member_b725e88a-31b3-443c-8d8f-1c7f2ab3b556_terseLabel_en-US" xlink:label="lab_imux_TaxYearsPriorTo2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to 2018</link:label>
    <link:label id="lab_imux_TaxYearsPriorTo2018Member_label_en-US" xlink:label="lab_imux_TaxYearsPriorTo2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years Prior to 2018 [Member]</link:label>
    <link:label id="lab_imux_TaxYearsPriorTo2018Member_documentation_en-US" xlink:label="lab_imux_TaxYearsPriorTo2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years Prior to 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TaxYearsPriorTo2018Member" xlink:href="imux-20221231.xsd#imux_TaxYearsPriorTo2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_TaxYearsPriorTo2018Member" xlink:to="lab_imux_TaxYearsPriorTo2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_570bf292-ebfa-43a1-bde1-eb2390a0c462_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain or loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Unrealized Currency Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:to="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_LesseeOperatingLeasesNumberOfExistingLeases_a5501cf5-93ff-4f28-9166-31894b4d1032_terseLabel_en-US" xlink:label="lab_imux_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of existing operating leases</link:label>
    <link:label id="lab_imux_LesseeOperatingLeasesNumberOfExistingLeases_label_en-US" xlink:label="lab_imux_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:label id="lab_imux_LesseeOperatingLeasesNumberOfExistingLeases_documentation_en-US" xlink:label="lab_imux_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LesseeOperatingLeasesNumberOfExistingLeases" xlink:href="imux-20221231.xsd#imux_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_LesseeOperatingLeasesNumberOfExistingLeases" xlink:to="lab_imux_LesseeOperatingLeasesNumberOfExistingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_82224b0b-2397-4db3-8511-6673a1cb2cd8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock cash dividends paid (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_13ef518d-d5d5-47f6-bf7b-4401320a927a_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_c7287991-0170-4d65-b464-59597eb5dd30_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 130,000,000 shares authorized and 39,307,286 and 26,335,418 shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_6f7af036-0009-4a5e-bd13-a22a0867c5e6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_396e1283-e660-4b4f-b010-1e8471d3ab35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_afe4b4d8-b132-4b3f-8837-e56ca4e9644f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b0f5379f-e0ba-454b-8b46-6425c7998b1c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_37bf189f-ca2e-4b33-8774-8e3ebd8a0304_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_39806205-2249-48c3-86d7-6c41d90a9e0b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d74c14c5-f2df-4e66-ae9a-32a46a274deb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69c4a3be-1030-49c1-ad1b-11d02aaa073d_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b471d5a4-4f5b-4a80-ae9f-79efaf034c98_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_de8d248d-6695-4bd9-aa33-2317a545fc9b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_b43e12ac-2cf6-40ec-872e-9bfa479537b8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4af0225d-17e2-4bef-b1ab-d15b0ebe13da_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_10bb919b-d70a-40d4-9eb8-60e0601d3472_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ea2eca82-3533-4669-b0af-6768ac322d98_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_48946327-bb9e-425d-b4a7-e306084aff35_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_7c8e1c0e-60f7-41a8-a257-15b2a89c3245_terseLabel_en-US" xlink:label="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:label id="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_label_en-US" xlink:label="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]</link:label>
    <link:label id="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_documentation_en-US" xlink:label="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:href="imux-20221231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:to="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_246d449b-569b-4c1b-ab73-fecf5aa7ff62_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0e96a596-159c-44a1-b9ce-ef8e50a187c3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_88a4c1f1-6c32-4f6c-981f-49372c888c47_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_DuaneNashMDJDMBAMember_4954cd54-0a14-40b9-8c64-f91db899fcd0_terseLabel_en-US" xlink:label="lab_imux_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA</link:label>
    <link:label id="lab_imux_DuaneNashMDJDMBAMember_label_en-US" xlink:label="lab_imux_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA [Member]</link:label>
    <link:label id="lab_imux_DuaneNashMDJDMBAMember_documentation_en-US" xlink:label="lab_imux_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DuaneNashMDJDMBAMember" xlink:href="imux-20221231.xsd#imux_DuaneNashMDJDMBAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_DuaneNashMDJDMBAMember" xlink:to="lab_imux_DuaneNashMDJDMBAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_f85a621f-6e03-4407-8edf-fd3b77d1a2a4_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_85066a4f-c405-4a55-af40-de3d7ca45c1f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d2e84f76-a3fb-4b82-932e-7eea209b1e03_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8f75245a-3874-4412-abc3-c0ed89d5ba1d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in connection with the Company's employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_934f9c2f-feae-4ef7-aa78-ed0b08b20af5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_53cc9990-a625-4ca0-8f0c-1737efaf9a06_terseLabel_en-US" xlink:label="lab_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase or decrease not In excess of prior notice period</link:label>
    <link:label id="lab_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_label_en-US" xlink:label="lab_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period</link:label>
    <link:label id="lab_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_documentation_en-US" xlink:label="lab_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:href="imux-20221231.xsd#imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:to="lab_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5b54c8c4-968e-4a3a-8660-d9d921b7abd8_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_a65100f6-1485-4432-b5fe-8c78bc80e177_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0097cac1-f4c6-482f-a7fa-fcea76cebf6f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_bb423505-ae4e-4dfc-9d63-486d618668ef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f87f0605-186a-4d2a-b1dd-653026464abd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d3a2bc0e-807b-4a9f-868b-52a24121874d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_fad27049-2f73-4fc3-9adc-5c8de726d7a5_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_49171008-09c9-426a-b7e2-0e5376a8e65e_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e929b453-1b3e-457a-aeb2-0db80317f1ee_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_61aa5b9b-14f5-47b6-b780-e00a6379a080_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_3f358afb-c360-459c-b83e-2f93ed56ccca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7cf4ab38-5275-4d96-b2fb-81699aeb4429_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in connection with the Company's employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_dcb633a4-9314-4171-971b-d2eba2f0f6f0_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82188867-c781-4193-95ae-ad6e06bf89e0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_715d605b-ec4b-42e2-8724-80215dad3a49_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_90f923d7-0429-44f2-aa67-46e52a4417c5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_3a2acf8b-f8ca-4fe9-985e-9ae4a60a52da_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCommissions_7ade5373-b45e-4267-a12c-8d2fa0f8715b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter commissions</link:label>
    <link:label id="lab_us-gaap_PaymentsForCommissions_label_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCommissions" xlink:to="lab_us-gaap_PaymentsForCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_9590d3f3-dac8-407d-9a3b-c493782f199d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d8517d51-416a-4473-804a-7bf4a8095dbc_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_NewYorkCityMember_1b9a3b27-3ed9-4cf7-b744-4a6a1f26af92_terseLabel_en-US" xlink:label="lab_imux_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City</link:label>
    <link:label id="lab_imux_NewYorkCityMember_label_en-US" xlink:label="lab_imux_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City [Member]</link:label>
    <link:label id="lab_imux_NewYorkCityMember_documentation_en-US" xlink:label="lab_imux_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_NewYorkCityMember" xlink:href="imux-20221231.xsd#imux_NewYorkCityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_NewYorkCityMember" xlink:to="lab_imux_NewYorkCityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9517f299-00a8-4097-b0bc-ca962eaf7c4a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_bfe41ef2-8673-416b-b2b0-ce7c5bc47e11_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1f9d9376-310a-4866-93cc-01f6019f7457_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_16a4635f-854e-418f-b97c-f07def14ab6a_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_69cdf8c6-d428-41ae-a6fb-561e7adb8286_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9633ae84-25f6-4ee7-a412-1b8c3e1c25d4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_d62ed868-792e-4bf2-bd7a-87b827a45389_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_eaa7ce90-13cc-4108-8026-248aaa233b0a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b10ee0a9-a31e-4a7c-8d21-d17e45272775_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f0489b6c-b95e-4c65-9b36-fe5d9ab7e9a0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_d2a1c91e-093b-45b9-b046-3b33e594b256_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7b20268a-fafd-4eb6-a182-968eb06c48aa_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75908622-6712-41e7-bd5f-6cb516d187cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_624ecf9f-5c12-471b-ae06-c6a44a40bc0c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_fb150ed6-b4d3-4899-a82c-5db1a9f84e0a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_RoyaltySettlementAgreementCashPaymentPercent_746119a6-e813-4aed-a58f-130c724ab83c_terseLabel_en-US" xlink:label="lab_imux_RoyaltySettlementAgreementCashPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty settlement agreement, cash payment, percent</link:label>
    <link:label id="lab_imux_RoyaltySettlementAgreementCashPaymentPercent_label_en-US" xlink:label="lab_imux_RoyaltySettlementAgreementCashPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Cash Payment, Percent</link:label>
    <link:label id="lab_imux_RoyaltySettlementAgreementCashPaymentPercent_documentation_en-US" xlink:label="lab_imux_RoyaltySettlementAgreementCashPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Cash Payment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_RoyaltySettlementAgreementCashPaymentPercent" xlink:href="imux-20221231.xsd#imux_RoyaltySettlementAgreementCashPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_RoyaltySettlementAgreementCashPaymentPercent" xlink:to="lab_imux_RoyaltySettlementAgreementCashPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2546053d-2f72-454d-bff6-68684eff9c71_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_8f770e5e-2902-400e-91e8-b44d1747823e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_34925eb1-9c73-4c19-98a0-9fca46b93cac_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_A4SCRoyaltySettlementMember_d593c157-5c21-4744-a6da-5429f4d8d5e3_terseLabel_en-US" xlink:label="lab_imux_A4SCRoyaltySettlementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC Royalty Settlement</link:label>
    <link:label id="lab_imux_A4SCRoyaltySettlementMember_label_en-US" xlink:label="lab_imux_A4SCRoyaltySettlementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC Royalty Settlement [Member]</link:label>
    <link:label id="lab_imux_A4SCRoyaltySettlementMember_documentation_en-US" xlink:label="lab_imux_A4SCRoyaltySettlementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC Royalty Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A4SCRoyaltySettlementMember" xlink:href="imux-20221231.xsd#imux_A4SCRoyaltySettlementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_A4SCRoyaltySettlementMember" xlink:to="lab_imux_A4SCRoyaltySettlementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_6396fe28-cf4c-4aa8-b5fe-b0aa710ef53e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, cash dividends declared (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_December2020ATMMember_b976d7b8-77a0-4f0b-be92-7bc9a8ed7fd4_terseLabel_en-US" xlink:label="lab_imux_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM</link:label>
    <link:label id="lab_imux_December2020ATMMember_label_en-US" xlink:label="lab_imux_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM [Member]</link:label>
    <link:label id="lab_imux_December2020ATMMember_documentation_en-US" xlink:label="lab_imux_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_December2020ATMMember" xlink:href="imux-20221231.xsd#imux_December2020ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_December2020ATMMember" xlink:to="lab_imux_December2020ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_d102bb25-1d23-4510-b8ff-f97d00464204_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_5d607554-7673-42af-8d73-8e56f9005059_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued in connection with the 4SC royalty settlement (see Note 4)</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_8f6ec1cf-ff3d-47a5-90cb-68b122263b6a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9b100983-b5f0-4654-819e-d72c314858ca_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_dfad3496-b60e-4c11-b62f-aff44f69ab07_terseLabel_en-US" xlink:label="lab_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in operating lease, right-of-use asset</link:label>
    <link:label id="lab_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="imux-20221231.xsd#imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62e36901-172c-4775-8e2e-77118cf4ce73_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c4b56f3-2999-4d9a-b09f-539642411d6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2ba6b2dd-b158-4d20-a628-f3a34e331e80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_OperatingAndVariableLeasesCost_27d0e2e2-e52a-4142-a075-cf5530673b1e_terseLabel_en-US" xlink:label="lab_imux_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and variable lease cost</link:label>
    <link:label id="lab_imux_OperatingAndVariableLeasesCost_label_en-US" xlink:label="lab_imux_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:label id="lab_imux_OperatingAndVariableLeasesCost_documentation_en-US" xlink:label="lab_imux_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_OperatingAndVariableLeasesCost" xlink:href="imux-20221231.xsd#imux_OperatingAndVariableLeasesCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_OperatingAndVariableLeasesCost" xlink:to="lab_imux_OperatingAndVariableLeasesCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bd700e2a-bc4e-486a-a459-7aa177f32968_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_b2077f85-08fb-4429-8475-08e1643fc3bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_60933577-5670-42c4-9cda-cda4f35c0e3f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ba84fcd8-fdd5-4445-a09c-af300a4983b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_bb54b0ce-58e7-4897-b283-0c9eff1e8857_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ForeignExcludingGermanyMember_e5ebd394-f0c8-4a9e-a610-36f5146b2a27_terseLabel_en-US" xlink:label="lab_imux_ForeignExcludingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_imux_ForeignExcludingGermanyMember_label_en-US" xlink:label="lab_imux_ForeignExcludingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign, Excluding Germany [Member]</link:label>
    <link:label id="lab_imux_ForeignExcludingGermanyMember_documentation_en-US" xlink:label="lab_imux_ForeignExcludingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign, Excluding Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ForeignExcludingGermanyMember" xlink:href="imux-20221231.xsd#imux_ForeignExcludingGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ForeignExcludingGermanyMember" xlink:to="lab_imux_ForeignExcludingGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_A2021EmployeeStockPurchasePlanMember_ec29e229-0cfb-409f-9d93-1d3e42ba9ca2_terseLabel_en-US" xlink:label="lab_imux_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee stock purchase plan</link:label>
    <link:label id="lab_imux_A2021EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_imux_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_imux_A2021EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_imux_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2021EmployeeStockPurchasePlanMember" xlink:href="imux-20221231.xsd#imux_A2021EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_A2021EmployeeStockPurchasePlanMember" xlink:to="lab_imux_A2021EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7d3bb1dd-1712-4ae3-b3c1-aafeb49926a6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5be0f4bd-44b4-4213-a171-3c6f52b040a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_18f9ceec-6a26-4ef2-a7cf-14431989b2bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06fa3775-9b9e-47ee-adc7-9dc0af8db116_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_05636fe3-91e7-4ef1-ae92-4fdd01b398a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_6036f8d7-4254-4d64-b365-3472cd7011eb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_RoyaltySettlementAgreementSalesNet_bbecbc6e-39eb-4846-a74a-f7ad103e855e_terseLabel_en-US" xlink:label="lab_imux_RoyaltySettlementAgreementSalesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC Royalty Settlement (See Note 4)</link:label>
    <link:label id="lab_imux_RoyaltySettlementAgreementSalesNet_b0c48131-8fd5-41cb-86b8-1a73203b4bd9_verboseLabel_en-US" xlink:label="lab_imux_RoyaltySettlementAgreementSalesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC royalty settlement</link:label>
    <link:label id="lab_imux_RoyaltySettlementAgreementSalesNet_label_en-US" xlink:label="lab_imux_RoyaltySettlementAgreementSalesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Sales Net</link:label>
    <link:label id="lab_imux_RoyaltySettlementAgreementSalesNet_documentation_en-US" xlink:label="lab_imux_RoyaltySettlementAgreementSalesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Sales Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_RoyaltySettlementAgreementSalesNet" xlink:href="imux-20221231.xsd#imux_RoyaltySettlementAgreementSalesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_RoyaltySettlementAgreementSalesNet" xlink:to="lab_imux_RoyaltySettlementAgreementSalesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8e384aaa-4bc0-432d-90ef-f723ac8a9e0a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_5e15a3f8-32c8-4d5c-a145-41e9bdb41bed_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_abe71de5-e6be-436f-b0da-346c3a23fe78_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_5f497cbd-d699-44e4-b73e-81160c3f2b62_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ShelfRegistrationTerminationPriorWrittenNotice_c9ac7236-6b29-4a71-8e66-66259bd8ade2_terseLabel_en-US" xlink:label="lab_imux_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf registration, termination, prior written notice</link:label>
    <link:label id="lab_imux_ShelfRegistrationTerminationPriorWrittenNotice_label_en-US" xlink:label="lab_imux_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, Termination, Prior Written Notice</link:label>
    <link:label id="lab_imux_ShelfRegistrationTerminationPriorWrittenNotice_documentation_en-US" xlink:label="lab_imux_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, Termination, Prior Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShelfRegistrationTerminationPriorWrittenNotice" xlink:href="imux-20221231.xsd#imux_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ShelfRegistrationTerminationPriorWrittenNotice" xlink:to="lab_imux_ShelfRegistrationTerminationPriorWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_SalaryCostsMonthlyBaseSalary_3d057d99-f070-4476-b708-82e03ac006e7_terseLabel_en-US" xlink:label="lab_imux_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base salary</link:label>
    <link:label id="lab_imux_SalaryCostsMonthlyBaseSalary_label_en-US" xlink:label="lab_imux_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary Costs, Monthly Base Salary</link:label>
    <link:label id="lab_imux_SalaryCostsMonthlyBaseSalary_documentation_en-US" xlink:label="lab_imux_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary Costs, Monthly Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SalaryCostsMonthlyBaseSalary" xlink:href="imux-20221231.xsd#imux_SalaryCostsMonthlyBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_SalaryCostsMonthlyBaseSalary" xlink:to="lab_imux_SalaryCostsMonthlyBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_fc1cf43f-cc9d-40bf-bfab-ddf8e5257858_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest , aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityNumberOfEmployees_a4a244c0-64c5-48cc-82bd-113c8664553a_terseLabel_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_dei_EntityNumberOfEmployees_label_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Number of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_RoyaltySettlementAgreementSharesPaymentPercent_f6f9abef-9754-44a7-948b-8d289068441c_terseLabel_en-US" xlink:label="lab_imux_RoyaltySettlementAgreementSharesPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty settlement agreement, shares payment, percent</link:label>
    <link:label id="lab_imux_RoyaltySettlementAgreementSharesPaymentPercent_label_en-US" xlink:label="lab_imux_RoyaltySettlementAgreementSharesPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Shares Payment, Percent</link:label>
    <link:label id="lab_imux_RoyaltySettlementAgreementSharesPaymentPercent_documentation_en-US" xlink:label="lab_imux_RoyaltySettlementAgreementSharesPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Shares Payment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_RoyaltySettlementAgreementSharesPaymentPercent" xlink:href="imux-20221231.xsd#imux_RoyaltySettlementAgreementSharesPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_RoyaltySettlementAgreementSharesPaymentPercent" xlink:to="lab_imux_RoyaltySettlementAgreementSharesPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_ad2661a8-e256-467b-aa8e-a6bb8eda66a2_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_13f39727-c9b7-431f-80b9-4284b96ace3b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_043285d6-c3a4-42f0-a30b-de0891d22157_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6cf90e12-d0da-46c6-b52b-2e73f10f67c1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5c88de37-32b2-499c-9326-aa89494c3f87_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5b54947f-cc0f-49ca-96ec-49b72cdeae23_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5d2f1868-10a5-4b1a-beec-fd8a1903f0de_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_6706fc5b-25d1-4552-88fb-c359a55e9197_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_feb78eb0-f02f-49b2-8a83-4ff01bd7d1c5_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_fe92976f-a53e-4021-90af-fbf04e0648fb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (note 4)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_88179666-249b-40d6-94e1-3a94e627ab24_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ecbf97be-2231-4229-9302-3795506311ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f24a66aa-5434-4ba5-9cc6-c584a4fc4ebe_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_13502500-38c0-4260-87bf-ed9237181447_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued in connection with the 4SC royalty settlement (see Note 4)</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_4ad6988d-4c9f-4b76-9a1a-655b2aa3f0a3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at December&#160;31, 2022 and 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_515dfcde-68fb-4360-8f1c-bf5935f66373_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_c6b1ab60-f40f-4b02-9fbe-270c56c96fe9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_e15ec2e8-f9dd-4620-bf40-2e42cb4d0762_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_LegalAndAuditCostsPayableCurrent_0460e7f4-63a2-4d27-98bf-e54d3a623dfe_terseLabel_en-US" xlink:label="lab_imux_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal and audit costs</link:label>
    <link:label id="lab_imux_LegalAndAuditCostsPayableCurrent_label_en-US" xlink:label="lab_imux_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:label id="lab_imux_LegalAndAuditCostsPayableCurrent_documentation_en-US" xlink:label="lab_imux_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LegalAndAuditCostsPayableCurrent" xlink:href="imux-20221231.xsd#imux_LegalAndAuditCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_LegalAndAuditCostsPayableCurrent" xlink:to="lab_imux_LegalAndAuditCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_96e37857-1107-4e08-b4f5-8aa3229e91a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_7de0c3e2-09af-4a75-90eb-4c5f28a43a5b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e0fae4ba-03a6-4bef-8611-03b6fa161491_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_e55387a5-5354-4c1d-a935-0af439149cda_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_AtTheMarketSalesAgreementMember_c360651f-6976-4aaf-a4ad-fb78f5d41060_terseLabel_en-US" xlink:label="lab_imux_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Sales Agreement</link:label>
    <link:label id="lab_imux_AtTheMarketSalesAgreementMember_label_en-US" xlink:label="lab_imux_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Sales Agreement [Member]</link:label>
    <link:label id="lab_imux_AtTheMarketSalesAgreementMember_documentation_en-US" xlink:label="lab_imux_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AtTheMarketSalesAgreementMember" xlink:href="imux-20221231.xsd#imux_AtTheMarketSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_AtTheMarketSalesAgreementMember" xlink:to="lab_imux_AtTheMarketSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c70aae4d-8602-47a5-92b2-9cf4d41c5616_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_79bcc869-37d9-4067-aa70-985551f5a3ea_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_5861b717-9d6d-4922-96f5-24bbebebeeb1_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_02df6a41-78cb-4530-ae86-929f5ab7aecd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment (see Note 2)</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_8b1a8af2-e86a-40f2-988b-b09825b1e847_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_0aae09e1-6388-41f3-bbb4-38398e40f47d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill during the year ended December 31, 2022</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b6ecf856-00c8-45d2-9eca-5a7a6ec6d9a5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_dba5e7f2-196d-4760-85ef-9b679a8a9dab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_21849bd3-1474-450c-ae80-7e1ce9ba75ca_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_59144461-4244-4179-8f7c-1e1691634fd6_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_TaxYearsPost2017Member_6c789ae8-c34a-4ca7-9a03-fea152545674_terseLabel_en-US" xlink:label="lab_imux_TaxYearsPost2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post 2017</link:label>
    <link:label id="lab_imux_TaxYearsPost2017Member_label_en-US" xlink:label="lab_imux_TaxYearsPost2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years Post 2017 [Member]</link:label>
    <link:label id="lab_imux_TaxYearsPost2017Member_documentation_en-US" xlink:label="lab_imux_TaxYearsPost2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years Post 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TaxYearsPost2017Member" xlink:href="imux-20221231.xsd#imux_TaxYearsPost2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_TaxYearsPost2017Member" xlink:to="lab_imux_TaxYearsPost2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_fccc3e11-83cd-4a77-9dd6-82106fff85c5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_feb4a68f-0e60-4944-a521-e3c451f44c52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_813485af-4715-4432-80ee-c1ce150b01af_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1f091493-30fc-4869-b197-2c8f783e6241_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_33aedd2c-4c63-44d3-9cde-967924ba7840_terseLabel_en-US" xlink:label="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized, percent</link:label>
    <link:label id="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_label_en-US" xlink:label="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:label id="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_documentation_en-US" xlink:label="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:href="imux-20221231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:to="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_afe264f7-37df-425f-ab9d-d4717c4f01dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_0f5f6867-9428-4b0b-9272-70b15bfa87c7_terseLabel_en-US" xlink:label="lab_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreement, royalties as percent of aggregated net sales</link:label>
    <link:label id="lab_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_label_en-US" xlink:label="lab_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales</link:label>
    <link:label id="lab_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_documentation_en-US" xlink:label="lab_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:href="imux-20221231.xsd#imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:to="lab_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_84fcdad8-3935-4577-a810-89a6a0573afd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued in connection with the Company's employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_AccruedClinicalCostsCurrent_f2ccb04f-d0c4-4fd6-9183-8a310b4b62a0_terseLabel_en-US" xlink:label="lab_imux_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical and related costs</link:label>
    <link:label id="lab_imux_AccruedClinicalCostsCurrent_label_en-US" xlink:label="lab_imux_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:label id="lab_imux_AccruedClinicalCostsCurrent_documentation_en-US" xlink:label="lab_imux_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedClinicalCostsCurrent" xlink:href="imux-20221231.xsd#imux_AccruedClinicalCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_AccruedClinicalCostsCurrent" xlink:to="lab_imux_AccruedClinicalCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_744378ca-6338-4134-87d6-b0a45e0ca62e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_08dffcc8-cf16-43f1-b8ae-85722e038af1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_2f371d06-f707-48c9-b121-7f7de3ca095f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b28422d3-decc-4656-9194-152a1696e1e2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_28293ab7-a971-4a45-9cb7-2f05a3112d8a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1ed089eb-e48b-4adf-ab86-4fa49381afcf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss before Income Tax Based on Jurisdictions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_27ba6a10-5026-4b76-a08d-af565d049962_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_aa2ced95-04fb-4c95-937d-b7dd0897f058_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_714d6d6d-a50d-4fc9-922c-ec4aa7251a6f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5a8f0cfd-fd01-4086-bb17-41f9090cf021_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: interest portion</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6e6f3b91-6531-4666-830a-ab6b91cac993_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b458ce14-3ee8-4225-a6d7-1d415a5cd556_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_287d161a-f1ab-437e-af5c-2afec6a40f98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_ae715b7e-4925-4dc6-b2fc-c1fc48c146b3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2ab7aea0-8a3e-498d-92f8-5a49904b555d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_408f5eea-8e2a-40eb-8242-653a30d63b04_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2949f41e-3665-4a44-9722-23822696f631_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_56b5d6ba-0c8a-471d-b452-6cf83b954a1a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ShelfRegistrationStatementAmountRemaining_d1bee46e-e3e4-4d59-8a5d-eb883a902983_terseLabel_en-US" xlink:label="lab_imux_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement, Amount Remaining</link:label>
    <link:label id="lab_imux_ShelfRegistrationStatementAmountRemaining_label_en-US" xlink:label="lab_imux_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement, Amount Remaining</link:label>
    <link:label id="lab_imux_ShelfRegistrationStatementAmountRemaining_documentation_en-US" xlink:label="lab_imux_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement, Amount Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShelfRegistrationStatementAmountRemaining" xlink:href="imux-20221231.xsd#imux_ShelfRegistrationStatementAmountRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ShelfRegistrationStatementAmountRemaining" xlink:to="lab_imux_ShelfRegistrationStatementAmountRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_6c48a9e8-c37d-40bc-a979-21bbae816901_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d2e360e7-6ba2-4f35-8ba6-a772f771683f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_October2022PIPETransactionMember_837ddea9-ffb7-480f-a9bc-3ad63a1b9809_terseLabel_en-US" xlink:label="lab_imux_October2022PIPETransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2022 PIPE Transaction</link:label>
    <link:label id="lab_imux_October2022PIPETransactionMember_label_en-US" xlink:label="lab_imux_October2022PIPETransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2022 PIPE Transaction [Member]</link:label>
    <link:label id="lab_imux_October2022PIPETransactionMember_documentation_en-US" xlink:label="lab_imux_October2022PIPETransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2022 PIPE Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_October2022PIPETransactionMember" xlink:href="imux-20221231.xsd#imux_October2022PIPETransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_October2022PIPETransactionMember" xlink:to="lab_imux_October2022PIPETransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_deca9944-a0c8-4463-8655-0c7cc82743b0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_98eed913-9905-414e-8ee5-102e2f9658f0_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1f3ee8a6-2ce2-4496-b7ff-cd9240dd0524_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ba8fd84e-781d-4a2b-809e-94f61ed08093_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Operating Lease Obligations</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_213d45fb-a461-48e9-a983-a6ce3d185102_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_dfef38a7-f38c-4f3d-98e3-e9cc1cc7ea38_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_65ac9cc7-135e-42ec-83a7-d63d94f91c72_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_A2019OmnibusEquityIncentivePlanMember_91a7cc3a-9336-4544-a099-15fc83007474_terseLabel_en-US" xlink:label="lab_imux_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_imux_A2019OmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_imux_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_imux_A2019OmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_imux_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2019OmnibusEquityIncentivePlanMember" xlink:href="imux-20221231.xsd#imux_A2019OmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_A2019OmnibusEquityIncentivePlanMember" xlink:to="lab_imux_A2019OmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_May2022ATMMember_e24523cd-81bf-422e-9943-773fbfcd081b_terseLabel_en-US" xlink:label="lab_imux_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM</link:label>
    <link:label id="lab_imux_May2022ATMMember_label_en-US" xlink:label="lab_imux_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM [Member]</link:label>
    <link:label id="lab_imux_May2022ATMMember_documentation_en-US" xlink:label="lab_imux_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_May2022ATMMember" xlink:href="imux-20221231.xsd#imux_May2022ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_May2022ATMMember" xlink:to="lab_imux_May2022ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_abeccda3-e18d-4901-bcd0-a7d6c422e6c7_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance increase</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_367ac890-2ada-42d5-bf86-4cd2649ea366_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_12d4d6b5-c1d0-4e1f-a6f6-96982cc629e3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect of rate change</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8cfc3bb1-0a32-4734-a79c-a9544f9e4a59_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_881aaac5-92f9-40b3-8693-992dacc6ea35_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2df9f3d1-6dec-4dbd-b68a-51ce814d3fbb_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_74758532-2bbd-42f3-a8a8-52d73205345f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1c5c1454-dec9-453c-ac1b-490de33e80f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of the stock, at discount from market price at purchase date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_7dfe5d7e-9a54-469a-bd99-7d360a1a223e_terseLabel_en-US" xlink:label="lab_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission, percent of gross proceeds from sale of common stock</link:label>
    <link:label id="lab_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_label_en-US" xlink:label="lab_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:label id="lab_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_documentation_en-US" xlink:label="lab_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:href="imux-20221231.xsd#imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:to="lab_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_10f90d57-2e17-4b3b-819f-153cd0245014_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_2b5adf17-0384-4990-8dc5-48110ca8d466_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e4ff4961-179a-454b-999d-286aba968405_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2b589096-32fa-4777-94fa-c8eccea99aa0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_IncentiveEmployeeStockOptionMember_d20ec1cd-9561-4b78-a1f7-d3a0a09a2fe5_terseLabel_en-US" xlink:label="lab_imux_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option</link:label>
    <link:label id="lab_imux_IncentiveEmployeeStockOptionMember_label_en-US" xlink:label="lab_imux_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:label id="lab_imux_IncentiveEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_imux_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_IncentiveEmployeeStockOptionMember" xlink:href="imux-20221231.xsd#imux_IncentiveEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_IncentiveEmployeeStockOptionMember" xlink:to="lab_imux_IncentiveEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e88b6bf5-0584-4519-96de-7ab8aaa71553_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0dea2d0b-05a1-4922-8466-29babd460234_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_NumberOfDevelopmentPrograms_1c1a0f7d-af21-4cc6-abdf-d5cf60511c23_terseLabel_en-US" xlink:label="lab_imux_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of development programs pursued</link:label>
    <link:label id="lab_imux_NumberOfDevelopmentPrograms_label_en-US" xlink:label="lab_imux_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs</link:label>
    <link:label id="lab_imux_NumberOfDevelopmentPrograms_documentation_en-US" xlink:label="lab_imux_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_NumberOfDevelopmentPrograms" xlink:href="imux-20221231.xsd#imux_NumberOfDevelopmentPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_NumberOfDevelopmentPrograms" xlink:to="lab_imux_NumberOfDevelopmentPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_ca1321dc-5773-4340-80fa-5d407d6a9220_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4789f9d3-7ba2-4b87-bc9c-f5c8a1328e9b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_92a38ba4-7124-495e-adbe-128250a15778_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6af6338c-b47a-45b0-a1f3-faec337860e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_531dd81b-7bab-43b6-8595-9ce76bc8c26d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_74c72cd4-0269-406f-a67e-ecef4b559356_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_97311ef1-bf0b-4704-aab5-b07f615bf9da_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_53e424f9-94a8-435b-8806-d03a0bc27af0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0ea1c581-5195-4319-9686-0612e85195c3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2e6acbc5-3795-4191-98a9-9b6dcd0722ba_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_dcfca861-ace2-4703-ac01-b378c9fa20b2_terseLabel_en-US" xlink:label="lab_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="imux-20221231.xsd#imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="lab_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_20cde06b-91f8-4455-969d-a1f4d6c4324f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_PublicOfferingMember_799d2027-15d5-4ef4-9745-c850ce15def6_terseLabel_en-US" xlink:label="lab_imux_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_imux_PublicOfferingMember_label_en-US" xlink:label="lab_imux_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_imux_PublicOfferingMember_documentation_en-US" xlink:label="lab_imux_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PublicOfferingMember" xlink:href="imux-20221231.xsd#imux_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_PublicOfferingMember" xlink:to="lab_imux_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_SaleOfStockRemainingCapacity_2b57c9e2-3007-47d6-9ea3-e3d2accd5801_terseLabel_en-US" xlink:label="lab_imux_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining capacity</link:label>
    <link:label id="lab_imux_SaleOfStockRemainingCapacity_label_en-US" xlink:label="lab_imux_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Capacity</link:label>
    <link:label id="lab_imux_SaleOfStockRemainingCapacity_documentation_en-US" xlink:label="lab_imux_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SaleOfStockRemainingCapacity" xlink:href="imux-20221231.xsd#imux_SaleOfStockRemainingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_SaleOfStockRemainingCapacity" xlink:to="lab_imux_SaleOfStockRemainingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_41f1e13b-112b-4145-baa4-8fa9e8f94918_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_df2867be-4439-4c11-888e-b4cbd3120119_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8a4384fb-bcdd-4b66-bf8d-3f9f01225b53_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ff8a0bab-9888-4b93-8b51-0289415b3d72_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c60673db-0f09-4b51-bafc-042edc7355bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c295f26-6bf2-46d2-b5f2-e96cde4f5612_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_46db8ed3-0df1-45de-bb24-7f5559a9052a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15eaff61-f3f7-408f-a36d-2080f2b9c3cd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_94754110-9ede-473b-8da8-d9f8595baed4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a4f881bf-7123-48e4-bc71-b6137fd27e31_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of use asset obtained in exchange for lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_e8225480-ce35-48e4-acda-aaa85ec56969_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Basis of Financial Statements</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>imux-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:19abff6b-9d36-40e5-80a6-5fea77828601,g:313a8e66-68ba-4247-b883-d20269f0dca0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://imux.com/role/CoverPage" xlink:type="simple" xlink:href="imux-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://imux.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4e3052df-493c-4e76-add3-322c4ae295e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_DocumentType_4e3052df-493c-4e76-add3-322c4ae295e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_acf65114-4921-4754-817b-e26c6f9a7aac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_DocumentAnnualReport_acf65114-4921-4754-817b-e26c6f9a7aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d033c73a-dae1-4819-a1da-d12fd1e1b53e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_DocumentPeriodEndDate_d033c73a-dae1-4819-a1da-d12fd1e1b53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9dc94af0-e52a-482a-abfe-8fcfd6f35fb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_CurrentFiscalYearEndDate_9dc94af0-e52a-482a-abfe-8fcfd6f35fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_5a3cc63a-6625-467a-aa9c-d84380a62035" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_DocumentTransitionReport_5a3cc63a-6625-467a-aa9c-d84380a62035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c861345d-7fca-4d95-a41f-f68bf72740e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityFileNumber_c861345d-7fca-4d95-a41f-f68bf72740e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_999e670e-473e-44da-80d8-15df44d5da57" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityRegistrantName_999e670e-473e-44da-80d8-15df44d5da57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_75ec58a3-26cb-4100-a9af-6d16f986e5aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_75ec58a3-26cb-4100-a9af-6d16f986e5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_61fa8c30-db4e-4818-8a99-75391d90a7e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityTaxIdentificationNumber_61fa8c30-db4e-4818-8a99-75391d90a7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0cdd635c-f418-4d2b-9f20-722a73d5ccd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityAddressAddressLine1_0cdd635c-f418-4d2b-9f20-722a73d5ccd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_e88de867-290a-43e2-99a8-91307a33a55b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityAddressAddressLine2_e88de867-290a-43e2-99a8-91307a33a55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_df20381e-55f6-4566-9a5c-d1c735db3766" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityAddressCityOrTown_df20381e-55f6-4566-9a5c-d1c735db3766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4ffa2884-7567-4fb7-8d00-72af67456124" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityAddressStateOrProvince_4ffa2884-7567-4fb7-8d00-72af67456124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_eeed4134-9d47-4a8a-8434-4c107486ab12" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityAddressPostalZipCode_eeed4134-9d47-4a8a-8434-4c107486ab12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3855e2f5-5c89-4317-97ae-87fa9eefc5ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_CityAreaCode_3855e2f5-5c89-4317-97ae-87fa9eefc5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_da1dc84d-3ac4-4ae6-a452-f613988f9d9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_LocalPhoneNumber_da1dc84d-3ac4-4ae6-a452-f613988f9d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a706286f-7d33-4224-ae3c-994711dfaf31" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_Security12bTitle_a706286f-7d33-4224-ae3c-994711dfaf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b322c882-40cd-47e1-8fd0-359f4d9a47b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_TradingSymbol_b322c882-40cd-47e1-8fd0-359f4d9a47b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7916aca5-d0bb-4b38-8024-f8ef67b68b62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_SecurityExchangeName_7916aca5-d0bb-4b38-8024-f8ef67b68b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_45dd7511-64d2-4726-b01a-0a6a123b0bdc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_45dd7511-64d2-4726-b01a-0a6a123b0bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_13dd17b2-9c0b-4215-86a4-affc972d4929" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityVoluntaryFilers_13dd17b2-9c0b-4215-86a4-affc972d4929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_4a614d8b-a36a-4c81-96df-ae427b5cacb6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityCurrentReportingStatus_4a614d8b-a36a-4c81-96df-ae427b5cacb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d3e77517-45fa-4c58-a361-0bc40da6c840" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityInteractiveDataCurrent_d3e77517-45fa-4c58-a361-0bc40da6c840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_8fbc8108-627b-4a05-9189-a0bfca5c72f2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityFilerCategory_8fbc8108-627b-4a05-9189-a0bfca5c72f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d325c0b3-ed08-40d0-8ae1-2ecc473bd833" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntitySmallBusiness_d325c0b3-ed08-40d0-8ae1-2ecc473bd833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ef5b1c4f-920e-41d3-a7dc-7cedcf18ee36" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityEmergingGrowthCompany_ef5b1c4f-920e-41d3-a7dc-7cedcf18ee36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_3f744a9b-6cb7-4d5f-ae8f-fa4bc0bd36a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_IcfrAuditorAttestationFlag_3f744a9b-6cb7-4d5f-ae8f-fa4bc0bd36a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3a974219-9fd9-4056-8a30-ad91ef2b00e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityShellCompany_3a974219-9fd9-4056-8a30-ad91ef2b00e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_3d1bf674-5550-4b59-88ae-3361f5bdfdcd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityPublicFloat_3d1bf674-5550-4b59-88ae-3361f5bdfdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_53534457-99ea-4a33-b981-61587709fef1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_53534457-99ea-4a33-b981-61587709fef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f38c7553-5796-4dc6-850f-162f60194315" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f38c7553-5796-4dc6-850f-162f60194315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ae66def8-b66a-4398-8858-bb1fc9ca561f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_EntityCentralIndexKey_ae66def8-b66a-4398-8858-bb1fc9ca561f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a0d03737-cb5e-40f9-aab1-e5cc5c355e8c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_DocumentFiscalYearFocus_a0d03737-cb5e-40f9-aab1-e5cc5c355e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_eb7e3051-4d92-4015-858a-b48973218388" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_eb7e3051-4d92-4015-858a-b48973218388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c8625d98-6a65-459a-bf0d-3ab52abfe9ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b879e928-dcb0-4d4b-82cd-d858ffff48b5" xlink:to="loc_dei_AmendmentFlag_c8625d98-6a65-459a-bf0d-3ab52abfe9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/AuditInformation" xlink:type="simple" xlink:href="imux-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://imux.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_imux_AuditInformationAbstract_d8e8c466-01a5-4a0e-b3bf-6d5f8e35ae42" xlink:href="imux-20221231.xsd#imux_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_c88ee5ad-f2e5-4061-b5f1-7dc295d54ee2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imux_AuditInformationAbstract_d8e8c466-01a5-4a0e-b3bf-6d5f8e35ae42" xlink:to="loc_dei_AuditorName_c88ee5ad-f2e5-4061-b5f1-7dc295d54ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_f91760de-5b17-404f-8e43-80b8b345a58a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imux_AuditInformationAbstract_d8e8c466-01a5-4a0e-b3bf-6d5f8e35ae42" xlink:to="loc_dei_AuditorLocation_f91760de-5b17-404f-8e43-80b8b345a58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_2b75084f-7b23-4955-b788-76b10a31a2f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imux_AuditInformationAbstract_d8e8c466-01a5-4a0e-b3bf-6d5f8e35ae42" xlink:to="loc_dei_AuditorFirmId_2b75084f-7b23-4955-b788-76b10a31a2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fae1d920-61de-4da8-9ab0-291dbe8e0029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_10be0a27-a2e2-4051-97d5-0ac64db25898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fae1d920-61de-4da8-9ab0-291dbe8e0029" xlink:to="loc_us-gaap_AssetsAbstract_10be0a27-a2e2-4051-97d5-0ac64db25898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_369c56ab-9532-47a2-8610-e8d4642c1499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10be0a27-a2e2-4051-97d5-0ac64db25898" xlink:to="loc_us-gaap_AssetsCurrentAbstract_369c56ab-9532-47a2-8610-e8d4642c1499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6bc82dd6-ae24-4ef3-bd72-079bb5a43d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_369c56ab-9532-47a2-8610-e8d4642c1499" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6bc82dd6-ae24-4ef3-bd72-079bb5a43d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_b250254e-35fc-46ae-872c-c1d7f5f8792b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_369c56ab-9532-47a2-8610-e8d4642c1499" xlink:to="loc_us-gaap_OtherShortTermInvestments_b250254e-35fc-46ae-872c-c1d7f5f8792b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d9a5008d-82b2-4a8e-9f53-1324a5da542c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_369c56ab-9532-47a2-8610-e8d4642c1499" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d9a5008d-82b2-4a8e-9f53-1324a5da542c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a9e339ba-407e-4b31-bd5b-759eb7fd8ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_369c56ab-9532-47a2-8610-e8d4642c1499" xlink:to="loc_us-gaap_AssetsCurrent_a9e339ba-407e-4b31-bd5b-759eb7fd8ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_76163c0d-bc63-4025-8cdd-bdf2a99a4b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10be0a27-a2e2-4051-97d5-0ac64db25898" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_76163c0d-bc63-4025-8cdd-bdf2a99a4b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_068e5f39-34c0-4f95-9c0d-b691fa1f15ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10be0a27-a2e2-4051-97d5-0ac64db25898" xlink:to="loc_us-gaap_Goodwill_068e5f39-34c0-4f95-9c0d-b691fa1f15ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4e18ec51-b31c-4f7e-99cb-90bb33e70dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10be0a27-a2e2-4051-97d5-0ac64db25898" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4e18ec51-b31c-4f7e-99cb-90bb33e70dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b462bc58-db6e-4fb8-9939-3f5196910620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10be0a27-a2e2-4051-97d5-0ac64db25898" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b462bc58-db6e-4fb8-9939-3f5196910620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dc86e0b6-6dbf-433f-847a-ea3b1c2af83d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10be0a27-a2e2-4051-97d5-0ac64db25898" xlink:to="loc_us-gaap_Assets_dc86e0b6-6dbf-433f-847a-ea3b1c2af83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb7615ab-bf30-4d6e-997a-14e92b4150e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fae1d920-61de-4da8-9ab0-291dbe8e0029" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb7615ab-bf30-4d6e-997a-14e92b4150e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_110f6e1d-2334-43aa-875d-908c47e2ef7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb7615ab-bf30-4d6e-997a-14e92b4150e3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_110f6e1d-2334-43aa-875d-908c47e2ef7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b96c4ae1-a733-40e1-8222-8889deaf2d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_110f6e1d-2334-43aa-875d-908c47e2ef7a" xlink:to="loc_us-gaap_AccountsPayableCurrent_b96c4ae1-a733-40e1-8222-8889deaf2d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b71a6a26-c379-4de0-9483-d428eef6c5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_110f6e1d-2334-43aa-875d-908c47e2ef7a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b71a6a26-c379-4de0-9483-d428eef6c5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_efb28812-bea8-456e-a8a1-23389cabb3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_110f6e1d-2334-43aa-875d-908c47e2ef7a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_efb28812-bea8-456e-a8a1-23389cabb3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_85fb04bd-1699-4b65-9461-f5135c16ec6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_110f6e1d-2334-43aa-875d-908c47e2ef7a" xlink:to="loc_us-gaap_LiabilitiesCurrent_85fb04bd-1699-4b65-9461-f5135c16ec6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_594d7cd0-1e79-43d2-b071-bb26c6a788f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb7615ab-bf30-4d6e-997a-14e92b4150e3" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_594d7cd0-1e79-43d2-b071-bb26c6a788f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d15dfc8a-ae9b-4b71-85f6-fe149bd4d527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_594d7cd0-1e79-43d2-b071-bb26c6a788f9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d15dfc8a-ae9b-4b71-85f6-fe149bd4d527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_493bf470-e2f3-4f7a-bfb6-e8ec91fd2b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_594d7cd0-1e79-43d2-b071-bb26c6a788f9" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_493bf470-e2f3-4f7a-bfb6-e8ec91fd2b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e780c6de-f710-48fa-a1f2-77585bd2c3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb7615ab-bf30-4d6e-997a-14e92b4150e3" xlink:to="loc_us-gaap_Liabilities_e780c6de-f710-48fa-a1f2-77585bd2c3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_194d3a35-07d1-45ae-a612-94b76ddd7bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb7615ab-bf30-4d6e-997a-14e92b4150e3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_194d3a35-07d1-45ae-a612-94b76ddd7bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ef17857f-1bd5-4a59-8c1f-b3744d357f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb7615ab-bf30-4d6e-997a-14e92b4150e3" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ef17857f-1bd5-4a59-8c1f-b3744d357f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0810fa98-3864-4164-9650-4b9446467cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ef17857f-1bd5-4a59-8c1f-b3744d357f66" xlink:to="loc_us-gaap_PreferredStockValue_0810fa98-3864-4164-9650-4b9446467cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3b28ff0e-50b4-4e27-b8dc-30913fa6e57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ef17857f-1bd5-4a59-8c1f-b3744d357f66" xlink:to="loc_us-gaap_CommonStockValue_3b28ff0e-50b4-4e27-b8dc-30913fa6e57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8e64a7c9-4f76-4150-9363-3eb8d6332fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ef17857f-1bd5-4a59-8c1f-b3744d357f66" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8e64a7c9-4f76-4150-9363-3eb8d6332fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9c9ade81-40e0-4e76-ad41-dc5cb5f3fc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ef17857f-1bd5-4a59-8c1f-b3744d357f66" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9c9ade81-40e0-4e76-ad41-dc5cb5f3fc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f61da5c-a89c-4bec-beea-926d4d55ce5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ef17857f-1bd5-4a59-8c1f-b3744d357f66" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f61da5c-a89c-4bec-beea-926d4d55ce5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_68a5af86-b8e0-4ea4-8818-56469940fd56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ef17857f-1bd5-4a59-8c1f-b3744d357f66" xlink:to="loc_us-gaap_StockholdersEquity_68a5af86-b8e0-4ea4-8818-56469940fd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_39943330-9197-4e4c-8b0f-f8799968bf18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb7615ab-bf30-4d6e-997a-14e92b4150e3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_39943330-9197-4e4c-8b0f-f8799968bf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c8bee175-7f72-46fd-b619-ee4fb2dcb7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7073ade0-18fd-49bd-a123-06e4fb3bce72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c8bee175-7f72-46fd-b619-ee4fb2dcb7ab" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7073ade0-18fd-49bd-a123-06e4fb3bce72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_06b04ec9-56a7-42b2-9662-fd09475f2a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c8bee175-7f72-46fd-b619-ee4fb2dcb7ab" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_06b04ec9-56a7-42b2-9662-fd09475f2a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1577cce4-f88f-402f-b178-92498bde0458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c8bee175-7f72-46fd-b619-ee4fb2dcb7ab" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1577cce4-f88f-402f-b178-92498bde0458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_94920bbb-cd7d-4858-a528-02620bb79fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c8bee175-7f72-46fd-b619-ee4fb2dcb7ab" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_94920bbb-cd7d-4858-a528-02620bb79fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_698205f5-dced-4460-ba38-4fb7e5c87ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c8bee175-7f72-46fd-b619-ee4fb2dcb7ab" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_698205f5-dced-4460-ba38-4fb7e5c87ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_48bfb5db-48ed-4ac0-be1e-5def6078de5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c8bee175-7f72-46fd-b619-ee4fb2dcb7ab" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_48bfb5db-48ed-4ac0-be1e-5def6078de5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_dfa006e1-6972-4bc2-9bec-d6f23f93e2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c8bee175-7f72-46fd-b619-ee4fb2dcb7ab" xlink:to="loc_us-gaap_CommonStockSharesIssued_dfa006e1-6972-4bc2-9bec-d6f23f93e2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a2529f45-090b-4a0e-af55-4feb1ecf517e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c8bee175-7f72-46fd-b619-ee4fb2dcb7ab" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a2529f45-090b-4a0e-af55-4feb1ecf517e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a2e11b22-3c8b-4c3a-a8f3-bfa5d0b3c692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_280df0b2-c663-4c9a-a6c0-bb2c5096a2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a2e11b22-3c8b-4c3a-a8f3-bfa5d0b3c692" xlink:to="loc_us-gaap_OperatingExpensesAbstract_280df0b2-c663-4c9a-a6c0-bb2c5096a2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2cab87a4-5339-4bc7-aefd-b3d9a67cd024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_280df0b2-c663-4c9a-a6c0-bb2c5096a2f2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2cab87a4-5339-4bc7-aefd-b3d9a67cd024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8bd1031f-f463-4266-a20e-a6a4196fe69e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_280df0b2-c663-4c9a-a6c0-bb2c5096a2f2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8bd1031f-f463-4266-a20e-a6a4196fe69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d913fef6-5950-4419-bfbd-a89838ecf52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_280df0b2-c663-4c9a-a6c0-bb2c5096a2f2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d913fef6-5950-4419-bfbd-a89838ecf52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_RoyaltySettlementAgreementSalesNet_be6d121c-d110-4470-b0d7-e3dd699819ff" xlink:href="imux-20221231.xsd#imux_RoyaltySettlementAgreementSalesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_280df0b2-c663-4c9a-a6c0-bb2c5096a2f2" xlink:to="loc_imux_RoyaltySettlementAgreementSalesNet_be6d121c-d110-4470-b0d7-e3dd699819ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a56d25d7-ab12-4022-ad65-6a2c7b830c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_280df0b2-c663-4c9a-a6c0-bb2c5096a2f2" xlink:to="loc_us-gaap_OperatingExpenses_a56d25d7-ab12-4022-ad65-6a2c7b830c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_624856fa-976d-4b18-804e-4d77e6c4c8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a2e11b22-3c8b-4c3a-a8f3-bfa5d0b3c692" xlink:to="loc_us-gaap_OperatingIncomeLoss_624856fa-976d-4b18-804e-4d77e6c4c8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a2a32007-ada8-46fe-b821-b0d4970a956f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a2e11b22-3c8b-4c3a-a8f3-bfa5d0b3c692" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a2a32007-ada8-46fe-b821-b0d4970a956f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_594c9ec9-2311-4332-a5c8-880836e65620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a2a32007-ada8-46fe-b821-b0d4970a956f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_594c9ec9-2311-4332-a5c8-880836e65620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_430e6326-e46e-4870-a16e-91bb2ade0f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a2a32007-ada8-46fe-b821-b0d4970a956f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_430e6326-e46e-4870-a16e-91bb2ade0f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f098a44c-1e9b-4c52-b94e-0c8c9a98df01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a2a32007-ada8-46fe-b821-b0d4970a956f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_f098a44c-1e9b-4c52-b94e-0c8c9a98df01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1ffdf5bb-9a92-4fbc-bd41-b0f9546d3141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a2e11b22-3c8b-4c3a-a8f3-bfa5d0b3c692" xlink:to="loc_us-gaap_NetIncomeLoss_1ffdf5bb-9a92-4fbc-bd41-b0f9546d3141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2ebf0e33-247f-4ef7-a535-e825296a33c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a2e11b22-3c8b-4c3a-a8f3-bfa5d0b3c692" xlink:to="loc_us-gaap_EarningsPerShareBasic_2ebf0e33-247f-4ef7-a535-e825296a33c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_341bfe80-d346-4032-b3bb-973d68faa1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a2e11b22-3c8b-4c3a-a8f3-bfa5d0b3c692" xlink:to="loc_us-gaap_EarningsPerShareDiluted_341bfe80-d346-4032-b3bb-973d68faa1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6a641d5-4e79-42cf-bfe7-6626662e9bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a2e11b22-3c8b-4c3a-a8f3-bfa5d0b3c692" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6a641d5-4e79-42cf-bfe7-6626662e9bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e9fb7878-8c88-4d3d-8a3f-850dd0b75489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a2e11b22-3c8b-4c3a-a8f3-bfa5d0b3c692" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e9fb7878-8c88-4d3d-8a3f-850dd0b75489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cdfb7515-8044-4135-8417-f202a7b80371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_560ed41e-59c7-4020-a7ee-c449015a369a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cdfb7515-8044-4135-8417-f202a7b80371" xlink:to="loc_us-gaap_NetIncomeLoss_560ed41e-59c7-4020-a7ee-c449015a369a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b42d2436-7b62-45f8-852e-d842c1d5318a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cdfb7515-8044-4135-8417-f202a7b80371" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b42d2436-7b62-45f8-852e-d842c1d5318a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_07bd026c-378b-4462-9188-46a4b6f78dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b42d2436-7b62-45f8-852e-d842c1d5318a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_07bd026c-378b-4462-9188-46a4b6f78dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2255423c-8fd8-45c2-a235-372e20858876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b42d2436-7b62-45f8-852e-d842c1d5318a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2255423c-8fd8-45c2-a235-372e20858876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_fd100315-8f22-4020-adfb-2cdf6274eb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3e67b270-b41f-40f0-8e30-4fd74f30749d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fd100315-8f22-4020-adfb-2cdf6274eb5e" xlink:to="loc_us-gaap_StatementTable_3e67b270-b41f-40f0-8e30-4fd74f30749d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_accb73f3-e7e4-423c-9ae7-d2617fad506f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3e67b270-b41f-40f0-8e30-4fd74f30749d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_accb73f3-e7e4-423c-9ae7-d2617fad506f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_852a7322-cacc-4f42-b88f-121fd75ea179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_accb73f3-e7e4-423c-9ae7-d2617fad506f" xlink:to="loc_us-gaap_EquityComponentDomain_852a7322-cacc-4f42-b88f-121fd75ea179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f90938dd-6d9d-4c67-809a-a3b5dda21871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_852a7322-cacc-4f42-b88f-121fd75ea179" xlink:to="loc_us-gaap_CommonStockMember_f90938dd-6d9d-4c67-809a-a3b5dda21871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_14da6bfc-08b6-430b-a3fd-85fabda28aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_852a7322-cacc-4f42-b88f-121fd75ea179" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_14da6bfc-08b6-430b-a3fd-85fabda28aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb31e183-7109-413c-ab2d-168c107976f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_852a7322-cacc-4f42-b88f-121fd75ea179" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb31e183-7109-413c-ab2d-168c107976f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_02a17397-4c18-462f-bb86-6b8efcae8940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_852a7322-cacc-4f42-b88f-121fd75ea179" xlink:to="loc_us-gaap_RetainedEarningsMember_02a17397-4c18-462f-bb86-6b8efcae8940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_18e57377-c454-4f6c-975b-0585a28fa7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3e67b270-b41f-40f0-8e30-4fd74f30749d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_18e57377-c454-4f6c-975b-0585a28fa7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_031e491d-3d9e-4a65-b6c5-55bdfe69ff64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18e57377-c454-4f6c-975b-0585a28fa7a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_031e491d-3d9e-4a65-b6c5-55bdfe69ff64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_July2021PublicEquityOfferingMember_da8a2d45-c34e-4019-9cab-9e5faf200850" xlink:href="imux-20221231.xsd#imux_July2021PublicEquityOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_031e491d-3d9e-4a65-b6c5-55bdfe69ff64" xlink:to="loc_imux_July2021PublicEquityOfferingMember_da8a2d45-c34e-4019-9cab-9e5faf200850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AtTheMarketSalesAgreementMember_fcd5cce0-0ad9-48fb-8050-999031cd295a" xlink:href="imux-20221231.xsd#imux_AtTheMarketSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_031e491d-3d9e-4a65-b6c5-55bdfe69ff64" xlink:to="loc_imux_AtTheMarketSalesAgreementMember_fcd5cce0-0ad9-48fb-8050-999031cd295a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A4SCRoyaltySettlementMember_8dc12d7c-9a0e-4b95-b911-0bc652e4bf65" xlink:href="imux-20221231.xsd#imux_A4SCRoyaltySettlementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_031e491d-3d9e-4a65-b6c5-55bdfe69ff64" xlink:to="loc_imux_A4SCRoyaltySettlementMember_8dc12d7c-9a0e-4b95-b911-0bc652e4bf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_October2022PIPETransactionMember_07ffd661-b495-49a3-839d-9b02063f7ade" xlink:href="imux-20221231.xsd#imux_October2022PIPETransactionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_031e491d-3d9e-4a65-b6c5-55bdfe69ff64" xlink:to="loc_imux_October2022PIPETransactionMember_07ffd661-b495-49a3-839d-9b02063f7ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7a7d6170-6b38-4738-9b29-6de4496ae909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3e67b270-b41f-40f0-8e30-4fd74f30749d" xlink:to="loc_us-gaap_StatementLineItems_7a7d6170-6b38-4738-9b29-6de4496ae909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7a7d6170-6b38-4738-9b29-6de4496ae909" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c6482f23-6680-4722-baec-9ee237a1a2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c6482f23-6680-4722-baec-9ee237a1a2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fa89bf65-e161-4ad6-aaac-efd6eafe91b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_StockholdersEquity_fa89bf65-e161-4ad6-aaac-efd6eafe91b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_740679ad-8709-4671-8f3e-41721379680e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_NetIncomeLoss_740679ad-8709-4671-8f3e-41721379680e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a53aafda-9924-4a13-afd2-315967f5ee79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a53aafda-9924-4a13-afd2-315967f5ee79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01b39173-3e70-4963-bed5-95a9a2092434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01b39173-3e70-4963-bed5-95a9a2092434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb573cff-fed1-4c4a-975c-5570054e451e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb573cff-fed1-4c4a-975c-5570054e451e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f4d2967b-7698-47c9-a1f8-94ee4ecd2348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f4d2967b-7698-47c9-a1f8-94ee4ecd2348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1678e985-d61f-44e4-95e9-9dcf5b6e4a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1678e985-d61f-44e4-95e9-9dcf5b6e4a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_af2225b7-8160-4c7b-a24f-174b17e01472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_af2225b7-8160-4c7b-a24f-174b17e01472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0397856c-e356-4aaf-b1f6-e1f26e275f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0397856c-e356-4aaf-b1f6-e1f26e275f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_05878e4b-0c9f-400d-b76a-55cafa29feed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddd39ea8-f73c-438f-a86b-5130212b8525" xlink:to="loc_us-gaap_StockholdersEquity_05878e4b-0c9f-400d-b76a-55cafa29feed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5a6befcb-4efa-4f2b-a1a1-d843e3ae8644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_52079223-c3cd-4e88-8753-3e30aeb14c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5a6befcb-4efa-4f2b-a1a1-d843e3ae8644" xlink:to="loc_us-gaap_StatementTable_52079223-c3cd-4e88-8753-3e30aeb14c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_241f3468-7263-4a2e-977f-e64b65a645a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_52079223-c3cd-4e88-8753-3e30aeb14c3d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_241f3468-7263-4a2e-977f-e64b65a645a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c4f62e6-d8c2-48ff-b785-4a995b4ad641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_241f3468-7263-4a2e-977f-e64b65a645a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c4f62e6-d8c2-48ff-b785-4a995b4ad641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_July2021PublicEquityOfferingMember_02139ce0-0779-4e22-87eb-c59a84a487f1" xlink:href="imux-20221231.xsd#imux_July2021PublicEquityOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c4f62e6-d8c2-48ff-b785-4a995b4ad641" xlink:to="loc_imux_July2021PublicEquityOfferingMember_02139ce0-0779-4e22-87eb-c59a84a487f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AtTheMarketSalesAgreementMember_50fbc125-21ca-4001-a3b3-2f3eafe79816" xlink:href="imux-20221231.xsd#imux_AtTheMarketSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c4f62e6-d8c2-48ff-b785-4a995b4ad641" xlink:to="loc_imux_AtTheMarketSalesAgreementMember_50fbc125-21ca-4001-a3b3-2f3eafe79816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_October2022PIPETransactionMember_21cb0d10-566b-4a28-bd04-08f39d62723f" xlink:href="imux-20221231.xsd#imux_October2022PIPETransactionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c4f62e6-d8c2-48ff-b785-4a995b4ad641" xlink:to="loc_imux_October2022PIPETransactionMember_21cb0d10-566b-4a28-bd04-08f39d62723f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3a2509ab-1b18-4bf3-92b1-4f61d912262e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_52079223-c3cd-4e88-8753-3e30aeb14c3d" xlink:to="loc_us-gaap_StatementLineItems_3a2509ab-1b18-4bf3-92b1-4f61d912262e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1c416e64-e4c0-48db-ae64-ba0a2587a597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3a2509ab-1b18-4bf3-92b1-4f61d912262e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1c416e64-e4c0-48db-ae64-ba0a2587a597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6bed426f-7399-450c-91f8-5f4d3e28aad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_eb9d6928-4268-42eb-8dfb-44dc95c4c3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6bed426f-7399-450c-91f8-5f4d3e28aad4" xlink:to="loc_us-gaap_StatementTable_eb9d6928-4268-42eb-8dfb-44dc95c4c3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7090c97f-0ea5-4962-b00f-6ebfe0ea16c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_eb9d6928-4268-42eb-8dfb-44dc95c4c3fe" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7090c97f-0ea5-4962-b00f-6ebfe0ea16c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef83ef9b-b2ce-4273-8eee-b466689d1124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7090c97f-0ea5-4962-b00f-6ebfe0ea16c3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef83ef9b-b2ce-4273-8eee-b466689d1124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PublicOfferingMember_3b1add34-2bfa-47fc-b33a-55207084ba7c" xlink:href="imux-20221231.xsd#imux_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef83ef9b-b2ce-4273-8eee-b466689d1124" xlink:to="loc_imux_PublicOfferingMember_3b1add34-2bfa-47fc-b33a-55207084ba7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_October2022PIPETransactionMember_dff57758-5a02-4171-afc1-4b2620770f65" xlink:href="imux-20221231.xsd#imux_October2022PIPETransactionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef83ef9b-b2ce-4273-8eee-b466689d1124" xlink:to="loc_imux_October2022PIPETransactionMember_dff57758-5a02-4171-afc1-4b2620770f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_July2021PublicEquityOfferingMember_edb015a0-8af4-4917-8b4c-d8ae05eb02c0" xlink:href="imux-20221231.xsd#imux_July2021PublicEquityOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef83ef9b-b2ce-4273-8eee-b466689d1124" xlink:to="loc_imux_July2021PublicEquityOfferingMember_edb015a0-8af4-4917-8b4c-d8ae05eb02c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_eb9d6928-4268-42eb-8dfb-44dc95c4c3fe" xlink:to="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cf2474f6-5cbe-4184-8135-17062c62c28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cf2474f6-5cbe-4184-8135-17062c62c28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9f716ad6-d9bc-4df5-821a-fa84a55d5b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cf2474f6-5cbe-4184-8135-17062c62c28e" xlink:to="loc_us-gaap_NetIncomeLoss_9f716ad6-d9bc-4df5-821a-fa84a55d5b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cda6dccf-e129-4c6a-8fe3-40cc33deb79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cf2474f6-5cbe-4184-8135-17062c62c28e" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cda6dccf-e129-4c6a-8fe3-40cc33deb79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fa29d1c1-def9-4c6e-a585-a432373178e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cda6dccf-e129-4c6a-8fe3-40cc33deb79f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fa29d1c1-def9-4c6e-a585-a432373178e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ebc58e42-58c9-44ac-8565-9d9cf2565be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cda6dccf-e129-4c6a-8fe3-40cc33deb79f" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ebc58e42-58c9-44ac-8565-9d9cf2565be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5867fc1f-12da-4242-8fec-80ee2d32307c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cda6dccf-e129-4c6a-8fe3-40cc33deb79f" xlink:to="loc_us-gaap_ShareBasedCompensation_5867fc1f-12da-4242-8fec-80ee2d32307c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c0a3611e-f88d-4636-9634-53a8d8419287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cda6dccf-e129-4c6a-8fe3-40cc33deb79f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c0a3611e-f88d-4636-9634-53a8d8419287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_e07208d7-3dc7-4396-a67b-353f792f16e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cda6dccf-e129-4c6a-8fe3-40cc33deb79f" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_e07208d7-3dc7-4396-a67b-353f792f16e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a5de515-a9f9-4ea9-88fa-1d363fc06ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cf2474f6-5cbe-4184-8135-17062c62c28e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a5de515-a9f9-4ea9-88fa-1d363fc06ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fc392aeb-e321-4d2f-a8b5-7b7ddbb06f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a5de515-a9f9-4ea9-88fa-1d363fc06ee5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fc392aeb-e321-4d2f-a8b5-7b7ddbb06f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7be26c49-a62e-4412-adbe-b039f34d5e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a5de515-a9f9-4ea9-88fa-1d363fc06ee5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7be26c49-a62e-4412-adbe-b039f34d5e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_10c8541c-3fbf-4774-ae8e-1a1fa2e7a5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a5de515-a9f9-4ea9-88fa-1d363fc06ee5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_10c8541c-3fbf-4774-ae8e-1a1fa2e7a5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8d031b5f-000a-41ad-86ed-d977949749cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a5de515-a9f9-4ea9-88fa-1d363fc06ee5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8d031b5f-000a-41ad-86ed-d977949749cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_372255d3-53b0-44a7-9470-9e637f905aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cf2474f6-5cbe-4184-8135-17062c62c28e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_372255d3-53b0-44a7-9470-9e637f905aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cdb8fc1-72bb-45f6-abb7-df949ea73c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cdb8fc1-72bb-45f6-abb7-df949ea73c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_a3f94ff2-aef4-4481-a88d-6d55bf8eb019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cdb8fc1-72bb-45f6-abb7-df949ea73c20" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_a3f94ff2-aef4-4481-a88d-6d55bf8eb019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2e574c5b-5a18-4284-9794-13327afa84a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cdb8fc1-72bb-45f6-abb7-df949ea73c20" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2e574c5b-5a18-4284-9794-13327afa84a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d96f6849-b8ba-4c38-9a52-dfc4d1539ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cdb8fc1-72bb-45f6-abb7-df949ea73c20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d96f6849-b8ba-4c38-9a52-dfc4d1539ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6877ba70-0e7e-4d55-9ec9-0c763b8f2afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6877ba70-0e7e-4d55-9ec9-0c763b8f2afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ff42936a-e818-48a8-a9e5-fd9144a1e5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6877ba70-0e7e-4d55-9ec9-0c763b8f2afe" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ff42936a-e818-48a8-a9e5-fd9144a1e5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ec212e2a-bd72-48ba-b94e-0d5ea108e1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6877ba70-0e7e-4d55-9ec9-0c763b8f2afe" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ec212e2a-bd72-48ba-b94e-0d5ea108e1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_f44cfafd-bd83-4f1c-80ec-aaaf9cda869e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6877ba70-0e7e-4d55-9ec9-0c763b8f2afe" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_f44cfafd-bd83-4f1c-80ec-aaaf9cda869e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb6447f4-07e8-4034-ad57-aa015c3bd8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6877ba70-0e7e-4d55-9ec9-0c763b8f2afe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb6447f4-07e8-4034-ad57-aa015c3bd8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78732313-70cc-4ace-8a25-c69caf032739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78732313-70cc-4ace-8a25-c69caf032739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5cd2049b-8234-47ae-ba7f-82c9f4cce7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5cd2049b-8234-47ae-ba7f-82c9f4cce7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6ea5b59-7fa9-48be-a344-3c31a4c34ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6ea5b59-7fa9-48be-a344-3c31a4c34ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_564d1e0c-84ad-416c-a25d-1152fa573bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_564d1e0c-84ad-416c-a25d-1152fa573bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ba2df784-b509-4b1e-a087-47b6a0dbf499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775c0085-eb94-4891-a40d-de11ba3e1277" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ba2df784-b509-4b1e-a087-47b6a0dbf499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_fbb8f2b2-b977-47a5-a1bf-93f6e7892542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ba2df784-b509-4b1e-a087-47b6a0dbf499" xlink:to="loc_us-gaap_StockIssued1_fbb8f2b2-b977-47a5-a1bf-93f6e7892542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b962b996-8978-4c41-b889-60492fb5e961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ba2df784-b509-4b1e-a087-47b6a0dbf499" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b962b996-8978-4c41-b889-60492fb5e961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="imux-20221231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_68a3cda3-8616-4991-ac49-a4ee0ebf4df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_efdf7a5b-1163-4bae-b781-2ee72514e394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_68a3cda3-8616-4991-ac49-a4ee0ebf4df3" xlink:to="loc_us-gaap_StatementTable_efdf7a5b-1163-4bae-b781-2ee72514e394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_02ca7fbc-7a39-4c5c-8d1e-6f3f74df06df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_efdf7a5b-1163-4bae-b781-2ee72514e394" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_02ca7fbc-7a39-4c5c-8d1e-6f3f74df06df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73ea99d9-ee95-4019-a5e3-a08b83e14f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_02ca7fbc-7a39-4c5c-8d1e-6f3f74df06df" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73ea99d9-ee95-4019-a5e3-a08b83e14f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PublicOfferingMember_58d4f433-1c44-497f-9e3b-3703accd134c" xlink:href="imux-20221231.xsd#imux_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73ea99d9-ee95-4019-a5e3-a08b83e14f88" xlink:to="loc_imux_PublicOfferingMember_58d4f433-1c44-497f-9e3b-3703accd134c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_October2022PIPETransactionMember_93234c19-7ec2-46f2-8bc5-43e6fd0649e2" xlink:href="imux-20221231.xsd#imux_October2022PIPETransactionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73ea99d9-ee95-4019-a5e3-a08b83e14f88" xlink:to="loc_imux_October2022PIPETransactionMember_93234c19-7ec2-46f2-8bc5-43e6fd0649e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_July2021PublicEquityOfferingMember_1f3ec74d-f1e1-442b-b0f1-8f392b3a50b9" xlink:href="imux-20221231.xsd#imux_July2021PublicEquityOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73ea99d9-ee95-4019-a5e3-a08b83e14f88" xlink:to="loc_imux_July2021PublicEquityOfferingMember_1f3ec74d-f1e1-442b-b0f1-8f392b3a50b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_371fafad-b5b5-4ae0-8bfd-296033242dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_efdf7a5b-1163-4bae-b781-2ee72514e394" xlink:to="loc_us-gaap_StatementLineItems_371fafad-b5b5-4ae0-8bfd-296033242dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c7f43295-a74a-4b59-bcf5-8b3c8cc9ff67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_371fafad-b5b5-4ae0-8bfd-296033242dde" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c7f43295-a74a-4b59-bcf5-8b3c8cc9ff67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="simple" xlink:href="imux-20221231.xsd#DescriptionofBusinessandBasisofFinancialStatements"/>
  <link:presentationLink xlink:role="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_420bdfa6-cfec-491f-b946-65974210e35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_505173e2-4772-4462-b3f8-e8f262849d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_420bdfa6-cfec-491f-b946-65974210e35e" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_505173e2-4772-4462-b3f8-e8f262849d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="imux-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9c6780d6-77f6-45c2-97b7-2a04197ce180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_62dac50f-923d-4492-abd4-3da5a2b11bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c6780d6-77f6-45c2-97b7-2a04197ce180" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_62dac50f-923d-4492-abd4-3da5a2b11bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#BalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/BalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e945fc4d-4488-4e5f-ade3-96a16145f0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_a02d110d-9abc-4c6d-a997-c4f41bd143fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e945fc4d-4488-4e5f-ade3-96a16145f0bc" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_a02d110d-9abc-4c6d-a997-c4f41bd143fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="imux-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_56d05cd8-698d-44fa-b940-a8ef0524d563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_daa7ea0a-a9cf-4ab3-80b9-cc57402d6691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_56d05cd8-698d-44fa-b940-a8ef0524d563" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_daa7ea0a-a9cf-4ab3-80b9-cc57402d6691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/FairValue" xlink:type="simple" xlink:href="imux-20221231.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://imux.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_34a088f0-d5f4-45ee-8848-28807e1169b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b920d74b-c23a-468d-b6b1-05af31753d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_34a088f0-d5f4-45ee-8848-28807e1169b4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b920d74b-c23a-468d-b6b1-05af31753d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStock" xlink:type="simple" xlink:href="imux-20221231.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_17e2a968-651b-48bf-909f-f163732585b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e1aea8e4-b52d-452f-91a2-a23f1d8ead11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_17e2a968-651b-48bf-909f-f163732585b5" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e1aea8e4-b52d-452f-91a2-a23f1d8ead11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/StockbasedCompensationPlans" xlink:type="simple" xlink:href="imux-20221231.xsd#StockbasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://imux.com/role/StockbasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fcad09b2-c240-433c-bb24-d3b99b9172a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_72c27aa1-762f-427e-970a-601eb39794b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fcad09b2-c240-433c-bb24-d3b99b9172a0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_72c27aa1-762f-427e-970a-601eb39794b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxes" xlink:type="simple" xlink:href="imux-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://imux.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_38a78d7f-9836-4506-83f2-8c5405801a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3b636ac2-60ce-4512-bc8b-703c6e705a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38a78d7f-9836-4506-83f2-8c5405801a9d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3b636ac2-60ce-4512-bc8b-703c6e705a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="imux-20221231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://imux.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_8b171d10-ae05-421d-92fb-59d4e5ffa85c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_09f6f916-b664-4627-8b86-24ceaca9636a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_8b171d10-ae05-421d-92fb-59d4e5ffa85c" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_09f6f916-b664-4627-8b86-24ceaca9636a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="imux-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_76abf654-6d13-4250-bb1f-afdcb79abe41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_UseOfEstimates_76abf654-6d13-4250-bb1f-afdcb79abe41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_920029e2-bb5a-4f83-959f-79b8a5621345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_920029e2-bb5a-4f83-959f-79b8a5621345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_b2fae176-98da-4fff-ad4a-430cb8ba701c" xlink:href="imux-20221231.xsd#imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_b2fae176-98da-4fff-ad4a-430cb8ba701c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_84108dbb-6d30-447d-9bb8-6313a520d73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_84108dbb-6d30-447d-9bb8-6313a520d73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_aa66f40d-4974-4da4-9852-bc8ecaec986c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_aa66f40d-4974-4da4-9852-bc8ecaec986c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_02bd222c-4ada-4c51-a2d7-9f1806460744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_02bd222c-4ada-4c51-a2d7-9f1806460744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a4e00515-d43c-4f17-a66c-90c2b15881c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a4e00515-d43c-4f17-a66c-90c2b15881c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_fe948f8b-22ba-4aad-ae38-82fd37e0587c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_fe948f8b-22ba-4aad-ae38-82fd37e0587c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_17593698-6646-4b30-9ca4-4bf2721510ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_17593698-6646-4b30-9ca4-4bf2721510ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock_3cfcc64b-5264-4ef4-b085-ada7d66b591d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_GovernmentAssistancePolicyTextBlock_3cfcc64b-5264-4ef4-b085-ada7d66b591d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_153a9dff-5c8d-4cda-aa7f-d5c6c906012d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_153a9dff-5c8d-4cda-aa7f-d5c6c906012d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7db1f3b0-4d4b-4072-b269-3ef605d5deab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7db1f3b0-4d4b-4072-b269-3ef605d5deab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_6c77f1ea-2682-4724-99d6-155b35924fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_6c77f1ea-2682-4724-99d6-155b35924fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9c2a25d9-878b-4eb2-975e-2e7aef586604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9c2a25d9-878b-4eb2-975e-2e7aef586604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_0145fbe9-0ba5-4dd3-b8b5-d057631bf6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_0145fbe9-0ba5-4dd3-b8b5-d057631bf6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_c52388c5-3761-4186-8839-46a5b5b0ff53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_c52388c5-3761-4186-8839-46a5b5b0ff53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_1ae7e860-f246-4f37-93f0-4772427960dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_1ae7e860-f246-4f37-93f0-4772427960dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_955f3c77-cd1b-4ec1-a834-d268f9a34abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_853296b2-cd87-445f-92b4-18d5e4f25c4d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_955f3c77-cd1b-4ec1-a834-d268f9a34abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="imux-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_631aa940-f7a9-4ea2-8209-937d8735979c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock_ecfe0a87-3463-4f52-8c54-defb4be7f937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_631aa940-f7a9-4ea2-8209-937d8735979c" xlink:to="loc_us-gaap_InvestmentTableTextBlock_ecfe0a87-3463-4f52-8c54-defb4be7f937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2d1aeae3-9983-4685-8e93-530d237be876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_631aa940-f7a9-4ea2-8209-937d8735979c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2d1aeae3-9983-4685-8e93-530d237be876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_dae28b89-3967-47a2-8994-8c645318964e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_631aa940-f7a9-4ea2-8209-937d8735979c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_dae28b89-3967-47a2-8994-8c645318964e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsTables" xlink:type="simple" xlink:href="imux-20221231.xsd#BalanceSheetDetailsTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/BalanceSheetDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6aab567f-82bb-40b4-88eb-165a85f7a9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_ac8ddf01-b1c1-4460-b715-0c4e5043ea42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6aab567f-82bb-40b4-88eb-165a85f7a9db" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_ac8ddf01-b1c1-4460-b715-0c4e5043ea42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_317173dc-c983-40bd-b37b-550cb395d9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6aab567f-82bb-40b4-88eb-165a85f7a9db" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_317173dc-c983-40bd-b37b-550cb395d9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_0b82f5ba-cb90-45ea-9f0e-a9536a040215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6aab567f-82bb-40b4-88eb-165a85f7a9db" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_0b82f5ba-cb90-45ea-9f0e-a9536a040215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="imux-20221231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_af593beb-c55f-4aec-8e38-bed511357778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d17c7ab0-9a7e-499b-af4e-6fab5a707d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_af593beb-c55f-4aec-8e38-bed511357778" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d17c7ab0-9a7e-499b-af4e-6fab5a707d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/FairValueTables" xlink:type="simple" xlink:href="imux-20221231.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6aab906d-d02f-4cbe-8c96-f4e1e6e2efdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1796b861-0dac-471b-bc84-19fbd19f1543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6aab906d-d02f-4cbe-8c96-f4e1e6e2efdf" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1796b861-0dac-471b-bc84-19fbd19f1543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockTables" xlink:type="simple" xlink:href="imux-20221231.xsd#CommonStockTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0771b56d-afe0-4882-a52b-0c4a20306777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_264e6541-c162-4f0d-b6b2-d688889fb051" xlink:href="imux-20221231.xsd#imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0771b56d-afe0-4882-a52b-0c4a20306777" xlink:to="loc_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_264e6541-c162-4f0d-b6b2-d688889fb051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/StockbasedCompensationPlansTables" xlink:type="simple" xlink:href="imux-20221231.xsd#StockbasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/StockbasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50feeb62-9637-4501-b658-c9bf3c8627c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_05a66678-0c05-4a90-85c7-827a29b467f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50feeb62-9637-4501-b658-c9bf3c8627c2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_05a66678-0c05-4a90-85c7-827a29b467f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_07866a87-eebd-42f6-a403-40d2570b1585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50feeb62-9637-4501-b658-c9bf3c8627c2" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_07866a87-eebd-42f6-a403-40d2570b1585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9a682aa9-83f4-469f-9ae4-0787a64cdbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50feeb62-9637-4501-b658-c9bf3c8627c2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9a682aa9-83f4-469f-9ae4-0787a64cdbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="imux-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_33ace479-1856-46c8-af23-e4ed2685d42a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_cbc1dae8-92db-446d-851d-e9fa262f3e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33ace479-1856-46c8-af23-e4ed2685d42a" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_cbc1dae8-92db-446d-851d-e9fa262f3e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7c1ce82c-ba16-4d1b-bcea-fd66e4cc1515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33ace479-1856-46c8-af23-e4ed2685d42a" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7c1ce82c-ba16-4d1b-bcea-fd66e4cc1515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e578c1ed-5073-4f7f-bb79-88c1c0b3de66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33ace479-1856-46c8-af23-e4ed2685d42a" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e578c1ed-5073-4f7f-bb79-88c1c0b3de66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_14e4cdb1-f8de-41fb-a07e-d81c1f2a777b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_d8f0ea1f-04eb-4bd2-bba6-73fec7afafff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14e4cdb1-f8de-41fb-a07e-d81c1f2a777b" xlink:to="loc_dei_EntityNumberOfEmployees_d8f0ea1f-04eb-4bd2-bba6-73fec7afafff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_NumberOfDevelopmentPrograms_f23b3fe9-b60e-4263-81cd-dd72549bacac" xlink:href="imux-20221231.xsd#imux_NumberOfDevelopmentPrograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14e4cdb1-f8de-41fb-a07e-d81c1f2a777b" xlink:to="loc_imux_NumberOfDevelopmentPrograms_f23b3fe9-b60e-4263-81cd-dd72549bacac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3ab890db-7217-41d5-8c46-9a417c00214e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14e4cdb1-f8de-41fb-a07e-d81c1f2a777b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3ab890db-7217-41d5-8c46-9a417c00214e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_86ebe37a-e695-4db5-8a31-c8cef8f32b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14e4cdb1-f8de-41fb-a07e-d81c1f2a777b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_86ebe37a-e695-4db5-8a31-c8cef8f32b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0951f081-249d-43ae-b528-01beae5a7eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14e4cdb1-f8de-41fb-a07e-d81c1f2a777b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0951f081-249d-43ae-b528-01beae5a7eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_965846a1-6c91-4f3f-be89-27ab531ba508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14e4cdb1-f8de-41fb-a07e-d81c1f2a777b" xlink:to="loc_us-gaap_OtherShortTermInvestments_965846a1-6c91-4f3f-be89-27ab531ba508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4e59c4d7-2247-4fbb-a7f0-5885c83e9247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c54bdb-8ac5-4087-a457-92679b7dd12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e59c4d7-2247-4fbb-a7f0-5885c83e9247" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c54bdb-8ac5-4087-a457-92679b7dd12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_073931ac-2b8b-4d5f-b1cd-142f513af409" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c54bdb-8ac5-4087-a457-92679b7dd12c" xlink:to="loc_srt_StatementGeographicalAxis_073931ac-2b8b-4d5f-b1cd-142f513af409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_674805d4-d8c3-4aae-8a9d-ec291a1f8c52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_073931ac-2b8b-4d5f-b1cd-142f513af409" xlink:to="loc_srt_SegmentGeographicalDomain_674805d4-d8c3-4aae-8a9d-ec291a1f8c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b81665dd-f0d0-4b3c-91c6-5643b6fe857a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_674805d4-d8c3-4aae-8a9d-ec291a1f8c52" xlink:to="loc_country_US_b81665dd-f0d0-4b3c-91c6-5643b6fe857a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AustraliaAndGermanyMember_6cb71caa-c1ef-4904-8c53-ee027e2eb3cb" xlink:href="imux-20221231.xsd#imux_AustraliaAndGermanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_674805d4-d8c3-4aae-8a9d-ec291a1f8c52" xlink:to="loc_imux_AustraliaAndGermanyMember_6cb71caa-c1ef-4904-8c53-ee027e2eb3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_f2cca15a-2c66-4d50-bf6a-6546140b0e70" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imux_AustraliaAndGermanyMember_6cb71caa-c1ef-4904-8c53-ee027e2eb3cb" xlink:to="loc_country_DE_f2cca15a-2c66-4d50-bf6a-6546140b0e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_d9d1e435-9536-4edd-a5e9-1f1eeabb0a90" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imux_AustraliaAndGermanyMember_6cb71caa-c1ef-4904-8c53-ee027e2eb3cb" xlink:to="loc_country_AU_d9d1e435-9536-4edd-a5e9-1f1eeabb0a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdfb6faf-6b83-4531-b310-243808de151a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c54bdb-8ac5-4087-a457-92679b7dd12c" xlink:to="loc_srt_RangeAxis_fdfb6faf-6b83-4531-b310-243808de151a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae40ad5e-e73a-4de1-a067-cae248eee54f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fdfb6faf-6b83-4531-b310-243808de151a" xlink:to="loc_srt_RangeMember_ae40ad5e-e73a-4de1-a067-cae248eee54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8cbb0d0e-d5c4-4f85-b1d7-0f656f637f69" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ae40ad5e-e73a-4de1-a067-cae248eee54f" xlink:to="loc_srt_MinimumMember_8cbb0d0e-d5c4-4f85-b1d7-0f656f637f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9e6c9e35-a683-4290-bd3b-da623ed7e13b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ae40ad5e-e73a-4de1-a067-cae248eee54f" xlink:to="loc_srt_MaximumMember_9e6c9e35-a683-4290-bd3b-da623ed7e13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_e82e6045-a821-462d-aebd-61784d35b0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c54bdb-8ac5-4087-a457-92679b7dd12c" xlink:to="loc_us-gaap_InvestmentTypeAxis_e82e6045-a821-462d-aebd-61784d35b0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2a91cd79-4b43-4b22-8058-67122b740f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_e82e6045-a821-462d-aebd-61784d35b0e0" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2a91cd79-4b43-4b22-8058-67122b740f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ec4c77f6-58f2-4b68-8479-563b7ecf15c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2a91cd79-4b43-4b22-8058-67122b740f50" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ec4c77f6-58f2-4b68-8479-563b7ecf15c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_2e25e769-b67d-4d56-b835-9d686926c9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2a91cd79-4b43-4b22-8058-67122b740f50" xlink:to="loc_us-gaap_BankTimeDepositsMember_2e25e769-b67d-4d56-b835-9d686926c9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c54bdb-8ac5-4087-a457-92679b7dd12c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48e5cd13-5e5d-4e4f-bd9c-9166294413e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48e5cd13-5e5d-4e4f-bd9c-9166294413e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_NumberOfFinancialInstitutionsUsedForCashDeposits_dfee4dbe-d86e-43df-b2f4-a4811eb5d74c" xlink:href="imux-20221231.xsd#imux_NumberOfFinancialInstitutionsUsedForCashDeposits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_imux_NumberOfFinancialInstitutionsUsedForCashDeposits_dfee4dbe-d86e-43df-b2f4-a4811eb5d74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_fa5f9604-9026-4a8e-8bff-15aadd3a2fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_InvestmentInterestRate_fa5f9604-9026-4a8e-8bff-15aadd3a2fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_InvestmentEarningInterestRateRemainingMaturityPeriod_b28d1066-28a0-46c7-8c98-9bef24bbff1f" xlink:href="imux-20221231.xsd#imux_InvestmentEarningInterestRateRemainingMaturityPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_imux_InvestmentEarningInterestRateRemainingMaturityPeriod_b28d1066-28a0-46c7-8c98-9bef24bbff1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1a457dbf-9b7a-4719-b431-9e452dcab2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1a457dbf-9b7a-4719-b431-9e452dcab2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_2a7f6274-6e12-45eb-9c05-6b171b14fb61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_DepreciationAndAmortization_2a7f6274-6e12-45eb-9c05-6b171b14fb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_4a3339e2-e3a0-4776-8e68-267a49e3c424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_4a3339e2-e3a0-4776-8e68-267a49e3c424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ba5bbb38-fca4-4d2c-a2ae-55b3e4e82dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ba5bbb38-fca4-4d2c-a2ae-55b3e4e82dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_GovernmentAssistanceRate_4d6619d3-818f-447c-b230-b8852dbdef5a" xlink:href="imux-20221231.xsd#imux_GovernmentAssistanceRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_imux_GovernmentAssistanceRate_4d6619d3-818f-447c-b230-b8852dbdef5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_114e1665-3dd2-47d0-9898-665236a48a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_114e1665-3dd2-47d0-9898-665236a48a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_43fe02ec-a755-44b1-8ab4-1f2e8ad8d394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_43fe02ec-a755-44b1-8ab4-1f2e8ad8d394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6c264fe7-7efb-40ee-a04d-385ed1b6fc60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6c264fe7-7efb-40ee-a04d-385ed1b6fc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LesseeOperatingLeasesNumberOfExistingLeases_13923b10-966f-436d-8249-35a93ae79898" xlink:href="imux-20221231.xsd#imux_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_232269d8-98fc-47d1-8bec-6647281fd7ac" xlink:to="loc_imux_LesseeOperatingLeasesNumberOfExistingLeases_13923b10-966f-436d-8249-35a93ae79898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#SummaryofSignificantAccountingPoliciesInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a789ad80-87ad-44f6-9768-54f0d3cc1d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d30759e4-bafd-4a30-82ce-c70c2dbf42de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a789ad80-87ad-44f6-9768-54f0d3cc1d01" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d30759e4-bafd-4a30-82ce-c70c2dbf42de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_03b56c4b-1c7f-4535-8a4b-61a702391347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d30759e4-bafd-4a30-82ce-c70c2dbf42de" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_03b56c4b-1c7f-4535-8a4b-61a702391347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8081d39d-8f97-4470-9143-1daf89a797f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_03b56c4b-1c7f-4535-8a4b-61a702391347" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8081d39d-8f97-4470-9143-1daf89a797f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_8d02097a-e6f4-4ef3-b83e-3297e42c3802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8081d39d-8f97-4470-9143-1daf89a797f5" xlink:to="loc_us-gaap_BankTimeDepositsMember_8d02097a-e6f4-4ef3-b83e-3297e42c3802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_bf6e7621-9498-4d62-8054-15234a862f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d30759e4-bafd-4a30-82ce-c70c2dbf42de" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_bf6e7621-9498-4d62-8054-15234a862f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_5a7b8507-772b-4390-a96d-df61498bc52a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_bf6e7621-9498-4d62-8054-15234a862f79" xlink:to="loc_us-gaap_OtherShortTermInvestments_5a7b8507-772b-4390-a96d-df61498bc52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#SummaryofSignificantAccountingPoliciesGoodwillDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a0b0af48-7474-405d-b666-ab73e86af694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_c7e0e8e9-3998-4c3c-9f5d-40b497677654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0b0af48-7474-405d-b666-ab73e86af694" xlink:to="loc_us-gaap_GoodwillRollForward_c7e0e8e9-3998-4c3c-9f5d-40b497677654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f055df60-17b4-4843-96bd-97d64c61281e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_c7e0e8e9-3998-4c3c-9f5d-40b497677654" xlink:to="loc_us-gaap_Goodwill_f055df60-17b4-4843-96bd-97d64c61281e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_28277ada-4d52-48c5-8903-0edc8b7c862a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_c7e0e8e9-3998-4c3c-9f5d-40b497677654" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_28277ada-4d52-48c5-8903-0edc8b7c862a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1265c803-5033-455a-9f81-c045843ff967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_c7e0e8e9-3998-4c3c-9f5d-40b497677654" xlink:to="loc_us-gaap_Goodwill_1265c803-5033-455a-9f81-c045843ff967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d57cf15f-c00b-4e03-b456-ac7bf462f36c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51646de7-7375-4764-8d83-baa7fd8acb57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d57cf15f-c00b-4e03-b456-ac7bf462f36c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51646de7-7375-4764-8d83-baa7fd8acb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02f6382b-f1ce-44a4-b757-140897d971da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51646de7-7375-4764-8d83-baa7fd8acb57" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02f6382b-f1ce-44a4-b757-140897d971da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2615d3e8-8684-42bc-a8b1-7606d751780d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02f6382b-f1ce-44a4-b757-140897d971da" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2615d3e8-8684-42bc-a8b1-7606d751780d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_65d274be-7b35-4b81-9b52-4154dbb58704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2615d3e8-8684-42bc-a8b1-7606d751780d" xlink:to="loc_us-gaap_StockOptionMember_65d274be-7b35-4b81-9b52-4154dbb58704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_28fbaf5b-c18d-4cc1-95a9-5a18fbd63144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2615d3e8-8684-42bc-a8b1-7606d751780d" xlink:to="loc_us-gaap_WarrantMember_28fbaf5b-c18d-4cc1-95a9-5a18fbd63144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_904489ec-a4d9-423a-8274-5fe5ba359dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51646de7-7375-4764-8d83-baa7fd8acb57" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_904489ec-a4d9-423a-8274-5fe5ba359dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_828bd878-3d64-44d5-be77-21ca333d4641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_904489ec-a4d9-423a-8274-5fe5ba359dd1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_828bd878-3d64-44d5-be77-21ca333d4641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05cb2b94-e702-481e-85a0-e835ac0b3e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PrepaidClinicalAndRelatedCostsCurrent_1f6c6e1f-6ec5-4b8c-989e-0210aa345274" xlink:href="imux-20221231.xsd#imux_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05cb2b94-e702-481e-85a0-e835ac0b3e41" xlink:to="loc_imux_PrepaidClinicalAndRelatedCostsCurrent_1f6c6e1f-6ec5-4b8c-989e-0210aa345274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_522dde7a-758a-4ee9-afc3-b8873507ab75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05cb2b94-e702-481e-85a0-e835ac0b3e41" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_522dde7a-758a-4ee9-afc3-b8873507ab75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ResearchAndDevelopmentTaxIncentiveCurrent_b9cd9599-3d47-4811-8012-68b2f1f3839f" xlink:href="imux-20221231.xsd#imux_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05cb2b94-e702-481e-85a0-e835ac0b3e41" xlink:to="loc_imux_ResearchAndDevelopmentTaxIncentiveCurrent_b9cd9599-3d47-4811-8012-68b2f1f3839f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_005182a1-119f-449b-8e08-b64e6ac0d796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05cb2b94-e702-481e-85a0-e835ac0b3e41" xlink:to="loc_us-gaap_OtherAssetsCurrent_005182a1-119f-449b-8e08-b64e6ac0d796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1c7d2165-fca5-4498-bf39-6c263ce0488b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05cb2b94-e702-481e-85a0-e835ac0b3e41" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1c7d2165-fca5-4498-bf39-6c263ce0488b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7c222fad-df11-4f28-b746-5cfe32b8c565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ClinicalCostsPayableCurrent_7d24a537-ae4a-44ed-b6cd-229e554caec4" xlink:href="imux-20221231.xsd#imux_ClinicalCostsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7c222fad-df11-4f28-b746-5cfe32b8c565" xlink:to="loc_imux_ClinicalCostsPayableCurrent_7d24a537-ae4a-44ed-b6cd-229e554caec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LegalAndAuditCostsPayableCurrent_4d58ffc5-60a2-4b09-a268-c75cfacc6366" xlink:href="imux-20221231.xsd#imux_LegalAndAuditCostsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7c222fad-df11-4f28-b746-5cfe32b8c565" xlink:to="loc_imux_LegalAndAuditCostsPayableCurrent_4d58ffc5-60a2-4b09-a268-c75cfacc6366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_ab43ff22-3e76-44d7-87db-cb867308d626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7c222fad-df11-4f28-b746-5cfe32b8c565" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_ab43ff22-3e76-44d7-87db-cb867308d626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_94671ce7-5185-42fb-b4e9-cb0c18cb0989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7c222fad-df11-4f28-b746-5cfe32b8c565" xlink:to="loc_us-gaap_AccountsPayableCurrent_94671ce7-5185-42fb-b4e9-cb0c18cb0989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6b118bf2-ca8d-495b-873c-88e7104ec2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedClinicalCostsCurrent_7fb5f9f5-008b-4eb5-9de7-a29daceb972d" xlink:href="imux-20221231.xsd#imux_AccruedClinicalCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6b118bf2-ca8d-495b-873c-88e7104ec2dc" xlink:to="loc_imux_AccruedClinicalCostsCurrent_7fb5f9f5-008b-4eb5-9de7-a29daceb972d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedLegalAndAuditCostsCurrent_a0725dc4-859d-454f-8563-239d9b081cf4" xlink:href="imux-20221231.xsd#imux_AccruedLegalAndAuditCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6b118bf2-ca8d-495b-873c-88e7104ec2dc" xlink:to="loc_imux_AccruedLegalAndAuditCostsCurrent_a0725dc4-859d-454f-8563-239d9b081cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedCompensationCurrent_401d201f-f7fb-47f3-bf27-a589cf039dc2" xlink:href="imux-20221231.xsd#imux_AccruedCompensationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6b118bf2-ca8d-495b-873c-88e7104ec2dc" xlink:to="loc_imux_AccruedCompensationCurrent_401d201f-f7fb-47f3-bf27-a589cf039dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_423bc4d1-4127-4178-ad63-f1af1c4dede6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6b118bf2-ca8d-495b-873c-88e7104ec2dc" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_423bc4d1-4127-4178-ad63-f1af1c4dede6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9da255d7-be10-4e82-bf9c-46187fd55566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6b118bf2-ca8d-495b-873c-88e7104ec2dc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9da255d7-be10-4e82-bf9c-46187fd55566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3aba916e-77db-458f-af8a-c2cff7e5af03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_41b307dc-2cfb-474e-bf17-da628950c092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3aba916e-77db-458f-af8a-c2cff7e5af03" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_41b307dc-2cfb-474e-bf17-da628950c092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_dd9ed7f3-c3be-450e-8e9e-48777e4bc18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3aba916e-77db-458f-af8a-c2cff7e5af03" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_dd9ed7f3-c3be-450e-8e9e-48777e4bc18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_80fc71b2-fcc6-4c19-9388-d88fd44d6663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3aba916e-77db-458f-af8a-c2cff7e5af03" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_80fc71b2-fcc6-4c19-9388-d88fd44d6663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0be1d6ce-7097-4217-84a5-1d572bf401be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3aba916e-77db-458f-af8a-c2cff7e5af03" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0be1d6ce-7097-4217-84a5-1d572bf401be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c3734342-effd-4a5c-b7b3-1a8fc9305153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_926e25cf-8381-40fd-a66a-1b8bf24ef410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c3734342-effd-4a5c-b7b3-1a8fc9305153" xlink:to="loc_us-gaap_LossContingenciesTable_926e25cf-8381-40fd-a66a-1b8bf24ef410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3f5cf1b3-8a63-4e20-85f9-1f39ca6ad0c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_926e25cf-8381-40fd-a66a-1b8bf24ef410" xlink:to="loc_srt_StatementGeographicalAxis_3f5cf1b3-8a63-4e20-85f9-1f39ca6ad0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e673516c-ec5d-465b-a70d-9178d74f3ac2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3f5cf1b3-8a63-4e20-85f9-1f39ca6ad0c9" xlink:to="loc_srt_SegmentGeographicalDomain_e673516c-ec5d-465b-a70d-9178d74f3ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_GrafelfingGermanyMember_ba9af99c-63fe-4eb6-8777-b470c9090620" xlink:href="imux-20221231.xsd#imux_GrafelfingGermanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e673516c-ec5d-465b-a70d-9178d74f3ac2" xlink:to="loc_imux_GrafelfingGermanyMember_ba9af99c-63fe-4eb6-8777-b470c9090620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_NewYorkCityMember_b2d2beb9-7c34-49d8-811c-3ab843f695c5" xlink:href="imux-20221231.xsd#imux_NewYorkCityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e673516c-ec5d-465b-a70d-9178d74f3ac2" xlink:to="loc_imux_NewYorkCityMember_b2d2beb9-7c34-49d8-811c-3ab843f695c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2128f151-7a0a-41e3-b221-843daf761cf1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_926e25cf-8381-40fd-a66a-1b8bf24ef410" xlink:to="loc_dei_LegalEntityAxis_2128f151-7a0a-41e3-b221-843daf761cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_05311456-d796-40d7-acd2-466dd073eab5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2128f151-7a0a-41e3-b221-843daf761cf1" xlink:to="loc_dei_EntityDomain_05311456-d796-40d7-acd2-466dd073eab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicAGMember_ea6dcfb5-5954-417b-8460-ec90ec4d7c31" xlink:href="imux-20221231.xsd#imux_ImmunicAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_05311456-d796-40d7-acd2-466dd073eab5" xlink:to="loc_imux_ImmunicAGMember_ea6dcfb5-5954-417b-8460-ec90ec4d7c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_926e25cf-8381-40fd-a66a-1b8bf24ef410" xlink:to="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e2476729-70f0-4ed9-9720-da5ddc1ae48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e2476729-70f0-4ed9-9720-da5ddc1ae48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LesseeOperatingLeaseRentHolidayPeriod_014d540c-062d-493d-b40a-a2e258507d5c" xlink:href="imux-20221231.xsd#imux_LesseeOperatingLeaseRentHolidayPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_LesseeOperatingLeaseRentHolidayPeriod_014d540c-062d-493d-b40a-a2e258507d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_e01d8fbc-b87f-45f5-a1da-529fb44ddf58" xlink:href="imux-20221231.xsd#imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_e01d8fbc-b87f-45f5-a1da-529fb44ddf58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_OperatingLeaseIncrementalBorrowingRate_6a0c8f85-d704-411d-84fc-cee354c68407" xlink:href="imux-20221231.xsd#imux_OperatingLeaseIncrementalBorrowingRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_OperatingLeaseIncrementalBorrowingRate_6a0c8f85-d704-411d-84fc-cee354c68407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_OperatingAndVariableLeasesCost_4a071e07-8282-48ac-9190-83c78d44b88f" xlink:href="imux-20221231.xsd#imux_OperatingAndVariableLeasesCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_OperatingAndVariableLeasesCost_4a071e07-8282-48ac-9190-83c78d44b88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_73a96b82-cf44-4b56-945e-6fe0f6d19a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_us-gaap_ContractualObligation_73a96b82-cf44-4b56-945e-6fe0f6d19a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_96fa1fef-6e7c-4f3a-8b73-63b07554a113" xlink:href="imux-20221231.xsd#imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_96fa1fef-6e7c-4f3a-8b73-63b07554a113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d281efe7-2004-4a35-88c0-0542bb59910f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_us-gaap_CommonStockSharesIssued_d281efe7-2004-4a35-88c0-0542bb59910f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9ad99b4e-8369-40b3-82be-29b1d6637070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_us-gaap_CommonStockValue_9ad99b4e-8369-40b3-82be-29b1d6637070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_RoyaltySettlementAgreementSalesNet_b4c64f5e-3906-4d3c-af5e-7f54205be0d0" xlink:href="imux-20221231.xsd#imux_RoyaltySettlementAgreementSalesNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_RoyaltySettlementAgreementSalesNet_b4c64f5e-3906-4d3c-af5e-7f54205be0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_RoyaltySettlementAgreementCashPaymentPercent_a9345733-ce45-4a85-bbdb-8104aef744c7" xlink:href="imux-20221231.xsd#imux_RoyaltySettlementAgreementCashPaymentPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_RoyaltySettlementAgreementCashPaymentPercent_a9345733-ce45-4a85-bbdb-8104aef744c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_RoyaltySettlementAgreementSharesPaymentPercent_76c74b93-ebff-4553-8c43-17fee59cbc68" xlink:href="imux-20221231.xsd#imux_RoyaltySettlementAgreementSharesPaymentPercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5bb2f68c-8399-43ea-865a-bdefcb838771" xlink:to="loc_imux_RoyaltySettlementAgreementSharesPaymentPercent_76c74b93-ebff-4553-8c43-17fee59cbc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_643c58d3-e35f-470b-bd75-7a9247e3ef60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_260e98d9-8cdd-440d-91ab-3082aaa6cbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_643c58d3-e35f-470b-bd75-7a9247e3ef60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_260e98d9-8cdd-440d-91ab-3082aaa6cbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d0a3a5e5-c185-4982-947c-3122f89aa2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_643c58d3-e35f-470b-bd75-7a9247e3ef60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d0a3a5e5-c185-4982-947c-3122f89aa2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_391bb7cf-861b-460e-818f-d22b3e881b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_643c58d3-e35f-470b-bd75-7a9247e3ef60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_391bb7cf-861b-460e-818f-d22b3e881b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a4df408f-642e-4202-b877-2697254f8cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_643c58d3-e35f-470b-bd75-7a9247e3ef60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a4df408f-642e-4202-b877-2697254f8cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bf6532b4-7ab2-443f-9cdf-71e7cea83e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_643c58d3-e35f-470b-bd75-7a9247e3ef60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bf6532b4-7ab2-443f-9cdf-71e7cea83e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_54ca2d1a-0efc-43f5-add6-d27401c1539c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_643c58d3-e35f-470b-bd75-7a9247e3ef60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_54ca2d1a-0efc-43f5-add6-d27401c1539c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13623caa-d8b5-4d47-bb95-088cb03115c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_643c58d3-e35f-470b-bd75-7a9247e3ef60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13623caa-d8b5-4d47-bb95-088cb03115c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b05a0a0d-10a3-4b1d-b370-a53c9fddc5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_643c58d3-e35f-470b-bd75-7a9247e3ef60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b05a0a0d-10a3-4b1d-b370-a53c9fddc5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0e26d77d-3421-4076-90eb-aaebcb812cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_643c58d3-e35f-470b-bd75-7a9247e3ef60" xlink:to="loc_us-gaap_OperatingLeaseLiability_0e26d77d-3421-4076-90eb-aaebcb812cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="imux-20221231.xsd#CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8877e352-378c-4dbd-b244-b18e25008e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0dd41c7-396e-424b-846f-d75f11829a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8877e352-378c-4dbd-b244-b18e25008e69" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0dd41c7-396e-424b-846f-d75f11829a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5dda88a-b69e-4b4c-ac7f-3cfc5a9ceb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0dd41c7-396e-424b-846f-d75f11829a9e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5dda88a-b69e-4b4c-ac7f-3cfc5a9ceb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06c446f6-fcb0-4652-923a-2a2dbc9f0016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5dda88a-b69e-4b4c-ac7f-3cfc5a9ceb3d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06c446f6-fcb0-4652-923a-2a2dbc9f0016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3d20dbcc-f154-4a66-b6d8-2808261208b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06c446f6-fcb0-4652-923a-2a2dbc9f0016" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3d20dbcc-f154-4a66-b6d8-2808261208b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_dfeeab51-4102-4965-b0f1-3a78bf2b9db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06c446f6-fcb0-4652-923a-2a2dbc9f0016" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_dfeeab51-4102-4965-b0f1-3a78bf2b9db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fc343a87-c8df-4201-b8c7-96a4f6ee6e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06c446f6-fcb0-4652-923a-2a2dbc9f0016" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fc343a87-c8df-4201-b8c7-96a4f6ee6e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a000c79d-9a78-4f5b-be65-0b8352348c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0dd41c7-396e-424b-846f-d75f11829a9e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a000c79d-9a78-4f5b-be65-0b8352348c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d98ccf5c-ec67-49a8-ba8a-42168a1ee77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a000c79d-9a78-4f5b-be65-0b8352348c75" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d98ccf5c-ec67-49a8-ba8a-42168a1ee77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6b2e7dab-490f-4b67-b98b-01c571383aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d98ccf5c-ec67-49a8-ba8a-42168a1ee77f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6b2e7dab-490f-4b67-b98b-01c571383aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_bacbd598-ec5f-4684-ba32-e8792765b9af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0dd41c7-396e-424b-846f-d75f11829a9e" xlink:to="loc_us-gaap_InvestmentTypeAxis_bacbd598-ec5f-4684-ba32-e8792765b9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_bf26b184-ce4a-4082-bd9a-d0a0fcf712bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_bacbd598-ec5f-4684-ba32-e8792765b9af" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_bf26b184-ce4a-4082-bd9a-d0a0fcf712bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_fc7215cd-043e-4367-a0ec-607393bbf3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_bf26b184-ce4a-4082-bd9a-d0a0fcf712bd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_fc7215cd-043e-4367-a0ec-607393bbf3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b222ce28-1812-4563-8b3f-fb7cc398c350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0dd41c7-396e-424b-846f-d75f11829a9e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b222ce28-1812-4563-8b3f-fb7cc398c350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_98634dd2-8e1d-442c-a0c4-cdd7c6ebf81a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b222ce28-1812-4563-8b3f-fb7cc398c350" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_98634dd2-8e1d-442c-a0c4-cdd7c6ebf81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a5dec2e3-9811-473f-8a55-cd0c2d4c736c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_98634dd2-8e1d-442c-a0c4-cdd7c6ebf81a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a5dec2e3-9811-473f-8a55-cd0c2d4c736c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/FairValueAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20221231.xsd#FairValueAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/FairValueAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d6b69d54-3be5-4320-8a17-d28f83f03a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14188b08-f0c4-4884-9021-87407338dce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d6b69d54-3be5-4320-8a17-d28f83f03a71" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14188b08-f0c4-4884-9021-87407338dce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1d790397-209f-454b-ad05-2adffd66620a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14188b08-f0c4-4884-9021-87407338dce3" xlink:to="loc_srt_StatementGeographicalAxis_1d790397-209f-454b-ad05-2adffd66620a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_91085dd7-ed98-44f3-acb7-629d66417869" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1d790397-209f-454b-ad05-2adffd66620a" xlink:to="loc_srt_SegmentGeographicalDomain_91085dd7-ed98-44f3-acb7-629d66417869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9f7e80f4-f7b7-415a-bf92-f4d303560bb5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_91085dd7-ed98-44f3-acb7-629d66417869" xlink:to="loc_country_US_9f7e80f4-f7b7-415a-bf92-f4d303560bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ff630ed9-3e2b-4c96-9e42-ba738e3f2e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14188b08-f0c4-4884-9021-87407338dce3" xlink:to="loc_us-gaap_InvestmentTypeAxis_ff630ed9-3e2b-4c96-9e42-ba738e3f2e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6e76a89b-d9e0-4037-a0dc-c901189e829f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_ff630ed9-3e2b-4c96-9e42-ba738e3f2e02" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6e76a89b-d9e0-4037-a0dc-c901189e829f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4e3f88a8-b34e-4b56-8836-30eda05253d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6e76a89b-d9e0-4037-a0dc-c901189e829f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4e3f88a8-b34e-4b56-8836-30eda05253d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91596688-ec06-4176-94d6-936a4d8c0124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14188b08-f0c4-4884-9021-87407338dce3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91596688-ec06-4176-94d6-936a4d8c0124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_d5775ba0-a5e5-4585-9e73-b6c2d4789c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91596688-ec06-4176-94d6-936a4d8c0124" xlink:to="loc_us-gaap_InvestmentInterestRate_d5775ba0-a5e5-4585-9e73-b6c2d4789c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#CommonStockShelfRegistrationStatementDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4effb448-8eef-4c39-8b32-904c45aac9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_40572417-d8bd-4fb9-884c-5305507f4a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4effb448-8eef-4c39-8b32-904c45aac9de" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_40572417-d8bd-4fb9-884c-5305507f4a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4f247f0b-7a1e-4e75-bf20-64b483722dff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40572417-d8bd-4fb9-884c-5305507f4a51" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4f247f0b-7a1e-4e75-bf20-64b483722dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_131b6374-50e1-4561-ba8c-06aefbf6b1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4f247f0b-7a1e-4e75-bf20-64b483722dff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_131b6374-50e1-4561-ba8c-06aefbf6b1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_024ca52e-dd13-4415-9d6f-9928b1c8ffc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_131b6374-50e1-4561-ba8c-06aefbf6b1d6" xlink:to="loc_us-gaap_SubsequentEventMember_024ca52e-dd13-4415-9d6f-9928b1c8ffc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2ebda75f-af38-412b-a294-b36a78fa4c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40572417-d8bd-4fb9-884c-5305507f4a51" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2ebda75f-af38-412b-a294-b36a78fa4c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_92e50ce6-3f7d-4db2-b3fa-915ba98b46d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2ebda75f-af38-412b-a294-b36a78fa4c22" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_92e50ce6-3f7d-4db2-b3fa-915ba98b46d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_December2020ATMMember_2ac28e11-bbc6-4f6c-b798-f28303be576b" xlink:href="imux-20221231.xsd#imux_December2020ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_92e50ce6-3f7d-4db2-b3fa-915ba98b46d4" xlink:to="loc_imux_December2020ATMMember_2ac28e11-bbc6-4f6c-b798-f28303be576b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_May2022ATMMember_0afedf7a-0908-46bb-a0a9-cb210534a58e" xlink:href="imux-20221231.xsd#imux_May2022ATMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_92e50ce6-3f7d-4db2-b3fa-915ba98b46d4" xlink:to="loc_imux_May2022ATMMember_0afedf7a-0908-46bb-a0a9-cb210534a58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40572417-d8bd-4fb9-884c-5305507f4a51" xlink:to="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_f5718b4a-9ee0-4166-abe6-a3df3fd02d25" xlink:href="imux-20221231.xsd#imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_f5718b4a-9ee0-4166-abe6-a3df3fd02d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShelfRegistrationStatementAmountRemaining_919c68c2-5f91-4ac3-ab3c-ee74878c9ae0" xlink:href="imux-20221231.xsd#imux_ShelfRegistrationStatementAmountRemaining"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_imux_ShelfRegistrationStatementAmountRemaining_919c68c2-5f91-4ac3-ab3c-ee74878c9ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShelfRegistrationTerminationPriorWrittenNotice_90b101bf-5018-4934-ade4-eb5dc5116717" xlink:href="imux-20221231.xsd#imux_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_imux_ShelfRegistrationTerminationPriorWrittenNotice_90b101bf-5018-4934-ade4-eb5dc5116717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SaleOfStockRemainingCapacity_a3756017-a12e-41d3-8594-dc7814ea2d81" xlink:href="imux-20221231.xsd#imux_SaleOfStockRemainingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_imux_SaleOfStockRemainingCapacity_a3756017-a12e-41d3-8594-dc7814ea2d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_b17cc89c-af65-4a93-a208-27717e255888" xlink:href="imux-20221231.xsd#imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_b17cc89c-af65-4a93-a208-27717e255888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d5111da3-d347-4726-ab1f-fa00168b4e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d5111da3-d347-4726-ab1f-fa00168b4e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a8d97524-1d59-4f6f-a383-c682aa3dc802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a8d97524-1d59-4f6f-a383-c682aa3dc802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SharesIssuedWeightedAverageSharePricePerShare_faa7395e-7a31-4ce9-ad6b-487873d89ecb" xlink:href="imux-20221231.xsd#imux_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_imux_SharesIssuedWeightedAverageSharePricePerShare_faa7395e-7a31-4ce9-ad6b-487873d89ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d1f98477-68f9-4d94-9cf0-7288127fe5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d1f98477-68f9-4d94-9cf0-7288127fe5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_57b38ca8-5d4e-4164-808c-4654b2c5535b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4b499055-2649-4d76-b41f-573752740892" xlink:to="loc_us-gaap_PaymentsForCommissions_57b38ca8-5d4e-4164-808c-4654b2c5535b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockEquityOfferingDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#CommonStockEquityOfferingDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockEquityOfferingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9f7e9f6d-75cf-4e23-8365-d037c271fdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_86fcbc68-016e-4c1a-81ed-e627e8c1d127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9f7e9f6d-75cf-4e23-8365-d037c271fdb4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_86fcbc68-016e-4c1a-81ed-e627e8c1d127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_503a8809-4f88-4a02-accc-5ab970595a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86fcbc68-016e-4c1a-81ed-e627e8c1d127" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_503a8809-4f88-4a02-accc-5ab970595a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3d182a88-bb8c-402e-a6ee-7841e40a1324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_503a8809-4f88-4a02-accc-5ab970595a89" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3d182a88-bb8c-402e-a6ee-7841e40a1324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2be2a068-3866-4564-adde-5e8e1ebae259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3d182a88-bb8c-402e-a6ee-7841e40a1324" xlink:to="loc_us-gaap_SubsequentEventMember_2be2a068-3866-4564-adde-5e8e1ebae259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_70c5dafe-d9bf-491f-a22a-dfa848d92a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86fcbc68-016e-4c1a-81ed-e627e8c1d127" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_70c5dafe-d9bf-491f-a22a-dfa848d92a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe5dd10f-0d2f-4869-ad9c-9e9c859a2b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_70c5dafe-d9bf-491f-a22a-dfa848d92a07" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe5dd10f-0d2f-4869-ad9c-9e9c859a2b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_aab97694-0cc7-4a37-baa2-294964619f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe5dd10f-0d2f-4869-ad9c-9e9c859a2b24" xlink:to="loc_us-gaap_CommonStockMember_aab97694-0cc7-4a37-baa2-294964619f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PreFundedWarrantsMember_76a25c02-d795-469a-9fdd-b2ba33faa77e" xlink:href="imux-20221231.xsd#imux_PreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe5dd10f-0d2f-4869-ad9c-9e9c859a2b24" xlink:to="loc_imux_PreFundedWarrantsMember_76a25c02-d795-469a-9fdd-b2ba33faa77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_July2021PublicEquityOfferingMember_89f6e318-2da3-4e9a-89d1-825c72101fa0" xlink:href="imux-20221231.xsd#imux_July2021PublicEquityOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe5dd10f-0d2f-4869-ad9c-9e9c859a2b24" xlink:to="loc_imux_July2021PublicEquityOfferingMember_89f6e318-2da3-4e9a-89d1-825c72101fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86fcbc68-016e-4c1a-81ed-e627e8c1d127" xlink:to="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_97ae2483-756d-438f-aebf-040a5ded78ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_97ae2483-756d-438f-aebf-040a5ded78ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2b984c81-1eda-44ff-ab8c-41bf6603a4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2b984c81-1eda-44ff-ab8c-41bf6603a4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_c8e8f239-f4ba-4b5f-b526-0ef8416ee7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_SharePrice_c8e8f239-f4ba-4b5f-b526-0ef8416ee7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_6c60d1f3-005c-40b8-a8d1-cb36bb4930a1" xlink:href="imux-20221231.xsd#imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_6c60d1f3-005c-40b8-a8d1-cb36bb4930a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_090b2761-adbb-4b8c-9bfc-1e80caddf69d" xlink:href="imux-20221231.xsd#imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_090b2761-adbb-4b8c-9bfc-1e80caddf69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_0ce5643d-f5ce-4741-a663-34e761a0ced3" xlink:href="imux-20221231.xsd#imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_0ce5643d-f5ce-4741-a663-34e761a0ced3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2075c732-73fc-4b40-8df9-9c5b94ac446d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2075c732-73fc-4b40-8df9-9c5b94ac446d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5c849c83-1676-465a-9031-06cf37d0868a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5c849c83-1676-465a-9031-06cf37d0868a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_40115dd8-e1f0-4d23-b3fe-2dc54be662cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_40115dd8-e1f0-4d23-b3fe-2dc54be662cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_551f8d3d-6134-4337-ac3e-1aea9d8533e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_551f8d3d-6134-4337-ac3e-1aea9d8533e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_cf9a0905-a28d-44c8-a07c-b0f45ea59967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_cf9a0905-a28d-44c8-a07c-b0f45ea59967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_145c00ed-d1bc-4544-8b84-dabbf1202864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_145c00ed-d1bc-4544-8b84-dabbf1202864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_612de7f9-3b5e-4c91-aa1e-43ab92dbda58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_612de7f9-3b5e-4c91-aa1e-43ab92dbda58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5d20bff9-a676-4775-9657-300de2ab7b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5d20bff9-a676-4775-9657-300de2ab7b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ad3fe961-81c6-4063-890c-49d3682b838b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87ce283c-d70b-45d9-bdb4-46f73e9d0bfa" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ad3fe961-81c6-4063-890c-49d3682b838b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockCommonStockDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#CommonStockCommonStockDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2bba1e83-f89c-47bf-b967-fb8316052292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c4413934-328f-4944-a375-436fe35514ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2bba1e83-f89c-47bf-b967-fb8316052292" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c4413934-328f-4944-a375-436fe35514ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_714ccaa3-cefe-4789-bfe5-9700c2238756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2bba1e83-f89c-47bf-b967-fb8316052292" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_714ccaa3-cefe-4789-bfe5-9700c2238756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_92d97b01-0d0f-4343-bfb0-11ff43465975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2bba1e83-f89c-47bf-b967-fb8316052292" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_92d97b01-0d0f-4343-bfb0-11ff43465975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_16e7ffa2-5e6d-4bc1-868c-33051c5fab87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2bba1e83-f89c-47bf-b967-fb8316052292" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_16e7ffa2-5e6d-4bc1-868c-33051c5fab87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockPreferredStockDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#CommonStockPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_53a70a9b-2a4e-4672-a0b2-969a95dd9774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_858e4a43-91c7-4650-96d9-5531ddfdc2db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_53a70a9b-2a4e-4672-a0b2-969a95dd9774" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_858e4a43-91c7-4650-96d9-5531ddfdc2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1edce3e1-28c3-4085-aeee-954f074516a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_53a70a9b-2a4e-4672-a0b2-969a95dd9774" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1edce3e1-28c3-4085-aeee-954f074516a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d774502b-93cb-4bec-9dac-5914bd09ff79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_53a70a9b-2a4e-4672-a0b2-969a95dd9774" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d774502b-93cb-4bec-9dac-5914bd09ff79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#CommonStockSharesReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_81727b06-420f-486c-ba16-3085f65a15f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_16561d5e-fb6f-4e74-b721-eaa979eda659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_81727b06-420f-486c-ba16-3085f65a15f7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_16561d5e-fb6f-4e74-b721-eaa979eda659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7e268cbf-558d-45c7-aac2-2fc23a5a51d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_16561d5e-fb6f-4e74-b721-eaa979eda659" xlink:to="loc_us-gaap_AwardTypeAxis_7e268cbf-558d-45c7-aac2-2fc23a5a51d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00b78b1e-737e-43f4-8cb4-2aa4dda4139b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7e268cbf-558d-45c7-aac2-2fc23a5a51d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00b78b1e-737e-43f4-8cb4-2aa4dda4139b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4ddd5d91-33e7-4676-8517-9ea88fbaa84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00b78b1e-737e-43f4-8cb4-2aa4dda4139b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4ddd5d91-33e7-4676-8517-9ea88fbaa84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PreFundedWarrantsMember_0c7eb696-fbed-4f4f-90b1-f5a652e52a86" xlink:href="imux-20221231.xsd#imux_PreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00b78b1e-737e-43f4-8cb4-2aa4dda4139b" xlink:to="loc_imux_PreFundedWarrantsMember_0c7eb696-fbed-4f4f-90b1-f5a652e52a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeStockOptionsforFutureGrantMember_318e46d5-ed4f-4947-8da5-5eae5f936cd7" xlink:href="imux-20221231.xsd#imux_EmployeeStockOptionsforFutureGrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00b78b1e-737e-43f4-8cb4-2aa4dda4139b" xlink:to="loc_imux_EmployeeStockOptionsforFutureGrantMember_318e46d5-ed4f-4947-8da5-5eae5f936cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_caa61e3a-ba67-47ca-86ad-6f3a8b25b19d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_16561d5e-fb6f-4e74-b721-eaa979eda659" xlink:to="loc_us-gaap_PlanNameAxis_caa61e3a-ba67-47ca-86ad-6f3a8b25b19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5e1ec449-9683-40d4-9ecf-e70ea8dc91da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_caa61e3a-ba67-47ca-86ad-6f3a8b25b19d" xlink:to="loc_us-gaap_PlanNameDomain_5e1ec449-9683-40d4-9ecf-e70ea8dc91da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2021EmployeeStockPurchasePlanMember_da6a8ac2-6bb2-4fb5-a299-c23c45192f65" xlink:href="imux-20221231.xsd#imux_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5e1ec449-9683-40d4-9ecf-e70ea8dc91da" xlink:to="loc_imux_A2021EmployeeStockPurchasePlanMember_da6a8ac2-6bb2-4fb5-a299-c23c45192f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_cfd63aa4-67e6-4d0b-94f8-b92a024c586b" xlink:href="imux-20221231.xsd#imux_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5e1ec449-9683-40d4-9ecf-e70ea8dc91da" xlink:to="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_cfd63aa4-67e6-4d0b-94f8-b92a024c586b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2017InducementEquityIncentivePlanMember_ca9142d8-c0d7-40c6-bd94-87eba79042c6" xlink:href="imux-20221231.xsd#imux_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5e1ec449-9683-40d4-9ecf-e70ea8dc91da" xlink:to="loc_imux_A2017InducementEquityIncentivePlanMember_ca9142d8-c0d7-40c6-bd94-87eba79042c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a8fb2dff-4ed6-4159-be9d-d92363ac7cd4" xlink:href="imux-20221231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5e1ec449-9683-40d4-9ecf-e70ea8dc91da" xlink:to="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a8fb2dff-4ed6-4159-be9d-d92363ac7cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_785aed5f-b702-49a0-9510-eb59ef68bd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_16561d5e-fb6f-4e74-b721-eaa979eda659" xlink:to="loc_us-gaap_ClassOfStockLineItems_785aed5f-b702-49a0-9510-eb59ef68bd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7281dd7f-4851-4811-8511-2ffe464e4932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_785aed5f-b702-49a0-9510-eb59ef68bd2b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7281dd7f-4851-4811-8511-2ffe464e4932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#StockbasedCompensationPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca49b1f8-905d-4d2e-8802-d0d1ab189e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d958c70-d74e-4dd3-9de0-56b918d0b413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca49b1f8-905d-4d2e-8802-d0d1ab189e5d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d958c70-d74e-4dd3-9de0-56b918d0b413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c3c5f351-d029-4d9c-af09-ec8a3b6aedc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d958c70-d74e-4dd3-9de0-56b918d0b413" xlink:to="loc_us-gaap_PlanNameAxis_c3c5f351-d029-4d9c-af09-ec8a3b6aedc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c7cc6de1-b8a6-46cf-b126-cd01b6aca287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c3c5f351-d029-4d9c-af09-ec8a3b6aedc3" xlink:to="loc_us-gaap_PlanNameDomain_c7cc6de1-b8a6-46cf-b126-cd01b6aca287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2021EmployeeStockPurchasePlanMember_a530e179-3763-45d6-aa1e-c4d27ea8c6ab" xlink:href="imux-20221231.xsd#imux_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c7cc6de1-b8a6-46cf-b126-cd01b6aca287" xlink:to="loc_imux_A2021EmployeeStockPurchasePlanMember_a530e179-3763-45d6-aa1e-c4d27ea8c6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2019OmnibusEquityIncentivePlanMember_0eed378a-9735-4026-9439-f699b336e466" xlink:href="imux-20221231.xsd#imux_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c7cc6de1-b8a6-46cf-b126-cd01b6aca287" xlink:to="loc_imux_A2019OmnibusEquityIncentivePlanMember_0eed378a-9735-4026-9439-f699b336e466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_379201dd-5497-4030-8329-17c37ac21964" xlink:href="imux-20221231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imux_A2019OmnibusEquityIncentivePlanMember_0eed378a-9735-4026-9439-f699b336e466" xlink:to="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_379201dd-5497-4030-8329-17c37ac21964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_88a91493-b1bc-4b6f-b476-9f688526232e" xlink:href="imux-20221231.xsd#imux_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c7cc6de1-b8a6-46cf-b126-cd01b6aca287" xlink:to="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_88a91493-b1bc-4b6f-b476-9f688526232e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2017InducementEquityIncentivePlanMember_f1f98e62-cab9-4dc4-8905-0454921b1ae1" xlink:href="imux-20221231.xsd#imux_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c7cc6de1-b8a6-46cf-b126-cd01b6aca287" xlink:to="loc_imux_A2017InducementEquityIncentivePlanMember_f1f98e62-cab9-4dc4-8905-0454921b1ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b8ffb847-c28c-4c80-a31b-c0a3f8b8e631" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d958c70-d74e-4dd3-9de0-56b918d0b413" xlink:to="loc_srt_RangeAxis_b8ffb847-c28c-4c80-a31b-c0a3f8b8e631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0e15c1dc-622f-4542-a6e7-ce4c18bc941d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b8ffb847-c28c-4c80-a31b-c0a3f8b8e631" xlink:to="loc_srt_RangeMember_0e15c1dc-622f-4542-a6e7-ce4c18bc941d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6d194041-0dbd-4899-871a-1c974bdf920e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0e15c1dc-622f-4542-a6e7-ce4c18bc941d" xlink:to="loc_srt_MinimumMember_6d194041-0dbd-4899-871a-1c974bdf920e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_df89a754-0b4b-4fbe-a005-1d21a5977603" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0e15c1dc-622f-4542-a6e7-ce4c18bc941d" xlink:to="loc_srt_MaximumMember_df89a754-0b4b-4fbe-a005-1d21a5977603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4c399da6-a31a-49c9-88ca-7f8df17600aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d958c70-d74e-4dd3-9de0-56b918d0b413" xlink:to="loc_us-gaap_AwardTypeAxis_4c399da6-a31a-49c9-88ca-7f8df17600aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_360cfcff-6b41-49cc-a949-e1323132511d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4c399da6-a31a-49c9-88ca-7f8df17600aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_360cfcff-6b41-49cc-a949-e1323132511d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_IncentiveEmployeeStockOptionMember_cac1686c-9af7-4b72-a12a-8a4e462574e4" xlink:href="imux-20221231.xsd#imux_IncentiveEmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_360cfcff-6b41-49cc-a949-e1323132511d" xlink:to="loc_imux_IncentiveEmployeeStockOptionMember_cac1686c-9af7-4b72-a12a-8a4e462574e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_NonStatutoryEmployeeStockOptionMember_4c0f6ee3-9a02-4d0f-8057-63501d154998" xlink:href="imux-20221231.xsd#imux_NonStatutoryEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_360cfcff-6b41-49cc-a949-e1323132511d" xlink:to="loc_imux_NonStatutoryEmployeeStockOptionMember_4c0f6ee3-9a02-4d0f-8057-63501d154998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d958c70-d74e-4dd3-9de0-56b918d0b413" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_aaa8c17c-4225-4531-a8d1-3fe1662f2806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_aaa8c17c-4225-4531-a8d1-3fe1662f2806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_86e6efe0-de81-425a-b5f3-10cd25bedde1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_86e6efe0-de81-425a-b5f3-10cd25bedde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_08b5b127-b14b-4749-874f-8a86132ec08b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_08b5b127-b14b-4749-874f-8a86132ec08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_72750108-460e-4570-bb94-e003cae996e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_72750108-460e-4570-bb94-e003cae996e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d169b9e1-89bc-4ff8-b420-aea71d0a626d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d169b9e1-89bc-4ff8-b420-aea71d0a626d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_34da1aeb-0873-4afd-804c-809a0368e3d6" xlink:href="imux-20221231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_34da1aeb-0873-4afd-804c-809a0368e3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_da5a35cd-ca7b-4171-9a4f-d7216a563733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_da5a35cd-ca7b-4171-9a4f-d7216a563733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c5c471db-e8dc-48df-b6d9-f5108894f3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c5c471db-e8dc-48df-b6d9-f5108894f3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8aff6099-f123-4eb9-a686-1451a9637898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8aff6099-f123-4eb9-a686-1451a9637898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9c4d88f4-1221-48a2-9d73-76518252b129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9c4d88f4-1221-48a2-9d73-76518252b129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_462b5154-3add-4d55-b513-7a9c9ee35a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_462b5154-3add-4d55-b513-7a9c9ee35a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_28d2689e-b848-4336-8b30-4b222e868437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_28d2689e-b848-4336-8b30-4b222e868437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_abcb22d2-8dd1-4836-ab9a-c2eaecedeefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9da7215b-da4f-41c2-a0e9-ccd70e2af4c5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_abcb22d2-8dd1-4836-ab9a-c2eaecedeefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#StockbasedCompensationPlansSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07cd8cb1-a559-4df5-8cb2-8cbd23873faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce15b711-3327-4e77-ac60-8fb534616d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07cd8cb1-a559-4df5-8cb2-8cbd23873faa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce15b711-3327-4e77-ac60-8fb534616d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a2e71b38-c7e4-4d05-aee3-9b521a92e1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce15b711-3327-4e77-ac60-8fb534616d32" xlink:to="loc_us-gaap_AwardTypeAxis_a2e71b38-c7e4-4d05-aee3-9b521a92e1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4c19c63-a3ba-4951-8b49-da3dcc6180b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a2e71b38-c7e4-4d05-aee3-9b521a92e1e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4c19c63-a3ba-4951-8b49-da3dcc6180b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dc92dd7c-dbad-48ec-9da1-8591617a631a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4c19c63-a3ba-4951-8b49-da3dcc6180b5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dc92dd7c-dbad-48ec-9da1-8591617a631a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4e768463-95f4-41c2-adfa-254f03bf2815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce15b711-3327-4e77-ac60-8fb534616d32" xlink:to="loc_us-gaap_PlanNameAxis_4e768463-95f4-41c2-adfa-254f03bf2815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e2e07b3f-f830-4fd3-a329-4dc1aa405ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4e768463-95f4-41c2-adfa-254f03bf2815" xlink:to="loc_us-gaap_PlanNameDomain_e2e07b3f-f830-4fd3-a329-4dc1aa405ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_dacfa579-22ce-4bdb-858c-53a1f7a80077" xlink:href="imux-20221231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e2e07b3f-f830-4fd3-a329-4dc1aa405ad7" xlink:to="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_dacfa579-22ce-4bdb-858c-53a1f7a80077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce15b711-3327-4e77-ac60-8fb534616d32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3744f2b-5dc7-4033-9f5c-f9fa4c91aee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3744f2b-5dc7-4033-9f5c-f9fa4c91aee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_36293d72-c321-468e-a58e-e74703f273cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3744f2b-5dc7-4033-9f5c-f9fa4c91aee2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_36293d72-c321-468e-a58e-e74703f273cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ce4e3585-c86d-47c4-a1e6-d406f7e27060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3744f2b-5dc7-4033-9f5c-f9fa4c91aee2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ce4e3585-c86d-47c4-a1e6-d406f7e27060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3d3ea76-db71-48e4-af2b-53896ada393e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3744f2b-5dc7-4033-9f5c-f9fa4c91aee2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3d3ea76-db71-48e4-af2b-53896ada393e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_305a3428-6fc9-41c5-9a49-53050f90d024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3744f2b-5dc7-4033-9f5c-f9fa4c91aee2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_305a3428-6fc9-41c5-9a49-53050f90d024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_454f4645-b142-417b-9ce1-608afc76be7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3744f2b-5dc7-4033-9f5c-f9fa4c91aee2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_454f4645-b142-417b-9ce1-608afc76be7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fb690ee6-1ac9-47d4-88fb-9157eccfe512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fb690ee6-1ac9-47d4-88fb-9157eccfe512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7d326d2a-40a8-489f-96c8-864381d42478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7d326d2a-40a8-489f-96c8-864381d42478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2dd359d2-8c46-43e4-bbc7-98aa4a54c13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2dd359d2-8c46-43e4-bbc7-98aa4a54c13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3bad4393-06d1-43cb-8039-a8f9ddcb4462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2dd359d2-8c46-43e4-bbc7-98aa4a54c13a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3bad4393-06d1-43cb-8039-a8f9ddcb4462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ed0bef85-9278-48ba-9f1d-314fb53d1a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2dd359d2-8c46-43e4-bbc7-98aa4a54c13a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ed0bef85-9278-48ba-9f1d-314fb53d1a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9d6d63db-9bdc-48c7-9f9a-b0185ce01e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2dd359d2-8c46-43e4-bbc7-98aa4a54c13a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9d6d63db-9bdc-48c7-9f9a-b0185ce01e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2cbad858-f97d-423b-bb18-a0d7e8eee337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2dd359d2-8c46-43e4-bbc7-98aa4a54c13a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2cbad858-f97d-423b-bb18-a0d7e8eee337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_29390fd6-73ff-411d-bcc4-9ee7b347ddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2dd359d2-8c46-43e4-bbc7-98aa4a54c13a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_29390fd6-73ff-411d-bcc4-9ee7b347ddb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d277ea25-8f0f-44f5-b066-5d8cfe29fa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d277ea25-8f0f-44f5-b066-5d8cfe29fa6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_04de6cab-060a-48a2-9b9b-7d7eba7f238d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_04de6cab-060a-48a2-9b9b-7d7eba7f238d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8549f18-a036-4cec-b13d-7c700131b519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_af36be18-dff4-4261-834c-069c3894dd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_af36be18-dff4-4261-834c-069c3894dd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_cfcca0c4-e29c-4015-9fd4-a2090f722ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_cfcca0c4-e29c-4015-9fd4-a2090f722ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_01b8a5aa-cc76-4eeb-bb0f-268db950c61f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_01b8a5aa-cc76-4eeb-bb0f-268db950c61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6d33fbcd-9f66-4775-8ef7-584d428aeac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6d33fbcd-9f66-4775-8ef7-584d428aeac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_96759d04-0db9-4199-bf99-269d48085110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_96759d04-0db9-4199-bf99-269d48085110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2b2472af-cae3-4663-a8d6-a806ed86e854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7024a51a-ed2d-48b4-a751-d74a99c04e50" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2b2472af-cae3-4663-a8d6-a806ed86e854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cbfa5bce-7dfa-4877-a7bf-0ca831421869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5890d3e-5b5c-4ae2-81de-257e2386632d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cbfa5bce-7dfa-4877-a7bf-0ca831421869" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5890d3e-5b5c-4ae2-81de-257e2386632d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a12fc74b-4245-4fef-9da3-cc7ce0c66ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5890d3e-5b5c-4ae2-81de-257e2386632d" xlink:to="loc_us-gaap_PlanNameAxis_a12fc74b-4245-4fef-9da3-cc7ce0c66ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aa1ce657-793e-485a-9c44-529043246b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a12fc74b-4245-4fef-9da3-cc7ce0c66ff7" xlink:to="loc_us-gaap_PlanNameDomain_aa1ce657-793e-485a-9c44-529043246b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2019OmnibusEquityIncentivePlanMember_948cbcf0-ee27-4cda-9f71-35fe4a4d4ab2" xlink:href="imux-20221231.xsd#imux_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_aa1ce657-793e-485a-9c44-529043246b25" xlink:to="loc_imux_A2019OmnibusEquityIncentivePlanMember_948cbcf0-ee27-4cda-9f71-35fe4a4d4ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33da093f-dcfb-4005-8f49-8163d33a253d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5890d3e-5b5c-4ae2-81de-257e2386632d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33da093f-dcfb-4005-8f49-8163d33a253d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5bf0d714-fdfb-4492-be06-bc2b08cf613d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33da093f-dcfb-4005-8f49-8163d33a253d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5bf0d714-fdfb-4492-be06-bc2b08cf613d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d45e71f8-f521-40db-bc1d-2830b6ed9f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33da093f-dcfb-4005-8f49-8163d33a253d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d45e71f8-f521-40db-bc1d-2830b6ed9f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c75671fe-d965-49df-b7a1-ac5ba27f26c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33da093f-dcfb-4005-8f49-8163d33a253d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c75671fe-d965-49df-b7a1-ac5ba27f26c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0da9e783-73fe-415a-8a93-23cc54e4aa0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33da093f-dcfb-4005-8f49-8163d33a253d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0da9e783-73fe-415a-8a93-23cc54e4aa0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4ae75e9-3f9f-47b7-a2df-693ba5a87ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9eb9c358-aa4d-453f-9bc5-361d44b17675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4ae75e9-3f9f-47b7-a2df-693ba5a87ea5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9eb9c358-aa4d-453f-9bc5-361d44b17675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d51084da-a49a-45f3-b029-bd9b484a247a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9eb9c358-aa4d-453f-9bc5-361d44b17675" xlink:to="loc_srt_TitleOfIndividualAxis_d51084da-a49a-45f3-b029-bd9b484a247a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_217d10bc-bc8d-4461-ba7f-d3dbbd3cdf0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_d51084da-a49a-45f3-b029-bd9b484a247a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_217d10bc-bc8d-4461-ba7f-d3dbbd3cdf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeMember_f4b5f48c-dc9c-44a5-b9db-0b054fcda22e" xlink:href="imux-20221231.xsd#imux_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_217d10bc-bc8d-4461-ba7f-d3dbbd3cdf0f" xlink:to="loc_imux_EmployeeMember_f4b5f48c-dc9c-44a5-b9db-0b054fcda22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_65f7f2fd-7418-4059-8504-aa9723a367ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9eb9c358-aa4d-453f-9bc5-361d44b17675" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_65f7f2fd-7418-4059-8504-aa9723a367ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e485d87c-59e4-4147-abbc-449cae758325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_65f7f2fd-7418-4059-8504-aa9723a367ff" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e485d87c-59e4-4147-abbc-449cae758325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_908c4365-daa6-4a7c-aa81-2cc2f0505a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e485d87c-59e4-4147-abbc-449cae758325" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_908c4365-daa6-4a7c-aa81-2cc2f0505a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0e955b14-b1fc-453b-82c9-c51f699f9ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e485d87c-59e4-4147-abbc-449cae758325" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0e955b14-b1fc-453b-82c9-c51f699f9ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_817ffc72-f4e4-4cfb-b05c-bce13a0b1de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9eb9c358-aa4d-453f-9bc5-361d44b17675" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_817ffc72-f4e4-4cfb-b05c-bce13a0b1de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6c8fe0f8-6e43-4792-a1ab-8bfa63b89092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_817ffc72-f4e4-4cfb-b05c-bce13a0b1de0" xlink:to="loc_us-gaap_ShareBasedCompensation_6c8fe0f8-6e43-4792-a1ab-8bfa63b89092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7fef5f2e-c3f8-43a3-93a6-bef94602a045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_0472b01b-1f84-4b2a-81b3-2bc300b1c5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7fef5f2e-c3f8-43a3-93a6-bef94602a045" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_0472b01b-1f84-4b2a-81b3-2bc300b1c5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_83c002d1-7876-40db-ac4b-b87dca5b11c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_0472b01b-1f84-4b2a-81b3-2bc300b1c5b9" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_83c002d1-7876-40db-ac4b-b87dca5b11c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ff6ed75c-79c4-4b47-8d90-e1452aa0c828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_83c002d1-7876-40db-ac4b-b87dca5b11c8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ff6ed75c-79c4-4b47-8d90-e1452aa0c828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_61d2744a-099c-4b3f-8993-35f96b91dab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ff6ed75c-79c4-4b47-8d90-e1452aa0c828" xlink:to="loc_us-gaap_DomesticCountryMember_61d2744a-099c-4b3f-8993-35f96b91dab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_91d89a4c-cc7d-40cb-8d29-557e82379bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ff6ed75c-79c4-4b47-8d90-e1452aa0c828" xlink:to="loc_us-gaap_ForeignCountryMember_91d89a4c-cc7d-40cb-8d29-557e82379bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_75459e17-0ea3-4aa5-b819-a3c43291bea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_0472b01b-1f84-4b2a-81b3-2bc300b1c5b9" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_75459e17-0ea3-4aa5-b819-a3c43291bea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_18c6f368-19e9-4038-9d8a-c58a803c110a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_75459e17-0ea3-4aa5-b819-a3c43291bea2" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_18c6f368-19e9-4038-9d8a-c58a803c110a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_8bdaf490-4718-47de-814b-3f856792f513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_18c6f368-19e9-4038-9d8a-c58a803c110a" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_8bdaf490-4718-47de-814b-3f856792f513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalMinistryOfFinanceGermanyMember_91e65408-0d8c-4203-851a-b11df0510654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalMinistryOfFinanceGermanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_18c6f368-19e9-4038-9d8a-c58a803c110a" xlink:to="loc_us-gaap_FederalMinistryOfFinanceGermanyMember_91e65408-0d8c-4203-851a-b11df0510654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ForeignExcludingGermanyMember_bf348dcf-f551-4131-bdef-a75f2e2462e1" xlink:href="imux-20221231.xsd#imux_ForeignExcludingGermanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_18c6f368-19e9-4038-9d8a-c58a803c110a" xlink:to="loc_imux_ForeignExcludingGermanyMember_bf348dcf-f551-4131-bdef-a75f2e2462e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_d9f03414-d74f-4793-9388-45f8187eba51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_0472b01b-1f84-4b2a-81b3-2bc300b1c5b9" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_d9f03414-d74f-4793-9388-45f8187eba51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_34ded21d-af63-487f-9c35-f92d82e4fcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d9f03414-d74f-4793-9388-45f8187eba51" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_34ded21d-af63-487f-9c35-f92d82e4fcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#IncomeTaxesIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a043dccc-0992-4f22-9278-c3d0b8f4b594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c0bfe2ee-30f3-405c-bf30-7da6add1e64b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a043dccc-0992-4f22-9278-c3d0b8f4b594" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c0bfe2ee-30f3-405c-bf30-7da6add1e64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0716e616-c8cb-4f16-b334-9b7abdd78a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a043dccc-0992-4f22-9278-c3d0b8f4b594" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0716e616-c8cb-4f16-b334-9b7abdd78a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_4249a66d-8c7f-4cc9-ac51-fa8a6b2af536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a043dccc-0992-4f22-9278-c3d0b8f4b594" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_4249a66d-8c7f-4cc9-ac51-fa8a6b2af536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_ac943828-0f19-4db0-97fe-87477e23e08a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a043dccc-0992-4f22-9278-c3d0b8f4b594" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_ac943828-0f19-4db0-97fe-87477e23e08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_1cd9aece-8da4-41ff-ba16-639ea5e0d269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a043dccc-0992-4f22-9278-c3d0b8f4b594" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_1cd9aece-8da4-41ff-ba16-639ea5e0d269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_326daa54-852c-4b44-b322-76c01bf4383a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a043dccc-0992-4f22-9278-c3d0b8f4b594" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_326daa54-852c-4b44-b322-76c01bf4383a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a9fff796-b1c7-45ba-8740-f7782f9eb848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a043dccc-0992-4f22-9278-c3d0b8f4b594" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a9fff796-b1c7-45ba-8740-f7782f9eb848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a2602a97-93f0-4aff-862a-ec93008c1654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a043dccc-0992-4f22-9278-c3d0b8f4b594" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a2602a97-93f0-4aff-862a-ec93008c1654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b6d8fcaf-7037-4495-b7bc-e677cd60e90f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_562dd7f8-8e6e-416a-a16d-8ebbd6b6ccec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b6d8fcaf-7037-4495-b7bc-e677cd60e90f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_562dd7f8-8e6e-416a-a16d-8ebbd6b6ccec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ef7da105-6028-4832-9af6-6741398708ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_562dd7f8-8e6e-416a-a16d-8ebbd6b6ccec" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ef7da105-6028-4832-9af6-6741398708ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d3b0b67c-96c3-4c23-9273-9d3d049f4051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ef7da105-6028-4832-9af6-6741398708ff" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d3b0b67c-96c3-4c23-9273-9d3d049f4051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_cc161db8-aa24-400c-ad95-2a9da37dbffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d3b0b67c-96c3-4c23-9273-9d3d049f4051" xlink:to="loc_us-gaap_ForeignCountryMember_cc161db8-aa24-400c-ad95-2a9da37dbffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_8a48772b-80bc-42fa-866b-687eeda2d7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d3b0b67c-96c3-4c23-9273-9d3d049f4051" xlink:to="loc_us-gaap_DomesticCountryMember_8a48772b-80bc-42fa-866b-687eeda2d7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_1630a5c7-d252-46be-bc69-8ba15b02d19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_562dd7f8-8e6e-416a-a16d-8ebbd6b6ccec" xlink:to="loc_us-gaap_TaxPeriodAxis_1630a5c7-d252-46be-bc69-8ba15b02d19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_100428e1-814f-4645-ab1d-56fad634b399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_1630a5c7-d252-46be-bc69-8ba15b02d19b" xlink:to="loc_us-gaap_TaxPeriodDomain_100428e1-814f-4645-ab1d-56fad634b399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TaxYearsPriorTo2018Member_11bdb290-3367-4949-b09f-06147fbdc219" xlink:href="imux-20221231.xsd#imux_TaxYearsPriorTo2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_100428e1-814f-4645-ab1d-56fad634b399" xlink:to="loc_imux_TaxYearsPriorTo2018Member_11bdb290-3367-4949-b09f-06147fbdc219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TaxYearsPost2017Member_28edb879-ff1e-4e1f-b9bb-adaa4cf91ab2" xlink:href="imux-20221231.xsd#imux_TaxYearsPost2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_100428e1-814f-4645-ab1d-56fad634b399" xlink:to="loc_imux_TaxYearsPost2017Member_28edb879-ff1e-4e1f-b9bb-adaa4cf91ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_b01dde29-9604-4dc3-a22b-40266211bcff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_562dd7f8-8e6e-416a-a16d-8ebbd6b6ccec" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_b01dde29-9604-4dc3-a22b-40266211bcff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_25879fde-945e-41d5-9fdc-c35d26ce4d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b01dde29-9604-4dc3-a22b-40266211bcff" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_25879fde-945e-41d5-9fdc-c35d26ce4d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_09900a05-5fd1-4814-80fd-423825197d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b01dde29-9604-4dc3-a22b-40266211bcff" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_09900a05-5fd1-4814-80fd-423825197d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_9b76f095-0d07-4144-baea-26d9e1d7f1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b01dde29-9604-4dc3-a22b-40266211bcff" xlink:to="loc_us-gaap_OperatingLossCarryforwards_9b76f095-0d07-4144-baea-26d9e1d7f1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6db28ecc-cb3d-4bae-b874-2f167ab014e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b01dde29-9604-4dc3-a22b-40266211bcff" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6db28ecc-cb3d-4bae-b874-2f167ab014e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_df04bb13-063f-4195-8deb-fca291e182c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b01dde29-9604-4dc3-a22b-40266211bcff" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_df04bb13-063f-4195-8deb-fca291e182c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_97890381-6790-42fe-91f5-acc0330c2a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_09dc93a7-94ed-4692-b364-0d003823c74c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97890381-6790-42fe-91f5-acc0330c2a19" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_09dc93a7-94ed-4692-b364-0d003823c74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7589e769-33e1-4841-a4b0-0310a2460e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_09dc93a7-94ed-4692-b364-0d003823c74c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7589e769-33e1-4841-a4b0-0310a2460e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3a6ae814-916a-45c1-92ce-a75072d1fe61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_09dc93a7-94ed-4692-b364-0d003823c74c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3a6ae814-916a-45c1-92ce-a75072d1fe61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8a0b68e9-5af2-43fe-90fd-765184f633cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_09dc93a7-94ed-4692-b364-0d003823c74c" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8a0b68e9-5af2-43fe-90fd-765184f633cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_b8a160b8-5674-448e-8ef3-ce17f52e8f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_09dc93a7-94ed-4692-b364-0d003823c74c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_b8a160b8-5674-448e-8ef3-ce17f52e8f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_803f4f35-c059-437d-a7f9-363fb5503d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_09dc93a7-94ed-4692-b364-0d003823c74c" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_803f4f35-c059-437d-a7f9-363fb5503d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_ec032097-1c29-4eac-98c1-610f409cae4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_09dc93a7-94ed-4692-b364-0d003823c74c" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_ec032097-1c29-4eac-98c1-610f409cae4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6c25c087-8361-4677-8a3e-a33f033a5951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_09dc93a7-94ed-4692-b364-0d003823c74c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6c25c087-8361-4677-8a3e-a33f033a5951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_2c34d36c-c501-4257-96d1-f7796dd41926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97890381-6790-42fe-91f5-acc0330c2a19" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_2c34d36c-c501-4257-96d1-f7796dd41926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_86ba2581-97fa-4464-9723-facb5faf6a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_2c34d36c-c501-4257-96d1-f7796dd41926" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_86ba2581-97fa-4464-9723-facb5faf6a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_36794c7a-9067-45a0-a17e-5af8a110caf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_2c34d36c-c501-4257-96d1-f7796dd41926" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_36794c7a-9067-45a0-a17e-5af8a110caf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DeferredTaxAssetsAndLiabilitiesGross_9ddf605b-91e2-4c90-bb62-444eb02b34ac" xlink:href="imux-20221231.xsd#imux_DeferredTaxAssetsAndLiabilitiesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97890381-6790-42fe-91f5-acc0330c2a19" xlink:to="loc_imux_DeferredTaxAssetsAndLiabilitiesGross_9ddf605b-91e2-4c90-bb62-444eb02b34ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2f1e3ba7-95ae-4bc9-ba65-4c379fd09ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97890381-6790-42fe-91f5-acc0330c2a19" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2f1e3ba7-95ae-4bc9-ba65-4c379fd09ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8c29405b-a1de-418b-8e1a-feb7f78bb017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97890381-6790-42fe-91f5-acc0330c2a19" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8c29405b-a1de-418b-8e1a-feb7f78bb017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="imux-20221231.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a98988ec-b969-4a69-9fec-c92b51a715f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a98988ec-b969-4a69-9fec-c92b51a715f3" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4f46b425-24ce-435d-9035-f1d569435d0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:to="loc_srt_CounterpartyNameAxis_4f46b425-24ce-435d-9035-f1d569435d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6c2c0264-ef3b-4720-8212-0a9768aa559d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4f46b425-24ce-435d-9035-f1d569435d0d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6c2c0264-ef3b-4720-8212-0a9768aa559d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DuaneNashMDJDMBAMember_e4215808-ff01-4469-a6c0-0aedb80b04eb" xlink:href="imux-20221231.xsd#imux_DuaneNashMDJDMBAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6c2c0264-ef3b-4720-8212-0a9768aa559d" xlink:to="loc_imux_DuaneNashMDJDMBAMember_e4215808-ff01-4469-a6c0-0aedb80b04eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_4711fba0-1730-414b-b4f2-e33598e8bf06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:to="loc_srt_TitleOfIndividualAxis_4711fba0-1730-414b-b4f2-e33598e8bf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_19b6163e-474b-4861-bd60-dd67ea39da8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4711fba0-1730-414b-b4f2-e33598e8bf06" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_19b6163e-474b-4861-bd60-dd67ea39da8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_32d3594e-47d0-428e-b533-eb93ec415c62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_19b6163e-474b-4861-bd60-dd67ea39da8f" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_32d3594e-47d0-428e-b533-eb93ec415c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5d379f2e-005a-406a-93b6-6d25eba48962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5d379f2e-005a-406a-93b6-6d25eba48962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2f722dc7-2c0d-4db7-b6ff-b4a32ae3b9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5d379f2e-005a-406a-93b6-6d25eba48962" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2f722dc7-2c0d-4db7-b6ff-b4a32ae3b9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ExecutiveChairmanAgreementMember_555833f7-f641-4e03-a8cd-3edad33ce422" xlink:href="imux-20221231.xsd#imux_ExecutiveChairmanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2f722dc7-2c0d-4db7-b6ff-b4a32ae3b9c5" xlink:to="loc_imux_ExecutiveChairmanAgreementMember_555833f7-f641-4e03-a8cd-3edad33ce422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ede0d070-b499-4765-a8f3-4f7685344282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ede0d070-b499-4765-a8f3-4f7685344282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_182916d7-dc47-4d75-b5ff-dbc044d9416e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ede0d070-b499-4765-a8f3-4f7685344282" xlink:to="loc_us-gaap_RelatedPartyDomain_182916d7-dc47-4d75-b5ff-dbc044d9416e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_de255c00-e2dd-4ecd-b19e-78562b4d2edb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_182916d7-dc47-4d75-b5ff-dbc044d9416e" xlink:to="loc_srt_AffiliatedEntityMember_de255c00-e2dd-4ecd-b19e-78562b4d2edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_033d36d0-cbcd-40f4-9581-0801425895f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:to="loc_srt_StatementScenarioAxis_033d36d0-cbcd-40f4-9581-0801425895f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_78e1e742-aeee-4575-a20a-a803c7d9f590" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_033d36d0-cbcd-40f4-9581-0801425895f7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_78e1e742-aeee-4575-a20a-a803c7d9f590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_6d1e8e13-fca9-48a5-bb8e-6610c1e3a9e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_78e1e742-aeee-4575-a20a-a803c7d9f590" xlink:to="loc_srt_ScenarioForecastMember_6d1e8e13-fca9-48a5-bb8e-6610c1e3a9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_26ae8d8a-1e3e-415a-8049-b7c0419fa85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_45cb86cd-b52d-47e9-aebf-a8d93323278d" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_26ae8d8a-1e3e-415a-8049-b7c0419fa85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SalaryCostsMonthlyBaseSalary_a18cce7c-235b-4c12-96c3-c7489ddd93c9" xlink:href="imux-20221231.xsd#imux_SalaryCostsMonthlyBaseSalary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26ae8d8a-1e3e-415a-8049-b7c0419fa85d" xlink:to="loc_imux_SalaryCostsMonthlyBaseSalary_a18cce7c-235b-4c12-96c3-c7489ddd93c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_781d2f4f-f0bf-46fc-a3c6-ce325ea0fba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26ae8d8a-1e3e-415a-8049-b7c0419fa85d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_781d2f4f-f0bf-46fc-a3c6-ce325ea0fba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@    0   "S" (    A7"KD    )4E$051X7F-@
M (/_8 !ACW)&.:.<4<XH9Y0SRAGE#'D.A"*) P!_$47SY0GZP@    !)14Y$
$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>imux-20221231_g1.jpg
<TEXT>
begin 644 imux-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R
M4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M            ]M8  0    #3+4A0("
M                                 !%C<')T   !4    #-D97-C   !
MA    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV
M=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $
M/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M         !)S4D="($E%0S8Q.38V+3(N,0
M                                        6%E:(        /-1  $
M   !%LQ865H@                     %A96B        !OH@  ./4   .0
M6%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:
M                      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                        9&5S8P         L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                         '9I97<      !.D_@ 47RX $,\4  /MS  $
M$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                     H\    "<VEG(     !#4E0@8W5R=@        0
M    !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@
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M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K
M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X
M=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\
M(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82
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M4*=:+<C@Q=>I1:Y6>7?\+Z_X*R_]$O\ V>__  I=<_\ D:C_ (7U_P %9?\
MHE_[/?\ X4NN?_(U>HT5V?4:';\3D^MU^_X'EW_"^O\ @K+_ -$O_9[_ /"E
MUS_Y&H_X7U_P5E_Z)?\ L]_^%+KG_P C5ZC11]1H=OQ#ZW7[_@>7?\+Z_P""
MLO\ T2_]GO\ \*77/_D:C_A?7_!67_HE_P"SW_X4NN?_ "-7J-%'U&AV_$/K
M=?O^!Y=_POK_ (*R_P#1+_V>_P#PI=<_^1J/^%]?\%9?^B7_ +/?_A2ZY_\
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M/?\ X4NN?_(U'_"^O^"LO_1+_P!GO_PI=<_^1J]1HH^HT.WXA];K]_P/+O\
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M0[?B'UNOW_ \N_X7U_P5E_Z)?^SW_P"%+KG_ ,C4?\+Z_P""LO\ T2_]GO\
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M&KU&BCZC0[?B'UNOW_ \N_X7U_P5E_Z)?^SW_P"%+KG_ ,C4?\+Z_P""LO\
MT2_]GO\ \*77/_D:O4:*/J-#M^(?6Z_?\#R[_A?7_!67_HE_[/?_ (4NN?\
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M:O4:*?U&AV_$7UNOW_ \N_X7U_P5E_Z)?^SW_P"%+KG_ ,C4?\+Z_P""LO\
MT2_]GO\ \*77/_D:O4:*/J-#M^(?6Z_?\#R[_A?7_!67_HE_[/?_ (4NN?\
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MK+_T2_\ 9[_\*77/_D:O4:*/J-#M^(?6Z_?\#R[_ (7U_P %9?\ HE_[/?\
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MI=<_^1J/^%]?\%9?^B7_ +/?_A2ZY_\ (U>HT4?4:';\0^MU^_X'EW_"^O\
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M=?O^!Y=_POK_ (*R_P#1+_V>_P#PI=<_^1J/^%]?\%9?^B7_ +/?_A2ZY_\
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M5ZC11]1H=OQ#ZW7[_@CR[_A?7_!67_HE_P"SW_X4NN?_ "-1_P +Z_X*R_\
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M,@NYT#.[<LP55'_ :]HIUJ<J-5PEO%M?<[#I58UJ<9QV:3^]!1116984444
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M\K[&V_9YFS^+;_>QUVT!=%>BBB@84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5Y=\,O\ E+AI/_9N>M?^G[2:]1KR[X9?\I<-)_[-SUK_
M -/VDURXS^ _ZZG1A/XR^9UW_!8#_E'MXU_["_AO_P!2#3JZ.N<_X+ ?\H]O
M&O\ V%_#?_J0:=71UCEW\-_(Z,?O'YA1117H'GA1110!^>'Q5_:;^%/[*/\
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M$/VX/'W_  3 ^&O[5?BC2?A--I%MXGO[B6]\W6(-.:*)VL;.<_ZAY&G5)&&
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MO3I1LY-IMN][.^FBLFTNYX65X.K4P>'JUI:0BG%)6LW&UW=N[2]#\M_^"?\
M^R7XU_;N\">,H?CY\?/%MK\.O"_C[4H-"T#P]K!CN;G596S)<S2OO^2)%C5$
MQU9L8Y)[;]IKXI_#OQI^V1I_[!OQO_:KNOA]\'?A7X.LU\073>(6L;[Q9J0M
MX?+@FG526PK+GMA7.,N"/0O^"),%S;_LY?$1;JWEA/\ PN+4O];"R_P+ZUR'
M[3_A[P]^R#_P4>U+]K[XW? 9?&7PC^)?AV.RUS4E\-IJW]@ZG$D:>8\+J=N6
MA4CINCD(!)3%=LZRJYG5IO[*?*E9:Z:K3=J]M]3F=.I3R^E-/XI>\W=Z:VO9
M[)V1PUQ\5?V7?V*?VG_A;X@_8,_:JE\5>$/&/B)-!^(OP]_X2Q]3A2*5XTCO
M(UD ,;?O&PW)#1K@X<BO8?VO]2\?_M7?\%#-#_X)S:-\3=9\)>!-#\*GQ'\0
M[KPY>-!>:O\ +YB6V]?NIM\E1U&9'8@X%;OPJ_;)_P"";/Q0^+?AOX?_ +-_
M[/\ ;^(M;U35(XHM6TCX216<&B]_M<UQ)$I18]O+("0?2N,_:^U'Q1^Q1_P4
MBT'_ (* :UX'UGQ!\-_$OA >&_&-[H=GY\NC2K%Y0D9/[NU8Y%S@-M=<[JSB
MW.O:4&JBA+E<K7<K^[T6JU2OY!)*&'<HS3IN4;\M[):7UN]'I>Q[1^SW_P $
M_/"7[+?QJTWX@? CXS^-[/PW):S6_B;P'XAUAM1L]39E_<SH[X,+QO\ ,>#[
M$<UYW_P3,_Y/(_:UQ_T5"'_T=<UZ'\ O^"BGPI_:C^-^E_#']G/P%XMU[1OL
MLUUXC\=7^B2Z?I^D+&F8D_>+F261_DP=OMN[>??\$T;>ZB_;&_:R:XMY8U;X
MH0[7=&56_>W+?+G_ &:YDL2J-;ZQ?FY5OO;F5K_\'6QW-8=U:+H.ZN]M5MT\
MBU_P2^UO6]7_ &I/VHK;6-8O;R*U^+"):Q75R\BP)ON_E12QVK]*\'_X)U_L
MO^*_VU/AQXVB^/WQ\\7-\.=!^(>I6^G>#/#^MO:/?:@[;WN;NX;<6B5-JI'Z
M[CQ_%[E_P2SMKJ#]JK]JEKBWEC5OBXFWS49=WSW?3=5'_@B3;W-O^SS\2%NK
M>6%O^%Q:EM\V%E_@7UKHQ%3V,<1*&C_=V?;3IV?F84H.K.C&IJFYW5]]=+]U
MY%3_ ()_0^-OV;OVX_C!^P)<_$36?$7@O0]&MM?\$_\ "07C3W-BDOE,4#MV
M*3;648!,:L "36_\$M3UC4?^"UWQB\+SZY>M8+\.=,^SV37+M!&Q6R^98]V%
M;YO3^]ZU5^%5O<+_ ,%Q?BU=-;R^5_PJ73OWNQMG^JM._2I/@8)K/_@N#\9M
M0DLY?*7X::4V[8VUOELOXNG\-*KRSE4G;65*+?J^6[]7U*I*=.$(IZ*HTO35
MV]%LCSKX*?#R3_@K/\;?BE\5OC]\2?%5K\.? _B@^'/ _@3PUK;V,&Y=V;F9
MESN8I&K'C+-)U"IBOICX%?LB^)_V?O 7C;X1^ ?VE/&%YH_B*';X'EUS;>7W
MA"5HF25H96QYOS,KJ,+C;Z\U\J_LY?&S0O\ @DW\<OBK\ ?VJ_#GB&Q\(^+O
M%3>(_ _CG3-%EO+:YB;<OEE8N<E&7.,E6C8,!D&O9_&G[2GQ,_;8_8S^--_^
MRC\*O%^B_9=!6R\$:]JELUG>>(V;YKS[''UCVQ*R+AB6,F.&XJ,9#$RK*--V
MHOE46[66VOK>]^N]Q8&I05%RJ:U5S76M]WIZ6V_ \@^//['G_!.GX?\ @;Q!
M;^)/V^M:'Q8T_1;JZM?$>K_%E'OI=1BB9T5[9"0JM*NSRMWF#=US7IO[/_QL
M\>?M!_\ !&;6/B5\4-4>^UYOASXATZ_U*5]TMY]F2:))93_$Y3;N/<KD\FO!
MO@'\:?\ @G1I?[&^G_!#X??LDW'BKXU7'A2>PO\ PPWP]>?4WU=X9(WNY;R9
M"D<2,WF9S\H7 4$5ZA^PK97]O_P0TURQN+*=9_\ A$O%J^4\+*[?--V/-=E>
ME*-!*I=RC4BDY66CO=Q2Z.R\NW4X\/54\5>G;EE3DVHW:33C9-[-[GL?_!*K
M_E'/\*/^P#/_ .EL]>_UX%_P2MC>+_@G7\)XYHW5O^$>F^5DVM_Q^SU[[7SN
M.UQU7_$_S/HL!_N=/_"OR"BBBN8[ HHHH **** /FCXU_P#*5/X#_P#9,/&_
M_HW1:^EZ^:/C7_RE3^ __9,/&_\ Z-T6OI>IAN_Z[#?PQ]/U844450@HHHH
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M_P !^/\ _@L-I/Q'^#GP O? G@K4OA/?IX=6X\-KIBZO%"&B?4$MP!Y:2/\
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M_P %!_V_KJ\^)OBJ66]OK6+Q_+8+X8C+L(;:W@1&12J*I(/RC=MV]S[_ /\
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ME?.?_!0G_D9?V>_^SB=%_P#2'4*^C*F.[_KH5KR+Y_F%%%%42%%%% !1110
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M_P!J#X$ZU$NSQ/\ !>TM+65A_J+O;9/!*N[^[,L;?2O3O^"4?[1D?C7]BU]
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MZ7KYH^-?_*5/X#_]DP\;_P#HW1:^EZF.[_KL-_#'T_5A1115""BBB@ HHHH
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M C>F[<,@C*\@BJ$G_!+KXC,Q9?\ @IM\>E'IYN@?_*NM'_@M'N_X=R>,\_\
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MT'_Y64?\.M_B-_TDW^/7_?S0?_E97UUCVHQ[4>VJ_P S^]A[&G_*ON1\B_\
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M^9_>P]C3_E7W(^1?^'6_Q&_Z2;_'K_OYH/\ \K*/^'6_Q&_Z2;_'K_OYH/\
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M_P"5E'_#K?XC?])-_CU_W\T'_P"5E?76.>E&/:CVU7^9_>Q>QI_RK[D?(O\
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MT'_Y64?\.M_B-_TDW^/7_?S0?_E97UUCVHQ[4>VJ_P S^]A[&G_*ON1\B_\
M#K?XC?\ 23?X]?\ ?S0?_E91_P .M_B-_P!)-_CU_P!_-!_^5E?76/:C'M1[
M:K_,_O8>QI_RK[D?(O\ PZW^(W_23?X]?]_-!_\ E91_PZW^(W_23?X]?]_-
M!_\ E97UUCVHQ[4>VJ_S/[V'L:?\J^Y'R+_PZW^(W_23?X]?]_-!_P#E91_P
MZW^(W_23?X]?]_-!_P#E97UUCVHQ[4>VJ_S/[V/V-/\ E7W'R+_PZX^(O_23
M?X]?]_-!_P#E96+XA_X(\7'B_P 1Z#XQ\4?\%"OC=?:OX5O9KOPSJ$\FA>9I
MD\L+V\DD>W3 ,M#))&=P/#'&#S7VH2?3]:0E3U:E[>K_ #,/8TOY5]Q\C?\
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M_O8>QI_RK[D?(O\ PZW^(W_23?X]?]_-!_\ E91_PZW^(W_23?X]?]_-!_\
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M>U'MJO\ ,_O8>QI_RK[D?(O_  ZW^(W_ $DW^/7_ '\T'_Y64?\ #K?XC?\
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M?X]?]_-!_P#E91_PZW^(W_23?X]?]_-!_P#E97UUCVHQ[4>VJ_S/[V'L:?\
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M/7_?S0?_ )64?\.M_B-_TDW^/7_?S0?_ )65]=8]J,>WZT>VJ_S/[V/V-/\
ME7W(^1?^'7'Q&/3_ (*;_'K_ +^:#_\ *RN+_9]^!.O_ +.G_!772O!&N_M
M>-/B&^I?LW:U>Q:EXW>Q,MEM\0:2C10_8[: ;&W*3O#'*C!QQ7W;\R^@KY7U
MS)_X+:^%N_\ QBQKW_J2:/2=6I)6;'&E3B[I*X[_ (+2?\HY/&7_ &'_  K_
M .I+I=?4Z?=%?+'_  6D_P"4<GC+_L/^%?\ U)=+KZG3[HJ#7H+1110(****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $8$C KY0_X(
MS?\ )H>L?]ED\=?^I'?U]7L2!D5\H?\ !&;_ )-#UC_LLGCK_P!2._H&MCZP
MHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MR7/_ ,IT(?\ LTZ7_P!2:.OK2ODN?_E.A"/^K3I?_4FCH!'UI1110 4444 %
M%%% !1110 4444 %%%&0>AH **** "BBB@ HHR#T-% !1110 4444 %%%% !
M111D>M !1110 4444 %%%% !111D'H: "BBB@ HHHH **,C&<T4 %%%% !11
M10 44$@=310 4444 %%%&1ZT %%%% !1110 4444 %%%% !1110 4444 %%%
M&0>AH **** "BBC('4T %%%&0.IH **** "BBC(/0T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7Y:?\'0'_)&/A9_V-%]_P"DRU^I=?EI_P '0'_)&/A9_P!C
M/??^DRU]%PG_ ,E!1]7_ .DL^5XT_P"2:K^D?_2D?HA^S/\ \FX> O\ L3=+
M_P#26*N[KA/V9_\ DW#P%_V)NE_^DL5=W7AXC_>)>K_,^AP?^Z4_1?D@HK,;
MQ1X=1C%+K]DKJV&1KM,J??FK%CJVF:F&;3]1M[C9][R)0^/KBLG":5W$U56G
M)V4BW114?FP>=Y.]=^W.WOBD:$E%%% !15>WN[>\C8VLZ2!7*-Y; [6'5?J*
ML4 %%5[2[M+Q6EL[B.50Y5FC<-\PX*\>E6* "BN<\4?%+X>>"_%WAWP'XJ\9
M6&GZSXNNI[?PSIMU<A)=3E@A:>9(5_C9(E9R/1:Z.@ HHIK,BH6/04 .HKF_
MA7\5?AO\;O >G_%'X1^-=.\1^'=561M-UG2+D2VURJ2-&Y1QPV'1E/NIKI*
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M9?\ T[RU[W"^'H8K/*5*M%2BWJGML?.\58FOA,@KUJ,G&2CHUHT<[_Q$+_\
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MQKRTA5%)P.[=!5+CTJ%PYP^W;ZO"_HBWQ/Q+&*D\3.S\WT/N3_B(7_X*/?\
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M7M>U]KGV=_Q$+_\ !1[_ *&GPI_X2\?_ ,51_P 1"_\ P4>_Z&GPI_X2\?\
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M+5?ZM</V_P!WA]R,O]:N(T[?69_>S[D_XB%_^"CI_P"9I\*?^$O'_P#%4?\
M$0M_P4>Z_P#"4^%/_"7C_P#BJ^/_ !O\(?B;\-]!\/>*O'7@R]TO3_%FG'4?
M#=[=*JQZA:AL>;'M8_+GUQ7.<@9[&HI\/</5(\T:$&O))^OXFM7B7B:C/EJ8
MB:>FC;6Z377JC[C_ .(A?_@H]_T-/A3_ ,)>/_XJC_B(7_X*/?\ 0T^%/_"7
MC_\ BJ^&Z*T_U:R#_H'C_P" HR_UKXB_Z"I_>S[D_P"(A?\ X*/?]#3X4_\
M"7C_ /BJ/^(A?_@H]_T-/A3_ ,)>/_XJOANBC_5K(/\ H'C_ . H/]:^(O\
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M*GP_P[6CS0H0:\DGZ_<PK<2<44)<L\1-/31MIZI-;]]_F?<?_$0O_P %'O\
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MV@_VI_A3X?T#4_!:7&J?#KPS\/)9E:*=X?+LDU.[OM[3?,H\T0_,_P!U ",
M:7/H[]NR5)O^"A?[%\\,JD-X\\5E67^)3X9NZ^OZ^,?VNO\ D][]AK_L:_$G
M_J*W-?9U!)\F^*?^"M'PGC^+WC?]F[X3? [XC?$'XE^!_$ITN^\$^%=&@>5X
M!:PSMJ3W$LR6]M9YG6$//)'(\ORI&PYKT+]DC]M[X;_M>0>*_#&E>#_$O@[Q
MIX$U!++QOX \:6"6VJZ-+*C/ [B-Y(Y(9D4O'+&[*Z^G2O&?^":7B#P,W[:?
M[8WA&WUG3?\ A)4^,UM=WFGJZ"\^PG1[)(92/OM%YBS*#T#;^YJ+X;RPZW_P
M7D^+&H^")5ET[1?V<M!T[QHT)RL6LRZG<3VB2XZ/]BY&>=M!5EL>$_\ !('_
M (*!'X6?\$W?A[\)/@]^RC\4/B[JW@NPU1O'+> -+M?LVANVJ7DPM6EO+B$7
M-X8I(Y!;6_F.%D7=LR ?OKX6_MA? KXS_LN6_P"V)\._$=UJ'@F;1+G5'N+?
M39I+N-+?S!/ ;9%:1KB.2.2,PJ"V]<+NXSX3_P $ ;.SMO\ @DG\)'MX(D-Q
M%K,L[(@4R2'6K[<[?WF/<UYY^P[^TGX=_8V_X)O?M ?M&>(O#]QJ.F> _C7\
M0+R#1K%U1I]NL2"*!#@B-6E=06P=H9FP<8H!V/2=6_X*\Z;X"L[+XA_'+]AO
MXX?#OX9WMY;V\OQ*\7^'[**TTQ9W$<4]];17<EU90%V4;Y(LKO3<JYX]H_:M
M_:_^'O[)_A;0=3UOPQX@\5:[XPUI-(\$^#O!U@MWJ.O7S1M+Y<*LZ1HBQQM(
M\TCI'&BY+= ?A/\ X*?:+_P4K\4?\$NOB/\ &?\ :"_:F^%/AWP_J?@H7.J?
M#KPU\/)9E:*=XO+LTU2ZOMYF^95\T0X,GW4 QC[%_:8_9!'[5'PY^'VM^"OB
MWJ'P^^(WP_FCUKX>^.-.L8KUM,N7M?L\RS6DV([NWEBD9)(B5S\N&'<%H=/^
MS'^TWXK^/ESKWA_Q[^R]\1/AAK?AU[<W%EXWL;=K:]CF#[)+.\M)IH+D#RV#
M@,'C)&Y>03Y3KW_!532M6\2Z]#^SC^QS\7_B_P"&/"NI36&N^./ 6CV3:<UU
M Q6XALC<W4,FHO$RLK>0C*6^56:LSX6_M1?M7Z[XX^+'[ _[1GAOPS)\5_#G
MPO?Q+X1\8?#_ ,^/3=>L;GS[6"1[>X9I+*[6XC4-%OD5MQ*$*HW>+?\ !)CX
M-?MQ^./^"=7PIUGX!?\ !1#PEX;\.0^&1:Q>'!\#+:[DTJYBFD2YMIICJ$9D
MF299 [E%+/N8CYJ MI<^^/V>OV@OA3^U)\']$^._P3\3C5O#?B"W:6PNC"T3
MJR.T<L4D;@-'+'(C(Z,,JRD5F?M/?#;X\_%CX?6_@3X#?'=?AS=WNK0C7_%$
M&AI?7T>E[7\Z*Q$K>7#=.?+59Y%D$0WL$+;<<G^P'^QWK?[%/PGU_P  >)?B
MV/&FJ>)O'VK>*]2U:'P\NE01W-_*LLL,-LDLJQ1A]Q #8^8\"O>*!'P1_P $
M>OA1H'P,_:2_:V^$_A/6=:U"QTCXJZ4D5[XCUN;4+ZYD?1X)))I[B9B\LLCL
MS,Q_D *SOVI_VE_ G[+'_!:_1O'7CC1=>U:YUC]EF?1_#/AKPMI#WVJ:]J;^
M)(Y4LK6%<;G*12.68K&JQLSLJC-=Y_P39_Y/@_;/_P"RN:3_ .F2VJGXLU[P
MEHO_  <">%++Q7JEC;WFJ?LJ7]KX<6]=%>XO!X@CE>.#=UE^SQS.0O.Q7[ T
M#ZGI/[/7_!1#PW\7OC@?V9OBU\ /'OPD^(%UH\FL:%X?\>V=KLURQC91++9W
M-I--!,\6Y=\6X2*.<$ D?1]?%W_!0J2WU7_@HA^QGX<\,.DGBFW\?>(=1VQI
MN>#1DT69+YVQ]Q&W0ID\%MHZU]H-NVG'7% CY4\<_P#!4CP_%\1/%/@']G#]
ME'XL?&>+P)JLFF^-]?\ A[I%HVGZ9?Q+F:PBEN[F'[9=Q#;OA@#[2R@G<<5W
M][^WO^SCHG[),/[:/B;7=4TGP?<08CMM3T.>#4VO/M#6W]GBR9?.:[^TJT(A
M .6Z$K\U>/?\$%;C3$_X)R:'HDYV^)=)\:>*+/QY%*ZFYBUH:W=O,MQC_EJ4
M>%N>=K)7)_\ !:BX\0^*+7]FC7? /Q0TG1=)M_VDM+BN?%=WI::MI^E7_DW=
MO:3SP>:B2".YW)\\B!),9(84#TO8]*\*?\%2;"V\<>&M _:-_8Z^+OP>T;QI
MJD.F^%?%_CO2++^SYKZ?_CWM+IK2ZF>PFE)"HLZA=VY2P(K.\0''_!>GPP?^
MK3M8_P#4DL*Y_P#:-_X)K_MY?M9_!_4/@+\=/^"E.A7WAK5[JSEU*'3O@1;6
MMS_HUU#<HT,PU(F)]\2X<#(KH-> _P"'\WAA,_\ -I^L?^I)84!I<[/]E:[_
M &8)_P!LS]I"T^#OP]UG3/'=GK_AZ+XI:S?W;26VL7+:4LUF]LAF<1K';R;&
MPD66['@UQWB__@K#+HEAJGQ!\,?L!?'W7_AYH;S-J7CZU\)VMM ]O"?WMW!9
MW5S%>3VZJ&;?Y(R%) (&:R/V+=<LO"__  4)_;D\1:J76VT_Q1X2NK@QQY;8
MGAF%VP/XOE6N4\"_&+_@HS^WA^RK=_MB>!_C_P##+X,_#S7]$U#4/#WAZ\\!
MOKU^FE1><GFZC>37L,$<K+&S$11[(U/)8@T"M8^I_'G[:W[-GP[_ &6H?VS=
M<^)44GP_OM(M=1TK5K.W>634$N=OV:*WA"^9)-*SJBQ8W;FP0,''FWPT_P""
MELWB+XE^'/ /QE_8F^-/PNM/&E^MEX2\2^,O#=LUC<W3C=%;7)L[B9[":0?=
M2=5&58%@17Q9H4VFZ9_P2X_X)W^(O&,4B^$]-^-'A"7Q'++)^XARE^EM+/GC
MRA<M"<G@<9[5^LVJZ[H>AB#^VM:M;0W=REK:_:;E8_.G?[D2;B-SGLHY- [)
M&A7R?XS_ ."J'AF/Q]XG\*_L_P#[*7Q:^+^E> M7DTOQSXJ^'FB6L]CI]]%_
MK[*#[1<127]Q#_RTCMT;:=HR2<5]57OVK[))]BV^=Y;>5NZ;L<5\8?\ ! &:
MV7_@F!X-TF^(_P"$BTWQ%XCM?&T3?ZV+6!K-XTZS9YWX:,\_PLE +<\N_P""
M;WQ7^ 7QH^$_[</QEEENO$GPVU_XH:]?Z@EE%-;3WVE-H-L;B)4D\J2&4Q^8
MFT^6P;N.M?1'@?\ :@_91_9'_P"";7PQ^-'@WPKXBT_X?7OA'P_!\.?!]K;/
MJ&MWQOX8?[/TN&/S7,]W)YBIM\PC.XEMH)KYO_9,\0>%/%7P3_X*(Z_X*UBQ
MU#3+KXE^+C;WNES))!*?[ B#LC)PWS[LL.IR:]<^!_[*?A3]L'_@D%^SK\.-
M>\9:CX7U?2/AMX)\0^"O%6BLGVO1-:L=,MI;6]C27*3;&W;D<89&8<'# ![G
ML/[.'[6_CGXW^/-0^''Q'_8U^*'POU&STA=3M+WQ?86DVFWT!D5/+CO+*XFB
M%PK,"UNY5]OS#(!QQOQ,_P""F6CZ7\5_$7P=_9S_ &6OB;\9]1\$WGV3QOJ/
M@&PM%T[1KS;O-BUS>7$*3W:J59H8MY3< Q#?+67^S]^TK^UC\*/VN=)_8/\
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MO^ ?A;-?Z-X@^'EQ.VF>(8-0L;M;.:*&;,UE<"6+8T+L_P WS(2N*!&W=?\
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M$%[-;K_JY969OO<G[O\ RSXX*T_X)@'PM%H'AS]H[]L+X;_"[QIXHLX;O1_
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MY3Q$FY/F:NDO=N[:+9M6;7F>%F]' X?/84L-#EC'E35V]=+ZO=)NR]#]:_\
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M/V<+/]E7]L'QE\*M&"G0/M_]J>%IXY5=)-+NQY]L0XX955O+R/\ GG7Z%?L
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M7"8:MD]:<X)N,6TVMM.G;9;'S?".,Q5'/:5.$VHRDKI-V?JNIG:G^V5^WO\
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MLT?M1_L[#X@_"#Q/K1U:VA^TRV%[INHQQ>3)=V-T/E9P-NY/PW .P._M\?\
M7<54PWQ/V5[6O;EUY;Z-]KZ&+PF6K!86EBE[L?:I7O:ZDDN9K5*_5'E7[0/P
M:TOX%^/HO">A?&+PKXZTV\TRWU'3O$7A*\>:VEBEW81U=0\4RE6#1.,K7" 9
M[U]#_P#!1#]D[X9?LO\ C3P;KOP2\2ZQJ/@SXD^"K;Q1X=M?$ELL6I:?!.S#
M[-<;5 8@='QSTYQO/SSU/I7U>68F.*P4*JDY76[5GH[.Z6B=T[GPN<X66"S"
M=*45&SV3NDFDU9O6S6UQ****[SRPHHHH **** "BBB@ HHHH **** "BBB@
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M /8P_9T^&GP4\2_L\:+\/TO/!_C'4M5O?$NC:S<O=QWTNHRM)=JYD).UVD;
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MA3^T#X0T?P#\2M"EFTK0?$>F:YIMK8W+VPCN["X6XMO]7CY%>-?DZ$<5W]%
M!1110 4444 %%%% !1110 5\K:__ ,IM?"__ &:QKW_J2:/7U37RMK__ "FU
M\+_]FL:]_P"I)H] T+_P6D_Y1R>,O^P_X5_]272Z^IT^Z*^6/^"TG_*.3QE_
MV'_"O_J2Z77U.GW10'0Q6\=^"5\4_P#"$'Q=IG]M>7O_ +(^WQ_:MFW=N\G=
MOQMYSCI6A>WEKI]K)>7EQ'##"A>665PJQJ!DL2>% '>ORE_X+2Z)??LA_P#!
M0CX*_P#!0GPU:$6L][#:>(6C_C>U=0X;_:ELYGC'_7&OHK_@N5^TGI_PI_X)
MSZQ%X9U>,W?Q$DMM$TF:%_\ 6V\_[V=Q@CY3;QR+G_IH/6O>CD<JCPCI2NJV
MFWPM.S6^MM^ESY9\1*BL8JT.5T-;7^)-73^>Q]*^/_VI?V</A7X1L_B!\1?C
MKX5T?0]0OOL=AJ]YKD"V]Q.%+&-)-VUF 5B<= .:[JPO;/4;*._L+E)8)HU>
M&:)PR2(0"&4C@J1C!K\H_P!J'X.?LP_L4?\ !*+X(^"_VJ_@#JGC28:JMS/9
MZ3XADTR6VU.]MYKJXWRJ&W*J_N=N/^6:GBOL']M#_@H?\$O^"<WP \)ZO=^#
M;O5+W6;.&T\&^#=-N5C>2.*%/ORMGRXHU:-"^&)+* IYP5\F;<(X52G*4I13
MLDFHO=:W6FKN&&S])U)8QQA&$82:NVTY*]GHD]=%8]>^/_[57[/W[+>G:3K'
MQ\^)=GX:M=<U#[%IDUY%*PGGQG;^[1MH ZL< =S7HJ21S(K)\P(RK5^&_P#P
M5>_X*":W^USX&^&_@'XH_LS>*_A9XRT7Q6-3.A^(8':*ZT^6+8D\,LL4+M\P
MP08L>C'D#])OV\/^"F_PM_8/_P"$;\$7O@O6?&GCCQ7&H\/>#] P)YU+B-7D
M;!**S_(@1'=WR O!(UQ/#N*HT,.H1;J5'*\;II*+6J>UK:MWL8X/BK!XC$8F
M4Y)4:?)9V:=Y+5-/6]]$K'U&R\],8K@_CS^TA\#?V9/!J_$#X^_$O3?#&DR7
M M[>YU&1LSS%6;RXD0%Y7VJQVHI.%)Z5\C_!;_@MC_:'Q\T/]G/]K[]D?Q3\
M'-;\42PQZ#=:U>&>"9YGV0^9YD,#1HS_ ";P' ?AL<D?)O\ P7+_ &@O$'Q'
M_;?^''PL\8_LZ^*GT'P/X@*6^G7L4BQ>-(YIK0R?8@$_>;U7[/E=QRV.#Q3R
MWAO%XC,88?$+EBTY733NEV=[/7U%F?%>"P^5RQ.%?-)24;--6;MNK76FO2Y^
MA_A7_@KQ_P $Y?&=]I>E>&_VH-'N+S6+^.RL+5K"\CEDGD*JBE'A!CRS*-SX
M'/6OI@'=C;R.]?BM_P %#?#WPNG\;_LD?%CP%^RE9_!^_P#%/BB<ZSX53P[%
MI][!Y&HV4<2SHD419@NYERF<2U^A/Q&_X*2>'?AS_P %"/"/[ DOPMO;J\\5
M::EV/$BZDB16V^.=U7R=A+_\>[9.X?>Z4\PR*,*5.IA(R?-&;DFTVE!V>JLG
M\KDY5Q'4J5:L,=**Y7",7%-)N:NM'=KYGT_DGJ:4YY]*^:?VD/\ @HEH?[._
M[9/PR_9%O?A?>:G/\2#&(M=AU)(H[#?.T*YB*$R?,N3\R\=,UP'[:O\ P6$T
M;]FO]H"V_96^"'[/>O?%CQ]Y4<NI:1H=RT:VF]/,6(>7#-)++Y7SE5CVJK+E
MLY \NAE&88F45"%^9.2U5K)V;;O9)/34]G$9[E>%C-U:EN62B]&W=JZ225WH
M?1MQ^U9^SY:?M P?LJW/Q-LH_B#<V/VRW\-M%+YKP^6TF[?L\O.Q6?;NW8&<
M5>T;]HCX%>(OBY?? ;1/BUX?NO&>EP>?J'AF'58FOH4VJV6A!W8"NA/H&&>M
M?EG^S?\ M-:#^UI_P7R\)?%S1/!NM^'+AO"ES8ZSX>\16WDW6FWUOI=S%/ X
M_BVOT)"D]U4\5]"? S7/V0I_^"VGQ"\&>$_V=]3T[XCZ=H<UYJ7C.;Q&\MI<
MO)!:&9DL\;8V9)U7?N_O?*,UZN*R&.%O"7-S*DINUM'>UGMIZ79XF"XFJ8Q*
M<>7D=9TTW?5)736F_K;8_0)C@Y/3'-&2"0!],FO@#QY_P79\&>%?BYX_^ /A
MO]E_QAXH\<>%O%$VB>&O#WAV0W4FNM \JS3GRHBUNB^7]U5F8[AQP<8?P]_X
M.&/AOXZ\#76GVW[+WC.?XJIJOV#3_AAHJ/>37SA69W6980ZA-C!T,/F XPK#
M<4XH\.YS*FIJD[:=5LU=/?;SV7<]"7%611J<CK*^JV>Z=FD[:ORW/T<XZ$\T
M 8'UKY"_X)T?\%6O"/[>FH>*/ ^K_"G4? OC/PE!]HU3PW?WOVC= )&C=D<Q
MQ.KQR81T>-2I=>O..A_X)Q?\%'-"_P""AOASQ=KVB_"Z]\+KX3U>.R:*[U1+
MG[2LBLR/E43:?E.5Y^IKFKY1F&&]I[2%N2W-JM.;;KK?R.S#9YEF+]E[*I?V
ME^71Z\N_32WG8^FP1V'UH1@U?+/[&_\ P4Z\#_M8ZW\7-.O?A[=^%++X2WS1
MZGJ5]J*W"7$*M<AYL(@*;1;,Q7YNO6O'O"W_  6Y^)_Q3BOOB5\$O^"<7Q#\
M6_#+3M2>UN?%VFWJM=,%(RZ6:0OOPK*Q42_+_$PK19)F;J3AR6Y;7NTDKJZU
M;LVULMS*7$.4QIPFJE^>]K)MNSL]$KV3ZM6/T)  X%%16TR3VZ3J" Z@C=UY
MJ6O+/;3NKB,"1@5\H?\ !&;_ )-#UC_LLGCK_P!2._KZO8D#(KY0_P"",W_)
MH>L?]ED\=?\ J1W]!2V/K"BBB@04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 -P#P*_"?_@YU)/\ P40^'61_S167_P!.\M?NR"6Y
MK\-/^#E/PUXF\5_\%'?A]I_A?P[?:E-'\$97EBL;.29E7^UY1N8(IXKZ/A&2
MCQ!1;[O\CYGC",I\-XA)7?+^I^=G7  KLOBI\?\ XJ_&GP_X1\,_$;7X;ZR\
M">'DT3PQ$EI%#]EL5;*QLR*#(W^V^36?_P *<^+?;X5>)/\ P2W'_P 11_PI
MSXN?]$J\2?\ @EN/_B*_>I3P<YQE*2;CL^UU;3Y'\V4X8^E3G3C&2C*UU9ZV
M=U?YFQ??M)?&+5?V=;/]E/4?$L5SX&T_7WUJQTN73X6>VO&5@[)/M\Q4.YLQ
M[MN6SBO4O /_  58_;7\ ^ -+^'(\?Z1X@TW0XEBT%O&'A6RU6XTV,*%$<,U
MQ$S[0JJ "3@+@<5XK_PISXN?]$J\2?\ @EN/_B*/^%.?%S_HE7B3_P $MQ_\
M17+/"9/6CRU(P:NWJEN]WZOJSNHYAGM"2E3E--)+KLMEZ+H=7J7[8?[1>N?M
M*6O[7>O_ !&:^^(5E?PWEMKMU80L(GB39&JP[!%L5/E";<4_X1?MD?M&? GX
MU:M^T%\+OB'+IOB;Q!+<OKLGV.*2VU,7$OFS)-;.ICD0NV[:1P>5Q7(_\*<^
M+G_1*O$G_@EN/_B*/^%._%W&/^%5>).?^H+<?_$5;HY4XN+4;./+;2W+VMM;
MLNAG'%9S&:FG.Z?-?6]W9-^K/6O'_P#P4T_;)^(_AO6? ^L?$.QLO#.O>'Y-
M&O\ PKHGAVTL=,^S2RK)(R6\,05)F95S-_K,?+NV\5[3\"/VJ?$7[.G_  1_
M&I_!GXS6^@>/]/\ VA1>P:=:W\37DMF;!4=I;5\^;;/T8,IC;H:^//\ A3GQ
M<_Z)5XD_\$MQ_P#$4G_"F_BWO\P_"OQ'N_O?V)<?_$5Y^)RK*:U&-*'+&*DI
M-*UI6TLUYH]/"9YG>&K2K34Y2<7%-WNKVU7^1Z)^TU^WY^U+^UQX>TWP;\9/
M'\#^'])E\^P\-:)I<&G:>L_S?OVA@51)+\S8+YQN;;C)KI?AC_P54_;2^$G@
MG1? 7AKQQH-U;>&;);3PS?:UX.L+Z]TF!/N1P7,T1D4+_#DG':O%_P#A3GQ<
M_P"B5>)/_!+<?_$4'X.?%T_\TJ\2?^"6X_\ B*ZOJ62RH*BX0Y4[I65DWO\
M\$XUF?$$,0ZRG/F:LWK>W;Y=#I/A]^UI^T!\,?BQKWQS\.?$2X?Q7XEL;VRU
MS6M3A2[EO(KM<3[_ #E(W'L>J]L5G^ OVB?BU\,/@_XS^ _@KQ%#:>%_'\=F
MOBS3GL8I&O/LKL\.V5U+Q89OX",]ZR_^%.?%S_HE7B3_ ,$MQ_\ $4?\*<^+
MG_1*O$G_ ();C_XBMW2RQK51^SV^R[Q^Y[=CGCB,X5K.>E^_VM']_4T?A9\?
M_BI\&?#/C#P?\.M?AL;#QYH/]C>*(GLXI?M-GNSL5G4F-L_Q)@U]M? #Q=X@
M\2_\$_/ /PO_ &"_VQ_"/PH\;:3K>I7_ ,6M)\0>+QH-_K%U(ZI;3Q7$F1+;
MI"JKY8( ^7/S"OA3_A3GQ<_Z)5XD_P#!+<?_ !%(_P &/BS)][X3^)&'^UH-
MQ_\ $5PYE@<#CXJTU%\RELFFTN5<R>^C\MEV/1RG-<PRV34J<I1Y6ENFDVF[
M-+2[W/LW]NCXUS67[!NC_LV?M'_M/^&_C'\7QX]&KV&K^'-135?^$;TKR=KV
MTFHJHWO*X_U2$XSSPB5\*V-[=:9J$.I64A66WE22)_[KJVY6_.MY?@W\60-J
M_"OQ)CU_L2X_^(H_X4Y\7,?\DJ\2?^"6X_\ B*VRW"X3+L,Z7M$^9MO9*[[)
M:)>7ZF&;8['9KBHU_9./*DENW9;-MZM^9I_'O]H3XM?M,?%N]^.'QE\3+J?B
M?48X%N=2M[.*U_U$2Q1;4A547"QKT'O5S]H[]J?X[?M;>,K+Q]^T#XYEU_5M
M.TF'3+.>2!(EBMHV9@NQ !N+,S,_5BV36!_PISXN=/\ A57B3_P2W'_Q%'_"
MG/BY_P!$J\2?^"6X_P#B*Z84LL@X<JBN1-1VT3Z+LCCJ5LVJ*:DY-3:<M]6M
M4WW-#XI?'WXI?&7PMX.\%?$77X;[3O >A?V/X9@2RBB^S6><[&9%!DY_B?)K
MUK2?^"KW[=VA_!^U^"^G?&?;8Z=I;Z;I>L2Z3;/K%C9L-I@AOF0S(-GR!@=X
M&T!AM%>*_P#"G/BY_P!$J\2?^"6X_P#B*/\ A3GQ<_Z)5XD_\$MQ_P#$5G4P
MV4UH*$XP:B[I.S2;=V_GU-J..SRA4<X2FG))-J^J2LD_1'3^+OVM?CUXZ^+W
MA;X\>*/&2W/BCP79Z;;>'=2^P1+Y$=B<VV]-NV9AW9P2W\6:RM8_:%^+^L_'
MJ?\ ::E\:7%MXXN-?_MEM=LH4A=;[?O\U$10B\_P8VXXQBLW_A3GQ;Q_R2KQ
M)_X);C_XBC_A3GQ<_P"B5>)/_!+<?_$54:660LHJ*LN7IL^GIY&4L1G%1MR<
MW>7-U^);/U\SU+XS?\%'OVM/CWXR\(_$/XB^-=*DU?P1KG]L:#/I_AFRM56_
MW1L9YECB G8^5']_(^7I7K'_  2^_: E\3_\%!?%7QZ^.7Q$TW3=4\1^"?$=
MUJFLWMU%I\4M[/ -NS[J1L3]T)^%?*H^#OQ='(^%7B3_ ,$MQ_\ $4C?!SXN
M.=K_  K\1M_W ;C_ .(KDKY?E57!RH4^6"<7&ZMHF[OY7UL>CA<XSFCC8XBM
MS3LT[.^K2LNG0]KU'_@K'^WGJ_PHF^$U]\;=MO>:8-.OM=CTBVCUB[LP,""2
M_5!.PV_+NSO(ZM7E'PC_ &@?BQ\#-%\6Z!\,/$D6GVGCCPX^A^)4>RBE^TV+
M-EHU9U)C;_;3!]ZS/^%._%W.?^%5>)/_  2W'_Q%*?@[\73U^%?B3_P2W'_Q
M%;TL+E%&FX0C!)N[2LKM.ZOZ,Y*V/SS$55.<IW2:5[Z)JS2]5H=3^S3^V#^T
M1^R+J]_J_P !/B')I4>KPB'6M)NK6*ZL-20*RJ)[:96CD8*S8;&1N;!YK?\
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M6S#/:T(PJ3FU&S2UW6S]4>P_%W_@J!^V-\9?A_JOPQ\2>.=(T[2?$7R^)O\
MA&?"MEID^L+\V5N9K:-7D4[N5R W<&O,;S]H+XL7O[/UK^R]=>(86\%6?B1]
M=M=*^PQ*ZZ@T7EM)YVWS-NW^#./:LS_A3GQ<_P"B5>)/_!+<?_$4?\*<^+G_
M $2KQ)_X);C_ .(ITL-E%&"C3C!)/FTLM>_K8FMCL\KR<JDIMM6=[[-WM]Y[
MKIO_  5W_;QTGP[;Z-9?$W1_M]GI8T^S\42>$-/;68+8)Y8C2\\GS,A/EWYW
M>^:^;+V^O=5OIM3U*]FN;BZE>6ZN;B8O)+(QRSNS<LQ/))K>_P"%.?%S_HE7
MB3_P2W'_ ,11_P *<^+G_1*O$G_@EN/_ (BJPU'*L))RHJ,7+>UE<SQ>*SG'
MPC"NYR4=KWT_X/F?0?\ P3^^+'@#5O@Q\:OV+?B]XSTO0=*^)'A(:AX;UG69
MHXK6UU[3F\ZW5Y96 C\X+LSU)4*.M>(> ?VBOB]\-/A'XS^!_@[Q&EGX:\?Q
MVJ>+-->QBD:Z6V??%ME=2\6#_<(SWK+_ .%.?%S&/^%5>)/_  2W'_Q%'_"G
M/BY_T2KQ)_X);C_XBL887 1KU9N2:FXR:=K*4;6?KHON.B>-S*6'I0C!QE!.
M*DKW<6[V?EJ_O-G]GG]I7XR_LM^-KGX@?!+Q+%I>HWNDW&EW_P!HT^*Z@NK.
M;;YD4L,RLDBG:IY'!J/P9^T5\6_A[\&O%_P"\)^)(;7PKXYELY?%&F_8(7:Z
M:V??#B1E+PX;^X1GO65_PIWXNXQ_PJKQ)Q_U!;C_ .(H_P"%.?%O_HE7B3_P
M2W'_ ,171*&6U).4N5M\MWI=\KO'[NG8Y85\VIPC"#FHJZ25]$]&OGU.B^#O
M[5?Q[^ /@7QE\-?A+\0I](T;X@:8+#Q39QP(WVF +(GRLP)B;9)(A=,$JQ%9
M_P #/C_\5OV;O$^H>+O@]K\6EWVJ:#=:+>RR644ZM9W 43)MD4A6(7[PY':L
MW_A3GQ<_Z)5XD_\ !+<?_$4?\*<^+G_1*O$G_@EN/_B*)0RU\]^7W_B_O=->
M_P PC6S:/)9R]SX=]+[V[':_LQ?MN?M,?L>R:A;? 3XA_P!FV&L*HU?1;ZPA
MO;&]VC"L\$Z,F[;\N\8..]7?VF?V_/VJ_P!K71;'PG\9_B.DV@:9-YNG>&M&
MTV&PTZ*0;MLGD0(JR.-S8+Y(W<5Y[_PISXN?]$J\2?\ @EN/_B*/^%.?%S_H
ME7B3_P $MQ_\163PV4O$>WY8<_\ -I?[^]C58[/(X7ZLI3]GVUMZ>GD?07Q3
M^)_P]^$__!,#P'^S#X#\7Z5JWB7Q_P"*Y_&?C]=*NXYWTJ*']S964Y1OW<NU
M?,,;<C;Z,#7RUCUKH_\ A3GQ<_Z)5XD_\$MQ_P#$4'X._%T]?A7XD_\ !+<?
M_$56"AA,'"2]I=RDY-]V_P#)62\D3F-;&YC.#=/E4(J*23T27IU>K]3G**Z/
M_A3GQ<_Z)5XD_P#!+<?_ !%'_"G/BY_T2KQ)_P""6X_^(KM^LX?^='G_ %3$
M_P C^YFI^SY^T7\7OV6OB?:_&+X'^*(M'\16EM-;P7LMC#<+Y4R;) 8YD9#D
M>HKW'5O^"T/_  41US1KS0=0^+FA&VOK*6VN4B\!Z4C/%*C(Z[A; C*LPXKY
MZ_X4Y\7/^B5>)/\ P2W'_P 10/@[\70,#X5^)/\ P2W'_P 17!B,)DV*J^TK
M0A*6BN[-Z>9Z>&QV>8.C[&A*<8]E>VNYI?#W]H#XK?"SX8^,O@[X'\1)9^'O
M'UG;6OBJS>TBE:[BMW\R-5=U+QX+<E",]ZI_!OXR_$O]GSXEZ5\7_@]XKN-#
M\1Z+<>;IVHVZ*VW*[65T<%)$96961@0PX(J'_A3GQ<_Z)5XD_P#!+<?_ !%'
M_"G/BY_T2KQ)_P""6X_^(K=K+G&<7RVG\6VNEM>^FASJIFJ<&N:\/AWTUOIV
MUU.UTG]N+]J3P_\ M):A^UQX=^*USI_Q!U:<MJFN65M"B72D1@Q/!L\EHCY:
MY0KCY5KM/C/_ ,%6?VX/CG\/[_X6^*/B?9Z9HFL?\AJS\+Z!::6VI9#!EN)8
M$5Y%<-\R9P>XKQ;_ (4Y\7/^B5>)/_!+<?\ Q%'_  ISXN?]$J\2?^"6X_\
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M$G_@EN/_ (BC_A3GQ<_Z)5XD_P#!+<?_ !%'UG#_ ,R#ZIBOY']S.<HKH_\
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M;PY\4?$WC>^L_%]KX6LTM9-7\)"QE:_EOXH0!-'$Z0^7)*#A_NG(X!:[&?\
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M#WQM_8Q^"?AKX;_%2U^-/AO0?"%SX&TB+39];2[N?*N]/N4A"_;8I+99F;S
MYQ'U +9[3_@DS\0/!/P4_P"";WB/]L'XV:W%X2\)>,O'_BKX@O?ZYF);73+W
M4I6MI"O7][$L;(@!:3SD"@EP*Z#]FKX5?%;]M;]H?3/^"B/[3?A6]\.^&/#M
MO-'^S[\+]4CVW.FV\Z[)/$&IQG.W4+F+Y8X?^76%L',I+ "]F>[?M2_LN_ [
M]J[P3IW@S]HS3+C4_#&D:Q%JMSHC:S-:V.HR1*PC2]2-U%S &;?Y,A,994+
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M#_-%&=K[A\HXJA^U+^P]^S#^V=IFGZ7^T9\+;;7CI)<Z9=+<S6UQ:;]N\)-
MZOM;:N4)*G:#C(HP6?X.C2H4:D9<L85(2:M?WW>ZUZ>8\?PUCJ]:O6I3CS2G
M3G%.]KP233TTOY'YT_MD?M*_!;]HS_@MA^S^GP4\=V7B*V\-:E8:?J>IZ9,L
MUH9VNY)O+BF0E)<*ZY*Y&>,Y!P_]FKXG_#?]FS_@O1\:KG]I/7M.\/-KEK?1
M:#K6OS);PQM,]I<P_O9,)'OMEP&) /3OBOOGPI_P36_8?\"W_@G4_"7[/NE6
M%S\.[V2[\)W-M<7"RVUQ(59Y9&$N;I]RJ<S^9C:,8Q4_[3__  3L_8Z_;%UV
MR\5?M ?!FWU?5K"%8+?58+ZXL[EH0VX1.\#H9$!+85\[=S;<9-7'.\K45AU&
M2I^S<&].;XN9/>WJC&7#F<N;Q+G!U?:JHEKRM*-FGITZ,^ ?AC\;?@W\?/\
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MHNPY8]AODQ?\\E_[YH\F+_GDO_?-.HHNPY(]AODQ?\\E_P"^:/)B_P">2_\
M?-.HHNPY8]AODQ?\\E_[YH\F+_GDO_?-.HHNPY(]AODQ?\\E_P"^:/)B_P">
M2_\ ?-.HHNPY8]AODQ?\\E_[YH\F+_GDO_?-.HHNPY(]AODQ?\\E_P"^:/)B
M_P">2_\ ?-.HHNPY8]AODQ?\\E_[YH\F+_GDO_?-.HHNPY8]AODQ?\\E_P"^
M:/)B_P">2_\ ?-.HHNPY(]AODQ?\\E_[YH\F+_GDO_?-.HHNPY(]AODQ?\\E
M_P"^:/)B_P">2_\ ?-.HHNPY(]AODQ?\\E_[YH\F+_GDO_?-.HHNPY(]AODQ
M?\\E_P"^:/)B_P">2_\ ?-.HHNPY(]AODQ?\\E_[YH\F+_GDO_?-.HHNPY8]
MAODQ?\\E_P"^:/)B_P">2_\ ?-.HHNPY8]AODQ?\\E_[YH\F+_GDO_?-.HHN
MPY(]AODQ?\\E_P"^:/)B_P">2_\ ?-.HHNPY8]AODQ?\\E_[YH\F+_GDO_?-
M.HHNPY8]AODQ?\\E_P"^:/)B_P">2_\ ?-.HHNPY(]AODQ?\\E_[YH\F+_GD
MO_?-.HHNPY8]AODQ?\\E_P"^:/)B_P">2_\ ?-.HHNPY(]AODQ?\\E_[YH\F
M+_GDO_?-.HHNPY8]AODQ?\\E_P"^:/)B_P">2_\ ?-.HHNPY8]AODQ?\\E_[
MYH\F+_GDO_?-.HHNPY8]AODQ?\\E_P"^:/)B_P">2_\ ?-.HHNPY8]AODQ?\
M\E_[YH\F+_GDO_?-.HHNPY8]AODQ?\\E_P"^:/)B_P">2_\ ?-.HHNPY(]AO
MDQ?\\E_[YH\F+_GDO_?-.HHNPY8]AODQ?\\E_P"^:/)B_P">2_\ ?-.HHNPY
M8]AODQ?\\E_[YH\F+_GDO_?-.HHNPY8]AODQ?\\E_P"^:/)B_P">2_\ ?-.H
MHNPY8]AODQ?\\E_[YH\F+_GDO_?-.HHNPY8]AODQ?\\E_P"^:/)B_P">2_\
M?-.HHNPY8]AODQ?\\E_[YH\F+_GDO_?-.HHNPY8]AODQ?\\E_P"^:/)B_P">
M2_\ ?-.HHNPY8]AODQ?\\E_[YH\F+_GDO_?-.HHNPY8]AODQ?\\E_P"^:/)B
M_P">2_\ ?-.HHNPY8]AODQ?\\E_[YH\F+_GDO_?-.HHNPY8]AODQ?\\E_P"^
M:/)B_P">2_\ ?-.HHNPY8]AODQ?\\E_[YH\F+_GDO_?-.HHNPY8]AODQ?\\E
M_P"^:/)B_P">2_\ ?-.HHNPY8]AODQ?\\E_[YH\F+_GDO_?-.HHNPY8]AODQ
M?\\E_P"^:/)B_P">2_\ ?-.HHNPY8]AODQ?\\E_[YH\F+_GDO_?-.HHNPY8]
MAODQ?\\E_P"^:/)B_P">2_\ ?-.HHNPY8]AODQ?\\E_[YH\F+_GDO_?-.HHN
MPY8]AODQ?\\E_P"^:/)B_P">2_\ ?-.HHNPY8]AODQ?\\E_[YH\F+_GDO_?-
M.HHNPY8]AODQ?\\E_P"^:/)B_P">2_\ ?-.HHNPY8]AODQ?\\E_[YH\F+_GD
MO_?-.HHNPY8]AODQ?\\E_P"^:/)B_P">2_\ ?-.HHNPY8]AODQ?\\E_[YH\F
M+_GDO_?-.HHNPY8]AODQ?\\E_P"^:/)B_P">2_\ ?-.HHNPY8]AODQ?\\E_[
MYH\F+_GDO_?-.HHNPY8]AODQ?\\E_P"^:/)B_P">2_\ ?-.HHNPY8]AOE19_
MU2_]\U^6_P#P<_*J_!CX7;5 _P"*IOLX'_3LM?J5W_"ORU_X.@/^2,?"S_L:
M+[_TF6OH>$V_]8*/J_\ TEGRW&D8KAFOI_+_ .E(_0_]F?\ Y-P\!?\ 8FZ7
M_P"DL5=W7"?LS_\ )N'@+_L3=+_])8J[NO#Q'^\2]7^9]%@O]TI^B_)!1116
M)TA7#ZA^S]\(]6^/FF_M.:CX-63QSI'AJXT#3=<-Y,&BTZ>:.:6#R@_E-F2-
M6WE"PZ!@"17<44 <1X)^ 'PC^''Q3\:_&KP5X/2P\4?$6:PE\9:I'=RNVHM9
M6_V:V9D=RD>R+Y/W87/4Y/-5?#/[,/P(\'_M >)?VH_#7PYM;/Q]XOTFTTWQ
M'XD2:4RWEK;?ZF,HS&-<?+DHH+;$W$[%QZ#10!Q%S\ OA->?'NS_ &G+KP<C
M>-]/\*S>'+77S>3;H],EN%N7M_*W^6<RHK;RN\= <$BL+]IW]C?]FO\ ;&\+
M67@[]H[X5VGB*#2KK[5H]Z;B:UO=-G^7]Y;7=N\<]NQVKGRW&[:-V<5ZI10!
MX-^S=_P3<_8[_92\<W7Q4^$GPJE;Q;>6WV6;Q;XEU^^UK4T@[PQW-_--)#&>
MZ1E0?XLU[S110!Q_QI^!OPA_:+^'.I?"7XY_#G2_%/AK5D"7^CZQ:K+%)@Y5
MAW5U;YE=2&4\J0:\,\&?\$=_V!/!?B;1?$[?"O6=?_X1N[2Z\.:9XS\>:QK>
MGZ9*GW)(;.^NY8-Z_P +%"5[5]1T4 >+_M.?L"_LK_M?:QI7BCXY_#>:^UO0
MH'@T7Q'I&NWNE:C9Q.VYHTN;*:*386YV$E<\XI/V9OV OV4OV0M8U/Q7\#_A
MA]DU_6H1!JWBC6-7N]5U6ZA#*1"UY>RRS"+*J?*5@F5!QD9KVFB@=V>0?M/?
ML.?LQ_MAKHMQ\>?AN=0U'PW</+X=U_3-6NM,U/2F? ?[/>6<D4\:MM7<@?8V
MT9!P*F_9E_8J_9I_8^M-6A^ ?PTBTJ]U^X6?7]=OK^XU#4]5D7=L-S?7<DMQ
M,%W-M5W*IN;:!DUZS10%V%?+OC7_ ((\?L ^._&^M>.Y?A%JVBW/B2[:Z\2Z
M?X1\=:QHMAJLS??DGM+"[B@9W_B8*"W5LFOJ*B@1Y%9_L/?LKZ9:_#33-.^#
M]C;6'P?NY+GX=:5!+.EGI%S(FPSB!7\N:4!F*R2AV1W=U(8DUO\ Q-_9M^"O
MQ@^(G@CXL?$+P8EYXF^'.J3:CX-UJ*\FM[C3YIHFAF4/"Z>9%(C;7A?=&^%W
M*<"N^HH ^ ?@1_P3N^$W[0_QO_:,\0?M+?!36;&]C_:!N=2\"^+;6YOM#U/[
M+)HNG1.]G?VCPSO;.RR*RI(8F9>1N3CZY_9P_9=^ W[)/P_'PP_9Z^'%GX<T
MB2\DO+P0RR37%]=2<O<W-Q,SS7,S<9DE=FPH&<  >BT4 ?.7QE_X)5?L1_''
MXHZE\:?%'PTU32?%&MJJ^(-7\%^,]5T%]74#:/M2Z?<PK<-CC>X+>]>H_ ;]
MFWX'?LR?"Z'X,? WX=6/A_PU%)-)_9D+22^?)*V99)GF9Y)Y'_B>1F9NYKO*
M* /E33/^"+7_  3;TGQ4OB*T_9S3[#'JG]I0^$)?$VI/X>CN]V[S!I#7!L>O
M.SR=@[+7I_[3W[%/[.'[85CH-M\=/ T][=>%[Y[KPWK.D:U=Z7J&ER2)LD\B
MZLY8IHU=/E9 VUMJY&5&/7** NSR/Q[^Q%^RW\4/V>-,_93^(OP@L]<\"Z-:
MVUOI.DZE<W$DMGY";(98KHR?:(YE7_ENLGF\M\W)KDO@G_P2Y_8O^ ?Q.TWX
MS>#OAUK&I>*=%BDCT+6_%_C;5=<ETI9$9'^S"_N94@)1F4L@#8;&<5]$T4#N
MSQO]IC]A']F3]K?5-&\3_&?P+=2:]X=5TT+Q1X?UV\TC5;&.3[\27EC+%-Y3
M=XRQ3OC/-0?!#_@GQ^Q]^SAXKT?QQ\$_@A8>']9T'0[W2;'5;:\N))Y;>\GB
MGN6N'ED8W<TDL,;&>?S)?EQOP2*]KHH"[*]_8VVIV4VGWL8DAGC:.5#_ !*1
M@BO+5_8G_9E3]DW_ (8>7X:+_P *O_L3^R?^$9_M6[_X\]^_R_M'F^?]_P";
M?YF[WKUJB@1SWCGX>^#?B/\ #C5_A%XST07?A_7M%GTC5M/\YT$]G/"T,L6]
M"'7*,R[@0>>#FG_#SP'X1^%7@+0_A=X!TC^S] \-Z-;:5HE@L[R"VM+>)888
MM[LSMM1%7+$DXY)-;U% '%^,O@5\)_B#\4_!GQK\8>$UO?$_P];4&\(:H;J5
M#I[7UO\ 9KK"(X23S(AL_>!L=5P>:/'GP(^%7Q-^(/@SXK^./"@O]?\ A]?W
M5[X1OVO)HSI\]S;M;3-L1PDFZ%V3$@8#.1@\UVE% '$_%']G_P"$?QE\4^#O
M&GQ(\()J6I> /$']M^$[AKN>(V-]Y,D/G;8W59/DD8;9 R]\9 (?H?P+^%GA
MOXSZ_P#M!Z)X7,/B_P 3Z-8Z5KFK_;)V^TVEFTS6\?EES&NTSR?,BACN^8G
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M+RQA;[T=M)J%Q-]FSN8$Q;"P8@DBOH*B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OE;7_\ E-KX7_[-8U[_ -231Z^J:^5M?_Y3:^%_^S6-
M>_\ 4DT>@:%_X+2?\HY/&7_8?\*_^I+I=?4Z?=%?+'_!:3_E')XR_P"P_P"%
M?_4ETNOJ=/NB@.@@ P=PI 1D<=Z^3?\ @JK_ ,%+=+_X)Z?#+3&\->&[?7_'
M/BJ66+PUI%T["&)(]OF7,X3#F-2R*$4@NS8RH!(^=]*^)?\ P<8>'/"L'QXU
MGP!X-UK3C&M]<?#U+*W6^^SGYC&(X\2[]O\  )6E!XVEOEKV,+DF*Q&&5>4H
MPC*ZCS22YFM[?YO0^>Q?$.$PN,>&C"4Y1LY<BORI[7_R/T\QZGCTHQ^7I7!>
M+_VAOA+\*O!^G^+OCI\0]!\$+J%I'*8_$FM0VFQRJEHP9F7<5+8.!5_X6?&S
MX/\ QPT63Q%\'?BGH'BJQB?RY;OP_K$-Y&C?W6,3':W'0UY;H5HQYW%VVO;3
M[]CUHXK#2GR*:YM[7U^XZX,"<4#:5QVK\Z_V!_C]\;?''_!8C]H7X3^,_BIK
MNI^&=%M+MM&\/WVIRRV=D8[VVC3R8F;9'A'9?E ^]S7V=X__ &KOV9_A1XIB
M\"_$_P#:!\&^'M9G"^3I6M>);6VN&W?=_=R2 C/;-=>+RW$86LJ2]YN*EHF]
M&D_POJ<6"SC"XS#NL_<2E*/O-+5-K\3T4YS@&@XP"?QKY%_X*BZC^U=+X=\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?EK_P '0'_)&/A9_P!C1??^DRU^
MI5?EK_P= ?\ )&/A9_V-%]_Z3+7T7"?_ "4%'U?_ *2SY7C3_DFJ_P#V[_Z4
MC]#_ -F?_DW#P%_V)NE_^DL5=W7"?LS_ /)N'@+_ +$W2_\ TEBKNZ\/$?[Q
M+U?YGT.#_P!TI^B_)!1116)TA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>_\ 1TD'_A*:O_\ (E?5>Q?2C8OI0&A\J?\ #[K_ ()>_P#1TD'_ (2FK_\
MR)1_P^Z_X)>_]'20?^$IJ_\ \B5]5[%]*-B^E :'RI_P^Z_X)>_]'20?^$IJ
M_P#\B4?\/NO^"7O_ $=)!_X2FK__ ")7U7L7THV+Z4!H?*G_  ^Z_P""7O\
MT=)!_P"$IJ__ ,B4?\/NO^"7O_1TD'_A*:O_ /(E?5>Q?2C8OI0&A\J?\/NO
M^"7O_1TD'_A*:O\ _(E'_#[K_@E[_P!'20?^$IJ__P B5]5[%]*-B^E :'RI
M_P /NO\ @E[_ -'20?\ A*:O_P#(E'_#[K_@E[_T=)!_X2FK_P#R)7U7L7TH
MV+Z4!H?*G_#[K_@E[_T=)!_X2FK_ /R)1_P^Z_X)>_\ 1TD'_A*:O_\ (E?5
M>Q?2C8OI0&A\J?\ #[K_ ()>_P#1TD'_ (2FK_\ R)1_P^Z_X)>_]'20?^$I
MJ_\ \B5]5[%]*-B^E :'RI_P^Z_X)>_]'20?^$IJ_P#\B4?\/NO^"7O_ $=)
M!_X2FK__ ")7U7L7THV+Z4!H?*G_  ^Z_P""7O\ T=)!_P"$IJ__ ,B4?\/N
MO^"7O_1TD'_A*:O_ /(E?5>Q?2C8OI0&A\J?\/NO^"7O_1TD'_A*:O\ _(E'
M_#[K_@E[_P!'20?^$IJ__P B5]5[%]*-B^E :'RJO_!;3_@F$R-*O[4=OM3&
M_P#XI75N_3_ETI/^'W7_  2]_P"CI(/_  E-7_\ D2OJO8OI1L7TH#0^5/\
MA]U_P2]_Z.D@_P#"4U?_ .1*/^'W7_!+W_HZ2#_PE-7_ /D2OJO8OI1L7TH#
M0^5/^'W7_!+W_HZ2#_PE-7_^1*/^'W7_  2]_P"CI(/_  E-7_\ D2OJO8OI
M1L7TH#0^5/\ A]U_P2]_Z.D@_P#"4U?_ .1*/^'W7_!+W_HZ2#_PE-7_ /D2
MOJO8OI1L7TH#0^5/^'W7_!+W_HZ2#_PE-7_^1*/^'W7_  2]_P"CI(/_  E-
M7_\ D2OJO8OI1L7TH#0^5/\ A]U_P2]_Z.D@_P#"4U?_ .1*/^'W7_!+W_HZ
M2#_PE-7_ /D2OJO8OI1L7TH#0^5/^'W7_!+W_HZ2#_PE-7_^1*/^'W7_  2]
M_P"CI(/_  E-7_\ D2OJO8OI1L7TH#0^5/\ A]U_P2]_Z.D@_P#"4U?_ .1*
M/^'W7_!+W_HZ2#_PE-7_ /D2OJO8OI1L7TH#0^5/^'W7_!+W_HZ2#_PE-7_^
M1*/^'W7_  2]_P"CI(/_  E-7_\ D2OJO8OI1L7TH#0^5/\ A]U_P2]_Z.D@
M_P#"4U?_ .1*/^'W7_!+W_HZ2#_PE-7_ /D2OJO8OI1L7TH#0^5/^'W7_!+W
M_HZ2#_PE-7_^1*/^'W7_  2]_P"CI(/_  E-7_\ D2OJO8OI1L7TH#0^5/\
MA]U_P2]_Z.D@_P#"4U?_ .1*/^'W7_!+W_HZ2#_PE-7_ /D2OJO8OI1L7TH#
M0^5/^'W7_!+W_HZ2#_PE-7_^1*/^'W7_  2]_P"CI(/_  E-7_\ D2OJO8OI
M1L7TH#0^5/\ A]U_P2]_Z.D@_P#"4U?_ .1*/^'W7_!+W_HZ2#_PE-7_ /D2
MOJO8OI1L7TH#0^5/^'W7_!+W_HZ2#_PE-7_^1*/^'W7_  2]_P"CI(/_  E-
M7_\ D2OJO8OI1L7TH#0^5/\ A]U_P2]_Z.D@_P#"4U?_ .1*/^'W7_!+W_HZ
M2#_PE-7_ /D2OJO8OI1L7TH#0^5/^'W7_!+W_HZ2#_PE-7_^1*%_X+:_\$P&
MC:1?VHX,)C>?^$5U?C/_ &Z5]5[%]*-B^E :'RI_P^Z_X)>_]'20?^$IJ_\
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MX2FK_P#R)1_P^Z_X)>_]'20?^$IJ_P#\B5]5[%]*-B^E :'RI_P^Z_X)>_\
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MC8OI0&A\J?\ #[K_ ()>_P#1TD'_ (2FK_\ R)1_P^Z_X)>_]'20?^$IJ_\
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MPE\1?"FG>// 7BG3]:T75[..[TG5M*NTGMKRWD7<DL<B$JZ%>0P.#6Q7Q/\
ML*?M7?#3]FC_ ()W_LA>&OB=::O''\2_#GA_PMHVKVEJC6=GJ4VG[[>.ZD9U
M,0F:-HTP&)? P!DCZ+_:J_:C^'/['_PAF^,OQ-L]6O;)=6L-+L=*T"S6XO\
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MTJ3_ (37PSX8AO=,TZ :G;)-9W,TKXBFN(G:*)-AWEL;EZU[9\-/VY])\;_
M?QW^T%XT_9J^+GP]TOX?V%W?:EIGQ#\)1Z?J%_;V]JUS)+:0K/()EVJR#++\
MPQ[T!9GO%%?+'P&_X*L_!S]I[XD^&_"?P&^!GQ8\3>&_$,,*M\3]+\'K)X:T
MR[>T-RUE<WBS<2Q#]U(T:R11S,(R^[.(OV0?BE^QE\'_ (0_'CXO_"-/%.E^
M'/#?QD\5W'Q*N->^T7TK:Y;O&-0DM8D::1H257RT0;F_N9- 69]65S_BSXB^
M / 6IZ)H_C3QII>E7?B/5!IOA^UU&_CADU*\,;R"W@5V!EDV1R/L7)PI/:OF
M*T_X*_\ PPTG7M&/Q@_9)^._PW\)>(-6@TW3?B%\0/ "V.CK/.XB@^TL+AY[
M197955YXD'S#=MJ+_@J"V[X]_LA\?\W'6W_IHU&@+,^PJ**^<OV(IOV8K;Q/
M\??$'[/VE>);:[MOC3JD'Q(;7;EY5GUV.UM9;A[16D?;;[)8]H&SG<-N M C
MZ-HKXM\+_P#!;7]G_P"*G@*U^)7[.G[.WQJ^*.FKI?VWQ(W@/P3%>'PY\Q'V
M:\+7*)]KV_O#;0M+*L9#,HR,_3OP%^.GPQ_:9^#OA[X\?!CQ1'K'A?Q/IZWN
MD:BD;)YB$E2K(^&1U=61D895E(/(H [6BOC'_@OWJFJZ7_P2G^)$VDZG=6DL
M^H^';666SN7B?RIM?TZ*1-Z$%0R,RGV:O+?V[O\ @GI\ ?\ @GQ^R=XO_;(_
M8@\2>*OA5XX^'%BFN:=>0>/M5O-/U?RI8]VGWUG>7,L-Q%<#]UMP&W,G/\)!
MI7/T@HK\T_\ @L9X1^(_[7-K^R;\-O#?C75_ .N?$#Q#J%Y:SZ??RVSZ?JJ^
M'YKNU5V3YOW=PJJ>^-U?77_!.C]J2X_;$_8[\&_&[6[-[/Q!<V+:=XRTV6/R
MWL=;LW:VOX63^#_2(I"H_N,A[T!;2Y[E17Y%?\%OOB5X]^/?Q"\2GX>_$+5M
M&\)?LT:OX/2_&EW;Q)J_BS6M6M/W3,G$BV>G?,1G*RWG.-O/T/\ \%:O$VBZ
MG^T5^SM\!OVB?B#JGA7X"^.M;UN'X@W]EK,VF6^J:E#:1MI>EWMY"Z/!;3.T
MS%-RB1HQDC9D 69]W45\^?LS?\$W?V6_V0?B1)\1_P!EW2=>\(6%]I,EGJ'A
M#3/%5W-H-XTCQN+MK.=Y$6X3R]JR1E/ED?(.ZOH.@04444 %?+&NVLW_  ^L
M\-7BIB,?LN:ZF[_:/B/23_2OJ>OE77_^4V_A?_LUC7O_ %)-'H&AW_!:3_E'
M)XR_[#_A7_U)=+KZG3[HKY8_X+2?\HY/&7_8?\*_^I+I=?4Z?=% =!N,\*?I
M2\#C'05\Q?\ !53]NK4?V"/V8W^)/A+3;"^\5:OJT.F>&++4$=X6F;<\DKHC
M*[*D2-P"/F9!GFF?M ?M]:M^P_\ L8>"OVA/VJ/ 4NI>(=:^P6.MZ5X2C$4<
M&H7%K),ZH+A\JB^4Z\DG-=U++,76I4ZD(WYY-15]6UO;RU^\\FMG&!H5ZE*<
MK>S2E)VT2>U_/]#ZAP0<TC#)^[TKY3_:W_X*L_!O]D;X$?#KX[>*O /B35K;
MXD64=UHNF::D*S01-;1W!\YI' 4A98UPN<D^@KT+]A_]M_X3?MZ?!R3XP_":
MTU"QCM=2ET_5-(U=(UNK*Y15?:XC=U*LCHZD'D-V(($U,MQU/"_690:A>W-T
MNGM]]T52S?+:V,^JPJ)U+)\O6S5U^#N>U !>>_UH&"<,?I7R7_P4#_X*X_ /
M_@GWXPTCX<^-O".O>(]?U;3CJ#6.A"'_ $.VWLB23-*XV[V63: &_P!6Q..,
M]=XM_P""AOPN\+?L#I_P4&_X1+6[OPU+I%I?1Z*B1)??O[I+98SE]F1))R=V
M,+D5?]E9@Z5.K[-\M1VB^[>R1']LY9[:K1]HN:FFY+LENWZ'T,0?K1@@Y/->
M>?LQ_'[0/VI/@'X9^/\ X5T2\TS3_$^G?:[6QU'9Y\*[V3:^PLN<KV->9_L\
M?\%%OAM^T5^US\0OV0_#7@;7+'6/A]]I_M#5KYX?LUWY%PEN_E['+CYY 1N'
M3TZ5BL'B6ZBY?@^+RUMK\SH>88->RO+^)\/G=7T^1]'=.V/:E )Y84$X!QV'
M-?$/QQ_X+9?"SP-\:==^!7P)_9\\?_%G5_"SNGB*Y\&:9YMM9O&VV50RAG;8
M=RL^P)E<!CUIX3 8K'S<:$')I7?9+S;T0L=F6"RV"GB)J*;LMVV_)+5GV][G
MC'I03@<"OG;]A/\ X*/_  )_;W\!:OXM^&\6HZ/?^&W0>(] UJ-%N;$.&9)<
MHS+)$WER88'/RD$*17SKX\_X.'O@CH+S^)_ O[,GQ'\0^"[6^^S2>-O[/6TL
MI7SM_=LY(.3T5VC;U KJHY)FE:O*C&D^:-KK16OMJW;7IWZ''5X@RBCAX5Y5
M5R2O9ZN]M]$KZ=3]$\\AC1\H&17B_P +OVZOV;_BK^RC-^V7HGC)[;P59Z=/
M=:K<W\#)/8-#_K8)(ER?-#?*$3=O++L+!E)^4KO_ (.&?AG#I+?$>#]C;XK2
M_#Q=0^R_\)P-.B%L7W[=H;=Y._\ V/.SVJ:&39GB92C3I-N+L]E9]M;:^2U*
MQ&?93A(0G5JI*:NMW==]-EZGZ+\D>E-((&#7QS^W?_P4(\??#3]A+P]^W/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT_:(^/?AGQ1KOCCP+8:'<6'@[P3+H]MBQ^T&.YE62[N#-+MFV Y&%XZ5F_\
M!!+PYH?AW_@DS\'&T31K>T.H:#<7M\\$*JUS<27DY>5ROWG/<GGH.U>O_LS_
M +%?PW_9BTGQ!::+X_\ '_B[5O%BQ+XB\3_$/QM=ZQJ-XD2R)$F^9MD*J)9,
M+$B#GG.!CIOV9_V>?AU^R=\"?#?[.WPG2]7PYX4T_P"QZ4NHW/GS^679_G?
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M[/\ X:\#_!?XA?M7:7\-Y?"LGQY^)>J^*-,T.X@,<NGZ']IE338&1N5RC37
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M_'WQU^RI^R?X7\$?!;Q3K.H^'+*SM]?L-)T.>YETV3[%9)MN%B4^3ADD4L^
M"K5O?\%^/V2/CGXMU[X>_M5?LO\ @WQ)J?B?2(KC0]7/A#3I[B^CMY SP2[8
M%+[!ON8V.,?O@#UKLPV(PV(P=+ 5)I1JJJKMZ)\RE%O[M.]SSL1A<9AL;5S&
ME3;G2]B[6W7):27Z^A\Q?&2]N?VSM$_;"_X*'Z@GVC1=)@T[POX%>4;E$#:E
M9QB1!QM86\2L?>\8]>:^D/BG_P JRME_V*VD?^GRWK>\1_L1?$/X*_\ ! 36
MO@#X;^'6JZCXXUK2K+6=;T+3=/>>^DO9M1M;B6(0QJ79X845"H&?W!KTKX7?
ML?>.OCI_P1(T;]DOQ1HUUX=\2:GX&6**SUVVEMY+2]BN?M-NLZ%0\8+QQ[LC
M(#'CM6>(S/".G2:DE"G7BEKM&,4K^CLW\S7"95C(U:UX/VE7#R<M-YSDW:^U
MU=*QZ7_P2!_Y1K?"0?\ 4LG_ -'RU\=?\$W]?TCPG_P6:_:I\4>(]0BL[#3+
M76[J]NISA(84U2%WD)] JY-8/[)?[<W_  4!_P""=?P5B_9 ^*G_  3?\:^+
M+SP[)<P^&M4TN&X\EHY)6=8B\-M-'<())&P\<GW2%QQFO8?^"0G[#WQ_L?B)
M\5/VROVS?!B:/K7Q96X@'A*]A57^RW,WGW+30Y/E*S>7&L3_ #A4?<!D9Y,1
MAOJ,<;7JRCR5=(6DFY7G?1)MZ+>]K';A\3+,7E^'H0EST?CO%I1M"VK:2U>U
MCZ8^&G_!3C]A#XR>.=,^&/PS_:/T35]>UF;R=,TV&&=7GDVLVU2\8&<*W4]J
M_,2R^/WC[_@D-^WM\8O W[/&E:/\8='\207&IZIIVF^=)=:&T;S2(MU+"C>6
MUNTS+,O(=-I+1/POZF>"?^">7[%?PN\46OCWX8?LU>$="\0::SR:5K%CH\?G
MVDI1D\Q">X#&OS7_ &+?%?[3_P#P2!^)OQ(\'?&3]A7QOX^N?%6I12V/C/PK
MISW/VQ(FE_Y;)%()$D\U9-NX.K'YER>#(_[.<:ZPR<XN,4Z<Y1BY.^ZDK6Y5
MKW*XACFCEAI8IJ#4I/VD%*2BK6LUK?F;MY6/</\ @WM\$_#/Q!\/OB+^T2OQ
M5TWQ!XV\?:X)?&7AVQLVMUT(>9<2QQ/$X&[S3-(X<#R\?(I)1JY3_@JC_P %
M"/B]X0^"7Q,_9,\,?\$^?$GA_P )QO-X=A\>WVERKHRV>\+Y\"I;+"-R_P"K
MQ+A20W)7%;/_  2&_9?_ &JO!/Q2^-O[:?B?X%'P"?'-G>-X)^'^IJ;;=/+<
M/<HKQ-L>*)&$<0+A"?,<J%6LWX[?\%3?VX/'WP5\1_LW>)_^"5?C>U\:^(-%
MN-$N9X["[NM.)N(FA>>-%MCYBX9BJ>:5_P"FA%=,H*KQ).O!1JQBXNSFER[;
M6:34=KZ^9RJI['A>G0G*5&4E-)J#?,KO>Z;3EOTWT-[]CW]F;]GCXD?\$1/%
M/P1\&_M-Z5>Z9K<-WJ7B?Q?+'+:6NB:FC07)BFCFV21Q1>1"&+XWIEP-K@5\
M.1?\%$?CAIW_  3XD_8&UCP7I)\%MXC_ .$?7XMV]C<O8K8"Y\]XD40XEES^
M\#C$OD_\LM_S5]-_![_@DW^UUX5_X)"?$;X4/:267CWQSK]GK<?@W[:BNUG:
MM$5M)7W[%FD"L^W.,K$K$'..;@_:@_:!N?\ @G6?^":\7_!+7Q^?%"^'O["%
M\?#TPLUFW9_M#:;?*S;OWN<X\SYM^*]/"3POMJKC)5E[92UDHN.BO/I?>W;2
MYY&-IXKZO14HRH2]@UI%OGUTA;6UUKKJKGU]XG^ GPA\*?\ !#K7/A!\+/'\
M/BKPU9?"6_O=/\1P_-'?RA);UIU7G8#<;B$/,?W3RIH_X-_O'.I>+_\ @FWX
M<TS4I2_]@Z[J>G6[-_SR%P9E'X>=C\*X+2OA/X[_ ."?G_!!3QAX$^-=['!K
M[^$]36YL//#K8SZI,T,5J'5BK,IN%W;?EW%\9')]*_X(._#;4/AY_P $VO!]
MSJT7ES>([^_UA(FSD12W#+$W/]Y(E<>S"OF\;R1R7$>_SIU]'W=G=]NQ]9EW
M/+/L+[G(UA_>79722_,^SJ***^0/O HHHH **** $8$C KY0_P"",W_)H>L?
M]ED\=?\ J1W]?5[$@9%?*'_!&;_DT/6/^RR>.O\ U([^@:V/K"BBB@04444
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M7_;U_P"CQOB3_P"%C>?_ !RC_AXO^WK_ -'C?$G_ ,+&\_\ CE'_ !#?,_\
MG['\?\@_XBKEG_/B7WH_IWW1>HHW1>HK^8C_ (>+_MZ_]'C?$G_PL;S_ ..4
M?\/%_P!O7_H\;XD_^%C>?_'*/^(;YG_S]C^/^0?\15RS_GQ/[T?T[[HO44;H
MO45_,1_P\7_;U_Z/&^)/_A8WG_QRC_AXO^WK_P!'C?$G_P +&\_^.4?\0WS/
M_G['\?\ (?\ Q%7+/^?$_P #^G?=%ZBC=%ZBOYB/^'B_[>O_ $>-\2?_  L;
MS_XY1_P\7_;U_P"CQOB3_P"%C>?_ !RC_B&^9_\ /V/X_P"0?\15RS_GQ/\
M _IWW1>HHW1>HK^8C_AXO^WK_P!'C?$G_P +&\_^.4?\/%_V]?\ H\;XD_\
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M*-T7J*_F(_X>+_MZ_P#1XWQ)_P#"QO/_ (Y1_P /%_V]?^CQOB3_ .%C>?\
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MQVW[<=R]UXF\#M::3>V=UX?V,US9ZA<V\,-RGFL@V!;E96R0=BGC/% 69[>
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MFY#ZU[!7B'[%7Q$U?XB?#:&/6OV1O$WPFC\.Z;8Z7I%EXI73LW-FMNI3[/\
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M;:]65&=);*\M)I8+M %VOM(*-PPY&?6J!!1110 4444 %%%% !1110 4444
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MY(Q\+/\ L:+[_P!)EK]2J_+7_@Z _P"2,?"S_L:+[_TF6OHN$_\ DH*/J_\
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M/$.K?#+P3/HEA<3H+FZMH$O_ +2T*GEE1I+??C^\A-?;%? ][^PY\._VH/\
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M@]:53!1GCH8B_P $91MWYFG^%AT<TE2RZKA7'XY*5[[6O]][GWOX[^'^B?\
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MW_M/_L7^+)/'EY:V\?B*Z\%?$1;33M5EA18UE,,D+/#E%52%/XD\UXW^V/\
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MW+7MW;97RF+-M#G+EE^\5^3X0^&OBI? ?Q)\.^.6#8T/7K'46"?>VPW$<O\
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M#H#_ )(Q\+/^QHOO_29:_4JORU_X.@/^2,?"S_L:+[_TF6OHN$_^2@H^K_\
M26?*\:?\DU7_ .W?_2HGZ'_LS_\ )N'@+_L3=+_])8J[NN$_9G_Y-P\!?]B;
MI?\ Z2Q5W=>'B/\ >)>K_,^AP7^Z4_1?D@HHHK$Z0HHKYY_:8_;HO?A+\8-*
M_9@^ ?P%UOXL_%/5-%;6Y?"FCZK;:=;:1I0E\O[9?WURPCMD9]R1IAGD*L O
M3(!]#45\_?!?]MS4]<\&^._$/[5W[/7B7X(WGPTL$U'Q5_PE,L-YI36+QRR_
M:[+4K;,-Z@6&3>$Q)&V%9,L,^6#_ (*??M.ZIX ;]HOP=_P2O^(VJ_"4V?\
M:=KXC_X2K2HM<O-*"[_ML.B,_GL"GSI&9!(Z;6"\T#LS[4HKYW^./_!1?X*?
M"G]@6;_@HKX-@N/&'@@Z5IVH6?\ 9K^1+/;75W!;;CO7,;1&9BZ,-P,;KC=Q
M7F_BC_@K1XC\ :1I_P"T#\3/V)/''AOX ZGJUO:1?%W5M5M8Y[:VGE$,&IW.
MC?\ 'W;6,CLI$CXE\MD9HAO52!9GVA17Q9XN_P""M?BGP/X;A_:-\0_L.^.;
M/]G^34X8'^+5_J5K!=QVDLJPQZL=%?\ TM=/9V4K,Y60Q,LGE;2,^E_MM_\
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M !1110 4444 %%%% !7RMK__ "FU\+_]FL:]_P"I)H]?5-?*VO\ _*;7PO\
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M ,%-/^C2]<_\&5A_\D5_2)S_ '!1S_<%'_$1LW_Y]P^Y_P"8?\0MR3_G[/\
M\E_R/YN_^'-?_!33_HTO7/\ P96'_P D4?\ #FO_ (*:?]&EZY_X,K#_ .2*
M_I$Y_N"CG^X*/^(C9O\ \^X?<_\ ,?\ Q"W)/^?L_P#R7_(_F[_X<U_\%-/^
MC2]<_P#!E8?_ "11_P .:_\ @II_T:7KG_@RL/\ Y(K^D3G^X*.?[@H_XB-F
M_P#S[A]S_P Q?\0MR3_G[/\ \E_R/YN_^'-?_!33_HTO7/\ P96'_P D4?\
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MQ_\ $+<D_P"?L_\ R7_(_F[_ .'-?_!33_HTO7/_  96'_R11_PYK_X*:?\
M1I>N?^#*P_\ DBOZ1.?[@HY_N"C_ (B-F_\ S[A]S_S%_P 0MR3_ )^S_P#)
M?\C^;O\ X<U_\%-/^C2]<_\ !E8?_)%'_#FO_@II_P!&EZY_X,K#_P"2*_I$
MY_N"CG^X*/\ B(V;_P#/N'W/_,/^(69)_P _9_\ DO\ D?S=_P##FO\ X*:?
M]&EZY_X,K#_Y(I?^'-?_  4T_P"C2]<_\&5A_P#)%?TA\_W!1S_<%'_$1LW_
M .?</N?^8?\ $+<D_P"?L_\ R7_(_F[_ .'-?_!33_HTO7/_  96'_R12_\
M#FO_ (*:?]&EZY_X,K#_ .2*_I#Y_N"CG^X*/^(C9O\ \^X?<_\ ,/\ B%N2
M?\_9_P#DO^1_-Y_PYK_X*:?]&EZY_P"#*P_^2*3_ (<U_P#!33_HTO7/_!E8
M?_)%?TB<_P!P4<_W!1_Q$;-_^?</N?\ F'_$+<D_Y^S_ /)?\C^;S_AS7_P4
MT_Z-+US_ ,&5A_\ )%)_PYK_ ."FG_1I>N?^#*P_^2*_I$Y_N"CG^X*/^(C9
MO_S[A]S_ ,P_XA;DG_/V?_DO^1_-W_PYK_X*:?\ 1I>N?^#*P_\ DBC_ (<U
M_P#!33_HTO7/_!E8?_)%?TB<_P!P4<_W!1_Q$;-_^?</N?\ F'_$+<D_Y^S_
M /)?\C^;O_AS7_P4T_Z-+US_ ,&5A_\ )%+_ ,.:_P#@II_T:7KG_@RL/_DB
MOZ0^?[@HY_N"C_B(V;_\^X?<_P#,/^(6Y)_S]G_Y+_D?S>?\.:_^"FG3_ADO
M7/\ P9V'_P D4G_#FO\ X*:?]&EZY_X,K#_Y(K^D3G^X*.?[@H_XB+F__/N'
MW/\ S#_B%N2?\_9_^2_Y'\W?_#FO_@II_P!&EZY_X,K#_P"2*/\ AS7_ ,%-
M/^C2]<_\&5A_\D5_2)S_ '!1S_<%'_$1LW_Y]P^Y_P"8?\0MR3_G[/\ \E_R
M/YN_^'-?_!33_HTO7/\ P96'_P D4?\ #FO_ (*:?]&EZY_X,K#_ .2*_I$Y
M_N"CG^X*/^(C9O\ \^X?<_\ ,/\ B%N2?\_9_P#DO^1_-W_PYK_X*:?]&EZY
M_P"#*P_^2*/^'-?_  4T_P"C2]<_\&5A_P#)%?TB<_W!1S_<%'_$1<W_ .?<
M/N?^8?\ $+<D_P"?L_\ R7_(_F[_ .'-?_!33_HTO7/_  96'_R11_PYK_X*
M:?\ 1I>N?^#*P_\ DBOZ1.?[@HY_N"C_ (B-F_\ S[A]S_S#_B%F2?\ /V?_
M )+_ )'\W?\ PYK_ ."FG_1I>N?^#*P_^2*/^'-?_!33_HTO7/\ P96'_P D
M5_2)S_<%'/\ <%'_ !$;-_\ GW#[G_F'_$+<D_Y^S_\ )?\ (_F[_P"'-?\
MP4T_Z-+US_P96'_R11_PYK_X*:?]&EZY_P"#*P_^2*_I$Y_N"CG^X*/^(C9O
M_P ^X?<_\P_XA;DG_/V?_DO^1_-W_P .:_\ @II_T:7KG_@RL/\ Y(H_X<U_
M\%-/^C2]<_\ !E8?_)%?TB<_W!1S_<%'_$1LW_Y]P^Y_YC_XA;DO_/V?WQ_R
M/YN_^'-?_!33_HTO7/\ P96'_P D4?\ #FO_ (*:?]&EZY_X,K#_ .2*_I$Y
M_N"CG^X*/^(C9O\ \^X?<_\ ,7_$+<D_Y^S_ /)?\C^;O_AS7_P4T_Z-+US_
M ,&5A_\ )%'_  YK_P""FG_1I>N?^#*P_P#DBOZ1.?[@HY_N"C_B(V;_ //N
M'W/_ ##_ (A;DG_/V?\ Y+_D?S=_\.:_^"FG_1I>N?\ @RL/_DBC_AS7_P %
M-/\ HTO7/_!E8?\ R17](G/]P4<_W!1_Q$;-_P#GW#[G_F'_ !"W)/\ G[/_
M ,E_R/YO/^'-?_!33_HTO7/_  96'_R12?\ #FO_ (*:?]&EZY_X,K#_ .2*
M_I$Y_N"CG^X*/^(BYO\ \^X?<_\ ,/\ B%N2?\_9_P#DO^1_-W_PYK_X*:?]
M&EZY_P"#*P_^2*/^'-?_  4T_P"C2]<_\&5A_P#)%?TB<_W!1S_<%'_$1<W_
M .?</N?^8?\ $+,D_P"?L_\ R7_(_F[_ .'-?_!33_HTO7/_  96'_R11_PY
MK_X*:?\ 1I>N?^#*P_\ DBOZ1.?[@HY_N"C_ (B-F_\ S[A]S_S'_P 0MR7_
M )^S^^/^1_-W_P .:_\ @II_T:7KG_@RL/\ Y(H_X<U_\%-/^C2]<_\ !E8?
M_)%?TB<_W!1S_<%'_$1LW_Y]P^Y_YB_XA;DG_/V?_DO^1_-W_P .:_\ @II_
MT:7KG_@RL/\ Y(H_X<U_\%-/^C2]<_\ !E8?_)%?TB<_W!1S_<%'_$1<W_Y]
MP^Y_YA_Q"W)/^?L__)?\C^;O_AS7_P %-/\ HTO7/_!E8?\ R11_PYK_ ."F
MG_1I>N?^#*P_^2*_I$Y_N"CG^X*/^(BYO_S[A]S_ ,P_XA9DG_/V?_DO^1_-
MW_PYK_X*:?\ 1I>N?^#*P_\ DBC_ (<U_P#!33_HTO7/_!E8?_)%?TB<_P!P
M4<_W!1_Q$7-_^?</N?\ F'_$+,D_Y^S_ /)?\C^;O_AS7_P4T_Z-+US_ ,&5
MA_\ )%'_  YK_P""FG_1I>N?^#*P_P#DBOZ1.?[@HY_N"C_B(N;_ //N'W/_
M ##_ (A9DG_/V?\ Y+_D?S=_\.:_^"FG_1I>N?\ @RL/_DBC_AS7_P %-/\
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M96'_ ,D4?\.:_P#@II_T:7KG_@RL/_DBOZ1.?[@HY_N?K1_Q$7-_^?</N?\
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MT &T1S3:?/"\Z@< 2%MHZ8H'<\?UW]A#Q5\'?V:?VL]<\)_M%:]\3/BC\7/
MUXFK:AJ5A86TT=];Z'/:6<26]C%''&[(T8^Z"WR'W/HO_!-GXR_!:'_@E?\
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M%>$O@+\(_ OQ<\6_'GPIX-ALO%OCR+3XO%NLI-*SZBEC$T5JK*SE%\M'91L
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M$D(:1#CS"5PW->H_$[_@FY\7/BM'X=T7]I'_ (*:^.O$OAW2_&FD:U;Z)?\
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M%\1O@OJ/[._B[P'92^"M4T%M%O/#EH&M+?\ L\Q^5]F3R"AB0)\H\LKM'3%
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M2?\ *.3QE_V'_"O_ *DNEU]3I]T5\L?\%I/^4<GC+_L/^%?_ %)=+KZG7[M
M=!:***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M C D8%?*'_!&;_DT/6/^RR>.O_4COZ^KV) R*^3_ /@C-_R:'K'_ &6/QU_Z
MD=_0-;'UC1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "ODN?_E.A#_V:=+_ZDT=?6E?)<_\ RG0A_P"S3I?_ %)HZ!H^M***
M*!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6<G)AYU>:_P*]K6WU\_P/U_W'UHW'UK\?O\ AGW_ (.6_P#HJ][_ .%7I/\
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M^%'^K=#_ *#:/_@7_ #_ %MQ'_0!6_\  3]@=Q]:-Q]:_'[_ (9]_P"#EO\
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M_@G[?[CZT;CZU^/W_#/O_!RU_P!%7O?_  J])_PH_P"&??\ @Y;_ .BKWO\
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M_HJ][_X5>D_X4?ZMT/\ H-H_^!?\ /\ 6W$?] %;_P !/V!W'UHW'UK\?O\
MAGW_ (.6_P#HJ][_ .%7I/\ A1_PS[_P<M_]%7O?_"KTG_"C_5NA_P!!M'_P
M+_@!_K;B/^@"M_X"?L#N/K1N/K7X_?\ #/O_  <M_P#15[W_ ,*O2?\ "C_A
MGW_@Y;_Z*O>_^%7I/^%'^K=#_H-H_P#@7_ #_6W$?] %;_P$_8'<?6C<?6OQ
M^_X9]_X.6_\ HJ][_P"%7I/^%'_#/O\ P<M_]%7O?_"KTG_"C_5NA_T&T?\
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M.6_^BKWO_A5Z3_A1_P ,^_\ !RW_ -%7O?\ PJ])_P */]6Z'_0;1_\  O\
M@!_K;B/^@"M_X"?L#N/K1N/K7X_?\,^_\'+?_15[W_PJ])_PH_X9]_X.6_\
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MS[_P<M_]%7O?_"KTG_"C_AGW_@Y;_P"BKWO_ (5>D_X4?ZMT/^@VC_X%_P
M/];<1_T 5O\ P$_8'<?6C<?6OQ^_X9]_X.6_^BKWO_A5Z3_A1_PS[_P<M_\
M15[W_P *O2?\*/\ 5NA_T&T?_ O^ '^MN(_Z *W_ ("?L#N/K1N/K7X_?\,^
M_P#!RW_T5>]_\*O2?\*/^&??^#EO_HJ][_X5>D_X4?ZMT/\ H-H_^!?\ /\
M6W$?] %;_P !/V!W'UHW'UK\?O\ AGW_ (.6_P#HJ][_ .%7I/\ A1_PS[_P
M<M_]%7O?_"KTG_"C_5NA_P!!M'_P+_@!_K;B/^@"M_X"?L#N/K1N/K7X_?\
M#/O_  <M_P#15[W_ ,*O2?\ "C_AGW_@Y;_Z*O>_^%7I/^%'^K=#_H-H_P#@
M7_ #_6W$?] %;_P$_8'<?6C<?6OQ^_X9]_X.6_\ HJ][_P"%7I/^%'_#/O\
MP<M_]%7O?_"KTG_"C_5NA_T&T?\ P+_@!_K;B/\ H K?^ G[ [CZT;CZU^/W
M_#/O_!RW_P!%7O?_  J])_PH_P"&??\ @Y;_ .BKWO\ X5>D_P"%'^K=#_H-
MH_\ @7_ #_6W$?\ 0!6_\!/V!W'UHW'UK\?O^&??^#EO_HJ][_X5>D_X4?\
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M (4?ZMT/^@VC_P"!?\ /];<1_P! %;_P$_8')]?Y49/K_*OQ^_X9\_X.6_\
MHJ][_P"%9I/^%21_L_\ _!RKY$@?XIWV\[=G_%5Z3Z\]J/\ 5O#_ /0;1_\
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M ,"_X ?ZVXC_ * *W_@)^P.X^M&X^M?C]_PS[_P<M_\ 15[W_P *O2?\*/\
MAGW_ (.6_P#HJ][_ .%7I/\ A1_JW0_Z#:/_ (%_P _UMQ'_ $ 5O_ 3]@=Q
M]:-Q]:_'[_AGW_@Y;_Z*O>_^%7I/^%'_  S[_P '+?\ T5>]_P#"KTG_  H_
MU;H?]!M'_P "_P" '^MN(_Z *W_@)^P.X^M&X^M?C]_PS[_P<M_]%7O?_"KT
MG_"C_AGW_@Y;_P"BKWO_ (5>D_X4?ZMT/^@VC_X%_P  /];<1_T 5O\ P$_8
M'<?6C<?6OQ^_X9]_X.6_^BKWO_A5Z3_A1_PS[_P<M_\ 15[W_P *O2?\*/\
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M  J])_PH_P"&??\ @Y;_ .BKWO\ X5>D_P"%'^K=#_H-H_\ @7_ #_6W$?\
M0!6_\!/V!W'UHW'UK\?O^&??^#EO_HJ][_X5>D_X4?\ #/G_  <M_P#15[W_
M ,*O2?\ "C_5NA_T&T?_  +_ ( ?ZVXC_H K?^ G[ [CZT;CZU^0MI^S]_P<
MGQ^=]J^*5^W[AO*_XJO2OO\ ;M4/_#/G_!RW_P!%7O?_  K-)_PH_P!6Z'_0
M;1_\"_X ?ZV8G_H K?\ @/\ P3]@-Q]:-Q]:_'[_ (9]_P"#EO\ Z*O>_P#A
M5Z3_ (4?\,^_\'+?_15[W_PJ])_PH_U;H?\ 0;1_\"_X ?ZVXC_H K?^ G[
M[CZT;CZU^/W_  S[_P '+?\ T5>]_P#"KTG_  H_X9]_X.6_^BKWO_A5Z3_A
M1_JW0_Z#:/\ X%_P _UMQ'_0!6_\!/V!W'UHW'UK\?O^&??^#EO_ **O>_\
MA5Z3_A1_PS[_ ,'+?_15[W_PJ])_PH_U;H?]!M'_ ,"_X ?ZVXC_ * *W_@)
M^P.X^M&X^M?C]_PS[_P<M_\ 15[W_P *O2?\*/\ AGW_ (.6_P#HJ][_ .%7
MI/\ A1_JW0_Z#:/_ (%_P _UMQ'_ $ 5O_ 3]@=Q]:-Q]:_'[_AGW_@Y;_Z*
MO>_^%7I/^%'_  S[_P '+?\ T5>]_P#"KTG_  H_U;H?]!M'_P "_P" '^MN
M(_Z *W_@)^P.X^M&X^M?C]_PS[_P<M_]%7O?_"KTG_"C_AGW_@Y;_P"BKWO_
M (5>D_X4?ZMT/^@VC_X%_P  /];<1_T 5O\ P$_8'<?6C<?6OQ^_X9]_X.6_
M^BKWO_A5Z3_A1_PS[_P<M_\ 15[W_P *O2?\*/\ 5NA_T&T?_ O^ '^MN(_Z
M *W_ ("?L#N/K1N/K7X_?\,^_P#!RW_T5>]_\*O2?\*/^&??^#EO_HJ][_X5
M>D_X4?ZMT/\ H-H_^!?\ /\ 6W$?] %;_P !/V!W'UHW'UK\?O\ AGW_ (.6
M_P#HJ][_ .%7I/\ A1_PS[_P<M_]%7O?_"KTG_"C_5NA_P!!M'_P+_@!_K;B
M/^@"M_X"?L#N/K1N/K7X_?\ #/O_  <M_P#15[W_ ,*O2?\ "C_AGW_@Y;_Z
M*O>_^%7I/^%'^K=#_H-H_P#@7_ #_6W$?] %;_P$_8'<?6C<?6OQ^_X9]_X.
M6_\ HJ][_P"%7I/^%'_#/O\ P<M_]%7O?_"KTG_"C_5NA_T&T?\ P+_@!_K;
MB/\ H K?^ G[ [CZT;CZU^/W_#/O_!RW_P!%7O?_  J])_PH_P"&??\ @Y;_
M .BKWO\ X5>D_P"%'^K=#_H-H_\ @7_ #_6W$?\ 0!6_\!/V!W'UHW'UK\?O
M^&??^#EO_HJ][_X5>D_X4?\ #/O_  <M_P#15[W_ ,*O2?\ "C_5NA_T&T?_
M  +_ ( ?ZVXC_H K?^ G[ [CZT;CZU^/W_#/O_!RW_T5>]_\*O2?\*/^&??^
M#EO_ **O>_\ A5Z3_A1_JW0_Z#:/_@7_   _UMQ'_0!6_P# 3]@=Q]:-Q_R:
M_'[_ (9]_P"#EO\ Z*O>_P#A5Z3_ (4?\,^_\'+?_15[W_PJ])_PH_U;H?\
M0;1_\"_X ?ZVXC_H K?^ G[ [UZ[@#WK\MO^#H#_ )(Q\+/^QGOO_29:X?\
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MLATADD+&%2"01'MR.#Q0%V5?VE_VH/ W[!/P(\,^'O[(N/%'C'4XK;PU\-/
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M%K&H::%O?*7=MB-Q&5D9!N;"%MHW=*ZWX"?LS?L__LN>"_\ A7G[._P?\/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH_X?^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\
M,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&
MJ/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W
M_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X
M$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!J_\ X25]
M_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\
MA)7W_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H
M)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!J_\
MX25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&
MK_\ A)7W_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'
M_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!
MJ_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O
M_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/
M]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_
M *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G
M_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_
M^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\
M!,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O
M^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\
MZ!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?
M^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:
M*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&J/[
MSO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :
MH_X?^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\
M,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&
MJ/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W
M_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X
M$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!J_\ X25]
M_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\
MA)7W_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H
M)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!J_\
MX25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&
MK_\ A)7W_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'
M_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!
MJ_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O
M_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/
M]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_
M *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G
M_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_
M^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\
M!,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O
M^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\
MZ!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?
M^?\ !,O_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:
M*^*O^'_G_!,O_HL&K_\ A)7W_P :H_X?^?\ !,O_ *+!J_\ X25]_P#&J/[
MSO\ Z!Y_^ L/]9N'_P#H)A_X$O\ ,^U:*^*O^'_G_!,O_HL&K_\ A)7W_P :
MH_X?^?\ !,K_ *+!J_\ X25]_P#&J/[ SO\ Z!Y_^ L/]9N'_P#H)A_X$O\
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M )1R>,O^P_X5_P#4ETNOJ=/NB@.@M%%% @HHHH **** "BBB@ HHHH ****
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MK_@K=XM\ >#/^":WQLOOB5<VZ6-_\.-5TVT@N'"M<W]S:R06D,?]Z5[B2%5
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M;9?$?AR3<='U=?[WF6RK%*1G$L+[CEJP/^"Y/_)M7PW_ .SA_!/_ *<UJ?\
MX*5^#->_9_\ B)X(_P""IWPITN>74OA;NTOXLV&GP;I=<\"7,@-ZK*.9'LGV
MWT:\?ZN7Z4!T/+_^"?[?&&+]@;]KQOV?4E/CM/CA\4/^$-6+YI/[3Y^S;/\
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M[?\ *1#X=?\ 9%9/_3O+7[L-_0U^$_\ P<[?\I$/AU_V163_ -.\M?3<'_\
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M9X'_ &0[7PK?0ZGX2\:ZAKESK$LR?9YXKE'41HB_/N&[G/%'[,O[4GAWX#_
MGXT_";6?"M]?W7Q2\)6^DZ=>6LZ+'8R13-(7D#<LIW?P\UU?V34C@JK5/]Y*
MK>^EW'VB:U[65[')'.:+S'#Q=7]U&E:VME+V;5K=[NQZA^RQX+_;>U7]DM=:
MT;]L?3/@A\&;?Q'=?9=:UCQ)+I2ZOJDBQB:.(6:&YN\"-?E/[M?+?;SNKT7_
M (*B6-SJG_!/[]G'QKXR^,VB?%/7[;5==TNX^(&D37$O]K6D<H=(7FG199#'
MMV$N.JL><DGRGX5?MD?LK^-/V0O#?[(/[:7PH\<:C8> ]:O=0\&>)?A[JUM;
MW<<=T6>6VF2Y0H5+LQW\G&W&,<Y_[5'[;_P<^-W[//PV_9[^%G[/;^$-&^&O
MB>^N[#3YM5^U)?6,^S"SR_?DN9&\QI7P%^;Y!BN5X/,)YM"HZ7*HSD[Q44N5
MQ:3O?F;=U?I]QVQQ^54LFE35=2<H):MMJ2:;7+:R2Z6U/J'XI>)/B]^WEKVD
M?'?_ ()C?MJW&CZOHO@NUM7_ &?CXBFTJ_TK[-;^7-#9VY;[/>QE4W'L>/FZ
M*/&/V+H;VU_X)5?MEVU_;RPW$3^&$N8I5*/'(+V0.K+_  L#P14/PM_;$_X)
MF?L]?$RT_:A^!G[*?Q,L_B#I37-SH'A?5_&5O+X>TVYEBD0,LJK]IDB7>V$)
MY'6O,_A1^VOIW@K]E_X_? _Q;X0O=0UKXU7FGW<.K6<L<=M92V]U)<2[T;E@
MQDXQ65+ 8YX=T:=)J"E2MS**E933DFT]4EJF]=7N:U,SRYXF->I7BYN%1.SD
MXZPLFDTK-O2RT/>OV>_B'X<_:9_8>^'G[(_P&_;"C^"'Q,\$ZWJ,]UI6IZQ<
M:18>,Y;B5I89_MMOC]_&%5%23)ST'0U\C_M9^%?VBO!/[0GB3PY^U?\ VB_C
M^WNT77I]3F666Y/EJ(I?-7Y9D>)5*N/O#GK7I'PI^)7_  3$NOA[H$'Q]_9P
M^)<?BS0K)8;^[\#^*;=-/\12K(SK+<1W(+VSE&5&\DX^7(Y-<5^VY^U3K'[9
M_P"TCKWQ^U?PQ;Z''J26]KI>CV\YE^QV=O$L,,;2''F/M7<SX )9L #BO5RO
M#8C#YI/DIM4WS-N2C=2;3]UIMM/5Z[?@>'G.+PV)R:GS55*HN5)1;LTEUB[)
M-::K<\FHHHKZH^'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "OO'_ (-T\_\ #Q-/^Q%U/_T."O@ZOO'_ (-T
M\_\ #Q-/^Q%U/_T."O"XF_Y$&(_PL^BX2_Y*/"_XU^9^]]%%%?SH?U,%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y:_P#!T!_R1CX6?]C1
M??\ I,M?J57Y:_\ !T!_R1CX6?\ 8T7W_I,M?1<)_P#)04?5_P#I+/E>-/\
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M?V31]!TN#3M+M#(S^1;01+%$F7)+815&22?6MNB@#R+PM^Q#^S#X)_9HU?\
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M^1*/^(:[]@[_ *'?XD?^#ZT_^1*_6O\ B(.1=I?=_P $_%/^(;<2=H_?_P
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M=H_?_P  _"VBOW2_XAKOV#O^AW^)'_@^M/\ Y$H_XAKOV#O^AW^)'_@^M/\
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M/^(@Y%VE]W_!#_B&W$G:/W_\ _"VBOW2_P"(:[]@[_H=_B1_X/K3_P"1*/\
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MU_X26OQSTWQ5:MX4O/#Z:Y!K;/\ N#I[0?:!<$_W/*._Z5^4?[*NEZS\4/\
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MS<^*;.QUJ?2%7?)JEOH<B^>]N$'F*))(I9(OGV*M=-_P7-5F_P""3'QQ"_\
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M.R[X'0-M^<96N7N/^4^UF?\ JT"Y_P#4I@JO^U1E?^"RW[*#KW\$_$)6_P#
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MN)YTLUAA:D(M2;CI.[3MU5K)>5]#];Y_%/AJTMKN]N]?L8H=/'^GRR7:!;;
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M^"_[-6C:3XDM8YETS49+FZN_[,65F+BSCN99([+.]E_<+'\K%?N\5]"5Y_\
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M?:7UKX:UIV<2V,-XJ)<J@#;3O6.,'(/W>,5U]?/GP0_X*1_LZ?M%?&67X/\
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M !M\(Y_"&I^"/"&G0RZ?X>\4:BZ0-J'G,\[30A#YJR*L*'GE5V\<Y_1S*DX
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MSK'1ORM)\_M+I:\W^7D5/A[+ZEN9-KV?LK7^S=/[]-S\YOAKX?\ ^#@;X?\
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M  OSX%_]%J\)?^%):_\ Q= '745R/_"_/@7_ -%J\)?^%):__%T?\+\^!?\
MT6KPE_X4EK_\70!UU%<C_P +\^!?_1:O"7_A26O_ ,71_P +\^!?_1:O"7_A
M26O_ ,70!UU%<C_POSX%_P#1:O"7_A26O_Q='_"_/@7_ -%J\)?^%):__%T
M==17(_\ "_/@7_T6KPE_X4EK_P#%T?\ "_/@7_T6KPE_X4EK_P#%T ==17(_
M\+\^!?\ T6KPE_X4EK_\71_POSX%_P#1:O"7_A26O_Q= '745R/_  OSX%_]
M%J\)?^%):_\ Q='_  OSX%_]%J\)?^%):_\ Q= '745R/_"_/@7_ -%J\)?^
M%):__%T?\+\^!?\ T6KPE_X4EK_\70!UU%<C_P +\^!?_1:O"7_A26O_ ,71
M_P +\^!?_1:O"7_A26O_ ,70!UU%<C_POSX%_P#1:O"7_A26O_Q='_"_/@7_
M -%J\)?^%):__%T ==17(_\ "_/@7_T6KPE_X4EK_P#%T?\ "_/@7_T6KPE_
MX4EK_P#%T ==17(_\+\^!?\ T6KPE_X4EK_\71_POSX%_P#1:O"7_A26O_Q=
M '745R/_  OSX%_]%J\)?^%):_\ Q='_  OSX%_]%J\)?^%):_\ Q= '745R
M/_"_/@7_ -%J\)?^%):__%T?\+\^!?\ T6KPE_X4EK_\70!UU%<C_P +\^!?
M_1:O"7_A26O_ ,71_P +\^!?_1:O"7_A26O_ ,70!UU%<C_POSX%_P#1:O"7
M_A26O_Q=+_POOX&_]%I\)?\ A1VO_P 70!UM%<C_ ,+\^!?_ $6KPE_X4EK_
M /%T?\+\^!?_ $6KPE_X4EK_ /%T ==17(_\+\^!?_1:O"7_ (4EK_\ %T?\
M+\^!?_1:O"7_ (4EK_\ %T ==17(_P#"_/@7_P!%J\)?^%):_P#Q='_"_/@7
M_P!%J\)?^%):_P#Q= '745R/_"_/@7_T6KPE_P"%):__ !='_"_/@7_T6KPE
M_P"%):__ != '745R/\ POSX%_\ 1:O"7_A26O\ \71_POSX%_\ 1:O"7_A2
M6O\ \70!UU%<C_POSX%_]%J\)?\ A26O_P 71_POSX%_]%J\)?\ A26O_P 7
M0!UU%<C_ ,+\^!?_ $6KPE_X4EK_ /%T?\+\^!?_ $6KPE_X4EK_ /%T ==1
M7(_\+\^!?_1:O"7_ (4EK_\ %T?\+\^!?_1:O"7_ (4EK_\ %T ==17(_P#"
M_/@7_P!%J\)?^%):_P#Q='_"_/@7_P!%J\)?^%):_P#Q= '745R/_"_/@7_T
M6KPE_P"%):__ !='_"_/@7_T6KPE_P"%):__ != '745R/\ POSX%_\ 1:O"
M7_A26O\ \71_POSX%_\ 1:O"7_A26O\ \70!UU%<C_POSX%_]%J\)?\ A26O
M_P 71_POSX%_]%J\)?\ A26O_P 70!UU%<C_ ,+\^!?_ $6KPE_X4EK_ /%T
M?\+\^!?_ $6KPE_X4EK_ /%T ==17(_\+\^!?_1:O"7_ (4EK_\ %T?\+\^!
M?_1:O"7_ (4EK_\ %T ==17(_P#"_/@7_P!%J\)?^%):_P#Q='_"_/@7_P!%
MJ\)?^%):_P#Q= '745R/_"_/@7_T6KPE_P"%):__ !='_"_/@7_T6KPE_P"%
M):__ != '745R*_'SX&-]WXT^$C_ -S':_\ Q='_  OSX%_]%J\)?^%):_\
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M7_@H1\>/ ?C/X>W5_H'CSX<Z#\0;"QC\-7UO>SAH_LSV;O%&Z[9%9B=P;KU
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M  1X_:/\<^'))'T[6_%'Q/O[!Y[9XI&@F%RZ%XG4/&VUERA ([T >T_L7?\
M!0+]K;]N"T\$?&3X>?L6V6C_  DU^SMTUGQ-XB\9?9]2^TFWW7,]E9_9_P!_
M9PW(:W65WC>;;YBH%KG] _X*>_M7_'CXN_$[X"_LB_L16?B/7?A3\0=3T3Q)
MK/B3QG_9NCFSMV5;;R[C[.[27UR?./D*I2!8U:23]X!7NG_!,5$C_P"";OP
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MN?L*?LZZ-XXU;X>6]H_Q"\4^,O%KZ1H^F7-U'YUOI\+16\\ES=&/YWVJ$B&
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M*48QY(4Y3@[.\N5VN]=FTS]&_A#\7OA[\>/AII'Q?^%'B :IX?UVS^TZ7?\
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MXN?$O^V=(G?^TOASHEG=6UD_S(L4S7%W"5<_>^4'Y>?:O!/^"*?C[XV?"?\
M9F^''[$'QF_8H^+7@_5O"GAR[34O%WB#1[)-#:47,LRHDR7;RLS+*N,Q#E3]
M:^\Z*!WTL?)O[=OP=^+'[6'[2?P6_9L7P+?-\)-*UT^.?BEX@=1]DOFTYE.F
MZ,<_ZWS;MEFD3_GG #SS7UE110(^9O\ @K-\:_%7PE_8RUKPE\+9L>//B?J-
MIX!^'T:/M=M5U:3[,LBM_"8H6FGS_P!,:]E_9^^"OA']G#X&>$?@)X#MS'H_
M@[P]::1IY*_,\<$2Q^8^.KMMWL>[,357XE?L\?"WXN_$?P+\4O'NC3WNJ_#C
M5;K4O"J&_E2""[GMVMFG>$,$F=8G8(7!\LN2N#7?4 5]3B>;3YXXER[0.JKZ
MDBOE/_@D!^S_ .-?AA_P2G^''[._[1GPVGTK5(/#^IV'B7PUK,2[EBGOKMC'
M(H)&UXI%X]&KZTHH _/+X0_L#_&SXN_\$R_B'_P3-^,0U3P]J'P]\776F?!_
MQ]J";DN]/M+J._T+4$=.66+]W;NH&0L)7DUV?@O_ (*2?M?_  Y\,6W@#]J+
M_@EE\:]0^(%A"+>_U'X7Z58:OX>U68?*MS#=F[C\B.7[Y21<Q!MIR17VU10.
M[/D_]AW]G;X^:Q^T'XX_X*$?MA>&++PUX\\=:-:>'O#'@&QU)+Y?"'ARU=I4
MM)+I/EGN)IV:>79^[#;=O<*_]@7X/_%#X9_M.?M3>*_'O@>]TO3?&'Q9MM2\
M+W]T@$>I6HTRWB:6/GYE$BLOUXKZMHH"[/DO]D_X,_%3]F+_ (* _&_P)I'@
M2^'PD^)R6WQ"\/ZS!"OV/3?$,I%MJUDS!OEEG9(;L#;C&_DFOEGPU^RU\1OC
M+_P45^.O_!.A;*ULO@</BSI/Q@^(TOVGY];2^M()HM"6#&/(N-0M9)IG&/DL
M]O!<;_U:KR3P-^RQH_@G]K[QY^US:>*[N>^\>>%M&T6ZT9[5%BM%T]KEEE1\
MY8R?:.01QL]^ +ZW/-O^"LWP1^*/QJ_9:TZY^#/@R7Q)KW@3XB>'O&%KX9LI
MDBGU6+3K])IK:%G^3S3%YFU21DKCJ0*]7_9D_:%U3]I'P3=^.+_]GWXA?#F*
MWU1K.UTOXE:/#8:A=JJ1LTZP1S2E8MS,@+D$F-CC&"?3:*!!1110 5\-_&_X
M _ _]I+_ (+1:?X$_:"^$'AKQOHMC^R_)?V6E>*M$AOH+>Z_X2-4\]$F5@K[
M&9=PYQQ7W)7R9+_RG2A_[-.E_P#4FCH [+_AU)_P3-_Z,"^$'_AO=/\ _C5'
M_#J3_@F;_P!&!?"#_P -[I__ ,:KZ!HH'=GS]_PZD_X)F_\ 1@7P@_\ #>Z?
M_P#&J/\ AU)_P3-_Z,"^$'_AO=/_ /C5?0-% 79\_?\ #J3_ ()F_P#1@7P@
M_P##>Z?_ /&J/^'4G_!,W_HP+X0?^&]T_P#^-5] T4!=GS]_PZD_X)F_]&!?
M"#_PWNG_ /QJC_AU)_P3-_Z,"^$'_AO=/_\ C5?0-% 79\_?\.I/^"9O_1@7
MP@_\-[I__P :H_X=2?\ !,W_ *,"^$'_ (;W3_\ XU7T#10%V?/W_#J3_@F;
M_P!&!?"#_P -[I__ ,:H_P"'4G_!,W_HP+X0?^&]T_\ ^-5] T4!=GS]_P .
MI/\ @F;_ -&!?"#_ ,-[I_\ \:H_X=2?\$S?^C OA!_X;W3_ /XU7T#10%V?
M/W_#J3_@F;_T8%\(/_#>Z?\ _&J/^'4G_!,W_HP+X0?^&]T__P"-5] T4!=G
MS]_PZD_X)F_]&!?"#_PWNG__ !JC_AU)_P $S?\ HP+X0?\ AO=/_P#C5?0-
M% 79\_?\.I/^"9O_ $8%\(/_  WNG_\ QJC_ (=2?\$S?^C OA!_X;W3_P#X
MU7T#10%V?/W_  ZD_P""9O\ T8%\(/\ PWNG_P#QJC_AU)_P3-_Z,"^$'_AO
M=/\ _C5?0-% 79\_?\.I/^"9O_1@7P@_\-[I_P#\:H_X=2?\$S?^C OA!_X;
MW3__ (U7T#10%V?/W_#J3_@F;_T8%\(/_#>Z?_\ &J/^'4G_  3-_P"C OA!
M_P"&]T__ .-5] T4!=GS]_PZD_X)F_\ 1@7P@_\ #>Z?_P#&J/\ AU)_P3-_
MZ,"^$'_AO=/_ /C5?0-% 79\_?\ #J3_ ()F_P#1@7P@_P##>Z?_ /&J/^'4
MG_!,W_HP+X0?^&]T_P#^-5] T4!=GS]_PZD_X)F_]&!?"#_PWNG_ /QJC_AU
M)_P3-_Z,"^$'_AO=/_\ C5?0-% 79\_+_P $J?\ @FDL30K^P3\(MKXW+_PK
M_3_FQ_VRH_X=2?\ !,W_ *,"^$'_ (;W3_\ XU7T#10%V?/W_#J3_@F;_P!&
M!?"#_P -[I__ ,:H_P"'4G_!,W_HP+X0?^&]T_\ ^-5] T4!=GS]_P .I/\
M@F;_ -&!?"#_ ,-[I_\ \:H_X=2?\$S?^C OA!_X;W3_ /XU7T#10%V?/W_#
MJ3_@F;_T8%\(/_#>Z?\ _&J/^'4G_!,W_HP+X0?^&]T__P"-5] T4!=GS]_P
MZD_X)F_]&!?"#_PWNG__ !JC_AU)_P $S?\ HP+X0?\ AO=/_P#C5?0-% 79
M\_?\.I/^"9O_ $8%\(/_  WNG_\ QJC_ (=2?\$S?^C OA!_X;W3_P#XU7T#
M10%V?/W_  ZD_P""9O\ T8%\(/\ PWNG_P#QJC_AU)_P3-_Z,"^$'_AO=/\
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M-_Z,"^$'_AO=/_\ C5?0-% 79\_?\.I/^"9O_1@7P@_\-[I__P :H_X=2?\
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MF_\ 1@7P@_\ #>Z?_P#&J/\ AU)_P3-_Z,"^$'_AO=/_ /C5?0-% 79\_?\
M#J3_ ()F_P#1@7P@_P##>Z?_ /&J/^'4G_!,W_HP+X0?^&]T_P#^-5] T4!=
MGS]_PZD_X)F_]&!?"#_PWNG_ /QJC_AU)_P3-_Z,"^$'_AO=/_\ C5?0-% 7
M9\_?\.I/^"9O_1@7P@_\-[I__P :H_X=2?\ !,W_ *,"^$'_ (;W3_\ XU7T
M#10%V?/W_#J3_@F;_P!&!?"#_P -[I__ ,:H_P"'4G_!,W_HP+X0?^&]T_\
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M&/A9_P!C1??^DRU]#PG=\04/5_\ I+/E>-)-<-8BSZ+_ -*1^A_[-3EOV=O
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M@?I?XB^$7PL\8:BFN^*_AMH.J7L8'EWE_I,$TJXZ8=T)KH+>VAMHEM[:-41
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M7#D!%X&6=%(%M3R+]IO1/#NN_P#!;K]FU/A-I]O'XQT?P5XKU/XHWU@ LO\
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M ":'K'_99/'7_J1W] UL?6%%%% @HHHH **** "BBB@ HHHH **** "BBB@
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M] UL?6%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\56^@^,?!_CU[>>>U:<;H;F&>W4!D)95P<_Q=-G/7?\ !,WX0:/K?[,GQ?\
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MS7/?';P#K/[$_P#P253]F;XWE=.^(_Q2^(\?B-/!TMTDESI&E6T*JLMPBL3
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M/M/VO?\ N?*W[MGE\XQGO7@NAH?^'"6N'9_S<7;\_P#;@E=E?? OXP?M9?\
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M4=X23NHRCRIRLM5>S=M?F+&0RO!X7$XFGAES)TTE.-DFTTVHW=D]T?'4C/'
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MZ*32_!([XI?Z^T7U<H-^K2;_ !/WOHHHK\//Z#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K\M?^#H#_DC'PL_[&B^_])EK]2J_+7_@Z _Y
M(Q\+/^QHOO\ TF6OHN$_^2@H^K_])9\KQI_R35?_ +=_]*B?H?\ LS_\FX>
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M&7_8?\*_^I+I=?4Z?=%?+'_!:3_E')XR_P"P_P"%?_4ETNOJ=/NB@.@M%%%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1@2,"O
ME#_@C-_R:'K'_99/'7_J1W]?5[$@9%?*'_!&;_DT/6/^RR>.O_4COZ!K8^L*
M***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 T'
MYOF/TK\*/^#G4_\ &Q#X<X_Z(K+_ .G>6OW6X[>E?C3_ ,%Y/V4OVA/VM?\
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M^0[GT%-8F^QM]8=^S]*^B1_P18_X*=_]&I:F?^XUIW_R30?^"+'_  4[Z_\
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ME275'O-2EE:^D7[DDVYCYC+V+YQVKZ._X<L_\%._^C4]3_\ !UIW_P DT?\
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MY=W +C'7O5J[UW6]0L;72]0UR\GM;%&6PMKBY>2*V5FRRQHS8CR>N,5],?\
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MJZ,#M-6;;QWX]L?%+>.[3QOK,&N-*SOK<6J3+>-(>K&8-OW?C7T9_P .6?\
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MNMZ[/'<Z[K=Y?2PQ+#%+>W#RLB+TC5G8[5'9>@KZ9_X<L?\ !3L]/V4]3_\
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MV#PW?)9HUO>:#>+YCP2R9#K+%,J[1@C9WS73'_@BQ_P4[_Z-3U/_ ,'6G?\
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M?LDZ;X&U;QMX:U748_'GQ-T?P5IPTM8RUO=ZB[)%/)O=?W2[#NQEO0&ODO\
M::_;R_:J^''_  5C\#_"CPA^S!\5-7\,1> _$6?"ND:EI"0^+)(G@,>I0"6\
M0;(?N_O3'*/,^5#DY!V9^A]%<_\ #;Q5K?C?P#H_B[Q%X$U+PQ?ZE817-UX=
MUEX6NM.=ER8)3"[QEUZ'8Q'O7F7[5W[:G@W]F/5_#7P[TWX?^)?'WQ"\9R3#
MPE\/?!EM%)J%]'" 9KF1YGCAMK:+<N^:5U4;L#<<B@1[;17SO^SM^WS;?%KX
MQS?LU_&K]GSQA\(OB-_8KZSI?AKQ>]I/%K.GJZI)/8WEG-+!.8F9?,BR)$W
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MI'?U]7L2!D5\H?\ !&;_ )-#UC_LLGCK_P!2._H&MCZPHHHH$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R7.3_P /T(>?^;3I
M?_4FCKZTKY+G_P"4Z$/_ &:=+_ZDT= (^M,#THHHH"R"BBB@ HHHH " >HHP
M!T%%% 608'3%%%% 60$ ]11@>E%% !00#U%%% 6048'I110 4444 %%%% !@
M#H**** "BBB@ HP/2BB@+(, =!1@>E%% 6048'I110%D& >HHHHH"R"BBB@
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M*L4,(=V +O(RHJ=69@!S7P!XTU_]LS]I+_@JYXS^-/['G@7X<>(]$^ 7AH>
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MGQDM_CYXPTCQ%IWB?[%;V6KW_A+QCJ&C?VY9PR^9#;7Z6<T8NXD;H),G'&<
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M,.I6DMTVW^)1;I([#H55@>*@C_9+_;E^-GP?6RTS_@K%IVJ^#O%WAO9!]D^
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M37&_M1_L<?L^_MA^'=+\/?';P0^H2Z#?_;_#NLZ=J5QI^I:1=8QYMI>6SI-
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M2:.OK2ODN?\ Y3H0_P#9ITO_ *DT= T?6E%%% @HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *_+7_@Z _P"2,?"S_L:+[_TF6OU*K\M?^#H#_DC'
MPL_[&B^_])EKZ+A/_DH*/J__ $EGRO&G_)-5_2/_ *5$_0_]F?\ Y-P\!?\
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MEL[WMO<_'[_A[S_P6Y_Z,$N?_#5:[_\ ':/^'O/_  6Y_P"C!+G_ ,-5KO\
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M $,*GW(_'W_A[S_P6Y_Z,$N?_#5:[_\ ':/^'O/_  6Y_P"C!+G_ ,-5KO\
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M_>P_U:S7_H85/N1^/O\ P]Y_X+<_]&"7/_AJM=_^.T?\/>?^"W/_ $8)<_\
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M_!;G_HP2Y_\ #5:[_P#':/\ A[S_ ,%N?^C!+G_PU6N__':_8+RX_P#GF/\
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M+C_YYC_OFCRX_P#GF/\ OFC^W\M_Z :?WL/]6LU_Z&%3[D?C[_P]Y_X+<_\
M1@ES_P"&JUW_ ..T?\/>?^"W/_1@ES_X:K7?_CM?L%Y<?_/,?]\T>7'_ ,\Q
M_P!\T?V_EO\ T T_O8?ZM9K_ -#"I]R/Q]_X>\_\%N?^C!+G_P -5KO_ ,=H
M_P"'O/\ P6Y_Z,$N?_#5:[_\=K]@O+C_ .>8_P"^:/+C_P">8_[YH_M_+?\
MH!I_>P_U:S7_ *&%3[D?C[_P]Y_X+<_]&"7/_AJM=_\ CM'_  ]Y_P""W/\
MT8)<_P#AJM=_^.U^P7EQ_P#/,?\ ?-'EQ_\ /,?]\T?V_EO_ $ T_O8?ZM9K
M_P!#"I]R/Q]_X>\_\%N?^C!+G_PU6N__ !VC_A[S_P %N?\ HP2Y_P##5:[_
M /':_8+RX_\ GF/^^:/+C_YYC_OFC^W\M_Z :?WL/]6LU_Z&%3[D?C[_ ,/>
M?^"W/_1@ES_X:K7?_CM'_#WG_@MS_P!&"7/_ (:K7?\ X[7[!>7'_P \Q_WS
M1Y<?_/,?]\T?V_EO_0#3^]A_JUFO_0PJ?<C\??\ A[S_ ,%N?^C!+G_PU6N_
M_':/^'O/_!;G_HP2Y_\ #5:[_P#':_8+RX_^>8_[YH\N/_GF/^^:/[?RW_H!
MI_>P_P!6LU_Z&%3[D?C[_P />?\ @MS_ -&"7/\ X:K7?_CM'_#WG_@MS_T8
M)<_^&JUW_P".U^P7EQ_\\Q_WS1Y<?_/,?]\T?V_EO_0#3^]A_JUFO_0PJ?<C
M\??^'O/_  6Y_P"C!+G_ ,-5KO\ \=H_X>\_\%N?^C!+G_PU6N__ !VOV"\N
M/_GF/^^:/+C_ .>8_P"^:/[?RW_H!I_>P_U:S7_H85/N1^/O_#WG_@MS_P!&
M"7/_ (:K7?\ X[1_P]Y_X+<_]&"7/_AJM=_^.U^P7EQ_\\Q_WS1Y<?\ SS'_
M 'S1_;^6_P#0#3^]A_JUFO\ T,*GW(_'W_A[S_P6Y_Z,$N?_  U6N_\ QVC_
M (>\_P#!;G_HP2Y_\-5KO_QVOV"\N/\ YYC_ +YH\N/_ )YC_OFC^W\M_P"@
M&G][#_5K-?\ H85/N1^0$/\ P5Q_X+:-937#_L#S*\;)L3_A5>N_-G=G_EK[
M4S_A[S_P6Y_Z,$N?_#5:[_\ ':_8+RX_^>8_[YH\N/\ YYC_ +YI?V_EO_0#
M#[V'^K6:_P#0PJ?<C\??^'O/_!;G_HP2Y_\ #5:[_P#':/\ A[S_ ,%N?^C!
M+G_PU6N__':_8+RX_P#GF/\ OFCRX_\ GF/^^:?]OY;_ - -/[V'^K6:_P#0
MPJ?<C\??^'O/_!;G_HP2Y_\ #5:[_P#':/\ A[S_ ,%N?^C!+G_PU6N__':_
M8+RX_P#GF/\ OFCRX_\ GF/^^:/[?RW_ * :?WL/]6LU_P"AA4^Y'X^_\/>?
M^"W/_1@ES_X:K7?_ ([1_P />?\ @MS_ -&"7/\ X:K7?_CM?L%Y<?\ SS'_
M 'S1Y<?_ #S'_?-']OY;_P! -/[V'^K6:_\ 0PJ?<C\??^'O/_!;G_HP2Y_\
M-5KO_P =H_X>\_\ !;G_ *,$N?\ PU6N_P#QVOV"\N/_ )YC_OFCRX_^>8_[
MYH_M_+?^@&G][#_5K-?^AA4^Y'X^_P##WG_@MS_T8)<_^&JUW_X[1_P]Y_X+
M<_\ 1@ES_P"&JUW_ ..U^P7EQ_\ /,?]\T>7'_SS'_?-']OY;_T T_O8?ZM9
MK_T,*GW(_'W_ (>\_P#!;G_HP2Y_\-5KO_QVC_A[S_P6Y_Z,$N?_  U6N_\
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M+<_]&"7/_AJM=_\ CM'_  ]Y_P""W/\ T8)<_P#AJM=_^.U^P7EQ_P#/,?\
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M:_8+RX_^>8_[YH\N/_GF/^^:/[?RW_H!I_>P_P!6LU_Z&%3[D?C[_P />?\
M@MS_ -&"7/\ X:K7?_CM'_#WG_@MS_T8)<_^&JUW_P".U^P7EQ_\\Q_WS1Y<
M?_/,?]\T?V_EO_0#3^]A_JUFO_0PJ?<C\??^'O/_  6Y_P"C!+G_ ,-5KO\
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M_AJM=_\ CM'_  ]Y_P""W/\ T8)<_P#AJM=_^.U^P7EQ_P#/,?\ ?-'EQ_\
M/,?]\T?V_EO_ $ T_O8?ZM9K_P!#"I]R/Q]_X>\_\%N?^C!+G_PU6N__ !VC
M_A[S_P %N?\ HP2Y_P##5:[_ /':_8+RX_\ GF/^^:/+C_YYC_OFC^W\M_Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^
M6O\ P= ?\D8^%G_8T7W_ *3+7ZE5^6O_  = ?\D8^%G_ &-%]_Z3+7T7"?\
MR4%'U?\ Z2SY7C3_ ))JOZ1_]*B?H?\ LS_\FX> O^Q-TO\ ])8J[NN$_9G_
M .3</ 7_ &)NE_\ I+%7=UX>(_WB7J_S/H<%_NE/T7Y(****Q.D**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OE;7_\ E-KX7_[-8U[_ -23
M1Z^J:^5M?_Y3:^%_^S6->_\ 4DT>@:%_X+2?\HY/&7_8?\*_^I+I=?4Z?=%?
M+'_!:3_E')XR_P"P_P"%?_4ETNOJ=/NB@.@M%%% @HHHR,9S0 4444 %%%%
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MXB!/^":/_15=<_\ "1O?_C=?S\45^J?\0[R7^:7WK_(_&/\ B)_$'\L/N?\
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M5=<_\)&]_P#C=?S\44?\0[R7^>7WK_(/^(G\0?RP^Y_YG] __$0)_P $T?\
MHJNN?^$C>_\ QNC_ (B!/^":/_15=<_\)&]_^-U_/Q11_P 0[R7^:7WK_(/^
M(G\0?RP^Y_YG] __ !$"?\$T?^BJZY_X2-[_ /&Z/^(@3_@FC_T577/_  D;
MW_XW7\_%%'_$/,E_GE]Z_P @_P"(G\0?RP^Y_P"9_0/_ ,1 G_!-'_HJNN?^
M$C>__&Z/^(@3_@FC_P!%5US_ ,)&]_\ C=?S\44?\0[R7^>7WK_(/^(G\0?R
MP^Y_YG] _P#Q$"?\$T?^BJZY_P"$C>__ !NC_B($_P"":/\ T577/_"1O?\
MXW7\_%%'_$.\E_FE]Z_R#_B)_$'\L/N?^9_0/_Q$"?\ !-'_ **KKG_A(WO_
M ,;H_P"(@3_@FC_T577/_"1O?_C=?S\44?\ $/,E_GE]Z_R#_B)_$'\L/N?^
M9_0/_P 1 G_!-'_HJNN?^$C>_P#QNC_B($_X)H_]%5US_P )&]_^-U_/Q11_
MQ#S)?YY?>O\ (/\ B)_$'\L/N?\ F?T#_P#$0)_P31_Z*KKG_A(WO_QNC_B(
M$_X)H_\ 15=<_P#"1O?_ (W7\_%%'_$/,E_GE]Z_R#_B)_$'\L/N?^9_0/\
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MRP^Y_P"9_0/_ ,1 G_!-'_HJNN?^$C>__&Z/^(@3_@FC_P!%5US_ ,)&]_\
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M,E_GE]Z_R#_B)_$'\L/N?^9_0/\ \1 G_!-'_HJNN?\ A(WO_P ;H_XB!/\
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M ='1110 4444 %%%1-<0PNJRR*ID;"AF^\?:@"6BBB@ HHHH **** "BBB@
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M"_9L^(5PFG^#-5TZ[\6^'<LH58X(I+V.-/<VLLT?NULHQFOG#7_"/B[XA_\
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M0L_:'\$_LI_L=?'GX^_$?3]2NM'\.>)-.FO;?1;19[EED4PKL1G5?O2+DE@
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MGSK?PN\%^&?#WARR_P"$BU+5O$GA^'4_%.HO%OGGO5U!O/,19MJH0!MZ?+M
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M\D8^%G_8T7W_ *3+7ZE5^6O_  = ?\D8^%G_ &-%]_Z3+7T7"?\ R4%'U?\
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M* Z'8?\ !32[N(/VL?V-WM;ED63XYW"N(Y" ZG2+L=NO%>>?MB>'_@E\=/\
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MCX2:S#H/B'Q?XT\.W6LZAJNKO;+.\=K:Q7$$<-O$LBJ9)&9G;[H S0+0]O\
MV2/VNOA=^V9\-;KX@_#:RUG2[K1]9N-&\4^%?$^FFSU7P_JD&WSK&\@R?+E4
M,IX+*0P()KQC4O\ @K]\,[K5=8UOX5_LP_&'Q[\._#.K2Z?XC^*W@WPE'=Z+
M;20OLN9(%,PN;V&!E;S);>&10%8KOQ7E7_!/?2OC-:^%/VW=%UWXAZ9XM\>P
M_$O4[?\ X2#P_H_V"WO-27P[:(GEVPEE\E@^U"GF,=RMSFO;?^",.J>!YO\
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M?^*M<_9U^(GPUEL=4>R72?B1I5M:WERH1'\^-+:XG1HCNV[MWWD;C')^8?\
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M&<'7J*I"I.$N51;B[<T5LGH[GR__ ,$N/^"?-M^P#^SG+\-O$6M6>L^)=>U
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MIWCSP#XEL-:T76+..\TG5M+N4GMKVVD4.DT<B$JZ,I!# X- &Q1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5]X_\&Z>?^'B:?\ 8BZG_P"AP5\'5]X_\&Z>?^'B:?\ 8BZG_P"AP5X7$W_(
MAQ'^%GT7"7_)187_ !K\S][Z***_G0_J8**** "BBB@ HHHH **** "BBB@
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M\DN="U'^T/#/B#1-5GT[5=#O-NWS[.\MW62%\=0#M;:-P.!7JU% 'SW\"_\
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MUC7O_4DT>OJFOE;7_P#E-KX7_P"S6->_]231Z!H7_@M)_P HY/&7_8?\*_\
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ML#ZI(MA-#:,Y^57D2.38#RY7"Y-<A^WA\;OA3XF_X*W_ +(/P/\ #GC>PO\
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M#_5/AO\ Z!H_<?GM_P 0V/[!'_0Y?$G_ ,']I_\ (E'_ !#8_L$?]#E\2?\
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MP_U3X;_Z!H?<?GM_Q#8_L$?]#E\2?_!_:?\ R)1_Q#8_L$?]#E\2?_!_:?\
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M_(E?H3L]Q^5&SW'Y4?ZR9]_T$2^]A_JGPW_T#0^X_/;_ (AL?V"/^AR^)/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7Y:_P#!T!_R1CX6?]C1??\
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MK_W95VWD*<?\M@,DFO?_ (>$/_P7V^) (_YMGT+_ -/%S7'_  =_9,N_VO\
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M(C:^$-+\7Z/!;>+/+FM]FJHDUVD<:Q;=@6<K-^\^1.3G]%*^,/CB/(_X+C_
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MQSX3\ 76F27_ (-^(?B6:TBA\00+.L:,MFLINK02HWG1>>BF2+YL+D"ODO\
M;P_9"T']D?\ X([ZK\#V^(<OCB._^,FB:KJVJ:AIMO EU/?>*[2:XC%O#^ZC
M3?(R^6..O':OTMCC2! B#"CA56@-+$E%%% @HHHH **** "BBB@ HHHH *^5
MM?\ ^4VOA?\ [-8U[_U)-'KZIKY6U_\ Y3:^%_\ LUC7O_4DT>@:%_X+2?\
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M0H_\*.T<9(_V:Z6B@#R']I/]A3]C_P#:_N=/U']I?]G?POXRN]*B:+3K_5K
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MG=NW9->OT44""BBB@ HHHH **** "BBB@ HHHH *^5M?_P"4VOA?_LUC7O\
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M -'/?M(_^)!Z_P#_ "11_P .D/@O_P!'/?M(_P#B0>O_ /R10%F?5E%?*?\
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M;OL7F"7[)Y_G[_(\P!_+SMW?-C/- :'U]17RG_PZ0^"__1SW[2/_ (D'K_\
M\D4?\.D/@O\ ]'/?M(_^)!Z__P#)% 69]645\I_\.D/@O_T<]^TC_P")!Z__
M /)%'_#I#X+_ /1SW[2/_B0>O_\ R10%F?5E%?*?_#I#X+_]'/?M(_\ B0>O
M_P#R11_PZ0^"_P#T<]^TC_XD'K__ ,D4!9GU917RG_PZ0^"__1SW[2/_ (D'
MK_\ \D4?\.D/@O\ ]'/?M(_^)!Z__P#)% 69]645\I_\.D/@O_T<]^TC_P")
M!Z__ /)%'_#I#X+_ /1SW[2/_B0>O_\ R10%F?5E%?*?_#I#X+_]'/?M(_\
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M  Z0^"__ $<]^TC_ .)!Z_\ _)% 69]645\I_P##I#X+_P#1SW[2/_B0>O\
M_P D4?\ #I#X+_\ 1SW[2/\ XD'K_P#\D4!9GU917RG_ ,.D/@O_ -'/?M(_
M^)!Z_P#_ "11_P .D/@O_P!'/?M(_P#B0>O_ /R10%F?5E%?*?\ PZ0^"_\
MT<]^TC_XD'K_ /\ )%'_  Z0^"__ $<]^TC_ .)!Z_\ _)% 69]645\I_P##
MI#X+_P#1SW[2/_B0>O\ _P D4?\ #I#X+_\ 1SW[2/\ XD'K_P#\D4!9GU91
M7RG_ ,.D/@O_ -'/?M(_^)!Z_P#_ "11_P .D/@O_P!'/?M(_P#B0>O_ /R1
M0%F?5E%?*?\ PZ0^"_\ T<]^TC_XD'K_ /\ )%'_  Z0^"__ $<]^TC_ .)!
MZ_\ _)% 69]645\I_P##I#X+_P#1SW[2/_B0>O\ _P D4?\ #I#X+_\ 1SW[
M2/\ XD'K_P#\D4!9GU917RG_ ,.D/@O_ -'/?M(_^)!Z_P#_ "11_P .D/@O
M_P!'/?M(_P#B0>O_ /R10%F?5E%?*?\ PZ0^"_\ T<]^TC_XD'K_ /\ )%'_
M  Z0^"__ $<]^TC_ .)!Z_\ _)% 69]645\I_P##I#X+_P#1SW[2/_B0>O\
M_P D4?\ #I#X+_\ 1SW[2/\ XD'K_P#\D4!9GU917RG_ ,.D/@O_ -'/?M(_
M^)!Z_P#_ "11_P .D/@O_P!'/?M(_P#B0>O_ /R10%F?5E%?*?\ PZ0^"_\
MT<]^TC_XD'K_ /\ )%!_X))_!D(5_P"&G/VC^<<_\-!Z_D?3_2* LSZLHKY3
M_P"'2'P7_P"CGOVD?_$@]?\ _DBC_ATA\%_^CGOVD?\ Q(/7_P#Y(H"S/JRB
MOE/_ (=(?!?_ *.>_:1_\2#U_P#^2*/^'2'P7_Z.>_:1_P#$@]?_ /DB@+,^
MK**^4_\ ATA\%_\ HY[]I'_Q(/7_ /Y(H_X=(?!?_HY[]I'_ ,2#U_\ ^2*
MLSZLHKY3_P"'2'P7_P"CGOVD?_$@]?\ _DBC_ATA\%_^CGOVD?\ Q(/7_P#Y
M(H"S/JRBOE/_ (=(?!?_ *.>_:1_\2#U_P#^2*/^'2'P7_Z.>_:1_P#$@]?_
M /DB@+,^K**^4_\ ATA\%_\ HY[]I'_Q(/7_ /Y(H_X=(?!?_HY[]I'_ ,2#
MU_\ ^2* LSZLHKY3_P"'2'P7_P"CGOVD?_$@]?\ _DBC_ATA\%_^CGOVD?\
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M% 69]645\I_\.D/@O_T<]^TC_P")!Z__ /)%'_#I#X+_ /1SW[2/_B0>O_\
MR10%F?50 /1OK7Y;_P#!T ,?!;X6@?\ 0S7W_I,M?3O_  Z0^#'_ $<_^TA_
MXD'K_P#\D5A^-O\ @B7^R+\3K&+3/BS\1OC1XMM;.5I+6U\4_&/5]0BMY&7#
M/&D\S!&9?E) !(XZ5Z63X^.59E3Q4U=1;T]4U^IX^>9;/.,JJ86$K.5E?M9I
M_H?1W[,ZD?LY^ C_ -27I?\ Z2Q5W07 ]Z^3H/\ @D=\$;6UBM;3]I;]HR&W
MAA6.WMX?V@->2.*)5"K&JK< *H4!0!P  *E'_!)'X,<_\9/_ +2'_B0>O_\
MR17!4G[2I*7=L]2C2]E1C"^R2^[0^K:*^4O^'2'P7_Z.?_:0_P#$@]?_ /DB
ME_X=(?!?_HY[]I'_ ,2#U_\ ^2*@TLSZLHKY3_X=(?!?_HY[]I'_ ,2#U_\
M^2*/^'2'P7_Z.>_:1_\ $@]?_P#DB@+,^K**^4_^'2'P7_Z.>_:1_P#$@]?_
M /DBC_ATA\%_^CGOVD?_ !(/7_\ Y(H"S/JRBOE/_ATA\%_^CGOVD?\ Q(/7
M_P#Y(H_X=(?!?_HY[]I'_P 2#U__ .2* LSZLHKY3_X=(?!?_HY[]I'_ ,2#
MU_\ ^2*/^'2'P7_Z.>_:1_\ $@]?_P#DB@+,^K**^4_^'2'P7_Z.>_:1_P#$
M@]?_ /DBC_ATA\%_^CGOVD?_ !(/7_\ Y(H"S/JRBOE/_ATA\%_^CGOVD?\
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MB@+,^K**^4_^'2'P7_Z.>_:1_P#$@]?_ /DBC_ATA\%_^CGOVD?_ !(/7_\
MY(H"S/JRBOE/_ATA\%_^CGOVD?\ Q(/7_P#Y(H_X=(?!?_HY[]I'_P 2#U__
M .2* LSZLHKY3_X=(?!?_HY[]I'_ ,2#U_\ ^2*/^'2'P7_Z.>_:1_\ $@]?
M_P#DB@+,^K**^4_^'2'P7_Z.>_:1_P#$@]?_ /DBC_ATA\%_^CGOVD?_ !(/
M7_\ Y(H"S/JRBOE/_ATA\%_^CGOVD?\ Q(/7_P#Y(H_X=(?!?_HY[]I'_P 2
M#U__ .2* LSZLHKY3_X=(?!?_HY[]I'_ ,2#U_\ ^2*/^'2'P7_Z.>_:1_\
M$@]?_P#DB@+,^K*^5M?'_&[;POC_ *-9U[_U)-'J/_ATA\%_^CG_ -I#_P 2
M#U__ .2*[#]G/_@GC\$OV;/BY<?'3PWXV^(WB3Q+<>&I= BU'Q_\0]0UTVVG
6RW,-Q)#$+N1Q&&EAC8X_N^YR!L?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456769392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immunic, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2358443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1200 Avenue of the Americas,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-9818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMUX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,403,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Certain portions of the registrant&#8217;s definitive Proxy Statement for its 2023 Annual Meeting of Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001280776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456902704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Baker Tilly US, LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Minneapolis, MN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003457588320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 106,745<span></span>
</td>
<td class="nump">$ 86,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Investments - other</a></td>
<td class="nump">9,629<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">9,490<span></span>
</td>
<td class="nump">18,125<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">125,864<span></span>
</td>
<td class="nump">104,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (note 2)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">1,552<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">127,753<span></span>
</td>
<td class="nump">139,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,281<span></span>
</td>
<td class="nump">3,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,986<span></span>
</td>
<td class="nump">7,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">810<span></span>
</td>
<td class="nump">585<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,077<span></span>
</td>
<td class="nump">11,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,069<span></span>
</td>
<td class="nump">11,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at December&#160;31, 2022 and 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 130,000,000 shares authorized and 39,307,286 and 26,335,418 shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">427,925<span></span>
</td>
<td class="nump">324,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">3,035<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(317,280)<span></span>
</td>
<td class="num">(196,873)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">113,684<span></span>
</td>
<td class="nump">127,115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 127,753<span></span>
</td>
<td class="nump">$ 139,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003457526272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">39,307,286<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">39,307,286<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003457551120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 71,255<span></span>
</td>
<td class="nump">$ 61,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,263<span></span>
</td>
<td class="nump">13,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment (see Note 2)</a></td>
<td class="nump">32,970<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_RoyaltySettlementAgreementSalesNet', window );">4SC Royalty Settlement (See Note 4)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">119,488<span></span>
</td>
<td class="nump">91,665<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(119,488)<span></span>
</td>
<td class="num">(91,665)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(1,960)<span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(919)<span></span>
</td>
<td class="num">(1,280)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (120,407)<span></span>
</td>
<td class="num">$ (92,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in USD per share)</a></td>
<td class="num">$ (3.78)<span></span>
</td>
<td class="num">$ (3.93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in USD per share)</a></td>
<td class="num">$ (3.78)<span></span>
</td>
<td class="num">$ (3.93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">31,819,006<span></span>
</td>
<td class="nump">23,652,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">31,819,006<span></span>
</td>
<td class="nump">23,652,779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_RoyaltySettlementAgreementSalesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Settlement Agreement, Sales Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_RoyaltySettlementAgreementSalesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003454060528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (120,407)<span></span>
</td>
<td class="num">$ (92,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation income, net of tax</a></td>
<td class="nump">3,287<span></span>
</td>
<td class="nump">3,860<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (117,120)<span></span>
</td>
<td class="num">$ (89,085)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003453100016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>July 2021 Public Equity Offering</div></th>
<th class="th"><div>At The Market Sales Agreement</div></th>
<th class="th"><div>4SC Royalty Settlement</div></th>
<th class="th"><div>October 2022 PIPE Transaction</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>July 2021 Public Equity Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>At The Market Sales Agreement</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>4SC Royalty Settlement</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>October 2022 PIPE Transaction</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>July 2021 Public Equity Offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>At The Market Sales Agreement</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>4SC Royalty Settlement</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>October 2022 PIPE Transaction</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,168,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 158,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,112)<span></span>
</td>
<td class="num">$ (103,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(92,945)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="nump">3,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">73,221<span></span>
</td>
<td class="nump">581,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,020<span></span>
</td>
<td class="nump">$ 729<span></span>
</td>
<td class="nump">$ 8,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,019<span></span>
</td>
<td class="nump">$ 729<span></span>
</td>
<td class="nump">$ 8,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued in connection with the Company's employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued in connection with the Company's employee stock purchase plan</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 127,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="num">(196,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(120,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,407)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="nump">3,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,204,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,696,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued in connection with the Company's employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued in connection with the Company's employee stock purchase plan</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">39,307,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 113,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 427,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,035<span></span>
</td>
<td class="num">$ (317,280)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456645760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_July2021PublicEquityOfferingMember', window );">July 2021 Public Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_AtTheMarketSalesAgreementMember', window );">At The Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 1,226<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_October2022PIPETransactionMember', window );">October 2022 PIPE Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 4,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_July2021PublicEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_July2021PublicEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_October2022PIPETransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_October2022PIPETransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003452945696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (120,407)<span></span>
</td>
<td class="num">$ (92,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment (see Note 2)</a></td>
<td class="nump">32,970<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,929<span></span>
</td>
<td class="nump">5,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency loss</a></td>
<td class="nump">4,757<span></span>
</td>
<td class="nump">4,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common stock issued in connection with the 4SC royalty settlement (see Note 4)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">7,493<span></span>
</td>
<td class="num">(12,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">799<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Other liabilities</a></td>
<td class="num">(124)<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">3,175<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(65,144)<span></span>
</td>
<td class="num">(83,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchases of Investments-other</a></td>
<td class="num">(9,629)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(112)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(9,741)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued in connection with the Company's employee stock purchase plan</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">95,760<span></span>
</td>
<td class="nump">42,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(993)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">19,882<span></span>
</td>
<td class="num">(40,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">86,863<span></span>
</td>
<td class="nump">127,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">106,745<span></span>
</td>
<td class="nump">86,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued in connection with the 4SC royalty settlement (see Note 4)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of use asset obtained in exchange for lease obligation</a></td>
<td class="nump">974<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">39,584<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_October2022PIPETransactionMember', window );">October 2022 PIPE Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">55,989<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_July2021PublicEquityOfferingMember', window );">July 2021 Public Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 42,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_October2022PIPETransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_October2022PIPETransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_July2021PublicEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_July2021PublicEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003459305008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 1,226<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_October2022PIPETransactionMember', window );">October 2022 PIPE Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 4,012<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_July2021PublicEquityOfferingMember', window );">July 2021 Public Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_October2022PIPETransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_October2022PIPETransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_July2021PublicEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_July2021PublicEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003544120192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Financial Statements</a></td>
<td class="text">Description of Business and Basis of Financial Statements<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic, Inc. ("Immunic" or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#228;felfing near Munich, Germany. The Company currently has approximately 66 employees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is currently pursuing clinical development of three orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;); the izumerogant (proposed International Nonproprietary Name (&#8220;INN&#8221;) for IMU-935) program, which is an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (&#8220;ROR&#947;t&#8221;) that inhibits the interleukin-17 (&#8220;IL-17&#8221;) pathway in diseases such as psoriasis; and the IMU-856 program, which is targeted to restore intestinal barrier function and regenerate bowel epithelium.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. Immunic has never been profitable and has incurred operating losses in each year since inception (2016). Immunic has an accumulated deficit of approximately $317.3&#160;million as of December&#160;31, 2022 and approximately $196.9&#160;million as of December&#160;31, 2021. Substantially all of Immunic&#8217;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December&#160;31, 2022, Immunic has raised net cash of approximately $355.5 million from private and public offerings of preferred and common stock. As of December 31, 2022, the Company had cash and cash equivalents of approximately $106.7&#160;million and investments - other of $9.6&#160;million. With these funds the Company expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div>The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG (which began operations in 2016) and Immunic Australia Pty Ltd. (which began operations in 2018).  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456932080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments- other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments-other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S of approximately $85.7&#160;million, Germany of approximately $19.1&#160;million and Australia of approximately $1.9&#160;million. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions. Our Cash and Cash equivalents in the U.S. is primarily held in a U.S. Government money market fund account and was earning interest at a rate of 4.3%. Our cash and cash equivalents in Germany and Australia were earning interest at a rate of &#8212;% to 0.87%</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of 0.61% to 0.87% and have a remaining maturity 3-4 months.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from three years to thirteen years. Depreciation and amortization expense was $77,000 and $85,000 for the years ended December&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the years ended December&#160;31, 2022 and 2021 other than goodwill which is described below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired.  The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $33.0&#160;million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance.  The Company did not have any goodwill impairment during the year ended December 31, 2021.  The changes in the carrying amount of goodwill for the years presented are as follows (amounts in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"/><td style="width:75.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.073%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount of goodwill at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill during the year ended December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount of goodwill at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. Government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred.  We recognized $2.3&#160;million and $1.7&#160;million of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3221b224-b06b-4599-934b-4790913ca766"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3cdcee94-7c82-4bf3-999e-30ecd1c05a92">other income</span></span> related to research activities performed during the years ended December 31, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December&#160;31, 2022 and 2021, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prefunded stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,096,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,888,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003544122592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text">Balance Sheet Details<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid Expense and Other Current Assets consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.060%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,745&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist  of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.296%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_4a1a30a6-155d-4e96-9d47-e78ee944ec76"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_58a0a228-b7d2-495a-8002-5c76ada4c7a6">Lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003544148448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office and June 30, 2025 for the Gr&#228;felfing, Germany office.  The Company formerly leased office space in </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Planegg-Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025.  The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a five year lease for its facility in Gr&#228;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#228;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease as well as a three month rent holiday upon the 27 month extension starting May 2023.  There were net additions to right of use assets of $435,000 and $642,000 as a result of signing for additional lease space at the Gr&#228;felfing, Germany office in March 2021 and August 2022, respectively.  There were net additions to right of use assets of $332,000 as a result of extending the New York City lease in December 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6% for the original leases and 8% for the New York City extension, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $727,000 and $503,000 for the years ended December&#160;31, 2022 and 2021, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Maturities of the operating lease obligation are as follows as of December&#160;31, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2022, the Company has non-cancelable contractual obligations under certain agreements related to its development programs in vidofludimus calcium, izumerogant and IMU-856 totaling approximately $4.5 million, all of which is expected to be paid in 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, the Company entered into a purchase agreement (the &#8220;Agreement&#8221;) with 4SC AG, whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to 4.4% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing 120,070 shares of the Company&#8217;s common stock, immediately following the Transaction, to 4SC AG while keeping Tranche III in effect. Approximately $1.5 million of expense was recorded as a result of the issuance of these shares on April 12, 2019. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, Immunic AG, a wholly-owned subsidiary of the Company, and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.25&#160;million </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Tranche III of the Agreement). The payment was made 50% in cash and 50% in shares of Immunic&#8217;s common stock (the &#8220;Shares&#8221;). Pursuant to the Agreement, the Company filed a resale shelf registration statement on Form S-3 covering the resale of the Shares. With the execution of the Agreement, no further payment obligations remain between Immunic AG and 4SC AG.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003544148448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of 4.3% in a U.S. Government money market fund.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of December 31, 2022. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.  For the assessment of the fair value of goodwill and the related impairment of goodwill we used a level one assessment in our testing of goodwill.  See Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of significant accounting policies "Goodwill".</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003544148448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common StockShelf Registration Statements<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of February 17, 2023, there is $75.0&#160;million remaining on this shelf registration statement </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 17, 2023, $8.4&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.  As of February 17, 2023, $80.0&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company has agreed to pay SVB Leerink a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, the Company raised gross proceeds of $40.9&#160;million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were  $39.6&#160;million after deducting underwriter commissions of $1.2&#160;million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2021, the Company raised gross proceeds of $0.8&#160;million pursuant to the December 2020 ATM through the sale of 73,221 shares of common stock at a weighted average price of $10.27 per share. The net proceeds from the December 2020 ATM were  $0.7&#160;million after deducting underwriter commissions of $22,555.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">$60 Million Private Placement Equity Financing</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) for a private placement (the &#8220;Private Placement&#8221;) with select accredited investors and certain existing investors (each, a &#8220;Purchaser&#8221; and collectively, the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Shares&#8221;), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase Common Stock (the &#8220;Warrant Shares&#8221; and together with the Shares and the Pre-Funded Warrants, the &#8220;Securities&#8221;), at a purchase price of $4.34 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.01 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days&#8217; prior notice to the Company.  The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return.  All of the pre-funded warrants were exercised in January of 2023.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Private Placement closed on October 12, 2022. The gross proceeds of the Private Placement were approximately $60.0&#160;million, before deducting offering expenses payable by the Company of approximately $4.0 million. The Company intends to use the net proceeds from the Private Placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), izumerogant (IMU-935) and IMU-856, and for other general corporate purposes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registration statement for these securities was deemed effective by Securities and Exchange Commission on December 20, 2022.   </span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">July 2021 Public Equity Offering</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 15, 2021, the Company entered into an underwriting agreement with Piper Sandler &amp; Co., in connection with the Company&#8217;s public offering of 4,500,000 shares of the Company&#8217;s common stock, $0.0001 par value per share, at a public offering price of $10.00 per share. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 19, 2021, the Company closed the Offering. The net proceeds to the Company from the Offering was approximately $42.0&#160;million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:113%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through December&#160;31, 2022, no cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20,000,000 shares of $0.0001 par value preferred stock, rights and preferences to be set by the board of directors. No preferred shares were outstanding as of December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance as of December&#160;31, 2022 are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prefunded stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,096,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,283,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003462433712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation Plans</a></td>
<td class="text">Stock-based Compensation Plans<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#8217;s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has issued 70,351 and 12,758 shares under the ESPP for the twelve months ended December 31, 2022 and 2021, respectively. The Company recognized $96,000 and $46,000 of expense related to the plan in the twelve months ended December 31, 2022 and 2021, respectively.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#8217;s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to 4% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of 4,408,871 shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzkwMzI_3b155f68-f249-4b5a-829c-f22ff2797b9c">three</span> or four years.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the twelve months ended December 31, 2022 and 2021 under the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398,490&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153,509)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,954&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the years ended December&#160;31, 2022 and 2021 was $6.81 and $10.52, respectively. The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.526%"><tr><td style="width:1.0%"/><td style="width:57.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.93%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year<br/>&#160;Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,929&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 there was $15.6&#160;million  in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 2.74 years.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital&#8217;s 2012 Stock Option Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain 43,311 shares available for grant under the 2014 Plan as of December 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Vital&#8217;s Board of Directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense was recorded for the plans assumed from Vital during the twelve months ended December 31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003461238064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,049)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,448)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,408)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,945)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate reconciliation consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:72.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effect of rate change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes result from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in years in which those temporary differences are expected to be recovered or settled. As tax laws and rates change, deferred tax assets and liabilities are adjusted through income tax expense. There is no current or deferred income tax expense in the years ended December 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's net deferred tax assets are shown below. A valuation allowance has been established as realization of such net deferred tax assets has not met the more likely-than-not threshold requirement. If the Company's judgment changes and it is determined that the Company will be able to realize these net deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on the net deferred tax assets will be accounted for as a reduction to income tax expense.</span></div><div style="text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain or loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,053&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,819&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total deferred tax liability    </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net operating losses each year since inception due to its history as a development stage company with no realized revenues from its planned principal operations. These cumulative operating losses provide significant negative evidence in the determination of whether or not the Company will be able to realize deferred tax assets such as net operating losses and other favorable temporary differences. There can be no assurance that it will ever generate taxable income. As a result, the Company has maintained a full valuation allowance against the entire balance of its net deferred tax assets since the date of inception. The valuation allowance has increased by $14.2&#160;million and $22.3&#160;million and for the years ended December 31, 2021 and 20, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, Immunic had available NOLs of approximately $190.2&#160;million in Germany and Australia. These NOLs do not expire.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal NOL carryforwards of $15.6&#160;million were generated prior to 2018 and expire over 20 years beginning in 2023. The $78.9&#160;million of post 2017 federal NOL carryforwards do not expire. Sections 382 of the Internal Revenue Code of 1986 subject the future utilization of net operating losses, to an annual limitation in the event of certain ownership changes, as defined. The Company may have undergone ownership changes and therefore may be limited in the amount of net operating losses available for utilization in the future.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any uncertain tax positions for the years ended December 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the full valuation allowance that the Company has on its net deferred tax asset balance, there are no uncertain tax positions that would impact the effective tax rate if recognized.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2018 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div>Immunic, Inc. recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet. There were no such interest or penalties for any of the years presented.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003462594592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship with a base salary of $25,417 per month pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020. On October 15, 2020, the Company and Dr. Nash entered into an addendum (the &#8220;First Addendum&#8221;) to extend the term of the Executive Chairman Agreement to April 15, 2021.  In connection with the First Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 120,000 shares of Company common stock, which vests monthly over six months commencing on November 15, 2020.  On April 15, 2021, the Company and Dr. Nash entered into Addendum No. Two (the &#8220;Second Addendum&#8221;) to extend the term of the Executive Chairman Agreement to April 15, 2022.  In connection with the Second Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 90,000 shares of Company common stock, which vests monthly over 12 months commencing on May 15, 2021, and to increase Dr. Nash&#8217;s monthly base salary to $27,960 from $25,417. On March 15, 2022, the Company and Dr. Nash entered into Addendum No. Three (the &#8220;Third Addendum&#8221;), which extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $29,358 per month. In connection with the Third Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 75,000 shares of the Company&#8217;s common stock, which vests monthly over 12 months commencing on April 10, 2022.  On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456447216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock', window );">Cash And Cash Equivalents And Other Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments- other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments-other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S of approximately $85.7&#160;million, Germany of approximately $19.1&#160;million and Australia of approximately $1.9&#160;million. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions. Our Cash and Cash equivalents in the U.S. is primarily held in a U.S. Government money market fund account and was earning interest at a rate of 4.3%. Our cash and cash equivalents in Germany and Australia were earning interest at a rate of &#8212;% to 0.87%</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of 0.61% to 0.87% and have a remaining maturity 3-4 months.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from three years to thirteen years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div>On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div>The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government assistance</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. Government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred.  We recognized $2.3&#160;million and $1.7&#160;million of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3221b224-b06b-4599-934b-4790913ca766"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3cdcee94-7c82-4bf3-999e-30ecd1c05a92">other income</span></span> related to research activities performed during the years ended December 31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the </span></div>application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December&#160;31, 2022 and 2021, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting </span></div>for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Other Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342957-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003461204384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Schedule of Investment</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prefunded stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,096,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,888,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text">The changes in the carrying amount of goodwill for the years presented are as follows (amounts in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"/><td style="width:75.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.073%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount of goodwill at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill during the year ended December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount of goodwill at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI https://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI https://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003457466224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid Expense and Other Current Assets consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.060%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,745&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist  of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.296%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_4a1a30a6-155d-4e96-9d47-e78ee944ec76"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_58a0a228-b7d2-495a-8002-5c76ada4c7a6">Lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003462549552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Obligations</a></td>
<td class="text">Maturities of the operating lease obligation are as follows as of December&#160;31, 2022 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456460528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456785072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Shares Reserved for Future Issuance</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance as of December&#160;31, 2022 are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prefunded stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,096,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,283,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003457449696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the twelve months ended December 31, 2022 and 2021 under the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398,490&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153,509)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,954&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions Used</a></td>
<td class="text">The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.526%"><tr><td style="width:1.0%"/><td style="width:57.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.93%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year<br/>&#160;Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,929&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003452942944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Net Loss before Income Tax Based on Jurisdictions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,049)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,448)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,408)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,945)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Income Tax Rate Reconciliation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate reconciliation consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:72.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effect of rate change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets and Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain or loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,053&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,819&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total deferred tax liability    </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456746976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>employee </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_NumberOfDevelopmentPrograms', window );">Number of development programs pursued | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 317,280<span></span>
</td>
<td class="nump">$ 196,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">355,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,745<span></span>
</td>
<td class="nump">86,863<span></span>
</td>
<td class="nump">$ 127,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Investments - other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,629<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_NumberOfDevelopmentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Development Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_NumberOfDevelopmentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003451385328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>lease </div>
<div>financialInstitution</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>lease </div>
<div>financialInstitution</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 106,745,000<span></span>
</td>
<td class="nump">$ 106,745,000<span></span>
</td>
<td class="nump">$ 86,863,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_NumberOfFinancialInstitutionsUsedForCashDeposits', window );">Number of financial institutions used for cash deposits | financialInstitution</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 33,000,000<span></span>
</td>
<td class="nump">$ 32,970,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_GovernmentAssistanceRate', window );">Government assistance rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government assistance, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_LesseeOperatingLeasesNumberOfExistingLeases', window );">Number of existing operating leases | lease</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 85,700,000<span></span>
</td>
<td class="nump">$ 85,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=imux_AustraliaAndGermanyMember', window );">Australia and Germany | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=imux_AustraliaAndGermanyMember', window );">Australia and Germany | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">0.87%<span></span>
</td>
<td class="nump">0.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,100,000<span></span>
</td>
<td class="nump">$ 19,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany | Minimum | Time Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">0.61%<span></span>
</td>
<td class="nump">0.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_InvestmentEarningInterestRateRemainingMaturityPeriod', window );">Earning interest at a rate maturity (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany | Maximum | Time Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">0.87%<span></span>
</td>
<td class="nump">0.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_InvestmentEarningInterestRateRemainingMaturityPeriod', window );">Earning interest at a rate maturity (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_GovernmentAssistanceRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Assistance Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_GovernmentAssistanceRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_InvestmentEarningInterestRateRemainingMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment, Earning Interest Rate, Remaining Maturity Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_InvestmentEarningInterestRateRemainingMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_LesseeOperatingLeasesNumberOfExistingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Leases, Number Of Existing Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_LesseeOperatingLeasesNumberOfExistingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_NumberOfFinancialInstitutionsUsedForCashDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Financial Institutions Used For Cash Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_NumberOfFinancialInstitutionsUsedForCashDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=imux_AustraliaAndGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=imux_AustraliaAndGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456920128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Investments - other</a></td>
<td class="nump">$ 9,629<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Investments - other</a></td>
<td class="nump">$ 9,629<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456918752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Carrying amount of goodwill at December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill during the year ended December 31, 2022</a></td>
<td class="num">$ (33,000)<span></span>
</td>
<td class="num">(32,970)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Carrying amount of goodwill at December 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32,970<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003452974208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">8,888,240<span></span>
</td>
<td class="nump">2,157,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">3,791,688<span></span>
</td>
<td class="nump">2,157,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Prefunded stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">5,096,552<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456919744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_PrepaidClinicalAndRelatedCostsCurrent', window );">Prepaid clinical and related costs</a></td>
<td class="nump">$ 5,608<span></span>
</td>
<td class="nump">$ 14,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT receivable</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_ResearchAndDevelopmentTaxIncentiveCurrent', window );">Australian research and development tax incentive</a></td>
<td class="nump">2,361<span></span>
</td>
<td class="nump">1,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">1,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 9,490<span></span>
</td>
<td class="nump">$ 18,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_PrepaidClinicalAndRelatedCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical And Related Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_PrepaidClinicalAndRelatedCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ResearchAndDevelopmentTaxIncentiveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Incentive, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ResearchAndDevelopmentTaxIncentiveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003459083744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accounts Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_ClinicalCostsPayableCurrent', window );">Clinical and related costs</a></td>
<td class="nump">$ 3,749<span></span>
</td>
<td class="nump">$ 3,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_LegalAndAuditCostsPayableCurrent', window );">Legal and audit costs</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total</a></td>
<td class="nump">$ 4,281<span></span>
</td>
<td class="nump">$ 3,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ClinicalCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ClinicalCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_LegalAndAuditCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal And Audit Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_LegalAndAuditCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003451255792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_AccruedClinicalCostsCurrent', window );">Accrued clinical and related costs</a></td>
<td class="nump">$ 6,807<span></span>
</td>
<td class="nump">$ 6,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_AccruedLegalAndAuditCostsCurrent', window );">Accrued legal and audit costs</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">890<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 7,986<span></span>
</td>
<td class="nump">$ 7,071<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_AccruedClinicalCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_AccruedClinicalCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Compensation, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_AccruedLegalAndAuditCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal And Audit Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_AccruedLegalAndAuditCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456914864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">$ 571<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total<span></span>
</td>
<td class="text">Total<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003451597472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 07, 2020</div></th>
<th class="th"><div>Apr. 12, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_OperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate on operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_OperatingAndVariableLeasesCost', window );">Operating and variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 727<span></span>
</td>
<td class="nump">$ 503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales', window );">Asset purchase agreement, royalties as percent of aggregated net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_RoyaltySettlementAgreementSalesNet', window );">4SC royalty settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=imux_ImmunicAGMember', window );">Immunic AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales', window );">Asset purchase agreement, royalties as percent of aggregated net sales</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_RoyaltySettlementAgreementSalesNet', window );">4SC royalty settlement</a></td>
<td class="nump">$ 17,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_RoyaltySettlementAgreementCashPaymentPercent', window );">Royalty settlement agreement, cash payment, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_RoyaltySettlementAgreementSharesPaymentPercent', window );">Royalty settlement agreement, shares payment, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=imux_GrafelfingGermanyMember', window );">Grafelfing, Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Increase in operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=imux_NewYorkCityMember', window );">New York City</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_LesseeOperatingLeaseRentHolidayPeriod', window );">Rent holiday period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Increase in operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_OperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate on operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_LesseeOperatingLeaseRentHolidayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Rent Holiday Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_LesseeOperatingLeaseRentHolidayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_OperatingAndVariableLeasesCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Variable Leases, Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_OperatingAndVariableLeasesCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_OperatingLeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_OperatingLeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_RoyaltySettlementAgreementCashPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Settlement Agreement, Cash Payment, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_RoyaltySettlementAgreementCashPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_RoyaltySettlementAgreementSalesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Settlement Agreement, Sales Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_RoyaltySettlementAgreementSalesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_RoyaltySettlementAgreementSharesPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Settlement Agreement, Shares Payment, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_RoyaltySettlementAgreementSharesPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=imux_ImmunicAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=imux_ImmunicAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=imux_GrafelfingGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=imux_GrafelfingGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=imux_NewYorkCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=imux_NewYorkCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456681040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest portion</a></td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease obligation</a></td>
<td class="nump">$ 1,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003451564336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 85,521<span></span>
</td>
<td class="nump">$ 31,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">85,521<span></span>
</td>
<td class="nump">31,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">85,521<span></span>
</td>
<td class="nump">31,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">85,521<span></span>
</td>
<td class="nump">31,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003461169776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456397904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Shelf Registration Statement (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 17, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock', window );">Commission, percent of gross proceeds from sale of common stock</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_December2020ATMMember', window );">December 2020 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_ShelfRegistrationTerminationPriorWrittenNotice', window );">Shelf registration, termination, prior written notice | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 40,900,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="nump">4,204,113<span></span>
</td>
<td class="nump">73,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_SharesIssuedWeightedAverageSharePricePerShare', window );">Shares Issued, Weighted Average Share Price Per Share | $ / shares</a></td>
<td class="nump">$ 9.72<span></span>
</td>
<td class="nump">$ 10.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 39,600,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Underwriter commissions</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 22,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_May2022ATMMember', window );">May 2022 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_ShelfRegistrationTerminationPriorWrittenNotice', window );">Shelf registration, termination, prior written notice | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_ShelfRegistrationStatementAmountRemaining', window );">Shelf Registration Statement, Amount Remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | December 2020 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_SaleOfStockRemainingCapacity', window );">Remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | May 2022 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_SaleOfStockRemainingCapacity', window );">Remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Aggregate Offering Price Of Securities Under Shelf Registration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_SaleOfStockRemainingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_SaleOfStockRemainingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_SharesIssuedWeightedAverageSharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Weighted Average Share Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_SharesIssuedWeightedAverageSharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ShelfRegistrationStatementAmountRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Statement, Amount Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ShelfRegistrationStatementAmountRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ShelfRegistrationTerminationPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration, Termination, Prior Written Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ShelfRegistrationTerminationPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_December2020ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_December2020ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_May2022ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_May2022ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003451670992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Equity Offering (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2022</div></th>
<th class="th"><div>Oct. 10, 2022</div></th>
<th class="th"><div>Jul. 19, 2021</div></th>
<th class="th"><div>Jul. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 355.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, cash dividends declared (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock cash dividends paid (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issues in private placement transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,696,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage', window );">May not exercise of percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PreFundedWarrantsMember', window );">Prefunded stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issues in private placement transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,096,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent', window );">Increase or decrease not in excess of percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod', window );">Increase or decrease not In excess of prior notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_July2021PublicEquityOfferingMember', window );">July 2021 Public Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issues in private placement transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_July2021PublicEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_July2021PublicEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003459219664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, cash dividends declared (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock cash dividends paid (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003457471520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003451323568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Shares Reserved for Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">9,283,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">3,791,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options | 2021 Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">116,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=imux_PreFundedWarrantsMember', window );">Prefunded stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">5,096,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">43,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2017 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">188,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=imux_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=imux_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsforFutureGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsforFutureGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003453790736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Plans - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2021</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which compensation cost will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Purchase price of the stock, at discount from market price at purchase date (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares issued under the ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,351<span></span>
</td>
<td class="nump">12,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.81<span></span>
</td>
<td class="nump">$ 10.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Incentive Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Minimum | Non-Statutory Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Maximum | Non-Statutory Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember', window );">2019 Omnibus Equity Incentive Plan, Evergreen Provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent', window );">Additional shares authorized, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,408,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_A2017InducementEquityIncentivePlanMember', window );">2017 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=imux_IncentiveEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=imux_IncentiveEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=imux_NonStatutoryEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=imux_NonStatutoryEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003456402960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Plans - Summary of Stock Option Activity (Details) - Outstanding stock options - 2019 Omnibus Equity Incentive Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning balance (in shares)</a></td>
<td class="nump">2,157,460<span></span>
</td>
<td class="nump">1,117,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,886,263<span></span>
</td>
<td class="nump">1,193,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(852)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and expired (shares)</a></td>
<td class="num">(251,183)<span></span>
</td>
<td class="num">(153,509)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending balance (in shares)</a></td>
<td class="nump">3,791,688<span></span>
</td>
<td class="nump">2,157,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest (shares)</a></td>
<td class="nump">3,791,688<span></span>
</td>
<td class="nump">2,157,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, (shares)</a></td>
<td class="nump">1,398,490<span></span>
</td>
<td class="nump">752,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning balance (in USD per share)</a></td>
<td class="nump">$ 13.54<span></span>
</td>
<td class="nump">$ 12.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">8.73<span></span>
</td>
<td class="nump">14.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">5.67<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in USD per share)</a></td>
<td class="nump">10.79<span></span>
</td>
<td class="nump">13.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending balance (in USD per share)</a></td>
<td class="nump">11.33<span></span>
</td>
<td class="nump">13.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest, Weighted-Average Exercise Price (usd per share)</a></td>
<td class="nump">11.33<span></span>
</td>
<td class="nump">13.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, Weighted-Average Exercise Price (usd per share)</a></td>
<td class="nump">$ 13.33<span></span>
</td>
<td class="nump">$ 13.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted-average remaining contractual term (in years)</a></td>
<td class="text">8 years 4 months 6 days<span></span>
</td>
<td class="text">8 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest , weighted-average remaining contractual term (in years)</a></td>
<td class="text">8 years 4 months 6 days<span></span>
</td>
<td class="text">8 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted-average remaining contractual term (in years)</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 302,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest , aggregate intrinsic value</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">302,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 79,431<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003457530096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">0.93%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">97.80%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003457594800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 7,929<span></span>
</td>
<td class="nump">$ 5,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=imux_EmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,929<span></span>
</td>
<td class="nump">5,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=imux_EmployeeMember', window );">Employee | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,219<span></span>
</td>
<td class="nump">1,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=imux_EmployeeMember', window );">Employee | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 4,710<span></span>
</td>
<td class="nump">$ 4,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=imux_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=imux_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003458817104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before income tax</a></td>
<td class="num">$ (120,408)<span></span>
</td>
<td class="num">$ (92,945)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before income tax</a></td>
<td class="num">(47,049)<span></span>
</td>
<td class="num">(11,222)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before income tax</a></td>
<td class="num">(67,448)<span></span>
</td>
<td class="num">(78,869)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before income tax</a></td>
<td class="num">$ (5,911)<span></span>
</td>
<td class="num">$ (2,854)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_FederalMinistryOfFinanceGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_FederalMinistryOfFinanceGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=imux_ForeignExcludingGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=imux_ForeignExcludingGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003457532528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock options</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax effect of rate change</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Goodwill impairment</a></td>
<td class="num">(5.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(15.70%)<span></span>
</td>
<td class="num">(22.90%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003451191264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase</a></td>
<td class="nump">14,200,000<span></span>
</td>
<td class="nump">22,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Uncertain tax positions that would impact effective tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">190,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Prior to 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Post 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 78,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=imux_TaxYearsPriorTo2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=imux_TaxYearsPriorTo2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=imux_TaxYearsPost2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=imux_TaxYearsPost2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003451305568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 19,830<span></span>
</td>
<td class="nump">$ 18,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">742<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible Assets</a></td>
<td class="nump">2,923<span></span>
</td>
<td class="nump">3,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign net operating loss carryforwards</a></td>
<td class="nump">47,179<span></span>
</td>
<td class="nump">34,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses', window );">Unrealized gain or loss</a></td>
<td class="nump">1,686<span></span>
</td>
<td class="nump">1,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">693<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">73,053<span></span>
</td>
<td class="nump">58,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_DeferredTaxAssetsAndLiabilitiesGross', window );">Net deferred tax assets</a></td>
<td class="nump">73,053<span></span>
</td>
<td class="nump">58,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(73,053)<span></span>
</td>
<td class="num">(58,817)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets, valuation allowance total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_DeferredTaxAssetsAndLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets and Liabilities, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_DeferredTaxAssetsAndLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140003458848784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - Duane Nash, MD, JD, MBA - Board of Directors Chairman - Executive Chairman Agreement - Affiliated Entity - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 15, 2022</div></th>
<th class="th"><div>Apr. 15, 2021</div></th>
<th class="th"><div>Nov. 15, 2020</div></th>
<th class="th"><div>May 14, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_SalaryCostsMonthlyBaseSalary', window );">Monthly base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,417<span></span>
</td>
<td class="nump">$ 27,960<span></span>
</td>
<td class="nump">$ 29,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=imux_DuaneNashMDJDMBAMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_imux_SalaryCostsMonthlyBaseSalary', window );">Monthly base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_SalaryCostsMonthlyBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salary Costs, Monthly Base Salary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_SalaryCostsMonthlyBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=imux_DuaneNashMDJDMBAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=imux_DuaneNashMDJDMBAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=imux_ExecutiveChairmanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=imux_ExecutiveChairmanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>imux-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:imux="http://imux.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="imux-20221231.xsd" xlink:type="simple"/>
    <context id="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i43e0b65cbd3346aeb1f08c2809f43307_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i019b6a9949464c96b393742d493e84c2_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b28bf41d41a44729bb53cadae860beb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic389dfc27c9a4f599aa3e1e541429096_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibbaa6c3142f843bd9914319d7c76fd83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01764048ea4440fdbba38575095ead15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4273fe852996496a9bf00e5bd9ca421e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife1cbb9302f3417394aee800539a7c78_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7134d7b7af464feaa82036ca57d1ca9c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8350e86a9cac4049bf5f8412ebbbc922_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia88c39fd3b36467dbf626e7ce52cd7df_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i42cae9630d124c15823d3c9c381fc07a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2021PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5184b8a176204d52b8ec471db493c60c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2021PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2df795cc621b4f6e870a724ef84c27b1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2021PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i398768618fec47a5abec4be325449aae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0638ec649d204c94997a5155ac425b91_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00de82f73e494662bbcb2347d6aa2a68_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52b16c5e8d554ecfb4804e40b1137a63_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i69622c2fdecf4530a84d6ff11b19e1a6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:A4SCRoyaltySettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4ef0cd612dd459b89f27fa032430ea8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:A4SCRoyaltySettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b01402daaa6442ea66a3fe6b2b2dae4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:A4SCRoyaltySettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c967dfd128445f9a1b3ec335c1bb34f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i821d3d85d32247aba8a2d73345eaafda_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie05ff69c61e740ba9e894b118d4ead6c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6af8e102c5642eb926a526cbf7478d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38ccd4cb28be412ab9d49ec84d752b6a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1316860810fd4869b98945ba64d7b8a9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idc4516e5f23b4243bab5c3a7ad76b8b0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i629c982d47b84bd39b19868854e07c81_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:October2022PIPETransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5338bc359fb346e48caffc7500eefca1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:October2022PIPETransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib1fd6056fc8f469aa10b7e33b55ac2f5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:October2022PIPETransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if4645613f6b04714ad4c10813a979031_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i56f6368984944c099b13638b641e4e99_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8049d7b76a47447681fe40c4a72397ed_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i74203948938643e89bafdad4538d7216_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0b9266faad484741a6ceae1bdc3f0eb6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5e8bb23d203841bfa3a428096aca8874_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4f1f7503d0874f6ab90216689469562d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i10e76b47a8364dbb8b7aa258206cfd04_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic79be0a87a2d43ae992ef8e7625d53e2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6ceb990338fd46f69ef655c24c8d15d0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i90a687fe86e640878d4f8d1ab66c683b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:October2022PIPETransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1d3cdfb91b17451989132881fd694dac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2021PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i40702a7fad274b3590022abc86d2a149_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3028499b4524a48a11940db473e95c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic9487ab845434e10aca875ca321f6e67_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id15e6eed9a474921925790496d9be215_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6f6dda26ad1f41d48bc084b4d8b166fd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:AustraliaAndGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i24f459a16c08494da1b7e65020dc4fa7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:AustraliaAndGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i29c8be7c0e67485390b3fa4ca6373ec9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c7189562e3a451ea2101622fe50411a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02a6493060a2472cb585f29aefea30e5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i576a1a2a1e6f40819d31ad6cc0c9d135_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if4ebe77f21364c02a3042c9e9e034e31_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i824c6b2c61e244609c3ec75bfe251d84_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie62fec553f0c4425b46293481930bbc7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iff9b0c581c08407a9041a6bb9632fa7e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4bc235beae3e46b392aa9ef77f9e52a6_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6ea7cf83aad5416b96424f40bc7375a9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie1949ba12c82474aad6afbbd5c131134_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia76019b0488442de98cccc646c64f255_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i296998374f2942bf8199382e045c0c53_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i42582e672b9a458a8f771feaaf27fdb0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i49102a4b3a124b109aaa078cfdd43203_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ddd5b53cb394a72b342f64f7724bee5_I20200407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:GrafelfingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-07</instant>
        </period>
    </context>
    <context id="i4d811dce20e94755bbed81698a836062_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icc3845c2b8324eb192b6c5463738b9a4_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:GrafelfingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i790f3d1e376c426a93f31d939f0cc7d9_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:GrafelfingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i24562792a7ba48619d879bb127f6e25a_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib7723388552347f4a59e2d9f09a39771_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">imux:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1220fdabe2ee4fb28d42b5efca4ed2e5_D20160501-20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="id6d27db753c54b8eaeaf90c7573257b1_I20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2019-04-12</instant>
        </period>
    </context>
    <context id="i6672b35cda564e6499bcb6f461f08725_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia12960a663974117bd81295909c9cc3a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i42c64b30b3db47e08679854bf2c78b08_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff060470870f4782ab057c9bc17e5799_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief2a67c94b5d4e07875b949f040c609f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e11d04f3b714f7aa69b06869cf2dd60_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4387fb9fcb644cbfa9f299c3c426b334_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3c272f1e1b9c4a5ab2d79ed4552a88ca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8682b8fb49274d31915223706871afca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ice854542a5dd4a53ba69994da59a8099_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e7a9a04d1f5475985dad2756a363f66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b15df3b298345d2a6a8dd573021c03b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45b06aedd33f4a19969cd8bcfc7ae2ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92ef303dbac04f97b77afccd76a0ee69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d7c512c8dad49688494a40ed9a84a26_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia45eb959635c4618a8e96c1da9b0ea55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6499a7329114832bcca11b186e9322c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e590388cdee4815b9794125e1f4fc52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89236a268ded4c38beb10ce49d29d398_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i1903fef7aaee4f7aaa653511f97e3f03_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="i43a90b71f4874951ab64ba8e4d321ed5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i441cf983bb6b42c1bfc3a145240c4326_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i67bc3dd545e748af9503605c6cf6ad15_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="ia92a9ae619944848ae66ab4dd8a63242_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i21732f0264304e5fb28318d6dc2b7ecb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i936d8c3c556941e4a8c00636316ee92c_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="i7649036809b74b5683c233704941dc74_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i20ece55753144123bea427d4b5da5edd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88aea673e8c04440a92d7eb913623ddd_D20221010-20221010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="ib94fad9370444fab84415ff498015dc8_I20221010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="ida3ab5946fc24e23800223feb5a9d8ab_D20221010-20221010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="if8c0142cb42641dcb4f087976d7a8e60_I20221010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="i444f4698aac042ccbe20eda2d1da8d8b_D20221012-20221012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-10-12</startDate>
            <endDate>2022-10-12</endDate>
        </period>
    </context>
    <context id="i2eac70ade3724a7c9d3a5db3107626ea_D20210715-20210715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2021PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-15</startDate>
            <endDate>2021-07-15</endDate>
        </period>
    </context>
    <context id="ifce58657f57045a8a9d5fdddad892a48_I20210715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2021PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-15</instant>
        </period>
    </context>
    <context id="i9f1ba5cf7cba4f8c9251c46ff206c135_D20210719-20210719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2021PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-19</startDate>
            <endDate>2021-07-19</endDate>
        </period>
    </context>
    <context id="i1faf1225c920491e8209c19e9f4b2f1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a320bf359b749c7a617f5394f9b3c83_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7a7cbfffc237456380acaaec206786ea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i11965a3f2e9c4db38fbab16426b46799_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i857f39ef5fe54694b80c6fbe030a98d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib4677eaef5e04113aaa9e6c7d5aa9c4f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9caf2243577b40c7b672a10e37d9512e_D20210425-20210425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-25</startDate>
            <endDate>2021-04-25</endDate>
        </period>
    </context>
    <context id="i35242908a173404d86425605eca4a779_I20210425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-25</instant>
        </period>
    </context>
    <context id="i8554c441f8d04f83811d7362580665a3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i392c13496de949c3bd9f8fba9ec64518_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00d5cdeb5b7e43c1b31aa26556827c45_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i5cb3045344074d578abb47cff790ebe3_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i175d1c7c30d04a678f2f280df3ebfdc5_D20200101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia137d2b6cec944f3a9a6132548a13e6e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7b246b23033045b2b45563237e60fb03_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4c6904d8a9104fa49767d8541244097e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib6a978fed247440098141566fbf4052d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0414aabe31c45cfb03ec35d6944f613_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i46791b70b39149f995d04e9d61847f37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7338620b6330458489fcef670be67b56_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5621a4c9af0345529c9a631b26c01878_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id677ffe69ecb43f09a9efd781f682fd3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3da78567fb1749fca30fc791bedfd050_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i427aa8bde64a40738335743ec62dbe35_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia250755510204b7fb17b62e711d72da6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ida3606afb67f4fd6b20f8cb83d82b570_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f8826a093524faab9e1c7138d3c7734_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i16b6edf94a0a462ab55397b394789287_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1f9bdb96b5174dbb8d3bd65a0524bed5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ca30a45a6194bfe96a0c64a563c77ba_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="ib771df66db154a9d836d085b5ebc58d3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifabfaf9983d146db9bfff97adf3e07b1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i484c36bf82584e408934987b8269bc9a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i348724b28ae74d24885e46926e9b5cf1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6cac2d95041a44d49c19e83ff8a94426_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:FederalMinistryOfFinanceGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie3329f0d0a5a47fd8a67187745e514d4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:FederalMinistryOfFinanceGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i717b3c5bcd7648beb9aad1d139fdc6dc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">imux:ForeignExcludingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie6278909cd154de6bd0d29a81c57b4ec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">imux:ForeignExcludingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52447e4dbf09445884a309828fb3a7f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibbbf0f771acf458ab6e0e6253ecd4de4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">imux:TaxYearsPriorTo2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c0bbccc8e094072b09a4b7d1aafb3c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">imux:TaxYearsPost2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id31cbe772be540f6ae60d3269ef43568_D20210101-20210514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imux:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-05-14</endDate>
        </period>
    </context>
    <context id="ic97bdf6441d44e2b83eaf02fe42ee442_D20201115-20201115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imux:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-15</startDate>
            <endDate>2020-11-15</endDate>
        </period>
    </context>
    <context id="i4965c60a3c264702a9ac179a8a4a899a_D20210415-20210415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imux:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-15</startDate>
            <endDate>2021-04-15</endDate>
        </period>
    </context>
    <context id="i55271ce968e14d408bd351945f042b13_D20210515-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imux:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-15</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id672e13b1b3b42b79a062e019e44f37d_D20220315-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imux:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-15</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa6db4839145429ebadca83963b31d82_D20220315-20220315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imux:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-15</startDate>
            <endDate>2022-03-15</endDate>
        </period>
    </context>
    <context id="i268e6ad4baa74fa6836147f78ab7c782_D20221228-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imux:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>imux:employee</measure>
    </unit>
    <unit id="lease">
        <measure>imux:lease</measure>
    </unit>
    <unit id="financialinstitution">
        <measure>imux:financialInstitution</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV80L2ZyYWc6YTNmMTc3NzAxOTAzNDY1MmIwNzA1MzBlYmFlNjlhMjIvdGFibGU6MmI0MGI2Yzc5ZWEyNDJjNDllNjhhODBhYzRhMWYyYWUvdGFibGVyYW5nZToyYjQwYjZjNzllYTI0MmM0OWU2OGE4MGFjNGExZjJhZV8zLTEtMS0xLTM0ODYy_07b077b7-df8a-4b86-9009-8b6452acd3f7">0001280776</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV80L2ZyYWc6YTNmMTc3NzAxOTAzNDY1MmIwNzA1MzBlYmFlNjlhMjIvdGFibGU6MmI0MGI2Yzc5ZWEyNDJjNDllNjhhODBhYzRhMWYyYWUvdGFibGVyYW5nZToyYjQwYjZjNzllYTI0MmM0OWU2OGE4MGFjNGExZjJhZV80LTEtMS0xLTM0ODYy_3763920b-e939-4feb-87fb-e1456672f420">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV80L2ZyYWc6YTNmMTc3NzAxOTAzNDY1MmIwNzA1MzBlYmFlNjlhMjIvdGFibGU6MmI0MGI2Yzc5ZWEyNDJjNDllNjhhODBhYzRhMWYyYWUvdGFibGVyYW5nZToyYjQwYjZjNzllYTI0MmM0OWU2OGE4MGFjNGExZjJhZV81LTEtMS0xLTM0ODYy_e5d2f21b-7cbe-440a-ab46-a67bc6bb1827">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV80L2ZyYWc6YTNmMTc3NzAxOTAzNDY1MmIwNzA1MzBlYmFlNjlhMjIvdGFibGU6MmI0MGI2Yzc5ZWEyNDJjNDllNjhhODBhYzRhMWYyYWUvdGFibGVyYW5nZToyYjQwYjZjNzllYTI0MmM0OWU2OGE4MGFjNGExZjJhZV82LTEtMS0xLTM0ODYy_c179667f-d064-4488-8e29-45162724f5a4">false</dei:AmendmentFlag>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3221b224-b06b-4599-934b-4790913ca766">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3cdcee94-7c82-4bf3-999e-30ecd1c05a92">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_4a1a30a6-155d-4e96-9d47-e78ee944ec76">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_58a0a228-b7d2-495a-8002-5c76ada4c7a6">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4c6904d8a9104fa49767d8541244097e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzkwMzI_3b155f68-f249-4b5a-829c-f22ff2797b9c">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDcx_408871f3-e5a5-4554-90eb-f0f76a4fc928">10-K</dei:DocumentType>
    <dei:DocumentType
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDgz_f27ba1fd-3069-4340-b60c-72dfbb3cf374">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6NjYxZjJhZGM4OGM1NDUyOGJjMTZmZmRhMGQ2YjMwNzUvdGFibGVyYW5nZTo2NjFmMmFkYzg4YzU0NTI4YmMxNmZmZGEwZDZiMzA3NV8wLTAtMS0xLTM0ODYy_c951417e-c4df-40b4-9c90-d1e43ac46266">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8xMjg_71ca21a6-ec87-4a40-b0a5-ed20faca74ec">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8xMjg_4dbc0414-9558-4f6f-8385-9f2ba62cb930">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6OTlhYjIyOTc5ZTUzNGRiZGI3ZGQ3ZWQ0NGRkOTJmMmIvdGFibGVyYW5nZTo5OWFiMjI5NzllNTM0ZGJkYjdkZDdlZDQ0ZGQ5MmYyYl8wLTAtMS0xLTM0ODYy_7bf02ca8-ef6a-4dab-afb4-4ba6309780b2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDg0_448d5727-3ced-407e-870d-81589c135696">001-36201</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDc3_3eb6a804-c113-4757-be0b-5863d5170206">Immunic, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6N2Y0ZDk4ODYxMzA0NDcyOWJmMzdhMzAwYThlYmVkMzkvdGFibGVyYW5nZTo3ZjRkOTg4NjEzMDQ0NzI5YmYzN2EzMDBhOGViZWQzOV8wLTAtMS0xLTM0ODYy_9d00c138-4d3f-430a-a14a-8be3da00102e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6N2Y0ZDk4ODYxMzA0NDcyOWJmMzdhMzAwYThlYmVkMzkvdGFibGVyYW5nZTo3ZjRkOTg4NjEzMDQ0NzI5YmYzN2EzMDBhOGViZWQzOV8wLTItMS0xLTM0ODYy_bbac2f1e-7268-4577-ae00-2d8d9461e009">56-2358443</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6N2Y0ZDk4ODYxMzA0NDcyOWJmMzdhMzAwYThlYmVkMzkvdGFibGVyYW5nZTo3ZjRkOTg4NjEzMDQ0NzI5YmYzN2EzMDBhOGViZWQzOV8yLTAtMS0xLTM0ODYy_961a1dc0-a234-41d6-a5aa-359cd2ae957f">1200 Avenue of the Americas,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6N2Y0ZDk4ODYxMzA0NDcyOWJmMzdhMzAwYThlYmVkMzkvdGFibGVyYW5nZTo3ZjRkOTg4NjEzMDQ0NzI5YmYzN2EzMDBhOGViZWQzOV8yLTEtMS0xLTM0ODYy_e94e93a5-de9d-4b20-a41a-a98060777584">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6N2Y0ZDk4ODYxMzA0NDcyOWJmMzdhMzAwYThlYmVkMzkvdGFibGVyYW5nZTo3ZjRkOTg4NjEzMDQ0NzI5YmYzN2EzMDBhOGViZWQzOV8zLTAtMS0xLTM0ODYy_92d76f31-38b3-4c78-8715-1ed5c50426f6">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6N2Y0ZDk4ODYxMzA0NDcyOWJmMzdhMzAwYThlYmVkMzkvdGFibGVyYW5nZTo3ZjRkOTg4NjEzMDQ0NzI5YmYzN2EzMDBhOGViZWQzOV8zLTEtMS0xLTM0ODYy_d69ef3fc-bf71-4d38-b2bc-e8bc4ba14327">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6N2Y0ZDk4ODYxMzA0NDcyOWJmMzdhMzAwYThlYmVkMzkvdGFibGVyYW5nZTo3ZjRkOTg4NjEzMDQ0NzI5YmYzN2EzMDBhOGViZWQzOV8zLTItMS0xLTM0ODYy_27fce440-538f-4beb-95fd-613d412fc7cc">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDg1_148a2425-bded-4c07-90a8-45c72af787c5">332</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDc0_ef18292f-fa33-4e7e-9445-e848f2b92209">255-9818</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6ZTVhZDhlZmNlYzMxNDRlYzg3OWRmYmFhYjNmODcyNmQvdGFibGVyYW5nZTplNWFkOGVmY2VjMzE0NGVjODc5ZGZiYWFiM2Y4NzI2ZF8xLTAtMS0xLTM0ODYy_09409769-e853-420e-a66c-5161b557d430">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6ZTVhZDhlZmNlYzMxNDRlYzg3OWRmYmFhYjNmODcyNmQvdGFibGVyYW5nZTplNWFkOGVmY2VjMzE0NGVjODc5ZGZiYWFiM2Y4NzI2ZF8xLTEtMS0xLTM0ODYy_7e1c1144-451c-4695-b90a-b5647038059e">IMUX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6ZTVhZDhlZmNlYzMxNDRlYzg3OWRmYmFhYjNmODcyNmQvdGFibGVyYW5nZTplNWFkOGVmY2VjMzE0NGVjODc5ZGZiYWFiM2Y4NzI2ZF8xLTItMS0xLTM0ODYy_1a882214-d563-4044-91f3-bfe3dd1d14a9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDY5_3fbb81b2-873b-49cb-8c70-2470757f2c01">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDgw_b977f05b-a364-4f8b-a878-925bcc8dede0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8xMTI0_1cdb4f6b-22d6-4dee-b4cf-e93835e768b4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8xNDYx_28a2e28e-4820-415c-b27c-c49389d71839">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6YTNiYzUyYmI5ZGFkNGFjMmJhNDY0MTIyZmQxMTMzMTIvdGFibGVyYW5nZTphM2JjNTJiYjlkYWQ0YWMyYmE0NjQxMjJmZDExMzMxMl8xLTAtMS0xLTM0ODYy_c0916ebe-1c17-4677-9946-2ba973e2b8ab">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6YTNiYzUyYmI5ZGFkNGFjMmJhNDY0MTIyZmQxMTMzMTIvdGFibGVyYW5nZTphM2JjNTJiYjlkYWQ0YWMyYmE0NjQxMjJmZDExMzMxMl8xLTMtMS0xLTM0ODYy_8528df3f-87b1-4b0c-80b4-8c417a8a60dc">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGFibGU6YTNiYzUyYmI5ZGFkNGFjMmJhNDY0MTIyZmQxMTMzMTIvdGFibGVyYW5nZTphM2JjNTJiYjlkYWQ0YWMyYmE0NjQxMjJmZDExMzMxMl8yLTMtMS0xLTM0ODYy_308c387f-d168-4a66-ab4b-38da5bc5a2eb">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDgx_064adf8a-1855-4ef2-9f55-2c48f83ec058">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDgy_3fedc438-5543-4188-95d7-11715c2b855a">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i43e0b65cbd3346aeb1f08c2809f43307_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8yNzIy_e0149111-15a6-4e96-ad8c-52b65eeb297a"
      unitRef="usd">106100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i019b6a9949464c96b393742d493e84c2_I20230217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8yNzQ4_d73f7bf8-7e43-4935-ad84-06722e659f65"
      unitRef="shares">44403838</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xL2ZyYWc6ODAxY2ZkMzhlYmMxNDc5Njk5OTQyOGJjZWYzOTIzNDgvdGV4dHJlZ2lvbjo4MDFjZmQzOGViYzE0Nzk2OTk5NDI4YmNlZjM5MjM0OF8zMDcw_0476b4bf-6ca7-41df-8ef3-eb63086146c3">Certain portions of the registrant&#x2019;s definitive Proxy Statement for its 2023 Annual Meeting of Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMDkvZnJhZzozNmMyYTEzYWEyZWE0NjJjYjYxYTA4MWY5ZmExYjBiMy90YWJsZTpkOTVhMzMyYmU0Njg0MGVmYjliNzc3Y2ZkODU1MGM4Mi90YWJsZXJhbmdlOmQ5NWEzMzJiZTQ2ODQwZWZiOWI3NzdjZmQ4NTUwYzgyXzEtMC0xLTEtMzQ4NjIvdGV4dHJlZ2lvbjo2ZmM2ODEwZTQ0YWM0Mzk1OGU4MzVlMjRhMjRkNjU4Ml85Mg_d284138a-d48f-4802-8aa1-efe131550eb2">23</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTIvZnJhZzpjM2M3NDg4ZmM2M2M0NjBlOTlmM2JiNTM1NjgwMzE3My90ZXh0cmVnaW9uOmMzYzc0ODhmYzYzYzQ2MGU5OWYzYmI1MzU2ODAzMTczXzIxOTkwMjMyODk0ODY_d672eecb-e84d-4750-8744-8fd70ab4da74">Baker Tilly US, LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTIvZnJhZzpjM2M3NDg4ZmM2M2M0NjBlOTlmM2JiNTM1NjgwMzE3My90ZXh0cmVnaW9uOmMzYzc0ODhmYzYzYzQ2MGU5OWYzYmI1MzU2ODAzMTczXzIxOTkwMjMyODk0ODc_df4bfa6c-27e0-4d3e-b1b4-b0f9350c710b">Minneapolis, MN</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzQtMS0xLTEtMzQ4NjI_f20af40b-6957-4ebc-99c6-51cb197659db"
      unitRef="usd">106745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzQtMy0xLTEtMzQ4NjI_2608f7aa-dbae-4e9c-8abd-19baf5969da1"
      unitRef="usd">86863000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzUtMS0xLTEtMzk4NDc_1906042b-7c31-42b3-bb1a-d973fd4caf38"
      unitRef="usd">9629000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzUtMy0xLTEtMzk4NDc_4ce0f728-321d-437d-83b7-1990a64b9db3"
      unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzUtMS0xLTEtMzQ4NjI_5032852d-74d8-4747-b507-d43bc1162337"
      unitRef="usd">9490000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzUtMy0xLTEtMzQ4NjI_c33d9ada-250d-4427-9404-8ddbc7537f07"
      unitRef="usd">18125000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzYtMS0xLTEtMzQ4NjI_10acf1de-7de8-430e-ab09-deb232e1c646"
      unitRef="usd">125864000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzYtMy0xLTEtMzQ4NjI_433b02f7-3039-466a-8ec8-5da649e47326"
      unitRef="usd">104988000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzctMS0xLTEtMzQ4NjI_2c5bb9a7-b248-4299-8af8-4e68825d0136"
      unitRef="usd">294000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzctMy0xLTEtMzQ4NjI_e96b174c-c795-4d8a-999d-ba0f3bd1c87c"
      unitRef="usd">152000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzgtMS0xLTEtMzQ4NjI_b092a53b-26a8-422f-9447-bb75d7bf4fb2"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzgtMy0xLTEtMzQ4NjI_8d71f11f-eee6-4604-ad01-885a8ba88dd5"
      unitRef="usd">32970000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzktMS0xLTEtMzQ4NjI_5a96f241-b913-4c4a-ad84-41b80d2ad541"
      unitRef="usd">1552000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzktMy0xLTEtMzQ4NjI_2ec1dd89-f3d4-4b24-8930-5fa1116ad0c9"
      unitRef="usd">948000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzEwLTEtMS0xLTM0ODYy_f5bc927b-0ce5-498c-a99f-fd29dec7cb38"
      unitRef="usd">43000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzEwLTMtMS0xLTM0ODYy_9acccd27-5a10-4082-87f9-3342b15dcdc9"
      unitRef="usd">42000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzExLTEtMS0xLTM0ODYy_06e12a72-f302-48dd-be4b-a897f083beb3"
      unitRef="usd">127753000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzExLTMtMS0xLTM0ODYy_fbd631ee-f8ef-4933-a964-70fe3594c5f2"
      unitRef="usd">139100000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE0LTEtMS0xLTM0ODYy_f87c36c7-a048-496b-85ae-950892b7ed9b"
      unitRef="usd">4281000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE0LTMtMS0xLTM0ODYy_d59fb7cf-31bb-4619-8365-ee88558bc061"
      unitRef="usd">3745000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE1LTEtMS0xLTM0ODYy_d9dd73fc-b525-49c1-9256-994a47628161"
      unitRef="usd">7986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE1LTMtMS0xLTM0ODYy_f6bd9514-9049-467f-ab8e-62cd7441bd10"
      unitRef="usd">7071000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE2LTEtMS0xLTM0ODYy_40f52c5e-50fa-4a85-b5ef-3758f46c80ba"
      unitRef="usd">810000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE2LTMtMS0xLTM0ODYy_7271ebb3-1bc2-4424-aacf-b6c1ab057fd8"
      unitRef="usd">585000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE3LTEtMS0xLTM0ODYy_7901b082-2ae0-488e-87c5-b59e04a3e76e"
      unitRef="usd">13077000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE3LTMtMS0xLTM0ODYy_c2bf9a79-755d-4c1b-8225-e7b63ab53aa6"
      unitRef="usd">11401000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE5LTEtMS0xLTM0ODYy_c8a61a27-3357-4f64-b180-b73db45d0002"
      unitRef="usd">992000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzE5LTMtMS0xLTM0ODYy_7bae81cc-d0fb-4a85-babb-17b072190ff6"
      unitRef="usd">584000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzIwLTEtMS0xLTM0ODYy_f86219c5-f70c-42c9-8382-fe33e44cb702"
      unitRef="usd">992000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzIwLTMtMS0xLTM0ODYy_401dda25-01af-477f-b320-a5f662d7bc3b"
      unitRef="usd">584000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzIxLTEtMS0xLTM0ODYy_35e9f2d6-7218-4b1d-a70a-5a4c013c5503"
      unitRef="usd">14069000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzIxLTMtMS0xLTM0ODYy_4ffc4d3d-157d-46b9-a860-1c140c072918"
      unitRef="usd">11985000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzIyLTEtMS0xLTM0ODYy_b4799c07-3aa9-4c87-b317-6976938fce49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzIyLTMtMS0xLTM0ODYy_da71cc73-21ac-416c-842b-9f3fd222360c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzkxMA_6ed7eb7e-0bd5-48dd-a5ee-36d02f38234b"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzkxMA_e15ef16c-a56f-4442-ac0c-0769a16076c2"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzkzOQ_0fe29f1c-51ce-43fc-bd0b-abbd5a476513"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzkzOQ_91a6c8d4-101e-4b8c-8578-d2566825e153"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzk0NA_15131a19-0ba4-413f-a4ac-d5a69ae5cdf4"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzk0NA_79690e61-f4b0-4cff-ba30-e875e90571d7"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzk0NA_79cde244-5aa4-4d3a-ae01-85089ba5a9e3"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTAtMS0xLTM0ODYyL3RleHRyZWdpb246MjgxZDFlMmM1YThhNGQyM2EzOTg1MGE5NzRiNDBhYThfMTA5OTUxMTYyNzk0NA_92854a1e-fba0-4d48-a6d8-a23f9546ddae"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTEtMS0xLTM0ODYy_cfd40eff-c974-4923-8c4b-18af173a683f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI0LTMtMS0xLTM0ODYy_89df00a2-e35f-45d6-89bb-f9256a12175c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk1Mw_3c03cd9a-8090-4927-9bb2-370bb6582519"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk1Mw_3e812123-ebed-40fc-ba00-19624f46ed29"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk2Nw_17c8303a-56d3-47ac-906b-0cd43156b3c3"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk2Nw_dd761b58-88e2-4731-9bf8-d0a009d770e9"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk4MA_6e7dc3d5-6f08-407c-9c22-af9826ef559f"
      unitRef="shares">39307286</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk4MA_fd81ed9a-3452-4ed3-9968-56a4e06c9077"
      unitRef="shares">39307286</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk5Mw_a829b461-1ca6-4d3d-8c53-5a7041023fbf"
      unitRef="shares">26335418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTAtMS0xLTM0ODYyL3RleHRyZWdpb246NjkzZDA1MjkxYjUxNDM3NWI0OWFhYWVhOTExMTQ1ZDZfMTA5OTUxMTYyNzk5Mw_ab2800ff-3eea-440e-a4f2-fc0b4f68feff"
      unitRef="shares">26335418</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTEtMS0xLTM0ODYy_0052f6fb-f565-42db-bd09-8d41cc14e5f7"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI1LTMtMS0xLTM0ODYy_237e3a08-cef4-4524-8277-28ceb9636e03"
      unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI2LTEtMS0xLTM0ODYy_4c05eacf-6cff-403c-a7ad-729cf0c4a003"
      unitRef="usd">427925000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI2LTMtMS0xLTM0ODYy_d3826cbc-7af3-4a64-9192-cbc6c8c09bb3"
      unitRef="usd">324237000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI3LTEtMS0xLTM0ODYy_e21c4649-c799-4246-87b4-a3259c6fe9af"
      unitRef="usd">3035000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI3LTMtMS0xLTM0ODYy_afe705f5-6822-4589-aee0-b7bdafd6ee63"
      unitRef="usd">-252000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI4LTEtMS0xLTM0ODYy_30150d12-8f6d-40e7-885d-f039b77627f5"
      unitRef="usd">-317280000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI4LTMtMS0xLTM0ODYy_1dec4227-17aa-4d94-a6a3-8c3380fafaaa"
      unitRef="usd">-196873000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI5LTEtMS0xLTM0ODYy_fe02e00a-9b5d-4cdf-a12b-ee15a8da4026"
      unitRef="usd">113684000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzI5LTMtMS0xLTM0ODYy_eadd4fc8-aaa0-4b9f-b29a-9c76fb66ce99"
      unitRef="usd">127115000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzMwLTEtMS0xLTM0ODYy_6f4b5a1a-6e5d-4458-9779-6a4b56215c17"
      unitRef="usd">127753000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTUvZnJhZzoyN2M5M2U5N2U1NTY0M2JmYWVlOGQ2YWNhYzlmM2RjNC90YWJsZTphZmVjZjQ4NDJkZGE0MGU3OWY1ZThkNzhmZTMyYjQ1MS90YWJsZXJhbmdlOmFmZWNmNDg0MmRkYTQwZTc5ZjVlOGQ3OGZlMzJiNDUxXzMwLTMtMS0xLTM0ODYy_ad5ff95e-8b01-40f7-bc46-1f661ea43312"
      unitRef="usd">139100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzMtMS0xLTEtMzQ4NjI_1e0f06ea-e743-4845-ad27-b06a79547ed6"
      unitRef="usd">71255000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzMtMy0xLTEtMzQ4NjI_5961905f-a816-4cbc-8d53-30d9e85c2396"
      unitRef="usd">61115000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzQtMS0xLTEtMzQ4NjI_0a3a133c-7a67-488f-82da-13b18240e74f"
      unitRef="usd">15263000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzQtMy0xLTEtMzQ4NjI_399ef72b-789b-4cf8-9009-24867262f997"
      unitRef="usd">13300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzUtMS0xLTEtMzU4MTM_f935fbac-520b-40b5-b511-95916593a926"
      unitRef="usd">32970000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzUtMy0xLTEtMzU4MDE_f70453c0-9c14-42d2-9fdc-8e2c9f0c7708"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <imux:RoyaltySettlementAgreementSalesNet
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzUtMS0xLTEtMzQ4NjI_cb41e649-ce91-4535-bbe8-7be05727c015"
      unitRef="usd">0</imux:RoyaltySettlementAgreementSalesNet>
    <imux:RoyaltySettlementAgreementSalesNet
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzUtMy0xLTEtMzQ4NjI_6b2a567b-46fd-41eb-a3c7-94c2b7932b1b"
      unitRef="usd">17250000</imux:RoyaltySettlementAgreementSalesNet>
    <us-gaap:OperatingExpenses
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzYtMS0xLTEtMzQ4NjI_4082e27b-c4c3-41dd-8b87-58cb88f339a3"
      unitRef="usd">119488000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzYtMy0xLTEtMzQ4NjI_856324b7-a606-44c3-9882-74f16a143503"
      unitRef="usd">91665000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzctMS0xLTEtMzQ4NjI_883a958d-27a9-4e9a-b922-a4cbac8d03c0"
      unitRef="usd">-119488000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzctMy0xLTEtMzQ4NjI_f994a485-3a6a-4d51-b585-8f41e5893dba"
      unitRef="usd">-91665000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzktMS0xLTEtMzQ4NjI_91cb7f87-969b-446a-bbd8-b0bc669d45d9"
      unitRef="usd">1041000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzktMy0xLTEtMzQ4NjI_b0d855c1-49f7-4437-82b0-1bf40356c858"
      unitRef="usd">66000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzEwLTEtMS0xLTM0ODYy_2ee21f21-3559-406c-8edd-6457c624c81e"
      unitRef="usd">-1960000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzEwLTMtMS0xLTM0ODYy_7f76a42b-ac9d-47ad-b2e6-f138626c59a7"
      unitRef="usd">-1346000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzExLTEtMS0xLTM0ODYy_22eee007-335b-47d1-ae20-bff44004d689"
      unitRef="usd">-919000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzExLTMtMS0xLTM0ODYy_1665f106-e806-42b7-bc9d-788652fef3f6"
      unitRef="usd">-1280000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzEyLTEtMS0xLTM0ODYy_ac4d9de2-d3d0-40f4-812b-f38ca7b1dee8"
      unitRef="usd">-120407000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzEyLTMtMS0xLTM0ODYy_48778cbd-fbc5-47fb-8f14-457f266cac86"
      unitRef="usd">-92945000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE0LTEtMS0xLTM0ODYy_2f4f1aee-c802-4bc1-9cc0-5dd8c7b34a8c"
      unitRef="usdPerShare">-3.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE0LTEtMS0xLTM0ODYy_d0cf27b9-fb20-49ac-bd05-4473101719ed"
      unitRef="usdPerShare">-3.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE0LTMtMS0xLTM0ODYy_021937de-fa38-4d42-b95a-9b928cb6cdbe"
      unitRef="usdPerShare">-3.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE0LTMtMS0xLTM0ODYy_51f76ba2-dd30-49a5-8f14-d18e74907ad8"
      unitRef="usdPerShare">-3.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE2LTEtMS0xLTM0ODYy_90dee67e-ba8f-4feb-b0e8-15a93d2b61bb"
      unitRef="shares">31819006</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE2LTEtMS0xLTM0ODYy_c6e00cfe-0540-436b-a42d-c095516692e4"
      unitRef="shares">31819006</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE2LTMtMS0xLTM0ODYy_a8664581-6361-44f6-92a7-abac24683fb7"
      unitRef="shares">23652779</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMTgvZnJhZzozYjZmZDc4NTc1Y2U0ZGVlYWY1NGI2MTYyNGNmMTE5Yy90YWJsZTphYWRlNDI0YTU4OWY0Y2Q5YjRmZWRmY2U5NzFkZDZhNy90YWJsZXJhbmdlOmFhZGU0MjRhNTg5ZjRjZDliNGZlZGZjZTk3MWRkNmE3XzE2LTMtMS0xLTM0ODYy_d47f3004-9e9c-4958-9fd1-2c2cf10ccd5c"
      unitRef="shares">23652779</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjEvZnJhZzo0M2RmOTVjNzc1OTE0NTk5YTA4YjIxMWRiZDBlZjkxMy90YWJsZTpiM2RlNDFiMzEzZjE0OTViOGM2MGI4ZTFiOTI3MjM2NC90YWJsZXJhbmdlOmIzZGU0MWIzMTNmMTQ5NWI4YzYwYjhlMWI5MjcyMzY0XzItMS0xLTEtMzQ4NjI_ac4d9de2-d3d0-40f4-812b-f38ca7b1dee8"
      unitRef="usd">-120407000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjEvZnJhZzo0M2RmOTVjNzc1OTE0NTk5YTA4YjIxMWRiZDBlZjkxMy90YWJsZTpiM2RlNDFiMzEzZjE0OTViOGM2MGI4ZTFiOTI3MjM2NC90YWJsZXJhbmdlOmIzZGU0MWIzMTNmMTQ5NWI4YzYwYjhlMWI5MjcyMzY0XzItMy0xLTEtMzQ4NjI_48778cbd-fbc5-47fb-8f14-457f266cac86"
      unitRef="usd">-92945000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjEvZnJhZzo0M2RmOTVjNzc1OTE0NTk5YTA4YjIxMWRiZDBlZjkxMy90YWJsZTpiM2RlNDFiMzEzZjE0OTViOGM2MGI4ZTFiOTI3MjM2NC90YWJsZXJhbmdlOmIzZGU0MWIzMTNmMTQ5NWI4YzYwYjhlMWI5MjcyMzY0XzQtMS0xLTEtMzQ4NjI_e6598bb2-1900-430e-b9b5-173d4bae9abc"
      unitRef="usd">3287000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjEvZnJhZzo0M2RmOTVjNzc1OTE0NTk5YTA4YjIxMWRiZDBlZjkxMy90YWJsZTpiM2RlNDFiMzEzZjE0OTViOGM2MGI4ZTFiOTI3MjM2NC90YWJsZXJhbmdlOmIzZGU0MWIzMTNmMTQ5NWI4YzYwYjhlMWI5MjcyMzY0XzQtMy0xLTEtMzQ4NjI_1f44807c-f397-4e40-ba26-aa5fc6c20415"
      unitRef="usd">3860000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjEvZnJhZzo0M2RmOTVjNzc1OTE0NTk5YTA4YjIxMWRiZDBlZjkxMy90YWJsZTpiM2RlNDFiMzEzZjE0OTViOGM2MGI4ZTFiOTI3MjM2NC90YWJsZXJhbmdlOmIzZGU0MWIzMTNmMTQ5NWI4YzYwYjhlMWI5MjcyMzY0XzUtMS0xLTEtMzQ4NjI_1d53a1ea-73d4-4d00-a207-b3c65fa38e9a"
      unitRef="usd">-117120000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjEvZnJhZzo0M2RmOTVjNzc1OTE0NTk5YTA4YjIxMWRiZDBlZjkxMy90YWJsZTpiM2RlNDFiMzEzZjE0OTViOGM2MGI4ZTFiOTI3MjM2NC90YWJsZXJhbmdlOmIzZGU0MWIzMTNmMTQ5NWI4YzYwYjhlMWI5MjcyMzY0XzUtMy0xLTEtMzQ4NjI_2825d99d-944d-4e41-a05e-a9a985aefd24"
      unitRef="usd">-89085000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic389dfc27c9a4f599aa3e1e541429096_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzYtMi0xLTEtMzQ4NjI_96302624-9523-4e4e-be06-85dfc0837399"
      unitRef="shares">21168240</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic389dfc27c9a4f599aa3e1e541429096_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzYtNC0xLTEtMzQ4NjI_071cac23-83d9-4edc-b3aa-a4aacd52eebb"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibbaa6c3142f843bd9914319d7c76fd83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzYtNi0xLTEtMzQ4NjI_49d0fd37-69e6-4d0f-b811-f45786cf8a97"
      unitRef="usd">266823000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01764048ea4440fdbba38575095ead15_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzYtOC0xLTEtMzQ4NjI_5b74286b-45aa-4389-af37-cc1fe5775aed"
      unitRef="usd">-4112000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4273fe852996496a9bf00e5bd9ca421e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzYtMTAtMS0xLTM0ODYy_4dd28454-82a4-4591-847e-24dfcffc28a7"
      unitRef="usd">-103928000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ife1cbb9302f3417394aee800539a7c78_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzYtMTItMS0xLTM0ODYy_b9b27120-2586-4106-b9f5-43d587157a8c"
      unitRef="usd">158785000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i7134d7b7af464feaa82036ca57d1ca9c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzctMTAtMS0xLTM0ODYy_18dc2fdf-5f5d-4c37-9d1e-18d4ecdea906"
      unitRef="usd">-92945000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzctMTItMS0xLTM0ODYy_697bbcbe-fe41-468e-888f-1ee91b03f59b"
      unitRef="usd">-92945000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8350e86a9cac4049bf5f8412ebbbc922_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzgtOC0xLTEtMzQ4NjI_f24766f8-80ad-48b9-af73-e8ee95c9c009"
      unitRef="usd">3860000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzgtMTItMS0xLTM0ODYy_73511656-da03-4c61-bab9-ccf1a5e796f3"
      unitRef="usd">3860000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia88c39fd3b36467dbf626e7ce52cd7df_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzktNi0xLTEtMzQ4NjI_cefcafeb-b775-4f29-aa03-5e23057570e2"
      unitRef="usd">5949000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzktMTItMS0xLTM0ODYy_7c18a615-90b2-43b7-816c-e79fc454551b"
      unitRef="usd">5949000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i42cae9630d124c15823d3c9c381fc07a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEwLTAtMS0xLTM0ODYyL3RleHRyZWdpb246ZjhhNWNlZTk4NGYzNDNmY2I5NDVmMTMyNjI4NzgyNWRfMTA5OTUxMTYyNzg3NA_1d4716a1-8324-44dd-a94e-716e3adaa3a5"
      unitRef="usd">2980000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5184b8a176204d52b8ec471db493c60c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEwLTItMS0xLTM0ODYy_b3e3e092-c22c-4cd0-95ab-1a80c40a8657"
      unitRef="shares">4500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5184b8a176204d52b8ec471db493c60c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEwLTQtMS0xLTM0ODYy_fe29e72a-b61e-4084-a2eb-c94946fa8d65"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2df795cc621b4f6e870a724ef84c27b1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEwLTYtMS0xLTM0ODYy_92f82994-c76a-44d2-9138-ffbee4975700"
      unitRef="usd">42019000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i42cae9630d124c15823d3c9c381fc07a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEwLTEyLTEtMS0zNDg2Mg_17415cbd-470c-4930-9a05-d2d5fd6e6de5"
      unitRef="usd">42020000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i398768618fec47a5abec4be325449aae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzExLTAtMS0xLTM0ODYyL3RleHRyZWdpb246OTYzN2E5MTNlOGRiNDEwNGE3YjEwOWE5MzE4NzVlNzVfMTA5OTUxMTYyNzg2OA_ff617414-dad5-4e41-95dc-edc0159608e3"
      unitRef="usd">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0638ec649d204c94997a5155ac425b91_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzExLTItMS0xLTM0ODYy_4ab08944-3fce-400f-9c80-9b516e245f2e"
      unitRef="shares">73221</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i00de82f73e494662bbcb2347d6aa2a68_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzExLTYtMS0xLTM0ODYy_614de334-0a83-440c-9281-183dbd7bc87c"
      unitRef="usd">729000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i398768618fec47a5abec4be325449aae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzExLTEyLTEtMS0zNDg2Mg_8760c53e-28b0-4e1a-a961-53566f61cdc8"
      unitRef="usd">729000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i52b16c5e8d554ecfb4804e40b1137a63_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEyLTItMS0xLTM0ODYy_12e42f0b-7041-4705-aed9-9ee8cd21be70"
      unitRef="shares">12758</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia88c39fd3b36467dbf626e7ce52cd7df_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEyLTYtMS0xLTM0ODYy_285b7163-95ab-4155-ad59-7bc96cc5625e"
      unitRef="usd">92000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEyLTEyLTEtMS0zNDg2Mg_a511ab4a-eb2d-49e3-9a7e-d50aa05eabde"
      unitRef="usd">92000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i69622c2fdecf4530a84d6ff11b19e1a6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEzLTItMS0xLTM0ODYy_c5576b1f-22ea-4a69-9964-8c6ce992250c"
      unitRef="shares">581199</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if4ef0cd612dd459b89f27fa032430ea8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEzLTYtMS0xLTM0ODYy_4c02e6b5-ed82-480e-a175-4d69c109fbb7"
      unitRef="usd">8625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7b01402daaa6442ea66a3fe6b2b2dae4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzEzLTEyLTEtMS0zNDg2Mg_9d0474eb-d1ae-400e-9a59-5348c6d42b50"
      unitRef="usd">8625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8c967dfd128445f9a1b3ec335c1bb34f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE0LTItMS0xLTM0ODYy_04e72a60-3ce0-496f-9fea-dd226c02fac8"
      unitRef="shares">26335418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8c967dfd128445f9a1b3ec335c1bb34f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE0LTQtMS0xLTM0ODYy_198c9b7e-3f28-4757-a583-b44d59b437b1"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i821d3d85d32247aba8a2d73345eaafda_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE0LTYtMS0xLTM0ODYy_5b6a152e-c6fe-41f9-bcd3-44bcb6512045"
      unitRef="usd">324237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie05ff69c61e740ba9e894b118d4ead6c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE0LTgtMS0xLTM0ODYy_b32ef51c-9181-4415-9936-531a9cf7ed12"
      unitRef="usd">-252000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib6af8e102c5642eb926a526cbf7478d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE0LTEwLTEtMS0zNDg2Mg_bef118d4-0f6c-4c00-8e99-32cf66b9465e"
      unitRef="usd">-196873000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE0LTEyLTEtMS0zNDg2Mg_f82cf975-9461-4e57-b8fb-3735b4e8cde8"
      unitRef="usd">127115000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i38ccd4cb28be412ab9d49ec84d752b6a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE1LTEwLTEtMS0zNDg2Mg_f918cbbf-c4e6-4a06-af7a-8c57e7977440"
      unitRef="usd">-120407000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE1LTEyLTEtMS0zNDg2Mg_7c45dc20-e99e-4ee9-a542-12cf3aee9c7e"
      unitRef="usd">-120407000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1316860810fd4869b98945ba64d7b8a9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE2LTgtMS0xLTM0ODYy_305e2c15-5fda-4673-ab67-082d208bfe6b"
      unitRef="usd">3287000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE2LTEyLTEtMS0zNDg2Mg_99033fec-db40-43d3-848a-bc0bf727c0aa"
      unitRef="usd">3287000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idc4516e5f23b4243bab5c3a7ad76b8b0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE3LTYtMS0xLTM0ODYy_4ed2d30b-0e23-4370-bdef-4ceb3c6d09b6"
      unitRef="usd">7929000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE3LTEyLTEtMS0zNDg2Mg_ab54a138-d125-4f5f-a9c7-9fbd1bdf23a0"
      unitRef="usd">7929000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i629c982d47b84bd39b19868854e07c81_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE4LTAtMS0xLTM0ODYyL3RleHRyZWdpb246YzUzZjY3NWViNWNhNGYxYzkzNGMwNGNmZTMwZGIwYmJfMTA5OTUxMTYyNzkwMA_ec2b8ac2-b300-4e64-800c-c61e0d75d25f"
      unitRef="usd">4012000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5338bc359fb346e48caffc7500eefca1_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE4LTItMS0xLTM0ODYy_5ac75e3f-6ab7-4790-aa26-44da4d007464"
      unitRef="shares">8696552</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5338bc359fb346e48caffc7500eefca1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE4LTQtMS0xLTM0ODYy_04ea2e2f-f1d7-4d73-8651-3c462f59080d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib1fd6056fc8f469aa10b7e33b55ac2f5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE4LTYtMS0xLTM0ODYy_cf45d566-be55-4a8f-b6c8-a88775842842"
      unitRef="usd">55988000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i629c982d47b84bd39b19868854e07c81_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE4LTEyLTEtMS0zNDg2Mg_a2148edf-fb28-423f-bf26-d27d38c87f7e"
      unitRef="usd">55989000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="if4645613f6b04714ad4c10813a979031_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE5LTAtMS0xLTM0ODYyL3RleHRyZWdpb246YzliZGIzZTNiMDc3NDBjNjg4ODFkYjU5MjIyZWI2YzFfMTA5OTUxMTYyNzg3NA_f95c6681-b575-4fcc-bc99-f3cd98963049"
      unitRef="usd">1226000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i56f6368984944c099b13638b641e4e99_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE5LTItMS0xLTM0ODYy_c6e86b45-2209-40c3-b31e-1e116bfa85c2"
      unitRef="shares">4204113</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8049d7b76a47447681fe40c4a72397ed_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE5LTYtMS0xLTM0ODYy_516443d7-0ee9-4926-8bc1-a075ad88b6f1"
      unitRef="usd">39584000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if4645613f6b04714ad4c10813a979031_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzE5LTEyLTEtMS0zNDg2Mg_d2c8f7ae-f303-4c46-a6b0-419fb1cf06b4"
      unitRef="usd">39584000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i74203948938643e89bafdad4538d7216_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIwLTItMS0xLTM0ODYy_19206d1c-140c-4bf1-8b53-c65e646f2b5e"
      unitRef="shares">70351</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="idc4516e5f23b4243bab5c3a7ad76b8b0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIwLTYtMS0xLTM0ODYy_d49eb509-c2f1-42df-9fe7-341d6f849313"
      unitRef="usd">182000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIwLTEyLTEtMS0zNDg2Mg_05d2ce2a-ec4b-4c33-9418-e05c7e307d93"
      unitRef="usd">182000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i74203948938643e89bafdad4538d7216_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIxLTItMS0xLTM0ODYy_05b0b7c5-fc25-4a51-b2e2-95dccd36ce32"
      unitRef="shares">852</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idc4516e5f23b4243bab5c3a7ad76b8b0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIxLTYtMS0xLTM0ODYy_21aeb5b6-07bb-45b9-9e37-4ab89aa7c9fd"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIxLTEyLTEtMS0zNDg2Mg_179a2c13-3c9f-40f1-8fdf-20439e7ec127"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0b9266faad484741a6ceae1bdc3f0eb6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIyLTItMS0xLTM0ODYy_cbaba892-0528-4111-be98-109609d7b1e7"
      unitRef="shares">39307286</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0b9266faad484741a6ceae1bdc3f0eb6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIyLTQtMS0xLTM0ODYy_d2d11cfa-f184-4886-b914-bcb10bbd7662"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e8bb23d203841bfa3a428096aca8874_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIyLTYtMS0xLTM0ODYy_4240f5fe-79a5-4d73-95dc-1d73a7254a31"
      unitRef="usd">427925000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f1f7503d0874f6ab90216689469562d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIyLTgtMS0xLTM0ODYy_7c4e53f2-b1bd-4ab1-99cf-20352e80a559"
      unitRef="usd">3035000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i10e76b47a8364dbb8b7aa258206cfd04_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIyLTEwLTEtMS0zNDg2Mg_2c89cb11-1d2c-414c-98f5-f6c7bccfc864"
      unitRef="usd">-317280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjQvZnJhZzphNzAxOTUyZjIzMTk0NThmYjhkNjAxZTYyOWQ4MjU0YS90YWJsZTo5NGY3OTdiMzY4ZmQ0ZjNlODYxOGZjMmU1ZDY1MTM0Zi90YWJsZXJhbmdlOjk0Zjc5N2IzNjhmZDRmM2U4NjE4ZmMyZTVkNjUxMzRmXzIyLTEyLTEtMS0zNDg2Mg_309670d2-ef86-4bde-8e2e-90c379e246e4"
      unitRef="usd">113684000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMtMS0xLTEtMzQ4NjI_baddfecb-8d41-4d86-843f-c93b0cf93b42"
      unitRef="usd">-120407000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMtMy0xLTEtMzQ4NjI_99f0e3b5-7ffd-48fd-90e9-171643b50ded"
      unitRef="usd">-92945000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzUtMS0xLTEtMzQ4NjI_06dd07fe-f307-427b-ace3-0e75f0057dba"
      unitRef="usd">77000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzUtMy0xLTEtMzQ4NjI_6d955a49-b1d5-41b0-a01d-82b28dc03e73"
      unitRef="usd">85000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzYtMS0xLTEtMzQ4NjI_8d286097-8461-4bf3-89f4-b91d858de8a1"
      unitRef="usd">32970000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzYtMy0xLTEtMzQ4NjI_58d9992d-b872-4b5f-b0bc-f1edcb2baa01"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzgtMS0xLTEtMzQ4NjI_c5009cd7-8f80-4e78-bcd3-0cd7505ce48c"
      unitRef="usd">7929000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzgtMy0xLTEtMzQ4NjI_fa3afd34-fd02-4f21-994a-e4c8169e183d"
      unitRef="usd">5949000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzktMS0xLTEtMzQ4NjI_8e8ce2e6-abba-4f40-bd73-b9aed77e3fd0"
      unitRef="usd">-4757000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzktMy0xLTEtMzQ4NjI_85e62813-64df-48a3-98bb-640a518fc3ea"
      unitRef="usd">-4332000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzEwLTEtMS0xLTM0ODYy_a9b51e2c-7dd7-43b2-890f-86b919533da4"
      unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzEwLTMtMS0xLTM0ODYy_f585c087-ffca-47a2-8187-6f2795bae60d"
      unitRef="usd">8625000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzEzLTEtMS0xLTM0ODYy_4a49e548-ca42-437c-8670-c68cec0450a8"
      unitRef="usd">-7493000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzEzLTMtMS0xLTM0ODYy_90875958-1d79-4de4-83eb-fe75b099ac3e"
      unitRef="usd">12800000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE0LTEtMS0xLTM0ODYy_7929a952-0c73-43a6-b4a5-825f2e77b1e2"
      unitRef="usd">799000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE0LTMtMS0xLTM0ODYy_62648590-4075-43da-bbdc-e711c13ba123"
      unitRef="usd">176000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE1LTEtMS0xLTM0ODYy_81807691-d984-4f60-9cf3-205b0c846081"
      unitRef="usd">-124000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE1LTMtMS0xLTM0ODYy_47a6d07b-8389-4066-8de9-9dd6efeb985a"
      unitRef="usd">170000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE2LTEtMS0xLTM0ODYy_d51901a6-d06c-40a2-aa0f-57e2e3e8f246"
      unitRef="usd">1362000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE2LTMtMS0xLTM0ODYy_5030c771-f339-4ffb-a273-1005f0134ac4"
      unitRef="usd">3175000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE3LTEtMS0xLTM0ODYy_7453a543-4ec7-45cc-ae0e-366658fcc2fc"
      unitRef="usd">-65144000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE3LTMtMS0xLTM0ODYy_e56853ae-af47-49ca-b984-d8c5c6683cfa"
      unitRef="usd">-83233000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE5LTEtMS0xLTQwMDg3_52452f12-9901-49eb-abb9-a06ca78fd57c"
      unitRef="usd">9629000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE5LTMtMS0xLTQwMDk3_c6dc948c-afbb-4971-9613-cde31cf9b15c"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE5LTEtMS0xLTM0ODYy_c51f2e95-f8bf-4523-8f01-c0a2ceb1561e"
      unitRef="usd">112000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzE5LTMtMS0xLTM0ODYy_83e57b7d-aba3-46e7-bace-7416f032e8ad"
      unitRef="usd">67000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI0LTEtMS0xLTM0ODYy_d194632a-b67d-47f1-a145-f73ea2d656fe"
      unitRef="usd">-9741000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI0LTMtMS0xLTM0ODYy_0de57c7a-1e88-4527-8650-7524b9eb3826"
      unitRef="usd">-67000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ic79be0a87a2d43ae992ef8e7625d53e2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI4LTAtMS0xLTM0ODYyL3RleHRyZWdpb246ODUzYjNjZWU0OTc1NDY1YWJiZTI3YWY0NmMyNmQxN2NfMTA5OTUxMTYyNzkxNw_3db0081b-bbba-4734-8a27-c0b362d55360"
      unitRef="usd">1226000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i6ceb990338fd46f69ef655c24c8d15d0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI4LTAtMS0xLTM0ODYyL3RleHRyZWdpb246ODUzYjNjZWU0OTc1NDY1YWJiZTI3YWY0NmMyNmQxN2NfMTA5OTUxMTYyNzkyMw_c3d293e9-3b71-4f37-9006-6adc89cb5815"
      unitRef="usd">23000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic79be0a87a2d43ae992ef8e7625d53e2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI4LTEtMS0xLTM0ODYy_97ba6b68-4d03-4428-9465-fa37d8e36560"
      unitRef="usd">39584000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6ceb990338fd46f69ef655c24c8d15d0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI4LTMtMS0xLTM0ODYy_93d6696a-fba3-4976-999e-d9f158b5297d"
      unitRef="usd">729000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI5LTEtMS0xLTM0ODYy_7a3771b1-9d35-4980-8838-c5695417f9d3"
      unitRef="usd">182000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzI5LTMtMS0xLTM0ODYy_ff155833-1e4d-467e-80b7-023a79550ac5"
      unitRef="usd">92000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i629c982d47b84bd39b19868854e07c81_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMwLTAtMS0xLTM0ODYyL3RleHRyZWdpb246Zjk5MTJmYjRiNGJhNDk3ZGJmMzIyZWEwNmMxMTY5NDRfMTA5OTUxMTYyNzkyMQ_1ee95e80-97d2-4a6e-b6e6-16d0ff1b82d1"
      unitRef="usd">4012000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i90a687fe86e640878d4f8d1ab66c683b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMwLTAtMS0xLTM0ODYyL3RleHRyZWdpb246Zjk5MTJmYjRiNGJhNDk3ZGJmMzIyZWEwNmMxMTY5NDRfMTA5OTUxMTYyNzkyNg_eea7ea2e-edba-4977-adcc-065b8766f7c4"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i629c982d47b84bd39b19868854e07c81_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMwLTEtMS0xLTM0ODYy_bbfb67ce-9225-4680-b7f0-8c2a5ed42dea"
      unitRef="usd">55989000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i90a687fe86e640878d4f8d1ab66c683b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMwLTMtMS0xLTM0ODYy_4db98a07-60bf-41bf-940a-ab588d75293c"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMyLTEtMS0xLTM0ODYy_cb5e91f1-1bb3-4751-87ce-ae20ff30bf7d"
      unitRef="usd">5000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMyLTMtMS0xLTM0ODYy_42c2aa72-1d0c-4edc-aa7b-9d226335e5f8"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i42cae9630d124c15823d3c9c381fc07a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMzLTAtMS0xLTM0ODYyL3RleHRyZWdpb246ODlkZTMxYjFjZGQ3NGJhZTlmOGYzNWNkYmE5NDBlMDlfNzc_fbf0a6c7-e553-4b67-85ee-0fb72169d364"
      unitRef="usd">2980000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1d3cdfb91b17451989132881fd694dac_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMzLTEtMS0xLTM0ODYy_f5b6033f-59f8-4273-964b-6629a6889e0e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i42cae9630d124c15823d3c9c381fc07a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzMzLTMtMS0xLTM0ODYy_c70c17df-5553-4e96-8c84-cf1f5bcc6422"
      unitRef="usd">42020000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM1LTEtMS0xLTM0ODYy_ac799743-49db-4b6b-8547-92acdae5673c"
      unitRef="usd">95760000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM1LTMtMS0xLTM0ODYy_fc0556c2-d507-4928-856a-f1dcc4f09a53"
      unitRef="usd">42841000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM2LTEtMS0xLTM0ODYy_55315484-ff66-4a46-bc4b-1aba2aa735a2"
      unitRef="usd">-993000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM2LTMtMS0xLTM0ODYy_7a6dfe37-374a-4873-8b9d-85f74c71c32d"
      unitRef="usd">-130000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM3LTEtMS0xLTM0ODYy_699c1e92-c3db-4d0d-bfdc-c428ae10aa3b"
      unitRef="usd">19882000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM3LTMtMS0xLTM0ODYy_a7ce1b64-7eeb-4ecf-bfa2-aa4d04d57bb4"
      unitRef="usd">-40589000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM4LTEtMS0xLTM0ODYy_429c4811-5409-4a1e-8065-ec143b4975b5"
      unitRef="usd">86863000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ife1cbb9302f3417394aee800539a7c78_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM4LTMtMS0xLTM0ODYy_8acf393d-7ff1-45dd-9410-d757de8e2ed0"
      unitRef="usd">127452000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM5LTEtMS0xLTM0ODYy_ad9e0d82-191f-411e-9f7b-138d3b9111ce"
      unitRef="usd">106745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzM5LTMtMS0xLTM0ODYy_2bc9f04f-d34b-4f16-8acd-26d9b6b9926d"
      unitRef="usd">86863000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzQzLTEtMS0xLTM0ODYy_613b4fb3-27e0-4de6-83f7-aae4fff19337"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzQzLTMtMS0xLTM0ODYy_58c6ee2f-e150-43cd-92dc-955594d9d80c"
      unitRef="usd">8625000</us-gaap:StockIssued1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzQ0LTEtMS0xLTM0ODYy_03341312-7e6f-4188-a6d5-4f7a26d5c005"
      unitRef="usd">974000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMjcvZnJhZzpmM2NmMDMzOWI0Nzc0MTI4OTk4OWU1ZjRmODRiODhkOC90YWJsZToyODJmODVmMGU2YTU0YzEyOTdjNGQzODZkMWM2YjU1MS90YWJsZXJhbmdlOjI4MmY4NWYwZTZhNTRjMTI5N2M0ZDM4NmQxYzZiNTUxXzQ0LTMtMS0xLTM0ODYy_13b2e71a-b1b9-4232-9e79-143ca21922a9"
      unitRef="usd">435000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzQ2Mjc_7f6d125f-a6d2-4d76-a653-166abf7fe010">Description of Business and Basis of Financial Statements&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic, Inc. ("Immunic" or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#xe4;felfing near Munich, Germany. The Company currently has approximately 66 employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is currently pursuing clinical development of three orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#x201c;MS&#x201d;); the izumerogant (proposed International Nonproprietary Name (&#x201c;INN&#x201d;) for IMU-935) program, which is an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (&#x201c;ROR&#x3b3;t&#x201d;) that inhibits the interleukin-17 (&#x201c;IL-17&#x201d;) pathway in diseases such as psoriasis; and the IMU-856 program, which is targeted to restore intestinal barrier function and regenerate bowel epithelium.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Financial Condition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic has no products approved for commercial sale and has not generated any revenue from product sales. Immunic has never been profitable and has incurred operating losses in each year since inception (2016). Immunic has an accumulated deficit of approximately $317.3&#160;million as of December&#160;31, 2022 and approximately $196.9&#160;million as of December&#160;31, 2021. Substantially all of Immunic&#x2019;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From inception through December&#160;31, 2022, Immunic has raised net cash of approximately $355.5 million from private and public offerings of preferred and common stock. As of December 31, 2022, the Company had cash and cash equivalents of approximately $106.7&#160;million and investments - other of $9.6&#160;million. With these funds the Company expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG (which began operations in 2016) and Immunic Australia Pty Ltd. (which began operations in 2018).  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityNumberOfEmployees
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzIxOTkwMjMyNjM5NTQ_5d3a1dcb-fb9e-40ba-9964-2162238fc0e8"
      unitRef="employee">66</dei:EntityNumberOfEmployees>
    <imux:NumberOfDevelopmentPrograms
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzIxOTkwMjMyNjg5Mzk_7de723dc-354b-427b-a3a6-9c9b6af2dfd3"
      unitRef="lease">3</imux:NumberOfDevelopmentPrograms>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzIyMDg_f0e1a91d-9e30-4a07-a727-d67210b7e17c"
      unitRef="usd">-317300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzIyMzg_da8bb006-2fde-4a8e-a46f-ce776ca5a8dd"
      unitRef="usd">-196900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzU0OTc1NTgyMzQ2Ng_d344acaa-e66c-4571-a5c1-141ef8b1dc6d"
      unitRef="usd">355500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzU0OTc1NTgyMzQ3NQ_be6a03bb-3625-432e-a321-caaedf132375"
      unitRef="usd">106700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OtherShortTermInvestments
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzMvZnJhZzo4OTJhNGVmYWEwNzM0N2RjOWQ3MzRiZDM5ZjkwNTA5My90ZXh0cmVnaW9uOjg5MmE0ZWZhYTA3MzQ3ZGM5ZDczNGJkMzlmOTA1MDkzXzU0OTc1NTgyNzMyNA_32f7d449-e10d-46bc-9ac7-a809015d8a40"
      unitRef="usd">9600000</us-gaap:OtherShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3MzU3_0fd16432-8085-4e76-a13f-106a6c7d207a">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Investments- other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments-other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S of approximately $85.7&#160;million, Germany of approximately $19.1&#160;million and Australia of approximately $1.9&#160;million. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions. Our Cash and Cash equivalents in the U.S. is primarily held in a U.S. Government money market fund account and was earning interest at a rate of 4.3%. Our cash and cash equivalents in Germany and Australia were earning interest at a rate of &#x2014;% to 0.87%&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments - other consists of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of 0.61% to 0.87% and have a remaining maturity 3-4 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from three years to thirteen years. Depreciation and amortization expense was $77,000 and $85,000 for the years ended December&#160;31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the years ended December&#160;31, 2022 and 2021 other than goodwill which is described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired.  The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $33.0&#160;million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance.  The Company did not have any goodwill impairment during the year ended December 31, 2021.  The changes in the carrying amount of goodwill for the years presented are as follows (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount of goodwill at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of goodwill during the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount of goodwill at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Government assistance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. Government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred.  We recognized $2.3&#160;million and $1.7&#160;million of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3221b224-b06b-4599-934b-4790913ca766"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3cdcee94-7c82-4bf3-999e-30ecd1c05a92"&gt;other income&lt;/span&gt;&lt;/span&gt; related to research activities performed during the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December&#160;31, 2022 and 2021, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#x201c;ASC 480-10&#x201d;) or ASC 815-40, Accounting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prefunded stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,096,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,888,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzgy_e43924a8-766c-4b48-a121-1e0497cf4c90">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzgz_d846fa22-7fb3-4997-951c-1757120abd24">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <imux:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzcw_e7ec84b2-de59-43eb-9d16-1f4557519d0d">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Investments- other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments-other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S of approximately $85.7&#160;million, Germany of approximately $19.1&#160;million and Australia of approximately $1.9&#160;million. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions. Our Cash and Cash equivalents in the U.S. is primarily held in a U.S. Government money market fund account and was earning interest at a rate of 4.3%. Our cash and cash equivalents in Germany and Australia were earning interest at a rate of &#x2014;% to 0.87%&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments - other consists of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of 0.61% to 0.87% and have a remaining maturity 3-4 months.&lt;/span&gt;&lt;/div&gt;</imux:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i40702a7fad274b3590022abc86d2a149_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM1NDY_4021944e-7d91-4c79-8f67-255b5801f028"
      unitRef="usd">85700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib3028499b4524a48a11940db473e95c4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM1NjE_f8d018a7-9a9c-438c-8f99-224f68e520f8"
      unitRef="usd">19100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic9487ab845434e10aca875ca321f6e67_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM1NzY_7500f3fc-3bd4-45e9-8a90-a310150ee241"
      unitRef="usd">1900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <imux:NumberOfFinancialInstitutionsUsedForCashDeposits
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzU0OTc1NTgzNzQ1OA_2f71fd49-bc36-4911-8cf1-474c4da67888"
      unitRef="financialinstitution">2</imux:NumberOfFinancialInstitutionsUsedForCashDeposits>
    <us-gaap:InvestmentInterestRate
      contextRef="id15e6eed9a474921925790496d9be215_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzU0OTc1NTg3MzAwNQ_beecb6b9-b896-4141-9f5d-62d15734e131"
      unitRef="number">0.043</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate
      contextRef="i6f6dda26ad1f41d48bc084b4d8b166fd_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE2NDkyNjc1MDEwMDM_6e81c248-6a8c-4cf7-83b9-95c355750e43"
      unitRef="number">0</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate
      contextRef="i24f459a16c08494da1b7e65020dc4fa7_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE2NDkyNjc1MDEwMDk_d9ecef36-0089-40d4-abd6-33baeb5f32df"
      unitRef="number">0.0087</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentTableTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTQ4ODk_c7d100c1-2204-43b7-9f09-0b8cc911061a">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments - other consists of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentTableTextBlock>
    <us-gaap:OtherShortTermInvestments
      contextRef="i29c8be7c0e67485390b3fa4ca6373ec9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTozMDU0NjlkZjhkYWQ0MzEwODI5NTE0OGU5MWM0MGFkYS90YWJsZXJhbmdlOjMwNTQ2OWRmOGRhZDQzMTA4Mjk1MTQ4ZTkxYzQwYWRhXzEtMi0xLTEtMzk5NDg_be04bc68-6e1f-4746-a412-cc6aa3f66b96"
      unitRef="usd">9629000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="i1c7189562e3a451ea2101622fe50411a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTozMDU0NjlkZjhkYWQ0MzEwODI5NTE0OGU5MWM0MGFkYS90YWJsZXJhbmdlOjMwNTQ2OWRmOGRhZDQzMTA4Mjk1MTQ4ZTkxYzQwYWRhXzEtNC0xLTEtMzk5NDg_d4405bea-dbba-4b27-857c-41e5cd467ec1"
      unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTozMDU0NjlkZjhkYWQ0MzEwODI5NTE0OGU5MWM0MGFkYS90YWJsZXJhbmdlOjMwNTQ2OWRmOGRhZDQzMTA4Mjk1MTQ4ZTkxYzQwYWRhXzItMi0xLTEtMzk5Nzc_54adfa59-446d-4422-a19e-26d897ddf98a"
      unitRef="usd">9629000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTozMDU0NjlkZjhkYWQ0MzEwODI5NTE0OGU5MWM0MGFkYS90YWJsZXJhbmdlOjMwNTQ2OWRmOGRhZDQzMTA4Mjk1MTQ4ZTkxYzQwYWRhXzItNC0xLTEtMzk5Nzc_f409ab9e-79ed-4ca5-b34e-cbeda51ec92b"
      unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:InvestmentInterestRate
      contextRef="i02a6493060a2472cb585f29aefea30e5_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE2NDkyNjc1MDEwMzM_5079d2bf-6833-4932-b57b-101d283f29f4"
      unitRef="number">0.0061</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate
      contextRef="i576a1a2a1e6f40819d31ad6cc0c9d135_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE2NDkyNjc1MDEwNDc_febd2309-ff44-4ff7-ab8e-0fda198b4b26"
      unitRef="number">0.0087</us-gaap:InvestmentInterestRate>
    <imux:InvestmentEarningInterestRateRemainingMaturityPeriod
      contextRef="if4ebe77f21364c02a3042c9e9e034e31_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTQ5MDU_7bca7200-f559-41ce-9ce1-47af636f3262">P3M</imux:InvestmentEarningInterestRateRemainingMaturityPeriod>
    <imux:InvestmentEarningInterestRateRemainingMaturityPeriod
      contextRef="i824c6b2c61e244609c3ec75bfe251d84_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTQ5MDc_9a6d8953-7dee-4217-a3df-803ab65c9813">P4M</imux:InvestmentEarningInterestRateRemainingMaturityPeriod>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3MzYz_163b22c7-0143-4367-9ea7-86c9a563a666">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzcy_0e4fee78-0a7b-461b-a031-81af252367fe">Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from three years to thirteen years.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie62fec553f0c4425b46293481930bbc7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzQ1NjE_13084210-a596-4f63-b29b-b4bce115b630">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iff9b0c581c08407a9041a6bb9632fa7e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzQ1Njc_d1f68051-67a4-4df5-aad9-8d392e46d11c">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DepreciationAndAmortization
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzQ2MTM_0b0cc74c-c590-4677-a7f6-04c036c48ab5"
      unitRef="usd">77000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzQ2MjA_06fbf770-2088-48ff-bc21-2ea0d2d577bf"
      unitRef="usd">85000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzg2_0b3860b3-f930-44a3-acbc-e92acdc34439">Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzUwMTQ_6c2fd075-cddb-45ce-83fd-be2ede0c5108"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzUwMTQ_ca674eb3-16c8-4632-a585-bf1a0d0b24cf"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzkz_644f49c8-2509-411f-ad2f-2e2939d28c39">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. &lt;/span&gt;&lt;/div&gt;On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4bc235beae3e46b392aa9ef77f9e52a6_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzU0OTc1NTg0OTU4Mg_dd4c6492-89d7-46ba-9260-221d445d188d"
      unitRef="usd">33000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTIyNzI_dc55a02d-5f11-4ede-8748-05cd1a30ed5b">The changes in the carrying amount of goodwill for the years presented are as follows (amounts in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount of goodwill at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of goodwill during the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount of goodwill at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZToxZDNhZWYyYjIxMDk0YzYyYjYyMDA0YmQ0NjNmM2IyZC90YWJsZXJhbmdlOjFkM2FlZjJiMjEwOTRjNjJiNjIwMDRiZDQ2M2YzYjJkXzAtMS0xLTEtMzgwNDA_feb18992-ae4b-47bc-8bf3-9bc72b81800a"
      unitRef="usd">32970000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZToxZDNhZWYyYjIxMDk0YzYyYjYyMDA0YmQ0NjNmM2IyZC90YWJsZXJhbmdlOjFkM2FlZjJiMjEwOTRjNjJiNjIwMDRiZDQ2M2YzYjJkXzEtMS0xLTEtMzgwNDA_105e688e-289b-48d9-a06b-19a64f26a0b7"
      unitRef="usd">32970000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZToxZDNhZWYyYjIxMDk0YzYyYjYyMDA0YmQ0NjNmM2IyZC90YWJsZXJhbmdlOjFkM2FlZjJiMjEwOTRjNjJiNjIwMDRiZDQ2M2YzYjJkXzItMS0xLTEtMzgwNDA_d9e21e11-ec33-41c5-b606-ce6d9e623c3d"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3MzYy_3a197aff-01f9-4298-b57e-1dda63e3df37">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzk0_4840f9c7-43f5-4484-a5bb-9c2f2022e88f">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzk1_7c44aea3-40fb-440c-91ce-5fb75028ab31">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:GovernmentAssistancePolicyTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM1OTA_92bf989d-bf76-4034-ae4e-97505aa31e5b">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Government assistance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. Government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred.  We recognized $2.3&#160;million and $1.7&#160;million of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3221b224-b06b-4599-934b-4790913ca766"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3cdcee94-7c82-4bf3-999e-30ecd1c05a92"&gt;other income&lt;/span&gt;&lt;/span&gt; related to research activities performed during the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <imux:GovernmentAssistanceRate
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM1OTI_8a008099-d508-4a2f-b525-2d4789abdbf9"
      unitRef="number">0.435</imux:GovernmentAssistanceRate>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM1OTk_d078f1a3-9f43-422d-877d-14519f117ad8"
      unitRef="usd">2300000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MTM_b6d49c6b-3001-4df2-b43e-96d96458eaa9"
      unitRef="usd">1700000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzc4_8a554752-4b54-48a4-a3ef-333eaf4244cb">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzk2_361f7184-e81c-4410-be22-c4a6ae159d43">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the &lt;/span&gt;&lt;/div&gt;application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzc5_5cbf0612-bdfe-45a9-b9b3-3d31b2dd318c">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i6ea7cf83aad5416b96424f40bc7375a9_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzU0OTc1NTg2Mzc1OQ_8516e884-7145-44f3-8fd7-bc4329b3c0d8">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie1949ba12c82474aad6afbbd5c131134_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzU0OTc1NTg2Mzc3Mw_88bc6928-4d8a-464f-8415-cb0f86269222">P60M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <imux:LesseeOperatingLeasesNumberOfExistingLeases
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzU0OTc1NTg2MzkzNg_1ed94b6d-c4ce-4828-95c8-95fbe3a4a21e"
      unitRef="lease">2</imux:LesseeOperatingLeasesNumberOfExistingLeases>
    <imux:LesseeOperatingLeasesNumberOfExistingLeases
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzU0OTc1NTg2NDE5Ng_1ed94b6d-c4ce-4828-95c8-95fbe3a4a21e"
      unitRef="lease">2</imux:LesseeOperatingLeasesNumberOfExistingLeases>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3MzY4_ccf71a69-f01d-48d4-81cd-10ad9f4f04d5">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzg3_d674e07b-6b50-408c-b3ba-23f5b41da592">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December&#160;31, 2022 and 2021, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTA3MTc_faedc1f3-23a6-4987-ab0d-7a43e3f607da">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#x201c;ASC 480-10&#x201d;) or ASC 815-40, Accounting &lt;/span&gt;&lt;/div&gt;for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzg4_86c7e269-54ed-4f71-8f47-737915a59b43">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3MzY2_12ecd550-8bf3-415f-be78-5331964ae995">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prefunded stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,096,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,888,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia76019b0488442de98cccc646c64f255_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTpjYjFhNGIyZDQyMWQ0ZDYwYTUzZTdiYTRiZTg0N2MyMi90YWJsZXJhbmdlOmNiMWE0YjJkNDIxZDRkNjBhNTNlN2JhNGJlODQ3YzIyXzItMS0xLTEtMzQ4NjI_301db2fd-d31d-4940-a42b-931c9ba74228"
      unitRef="shares">3791688</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i296998374f2942bf8199382e045c0c53_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTpjYjFhNGIyZDQyMWQ0ZDYwYTUzZTdiYTRiZTg0N2MyMi90YWJsZXJhbmdlOmNiMWE0YjJkNDIxZDRkNjBhNTNlN2JhNGJlODQ3YzIyXzItMy0xLTEtMzQ4NjI_73f9fbb6-64db-4b69-b333-7fdd56e2463f"
      unitRef="shares">2157460</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i42582e672b9a458a8f771feaaf27fdb0_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTpjYjFhNGIyZDQyMWQ0ZDYwYTUzZTdiYTRiZTg0N2MyMi90YWJsZXJhbmdlOmNiMWE0YjJkNDIxZDRkNjBhNTNlN2JhNGJlODQ3YzIyXzMtMS0xLTEtMzY2ODk_3db6892e-401c-4193-9eb7-55e04d8d017b"
      unitRef="shares">5096552</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i49102a4b3a124b109aaa078cfdd43203_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTpjYjFhNGIyZDQyMWQ0ZDYwYTUzZTdiYTRiZTg0N2MyMi90YWJsZXJhbmdlOmNiMWE0YjJkNDIxZDRkNjBhNTNlN2JhNGJlODQ3YzIyXzMtMy0xLTEtMzY2ODk_4d624bbb-4c9a-47ff-88a7-552e9c0917ce"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTpjYjFhNGIyZDQyMWQ0ZDYwYTUzZTdiYTRiZTg0N2MyMi90YWJsZXJhbmdlOmNiMWE0YjJkNDIxZDRkNjBhNTNlN2JhNGJlODQ3YzIyXzQtMS0xLTEtMzY2ODk_9d67ef34-dc1a-4dea-84c8-f0656f105215"
      unitRef="shares">8888240</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90YWJsZTpjYjFhNGIyZDQyMWQ0ZDYwYTUzZTdiYTRiZTg0N2MyMi90YWJsZXJhbmdlOmNiMWE0YjJkNDIxZDRkNjBhNTNlN2JhNGJlODQ3YzIyXzQtMy0xLTEtMzY2ODk_f2bb75d5-123d-4f13-b61d-08e39ba2bdd8"
      unitRef="shares">2157460</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzE3Mzgw_a6679989-21ef-4315-a7b6-b8773a6211cf">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90ZXh0cmVnaW9uOjRjZDIxNmE2OGRiODRlYjM4OTA0NjE4YWMyYTNjYmM5XzM1OA_ace21db9-458d-4128-8514-9c3839ce49c0">Balance Sheet Details&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid Expense and Other Current Assets consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued Expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist  of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_4a1a30a6-155d-4e96-9d47-e78ee944ec76"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_58a0a228-b7d2-495a-8002-5c76ada4c7a6"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90ZXh0cmVnaW9uOjRjZDIxNmE2OGRiODRlYjM4OTA0NjE4YWMyYTNjYmM5XzM2MA_6a4a109c-81ce-406d-a99f-53dd3142ade0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid Expense and Other Current Assets consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <imux:PrepaidClinicalAndRelatedCostsCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzItMS0xLTEtMzQ4NjI_59287825-8edb-4080-99f5-51f8ed903a95"
      unitRef="usd">5608000</imux:PrepaidClinicalAndRelatedCostsCurrent>
    <imux:PrepaidClinicalAndRelatedCostsCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzItMy0xLTEtMzQ4NjI_c476e206-be7a-41b2-ad6c-1fbc7b3cc259"
      unitRef="usd">14853000</imux:PrepaidClinicalAndRelatedCostsCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzMtMS0xLTEtMzQ4NjI_1d198cb2-3694-4888-812c-f1a75e1c2dc8"
      unitRef="usd">296000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzMtMy0xLTEtMzQ4NjI_8ba959c1-77d5-46e9-a799-5cc9d28893d6"
      unitRef="usd">279000</us-gaap:ValueAddedTaxReceivableCurrent>
    <imux:ResearchAndDevelopmentTaxIncentiveCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzQtMS0xLTEtMzQ4NjI_06ae7a7e-0ba4-4959-96d1-93687d7aa4ef"
      unitRef="usd">2361000</imux:ResearchAndDevelopmentTaxIncentiveCurrent>
    <imux:ResearchAndDevelopmentTaxIncentiveCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzQtMy0xLTEtMzQ4NjI_c32db877-f9d8-4601-956c-687ad300d3c5"
      unitRef="usd">1871000</imux:ResearchAndDevelopmentTaxIncentiveCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzUtMS0xLTEtMzQ4NjI_56da47d8-662f-4e4f-8ff0-0f97632f5033"
      unitRef="usd">1225000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzUtMy0xLTEtMzQ4NjI_acdc8ea5-f082-49ea-916f-f75fc348fbd8"
      unitRef="usd">1122000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzYtMS0xLTEtMzQ4NjI_fab0acf1-3cfe-45dc-b6e2-5c36661ad625"
      unitRef="usd">9490000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTpiNDM0OWExOWYxNWM0OGZkODBjM2E2ZjkzNTQxZmEyMi90YWJsZXJhbmdlOmI0MzQ5YTE5ZjE1YzQ4ZmQ4MGMzYTZmOTM1NDFmYTIyXzYtMy0xLTEtMzQ4NjI_0e9852dd-5e28-4265-a78f-73586544b2b5"
      unitRef="usd">18125000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90ZXh0cmVnaW9uOjRjZDIxNmE2OGRiODRlYjM4OTA0NjE4YWMyYTNjYmM5XzM1Mg_c0bb4f91-2ff0-441f-bcf5-9659bc5e4647">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued Expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <imux:ClinicalCostsPayableCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzItMS0xLTEtMzQ4NjI_4d9f64da-48b0-4a6e-9b70-2a39e0a1f35c"
      unitRef="usd">3749000</imux:ClinicalCostsPayableCurrent>
    <imux:ClinicalCostsPayableCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzItMy0xLTEtMzQ4NjI_f586d066-990c-433a-8a89-fa7e660ed5e1"
      unitRef="usd">3427000</imux:ClinicalCostsPayableCurrent>
    <imux:LegalAndAuditCostsPayableCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzMtMS0xLTEtMzQ4NjI_9c2f7574-467d-407e-ae0d-e1fe7eca06f2"
      unitRef="usd">288000</imux:LegalAndAuditCostsPayableCurrent>
    <imux:LegalAndAuditCostsPayableCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzMtMy0xLTEtMzQ4NjI_841b7c28-5f4e-4632-8a42-95f5e5beea94"
      unitRef="usd">72000</imux:LegalAndAuditCostsPayableCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzQtMS0xLTEtMzQ4NjI_d34e6708-82ea-45c9-80db-9e7e795069f9"
      unitRef="usd">244000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzQtMy0xLTEtMzQ4NjI_d5eca9c3-0c0e-46ce-9958-f563815858de"
      unitRef="usd">246000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzUtMS0xLTEtMzQ4NjI_9a23dfbe-eb38-4851-b774-3b9b3c810a69"
      unitRef="usd">4281000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo1NWY3NjllNTMyYjY0ZmZkYjdlN2ExYjBjZTU3MjY3MS90YWJsZXJhbmdlOjU1Zjc2OWU1MzJiNjRmZmRiN2U3YTFiMGNlNTcyNjcxXzUtMy0xLTEtMzQ4NjI_5808211d-e43c-4459-b018-5ad714efb279"
      unitRef="usd">3745000</us-gaap:AccountsPayableCurrent>
    <imux:AccruedClinicalCostsCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzItMS0xLTEtMzQ4NjI_f8a045b8-d63b-4444-86b8-780a77c72e4a"
      unitRef="usd">6807000</imux:AccruedClinicalCostsCurrent>
    <imux:AccruedClinicalCostsCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzItMy0xLTEtMzQ4NjI_6dd01e37-fd9a-4be2-83c7-191215f91575"
      unitRef="usd">6214000</imux:AccruedClinicalCostsCurrent>
    <imux:AccruedLegalAndAuditCostsCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzMtMS0xLTEtMzQ4NjI_2558250b-6a8a-436f-a53d-12d03fe82337"
      unitRef="usd">169000</imux:AccruedLegalAndAuditCostsCurrent>
    <imux:AccruedLegalAndAuditCostsCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzMtMy0xLTEtMzQ4NjI_89abe7f5-44e9-43da-bf1e-4640b2b54de3"
      unitRef="usd">96000</imux:AccruedLegalAndAuditCostsCurrent>
    <imux:AccruedCompensationCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzQtMS0xLTEtMzQ4NjI_e5f90309-ca89-4a03-8b64-7eba73aeb5f1"
      unitRef="usd">890000</imux:AccruedCompensationCurrent>
    <imux:AccruedCompensationCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzQtMy0xLTEtMzQ4NjI_98b027ea-723f-41d4-9cb8-c280f7812ea3"
      unitRef="usd">674000</imux:AccruedCompensationCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzUtMS0xLTEtMzQ4NjI_db23afff-5b7e-42bb-885a-6b46fe49daee"
      unitRef="usd">120000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzUtMy0xLTEtMzQ4NjI_d12756ef-1d0d-4715-960f-78d99120df72"
      unitRef="usd">87000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzYtMS0xLTEtMzQ4NjI_3a66a3c0-4576-430d-8526-6659ad8dac74"
      unitRef="usd">7986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTo2ZWQxNDQ0NTM3Njc0NDg1YjQ4M2I2NzI0YzA4YmRiMS90YWJsZXJhbmdlOjZlZDE0NDQ1Mzc2NzQ0ODViNDgzYjY3MjRjMDhiZGIxXzYtMy0xLTEtMzQ4NjI_c09cd4f6-d6e3-4115-acd2-6c3e13a035ff"
      unitRef="usd">7071000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90ZXh0cmVnaW9uOjRjZDIxNmE2OGRiODRlYjM4OTA0NjE4YWMyYTNjYmM5XzM1Nw_8a65534d-f231-4324-b35f-4eee37078257">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist  of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_4a1a30a6-155d-4e96-9d47-e78ee944ec76"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_58a0a228-b7d2-495a-8002-5c76ada4c7a6"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMS0xLTEtMzQ4NjI_4a0ed4d0-8ecc-4d6c-b9a7-9b21a550c6e3"
      unitRef="usd">571000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMy0xLTEtMzQ4NjI_27586c94-2f0a-4bf7-9f01-ce3de9843924"
      unitRef="usd">408000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzMtMS0xLTEtMzQ4NjI_0b8a73d5-3256-4d08-a4e2-1c783a325e24"
      unitRef="usd">239000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzMtMy0xLTEtMzQ4NjI_b12f47d0-81b6-4594-a4c2-8b5d1ecf89fd"
      unitRef="usd">177000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzQtMS0xLTEtMzQ4NjI_d416311d-aa00-49f8-bca4-bdffd98c2603"
      unitRef="usd">810000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzQtMy0xLTEtMzQ4NjI_ce88e936-1e5b-4d2c-8300-4e629bb2f82b"
      unitRef="usd">585000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzU2MjQ_810ddf9a-2d8d-46d4-9d60-db038cfafad1">Commitments and Contingencies&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office and June 30, 2025 for the Gr&#xe4;felfing, Germany office.  The Company formerly leased office space in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Planegg-Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025.  The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a five year lease for its facility in Gr&#xe4;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#xe4;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease as well as a three month rent holiday upon the 27 month extension starting May 2023.  There were net additions to right of use assets of $435,000 and $642,000 as a result of signing for additional lease space at the Gr&#xe4;felfing, Germany office in March 2021 and August 2022, respectively.  There were net additions to right of use assets of $332,000 as a result of extending the New York City lease in December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6% for the original leases and 8% for the New York City extension, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Immunic&#x2019;s operating lease costs and variable lease costs were $727,000 and $503,000 for the years ended December&#160;31, 2022 and 2021, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Maturities of the operating lease obligation are as follows as of December&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: interest portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December&#160;31, 2022, the Company has non-cancelable contractual obligations under certain agreements related to its development programs in vidofludimus calcium, izumerogant and IMU-856 totaling approximately $4.5 million, all of which is expected to be paid in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments and Obligations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2016, the Company entered into a purchase agreement (the &#x201c;Agreement&#x201d;) with 4SC AG, whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to 4.4% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing 120,070 shares of the Company&#x2019;s common stock, immediately following the Transaction, to 4SC AG while keeping Tranche III in effect. Approximately $1.5 million of expense was recorded as a result of the issuance of these shares on April 12, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, Immunic AG, a wholly-owned subsidiary of the Company, and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.25&#160;million &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Tranche III of the Agreement). The payment was made 50% in cash and 50% in shares of Immunic&#x2019;s common stock (the &#x201c;Shares&#x201d;). Pursuant to the Agreement, the Company filed a resale shelf registration statement on Form S-3 covering the resale of the Shares. With the execution of the Agreement, no further payment obligations remain between Immunic AG and 4SC AG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i4ddd5b53cb394a72b342f64f7724bee5_I20200407"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzU2MjY_cb2f1688-6c14-4383-8a45-0120ee88a9f6">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <imux:LesseeOperatingLeaseRentHolidayPeriod
      contextRef="i4d811dce20e94755bbed81698a836062_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzU2MTk_9158de12-0d0c-472b-95c6-9e2fc36a8db4">P6M</imux:LesseeOperatingLeaseRentHolidayPeriod>
    <imux:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="icc3845c2b8324eb192b6c5463738b9a4_D20210301-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzIxOTkwMjMyNjM4NDE_cc6b06fc-c8c9-4345-acf0-bfcc9d8bd4d4"
      unitRef="usd">435000</imux:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <imux:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i790f3d1e376c426a93f31d939f0cc7d9_D20220801-20220831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzIxOTkwMjMyNjM4NTE_552934c3-0cef-428a-b9b8-3b9c9338e71e"
      unitRef="usd">642000</imux:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <imux:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i24562792a7ba48619d879bb127f6e25a_D20221201-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzIxOTkwMjMyNjMzOTU_9e77bd9b-04c5-4842-a25f-948b2bcf2e11"
      unitRef="usd">332000</imux:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <imux:OperatingLeaseIncrementalBorrowingRate
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzE5NDM_91b69b12-1e74-48a1-8a33-2eea2b84f233"
      unitRef="number">0.06</imux:OperatingLeaseIncrementalBorrowingRate>
    <imux:OperatingLeaseIncrementalBorrowingRate
      contextRef="ib7723388552347f4a59e2d9f09a39771_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzE2NDkyNjc0NDk5NzM_bf599df0-bd73-458d-b248-9d46cc2c7bb4"
      unitRef="number">0.08</imux:OperatingLeaseIncrementalBorrowingRate>
    <imux:OperatingAndVariableLeasesCost
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzIzMDk_1f9dd1e5-391c-48e5-8277-f867f63ed349"
      unitRef="usd">727000</imux:OperatingAndVariableLeasesCost>
    <imux:OperatingAndVariableLeasesCost
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzIzMTY_4b1d1f24-30d8-42ee-b062-f90156f3aa89"
      unitRef="usd">503000</imux:OperatingAndVariableLeasesCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzU2MjA_66f11155-aa28-4d35-9847-1326ad4c19f4">Maturities of the operating lease obligation are as follows as of December&#160;31, 2022 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: interest portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzAtMi0xLTEtMzQ4NjI_80f100e0-e064-4da5-959a-e51f23cdae90"
      unitRef="usd">647000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzEtMi0xLTEtMzQ4NjI_8edab702-9eac-41bb-b418-95f08cbd2c6e"
      unitRef="usd">680000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzItMi0xLTEtMzQ4NjI_0a29eaa0-5322-465d-8513-9e958ceab444"
      unitRef="usd">355000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzMtMi0xLTEtMzQ4NjI_3fb85ea3-696b-4bf6-ba9e-07cbad2abe4a"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzQtMi0xLTEtMzQ4NjI_883f2bac-b925-4e07-9ec5-5760afb0e84d"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzUtMi0xLTEtMzQ4NjI_a351293b-a82c-4361-b797-d526fbfbebe9"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzYtMi0xLTEtMzQ4NjI_24e544ae-711c-41f5-b6e3-1d1661c0cccf"
      unitRef="usd">1682000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzctMi0xLTEtMzQ4NjI_1f01dd2f-348c-4369-b965-ffb42c6b0660"
      unitRef="usd">147000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90YWJsZTo4YjA1ZjY2MTEyZjQ0MTA0YjMxMzI1OGRhOTQzNWVkMC90YWJsZXJhbmdlOjhiMDVmNjYxMTJmNDQxMDRiMzEzMjU4ZGE5NDM1ZWQwXzgtMi0xLTEtMzQ4NjI_6644feb2-4fa7-45dd-8a74-a0d50f9086f9"
      unitRef="usd">1535000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ContractualObligation
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzI4MjU_0c680218-7749-4f33-93b3-8b5faa83480e"
      unitRef="usd">4500000</us-gaap:ContractualObligation>
    <imux:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales
      contextRef="i1220fdabe2ee4fb28d42b5efca4ed2e5_D20160501-20160531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzM0NzQ_195779f9-3786-4ebd-a580-8e11843df90e"
      unitRef="number">0.044</imux:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales>
    <us-gaap:CommonStockSharesIssued
      contextRef="id6d27db753c54b8eaeaf90c7573257b1_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzM2OTI_9b712470-4d6a-4042-858c-05d7f1da597d"
      unitRef="shares">120070</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="id6d27db753c54b8eaeaf90c7573257b1_I20190412"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzM4MzM_0da50a97-045c-431e-ab6d-b348a1e2be44"
      unitRef="usd">1500000</us-gaap:CommonStockValue>
    <imux:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales
      contextRef="i6672b35cda564e6499bcb6f461f08725_D20210331-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzQxMTQ_a6ee5282-831f-4d9f-80e2-ab4c117f6493"
      unitRef="number">0.044</imux:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales>
    <imux:RoyaltySettlementAgreementSalesNet
      contextRef="i6672b35cda564e6499bcb6f461f08725_D20210331-20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzQxNDI_d666dee2-5ae8-4f5b-b715-9d25ed6a2477"
      unitRef="usd">17250000</imux:RoyaltySettlementAgreementSalesNet>
    <imux:RoyaltySettlementAgreementCashPaymentPercent
      contextRef="ia12960a663974117bd81295909c9cc3a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzQxOTg_fb61a69d-ad23-4983-98ec-e4a2e9a42d03"
      unitRef="number">0.50</imux:RoyaltySettlementAgreementCashPaymentPercent>
    <imux:RoyaltySettlementAgreementSharesPaymentPercent
      contextRef="ia12960a663974117bd81295909c9cc3a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDIvZnJhZzo3MDVmNGRlODJjNjI0NzljYjM4NjczZDk2YzFhMDRmOC90ZXh0cmVnaW9uOjcwNWY0ZGU4MmM2MjQ3OWNiMzg2NzNkOTZjMWEwNGY4XzQyMTM_ec6dd04f-f5df-43ac-af69-a51e9dc30323"
      unitRef="number">0.50</imux:RoyaltySettlementAgreementSharesPaymentPercent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90ZXh0cmVnaW9uOjJjMTM5MTkxOTcwMzQ0MGY4OWFlZmExZjkxZmY3Yjg1Xzg3MQ_0352dc84-9c39-4661-ba18-e4927a084b1f">Fair Value &lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Company&#x2019;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of 4.3% in a U.S. Government money market fund.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of December 31, 2022. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.  For the assessment of the fair value of goodwill and the related impairment of goodwill we used a level one assessment in our testing of goodwill.  See Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of significant accounting policies "Goodwill".&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90ZXh0cmVnaW9uOjJjMTM5MTkxOTcwMzQ0MGY4OWFlZmExZjkxZmY3Yjg1Xzg2OA_d772372e-de34-4d21-8be5-155639b90585">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i42c64b30b3db47e08679854bf2c78b08_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzMtMS0xLTEtMzQ4NjI_a10ce080-087c-4280-931f-b509930583a6"
      unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iff060470870f4782ab057c9bc17e5799_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzMtMy0xLTEtMzQ4NjI_6e7b17d0-d8e0-4df4-8526-eada176f082a"
      unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ief2a67c94b5d4e07875b949f040c609f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzMtNS0xLTEtMzQ4NjI_0b2c1cb2-4074-4005-8938-6e854ad06484"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2e11d04f3b714f7aa69b06869cf2dd60_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzMtNy0xLTEtMzQ4NjI_7c9b9faa-8d7f-4a6f-bf0b-34b4500b70b8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4387fb9fcb644cbfa9f299c3c426b334_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzQtMS0xLTEtMzQ4NjI_5e66be56-7c42-4fdb-9104-5ad3a2a86840"
      unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3c272f1e1b9c4a5ab2d79ed4552a88ca_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzQtMy0xLTEtMzQ4NjI_8b4e948f-f287-451a-8993-946d70c8d768"
      unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8682b8fb49274d31915223706871afca_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzQtNS0xLTEtMzQ4NjI_496ebafd-0250-4739-a4db-604af7464658"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ice854542a5dd4a53ba69994da59a8099_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzQtNy0xLTEtMzQ4NjI_677a07a5-9b9d-4ddd-9be9-4f8f0d57099c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9e7a9a04d1f5475985dad2756a363f66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzktMS0xLTEtMzQ4NjI_d441d96b-f7d3-46bb-b087-b5f0104832a1"
      unitRef="usd">31630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7b15df3b298345d2a6a8dd573021c03b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzktMy0xLTEtMzQ4NjI_77aa6555-4ba5-4f28-8d15-f821df1959e8"
      unitRef="usd">31630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i45b06aedd33f4a19969cd8bcfc7ae2ac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzktNS0xLTEtMzQ4NjI_a1101fce-961f-4f94-9ae7-ebd5714a4482"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i92ef303dbac04f97b77afccd76a0ee69_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzktNy0xLTEtMzQ4NjI_755d7ae3-5aa5-4498-bdd7-8e406a4ce008"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0d7c512c8dad49688494a40ed9a84a26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzEwLTEtMS0xLTM0ODYy_775e931f-1835-41c3-a255-ae7135f1db80"
      unitRef="usd">31630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia45eb959635c4618a8e96c1da9b0ea55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzEwLTMtMS0xLTM0ODYy_c8f283f1-2df1-4321-8857-a10f2ba77787"
      unitRef="usd">31630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia6499a7329114832bcca11b186e9322c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzEwLTUtMS0xLTM0ODYy_33ed670c-0a87-4f09-a7ba-83221846dd2f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7e590388cdee4815b9794125e1f4fc52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90YWJsZToyOWZiNTljYTNlM2I0ZmFmYmM1NDk4NmE0OWQ4YTJjZS90YWJsZXJhbmdlOjI5ZmI1OWNhM2UzYjRmYWZiYzU0OTg2YTQ5ZDhhMmNlXzEwLTctMS0xLTM0ODYy_3c7b559b-44a7-4292-b352-b5cf1e12aecb"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentInterestRate
      contextRef="id15e6eed9a474921925790496d9be215_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDUvZnJhZzoyYzEzOTE5MTk3MDM0NDBmODlhZWZhMWY5MWZmN2I4NS90ZXh0cmVnaW9uOjJjMTM5MTkxOTcwMzQ0MGY4OWFlZmExZjkxZmY3Yjg1XzIxOTkwMjMyNTc5NTA_beecb6b9-b896-4141-9f5d-62d15734e131"
      unitRef="number">0.043</us-gaap:InvestmentInterestRate>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzgxMjE_cde6d848-0d67-4436-bbfd-2462f451e387">Common StockShelf Registration Statements&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of February 17, 2023, there is $75.0&#160;million remaining on this shelf registration statement &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of February 17, 2023, $8.4&#160;million in capacity remains under the December 2020 ATM.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.  As of February 17, 2023, $80.0&#160;million in capacity remains under the May 2022 ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company has agreed to pay SVB Leerink a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2022, the Company raised gross proceeds of $40.9&#160;million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were  $39.6&#160;million after deducting underwriter commissions of $1.2&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2021, the Company raised gross proceeds of $0.8&#160;million pursuant to the December 2020 ATM through the sale of 73,221 shares of common stock at a weighted average price of $10.27 per share. The net proceeds from the December 2020 ATM were  $0.7&#160;million after deducting underwriter commissions of $22,555.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;$60 Million Private Placement Equity Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) for a private placement (the &#x201c;Private Placement&#x201d;) with select accredited investors and certain existing investors (each, a &#x201c;Purchaser&#x201d; and collectively, the &#x201c;Purchasers&#x201d;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;Shares&#x201d;), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase Common Stock (the &#x201c;Warrant Shares&#x201d; and together with the Shares and the Pre-Funded Warrants, the &#x201c;Securities&#x201d;), at a purchase price of $4.34 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.01 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days&#x2019; prior notice to the Company.  The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return.  All of the pre-funded warrants were exercised in January of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Private Placement closed on October 12, 2022. The gross proceeds of the Private Placement were approximately $60.0&#160;million, before deducting offering expenses payable by the Company of approximately $4.0 million. The Company intends to use the net proceeds from the Private Placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), izumerogant (IMU-935) and IMU-856, and for other general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The registration statement for these securities was deemed effective by Securities and Exchange Commission on December 20, 2022.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;July 2021 Public Equity Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 15, 2021, the Company entered into an underwriting agreement with Piper Sandler &amp;amp; Co., in connection with the Company&#x2019;s public offering of 4,500,000 shares of the Company&#x2019;s common stock, $0.0001 par value per share, at a public offering price of $10.00 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 19, 2021, the Company closed the Offering. The net proceeds to the Company from the Offering was approximately $42.0&#160;million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:113%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001. The voting, dividend and liquidation rights of the holders of the Company&#x2019;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through December&#160;31, 2022, no cash dividends had been declared or paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20,000,000 shares of $0.0001 par value preferred stock, rights and preferences to be set by the board of directors. No preferred shares were outstanding as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance as of December&#160;31, 2022 are as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prefunded stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,096,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,283,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <imux:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="i89236a268ded4c38beb10ce49d29d398_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTQzOTA_34008d8b-65a3-4701-9fcc-a63b4f383144"
      unitRef="usd">250000000</imux:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <imux:ShelfRegistrationStatementAmountRemaining
      contextRef="i1903fef7aaee4f7aaa653511f97e3f03_I20230217"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTQ1Njg_1452c974-2ac0-48a2-a878-55fcadebc7db"
      unitRef="usd">75000000</imux:ShelfRegistrationStatementAmountRemaining>
    <imux:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="i43a90b71f4874951ab64ba8e4d321ed5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTQ3NjQ_23a4dd30-ed10-4c40-94c3-6960580c650c"
      unitRef="usd">50000000</imux:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <imux:ShelfRegistrationTerminationPriorWrittenNotice
      contextRef="i441cf983bb6b42c1bfc3a145240c4326_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTU1NDg_58268d20-d8f5-4903-b81a-e12488599be9"
      unitRef="d">10</imux:ShelfRegistrationTerminationPriorWrittenNotice>
    <imux:SaleOfStockRemainingCapacity
      contextRef="i67bc3dd545e748af9503605c6cf6ad15_I20230217"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTU3MjM_4347cfd7-4e10-40cf-a163-873e0a612a73"
      unitRef="usd">8400000</imux:SaleOfStockRemainingCapacity>
    <imux:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="ia92a9ae619944848ae66ab4dd8a63242_I20220510"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTU5MTc_e9a79331-94c8-4725-bd45-b89ad94d93a6"
      unitRef="usd">80000000</imux:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <imux:ShelfRegistrationTerminationPriorWrittenNotice
      contextRef="i21732f0264304e5fb28318d6dc2b7ecb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTY2NTU_7b0a1212-b450-4f08-9aec-d3ae0eaea7b5"
      unitRef="d">10</imux:ShelfRegistrationTerminationPriorWrittenNotice>
    <imux:SaleOfStockRemainingCapacity
      contextRef="i936d8c3c556941e4a8c00636316ee92c_I20230217"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTY4MzA_2b7d2d5b-6dd0-4fe7-90bb-234d6c5b210a"
      unitRef="usd">80000000</imux:SaleOfStockRemainingCapacity>
    <imux:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTY5NDQ_e10d05e0-f440-44d6-a960-395da1495028"
      unitRef="number">0.030</imux:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7649036809b74b5683c233704941dc74_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTc3NzQ_999e23fc-6a7e-4fef-a866-65c6d249f2df"
      unitRef="usd">40900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7649036809b74b5683c233704941dc74_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTc3Nzg_a8145de0-0662-447c-a129-71b922e3cea7"
      unitRef="shares">4204113</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <imux:SharesIssuedWeightedAverageSharePricePerShare
      contextRef="i7649036809b74b5683c233704941dc74_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTc3ODI_40881c23-f7ef-407e-b076-0ae9ec9fb9ef"
      unitRef="usdPerShare">9.72</imux:SharesIssuedWeightedAverageSharePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7649036809b74b5683c233704941dc74_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTc3ODY_001bf7e0-356b-4e43-b23b-85bb31dc60f5"
      unitRef="usd">39600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions
      contextRef="i7649036809b74b5683c233704941dc74_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTc3OTA_2de5e60c-5ace-4aa3-98c7-c238819ee184"
      unitRef="usd">1200000</us-gaap:PaymentsForCommissions>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i20ece55753144123bea427d4b5da5edd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTg0NDI_5cccba45-9020-4a58-82c9-2d65f346ae33"
      unitRef="usd">800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i20ece55753144123bea427d4b5da5edd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTg1MDA_32dbecd5-2daa-4a71-855f-7ba5276cac77"
      unitRef="shares">73221</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <imux:SharesIssuedWeightedAverageSharePricePerShare
      contextRef="i20ece55753144123bea427d4b5da5edd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTg1NTg_d93d4764-fe79-4604-b2a1-6f031526eae8"
      unitRef="usdPerShare">10.27</imux:SharesIssuedWeightedAverageSharePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i20ece55753144123bea427d4b5da5edd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTg2MjM_fa43b463-0412-4ad8-a58e-ad54221b5b67"
      unitRef="usd">700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions
      contextRef="i20ece55753144123bea427d4b5da5edd_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NTg2NzA_89798fbb-4088-4840-a35c-569d6231ac6c"
      unitRef="usd">22555</us-gaap:PaymentsForCommissions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i88aea673e8c04440a92d7eb913623ddd_D20221010-20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjIzMTY_ddddcf52-84a1-4a02-bb05-cd26c5c70d70"
      unitRef="shares">8696552</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ib94fad9370444fab84415ff498015dc8_I20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjIzNjg_5fa964a8-189d-42ea-a0eb-c5e59474630e"
      unitRef="usdPerShare">0.0001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharePrice
      contextRef="ib94fad9370444fab84415ff498015dc8_I20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjI0MjE_233e73f4-6ba1-4551-9d40-585af02719a1"
      unitRef="usdPerShare">4.35</us-gaap:SharePrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ida3ab5946fc24e23800223feb5a9d8ab_D20221010-20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjI0NDU_ce8a9911-50fc-4f10-8acd-f3d34da95a1d"
      unitRef="shares">5096552</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharePrice
      contextRef="if8c0142cb42641dcb4f087976d7a8e60_I20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjI2NDQ_291e989d-9923-41f4-bef1-3a7006eba048"
      unitRef="usdPerShare">4.34</us-gaap:SharePrice>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="if8c0142cb42641dcb4f087976d7a8e60_I20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjI3Mjc_66b8f6fe-afc9-45d0-8a6a-6c864eb91031"
      unitRef="usdPerShare">0.01</us-gaap:SaleOfStockPricePerShare>
    <imux:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage
      contextRef="ib94fad9370444fab84415ff498015dc8_I20221010"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjI5ODQ_32d8da6a-e920-4b51-9fe7-bcd182297f61"
      unitRef="number">0.0999</imux:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage>
    <imux:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent
      contextRef="if8c0142cb42641dcb4f087976d7a8e60_I20221010"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjMxODQ_9484d09e-d252-496d-91d6-7e4e37595fa5"
      unitRef="number">0.1999</imux:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent>
    <imux:EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod
      contextRef="if8c0142cb42641dcb4f087976d7a8e60_I20221010"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjMyMTA_21c212b0-cf93-4542-98a4-18e7071302fa">P61D</imux:EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i444f4698aac042ccbe20eda2d1da8d8b_D20221012-20221012"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzEwOTk1MTE2NjMzNTg_ef6ffbc9-9391-4eaa-8466-5ada5232d485"
      unitRef="usd">60000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i2eac70ade3724a7c9d3a5db3107626ea_D20210715-20210715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzM4NjI_3f25f5eb-3aa3-4002-945c-537926147cfc"
      unitRef="shares">4500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ifce58657f57045a8a9d5fdddad892a48_I20210715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzM5MDM_5271e016-66ac-42d9-a98c-56e57bb1e044"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ifce58657f57045a8a9d5fdddad892a48_I20210715"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzM5NTc_960cf6c0-b2ed-464c-b00c-5ab4560c710f"
      unitRef="usdPerShare">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i9f1ba5cf7cba4f8c9251c46ff206c135_D20210719-20210719"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzQwOTI_61b847c9-345f-41ae-864a-b575af8b508c"
      unitRef="usd">42000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzcyMjc_b0659579-216d-4f08-9773-2b627f672c8a"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzcyNjc_e60ef970-cbc1-4912-835e-c0d316f36d6b"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2Xzc3MDg_718475c3-7836-40b8-a836-4f6ae814d1c1"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2Xzc3MDg_8a99a8af-5524-4e50-af53-7474406f929d"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2Xzc4NzA_e595eb20-99bf-4d41-9a9a-42687fc91e3f"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2Xzc4ODM_6abc89ba-8f33-415e-b510-de197d36708d"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2Xzc5NzM_9abd91ad-fe34-4372-979d-041c3ae14b19"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90ZXh0cmVnaW9uOmYxNjJiZGYwNGY0NzQwZTliOTM1NjdiYmQyOTU5OTM2XzgxMjI_c6b1cf2c-d890-489b-bb28-6fa596399ace">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance as of December&#160;31, 2022 are as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prefunded stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,096,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,283,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1faf1225c920491e8209c19e9f4b2f1d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90YWJsZTo1MzE2MzI5Nzg1YmQ0NzZhYjE4YTg0NWM3ZGI5ZGU5Mi90YWJsZXJhbmdlOjUzMTYzMjk3ODViZDQ3NmFiMThhODQ1YzdkYjlkZTkyXzItMS0xLTEtMzQ4NjI_68868cfc-320a-4def-ada9-4962a29cfe4f"
      unitRef="shares">116891</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i4a320bf359b749c7a617f5394f9b3c83_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90YWJsZTo1MzE2MzI5Nzg1YmQ0NzZhYjE4YTg0NWM3ZGI5ZGU5Mi90YWJsZXJhbmdlOjUzMTYzMjk3ODViZDQ3NmFiMThhODQ1YzdkYjlkZTkyXzMtMS0xLTEtMzY2NjU_ed6f9cf5-2c4e-415f-b9e8-af3e043890ec"
      unitRef="shares">5096552</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7a7cbfffc237456380acaaec206786ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90YWJsZTo1MzE2MzI5Nzg1YmQ0NzZhYjE4YTg0NWM3ZGI5ZGU5Mi90YWJsZXJhbmdlOjUzMTYzMjk3ODViZDQ3NmFiMThhODQ1YzdkYjlkZTkyXzMtMS0xLTEtMzQ4NjI_25bfb3b3-29ee-4fcd-8a99-9903cbc82042"
      unitRef="shares">3791688</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i11965a3f2e9c4db38fbab16426b46799_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90YWJsZTo1MzE2MzI5Nzg1YmQ0NzZhYjE4YTg0NWM3ZGI5ZGU5Mi90YWJsZXJhbmdlOjUzMTYzMjk3ODViZDQ3NmFiMThhODQ1YzdkYjlkZTkyXzUtMS0xLTEtMzQ4NjI_67bbbe7d-7d4c-4bcf-af33-81f32839366e"
      unitRef="shares">43311</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i857f39ef5fe54694b80c6fbe030a98d5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90YWJsZTo1MzE2MzI5Nzg1YmQ0NzZhYjE4YTg0NWM3ZGI5ZGU5Mi90YWJsZXJhbmdlOjUzMTYzMjk3ODViZDQ3NmFiMThhODQ1YzdkYjlkZTkyXzYtMS0xLTEtMzQ4NjI_d2a6f73e-70ec-423a-bd8d-4d56ea9fcc5d"
      unitRef="shares">46250</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib4677eaef5e04113aaa9e6c7d5aa9c4f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90YWJsZTo1MzE2MzI5Nzg1YmQ0NzZhYjE4YTg0NWM3ZGI5ZGU5Mi90YWJsZXJhbmdlOjUzMTYzMjk3ODViZDQ3NmFiMThhODQ1YzdkYjlkZTkyXzctMS0xLTEtMzQ4NjI_f8b4abbe-08b9-4ae2-83f2-6698d3dc0806"
      unitRef="shares">188655</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNDgvZnJhZzpmMTYyYmRmMDRmNDc0MGU5YjkzNTY3YmJkMjk1OTkzNi90YWJsZTo1MzE2MzI5Nzg1YmQ0NzZhYjE4YTg0NWM3ZGI5ZGU5Mi90YWJsZXJhbmdlOjUzMTYzMjk3ODViZDQ3NmFiMThhODQ1YzdkYjlkZTkyXzgtMS0xLTEtMzQ4NjI_38c3231d-da53-4209-b5f7-f62eb926e027"
      unitRef="shares">9283347</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzYxMDE_dd43ea9b-801e-48cf-b303-1a67818989e8">Stock-based Compensation Plans&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#x2019;s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;       &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has issued 70,351 and 12,758 shares under the ESPP for the twelve months ended December 31, 2022 and 2021, respectively. The Company recognized $96,000 and $46,000 of expense related to the plan in the twelve months ended December 31, 2022 and 2021, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company&#x2019;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#x2019;s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to 4% of the Company&#x2019;s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of 4,408,871 shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzkwMzI_3b155f68-f249-4b5a-829c-f22ff2797b9c"&gt;three&lt;/span&gt; or four years.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Movements during the year &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the twelve months ended December 31, 2022 and 2021 under the 2019 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock options granted under the 2019 Plan during the years ended December&#160;31, 2022 and 2021 was $6.81 and $10.52, respectively. The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.526%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.93%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;br/&gt;&#160;Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 there was $15.6&#160;million  in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 2.74 years.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Equity Incentive Plans Assumed from Vital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital&#x2019;s 2012 Stock Option Plan (the &#x201c;2012 Plan&#x201d;), Vital&#x2019;s 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) and Vital&#x2019;s 2017 Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There remain 43,311 shares available for grant under the 2014 Plan as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, Vital&#x2019;s Board of Directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#x2019;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expense was recorded for the plans assumed from Vital during the twelve months ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i9caf2243577b40c7b672a10e37d9512e_D20210425-20210425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzU0MTc_82c008e2-38e9-41c0-9d0c-53d8457f7f2b"
      unitRef="number">0.15</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="i9caf2243577b40c7b672a10e37d9512e_D20210425-20210425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzU2MzA_a6500521-1deb-41bf-b8d3-d0ecc8363388"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i35242908a173404d86425605eca4a779_I20210425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzU4NDA_38c18b79-c8bb-431f-9027-e8a1bc344e4b"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8554c441f8d04f83811d7362580665a3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0NDc_d38d2ee5-73ef-4fb5-8a70-ebe4e9b16893"
      unitRef="shares">70351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i392c13496de949c3bd9f8fba9ec64518_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzYxODA_e8041366-b541-44df-92f8-0fd98f5a63e1"
      unitRef="shares">12758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8554c441f8d04f83811d7362580665a3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0NTU_1719dcd5-ef39-4b41-b369-157b2f778dd2"
      unitRef="usd">96000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i392c13496de949c3bd9f8fba9ec64518_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzExNTc_b4d0fc78-2942-4301-8720-52e584c72218"
      unitRef="usd">46000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i00d5cdeb5b7e43c1b31aa26556827c45_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2Mzc5NTY_e897025e-b1ad-4e05-8526-2ab78c99a476"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
      contextRef="i5cb3045344074d578abb47cff790ebe3_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzgxMzQ_4c22533d-3420-415a-8274-94271cbc36a4"
      unitRef="number">0.04</imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i5cb3045344074d578abb47cff790ebe3_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzgyMjU_7dd169bd-91fe-451d-928c-e0509785387a"
      unitRef="shares">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i175d1c7c30d04a678f2f280df3ebfdc5_D20200101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0NjQ_ae0f3d93-de2b-47cf-b553-29701e45d2dd"
      unitRef="shares">4408871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia137d2b6cec944f3a9a6132548a13e6e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2Mzg4MjA_2f79d3fa-a57c-4d96-a73b-289f07158757">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7b246b23033045b2b45563237e60fb03_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2Mzg4OTA_361befa0-b418-44aa-885a-04dba273c69d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib6a978fed247440098141566fbf4052d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzkwMzk_a913ddfd-83c7-4c1d-9d43-cb29f52ad2a8">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzYxMDI_69344539-cb93-46aa-9a25-29e56138cbbb">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the twelve months ended December 31, 2022 and 2021 under the 2019 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEtMS0xLTEtMzQ4NjI_2561c375-8526-421e-9e4a-435ecae59f43"
      unitRef="shares">2157460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEtMy0xLTEtMzQ4NjI_4c3c2905-ac65-4fb7-be36-299044502395"
      unitRef="usdPerShare">13.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzItMS0xLTEtMzQ4NjI_3019a376-5a9b-4136-a8bb-d82349416815"
      unitRef="shares">1886263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzItMy0xLTEtMzQ4NjI_35e80e14-97fe-4fb5-9d4d-32f0603aa9ca"
      unitRef="usdPerShare">8.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzMtMS0xLTEtMzQ4NjI_bc54e4bf-fd48-4aa6-9a4a-87b9f0015158"
      unitRef="shares">852</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzMtMy0xLTEtMzQ4NjI_43c26702-92b9-4f50-a195-519376b1e79e"
      unitRef="usdPerShare">5.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzQtMS0xLTEtMzQ4NjI_96e95abc-c8df-41c6-8c32-c57d05f4d1e2"
      unitRef="shares">251183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzQtMy0xLTEtMzQ4NjI_0ae2f054-b202-4b05-8ba5-ec2804785b5a"
      unitRef="usdPerShare">10.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzUtMS0xLTEtMzQ4NjI_e0164e2a-1c79-4814-b183-974bd58ad1fb"
      unitRef="shares">3791688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzUtMy0xLTEtMzQ4NjI_78142247-e30e-46dd-b0ed-4ef4d0ae3c19"
      unitRef="usdPerShare">11.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzUtNS0xLTEtMzQ4NjI_f5863c7f-3ddf-44bc-af97-222b73082ef0">P8Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzUtNy0xLTEtMzQ4NjI_5b34737f-3d75-460f-9866-3a518679fe1e"
      unitRef="usd">375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzYtMS0xLTEtMzQ4NjI_cb945030-8f04-4470-b8f3-02574f567751"
      unitRef="shares">3791688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzYtMy0xLTEtMzQ4NjI_d494280d-1ad3-4ada-ab6d-147a5aae7927"
      unitRef="usdPerShare">11.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzYtNS0xLTEtMzQ4NjI_d98b9c0f-254f-4bf7-ace9-1c36fba89cd2">P8Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzYtNy0xLTEtMzQ4NjI_0893fa6f-7508-485c-9723-8450f483413f"
      unitRef="usd">375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzctMS0xLTEtMzQ4NjI_44ceef6a-1859-44bd-a5ca-632c3a706fce"
      unitRef="shares">1398490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzctMy0xLTEtMzQ4NjI_4a57b8a0-8d4c-40ba-90bd-a73827014fcb"
      unitRef="usdPerShare">13.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ie5cba4e70fc44c05a7955de0bf7187a0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzctNS0xLTEtMzQ4NjI_e8a95ab9-3b0c-4808-8c6d-da7c7da7d7e5">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ia92bb09749d043bfb7e5a2d3e39a0317_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzctNy0xLTEtMzQ4NjI_2c82603e-5cee-4447-8483-b60721e569c8"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i46791b70b39149f995d04e9d61847f37_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEwLTEtMS0xLTM0ODYy_876be1ee-b2f0-49bb-92c9-bf02f89bddc0"
      unitRef="shares">1117160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i46791b70b39149f995d04e9d61847f37_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEwLTMtMS0xLTM0ODYy_62306dc4-f004-4b03-a49a-85c8093c3997"
      unitRef="usdPerShare">12.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzExLTEtMS0xLTM0ODYy_b88e390e-e0df-4c4f-aaa3-c8e5b37b691b"
      unitRef="shares">1193809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzExLTMtMS0xLTM0ODYy_fbbbb54e-d08d-4af1-97f6-20954a50c806"
      unitRef="usdPerShare">14.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEyLTEtMS0xLTM0ODYy_84611b66-b22a-43bb-8d26-4fbcf1947ee9"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEyLTMtMS0xLTM0ODYy_8c9296f7-f0df-44f6-af25-a73badf033aa"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEzLTEtMS0xLTM0ODYy_ef3fefb9-7617-4c80-97e6-023f5d77e56c"
      unitRef="shares">153509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzEzLTMtMS0xLTM0ODYy_586c8e46-74b7-4a27-bf9c-83d699d240f2"
      unitRef="usdPerShare">13.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE0LTEtMS0xLTM0ODYy_a2f75a4b-4323-4c4b-b33d-69c168085b2d"
      unitRef="shares">2157460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE0LTMtMS0xLTM0ODYy_3cd6ec17-7722-40d4-82d4-6dc2e920cb4b"
      unitRef="usdPerShare">13.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE0LTUtMS0xLTM0ODYy_7ebb03a3-127b-4723-b5c1-eee24c91a582">P8Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE0LTctMS0xLTM0ODYy_75738fb5-f00f-4865-9fd4-0f1772aef0d4"
      unitRef="usd">302155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE1LTEtMS0xLTM0ODYy_0c2389dc-d604-4167-bb62-c31bdcca6fe4"
      unitRef="shares">2157460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE1LTMtMS0xLTM0ODYy_359257f7-509b-4c7b-8fa6-6ed7224905b7"
      unitRef="usdPerShare">13.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE1LTUtMS0xLTM0ODYy_4603b727-8293-4875-808c-2ba251964562">P8Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE1LTctMS0xLTM0ODYy_1ca5e1f6-972f-4786-9ad3-fcbc05cf3a0a"
      unitRef="usd">302155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE2LTEtMS0xLTM0ODYy_18b5918d-247f-4d68-a43c-dd0a97782246"
      unitRef="shares">752954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE2LTMtMS0xLTM0ODYy_4b85b700-673c-4518-987a-19c2292f28e1"
      unitRef="usdPerShare">13.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i7338620b6330458489fcef670be67b56_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE2LTUtMS0xLTM0ODYy_099e61dc-d3c6-4b37-8afa-0a55b47038c8">P8Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ia0414aabe31c45cfb03ec35d6944f613_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo2YTlkYjQ0YzA5NDM0Y2Y0YmUxMmMyOWNiZGNlMjNjMC90YWJsZXJhbmdlOjZhOWRiNDRjMDk0MzRjZjRiZTEyYzI5Y2JkY2UyM2MwXzE2LTctMS0xLTM0ODYy_69e61a89-cc43-4d30-94de-70b568919dc6"
      unitRef="usd">79431</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2NDAxODk_c84602e4-c3c0-46ea-8041-8f59b1652b0b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5621a4c9af0345529c9a631b26c01878_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzQ0NDM_2b501688-30c2-44af-a763-3c253e3ec6a6"
      unitRef="usdPerShare">6.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id677ffe69ecb43f09a9efd781f682fd3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0NzU_8cbf785e-4de3-4281-88ae-b41f20e42109"
      unitRef="usdPerShare">10.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzYxMDM_9b6554fd-0314-467a-b4d1-00485b8c9c5d">The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.526%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.93%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5621a4c9af0345529c9a631b26c01878_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzEtMS0xLTEtMzQ4NjI_c20d9460-8756-4ac8-83ba-d89119ae7fb9"
      unitRef="number">0.0209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id677ffe69ecb43f09a9efd781f682fd3_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzEtMi0xLTEtMzQ4NjI_5052931b-6327-4726-9759-8f64461730c4"
      unitRef="number">0.0093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5621a4c9af0345529c9a631b26c01878_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzItMS0xLTEtMzQ4NjI_94d19215-e5ee-42ef-a203-1973313aa92c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id677ffe69ecb43f09a9efd781f682fd3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzItMi0xLTEtMzQ4NjI_9c412ae6-f462-4440-9db5-432194c0d373"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5621a4c9af0345529c9a631b26c01878_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzMtMS0xLTEtMzQ4NjI_1e64127f-929d-4e7d-878b-baaa2d45918b"
      unitRef="number">0.978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id677ffe69ecb43f09a9efd781f682fd3_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzMtMi0xLTEtMzQ4NjI_33bcf31a-d329-4aa1-ad6a-6c248710cf4d"
      unitRef="number">0.930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5621a4c9af0345529c9a631b26c01878_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzQtMS0xLTEtMzQ4NjI_cc9bfe35-b299-442a-bea7-7df759b9ab6f">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id677ffe69ecb43f09a9efd781f682fd3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3MTczMzlmNDQ1MGY0ZGI3YWU2YzNkZWFkMTY3N2JmOC90YWJsZXJhbmdlOjcxNzMzOWY0NDUwZjRkYjdhZTZjM2RlYWQxNjc3YmY4XzQtMi0xLTEtMzQ4NjI_368f9eaa-9f21-4488-9de4-1cff24a4de8d">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzYxMDg_653ea402-8806-4a28-a032-759bdb539e3a">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;br/&gt;&#160;Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="i3da78567fb1749fca30fc791bedfd050_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3ZGQzMjRhMzdjMDc0NmRiYTgyZjQxZDNjMGMyODgwMC90YWJsZXJhbmdlOjdkZDMyNGEzN2MwNzQ2ZGJhODJmNDFkM2MwYzI4ODAwXzItMS0xLTEtMzQ4NjI_c08a1b66-2e15-4368-b37a-7ce3a7289c5a"
      unitRef="usd">3219000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i427aa8bde64a40738335743ec62dbe35_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3ZGQzMjRhMzdjMDc0NmRiYTgyZjQxZDNjMGMyODgwMC90YWJsZXJhbmdlOjdkZDMyNGEzN2MwNzQ2ZGJhODJmNDFkM2MwYzI4ODAwXzItMy0xLTEtMzQ4NjI_e1abadba-ceb1-4bd3-962e-ec61975a0f6c"
      unitRef="usd">1760000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia250755510204b7fb17b62e711d72da6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3ZGQzMjRhMzdjMDc0NmRiYTgyZjQxZDNjMGMyODgwMC90YWJsZXJhbmdlOjdkZDMyNGEzN2MwNzQ2ZGJhODJmNDFkM2MwYzI4ODAwXzMtMS0xLTEtMzQ4NjI_7dacd443-e41a-479d-a7c1-27f522002fb0"
      unitRef="usd">4710000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ida3606afb67f4fd6b20f8cb83d82b570_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3ZGQzMjRhMzdjMDc0NmRiYTgyZjQxZDNjMGMyODgwMC90YWJsZXJhbmdlOjdkZDMyNGEzN2MwNzQ2ZGJhODJmNDFkM2MwYzI4ODAwXzMtMy0xLTEtMzQ4NjI_928918ad-ae97-4426-a064-e47d8e70faa7"
      unitRef="usd">4189000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5f8826a093524faab9e1c7138d3c7734_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3ZGQzMjRhMzdjMDc0NmRiYTgyZjQxZDNjMGMyODgwMC90YWJsZXJhbmdlOjdkZDMyNGEzN2MwNzQ2ZGJhODJmNDFkM2MwYzI4ODAwXzQtMS0xLTEtMzQ4NjI_fb0244d6-4500-4d4c-a077-22cebbb78f6c"
      unitRef="usd">7929000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i16b6edf94a0a462ab55397b394789287_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90YWJsZTo3ZGQzMjRhMzdjMDc0NmRiYTgyZjQxZDNjMGMyODgwMC90YWJsZXJhbmdlOjdkZDMyNGEzN2MwNzQ2ZGJhODJmNDFkM2MwYzI4ODAwXzQtMy0xLTEtMzQ4NjI_b2642e44-7ee5-4833-9309-c149695d6365"
      unitRef="usd">5949000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0ODM_6bc3ff4d-6592-4f29-8334-b86c4e9e96fb"
      unitRef="usd">15600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0OTc_9acf8052-e8e0-413f-85aa-1aaaf94efbb0">P2Y8M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i1f9bdb96b5174dbb8d3bd65a0524bed5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzU0NTQ_edeab945-f958-4310-a059-b5db7853c19f"
      unitRef="shares">43311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i5ca30a45a6194bfe96a0c64a563c77ba_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzU2ODA_730ada02-a19f-4f6c-a784-1499f2aa9f34"
      unitRef="shares">46250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib771df66db154a9d836d085b5ebc58d3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0OTg_74b9c285-4bde-476a-aeeb-c0a6b8fecc18"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifabfaf9983d146db9bfff97adf3e07b1_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzIxOTkwMjMyNzA0OTg_9150384d-d7c3-4936-b98a-3e431ec6267e"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzM4ODk_02d76128-29a4-40c4-a96f-edb0f4b77c51">Income Taxes &lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,049)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The rate reconciliation consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax effect of rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes result from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in years in which those temporary differences are expected to be recovered or settled. As tax laws and rates change, deferred tax assets and liabilities are adjusted through income tax expense. There is no current or deferred income tax expense in the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company's net deferred tax assets are shown below. A valuation allowance has been established as realization of such net deferred tax assets has not met the more likely-than-not threshold requirement. If the Company's judgment changes and it is determined that the Company will be able to realize these net deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on the net deferred tax assets will be accounted for as a reduction to income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total deferred tax liability    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred net operating losses each year since inception due to its history as a development stage company with no realized revenues from its planned principal operations. These cumulative operating losses provide significant negative evidence in the determination of whether or not the Company will be able to realize deferred tax assets such as net operating losses and other favorable temporary differences. There can be no assurance that it will ever generate taxable income. As a result, the Company has maintained a full valuation allowance against the entire balance of its net deferred tax assets since the date of inception. The valuation allowance has increased by $14.2&#160;million and $22.3&#160;million and for the years ended December 31, 2021 and 20, respectively.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, Immunic had available NOLs of approximately $190.2&#160;million in Germany and Australia. These NOLs do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. federal NOL carryforwards of $15.6&#160;million were generated prior to 2018 and expire over 20 years beginning in 2023. The $78.9&#160;million of post 2017 federal NOL carryforwards do not expire. Sections 382 of the Internal Revenue Code of 1986 subject the future utilization of net operating losses, to an annual limitation in the event of certain ownership changes, as defined. The Company may have undergone ownership changes and therefore may be limited in the amount of net operating losses available for utilization in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any uncertain tax positions for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the full valuation allowance that the Company has on its net deferred tax asset balance, there are no uncertain tax positions that would impact the effective tax rate if recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2018 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;Immunic, Inc. recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet. There were no such interest or penalties for any of the years presented.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzM4OTA_ef9238a6-5f67-47c1-8703-a0354d0a250b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,049)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i484c36bf82584e408934987b8269bc9a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzItMS0xLTEtMzQ4NjI_152cfff7-2f44-4bef-a8b7-134370082fcd"
      unitRef="usd">-47049000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i348724b28ae74d24885e46926e9b5cf1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzItMy0xLTEtMzQ4NjI_2a957973-39f9-466e-91df-d9f20a8d0438"
      unitRef="usd">-11222000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i6cac2d95041a44d49c19e83ff8a94426_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzMtMS0xLTEtMzQ4NjI_b1ad1ca5-9f1d-4f21-8523-e58691cc94b6"
      unitRef="usd">-67448000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ie3329f0d0a5a47fd8a67187745e514d4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzMtMy0xLTEtMzQ4NjI_6b12f392-ab82-49d1-962f-c54e5139b45e"
      unitRef="usd">-78869000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i717b3c5bcd7648beb9aad1d139fdc6dc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzQtMS0xLTEtMzQ4NjI_29e93f59-b76e-4101-80b7-c185a57efa24"
      unitRef="usd">-5911000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ie6278909cd154de6bd0d29a81c57b4ec_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzQtMy0xLTEtMzQ4NjI_bbfe189e-dc74-48c5-84c3-3fb491889adf"
      unitRef="usd">-2854000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzUtMS0xLTEtMzQ4NjI_6bdca457-5c26-4a69-80dd-40cb47996c2c"
      unitRef="usd">-120408000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo1NzFhZjM2YjVhZmE0NWQ1YjRlMzRkOGUzMGE4ZDY4Zi90YWJsZXJhbmdlOjU3MWFmMzZiNWFmYTQ1ZDViNGUzNGQ4ZTMwYThkNjhmXzUtMy0xLTEtMzQ4NjI_fd1f8008-c11f-4da9-9382-0501edd842b0"
      unitRef="usd">-92945000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzM4ODU_ea63ce25-dd47-43d2-8587-b7928be38842">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The rate reconciliation consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax effect of rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzItMS0xLTEtMzQ4NjI_2f3e4808-1359-46d3-8ff9-67411dbed4b4"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzItMy0xLTEtMzQ4NjI_5206c320-71c3-4201-8273-0959c05ed0ae"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzQtMS0xLTEtMzQ4NjI_59c46ff3-d6e6-4324-9602-620c55ad9d81"
      unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzQtMy0xLTEtMzQ4NjI_788c2198-4df0-491f-81dd-a6cfc3e78599"
      unitRef="number">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzUtMS0xLTEtMzQ4NjI_f365e781-dd6a-4795-9c30-acc1e2f561bc"
      unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzUtMy0xLTEtMzQ4NjI_91011900-2dc7-4f90-ac26-c4c9ccb7f307"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzctMS0xLTEtMzQ4NjI_e5e42cda-7746-4da5-978b-09056e83a324"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzctMy0xLTEtMzQ4NjI_0f6be20d-264b-414e-940f-29e98317214d"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzgtMS0xLTEtNDAyMDE_838b1dd6-6278-4329-a88a-86dd4cab43b5"
      unitRef="number">-0.057</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzgtMy0xLTEtNDAyMDE_aa97b5c9-c23e-4296-b972-f105eb5cf80a"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzgtMS0xLTEtMzQ4NjI_4250e6d2-9b23-4deb-8625-3570b721eb45"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzgtMy0xLTEtMzQ4NjI_50adb011-267e-4696-8288-7b3c8e4702b7"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzktMS0xLTEtMzQ4NjI_f650e3bb-1426-414a-83c3-99db5afd8c44"
      unitRef="number">-0.157</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzktMy0xLTEtMzQ4NjI_52cff9be-4bbc-4457-8b8a-a2d42dc168ef"
      unitRef="number">-0.229</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzEwLTEtMS0xLTM0ODYy_e9b5798d-ea1b-49d7-9388-15389502d5e1"
      unitRef="number">-0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTpjMTY0MjViYjBiNDU0MGY0OTYxYzkxNWRlNDE0YzBlOC90YWJsZXJhbmdlOmMxNjQyNWJiMGI0NTQwZjQ5NjFjOTE1ZGU0MTRjMGU4XzEwLTMtMS0xLTM0ODYy_c3ae58e5-a477-41e9-a57f-29b292788e8d"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzczMg_59051c19-b0a7-42c7-9e70-4304447b660b"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzczMg_eae1e6e1-8c74-4a73-a3df-4b5888d5ddff"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzM4ODI_6037febd-bb1b-4b1a-a66f-a7e3f3ceed04">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total deferred tax liability    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzQtMS0xLTEtMzQ4NjI_12ec1776-38c2-406d-8d7d-31789b2b4afd"
      unitRef="usd">19830000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzQtMy0xLTEtMzQ4NjI_666f0fb3-5f9a-4ce8-a3de-7d9cef706f7d"
      unitRef="usd">18437000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzYtMS0xLTEtMzQ4NjI_f8c468a7-432a-445f-abdc-e030915a3a42"
      unitRef="usd">742000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzYtMy0xLTEtMzQ4NjI_a5cb601d-596f-4e41-9a40-ef117ed372a0"
      unitRef="usd">576000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzctMS0xLTEtMzQ4NjI_818e9f0d-8941-4cb0-980d-fc48e8ef3a96"
      unitRef="usd">2923000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzctMy0xLTEtMzQ4NjI_dadd2f63-8097-4145-a06e-d1b09bc2a659"
      unitRef="usd">3848000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzgtMS0xLTEtMzQ4NjI_c4ee84e1-dd61-4ee5-ac03-fc39ae828c20"
      unitRef="usd">47179000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzgtMy0xLTEtMzQ4NjI_bd481452-1481-4b11-831e-75f83d953621"
      unitRef="usd">34819000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzktMS0xLTEtMzQ4NjI_5019166d-0040-4ed1-91df-b8e2db021de5"
      unitRef="usd">1686000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzktMy0xLTEtMzQ4NjI_289e9ad5-f3a5-4fa2-970e-7e58958fa354"
      unitRef="usd">1130000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzEwLTEtMS0xLTM0ODYy_aa81fd9b-2f6c-45a0-933a-d9c6d758df7d"
      unitRef="usd">693000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzEwLTMtMS0xLTM0ODYy_7ecf80d6-7da8-465f-8466-58f183befddd"
      unitRef="usd">9000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzExLTEtMS0xLTM0ODYy_a5fcc70f-4b63-4ac2-b09e-34bfbb9ae40e"
      unitRef="usd">73053000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzExLTMtMS0xLTM0ODYy_87f63fa7-fae2-4eae-a313-0164f6c9b5cd"
      unitRef="usd">58819000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzEzLTEtMS0xLTM0ODYy_c686e1a2-563e-4da1-86b3-0523e755e260"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzEzLTMtMS0xLTM0ODYy_aeeb74e4-9d02-4fed-aa0f-c6a3fc4ba08a"
      unitRef="usd">2000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE0LTEtMS0xLTM0ODYy_585707e5-8f34-4318-91d6-bb09f57bcae4"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE0LTMtMS0xLTM0ODYy_61e244da-c098-4fe9-810b-fd515eefeff6"
      unitRef="usd">2000</us-gaap:DeferredIncomeTaxLiabilities>
    <imux:DeferredTaxAssetsAndLiabilitiesGross
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE1LTEtMS0xLTM0ODYy_d4276784-89c9-455c-8e12-5d66245fb89d"
      unitRef="usd">73053000</imux:DeferredTaxAssetsAndLiabilitiesGross>
    <imux:DeferredTaxAssetsAndLiabilitiesGross
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE1LTMtMS0xLTM0ODYy_264ca78b-e34c-4018-9abf-f06185890570"
      unitRef="usd">58817000</imux:DeferredTaxAssetsAndLiabilitiesGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE2LTEtMS0xLTM0ODYy_88cf6947-d2a4-4fcd-b182-16f233857d6b"
      unitRef="usd">73053000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE2LTMtMS0xLTM0ODYy_68b8ce10-bd5f-4c1e-a83e-3c49e4c010b4"
      unitRef="usd">58817000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE3LTEtMS0xLTM0ODYy_d793e47b-8527-4826-a3db-1e5f4ad947ee"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90YWJsZTo4YTA5M2ZlYmJiZjc0YTNjYTY0MzI3M2FmZDhjM2Y1Mi90YWJsZXJhbmdlOjhhMDkzZmViYmJmNzRhM2NhNjQzMjczYWZkOGMzZjUyXzE3LTMtMS0xLTM0ODYy_ea4b7a45-41e7-4006-9dec-0e16562684a2"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzIwNDg_6a8346a1-c5f8-493a-965e-9fbbe6f00c7f"
      unitRef="usd">14200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i13cca09d3abf45a8a9a8dfddebc122bd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzIwNTU_c13f604f-ee6f-41fe-863b-f80b9a00adeb"
      unitRef="usd">22300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i52447e4dbf09445884a309828fb3a7f5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzIxOTQ_772f5f7a-da75-4eaf-9430-9a88fed6cb54"
      unitRef="usd">190200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ibbbf0f771acf458ab6e0e6253ecd4de4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzIyODg_9b78a927-707d-485a-8b7e-29ae9d17f939"
      unitRef="usd">15600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0c0bbccc8e094072b09a4b7d1aafb3c3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzIzNjg_2a7cbe45-1f90-41c5-81c4-b739f372488f"
      unitRef="usd">78900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzI3ODQ_759efde2-f0db-407c-9865-bebaa9e1b502"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1b28bf41d41a44729bb53cadae860beb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzI3ODQ_96fb071f-00cd-4ffc-a10e-d9f7a3bf4598"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTQvZnJhZzoyNGU1ZTdhMzMwNDk0NjYwYWY1Njc5NDY0ZjQzNjRiOS90ZXh0cmVnaW9uOjI0ZTVlN2EzMzA0OTQ2NjBhZjU2Nzk0NjRmNDM2NGI5XzI5OTA_e7dd60fe-8030-4d39-9406-9962221a1b8e"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzExMjk_020b7214-1b44-4680-a398-a2a620826093">Related Party Transactions&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Executive Chairman Agreement with Duane Nash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#x201c;Executive Chairman Agreement&#x201d;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#x201c;at will&#x201d; employment relationship with a base salary of $25,417 per month pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020. On October 15, 2020, the Company and Dr. Nash entered into an addendum (the &#x201c;First Addendum&#x201d;) to extend the term of the Executive Chairman Agreement to April 15, 2021.  In connection with the First Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 120,000 shares of Company common stock, which vests monthly over six months commencing on November 15, 2020.  On April 15, 2021, the Company and Dr. Nash entered into Addendum No. Two (the &#x201c;Second Addendum&#x201d;) to extend the term of the Executive Chairman Agreement to April 15, 2022.  In connection with the Second Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 90,000 shares of Company common stock, which vests monthly over 12 months commencing on May 15, 2021, and to increase Dr. Nash&#x2019;s monthly base salary to $27,960 from $25,417. On March 15, 2022, the Company and Dr. Nash entered into Addendum No. Three (the &#x201c;Third Addendum&#x201d;), which extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $29,358 per month. In connection with the Third Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 75,000 shares of the Company&#x2019;s common stock, which vests monthly over 12 months commencing on April 10, 2022.  On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month (which includes the cash retainer payable for serving on the Company&#x2019;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <imux:SalaryCostsMonthlyBaseSalary
      contextRef="id31cbe772be540f6ae60d3269ef43568_D20210101-20210514"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1MjE_ad1ce67f-32cc-4a88-908a-3be76aa1bd80"
      unitRef="usd">25417</imux:SalaryCostsMonthlyBaseSalary>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic97bdf6441d44e2b83eaf02fe42ee442_D20201115-20201115"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1MzA_a50ac272-3280-4c22-b608-2fa57aaf07ff"
      unitRef="shares">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4965c60a3c264702a9ac179a8a4a899a_D20210415-20210415"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1Mzk_f3ee90be-b452-484d-876f-f24ca0dc93c9"
      unitRef="shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <imux:SalaryCostsMonthlyBaseSalary
      contextRef="i55271ce968e14d408bd351945f042b13_D20210515-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1NDc_5ad9c1e6-725f-4c80-883c-47105c11111b"
      unitRef="usd">27960</imux:SalaryCostsMonthlyBaseSalary>
    <imux:SalaryCostsMonthlyBaseSalary
      contextRef="id31cbe772be540f6ae60d3269ef43568_D20210101-20210514"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1NTY_4fdb0d8f-5844-4fdb-a4f9-5d022cd40032"
      unitRef="usd">25417</imux:SalaryCostsMonthlyBaseSalary>
    <imux:SalaryCostsMonthlyBaseSalary
      contextRef="id672e13b1b3b42b79a062e019e44f37d_D20220315-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1NjU_a187e619-e878-4575-96ee-1345ad2d1132"
      unitRef="usd">29358</imux:SalaryCostsMonthlyBaseSalary>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ifa6db4839145429ebadca83963b31d82_D20220315-20220315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1NzQ_3261b0fc-e7c9-4bd8-ae1e-0d1983696832"
      unitRef="shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <imux:SalaryCostsMonthlyBaseSalary
      contextRef="i268e6ad4baa74fa6836147f78ab7c782_D20221228-20231231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNjAvZnJhZzo5M2U1ZmFjNDYzM2Y0ZDVmYmQ2MmY4Y2E3OTE5OTk0Ny90ZXh0cmVnaW9uOjkzZTVmYWM0NjMzZjRkNWZiZDYyZjhjYTc5MTk5OTQ3XzIxOTkwMjMyNjU1ODI_157a392e-6f75-4475-98e0-027e17c4bd00"
      unitRef="usd">30250</imux:SalaryCostsMonthlyBaseSalary>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M-.I_LE>DZB913XPL?6%NI;%E[H>%[:N@7(#=WTEI3A-W0-NITW=02P,$%
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M$^ "?+E]#UZ]> U> %J!SSFK!:XRL5E)]66MOTJ[K[QKOX)FOO*>I)? ATN
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M-"U(4R@)9A89>@/1>(\HH8)5]Q>2\-*1C9VA\?<#?P+1)C.SPG#$A? 1Y>(
M!BUU$D5K YQ%SD^@-[/,<. M^#CB*BB^HP65E-C9"SXK?3V7M7.G!P*#;@9[
MFZ:LUJQPP _XKB!6AWU+.L1PNBZFE#]FMW.  W%!-W,I@+PF;@Z )B5%21Q.
M 5JDO C. !S("SZ%O4;)8T5J,E$,I]N816@=SP5R8"OX%+KZ&4X+&_E>%$V1
M6L1@X,W%=" M&#E+\8]^(_MI,3KI[\G%^$S6SMT>6!"Z:?"CHFHL:74/"J*F
MIY\NDLEW23*E&XO0.@YF%FC@1.@FQ3:9"MLR69%:2,]$:@K-(D4#,R(W,W9(
MW?B027@JC<-IYVL3@\E<::*!&I&;&G>L+&G7G3?3!*MT%I J57B[GBBP]D1N
MP_:$!=8IZK\;.G=^-"ZZ:?=6LO1KSHJ,</'REQC!Z$W3J,H'^^SXO,/C_\&^
M:&!?Y&;?&T[V1&W(&1 Z"DOPPKOT/ \J-N9 C9(U>:/&\J5ZI'\ KF7../U'
MR>LTJ1@0.5:X !5"<R3C@-522/52;R)8 C7<D_*.\!;SCT."1ML<][L FSP^
M)2BGR'DH!IY';I[7-< J1QP4__2!Z-R>Q,-/EHJCEB@.6P?#I>^OEP&,)V'2
M+Y\6IR50Z@?2G(H5#]:HF<W%=&ZRB,Q,]6AH/I"[^7B;952?V*DM3D_*%[0"
M*3Y0M>5909J-18"B!$V/("QR/@J0'\W '7H0Y.Y!5#-7EW71G(>QMF]BI:JL
M7!]='@F@E;HGX%7!A+#O=V;#X7N^@=^4ND!S,RH:NA+DGJ7'Z#.RIRFU3H'(
M') O?!BAV"@CBR!,PCB:2XNAD4#N1J(E/3&[LUIAFXT"A'X8&VELD4,1A',L
M./04Z%$]Q<#43?D]T8G$/&2S#9$V.=L0N1H=_NJ3]S\QOZ>54/W97BEZEY&J
M%-X>9K<WDAV:\^ [)B4KF\N<8 5>"ZCW>Z;(O+O11\S]OQ2V_P)02P,$%
M  @ %#A75BD1XKKT @  4PH  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6RM5EUOVC 4_2M6-DVMU)$O"-!!I):JVAXFH:)N#],>3'(A5A,[LPUT^_6[
M3M*,E/!5C0?BCWN.S[&ODSO:"/FD$@!-GK.4J[&5:)U?V[:*$LBHZH@<.,XL
MA,RHQJY<VBJ70.,"E*6VYSB!G5'&K7!4C$UE.!(KG3(.4TG4*LNH_'T+J=B,
M+==Z&7A@RT2; 3L<Y70),]"/^51BSZY98I8!5TQP(F$QMF[<ZXGK&$ 1\8W!
M1FVUB;$R%^+)=+[$8\LQBB"%2!L*BH\U3"!-#1/J^%616O6:!KC=?F&_+\RC
MF3E5,!'I=Q;K9&P-+!+#@JY2_2 VGZ$RU#-\D4A5\4\V96RO;Y%HI;3(*C J
MR!@OG_2YVH@M@-O= _ J@'<JP*\ ?F&T5%;8NJ.:AB,I-D2::&0SC6)O"C2Z
M8=P<XTQ+G&6(T^%$<"52%E,-,;FE*>41D)FA4^1B2B5PG8!F$4TOR4?RGMA$
M)3BJ1K;&U0V''54KW98K>7M6NH.H0WSWBGB.Y[7 )Z?#W2;<1L^U<:\V[A5\
M_AZ^F4;+F(^:B 6Y9QR-,YJ2J5"LR*\?-W.E)6;9SS:K)7>WG=M<O6N5TPC&
M%MXM!7(-5OCAG1LXG]J,_R>RQC;X]3;XA]C#*=X:D!(/'U,M>KHB.95D3=,5
MD O&R>/LCN0@RT._;-N)DGY0T)MWQCIT.H[CX!&MMST>#6NH[];JN^>I+Y.3
MT)5.A&1_<,*X*$=;Y9?\P98N? $6OU<&3@AL6.C5%GIOLL"46AV7W]M1]5KW
MH8B&X* 6'+Q),'XCE*8\9GQY3'5P5/6AB(;J?JVZ?U#U1&09WNHW)GG_M"0_
M&M:0/JBE#\Z0?G:&#W:VTO7;4_R4R(:#8>U@>+Z#TQ)\N*/)'_I.WQL$K\3O
M!GJ![_>Z[J!=N^O\^T(ZYZL_(]LK^A,\M$3N,6%O??%-N?65RB7CBJ2P0*C3
MZ>.UEV4%4W:TR(LB8"XTEA1%,\&J#Z0)P/F%$/JE8^J*NHX,_P)02P,$%
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MRPC+1%:#J-IH4=I>/A,:)X-=9CB[01H#?#\70F\WYH+FWT#\!U!+ P04
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M7;_*,G;0W%+C(]X6Q D1.=I[V-T.HS")1^!UM!SZ>?FCR=Y9%3GQ1:[D1$.
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MO/K)=FU5UN93HURWW>KF]K6I[/[GD_F)?_"Y7&]:?/#HU4\[O397IOVZ^]3
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MG:YO56M!UK\9E9NF!8!1)JRIZT)I!U"RPR5QE&Z57JU V6D&V(YM6@,O;?$
M#C<%[YO69:HJ];*LRA8.DRES _CF9$8<690NKZSK&CHE;!A/#_N7X?1>,@.>
M*MGRCW\[7\R?O70XT '%"HV;&"/'E.BVM:Y5+J%X/.*1B4=)2^0 7M&KR*W:
MXA2-J> 5)&-C<GMM&MXVL7EM;;$OJRI3.0@#+%ZIML%I>Q1Q&]V8">)>H7!Z
M^(68/%4?= VHC<NKI:E*<XU;AJW$ \"R2^2$=K;6R\JH#F"@H4/E99-W6SA
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M,1OTM:Z-)]@I;O7A5'TV(#Q_(93"]KNZ\7^NAV=B]45BT>E6HH=!7NBX.F?
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M[?L_6KNC#_F"F]O:+?US8S0(!;X OZ\L2*?\@0N$+SN_^G]02P,$%     @
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M&JFO<)"#MJV"WP:EC:<>1[>FE9E0:@,<?2M)#7."#F5D6_H^>:WTCWUX@!Z
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M-<UL:8F&+)-(EZEX^O[#C\^7LR5:BOX5"8;!G$HH/[Z<+9XQ+'G-XCQX]+V
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ME,@AM#0$"OR8"?@6&IG0[1C)][B$SW\O^1X2\47KS+]SAZO2D\[515N)O>\
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M\E\KXF$41G7\JLVB>#;<F_ =&+\-=\9O!VB,OVZ,-]X=XY'U'Y":@D9:)[Z
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MI(?NB'\;X&\J4_+W^(6I*I/SY5JA@+6T .^7QE3-#1W0_D#C_']02P,$%
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M2@15U=:!_K?QR!4A-*R5B@@DP>!9S8F1WBND"- 2R-L<R0M:Q7NLU0ZR(8[
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MB1T6?Z:!Y%)7.L0-;763*CXIY&!I[@MK1,FO=-V-!@D5*6!+^._O\6(EJ3Y
M&0V Y):8G9[N[D9O%\^4M&6NHAT\SK$1<7H^YL,.J B_NUYWPSO'8]^X0A<<
M<3:0'C2F<Y%*#SG3^R?5?S9 OHG\'JTXP@Q/QBBJ7;+^*"=TS)'$T/&8"6H[
MYD(\I]@&8Q^=YUJ4J*=G+[W@$1^L__?C9.J]$_YN@27HN&OQIW5?$O$:U8F
M&2T3\5'=2Z C%O!^_9J] ]VW*N)#1V [=X<TN6T^8#D.48.IS,63!6>/W%.
M &53E^HQSV7#X:BC/ZK&KBG3BMTJ)0 2X_3Y$-WM!4-T)Y;(CC3R/S@@FP(M
M!I8=CL,C>Y^$@B#:'G3*32RDQR[32A*S]X&E?^C;T6#GNUZ%BN2OEQ@+J;KB
M)[[MT^T'TIOX7?!A>?RZ^IMT(#\O2K7 UF%_<M83+GZQC#?!UOR5<&Y#L!5?
MKI2$^;0 [Q?6ANZ&%&P_&U__'U!+ P04    "  4.%=6\+2'"K\$   T#@
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MCGFF)]$S/1G/0Z2VXA=9M4I\!.<(FHIL&') ?P6.H,=7]%BC)0(E8&O=4+U
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M7'>6:*I(^.S;FR,"7A'5V:$M-?F*6C6QN9.K(] 63K)5["&'J.Y\1M%'F(/
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M1B'<.<WT8:O.+^?R^\6E^-E,$=+)T>QD$D'M%_RP_-X!+O8+#PZG(OL3IX+
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M0E6@<3?S%M'U,G'VC<$7@2?SY!U<)ENEOKK);\7,"QTAE)A;A\!IN,<52NF
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M9839!G?6XL8?X/9BN".HTL GF6/^'B DDAW3>,MT%A]$O,'L OJ]<XBC.#Z
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M!"H+('LFI=EO;(#^LQ/_!5!+ P04    "  4.%=6[*5W&08%  !_#   &0
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M/GFK/T$S;57+[BF[4#4**&90T&R@7@-K7 P Q0!##T)S#VKP(A-M20/.5GC
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M NKO\S25;S>Z@OHHY>0_4$L#!!0    ( !0X5U88Q=F;>@(  +('   9
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M^$;R-6=46G+!F*JEY7)#EDIPQL&0#V2%2937 ISU4EE  RK$3W+%1>U6@ZR
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M09H ?+\40N\FIO6W-WWT#U!+ P04    "  4.%=6K.X)=K,"   8!P  &0
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M(]<@G%W"31J0ZQK$/P RA>2"]'OGQ/=\OT,^>;^\]U;N8DO:OOAM7_S*KW_
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M)D!_GW.N-A/3B.M[-_H+4$L#!!0    ( !0X5U8-;(8GC <  "9+   9
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M5KV95QN9U8EDZW(O\(%)R;+R< 4D :X#U.\+QN33B=Y>;+:3YW\!4$L#!!0
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ME$E4PEQ#_=Y0GRCA;B4W4;RVC7W&E;XF[+#0%SD($Z#WYYRK]<0DZ/X:I+\
M4$L#!!0    ( !0X5U9YS-&!90(  (<&   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;*U576^;,!3]*Q:;IE;J8B ?JS*"U":;MH=)4:-N#],>'+@)
M5@VFM@GM?OVN#6%)E[39-![ '_<<GW,O7*):JCN= 1CRD(M"3[S,F'),J4XR
MR)GNR1(*W%E)E3.#4[6FNE3 4@?*!0U]?T1SQ@LOCMS:7,61K(S@!<P5T56>
M,_5X#4+6$R_PM@LW?)T9NT#CJ&1K6("Y+><*9[1C27D.A>:R( I6$^\J&$^'
M-MX%?.50ZYTQL4Z64M[9R>=TXOE6$ A(C&5@^-C %(2P1"CCON7TNB,M<'>\
M9?_HO*.7)=,PE>(;3TTV\2X]DL**5<+<R/H3M'Z<P$0*[>ZD;F*' X\DE38R
M;\&H(.=%\V0/;1YV ,$Q0-@"PE,!_1;0=T8;9<[6C!D61TK61-EH9+,#EQN'
M1C>\L%5<&(6[''$FGLH\QVPNC$SNR%LRQR2"4I"V*V<S,(P+?8Y[KPDE.F,*
M=$0-'FT):-(><]T<$QXY9@9)C_2#"Q+Z87@ /CT='NS#*1KN7(>=Z]#Q]8_P
M?;BON'DDWZ^6VBA\DWX<<M10# Y3V*]KK$N6P,3#ST>#VH 7OWD5C/SWA_S]
M)[(]M_W.;?\Y]OAW4;4MZD5;1<(JDTG%?^+&&2_:U?-#J6CX1X[?]H5-C%W"
M71'=[-H\(7#/PJ"S,/@["R539,-$!4[Z[6)&2E"-A8,.&OK+'6%^#U4%3_2_
M&+:G?MBI'_Y3 ;"K:L.*E!?KERHP_".Q3U/_7$2CFNZT"=NBOS"UYH4F E:(
M\7OOD$(U;:^9&%FZSK&4!ON0&V;XIP!E W!_):793FPSZOX]\2]02P,$%
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M+-"EI7Y<6C-G:*,WY1R&Y@."V$AZCPF/4LIW,GEK.1I[@@\7DPNAM<]G30.
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M:%;\W! <$Z8,Y/<5I>+XH :H+\D7_P%02P,$%     @ %#A75E\WP\%Y P
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M"X0)T->GG*NGB;E!>6J+_@)02P,$%     @ %#A75D;RV5PY P  LPH  !D
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M7)EO'Y!68)XOA-#/ WNZ;KZFLC]02P,$%     @ %#A75J TOG;5 P  #14
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M_R?5Y7QONC[^LOP^.7I[+S@'^)/@\0M02P,$%     @ %#A75B%=IR;- 0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( !0X5U9SR?2I[0   "L"   1
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M965T,BYX;6Q02P$"% ,4    "  4.%=6A#'RJ,0%  !>&   &
M    @(%N$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M%#A75BD1XKKT @  4PH  !@              ("!:!@  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !0X5U;7JN#32P0  *D/   8
M          " @9(;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    "  4.%=6EFQ*-M<"   9"   &               @($3(   >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ %#A75A&L2=DY"@  G'T
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !0X5U81&H.3TQT  .59   9
M      " @?1"  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ %#A75L857\=U P  @@@  !D              ("!_F   'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  4.%=6^[?6(^\*   @&P
M&0              @(&J9   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( !0X5U9 LKMV[ 0  -H+   9              " @=!O  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ %#A75C-DS47\
M"P  ?R4  !D              ("!\W0  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    "  4.%=6V]E=#'<,  "L(0  &0
M@($F@0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !0X
M5U9 .RK9V@@  $(6   9              " @=2-  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ %#A75O"TAPJ_!   - X  !D
M         ("!Y98  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    "  4.%=6EE'K=Y<:  #^4P  &0              @(';FP  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !0X5U: C)9+> ,  (@(
M   9              " @:FV  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ %#A75NV;@'BJ P  J@D  !D              ("!6+H
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  4.%=6^',*
MH[$"   "!@  &0              @($YO@  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( !0X5U:JKM;*\P(  %$'   9
M  " @2'!  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M%#A75LV2>*'D @  @@8  !D              ("!2\0  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    "  4.%=6[*5W&08%  !_#   &0
M            @(%FQP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( !0X5U:=A>Q[;00  'H*   9              " @:/,  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ %#A75H!63WW& P
ME0X  !D              ("!1]$  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    "  4.%=67&W.!HD'  !6.0  &0              @(%$
MU0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !0X5U88
MQ=F;>@(  +('   9              " @03=  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ %#A75H,K0MGB @  ' D  !D
M     ("!M=\  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !0X5U988!W&SP(  (,'   9              "
M@9WO  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ %#A7
M5@ULAB>,!P  )DL  !D              ("!H_(  'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    "  4.%=6X:)!"N8"   C"   &0
M        @(%F^@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( !0X5U82M:KDQ0,  %H6   9              " @8/]  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ %#A75JS\?&1* @  "04
M !D              ("!?P$! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    "  4.%=6JX<XP\<&  !,/0  &0              @($ ! $
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !0X5U9H5;(7
M&0<  +A    9              " @?X* 0!X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ %#A75NO:LJNP @  )@@  !D
M ("!3A(! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  4
M.%=6><S1@64"  "'!@  &0              @($U%0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( !0X5U8(2A=RE@,  "41   9
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M970T.2YX;6Q02P$"% ,4    "  4.%=6M2AN*%,#  #!#0  &0
M    @(&Z,0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M !0X5U9&\ME<.0,  +,*   9              " @40U 0!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ %#A75D%ATERR P  <Q   !D
M             ("!M#@! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    "  4.%=6:[K9#;,#  !9#0  &0              @(&=/ $ >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( !0X5U:@-+YVU0,
M  T5   9              " @8=  0!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ %#A75C_=TWPW P  [A,   T              ( !
MDT0! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  4.%=6EXJ[',     3 @
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8;6Q02P4&     #X /@#I$   >5$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>161</ContextCount>
  <ElementCount>281</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Description of Business and Basis of Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements</Role>
      <ShortName>Description of Business and Basis of Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/BalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Stock-based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/StockbasedCompensationPlans</Role>
      <ShortName>Stock-based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://imux.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/BalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/BalanceSheetDetails</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/CommitmentsandContingencies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/FairValue</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/CommonStock</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Stock-based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/StockbasedCompensationPlansTables</Role>
      <ShortName>Stock-based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/StockbasedCompensationPlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Description of Business and Basis of Financial Statements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails</Role>
      <ShortName>Description of Business and Basis of Financial Statements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Fair Value - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/FairValueAdditionalInformationDetail</Role>
      <ShortName>Fair Value - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Common Stock - Shelf Registration Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockShelfRegistrationStatementDetails</Role>
      <ShortName>Common Stock - Shelf Registration Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Common Stock - Equity Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockEquityOfferingDetails</Role>
      <ShortName>Common Stock - Equity Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Common Stock - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockCommonStockDetails</Role>
      <ShortName>Common Stock - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Common Stock - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockPreferredStockDetails</Role>
      <ShortName>Common Stock - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Stock-based Compensation Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Stock-based Compensation Plans - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation Plans - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Stock-based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails</Role>
      <ShortName>Stock-based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Stock-based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails</Role>
      <ShortName>Stock-based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails</Role>
      <ShortName>Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="imux-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  imux-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="imux-20221231.htm">imux-20221231.htm</File>
    <File>exhibit23111.htm</File>
    <File>exhibit422022.htm</File>
    <File>imux-123122xexhibit211.htm</File>
    <File>imux-123122xexhibit311.htm</File>
    <File>imux-123122xexhibit312.htm</File>
    <File>imux-123122xexhibit321.htm</File>
    <File>imux-123122xexhibit322.htm</File>
    <File>imux-20221231.xsd</File>
    <File>imux-20221231_cal.xml</File>
    <File>imux-20221231_def.xml</File>
    <File>imux-20221231_lab.xml</File>
    <File>imux-20221231_pre.xml</File>
    <File>imux-ex105dienstvertragand.htm</File>
    <File>imux-ex106dienstvertragdan.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>imux-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="514">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "imux-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 514,
    "http://xbrl.sec.gov/dei/2022": 40
   },
   "contextCount": 161,
   "dts": {
    "calculationLink": {
     "local": [
      "imux-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "imux-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "imux-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "imux-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imux-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "imux-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 442,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 5,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 9
   },
   "keyCustom": 34,
   "keyStandard": 247,
   "memberCustom": 27,
   "memberStandard": 28,
   "nsprefix": "imux",
   "nsuri": "http://imux.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "dei:DocumentType",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://imux.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "dei:DocumentType",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ic79be0a87a2d43ae992ef8e7625d53e2_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000010 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "menuCat": "Statements",
     "order": "10",
     "role": "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ic79be0a87a2d43ae992ef8e7625d53e2_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Description of Business and Basis of Financial Statements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements",
     "shortName": "Description of Business and Basis of Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://imux.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Balance Sheet Details",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://imux.com/role/BalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://imux.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Fair Value",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://imux.com/role/FairValue",
     "shortName": "Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Common Stock",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://imux.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Stock-based Compensation Plans",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://imux.com/role/StockbasedCompensationPlans",
     "shortName": "Stock-based Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://imux.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://imux.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://imux.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "imux:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "imux:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Balance Sheet Details (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://imux.com/role/BalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://imux.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Fair Value (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://imux.com/role/FairValueTables",
     "shortName": "Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Common Stock (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://imux.com/role/CommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Stock-based Compensation Plans (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://imux.com/role/StockbasedCompensationPlansTables",
     "shortName": "Stock-based Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://imux.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityNumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Description of Business and Basis of Financial Statements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails",
     "shortName": "Description of Business and Basis of Financial Statements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityNumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://imux.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "imux:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherShortTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails",
     "shortName": "Summary of Significant Accounting Policies - Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "imux:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i29c8be7c0e67485390b3fa4ca6373ec9_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i1b28bf41d41a44729bb53cadae860beb_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails",
     "shortName": "Summary of Significant Accounting Policies - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "imux:PrepaidClinicalAndRelatedCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "imux:PrepaidClinicalAndRelatedCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "imux:ClinicalCostsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails",
     "shortName": "Balance Sheet Details - Schedule of Accounts Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "imux:ClinicalCostsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "imux:AccruedClinicalCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails",
     "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "imux:AccruedClinicalCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails",
     "shortName": "Balance Sheet Details - Schedule of Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "imux:OperatingLeaseIncrementalBorrowingRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "imux:OperatingAndVariableLeasesCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails",
     "shortName": "Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i4387fb9fcb644cbfa9f299c3c426b334_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i4387fb9fcb644cbfa9f299c3c426b334_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "imux:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "id15e6eed9a474921925790496d9be215_I20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentInterestRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Fair Value - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://imux.com/role/FairValueAdditionalInformationDetail",
     "shortName": "Fair Value - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i89236a268ded4c38beb10ce49d29d398_I20201130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "imux:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Common Stock - Shelf Registration Statement (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://imux.com/role/CommonStockShelfRegistrationStatementDetails",
     "shortName": "Common Stock - Shelf Registration Statement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i89236a268ded4c38beb10ce49d29d398_I20201130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "imux:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i444f4698aac042ccbe20eda2d1da8d8b_D20221012-20221012",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Common Stock - Equity Offering (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://imux.com/role/CommonStockEquityOfferingDetails",
     "shortName": "Common Stock - Equity Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i88aea673e8c04440a92d7eb913623ddd_D20221010-20221010",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Common Stock - Common Stock (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://imux.com/role/CommonStockCommonStockDetails",
     "shortName": "Common Stock - Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Common Stock - Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://imux.com/role/CommonStockPreferredStockDetails",
     "shortName": "Common Stock - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
     "shortName": "Common Stock - Shares Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Stock-based Compensation Plans - Additional Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails",
     "shortName": "Stock-based Compensation Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ia0414aabe31c45cfb03ec35d6944f613_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Stock-based Compensation Plans - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails",
     "shortName": "Stock-based Compensation Plans - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i46791b70b39149f995d04e9d61847f37_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Stock-based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails",
     "shortName": "Stock-based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5621a4c9af0345529c9a631b26c01878_D20220101-20221231",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Stock-based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails",
     "shortName": "Stock-based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5f8826a093524faab9e1c7138d3c7734_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://imux.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails",
     "shortName": "Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://imux.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "id31cbe772be540f6ae60d3269ef43568_D20210101-20210514",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "imux:SalaryCostsMonthlyBaseSalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "id31cbe772be540f6ae60d3269ef43568_D20210101-20210514",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "imux:SalaryCostsMonthlyBaseSalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ic389dfc27c9a4f599aa3e1e541429096_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "ic389dfc27c9a4f599aa3e1e541429096_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i42cae9630d124c15823d3c9c381fc07a_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i42cae9630d124c15823d3c9c381fc07a_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://imux.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20221231.htm",
      "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 58,
   "tag": {
    "country_AU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA",
        "terseLabel": "Australia"
       }
      }
     },
     "localname": "AU",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://imux.com/role/FairValueAdditionalInformationDetail",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of persons employed by the Entity",
        "label": "Entity Number of Employees",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "EntityNumberOfEmployees",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "imux_A2017InducementEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Inducement Equity Incentive Plan [Member]",
        "label": "2017 Inducement Equity Incentive Plan [Member]",
        "terseLabel": "2017 Inducement Equity Incentive Plan"
       }
      }
     },
     "localname": "A2017InducementEquityIncentivePlanMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_A2019OmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Omnibus Equity Incentive Plan [Member]",
        "label": "2019 Omnibus Equity Incentive Plan [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan"
       }
      }
     },
     "localname": "A2019OmnibusEquityIncentivePlanMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails",
      "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_A2021EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Employee Stock Purchase Plan",
        "label": "2021 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee stock purchase plan"
       }
      }
     },
     "localname": "A2021EmployeeStockPurchasePlanMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_A4SCRoyaltySettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4SC Royalty Settlement",
        "label": "4SC Royalty Settlement [Member]",
        "terseLabel": "4SC Royalty Settlement"
       }
      }
     },
     "localname": "A4SCRoyaltySettlementMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_AccruedClinicalCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Costs, Current",
        "label": "Accrued Clinical Costs, Current",
        "terseLabel": "Accrued clinical and related costs"
       }
      }
     },
     "localname": "AccruedClinicalCostsCurrent",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_AccruedCompensationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Compensation, Current",
        "label": "Accrued Compensation, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedCompensationCurrent",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_AccruedLegalAndAuditCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Legal And Audit Costs, Current",
        "label": "Accrued Legal And Audit Costs, Current",
        "terseLabel": "Accrued legal and audit costs"
       }
      }
     },
     "localname": "AccruedLegalAndAuditCostsCurrent",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales",
        "label": "Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales",
        "terseLabel": "Asset purchase agreement, royalties as percent of aggregated net sales"
       }
      }
     },
     "localname": "AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_AtTheMarketSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Sales Agreement",
        "label": "At The Market Sales Agreement [Member]",
        "terseLabel": "At The Market Sales Agreement"
       }
      }
     },
     "localname": "AtTheMarketSalesAgreementMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://imux.com/20221231",
     "xbrltype": "stringItemType"
    },
    "imux_AustraliaAndGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Australia and Germany",
        "label": "Australia and Germany [Member]",
        "terseLabel": "Australia and Germany"
       }
      }
     },
     "localname": "AustraliaAndGermanyMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents And Other Investments",
        "label": "Cash And Cash Equivalents And Other Investments [Policy Text Block]",
        "terseLabel": "Cash And Cash Equivalents And Other Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imux_ClinicalCostsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Costs Payable, Current",
        "label": "Clinical Costs Payable, Current",
        "terseLabel": "Clinical and related costs"
       }
      }
     },
     "localname": "ClinicalCostsPayableCurrent",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_December2020ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2020 ATM",
        "label": "December 2020 ATM [Member]",
        "terseLabel": "December 2020 ATM"
       }
      }
     },
     "localname": "December2020ATMMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_DeferredTaxAssetsAndLiabilitiesGross": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets and Liabilities, Gross",
        "label": "Deferred Tax Assets and Liabilities, Gross",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsAndLiabilitiesGross",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_DuaneNashMDJDMBAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duane Nash, MD, JD, MBA",
        "label": "Duane Nash, MD, JD, MBA [Member]",
        "terseLabel": "Duane Nash, MD, JD, MBA"
       }
      }
     },
     "localname": "DuaneNashMDJDMBAMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_EmployeeStockOptionsforFutureGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options for Future Grant [Member]",
        "label": "Employee Stock Options for Future Grant [Member]",
        "terseLabel": "Common stock options available for future grant:"
       }
      }
     },
     "localname": "EmployeeStockOptionsforFutureGrantMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent",
        "label": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent",
        "terseLabel": "Increase or decrease not in excess of percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage",
        "label": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage",
        "terseLabel": "May not exercise of percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period",
        "label": "Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period",
        "terseLabel": "Increase or decrease not In excess of prior notice period"
       }
      }
     },
     "localname": "EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "imux_ExecutiveChairmanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Chairman Agreement",
        "label": "Executive Chairman Agreement [Member]",
        "terseLabel": "Executive Chairman Agreement"
       }
      }
     },
     "localname": "ExecutiveChairmanAgreementMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_ForeignExcludingGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign, Excluding Germany",
        "label": "Foreign, Excluding Germany [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignExcludingGermanyMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_GovernmentAssistanceRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Assistance Rate",
        "label": "Government Assistance Rate",
        "terseLabel": "Government assistance rate"
       }
      }
     },
     "localname": "GovernmentAssistanceRate",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_GrafelfingGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grafelfing, Germany",
        "label": "Grafelfing, Germany [Member]",
        "terseLabel": "Grafelfing, Germany"
       }
      }
     },
     "localname": "GrafelfingGermanyMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_ImmunicAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunic AG [Member]",
        "label": "Immunic AG [Member]",
        "terseLabel": "Immunic AG"
       }
      }
     },
     "localname": "ImmunicAGMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_IncentiveEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Employee Stock Option [Member]",
        "label": "Incentive Employee Stock Option [Member]",
        "terseLabel": "Incentive Employee Stock Option"
       }
      }
     },
     "localname": "IncentiveEmployeeStockOptionMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "terseLabel": "Increase in operating lease, right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_InvestmentEarningInterestRateRemainingMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment, Earning Interest Rate, Remaining Maturity Period",
        "label": "Investment, Earning Interest Rate, Remaining Maturity Period",
        "terseLabel": "Earning interest at a rate maturity (in months)"
       }
      }
     },
     "localname": "InvestmentEarningInterestRateRemainingMaturityPeriod",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "imux_July2021PublicEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July 2021 Public Equity Offering",
        "label": "July 2021 Public Equity Offering [Member]",
        "terseLabel": "July 2021 Public Equity Offering"
       }
      }
     },
     "localname": "July2021PublicEquityOfferingMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_LegalAndAuditCostsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal And Audit Costs Payable, Current",
        "label": "Legal And Audit Costs Payable, Current",
        "terseLabel": "Legal and audit costs"
       }
      }
     },
     "localname": "LegalAndAuditCostsPayableCurrent",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_LesseeOperatingLeaseRentHolidayPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Rent Holiday Period",
        "label": "Lessee, Operating Lease, Rent Holiday Period",
        "terseLabel": "Rent holiday period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentHolidayPeriod",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "imux_LesseeOperatingLeasesNumberOfExistingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Leases, Number Of Existing Leases",
        "label": "Lessee, Operating Leases, Number Of Existing Leases",
        "terseLabel": "Number of existing operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesNumberOfExistingLeases",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration",
        "label": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration",
        "terseLabel": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_May2022ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2022 ATM",
        "label": "May 2022 ATM [Member]",
        "terseLabel": "May 2022 ATM"
       }
      }
     },
     "localname": "May2022ATMMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_NewYorkCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York City",
        "label": "New York City [Member]",
        "terseLabel": "New York City"
       }
      }
     },
     "localname": "NewYorkCityMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_NonStatutoryEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Statutory Employee Stock Option [Member]",
        "label": "Non-Statutory Employee Stock Option [Member]",
        "terseLabel": "Non-Statutory Employee Stock Option"
       }
      }
     },
     "localname": "NonStatutoryEmployeeStockOptionMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_NumberOfDevelopmentPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Development Programs",
        "label": "Number Of Development Programs",
        "terseLabel": "Number of development programs pursued"
       }
      }
     },
     "localname": "NumberOfDevelopmentPrograms",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "imux_NumberOfFinancialInstitutionsUsedForCashDeposits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Financial Institutions Used For Cash Deposits",
        "label": "Number of Financial Institutions Used For Cash Deposits",
        "terseLabel": "Number of financial institutions used for cash deposits"
       }
      }
     },
     "localname": "NumberOfFinancialInstitutionsUsedForCashDeposits",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "imux_October2022PIPETransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "October 2022 PIPE Transaction",
        "label": "October 2022 PIPE Transaction [Member]",
        "terseLabel": "October 2022 PIPE Transaction"
       }
      }
     },
     "localname": "October2022PIPETransactionMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_OperatingAndVariableLeasesCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Variable Leases, Cost",
        "label": "Operating And Variable Leases, Cost",
        "terseLabel": "Operating and variable lease cost"
       }
      }
     },
     "localname": "OperatingAndVariableLeasesCost",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_OperatingLeaseIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Incremental Borrowing Rate",
        "label": "Operating Lease, Incremental Borrowing Rate",
        "terseLabel": "Incremental borrowing rate on operating leases"
       }
      }
     },
     "localname": "OperatingLeaseIncrementalBorrowingRate",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Prefunded stock warrants"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_PrepaidClinicalAndRelatedCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Clinical And Related Costs, Current",
        "label": "Prepaid Clinical And Related Costs, Current",
        "terseLabel": "Prepaid clinical and related costs"
       }
      }
     },
     "localname": "PrepaidClinicalAndRelatedCostsCurrent",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_ResearchAndDevelopmentTaxIncentiveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Incentive, Current",
        "label": "Research And Development Tax Incentive, Current",
        "terseLabel": "Australian research and development tax incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxIncentiveCurrent",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_RoyaltySettlementAgreementCashPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Settlement Agreement, Cash Payment, Percent",
        "label": "Royalty Settlement Agreement, Cash Payment, Percent",
        "terseLabel": "Royalty settlement agreement, cash payment, percent"
       }
      }
     },
     "localname": "RoyaltySettlementAgreementCashPaymentPercent",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_RoyaltySettlementAgreementSalesNet": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Settlement Agreement, Sales Net",
        "label": "Royalty Settlement Agreement, Sales Net",
        "terseLabel": "4SC Royalty Settlement (See Note 4)",
        "verboseLabel": "4SC royalty settlement"
       }
      }
     },
     "localname": "RoyaltySettlementAgreementSalesNet",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_RoyaltySettlementAgreementSharesPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Settlement Agreement, Shares Payment, Percent",
        "label": "Royalty Settlement Agreement, Shares Payment, Percent",
        "terseLabel": "Royalty settlement agreement, shares payment, percent"
       }
      }
     },
     "localname": "RoyaltySettlementAgreementSharesPaymentPercent",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_SalaryCostsMonthlyBaseSalary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salary Costs, Monthly Base Salary",
        "label": "Salary Costs, Monthly Base Salary",
        "terseLabel": "Monthly base salary"
       }
      }
     },
     "localname": "SalaryCostsMonthlyBaseSalary",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_SaleOfStockRemainingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Remaining Capacity",
        "label": "Sale Of Stock, Remaining Capacity",
        "terseLabel": "Remaining capacity"
       }
      }
     },
     "localname": "SaleOfStockRemainingCapacity",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent",
        "label": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent",
        "terseLabel": "Additional shares authorized, percent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_SharesIssuedWeightedAverageSharePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Weighted Average Share Price Per Share",
        "label": "Shares Issued, Weighted Average Share Price Per Share",
        "terseLabel": "Shares Issued, Weighted Average Share Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedWeightedAverageSharePricePerShare",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "label": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "terseLabel": "Commission, percent of gross proceeds from sale of common stock"
       }
      }
     },
     "localname": "ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_ShelfRegistrationStatementAmountRemaining": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Statement, Amount Remaining",
        "label": "Shelf Registration Statement, Amount Remaining",
        "terseLabel": "Shelf Registration Statement, Amount Remaining"
       }
      }
     },
     "localname": "ShelfRegistrationStatementAmountRemaining",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_ShelfRegistrationTerminationPriorWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration, Termination, Prior Written Notice",
        "label": "Shelf Registration, Termination, Prior Written Notice",
        "terseLabel": "Shelf registration, termination, prior written notice"
       }
      }
     },
     "localname": "ShelfRegistrationTerminationPriorWrittenNotice",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "imux_TaxYearsPost2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Years Post 2017",
        "label": "Tax Years Post 2017 [Member]",
        "terseLabel": "Post 2017"
       }
      }
     },
     "localname": "TaxYearsPost2017Member",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_TaxYearsPriorTo2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Years Prior to 2018",
        "label": "Tax Years Prior to 2018 [Member]",
        "terseLabel": "Prior to 2018"
       }
      }
     },
     "localname": "TaxYearsPriorTo2018Member",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_TwoThousandFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "label": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan, Evergreen Provision"
       }
      }
     },
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanMember",
     "nsuri": "http://imux.com/20221231",
     "presentation": [
      "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r438",
      "r517",
      "r552",
      "r553",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Directors Chairman"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r229",
      "r233",
      "r442",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r256",
      "r380",
      "r403",
      "r439",
      "r440",
      "r451",
      "r456",
      "r461",
      "r514",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r256",
      "r380",
      "r403",
      "r439",
      "r440",
      "r451",
      "r456",
      "r461",
      "r514",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r248",
      "r256",
      "r287",
      "r288",
      "r289",
      "r379",
      "r380",
      "r403",
      "r439",
      "r440",
      "r451",
      "r456",
      "r461",
      "r508",
      "r514",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r248",
      "r256",
      "r287",
      "r288",
      "r289",
      "r379",
      "r380",
      "r403",
      "r439",
      "r440",
      "r451",
      "r456",
      "r461",
      "r508",
      "r514",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r229",
      "r233",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r257",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r178",
      "r257",
      "r473",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r202",
      "r203",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r452",
      "r460",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://imux.com/role/FairValueAdditionalInformationDetail",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r202",
      "r203",
      "r425",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r452",
      "r460",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://imux.com/role/FairValueAdditionalInformationDetail",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r178",
      "r257",
      "r473",
      "r474",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r489",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r16",
      "r459"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails",
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails",
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r143",
      "r399",
      "r408",
      "r409"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r23",
      "r26",
      "r108",
      "r368",
      "r404",
      "r405",
      "r479",
      "r480",
      "r481",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r11",
      "r459"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r485",
      "r486",
      "r487",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r90",
      "r91",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r72",
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r115",
      "r123",
      "r139",
      "r161",
      "r196",
      "r198",
      "r200",
      "r204",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r329",
      "r331",
      "r344",
      "r459",
      "r512",
      "r513",
      "r556"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r134",
      "r145",
      "r161",
      "r204",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r329",
      "r331",
      "r344",
      "r459",
      "r512",
      "r513",
      "r556"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails",
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time Deposits",
        "verboseLabel": "Time Deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r51",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Basis of Financial Statements"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r46",
      "r136",
      "r441"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r40",
      "r46",
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r40",
      "r112"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r118",
      "r127"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (note 4)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r213",
      "r214",
      "r426",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total common shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Common stock cash dividends paid (in USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockCommonStockDetails",
      "http://imux.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, cash dividends declared (in USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockCommonStockDetails",
      "http://imux.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r485",
      "r486",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockCommonStockDetails",
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockCommonStockDetails",
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r10",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r10",
      "r459"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 130,000,000 shares authorized and 39,307,286 and 26,335,418 shares issued and outstanding at December\u00a031, 2022 and 2021, respectively",
        "verboseLabel": "Common stock issued"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r27",
      "r148",
      "r150",
      "r156",
      "r396",
      "r401"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r44",
      "r104",
      "r316",
      "r321",
      "r322",
      "r484"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r7",
      "r8",
      "r116",
      "r122",
      "r310"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "imux_DeferredTaxAssetsAndLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "imux_DeferredTaxAssetsAndLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r545"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets, valuation allowance total"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r102",
      "r546"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Foreign net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r102",
      "r546"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r102",
      "r546"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r102",
      "r546"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": {
     "auth_ref": [
      "r102",
      "r546"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.",
        "label": "Deferred Tax Assets, Unrealized Currency Losses",
        "terseLabel": "Unrealized gain or loss"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r102",
      "r546"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum annual contributions per employee (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r44",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r44",
      "r195"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r261",
      "r292",
      "r293",
      "r295",
      "r300",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r157",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r179",
      "r181",
      "r183",
      "r184",
      "r185",
      "r187",
      "r335",
      "r336",
      "r397",
      "r402",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r157",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r181",
      "r183",
      "r184",
      "r185",
      "r187",
      "r335",
      "r336",
      "r397",
      "r402",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r162",
      "r304",
      "r323"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r544",
      "r547"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r323",
      "r544"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Tax effect of rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r544",
      "r547"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r544",
      "r547"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r544",
      "r547"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period over which compensation cost will be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r72",
      "r132",
      "r152",
      "r153",
      "r154",
      "r165",
      "r166",
      "r167",
      "r169",
      "r175",
      "r177",
      "r188",
      "r205",
      "r247",
      "r296",
      "r297",
      "r298",
      "r318",
      "r319",
      "r334",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r368",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueAdditionalInformationDetail",
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r337",
      "r338",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueAdditionalInformationDetail",
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r230",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r338",
      "r376",
      "r377",
      "r378",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r230",
      "r249",
      "r254",
      "r338",
      "r376",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r230",
      "r249",
      "r254",
      "r338",
      "r377",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r230",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r338",
      "r378",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r230",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r376",
      "r377",
      "r378",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r341",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalMinistryOfFinanceGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Germany.",
        "label": "Federal Ministry of Finance, Germany [Member]",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "FederalMinistryOfFinanceGermanyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Foreign currency loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation and Presentation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r137",
      "r206",
      "r394",
      "r448",
      "r459",
      "r497",
      "r504"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Carrying amount of goodwill at December 31, 2022",
        "periodStartLabel": "Carrying amount of goodwill at December 31, 2021",
        "verboseLabel": "Goodwill (note 2)"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r209",
      "r210",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r44",
      "r207",
      "r208",
      "r209",
      "r448"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Impairment of goodwill during the year ended December 31, 2022",
        "terseLabel": "Goodwill impairment (see Note 2)",
        "verboseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofOperations",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of government assistance recognized.",
        "label": "Government Assistance, Amount",
        "terseLabel": "Government assistance, amount"
       }
      }
     },
     "localname": "GovernmentAssistanceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "auth_ref": [
      "r359",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for government assistance.",
        "label": "Government Assistance [Policy Text Block]",
        "terseLabel": "Government assistance"
       }
      }
     },
     "localname": "GovernmentAssistancePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes government assistance.",
        "label": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r31",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "terseLabel": "Net loss before income tax"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r162",
      "r305",
      "r308",
      "r315",
      "r320",
      "r324",
      "r325",
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r151",
      "r302",
      "r303",
      "r308",
      "r309",
      "r314",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r33",
      "r194"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentInterestRate": {
     "auth_ref": [
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of interest on investment.",
        "label": "Investment Interest Rate",
        "terseLabel": "Investment interest rate"
       }
      }
     },
     "localname": "InvestmentInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueAdditionalInformationDetail",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_InvestmentTableTextBlock": {
     "auth_ref": [
      "r492",
      "r493",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment.",
        "label": "Investment [Table Text Block]",
        "terseLabel": "Schedule of Investment"
       }
      }
     },
     "localname": "InvestmentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueAdditionalInformationDetail",
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueAdditionalInformationDetail",
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Common stock issued in connection with the 4SC royalty settlement (see Note 4)"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: interest portion"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term (in years)",
        "verboseLabel": "Lease term (in months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r161",
      "r204",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r330",
      "r331",
      "r332",
      "r344",
      "r446",
      "r512",
      "r556",
      "r557"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r15",
      "r117",
      "r125",
      "r459",
      "r483",
      "r494",
      "r549"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r135",
      "r161",
      "r204",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r330",
      "r331",
      "r332",
      "r344",
      "r459",
      "r512",
      "r556",
      "r557"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r161",
      "r204",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r330",
      "r331",
      "r332",
      "r344",
      "r512",
      "r556",
      "r557"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r65",
      "r66",
      "r215",
      "r216",
      "r217",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueAdditionalInformationDetail",
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r40",
      "r42",
      "r45"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r29",
      "r45",
      "r120",
      "r129",
      "r133",
      "r146",
      "r149",
      "r154",
      "r161",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r182",
      "r196",
      "r197",
      "r199",
      "r201",
      "r204",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r336",
      "r344",
      "r447",
      "r512"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://imux.com/role/ConsolidatedStatementsofOperations",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r196",
      "r197",
      "r199",
      "r201",
      "r447"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease obligation"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use asset, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r144",
      "r459"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r105",
      "r106",
      "r107"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r72",
      "r147",
      "r150",
      "r155",
      "r350",
      "r355",
      "r356",
      "r395",
      "r400",
      "r479",
      "r480"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Foreign exchange translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r459"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails",
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherShortTermInvestments": {
     "auth_ref": [
      "r119",
      "r128",
      "r476"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term investments classified as other.",
        "label": "Other Short-Term Investments",
        "terseLabel": "Investments - other"
       }
      }
     },
     "localname": "OtherShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r67"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForCommissions": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for commissions during the current period.",
        "label": "Payments for Commissions",
        "terseLabel": "Underwriter commissions"
       }
      }
     },
     "localname": "PaymentsForCommissions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Purchases of Investments-other"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails",
      "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails",
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails",
      "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails",
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/CommonStockPreferredStockDetails",
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/CommonStockPreferredStockDetails",
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r9",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/CommonStockPreferredStockDetails",
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r9",
      "r459"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at December\u00a031, 2022 and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Other current assets and prepaid expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from issuance of private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r38",
      "r88"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from shares issued in connection with the Company's employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r88"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r61",
      "r126",
      "r398",
      "r459"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r255",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r131",
      "r371",
      "r372",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r255",
      "r371",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r369",
      "r370",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r93",
      "r130",
      "r564"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r12",
      "r79",
      "r124",
      "r407",
      "r409",
      "r459"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r132",
      "r165",
      "r166",
      "r167",
      "r169",
      "r175",
      "r177",
      "r205",
      "r296",
      "r297",
      "r298",
      "r318",
      "r319",
      "r334",
      "r404",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r366",
      "r458"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of use asset obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares issues in private placement transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r86",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense for Stock Awards Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r448",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Net Loss before Income Tax Based on Jurisdictions"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r258",
      "r260",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails",
      "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails",
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r81",
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r68",
      "r69",
      "r71",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r140",
      "r141",
      "r142",
      "r189",
      "r231",
      "r232",
      "r233",
      "r235",
      "r239",
      "r244",
      "r246",
      "r451",
      "r472",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Purchase price of the stock, at discount from market price at purchase date (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares issued under the ESPP (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails",
      "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails",
      "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails",
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Other Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, Weighted-Average Exercise Price (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited and expired (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending balance (in shares)",
        "periodStartLabel": "Outstanding, Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending balance (in USD per share)",
        "periodStartLabel": "Outstanding, Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest , aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest, Weighted-Average Exercise Price (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails",
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r265",
      "r284",
      "r285",
      "r286",
      "r287",
      "r290",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails",
      "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, weighted-average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, weighted-average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest , weighted-average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r51",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r22",
      "r72",
      "r132",
      "r152",
      "r153",
      "r154",
      "r165",
      "r166",
      "r167",
      "r169",
      "r175",
      "r177",
      "r188",
      "r205",
      "r247",
      "r296",
      "r297",
      "r298",
      "r318",
      "r319",
      "r334",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r368",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r188",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Common stock issued in connection with the 4SC royalty settlement (see Note 4)"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r9",
      "r10",
      "r72",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued in connection with the Company's employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r72",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r9",
      "r10",
      "r72",
      "r79",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r9",
      "r10",
      "r72",
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Shares issued in connection with the Company's employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r72",
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r10",
      "r13",
      "r14",
      "r58",
      "r459",
      "r483",
      "r494",
      "r549"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r160",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r247",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r357",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r357",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r357",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/CommonStockEquityOfferingDetails",
      "http://imux.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r0",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r301",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Uncertain tax positions that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r190",
      "r191",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance increase"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "VAT receivable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Prefunded stock warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r180",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r179",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.5)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342943-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342943-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342957-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r463": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r464": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r465": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r466": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r467": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r468": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r469": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r471": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "https://asc.fasb.org/topic&trid=75115024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "https://asc.fasb.org/topic&trid=2197064",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001280776-23-000004-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001280776-23-000004-xbrl.zip
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MXG :CO9'[\UP>'8QB:/)6QA'T]/;03P&_)I7>'P<+D$<EPP2*<HJ<;0$O63
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M#,6XK->"(8&;YBJGL'>98HP)D2F6Z/OYZ1+[D=?+C2B^L,7<#."(F2+"6$L
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MN'.F]V&F\@F!\C'_6Q[TKXH\_R]02P,$%     @ %#A75@VOB%Y: P  ;0T
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M>"TQ,C,Q,C)X97AH:6)I=#,Q,BYH=&WM6FUOV[H5_KY?P>M@O0G@]Y>D<=(
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M0S]B#]ZB;#ZK.QU[NW3Q!U!+ P04    "  4.%=619B@T*D$  "C$@  &@
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M?RK#["II*#',)*%AE/)8*IE(:F+&>&BE3(U\,J191&+*_9')!F&:1D)'Q,8
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M)T*;*$69 8E+.%&I9))C89A(:IDD,7\RI%G$HMC]D8FG)(W#@)D :))&4HD
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M*Q((*640)SHUAC,:K#7#0EAA,5K!&!/B,;D*3UH#Y< X30$NQ#%PAJW778(
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MC(HDH2(*9!2!QN6$Q J\%"I"$0@M /W6*95K@MW4N]=H\%,'VNN(*Q8HAIO
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M_IM$P6]-#X92=6W3!947($ ^]*0K!Z5]V?SQF\G*05>.7V9]UYY[Z;>>+$Y
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M/@5#%(=Q2G5 P!7(;RR1?N\>Q*_M0+\;3TYJZ"Q#D.5[!*2?#T%%_&>4H8(
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M-.6F<5%HRGV\,H+.U[PJ+O4T5;@?3P LT 6!EMV#,'%F!',**,1D!N'V!%8
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M0IVO.T4.'T4=WY4]4/)Y4>$!.1KFKA5 +%EI\03:+>^S=1F+'8 X_QG) G1
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M9NZYIC\?]C_\SW\+'O\V395W #_KU[Z!&S0.KVM'@ E]$D_'\@Y^35Z#*>T
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M^O]C[UN;VS:R;?\**O?X7+F*9$3J925U3Y4LV6/-^*&RE,FM^PTB(1%C$N
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MM.KS^2*2+:SV(VF0_LMQQT$@6O NH2P"*?@T<%UZA:[SWRJ213(<DHD)& @
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M3?^6P3II,GH&6_$)[#_:4Q#D4)5CS&=08Q^^1[: _G?"^\212EC;>7S\W?,
M9FJ44PS?O$8:H>AS\]0DSQJE \$O<:;0D)EH\2BF&QH%M^&JK><!N<RBK!MJ
MIZ&+8.^&1V?#OF91W= Y@ D>/6.'@AQ.A]XNV0V!E*5CYN'38^*>4"DW8F)0
MSH1Y!9]KJ!<#!(XSF?OZ*SIG0$%@>L9Y<35+YW-%MIT;;Y(7,\:'L,;_'YEA
M1C"Q BK@0?E";H+R*J\6GR>S* P?#BF=P,3N8$%(L^>3?G>)\3_2,O2?3X1
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M)AP&S%EI*P4 E'L\5RRAP:&L6Q(I8#.'$95(MV*#&Q760JB@H'1(;C2AFD;
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M%^^UP?-ARK1LH):[KSKFL/Y8B **0N4+JW$)[.Y"^!=/WYYT%K44Z0[_R;T
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M]/\*"4BUE<W8:[7)2X)1OH%+B6E;A>D1Q[_F!O?HJIIA7?U8<#LPW[D9$\
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M&+:--%A(S!^CX),TUNZB\;A4/LYWD4ZOR1=#P:]BQ(,4M\ID!*&(-1TW/>L
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MYVP)YLEE%72V15]A_T-:PFD2$6_BC<5FF0:S7#@ #)H@0*9$)P<H77"R%DO
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M:"+1'8NJC\:O2C_/(AH*+ZHY6X]ZEIPCDM(+A(*C:/$1GBY<0PA/&!<D=_I
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MR&2P8 A!(VG+/>5NM#I#EMN"L\N<W%XAE!9!D@#3FIH<A)K_HLX0 (I M/(
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MD>E4B7-*IIUQ%3'AAMSWN?9>>->0V^9R=&:]^.=S>X'C_'WX^<N7_MRDNFT
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M+$H1X6MDMRF;@?2)/V$R@<!([Y6Y*IJ9]7SVKA=-F5][!&\SJMEI 4>?A,=
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M]"\GV!X^RGE-FUH*1[V)/R()RF'T85#Y+( 1WP*)_3%S$.\?I8ZMJ\-E<A#
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MG%QZ9XZO$SK3X\1_^(G76$YFF I<$D+"<_![$\7Z*(_5BV2/<_+AY\0/\*Y
M'C%"X*EU7$8^F\6?0G-<5(K27IAI__ X9Q]^S@;YCH3 .99QATRLQWGZF/.4
MY([W!AH?$KL^C&\[U\:NV][!%@0"5P#H#V/N0R)#E(UKM1>1;Y0-$1Z+I@LM
M<]D,@.]&I*Y.NBUNK$BMV)@:;<4F_[>Q VA61E(3^4WY;53P-<"#X8(]+L%;
M6(*!ZSWGZG#6HXQ?4CJZF'=2$EDUN?]_!Z>(0UF3R;)BA+PD0U<"90&FLV0F
MTZ 6J'7EZCCA'W["4=KW]_(37U<NFS7U/B\Y.RQ<+OF>R;7AAF-*;1ZK+!:4
M4#!<_\=9NJ43'/E2AGEDD<^1]6$UOS-.S4D&U)OHHC[.S>W-C:@O:>*^?5OX
MB5B:MC7DU%2NR7C/^H$?Z1/'";J%,-)T_E)@$FNX?- HF:9H;U?^S-DP2K'=
MMSOG@\XHFF5KMF%FC9MBO:N^<S9$04K"Z0$FN(6D@PL$"6Y&4MR@+I"^T*3*
M5NZY6D(D(N3R^L'5'VD0@<_POZ-_,_9:@;C+I>OP9%>?2/\AJ[47;02!3JN!
M*-WQ[)P8-:+V7J_DZK^$U0&QG)]%S#C6+#B"VE@@7DF$=2Q-*_DD&A'6+8[<
MG]PX@#6"YD7H$8_WG@?=06/V8W=S  +2K^T"E*66?&U;;(%Q!QW&,"2 >(*D
M1GMX@]M?L/?R4I\E@O&'(X+Q V&6>RTR52V\%'9_,F;7PM\C(-B;Q"I\4#_B
M=_$\J:8^3 3'84RC='8/L,]U(A%R"._X:VJ+ SZD/]P,3Q"B[IX!GP9]3..5
M8B V@F42J#FZY=C6DX-RHD&9*5?U6GY&"8WEG<BW2:"@%MJ4A/-3U,938S4)
M,#V <FFYHUR'E="LLZH#()8FSQ"Q>+\:D(KHH:7#?RQEWT;TTUO2V]+M>O"^
MJ0*W3CZH5Z9F_QBQWFJ2#\>'>(S"RR(QD2FRICI]0RG'3%@K04 7T$?TN]*=
MYV%A$!?ML'Q[G/*/,>4'8'@PQGZ*W05#'.,GNMVZ;D([Y[_]E+5+97$,M*'<
M7VK ?,=ZT<>:U#+O*K6Q4WGW/B0B,M!-9=\E"[*:\>71+LRG+US3+/5B!@4#
MNLO"]6N,ARL'Q\5Q:SM^864V@VV.3NL I$K=OPU@%[%_)-(^C$%8H[]U'JA@
MY8_'B;V%=*;@D ?@8Z;AJO:ABSHXZ\=IN$4GRN3<I )_+:&T8[;_EK8'5UB(
M1+#1A"PFQUN^LE@5MB3S //N20M&CR.I(E+1NFLG>PG[)"HA<ANI:%B['TBW
M#^#]8V,6=R$EP6#L91_MQAA(TEN:Z5VQ$:7?V%\%!RAT)?2"2Z0R-"_$R8J(
ML:=<0X] <.[V-5=9_4Z6DH'2CB^*)3U0IFPKPFF^5/JDGY\_%0UB?V9RCJ3V
MA^YY->5HT[6DR&!1,@*A*^+L<M-&W4;"@9@]C#F=I%4DA.=CR"'S/ (B(D)^
MURZ\ST:YM+D_47@F8L*(>VC1V3L4K>NM)?8FU1GLBS)/>*QX-:$*T5/MGN8O
M;YX-1HN&DN3;MJL>^S#:C>#>S5:Q(B7^'PC](J!*BD<4OE%/L%LRYY<X$=A=
MKMDPBWD.E<A,R97AUG?2?UGF/A! S[.2-F*5)KS]HT:#W4A3?(NIO\^I//JF
MD"95TV#N[99MI9]L08Z-QY87$@5+IH&Y>5?)Z>QYU$P?[R9,''VC$V+ O\R6
M6E<G ^[[) VH<@G4DCCS <,>!%,GS'J-Q1P1W<D9%="-+(*0O_579F8%1I[!
MN$7N7Z'17J9[!V<$$O^0ZN-.?W;69").9S\3YO)=3A?,-'-^-85#_[=G,)<@
MW*(".&Y'W S??G-ZEG)&?.]]%_U-2@*1!=67T.T52;8FU@B'^$VD!;I1?S7&
M+U&;&..RX=;C9&3CLCQ 8+.K+_-&J4<Q8;+RIUHUTG/)^5/4+9G,?VHM9_(Y
ML2_,36P*/Y(U$2^A'RLE%QII3D>UB!D0KU.[D.+,8EWCI*X-'Q<NJ^R)22NW
M]N;YS>8F3M.I_OEL:FL>W(D$86+5@0$H/!O)!W/_,B>+(Y=>FNTA-OS>P=[&
MP:9)(3>LUS+, ^O=O.!B*$<91&.\V^J_\5=Q:L$,V.T6(J4&Q'33G?=IT6 P
MO*GIBX=@<XIJB=%9(;6<C0KHY1RYJ<WHX9+'"A]CGM7P7%,FINNLH#$7B(DJ
M=;SOJ4-T\'S\-3%YD-7D?40*+WWV8ZG\&0>XJTCU!3YR)TOXTGV^NH.,$.##
M '#%@7Y%6]<5TGO^X02^GX503>0<"=G?@%QRFD(BEJOE,,AB8\$$M\3I[ U]
M(EQ#FO,QN200X#U:C7<"^;?P &7,6QMX_O PE/&L6 @,QX< F+U#7)(.%FL0
MC MWA;W65]_IJ0OT&8 @+-4;5_6T1=-LE5_4' !*WL[H5J A(@Y.1>)->GRY
M&+[IH:S<)(:(@"<QL'(.[$JZE1XJB4?BM7"W>]'BK>%[P1;3#[1Z_=D&5#O.
M6L>)A4YX3ZMES^5*6O!U8LV1K5':1KAFQ0=?U738!_2B7Z#>*_Q:,@YZSN0L
M?%M?HI<&C Z1QV?B!8[X,S/Q3[ZZ/_BS3S1$=L'W^";ZJQW)K78VSX4-W#N>
MW6;;,X_P0H3&][*I-?^ %!/E"I!S).R-4OR&31.#!'OB),DK7OY!YB_C0Q^;
MH&@6W:9%L8,.%O'\.-X1%TF2=0RKK79-'1(8[#5V.@(4&AZP"SU <M[N1A\V
M>JIA"-[KL&6CH(F0,%C&JD2U4K#"#=%.1WC3+503 'TCH=.,.] 3!2EV[EO.
M)FA$%LK=,:%R..#.#D'?X,%P(-]/M!R;W3_*[-,$(T$QB.(LV_F5K'4'06Y,
M'M8/CFW"+01[F2'M31 5D<M[+$VRJ!M25T7._HB\^'BK)DV<O/?ZL$!?9?DR
ME')7,,H=)_D6X#4IQ'D*4CD1\V;2-RN%2PY%\Z:A[ 8?][EH7\1>-11FHC#N
ML=_VEK>P@,QQU*YSPA3XZ_LQ6X2N@80"92KU&]A3 Q;_.&&W@/HP]>-2:>CC
MUBKSR[8C.F=3%3'5@YBVND2''1E/L+[FYWX7>TO>'7?9+>VRD%J18C01;6J/
M=,3N#)JIC]-Q>W[+L-HT=XAJ-!$L_:K'.;C-.1#*78@UL4</[W]5E/B7..[=
MHN.00/T-_&?I5JP:+5T9!-S0*/00(-&&&]YZ2J[<Q!4C!3>X(O'#1TSC[:T*
MAKEE3,R[9>L8 6_:S8C*!G.X #E6,9NTRL?T@<$/$%GSM)]ML]W](1\)_-.E
MDT3=VFV89QTN-M,)T' 95!07$@,JZG3V8A7A]'PC^@J0CN$N^!:W+(J&VCQO
MBS;4C.8&,'@=6-4QQ7<+FVL$)=&G/3-ES0G1R7[I;;R1UVS%8X?4QXK2)Z4F
MXO3]Z"?G./JW,OHA,:( JIB^C("A1;[ED*VP#>]F>UD03(+"2?O>+%'+$-AV
M+\^Z&\*&7^<%DDHC0 3@9U #ZT,J0I4YQ58H-*)?'@2U)*.2N9K6$(F,_T6[
M%E=2+QS$@V1>Q]"&]W)6KD(B' *$**H&H,0YG>N"7I'HBE/X*<YFM7+D_K?9
M#21;X""6U'6]D T7<XXVU0C5FT3^@7/-S#9TX 5&%&^8,>C"1Q4%^3]XV*B"
MPV10]67EE]>ZV+*TJ6L#*#61^ (P8RZ+E=!(&H*D>=!KW1CSH8#*LO!?6<JH
M1W(-'S4U#D/%_E\? <0:7%C=(X_+ C^B*29BB[06YSNIPS '5(0U11'65?&.
M//(A2LGR07$P.%,@=$ M >8L>*<(M8('J;MUP$+"_%MF8NDQHW!5W012Q\/A
MHG=0G=OP,# 4;%&2#^RW*<EA+05XER#^P2;01USQ.\81)_8K,3OFL56NJ@?%
M6HVN5?;(=:7^X3TR2GI@-7-3*PAE.EJ'-S6'61!:TCEH8US251%$ALCBX0G8
MTB9[IJ[W\QZ.]F7P%YX:.F/"3;R2@7P6O>U[>:S<\+#_;>U&(-NF?4OZ_J@)
M38#(U^Q"HVU<NNI\M_;Q:-J=(1R)1/\@4%LC<1^X [1CK]RI''ILWCNHCC4)
MZD]4'O5P2/L?J&_EWO:''70I_EE7[NK6#39%5+)P8P3O 5B@+2V_5Y"L?+.S
M\:DT-U!BB60Z%=?%0/GS+B?CY'J=(2 ?P\WYKICI*+/]JYVZHNW-6N"6&#FJ
M)G'UR'3],96UB7[5PF1K-H3-:M 1(P,PC#?&+S$<7CI!ZHY\MX8\GKGD:WL\
M++I=(YT*1$E'M-_>^#,>8IVVD>%:C^>?@A#&:AW&'S,^X"1GS+7-":^ D2>1
MSL*\*/D 9<FQB96[83HWZM1HT^9C)_SSAT%PGR4V]NRN8F./694_4@RX<5LY
MD A%"]2(58\@F"O$CLC.DF5-2&^/$,.[.YNK0N+A=;>A5^GF_Z8P5>A'0NOC
MR#1ZVYF0M&W+G B;XL<HIJ7#^%'Q)8F&LIJO1*7^SZ1\ADZ[1QC3KWY\\<_G
M^.GLQR_)9)=*G9P'@@:.AW<X^C=%VZ)Q!HEW[2=FQ(7MLM3F1/\2CPK_)'"!
M&I9\&D@6[_@K=*<E8^VXDBHAHR0+CLOXMI9Q+&A%/]_(G6MLU_J%T1(>4HS,
M^U%D"-UWWY^ :YFO>%$[9&W(G:!=0$N/\A=UZRRY]W$EW(Y!,S3K_9VJU=B-
M<VP=2O+JL4/I[&F9<R!V7RP^ *<*$+)'T:!/M_DG-BR]SMEW/[:SI*^! ]"Y
MJ]R*MJT/1O! ?'RP.!7XBXXS>8>\D=2W5*A1LR7\7NC.S7<Y1XYCQ 3UT=W\
M2!.,>:!$N#\@J?Z 6+Z/=YC4B3-P&M. ;!10<,X'-P_>7'09K7LHWN,_GS\-
MWN/![.!4ULJ5K0,=[:=L\#\NUCMDC1 ;F2AGJ!ML<N0-]5(&\(%MV>$RI+=G
M@307+:54FTK4A5.2#Z9&D8M-D"$?<9*WMF!B&:0NR3@)7@%KA0NB[QEVH*:?
M= 4+&PDRQIPJEK2XZ/V4^7[$CMU/',IAMI9A-AM!_,S;=J;Y"L6D*ZB]A,A.
MKV(.&SX7J+P3L_'S6!%G'[/:XY;Q^ EM.- YU+(1 SNEU9(1U=)M<%&XRR32
M0/[!E+$2(L(7>$E[IA'97KU+;\!7S<*J8WX3+K8'[D;)5%BXQ8B'9!VGG6L9
M_4T(47J[B)JB]YX[6L_>:U8>0246X1I+?&:\ACZ;/%=K'\3<GUP'U!LNE2*S
M:PR4(6+%1;M6CNSI(F5FNO=34)$PC"'=$UD#M ,?Q:8 M.TQLMB!YJJ(O'FO
M:<LJO3&90:@W09AVRKN1%6.B2C4J?O$]Q/+CZW&+>*B0%,$H?@W\U!%V! OC
M[SD]/]>09\X?F>>QO9EV/_&O8G(3\H-5;ZS)E^3?]A1]>N?UQH\D3RJUAQ5U
M$PMK=%LL3R)F2[0-3F?F?9/'\&9G=D'(PTO_VJI3)Z52+E?RCQ&XPX< []P+
M1E<!5L,N@4FUCY81)6L6Q!EDF$XC1D+<=3$?W"U"B5)]$@M^5YLD['R:I#$?
M6=6=98F?[P_(0=@Z<=  .5PU[#W;LG:MY()R,>!CWU*CK0< SMM^H?IT]K?Z
MDLK0O/N'/*@'GL=.ODP;FQ<?MIRC-!@028,"=;\9&[[ LE@!3+9++GT:82O1
M^\1JRC<U<N RE$)(4@74UZ$^4ST&\"5_;46V,=U_^%Z^W/AY03ZFP.:B(TD4
M$XF!2P@ QUP@?>B%(-C82)MKCS)^#L-Y-?5\G3GW.8G>3 HQ 0'GY'-(JDD+
M'M0P6 8#+,S6O?ZUN"P!A5%'##R?\<NMB^5EY7&IM1)^:&A&6SR*56@5>7@'
M B&/ AEK(!B]%B0CA2B,F+VYW]BD0D$G"VS*(;B"][=*\ _QR?TN<+*4^YXK
M"1IDPJD$#,N209LH&MDVG/Z>-FGG*U%4MYR"N"% [).2#B;G19OBQ&;SSN_<
M_9;,@]\R3.4+@ ?3[ 8\AS+%)M7!0?4/#J>1W0M$]R.:<)*>"K2URZ+U[JL>
MQ5, EL2_'(28F0TP,SU@_?NY7IM>9+FE'%S2R7">K#E#=IG4,TFKA5-JU\BF
M]XE(Z:(X<.9N=TFLT3VW1ZGB)_R12\<G:@*J&K"1L)K4V"AFL64TOB<MF%Y8
M#?3R+,;R2<F.O;ZN=7TZ:LQ-&H)6XN<$#XY&CHK:""IP&R"O=W#RM_4V3B$J
MSA1MY9W\YC)O*F6XY#20?2BY5Z @R(F+D.Q2?$A)=\[+?/'6&[EWDO0T%U[-
M:*L%@08\A7^,-&3NH3&WWM:=Q#-ZT,A&5YHY )*#7[")W;V*C/;3^^B+US^]
M?//%EQD'/\V%\XX7%>"D!'_Q)0]96(QE7FBWY.#=0\R=J;YFC/.\,^663C:B
M+J5QEMPIMO*?@WV(',X"$^L'! =XHC5WP!NMU2*U?#1&,/IWG&SC6<2>NZ7S
M+X.469YDRH5+'<L$H%D2 HMKA(\:XF8#>PV^3[PI'5#>8<%&$CYE33XD1Z%W
M1'V4E1V1<@E2[O%=1<K=&1;)"5RFT<^=*!?-.2Q?-OEEI1T;J9Z+GB*6.^E&
M^'"-Y10@E)QLF6*;32R#>R0TC[9K)NO'>0>U#;6_@TY$[\LTYTY#];!CN9E[
M*0YMJNKN@@(P7T&^&O5KID=7+\]Z\>31"FLF#4(2Q5 "(!WL'GVP9+2"5J_Y
MLQ6;!E'FRAO?E$E4,ND36.W9B,;R(=+S>QHRW= [#TF< 6V]!/XF<<Z8IN (
M:.R%Z-:_2\RC"T''/1W!@_;G62_S35%%ZAM1T@2I<!-*F"X"Z4YA4 EH3(HV
M;6614>3 \.9M,T++/1I<@'%"NF/(W4>35S!(*1]5LA5^&C* W["*?XAVD/??
M!EW#XO'@RE>6^<?"XZOJ:<?H>"PZ3KE_DRF,5+.4%T_F1!WGA[C37^RP,XG;
MORU&)-^T4[F6J"(1/.*!4PNIRAF @W)E+[2[<PNFBNV06'71LH?;5YXQQIFT
MDCH%M+;.0-9"LN':RO:<"H7%ZH7 M0\XA"&:^; Y-74^)=EKLHV_D>)7K_K@
MR+>I&/!ME?'TF?2$G^_Y.S(Z2CRC(5_\XF2T=DA8Z.$MU%]'T/5YXTP]AG@K
MJ'SL#R _QP@[8TH #.;X[0Q2O5H T)3G,-^I3?!<4?,O[/\,$8H076MLJ&(&
M*C>$>FST(NA:J8I*+.-2<S[\$-1S,QMC-A.5,7TN[ZWDYR'7HB= +KI@Z5-'
M-$V@:*F;\[R2%449B6>O?VTI(V'"9__X=>!Q'T_WAQF)G0LD#W.YKB7L".(P
MYN *SS:=O)++Q_(.G?/+O%GBI%T6^7E5(_=/A[ZKM"JS@38;\2<TWB][64?"
M@Y'S^J)8UBM:'IN.ZHWEHN@V2A)/BRFLEM_?4@:*[<_KSMO)W+L?2ZEC8[J)
M-*'MVBUKEB$74-8L$M<3!O7CE"M8+US8VP*YKK_;SV[>=)0Z)+6S4,G)(6[F
MG9RF4XF .GVQGAB3]WHV4OS5Q<;LU"W9U=D#M!"_U>1/<2P&]U#:-.&0@GQ@
ML I"+4)UU%)0S2"2&C.UO_73YNK(CBBNR6VO06$EA^GXZ@HL9<N^99D0+$ 1
M@(9#,[&[^DAP=EN87_4$&K?J6EY*P= AITT\M\6N"W8>:<-Y#>L6&KU>_[6-
MG5[LBZEU,]\G4XM:P< MZYV.I\A@LI']3]3FX&5K.]+8I],N@N"Q\:_))![A
MMQ]^W9BT]\2QGT60)=F7\XY@,=3F?YR..X*&UKX,^"*APG'L^_WDLVD02@TH
M'@*A_Y@>,SN>UO219YR-Z,!HD)$P9:F[5O6*1XBCD3VKW'GM [M8(M12<1J7
M,E(I.L#T%.S[QWL?5\N'7RT13JO5:E<U=5D&U\[/56"]%]"MT2\@) (6@GR[
M-1RUJR%2ZSB#MV.]O7=L%$,P@=ZA,>E5F3([4329[#GA.RUHG!6@:5MFM_6E
M:QB,100 ]F]ELHW]]5R^P\KA)NGC?-_"?)<\'6N G:.:<>.00?-6MN'V-;LG
M:1_794?8M(8S0L=]>>M.;D#,(+&R]'$/YSN9CDESR;O:/R2W0#3U5E3=N+3)
M'SK.S2V(NN!W0,&,.3DFI56(LFW%J8@HFSKRM>-,??B9"D!Y)!)\?+\HNY:!
MYJA?3;?YC#0^V2:GH7,RXR:.?.[-98V^,?)FHT2:J.=R'C24-H^3_N$G74!L
MF(_2->K;T.R[INKA_:WZJJ0-DZ2AVE&I= N[D9]2T*W2\8DCLG%2 $"FNZM,
MH+1V>;E;'[DA;FNZTW0AI0)E*W-UD'>?Y)#3PLOH?(=M'8H_%(E0' , [)#G
MK_+KBA+8(.OE@'@B+76<_=OA\@?_\0EMR'VJJM!3N92R'DT]I3FP/FIMPSLT
M<8#O"3%0T80+$?NTY<5F694A4:?19YE> I\EN/7)706W'C?D^R<4AIN1PL:Y
M\QN-MMS2S?.F88<X:AMZ0PRX:9]-BR$L!PBT+HK:,"A,%@32,[\LN8OUOSLZ
M#KR[UD.MS:4?)+X ,Q(JSB30[Q<B8*9.1D.[GOH7($9FN_CX%L"W,E!-<MH)
M:D9[WX]'Q6TD*PM*:'FW?\\=$T&;CF'7BYUDLT/>@XQ-S$JIOKHT:!=5 !;3
MS!XG[#:SRT&M1Q%?@!YL&P+7S)9UZT\()NP[;IQ;RA'_MW=V1-"$YD)T;*_$
M\:Y(Q8(@%:ZL+VWY*$"4CA/V$9+Z/#,<!@VZ+/S4^D-M9YBA#DRH);_OIX&/
M[%&W,IONW<(Y 28MSP'/8D*;)>-]TW/-[[&N84X@@2;'+MTQ#=W>)#Y %JA7
MP](DN)]L[8E18%JB9$W3J99N^K*!;4^AR-!'2O AH$QS8*W%%1RV]F;:X?F.
M,&?[I/Y"6RZI!O"'G1_M0G-;WB'V@Y,':%[ZW%F"KEB-?D*!>&XD0=V:@G[A
M9T):NMDGEL?4WVU=0T:>98QB[VI :.=+HHS)SZ,,#-J,6,J9FTJ7#.TI P.2
M,$A%_5+_WWQ;I*!EF@;E<^1LK'INJ4Y?:-[6L;+]TM(!:*C%B?;CX>V)WP"$
MHU>UNR#)>:#-P8%PO>,%4%>'(,R:,>\O'4W!M5L_P'5#7;XDY7&^UL'V;C7]
MJ="J?^M*B:S@=*QH08S?%W+3%X5NMTU4$$@HM-9N+X*Z\2G'6S/\XB6"#M2S
MI9':_VJVJ:O"WT]LPM3N"=\*K>>]&Q0]0B1OJNMF&=.&]!7N<[3O*<6'4NBI
M8M%/FD7Y6O3=%_]\;D57I"K/4F83\U:@KU,Z6_MIS+P\ *Q'.@MY+H'U;DGF
M*%^X;B<W6OI%WY#Z$;?#-06A)]&IZ12).?%8 "3/B0F"F9]8'*[V3LF"T#[$
M&=<LLUD-/6*JJU$KFG<U6[_'$(U9,CX[#,FDI/<LF$-)%BT&!AQ0:-LK6J8"
M25(6-%RHXSAESW+GC?C(8#P20\[D= G=P*5E<[([,!2L& (QS>PTUFQCI:BR
MT-(KHHS<7<S%K(=HT?[E)+OC5QDUK,3F$NI!&MF*4R!Q?Z1W<L2BF$#K:^=G
MK04"N-CM7#RZ$G!Q4<GL1DT'N@^?;&'C9WKF!'FIEG 5A:A-X/I93!A),<M8
M(&"?V5"&^P1NEYL",;%1]%)]5E$^ 0 %:M'.RLJ4H?N*\F;L@N8&(C3B"AE0
MX0'[.V(1#^3C$SQH,(IT5\8BUA.>3D\Q-A;@WYO&/TD+87(WFHIG($8B8)(%
MDHVV[43>C!4F9^BM$NQ39@?-DM;G2D'/2)"N55^3_)[,<H*<>R^GJ0"B#79<
M7[O'NZ;DG*2Q230P=4]$/I1*I*U^.*RGL^<*Y;?K8\2%OCK&A/&ETR346P)U
MBD)-Q1,'O4#?0MHL;: -D$["ED<-RWVL/R7E4ZKVAC T[5(9:Y/"<VL'46P@
M\C-.R0_Z?Y_YJ$\[BE_^V]5^Y2U5*2V5G>,6!'WT*%H]>-&':.-?^HU8@TQQ
MXA"?4A9BW>.&5KHW_$A[T(E+.Z]HI7(,[J)RETO(U<E2 0T;13'T+[??LAP<
M@J6J%7Y== U68GA@N[#&Z*;%0NPL.[N1T*UQ* 0H14(\J#7VH8;']F#OH.D5
M],^6B5LEE00(7W(7[\YM\6':]1ME]8A!&8W;O,BM+8O[9.*Y(AD!C:Y0.3FA
MMJ(7@V,:W7 .,$7L6*0WQB\=>, D[LC'WQZ>)6TVM';1M5=EL9">455PM@Y;
MB-J'&A (UGWPN4_?BK[*?,6A4M1S]4QM1[?@4EN0XC2, ;ZB<K3W'TISL?ZQ
MN/,!T4JCUV@<ENFCHH&*#V-D60\4EZS^L=@W=:+]'A=FEQ&:FX71BGZ(>:(A
MB?4HSFLE!T,TY9'UE&8"G CMVIO\2ABNNBHTRQ. "*QJ_D"F>:2D!_L#6 T&
ML'0Z>R.[C[_ FLY\*([I3\>6ZH3B9HQ@C+ONF%0C?CH;(U&-1"8T)/Z[>(3^
MB9LW.V:9)^:!T9%ALJ,![?#(*NNQ^_I=M8"C.AP-(64>&Q+*8P4]V<!Y1)2K
M.Y959PU8!>TMUN OB:3OQ8+=*K_8R6E[D*?ITTI-#GDK"Y6(5Y(&(I9OI-;=
M%YU/(\V1"%.+I>SN!8\[TQ0&.W$]?VN3AR?2*&)FA-@!U<,R*ATZRC/B-,:*
MDHE."3F;V>'&XK"$#(V^7%GRI0=LX0$2P#<FGN_9<K&V(BQ/]\Y+]0TE^:K'
M^EP34+Q0(]>7$.ASGB<C0^./6J:>%MYDI>:,=.-!#MZ_UA&!9!%(7]]5!-*=
MH==S[P)H&J2H&H<$KN3(8.>6H\?-=*AVPPM%L'8XA=['"O6-T+TT[3<DE?J=
M636D6G,2/'1A' OYSS$CR39VA#YO2L@[:F^DS@#3:?R!X?[$Q^;98R*!JA "
M^O<!D5NF.3#CM$@2)CLPW(^^>"4<,L$X$[/^ACZ'4HSW!/58ZV<-QMCG4PJ.
ML6.)[A>H^_M5.VF^12Z(B&-;R;.M*!_EU\-BK^$*,J?R8>[JY)EN.911JCHN
M1E//'R6#<'2RDS4@RW;5<EL7(+!ZP\2V\?[2&NS#R++CZL$\U%HM 3N?GR1?
MH97,,46,9;X_V=4G2U+BHAR88/C]6#8Z(/QM%@.4N?/?T'HM_8U"-_H=4H;D
M4@+OVT^&R7;#F >9'QH@9?@C-T=V6-V8<0M=SL,\4J!9!H$2I>_6HTOA/A?R
MWY>J4I.E-.]P955ZN:52<TIQ'G?3Z>RO0CADA4=HT>=-6;AQ#BVJ"BE#>F%0
M%A>XC9"JA?XBN&4#<0RJ?%(=?$%W;E ,G1*DA6E8Y1<UYZ+U(?U**<E!'VM#
MT@S5B,;7_3SKKD>_^;YKX+=T[L=$0%'>]6MB_WZ"E.D2Z:TU3.,)/V,?C#-[
M-<HHS#/?!A3%V-JAT4!3$R4B%/Y!B4>3;E#;/B/6> (4N79+9LVO.0D^SAOB
M$5^&53HU./Y7S+_7?X$/LJ3N\>I\:IOGTPHY*DR5X6<%>\4RJ0>W;C?/%V^Y
MJX0M1I]9(^# M'(39M66EGC2_8RNBI(\$[\RZ? "#%/FFCL2K851,ZB3V9=W
MHG6FT,*K6RU!5.?$HUSX<SDS$HATH*==F-E$&Z;MP1S1G6/U'/<NI] ?< B"
M 708./]*OWK?@::#^.(X;>2ON6^+-J2-B\WLW"_V[0DK@".U*[O\U9H.Y+/Y
MH*2XFKUX^?O)#T^^,508DKC?U$MDA>$SD-"+-P=M[;]&]_1[&C:B=51KI&(;
M/ \_DVY>6SD!^%WZ(IRLHP=J=[6?<TI7T?ZFITK7#X%9$DX\H2<$@(+R[\3K
MS:&9]>G/ZWHIQ:R9@'\;LCA<+G_NCQ<LZ2=G&<;Q]'80D]<#;<X^*5WN<ZP.
M50"+O?GL*K1="RR<4,620\IE8EM^D)W1VP>T*L+GN'9(M\K;X OLF7URMJQM
M8(Q8+1.MDL.)U@.QPD"V,&('!U *.F[5SW=4@$*&E8X3M2182@-^9JL6D_5%
M"Z..S II8SZZ#%)/'/4ROX3+@RP8-QBU,6R:?.9X-L,9]W?.48SNJAV=FJ/0
M+2;Z%!N,>A[,MI($1H@3!S[8A1-(RH$JO4+/])F9#]4MNMT(W9PANSZ@13 R
M9H&%/QMS8\8"^15E%FD%T2<I$UOL5$IT2QV0:H=7/E+151Y  C9L]6>2?]X6
M*@O00YA6%VPCZ MC1$=7 ";$:/3219#64$1@8F#&Z_X!*J7)),%GS1WR3**H
MVG/;)GA2)]YJ68O^*A<:_*X\H>P3@QM#!)P-%2@8X$C?*#84SP(?2:<B_4>_
M2$J%!'+CH'E)?%U+VVQQ?60+EVD&3Y$ 4!(:,#XD22*(/0Q-%FL2/3@C ^T[
M'BC&F"8;6Y#0@O/H2VQ.*4[HC-FR!<1OTM(%3>9A#^'OG5^?XAXPLR-._<<C
MASY*K,2;&UPS8)G#8V6CM+E9./9U.9"QU D.<WH=3Z(K%TX@//[$\_;:[["G
MD>0TX_.!]RL#2/>Q3MA7=\@YI2,ZFL-+XRF(72;7@I\?2NO?1H=6+/ $)#1%
MR1/$#.]WCE)^8U1UE19:[*J([&;7])=?R;S15?CG)T/M1U2]N=.O93K"@Y[P
MU?'-O8]87DCW*F$;:5'SCI2X>IX"QGOT;C&T_#/M,-WZ.HX*ZX@\?=%N H"1
M;T;HZ#6\.22>IU=<N,A,9I#2+,1'#YZE;1F0PCO0E)$OUWS94!.L966<^R&O
M H(#AA'ZO]Z@T0YAY=0>OMPPAL!_D)U)K-_!;Z(=.L"5N<_7P8;@H 2!.._M
M400![78GJ=D_(]X5U&(\=ZJ0\KC2/9ARA^_E)K]A*O77Z2R6<.14<"EQZFM:
M0<"J,X"Q+EQ$5WB;C8/$E._')*>+9F0J,J.TF$(_*7?!E8Y8)V19/R02P.M-
M9F@,4$]KQ:\-MA%1QW-"M$)#NGLZ]P>WU.]F(BWD6',$WEN<<+)ZE$GU)#$#
M&C;\F4K\^UF<^75>#ON#\B!*'F<PYZH(0?@:29P*U7>8=_\,JE09ED#"*'X0
MOB$>\1$+8;$0WQRQ$%<,44)*<I24>@])J1<W%MU#OVTO>%0]6CF'LN1P(AU>
M2\"6ME6H]J#T RI?'S(#0\WB!/#0R,%D?TD)#ZG<=BUC']IN?F)$>WM]08G%
MI2B[I(0#G8EYB;PN_B_QG<I&FK=!CC$'G=R)=H+XTU8)N$]G+X%.3>)0.8>E
M2$.TN^OZDC$V:%^3 &<O5:@$]"I 6,YU(3Y+&_/X-$C>BOGQ^)1'[8C.^1%X
MZNGL=9I/D1-!3P.DG?+9VJ\E@=&:<= 16Z@#W[JX->WC()O)_4T5PCW)G2<W
M __XA&B(^/@W[@OB*]>-C]J55!(%_0F@+A]9^^LD.X*\*1,,L;1G/]?WW"^!
M$YQ7B)'M.6_@AWUDIT9!C5LT7;'3A6\!ME1B0BM]%*E.>2'00A_:TOIG^U#E
MJPPQ),L2/T2GZ\7D9$Y7ZT/)3-=U*SNP6**!99^8O0E7SJ8\*6MNZY&F4>IJ
MG]G.HXF]C](XM\EIN1\T9:IB<5@E+-!N9_E(J?/A9T3<AGF_@PM<<K%:1?8.
MX#\8P<L\W7]P9:3STLDEU((>)^UVB+J#<)2$DN21R4P:AHO8)F)('BP\,,XO
M?]02BVKSIA**F \CG>?/Q;J2C$?CZM5QJC^JQ51("7P861$,O"+=8K#.^%-5
M>"+946RQI0D;R'E@23[,48.<U^\T\W"9-Y4L& U)6/HQ>*+R"6ZZ%N;8Z*8=
M5\*M6&KM O8^:CZOFXBJZ)GOH#+EI^;U3R_?P'RC"D49**>SQ )B!-TM&<J,
ME#_/\VH0U3%B@7KKBWFG#$9'*__Q)]Q$=A+&K9W_!44;PC2$+A)QE8^3=.N4
MA'HN\DX$\@;)#NU\BP+7PM6@A0, VZR ?;D_D@W>'I]ZX[:=M,8SK()+[?>S
MH^#Z+;#(#>FBTR*5TD P5$-:PBUWL'1E2F9*TE'7:HF[O3;;S['!3?@UUBZ_
M* "D4WHE\>[],0TG?3*KEC&4)W!T,0\@@Y@ _1_!VR?)S'\YB_E7Z%0@9@%^
M4S-W(WD@P\C*D:5C]/2PP8?8IPDQ),)""7A*>GZI4FZ='6D:+G:*XD@Z+Q]D
MF5,!FDP90CE0>WXH,SNM!0$G,J+4,)(H#(D\1<FX^9V[$(X$8$HP_;R@_"56
M=5G4XUC*TQD5V*7(H6N1$.!VG?:Z8^5C!-+>][/&F4(9QA:(?YU Z&GZ:P&\
ME(K"V!,2A1H79"QS4E7K@2R<,. <$B-G$HL1W5]1\<+N@3!.3>^)\N%SW/O^
MT%\'H,#!.T[A M<YEQI61=/N>I*:0AD9D&RJ6K]BM;%\"V#2AK@,MI0-7I3.
M'P!%%,E^_?)-T,CV5_JG/YLVT@EQIK,GB"35J@+B-5^*HMRNWL(/8T,&J#MU
M)3"X*2*GH:BSHLM^<]N- 9-'Q/C,?*HJ*&XNYQ.@F%1<VK&RO/H/P,74FWKG
M#O?Q&OJ'0T>$3,_-JU8C&UGO(XH8H^;FJN;C2,<YCS0KC*\]^+9ZD$53.*(_
M:7L>1Y[/P-ZO:-4[-*( BA8K9I/-FRL>"87NN*$.7+@]@#R+U>K4IP@0>_I:
M=/ONIX-^<S^/1J23SFAMOXCG-L#\.B;]<WS;-6WGTM;O(!FE)K4>F0MV#J2G
M<I%O\;PX4_5K[>CW4NYI/7I7Q4ZA"C3[[+0QRA;4Y J%+HNWKBS6=;V43!.M
MN(?HK&D?]F6OJV9R6H_XFG#SL,"#N2 3?UY'PBVL^H)1!F@<ZJJ \P?66Y=P
M-DGG$2G2L9ZY#HT ES8$YDP7K<5L:H69W5]]4K >26Z56D';4)6Q<HSCN^V"
MTW<I,#20>?4WF)ZN]JWY60#V0#Q?!1@2]GAHX(\Z<A:I$7:[^? $1$,Z?!;)
M\*DYWQ>4C)3ZD+R*=[OE]?2=0E0)M ;0@:Q<Q0CH<W_QF/0$RZ*?!>D#,H[W
M,!9HA81"#I[X2D-X1MI[GK#E0R_)H A*0J+8N>'Q/]0'_EDB+;\](BVOQLM$
M]\EHF@2>44YQ@5=A@!0/2Y@*L@!'J2$8\KX,8[//O=WB4?$E191%]=\=4<Q@
MP$$]0I\3RME\A+@YD$1,V*:6@/T+8I/D+*I(^]7[G*1K\J8AW 2;KLLU.=L[
MRY,/U"&#(55!I-9N=E8T(L:D/E62-7IL(.-;C#># K/VJ/!C((<4T[TV U=R
M)'<AVI]0)T'3&P4*>02 7O>-C)W/[1A2?20.TSWU ]_/WX?P,F%O5>R(QXDR
M(Q&$.,%A=EY0[$9&0MU*@X$++9;K.G(D+HN6.:VB=SX1.E(DF&C7G,Z>)WI,
M_(R B>BM)OIAKMU-?$\G_K"]EP0K*_DL1?H%_S6)<9XWIFB"_%'I$@AJ:+'C
MO7C]_FP?=1'1#9\:U"?6-3'<^BV1A!I;89S%;;EGMPDU!^Z7WD4B3DJ^"[+V
MP[Y DK8Q+;.1OG[LL5G3W AFZ,J5V" J9CW$)4?3&EST434M'6XIM(S2+$E:
M/K:L1>@_DN1!M"K,]T0WZ$B>)U8=9-&HT!#,7C[<&9,;@Z'_.V=8<=WXDABH
M5U.I'E&9HN)(X*N@PB9#8.B)I!$A=/(.3T9"*C=,L<X]N#(P/.()&95TDCL5
MKF.I+R-!9MJW%9Q/>4+_\4HJ?-OUOF6ILI%-=6!*D;:+ K#@0)!+3URH/WZ:
M"V6A>'Y5#"=ESE<L,T!#@RO&!C@NYDAK\1BYXX',Y5RV^<,LXW$@,&K2Q.V/
M%,\L!A4^VO:D2++1[NH#-G78@2JD%-,3LDB90Z(,DZGKA=*:?C^IKQVZJ,PS
M4C)@;;),-,Q*6NX3M:WT )BR9/Y]QBI2='9!<9"^__M;0BYRX/6Z:]LB[UN&
MHKK(6[%[^NGY7C[\&9-$_09X2=1<^*0C\2D'0A:CNBG![T!:"0>4:B[(KA[A
M3^( "HGQ'DDJ*<-055]$=X1Q>H1/HA<CCE-33Y?73V>3S/DWH:9.,#HI:=L]
MM>,WC.Q^DHJ:*65.\#(<K!$J9KL'M[*U0] 58U*K\QI+;%Z*M*+VGW-!+>%6
M]E:Y<)>67&V<8F"@EN'\"@F_*_?957 PBU0-CQK0Z=%NV!Z&Q.%/O^D?(6<7
MGCY2NG/BZO3K3[I1,> AMTX;;7^EV)HY?KN*(#3L!.%EO*NYD52PF:?!=-S3
M-7V5;V)J[/DUJ^QA+;17+>S)5A/F%E^\S<_]+[,$;9Y%<HX+;N2DT@<^UOK'
MR,]=%M:6?'8'NJ-,  BJU<0DD6^=VT(.JM?;,K*Y_*R(5 R6K&RUB56%J+IU
MZ4HK1!W*7W13M%P5BM1B<2-LO84_B;:BKS+%K]QFH.EAC3N,BW+XM6:_]S5/
M%[^\?)6(Y=$%?WGV*MBA*7E;):G!LZ5'Q="JQ:^IY9L& <3R3\] 4,2IBGZ5
M"D[QII,B#=-DM&F-N0?#EJ=CI])</IQ4C/6*(J.-"L^F<T?WL*4@.H6)'=L.
MAU(&6^HFQC-]/1[:M5USX?Q*RX6"260PQSB,4S4LC%?DDATT>_C(=?83EQ)T
MU;PL5&YW]H83V-)&'[ES@0Y <U 8'3LXA[:RL+#"T.LR'XS?L.DDBZ$L(I&N
MTC^3*R]2CO'X*6/I3V1OP9X(W1SM;-)3A((#VZ6R<=X\+:-H@>X>/4CD#**1
M$Q4YU>>NR_;AV?9_Y)P1:Q?D5^Z%&?R">KQ*:KPFUJYJ</X-SKU$H=P:9FRK
M]# %Z8,("*\:;KS>9P(K,;=)CX14S]0<$'05*[QZY4DO6LJ4=1(8>V!S\,%<
M&T7P_(*8$RAPH(7'DK5,3JJ-4KH;H@E)7*E,R-)X>9&<PGE[\Y[R3]'&<?;-
M)V_C\(\PU0YIVET9HX1)2'8\$:6TRL)M3)'AW>Z=M$KY/I3%._9,W49/:SJ)
MO2;EIF\(DMQK%I@"^&"R6S&@0_EJ6 $7=>F#<:&8]1=>LGV(*2KJ=#].\RU,
M\XJR!%GH)2[=SI\\;09(]8YPW^$WU+)(:H3 +%UW_WV6 )OO[BK YKA-WM\:
MKKHV4O>1IT_X"/:W9HKFLSJW'-%LM\8K#NY9\CGBE0193L>;+-6[]UZ?@A5-
M:T\(Y8XF\<//M0YRZXK_=,R#1A(#%0?RF!->#$AW-5IZ9?DT25CAIS!?[;%A
M^':FJJC^W6EN47)$X%4)T?&BN"A*9E8@# 75T31!>3\;%JX$%7C3% @$MW5)
M%7I!-S,U$//2AZC]G +,:B,A=T@\27K&C]6"6?0"DZX AHS*!V.)QAC$>BYB
M,X*(NU;;CH5:QJZ$;%;E.]F@2/]ARXV^4.R#R!N*)>&#"GZZI$R#8B::0)&D
MD+<%;WM7L+((.\*_5T!RO=DI1IT#R'_[%VV7XC1K%P[:=:"SVQA1@WR9;SG5
MQ7*-0+R\*YCOL)\!9_*8>JLC1M+>_<_H7,-" ;<J=])^\40C,B0>CXC3LFZY
M[6VD_A.63<1,!KT=VZIFY!3X!!<E;VX%0%DO=$<S_^&A;OL':IEBK5(;>+E(
ML'2MM\YS&M)Y?<$C*L;E#PCV,N?*!RB'WLO)N&$U]$52ESO0W.U_G1BYH(,Z
ML(J3(CG:%1.MON!I:!_V+.B]'/NKB $H:5G9]MNK5C(0"D"!RZ$MC2WA5/)C
MZ6W)A;9+T<I6OT@*2Y:;2*1NH[G#+&F](JC!C;:+@JPW?%E1[DD1*TAET!]5
M=>Q0(2ZN+N2/E_Y0;ED_%\<T<!J-& #^466L KF:\ 0743F,/GX)WN$V$E%(
MF</:>8W#1D_VT]G+NG'D4$0L7<+A)3O%;@^EYZ8G5=>+P%-1=H2$9,;OEBB?
M02D"'5IZJ0-[;:P?8./7/C:>+BWNUB\V<UHN\) &S!S)9XEL8::MTC+VI[.G
M/1I[BH67M6-A+BG\6*K["7*\D:&J>QX4VV5[K;JZHKC]1QY$+YP\4'S)T]G?
MZDL7UH*I;HRM@BJU9=+1SM2VA!W:;//%X( ;N5!>#5U+WC5CXY!LI+95+6<4
M_(1S)-+'#42Q @R4IC1<JQ<PU(U9R[C0%( 8@AFKGDY#L"2ZAVV'NBH;V\\-
MSOW^P<'-A(U]OU%K&3MA+F]N@U/O+7$0QIR,ZQ CW<NS[89^Q=-S[^[13J*H
M+5@+&H<P.X%_K;9*<#19/W4DY9+;#<DEB3+L9=<K2\@("Y $FDC=>1*)!>IX
MIN?9;%7\4 @PEE=P0JRX;D54&/L:^.\:"MY$)M%$^YE%=!2HY@RVP:*W OGX
M0W1U7H_;V^LM!6AKAD4P,?%AJJ',2^SM*>%!3F8/Q>)M@R"#(^B("GM1F79,
M>XHF^MFR,,+4A]E&W*=&X_HZA^EX !6Q*B$/&+3K^#%"(B<5' )>BB$ _LO"
ML%.O5B?XJ]+#HKI:H9ZV-V]FWVC;%)1=J$="7]TS5X$C1_P.^CV+"@X$%A^U
M7V:V/R+PO/B75BD*#@;3DB'G0 A0:[KM<NT1V8F?!^5GU>3"D9;@DEBIIY!J
M9'P($K!@L.2,!A>:B)7>SX?P#F P.DB CRG]6;P\A_M4:%)L#I@+IJ]EW[J"
M0N'3DD0+2;H\?>?XFD!(4AH@M.K 9#$D2Z<4R\ZFTYP1ZAUR^. 1TB\_1/LR
MT FFK2?>>= !&1@(V=6R:U;>Q6!>LJ(M74X99MT_><L#26T<K1#RB21RLMM[
MFM^#!S',;P'?HNX$-V,P8@TKEYN8+NNH)<=IIK(\ 7TS<W&M_9.2$"?].\2N
MK2(<M-KS[G[+2KY^ %1)M[6T\&U'"%LV!>IPAC]7,@(1"UDWPC9,K:UH4OQ%
MWX,*Q]C(E^C5(FCDL'/-:7<5=7B0!GS>+,5@(D\\?O(*C(B_&QQ Z<%JG<ZO
M/84'P,9H/L>2$[I_IKIMTX$:/LP#W60CX>;44;:0\,81*';!1APG>1Y%QN$*
M^R%;%_/"XK2BT]8W73?QWLS<6?0; VC3*Q]3W]=V3O^I.1U@4M-S**;&F>F4
MK^6GD;DO0ZN#J@%1G!NF(<X[ATR2Q0&3X,F<FA^)I8>R5R21N]N5"A:$.@R2
MQXO&:0MR79TP[EN@NO0C]WXNZF9;-\JGP)!!PU93-T>.F 3"\OU=A;#<&8Z8
MI5NYIN%D0>L678\ J9?,4Z_ J%^USKT%?B"'/(<M9?.:%=VVH-2>.#,"D?2'
MMZQUBCFYE@@P_:(CFL/RWK;EWC#1\*O1\TN(M.3 61=;P2][G\D[Y8M<J+K4
MN4=;@-HK"#R3A?%F*!=S8Q+HQ,.[ZV@6_,!X TJ_B;0_X9?BFQ3-\H2"3'](
MY7M);0QKR.@F\+[H)7CXTKXJZK'Q<1B%OT*'QO_+!%1$.6P(X_H'.'E;+-Z2
M"KGW YN\XS)E/L=QQ\XN^TD6V^^?B^4$&S\G_E$9^<T#E?2W^'CQ(L@:^S7?
M%$EGC!G:L4,_[4,@D$Q@6PL=8O=TM1ZT%']+5AQ% $V;1,'OOT[@PFY+"?"+
M#:5.F[H,W.'41K7Q<[N,G29))D3JL'W!QMBR(UFL2>5JIK,;V7DIH]+=V'A"
M3Q*7W;RI\V6YMWNHMVFF5[?Q+AGM3&FFV!8E10*WI+AH]I1VYO^4G8FI["2T
MLY_Z&?OS&<<Q3[UU?_3%S\^>?O&E[0)=L/ZXS*]FG-%N$=DJ[=CS)K1F4)FR
MP@RW/KS,;$DO /7=E<OC\W6@#^R)Y.@?;Y,]:'RC^=1VJ%'+:_!-DH[0E61
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M*+1]<8!I4P91D(UYRO?E;0S5BE7#AZR.?6A%5]?AW74%9LD3HY[2XG7,<7X
MVQQXZWIC@8X[B!H9[@K;?3<'O"<!K^16E0@#6HMT#NZ0#(U]Z(@*5:>%A 9'
M,;/66,-[S=+,?H^Y;ZQT/X[4EMHNN,$<!W)-X?<NU\VO@EB9,W\$994=!N%%
M$4%IV%'? 1Y#9]BUT_E(>RFNX"/!?)H"@3G0QY9 <IX'D *6XN7:CX HXO&D
M+&M#>Q)=/=L10'>6A=M'\X=%16L^+*P^HY19PNSJ,L),$:;V*8>K1I=(%KE
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M,=FC@GX[RG;B]W48K;I)72U19@/6!RG8G=6 ,';I@,WDR%MQ&:$&G9"DB8;
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MF;(#:])N]J>ST\?4+,?4OL+LCQ.DI7=[$M@5'G_U^"S#0,7-U@"^%P#3YS5
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MMT6N*I)KDIX Z)&GE."#-*<_HL==D1  _%>]:(*5;MKNF!%<>'/A5SSXU&'
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M5STB)/A4(+Z SO;'\Q&BI)^8J2=J3HMQ0U-!?TA<GC!M?._,&8)9%NC:]=X
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M.\D.SLXTE^R#?-",ISQ8.XLQ9EPQ86"BK$"$]%U/$^]*-XWWI,Q;V]1[A3A
M]\5*&S>PJ9B9D%_,Y;FEKU6ON=Q;58!A"@C1UHTYPF9]4\,")&!JP3<K-IJ0
M8 1V/5$DZEN0A\2-6$V;;<0)V$.1=< 6TX"([P?_SZJ_RNZ\M(W'<!*7EYUS
M(@2?Z^F1N@Q:66@4S=;;&)*Q!G1@D\7%5;VP':_SA+0&>+\/&^,D5\%MC2DT
MTW!FI?N\S.&,&!USW$JQC:HIB&M.FK!S,S*[A>UGSBRV8WK&[K+8XO:#XQ9>
MWO!$],;'70HYK641RI\?\$),,<YA?3%*"I>960NRP&)/-YKO1'$[;NH!Q.":
M1 OB1I8IW:92M*#%R)2NJ>4Q('R [6&LZO7D>8OH:4721S'&5-<&=G6$KE.5
M.%G!K,5@V%MFVA^I>8?QWL+*K/O7K-*$$  1R7T[U>TSGSM*DD/V*\+YPYB4
MBZ'L+A'JC!I[93WL>3:1[U7PXB)CR0.[=-Q&)1!&;&#%=H8MLCV!UR)T&[ L
MD&*:*_Z9Y]4NC"Q/SORBNDEX&)@?(P:7&$ /C7]0G^0^AM55"U!J7'W2PN&R
M4PE+CU85ZHH"J8D9+3I=U0BZ-/*3%B$_$'7E1GQ[0C&.EYQAC$8_$SPR:)L7
M#2#'A[F#W\H+&.VJ[!I5":[<J.5]PK81MU:5 !#>@;YDP>I/H9'!],;X9>V(
MS8;;HB,7T-!5S#Z17>."+D2Q%EAS/5.[S.FP'G$L'$-U;Z4<YJV1G9LI,XR]
MC[1]Y_8NX\T9DLA4.MKRG9E=V]B0]  ;V4CQMT7AQ2IE-=-]E57+.H7#[D_)
M*YA]%%J]XGYKK)[:23A*Q"Q#DZ"J%@0+ST%+V3N^JZC9P6EZ/SSZ+V]I.0S4
M5 KDG34&!V!JN+BUC=G2+Y@.^-*[K")W)0W"R(#6N4U+=/?Z>19]APGECHGC
M1+%DOYK[PE,-^W"UWN[KM5L.YD]%P-*)(N<M)CXA^?>77E9M\DOE^]<C(&TK
M.&+T\TSH4RQH&UI9N#)P<4^D"K?FSG %OB]&!Y&1 .&O$1L.*VB[\#;[R>=/
MGF@"A9UM($\)31]05HFF*!"-^(N,]<IUDOP')REHL95X!*#XU<8OEO9&5J_Z
M:3R95U E>)(V51FU!J! V775%OH@7+/>>2=UN&]\^N%Y/,UCZ;9DP,9OTUD]
M/.#/=NZ-^AK<$!7U(%\LGL=FP<A:J]O^2-UVHM^Y;(=*6LC6[6JD5CSVE+%Y
M#N% 1/Z(33UK9$_V;JHX[*I*;6YN0WSLO43C17KU<0( G'SNZ2&ODCP:@AD;
M8Q2]:)[4([Q-8A\SSFL1O%>*7S1>("D?%MQBN@\Z3KA]D*CD<D=!:5A  R*+
M.")"8!2UH<YWX!;R\;$[;)4[N8-MIC'9=YO(B<A_L;_.M*-.&#YPLI$;,GK1
MG":094 :U&_EPU7<XC,$U$) O_Q0(:#OH6\G/T2:OIA?IN+&W66!AL JA(?,
MM<0M$I&S*!+I2O\C9H= 161[QEM"9-D"-J5F F%X!TO?%1NV92=XSC0PCSS.
M*$D_G\'4![$963\"-W,F?+;W#_T)]2Z0XK582/MY&"\3O4SX)&\/C#+1U+F_
MXAYJN/E$"5-613HVG>G#,!F<JU)R<3;Y@SD?S>\<B #/$(G[PJ>:Z4CX2\+>
MBDA+*10?*6N'_-Q#9*PR;%_0,*TB<.?)?H\;.&$,]BY4U?@?^RMDBNX@'\)$
MU-IX;FHE4?Y9R.MJ.(='0EGZ61[V?('S+-Y#1T"\8>G8W?HS'Y(I*)!-LKQ3
MF*OL,S_OG$$V2B/UGBG7XS-^6ARP'22)M/EW_A+G&7_G,ZZX%S_4RZH)7/=1
M,N *JHZL;FY7"+S4XZ^_ZZ?4@A3"YUC+M?R3N0SXG_X1\4HB!0TL@L1SA'X9
MY)O:9:VT_)030/<T%$=/$]YUQ]K!<]M'$+</L"D6&!:*(82(H0I9#_;9>W?)
MZ9+9TGE,\X?5:'\PZ\G-36%8WDK0#3T3Y/M[[T^TJG.K9*>*CP1!T^FLQ)J>
M&65.T&Q<1J$95@L1Q*LT'4QCP#5&@Q_(YW&DLA%UH83.D]6T)25^Z&SWB;73
MD68&]ZU<JT(?=L>C=E'?<Q8)P3W00Z'=9*22H?+&\&9K4_4/+4H7B]>453HX
MDG-<#J8B4^^+Q=(/FX]$MT#RL])*)$ 8<3A_'WU,N:Y$%(&;$05XV)JF2F)2
MNVUVI?*Y S$*W&==&&J$.1*) &D=.O!RG2!% $D)I2&NJ,#F;MRF8C21W^60
M\S,<!(:SUD*Q*.UFNH9,+Y',&OT* _4#JT)1FF)4E%PGF!E$@B+^P*K%AN*2
M0&9@6JHU5K\[9>_688.1VG3.B?VYB:4A0G*24PS*B .2'/A4?Z8(_]#(2*>8
M*UCK"!6V!SY4BO"  &\[,->01OA4=W.R/#8HY'539\ <BB^*ZG4%QVS>K%0[
MB C=JB)J2^\CC,,1]\)R%94=AOV.-_06B" 90/P<,TZTH$0>9O'?Y7;W7="(
M>2TB]I]^\ORGUY]\!N9S44(Z?H_>JI0:+UY?++YW8!'%L/^-]BX2YHU^AO12
M2$_@+\:UU%ZI*]$PM\@E)E:EU!=1:R%L:-%[2R5$7N."2/-T]RY$;)GR8VRD
M> 3CT5-.+@LE\B,&3XRIN4A]VT%63C2BPME/A&-@*^EUX,ML>+%^S()^O0@O
M3"<0MESCG[#.V7""]"(2SWYOU<)PSA2%J71"4)EJH\N0"^U47&(OR=!I8@(6
MP<J6CPQ7\B-=R;C0+A8OIQ_.V$F#/$XJ8 2P[P<XBBAF9B4JHV' TTDD^^@1
MP XMM&!:Z%4>Q1T0P&FHTI_%PH?AEQ6?_1L,[/B)%1[5.+"&95>!4A!:@CTS
M\,7KT:Q!B 9J!#0XS34O,.N+7\1[](%J%(8>]*L,E@EM,%T)L\PX+#J;FE)&
MAE9CPF$,0?'1?Y,Y=>J]OL">,O!V1(P31$E$\Q(;IA:*^("69.:L%U;B1IIS
M<-LFQ,08H2S+OGJ09\=+PYV76'!&5G+IPE+4 6L[L9:B#E5&53!R(HF93O0*
MC(>+?W@D!6'X7B2LR!#7P$#HI';#&@17,"M8](7U 3?P.Y@;Y"LHWOI+HB$@
M;M0"F-C*=1FQ:OOU [1BW@-APP0;@\JVQ$6\&\']]FL1@0Z-'&PKV?-C7XI@
MH3D1M\0"R5?7XW!%SF[4'6,&\-JO]\#E)^GRK8. O>H!U]1C:@6NH3/#;B;C
M._'LL,,=B.%#U"_/'X8[T/:2,J/979:,RR;SKP#^JQLN@5J#@*(*LA<)%LLV
MZXC8&A;VI>FWG5N5\A#!P4.?5+KN'^(._:GM7(MB]G;Q<[3H3_;9>(T/FUNH
M]:*PB/B@(4,?@  F#*' *!8MT=W+V(CH\$2Z%PACJ;J3<_/"5@ 5B3(AYPPB
MD<II+6>I,BWX]XS\C@BC'=2A3*5"EK]L:X;]-@U3+Q,$3IG:R XDYL<'L>B3
M8195HKHP5A-AQ?#-JMG4HV-RN&F,F$9XDQAQ+ACD+( 6FVMW6?72SDU[']TE
M[R3<-/C8UJQ-IMD/"1OY@I>5ZU==12S-Y)Q7L5*MF-"J#XHP7/438ZJU]XC"
MC_C701&3@F3+@S%=T#=7QN,T%#9=(@ )JZ03Z4T9?3BP&/MTB0CX;C'NO.UI
M!M69A9/'RB,MDQWCWP=<$]DOO$W8N&^0$SW"21J3:%=WI6F]..F6[5L)"#K)
MO3$IM'A?N%?$0<ZTRAW@KOPH\3)??6AXF0_XG'K\]HVHA$,T(:?!(>9%L'"/
M]4H<3G5$RH0&B86H\T%WR9(!UX*'BU)"H"90$%;E(7H)OV;@UUG0M68D=-B\
MN;[R5Z*TF40\>'CB[%GD*#MIOT^-G(+!"],--O^99=4:51?SA[$!$; ^R!^J
M"*,K.[]81$29H.IM5Z]O<AF)61Q]<&7A&""9:N67C=.&R1'UDS',IHXI#8V*
M2I)CI2FWV-W37C:5%L"-SN2<4F(17A9QM"EJ.P+)-+*BGQG92^?]\DYHC:%:
M7ZFD"[Q0//9XP,;SQ*+Q ;$J>Q,/&]Q:X2&6CE(F*+&N?)W)(%TL_H'!PFP'
M0>1)T)"&8!(]MZ$BKP%(" 5>'I$V#2Z@B*/<3Y9P&C4Y*/$3JYZLO%^YK5;1
M0HL]$D;S6@D-$D&.G)78-6/-='H<GEU=A-Z%X1K/8!U0LYPU=(HWJ4E8=$$E
MJ6(_KT\?0E'8H=>:=;>O(Y3S-6;N_0O!^.,33Q0B)_/[H"PJ=@:\B)U;- 65
MJU%I ESX<KNE1;5L;QPJ(8%C:_W^3$<%K)#G77O5:(E<OP=^:LX.OTSLS6P\
MY^K>W5#VG_48<I8ZM;WP3?\;*3H%JX02GJ_;K;-H]O 86O%!>Q V:VR\\C*Q
M! 2HM")V)\58L7IP<[;*]KEP@1,B-M)*$K.<P9O);@GF"+=F2&8:_R-N)<?:
M'+Z_4F2*\^$-?]-NR3+!$T_=^C0E;ILD$O]%7YH4P.UXF6=#>W38[.7++5'F
MRI22U**L2.,")HQ[]45^"2^-HAX&,;3,]B6DJP<":-<EB5<((!SP4]20]HZ&
M=6S"F)XF(.1P%6\Z2@<X]L$1 S/PX_?/1-2J)/D_:9,[0/9+'>BY*@N>[>6N
M6K/'3.X%IV(H11@.CQ+004"GSZ@3U1\B1UQZE^.N\L#] ]ONSP(1I.SCCV0_
M>**\.Q)7'2TAA1U@-L.?TF&U_QC:UV[#P],:GO")B"QJ"7(#_1!5W0)=:[M3
M&!:CH-R0^)=TK$8)L4"=$4P07BXIF?]YF9D3/;[O&(Y"B-0C'F"3Y*-Y_<Z#
MI2;E4? UM]SJ)LI1"A7I^W&["Z42/RDK/Y?(NH-I=8*_2J[[P%TY/]1OO>.'
M6Z<DSUKN?JH3=SO\*IV:2+OZT)#!@,_.5*H$DQ'>\..];YE#C$LHK'$M8X[U
MF\//1PE(+&4.CC5GP+Z$A6%S'^*M<=BU7[QIVIO:K3F'3K&%9(,M=DM=K<[M
MB)\B1"3>0EZ[/>0<:^CAO;R:T?)B\I1TS4*VM"4^D&79TSL$>V2AAT8:CYQ$
M>ZFJN6[K:Y%#A]":++/%IOP^KHG!1&IK7-^*M;H+WDI7CI]!(2U:#:XZ\]A8
M-8>$--68?=Q:@K Z([-0#4[AS OR Y7$CNV#?1$\& 38]O8;VO8]!>C:H0U^
MDOO[CH;Y9W=)49(YY#3.T9BK[="5=N">L U877GW V-U$XYAVF,<V@I4>9S$
M5S+VK!7) ;L_#Z''[C ? 5RPX4>,H<]R\CY4,_S6*EN<SH$M+:F12!+).&F9
M:255.W6>-G>:9TB%L1C?M:RC5(!W_B6XK2'S>4Y+AVA+(F9;P&2E,W"X,%C$
M=\<ZC='Q"\I737;AJW9&"U8F%;L*_G&F9FF"!TXPA*$M%E-EWK4+Y;BUVV*&
M\@#9&H7)/*YT-?3 PR6Q:WSLT>6&(P'3^%C^XS,"57%Y=*]:W-F<L%\;$4:1
M<DTF@D[B&4=)\* )SRC7,&4=\O*::'>E?"4Q@P5#--0CHU)AAS5?9B3PCD+-
MLY)]\JCV-]\>"852&A #9F,-),TA%K-]_B=JB>YX8"0(%X%X;4'5&H<JH8JQ
MWE:VAX5CL*BV^K9#^5&64[_^T,JI'\C"O@VWW;=(?J@PL9!Q!K2S4?I6B9Y4
MYMO"T1!9-D5I1)+*459%(QS"</?QL_!5A0DEL$/%F1F37/(F&96+%=))I@T8
M'G'&":&P&X+HWD0Y4O&B:3(2,]MP@V5R>46Q1& H6SWLX9G@M$$ :R-8C6DR
M%+%*41+* .Y0)\2"#+?^Z 3TT,7B%:;W,;LN.4J^NN;@HB,>#)'0,E$N?$7L
M"M,1%_!-9BZ0QE' -3*^]G4@_L'8AQ*) )?^Q6'BUH"@1HZ)1&$C7F#)(L1G
M*0'X224/PX&*_2++:L LW-(--W#CNKUYA*/-TM9^]<O/T84+G%D9D@A2@^L@
MW2?Y]F0^(0&[&Y_?BH'L!S^M4@BFI*G3GI]'6=;Y/#D&7<ZP=J@'6QE&6D[@
MXG%>X<))6\BZ@"55I,ZK$/&C'(K@DF:4@UC46_8@C MH?!&;2<= VRE^E;S=
MW/JWK1$TYA@3FT1$#D&+X?.D02[*[E=]U+>(14;J)0)**B(;ZAAV*C2@,CQ@
MQ1SRS8]-[Q^BIX3-7O=LQ/JN@?:?9SA\CT0V1PI08QI]\8KY6#\&!_ WV/?0
MA=Y$&P):*^M*L \L'3TAJ]VIR.LASN.2DX"2)5K)YND36E3*X7E+4E%HP74R
MNP'F:J)3OLJCZ"!/U,F_C;..V8Q"FI'):JEJX>+")^1K+3^X&OP(QG/47"/4
MJ2Y7;R1Z9V2+S(E6G_?4PJ(%\EMJNM1$DG^NWO\*$HY-/WA371 1,"YH6GD!
MMFS1L_J1/ ,S+G]\HJZ\44B2%)?#8XO$%F^7WO3:F$.4WBJ ;>3HC$$W)BX'
M<I!2]TGZ@/'L^?=K(2E'#3@6;@O&#9KQI(?+S* <?WI=3NDIL]TD;\-0(BB_
M<U*(:;Y;*LB;&0F47HGCF3,"N=%/1IAS*5OIKYA?)YI<&)79"$:!?!1D59G)
M>##RS([KVJ$TD0+=P /4?MVPB'<=L\&;(H<M%&"KEW.2T0]L9UC&[4?A@J3Y
M5D30O\82[P"I[779 0G9<EQ?.DF.>8,!.Y_\-WCZ(M]R0W^JZ2"G'AA$_\?#
MS!'//-1/VM)N(')(MNZ<*= 6.TQ"1A-]PRD'6#^<;5.E /_&FPU.@*$^*A9;
ML'#4W'G9)@TXXJ]IKF<%/JZ6<$$Q ?QKK%D48FILS_0DDS$='J[R'F$"8Q"<
M>?.]\:56[&HO]T4JPM$8*)DA[L"!*@@-,L$W%(=?)]$W*BD!331QNJ]Z,IW$
MJ3G=B@?7R$,\1W]%5EX]&B6XLT37NH@CK!?ETT%[@7)A\1^/VCU*>%$U/;=_
M<!(64"H4H&*7Z!([C/PU?O[^&9Z^<O0;?KAX#OW-N/Q )B.PT0ZP8D(I3RSV
MS$MNVFYBN>C4UT"=%Q,&Z@768J%VN%C]]:=7 +&(CC)<U<@[41),B<_5)76R
M*.<@*SI8V#6&2P>>= 4,S\,BD9P)-Y;C74)9+,3V@GU&#';(IXLKP\U],V\K
M*28_6X5.&R&U-B.)7#!$)DS>"_U*Z#U./@2FK>1J#^*$.Z4!R)R;<_XX18.V
M<!ROD,H'N%AZK]+NH@DOIY^0=:29/.=9Q@8JQA.2UU%FM Y2PZ4 \[DWFT5Y
M\7#\3!BOQ!E4>LZ#P*7X7$>9CYIJRS4""':026/8&!WM!.>>;)'^P"9)J$C7
MY?[1T#Y:<WI*C^\RM]:IJ2/ E!48"Y0-+X&R09,W-M2SFT6_DCYVN</,&KQ>
M7=[T-B5'J;60Y\/M;<+&_.>%X\Z/*(Z'AN"NN:ZZEE.BA73U$8(5M;S]B ^(
MJ+7R-J:MBWQTSA'EAQ\>J;#/0]<77XO/:4GUYIS)"5%+C]7:N[A5>,(">H0S
MB@9;JGZ"=R[;-ZC(=MOQKOD:&NG=.+#$6)+Z#?,N*PC=!YD.N)1?+*C^LV>=
M(EB-R8ZY:;LW-*"C=G4>@OW\*OVG7.04(QA=QQBW085]\E2817C?V/^3'A<
MKT#J 3*8F#3'H0;91^25B/5J_-H5C5YAZQ(ZWINR-VH^9.Z"+OG.Q[J:?2P;
MSF0&LF&L.3%//#Q%MA0;9ELJE%PWSH94X=. 6CQ9,9B#GM>KKO6CM^V#4R'A
M$!^KN&Q8SDM<HS2/A(E;8:6@_B3@?@8B/SI/X2+3G@PT!/!Y>ZJQ5EAHA;U8
M_*V]<=A*OBW?4&<R+"X,2T)G/2XU :3'0"4Z]";1?[1;0U^KOQ,(9$&Q +E
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MWG_$+<U/_,7BMXP^FDI=A4L'HBJ]![[8L-_Q6\6+UN"O>3E01[1RXX!K7+?
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M$N31 1:6N\"YD*JBYCLY@?10"(G$+, (T<.MUHD:'[R+=I5'%J\2_D;=X+K
M2-]WP)4!"2IZ(YCVB TQ>)"0/)%.T7/#S3U $BB-!/N1RC/@3!'U/\K(=OU
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MYF5=2?;<%+?X+8Y*)-IU-:61-*4W8>X-N6M;IC[4ZD;I^VS!'0C46GB^S?Y
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M7!&3Y+VH,0#6Z7CP^]XL1T!GA8IVN?1OW38B[46/'S6VY<?1ZBL(GRMQMVM
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MR3P_O!DSE!R@?O$WE/(G0U8N$!_BWZ;J>GA[L"AM]VAH'T&)%/_X^#L6'\(
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ME!%110/6PL!@X+2G4T(,-ELT_]AE-.6)RV7;1$=RN:=R*AG,PQ559!:K-H9
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M_CZB#<)+<$ !1AB3S7YOOW'[@! _C_V['_NH;Z2\Z<<JMYD*#=,#(KWEVA-
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M)<B1Z>M+WG<R+,C.N8KZ)FDE@$\%O^_3HR$/>H)M%JC,%@C_"Z78PQ;B:+^
M05N#@+0"G>*I[UNSH,D>[ZTEKK9$;F(0SK U_.#2"67L'(TT%Q<I3_:]6[GM
MTO_CZ>-B\>3SQU\OPHE4]70?*MH"*Z AEO[&'TJP[>+9"&QH'3"$M[RL^4-P
MR%P<]13,YR#G%R@Q[EB>S:PO. Z@"+XLB7P0T)%5"Y5+<T/_%;^2Q%N0K_ A
M@HC8#11R??!\UW52K?_O3ZKU9O/U-U]^^>V77WV]^N+QUT^77WWUI?OFZR_7
M7SS^=K7YXO'_]^2;3S*+:UMVESX,'-K=_W4WGI!WVC;W8G#;__ZOQU]]_MWC
MOUS0/_[9 '%I#9"2UT.Y@56T)23B[$8Q[Z*\*!+.?('Q[7L*VG\&#*A*?6=>
MX+@9?/KX%&;P"4_@*]*=SZ(O<\_^Y'8JF_=;X62"DLA"/'F"9TV-)*7(%_6'
MX$R>?%$\!4:W?XUPOFX DN\MR%\=<$<C*_%?N__^KR=/OOENX^J-]!7$EW@Z
MN8)R,RS\$*S48?CGQ>L+^#>\ZO_;=F\6S^&XF<^<G=*X(VFJ?2\:[2)H0SCM
ME,!P<_$S@-]ACKP%_[8 GPN[0?Q?_@[<;'[6OA2L!"2#>_(G.G]T5#N(+EHF
MPI"4#8XN1Y7:<)C,7J$S&S^=]UP".AMO3^OF<T$RP9D*8XXT4D $Z[]%'WE,
M=)3C)73;\6K# W"])E=5%D;;#I@?CE[4N[3PHG>SE@>6P'LUH)F5?*3)_.(4
M3.93-IG_P&+A*^BB=."PY%#2MR;K/NQZWS$]Q.!5,24"E%001+@/'F=@36]:
M[(5!?QLI39AD8,=A##J!F,%HD/)Y0LP^!I*%I:LK'^@S^LS2'4^QB<44F%AD
M <>H*M1?+39U>],3N6O0@>XAO &LB0->472<-YW$5'59,<N+>>R0I,CRS1?R
MM2!_R(*Q(:J!&*^&BMA(?7!P1(M +:$4Z1*;-BBL*/M*0AN1C[F6CCFN*%:[
M]AXVN,)4"-^%M3T%Q[^]8_3U*>SR+WB7_P1)C=?EQOF!_U[;L1^D7_LQ%^J>
MS!?JCE_97WRN*_N#J>[]AX8UOYU>/?OEU\6+%V]K*;YX>@J6XDNQ% %>\0MV
MR7:EZ5=Y3I5$ C\4_A.D6&.ZD+P[R4!N;]A?0$F]6[QB?B^,9A@X\3JT91T;
M,KRG,>(1>=&@!@]8A+O%.!^"E_,R@Y0AJ0=A*#B@$<$E)*02WV^7;;WXY,5/
M__Q_/OG0)^YO5/1Y$!$I90)^=,MN!& !9 E]J/6T(.X]:I#]XLE"ZUP;Y)6C
MSH<IQH@"1?<' G+ZN$1V@UT+#,'%ZUZY&MTJI)!VCA3..T@--.46BW'+KGWC
M.HY22W+TFA'CX01\K<JS?5SG@\45OL'/'O5^,GQH^K3HC@>:54[E4^8S>IG2
MO$O^!8S3RB^+[P2(;WVVZ1 3,2D4/:FB00H)\X/*'JL\RM!!L+V41GM AIZ"
M6?R>>?(6KZ#'</\@=IE6"1W4B0'94D*2!^*2LEJG_(#<*1@#['YS)HZDZA:U
M;A"57ETORNNRJAE[T# L)$>Q1_Q+FF_39-"DC0\+QA.&PUVYE]+RP4<^0'-(
M_"+<1,FUT5)*,3PZYN+"X; %:%TY</-AO_+O?KA3$FN"\&5BZ)"GS$2WV2A8
M: 0MM4&AFGPZ3(:Z-&SSJ ?J /$Z$AW[V,$!U?&'OC6#;[5X)AHBA 9[P65L
M/M+9%WL..J=-3U/[JO9W/CT/Q[AG#-M%>A%ZP95]P1V\($&%E<39GS5$8;O$
MMC?_[X8Z*$R5".N*K\INH)]?O'A!M7=_I8B7Z4-?'5#E4OJ;U])S,W'+3V\)
M_-SF8(@?UN ?%1&=8E;FT-!_E+F8I^\D%_/5!Y*+^=#2%5]QNN*UM-;_J,["
M]^50SL$9_M/PE21;>>XKB+;(%^]DBWS[ 6Z1]WC Z!;Y6C-Z$]H9* &,2$9(
M]5[!0$**0??1\XC#YA<FP_ ?>1G*TJ<2]<U"_^?K_T'C>1V/5FE&:R9,X58S
M';%0R%_T5\**U0&#"]$:_LZ4CH'5"!0T?%R]1M\T1X[&MZ#\JP_]G&FP<G7O
M;C OA+'=Q$&EE(9Y+9:8[ 4:]JANVS>L("3WPPB)JVR+KNK?T"-$W#M4;N0$
MD+R_R-5LO%MMBYQ,]X,<&?0H4)!T?M OA,9<Z)],3PI#21$AB>VS .RDBY/<
M"(\"Y7^DM!NP? 7?DND-*[DG8R/BIZD4Q&[)U07 ?OQX/P->4,&1(K,H_!ZP
M^2S%Q2US?P"MP.4EZMDHWU8ASW#C"KDU_V;L]3=^T>@_._D[ 8-5<AS^B-$-
M1C;;[=A4JP+T2"\HPS8@]KVOUE79_4D,U7NR?B^O0?K*W9R*79JQ0M\^#<B$
M<@']5=Z!J!^!GI=;+*MV!]KIY<J- _S>Z"(@B="NVCELC@0 -XG[(:V,_V0%
MD^X?_Q);8[MRA\R8[0I7)^1U(">+HB977=L@2].F+K=;9C<$ZS<.+5X%]PFV
MJF'2BY*KY1KP04HB&V.HU+@!GZ2UB1E@6@,]&3_! KU2F%.27*-VU B\]M57
M01SE-,EG#FH)\3"'(2"B-)@N7B)1XPAF)SI'4X\BVD3YYI#*MM]",G+;UD 6
MA"U/EUVY[0MBD58@/^#@_33\"TBC_-H8">PUD%XQI $Q38977W=BS,9F"\EU
MYTCC?.?G&<\07 'P\H#.N-L2(U$P2:[#3:ZK=;L!;,H6+E;6JVK<+CY]\=,_
M'WWS])O/Y(6TP1&7V2L(NA=/\^.%^)/H4;? X;4#09%5[;H6#OU/V;3^])HM
MZF??X=-4_QZW_B.70.7TJ:IN<FL5DT;Y*!G^XFTK=H?^#,4'N=Z+GW^6"U*F
MSK_'MT^_S+T',D@0*V%YV<*,4C'";]P6J8PK\ P -=YVC\1%:+L=U%F:T;])
MV>G?%Y<P]%"#:%;X.7F>7U[^\M__]>T77W\WZ&.Q!X -&33/2/U:N]'["H\>
M?QW>Y1_^)_V:']*KFQ+AIS*=2I&UZUOO#?AQ_4Y9UG "O_PJ\]Y^T"X=(_*!
MW:+MZ F =@,2O0AO[Y0?6T0;, _LG85E>^/JA=OYB?7F<=R>C/-Z5,EBOFM2
M.R9AE?P?3Q]_??%TX1^DIJ8]U)=5B#%C QGY289]1C1IVF]INBS+ 3&I5 -H
MT*_Y_]E[U^ZTT2U=]*]HI%/=]MZ"0EQ-LGN-X3A)E=?*Q2=.5IU]OO00((Q6
MA$1+8(?^]6?>WHN$P-BQ8\#:>_2JV ;IO<[K,Y^)*178)2I+J#MO^8LL+&SV
M1HWC4HS%H*1(SVEH6+'=$%E/ZC[/TU!!OK+,)I^>816=XHD%:Y"A>A$^"]=%
M)5\41:9=@L'4B$&L1Z":]$I[>RH'(JXMG",52:J/FT(<S:XWG"#FCY)*AGUJ
M_RRM+P'&#IQW2,G]8"GV_FZ4?],$7W8;SD>Y)A=I>(T7X"("HXL.GL1LQ5N.
MKPY"EGR.G<_@X6"BVVM8I08YL+MO!:IU'-LYO4J#0&M1)*#C%9OI%1/=3[@2
M?\A%K?3,:Q+E@@3514]"IJ3_7,=W8?)*]_E9?;?K6 X/Z$;X]<CPKN6_E6(!
M[K%SXG;[7;?3:5ID<06OB2(F>?S$##0H%R"_;-1A3SRL*>4G.$?X=5&$E_1,
MI0E=;M:NNAT:QI.7[7JK0X^@+S#>X2B$X77<A@P/RXHQ7XR2$12='\^%"D(>
M)LBL2R&16?^B-KWH A[WGA_W%S^.P1NKO\\T%7+P(TB'8>YY,'M[[LFX,(Y!
MGJ%%GD Y9M;.4]YM\VMLPA#I5Y$7@?TD>706]J)LH*H\3@_4+_D8RNFY?E:Q
M:1$5=H_'(+)AQ*A )%JCT"4159ES+00!5_KU?O\W=6H,2L2<)GM!J"1V[C-2
MW%X8+@6\"JE)KU!-J^"&FLW62P#:F+@]J,6'\'SH-I<HM?TKC56A\D)F]_5X
M*H.E%*D0>D#I\:[GC/RE[K(')X![; K1G'5EZL[:@T3."W:HYK@+U1H3EW(L
M[LJ,'#WJK<+R5?6.I=ZZ5'@"=UJOH(F+(;(^75B!*FHVBO!O8A>8@];5ARX+
MX/JNGD?-/KV&-9*.!]NB-!J"1A%G$#A3^+HU!]U5V PPL)+1DHJ-=6,4732J
MA!9W#E(7ER(R-!R6";@^4KYOT4JB+4\<WK @/] "+#F%N:D09:PY5KFB\?F:
MO5-,9T)F17T5P=6'OP5T[X5SG_J-+-(83L%I%*E[42:\:/UR]_SO?DS@-@2V
M':#WSK>B:$@@%)]C+UKU-I7UC=^X2I%01&H8M'I:?0XM9SX: A9,O:%,?93%
M8V+EYDIF8A08!RD)'&7USOPEW07N5(N5+?D'MLWSR#<P^":YI.1]Z,'J*[4Z
M7+M_:!)+(]TU00P,&7$@@TC/E14^1"DP8C&].1;@YKUS[5H31)G=3;Y?8\V-
MK-!#ILTW7$KTZ3=$1>]R^':H_OX.M$B4TH0'8XK5>8^[RP&5IO/NX\7D]/+\
MTOE*#ACLVC_M+3F3+8%;CICQ&=:_U[X$(,SH)'Y4<99+'6>Y7,Q,JZ3 >9LN
MKK0Q]BE88!@EF4MH\T+QTA^>T/ALE98*Z)=M<DXA<(<O-" TJ'"$>V-N7G%_
MYFI_2J\,TD?D(F"IWJU4[]:&J-B7+R8NQO*+WZ?!NZC]9A(.B^#BUQ!5B+'@
MN ;#Q_@,-@VGI)1ZYN</[TPLB::3+F*B1%G,4([TZQT553AE;M4TG)HL'9;#
M&L87FA0M$;Q(4<6'1OC*^J+[WFSTS6*PI6H%R4DX"7021L@CLUE08 /8<(XP
MT;=46GIDV8[>24.%43 @>A,$WV$I\S)WC-*/IG>L6T($UA!H0F5[6<%Q<EB#
MSJYQ&.Z]:/I0=GVW.)AT(ZU>,Y*UPAPL*5JR5F/LPA=@VCA3 ;2;),T"ID*Z
M%MIBEU-?9,0H D:RH2<A!@VLB"!+1<P>FR)?+3(_7CIHN@]5K?W;1:KT3K-=
MPVL)YN\"/ED#PYV:1X2V%&#J,!<,-_XL6A+J>V=Z)F_-3/[2,U$RSFO>_-YL
MWYR]_4N+.FIVE^<@\NK=WX25Z5_4;\'T-1J0<"I=;C-0/YU2>QQ>-(Z-M.J]
MWS2_$9IG@P1MSL6,_(*"=&-;/K%(C+2 1,>,U0[,!>9!N]SOX8C9N6V?B(##
MY>FWZQWUAWY7_K!.*5D3R(^=O+6YG\Z56:R':NC1% J![.-D0$U#V-#C]1:^
M7=6* 7[#>DL_BLL[LDER@_7<>$@#YM#F[CQE%$O/QB#D\DBL&XCGNC;AIXQ#
ML!\PZ'!Z]O7+.?SS?0)>/3F$!VG:Z7JN9E/5<R&O0!PG"V*PIE#&%S1,YL[?
MZ[ :/USG8_UMW15^(C*$HP31W/ '++*/G3-2LW3"5\UJ%U9^&-3.)GZ82HTG
MLPZZYEE#N/BP5/,%=O<YHPP)WI$S\LZLW[C.YTF8N)P-FO$A*%B?)"ZEP0E=
M*#\UO/:S.YNFZG3@HVDE)XJ=\12\.Y#?7* *9FK =%Q?C>1@"!LS+,*C2CR.
M(SETQ]:I<Y&3CD@-4#1:^]6J-3OXG$LX-V_#X K6X0S[4B5I'/I":)U@JEVM
MC,VF@"&91:HINZ@7IMKR_ +RDJ#PT3UC2ZWF0U"[N\]4=U?!2$T:'DXN(GXA
M"/#.(L0)=NGO<(KB _-Z52**V(2\CN7Q%L2BN2AXEW[6SZ4%1JS+(,#,+1-L
M6\R/ ?5YE77_%Z^[BS _;(*%47X5NT)!\S6%N4<:]2&"=2EBP9]AVH$[Q3(%
MRS!)D#K%MS)>&!].X&.[+OS#C M6(XR"JZP7\XQ(EV!8E>%RW48@B;"!J(W"
MR7*4PF(D1$@["NC'JR"F6#@#3W!1PGCKN(0Z#\>OD,31,N)=D'KQ*)EB:9RK
M+-^:T)3";/2)HH-4%[/\X&24!>OF"7NW"Z,_ [P[<%*P22L>X0NY2H<GB/[B
M9I\1P8Y\O40JJ 6_FB=S7JUFNR!2@E *R9THO+9Q22&M&T>W4_FC(*-(E$S"
M:%2[0%C.J?W#&X>;5AB6-S D8-78%PI^S"(*[R."&4-L<+*UZBF-#Y$TRN:+
MT5)[-W"1B,_4:MU+0<1_;"](UX^>)ZHG_\@]J39N:TF-YKY?Y&^SD3_7._:-
MC](E*(,D'.E P1K#0PR,@[J^E*MXXRM<\\1R_BE$+*'?03"_08U?>K@)D2(H
MU8R7TJ[(/SO]\/;SY;N:)0\6T3"0CLHPQW >9OIZD UC48^3?U";),.5@I*5
M72)31UF!^KI9EYY,%-V<U[J_8S7N3%8A4U=>XB),KZ8A?H@+MB:*0B8E$#K"
M<J<)^2 H8/(C01(.'=X6_FYZJ2M=B?X%3L'<"H$G<41")YWKUPUAYHP>5&4W
M*LZB F%86()%'[&V56"N_,>Z\SE6L7(K9%\R(K)[$!%!?/E,NHVA>/6RH[//
M_SQ_6_/ZN(I,*>TZP?!_@JGOROL'<""&$]Q;5S>4QA[%BQ31^' 27")WEW$0
MG/JX[GR$W39CHP68^"/Z))HQ:+70>O ZV#LG;2/P&W%H'IS1]^<WB::1+RRE
ML+%(%YG1PK!'J \6$AEP FE?^33CWK?K;8)]*&=QZO^ "S+-/<QKT$>DJ$BU
MN<LX*<RFNEY\/$IXGJ*EKH>QSQ$UYH5UHJU$%!F,79T3]4H*2\*2@Q^=,?^@
M=D77G$<%8<&E9NV(GBYN5J(')F!3_"M^>112394KO;*HW6<0")>&*C6BVBUE
M]B.D9!H0\16.'#X8$"W&4%"SU(B,L%TT'7;@%_F-7KWBZ) P<V]!(VM^UUC
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MNM2!'XV)LZ-#E+HYI5O]AJ- ?C2?+)T_%S VYU)2TH?E0TJ:[C*8S16[?VE
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M#JF8>,WSC4B#JYI>!>5"2[BFF]I3F7'0%[UB(@6^24-DPD# O1P=78*CWS7
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M$(-P,!DFTV3("B/(F0RL%9(AWM /Q&^,<4,U9C(P?/UMG4AG&,I1**,@_L]
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MOHSQI$)_[+7MV&671E9\*=\^G@8DAISJ^$>[AN=U=.V3OSX+9P&N07D#=%"
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M]R2[\WS,-<TB];-28%M-NGN'K-]Q>UTAD=]C&^? =ZG==$_:WM/M$HF$WRD
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MI6K );Y<@.U*/Z,E]-:?^WMS26\UZ&]-L1ABJ5F.]@8,PA ^0MI54US!(;]
MON?S?[J.66"OPW8Y?.4TCC$Y^B5 HY&C 62]ZA,W"&#YF"4(M#)X9+(W->_^
MI["U#Z>P+Z?0XE/'U7D;9E:^F#@_)*WH4ZP^MK.,^ 5SBDWNYH['=1?.YJ<D
MWC#LYQC$.&FL#V+<X3)T7^QDY./I[Y_*AQ*4)8E8]%\@X^P(TY][(_+7VF7E
MQ^H=IK\T&9N1&<Z:==B79=@XZ8]^[%\)S=6-XL(BEL%A.//M:,;9) S&SCNF
MR0(+[/-X#&96*HL"B@\^'UE"5_[N.@&OJQ R!HK?D"(C\NR16>RAO=@SO=@;
M,Z],;D>1(8PV-1NO;W^@2Y_T7A>8'+\LHL#Q6G[-ZQP%QRJ.K!-3IT-8IVF
M :?<<SDR9@V7B#!5A$K'ID8!AHLXFB4$T X:Q4E,\2GP)1<IN=C*O$W B6:W
M59-:$BA)YL?TZ.9%H8I0H%$A,;%P3OQ[%-8#)WF*\"I#IF7/#$-;*B[F\F3
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M*YW+EVZH?J_0[W;[(\+ZGKNR@#HV7=% 1*88$<A#!PK4V])J,M-Z4T-S,5B
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MMLAMZ$$OCMOPDCC6*VEDBC%'8**SY9\A8M A#&3@*=_6"R E<R! HHP0'(O
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MQGS-"9;9CF]IQZ>7['A]XUL0D#)B(5 6T50S&@,5G 728ZL"M$) ^8(/L%P
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M,.AW)R3F\C:W>5:C6D3PNDL1S3FPEQNJ:9[#V$5E[@QD\P,R.T-DI"1:,>D
M%EH!ZI4&1J7#K:F->B\=)!;>3&3N7+&['ASF*2K2O70,F .#R1CP3!@P16:"
M4E13R0#1/%7090@8%M_*0)%G4A%G](UDIF80\.(+TY6'6)R?%32.P?Q^OZUP
MMW8L[[6'[;:>XOQ;^'I6!#?3OE0_'(T5(J_^/5G ;;/W/8Y[6AZHIJF))/)4
M-;^IZG"&KBIDC0A2 ,53+B2-\Y4Q3@(#C>5<.<I<*J;:@!35:(T@K_S5/7QV
MLS5G@[V;P4YQ2P.=9,PB0%40T6") !(;"% 4'"2,6\GDT@KG-;+6UY.X7'')
M,8=L%#V?#X1ZEJ!7$D.KW^M?=7SSYHJYX]/&;#%>[#U& 2- &%. 0IX2'IT#
MG#)A.:96(I\8A>+Y3*@7:MF/&,K*EOV$ECU5#58$P37%!FBK'*#I3'N#/0<!
M$<EQ1'*ET[ZI!J&S[",?"_6(&43S81TO]$B8>E"2GV!6AJ6[P-+)+.&(C,-#
M*  AS$18<@AHCR$P(="H$M1QJ5*T73UBJ/TE+KB] GM_/**2.<H3@<'TX96<
MLX @!UZF/")L4L7ZR%:$E)SAX ,)Z6"X!YY(FT^%FI.QMORHZ/2',UE#CYOI
MN/C5O5[*D2(U(6=^E%,C'@6@3V?8FK;4*><Q<,3!=*0(!3*=W!F(M%H8Y+R7
MZ:PFV*!0/-R-K UC>V#%P@QXKP_P'I&=9L![/,";8J14"B&M<2 8RZ)[&@R0
M(=4#8")@SJVV,C)2A1N*/B09[(F3VB<-F2@W*]'L>2MZ7W-65 WKCM^VE:^&
M^Q?13R[*LV(:A='#MJT*D+?3B5 N%Q]?Y,J^/YWM/OC!YR3U^=)\?..DMZ$'
MO3ANP\ESURL-.Y_A8)[A;C/#P=D ;* !:>^!E1 #&MD)4-9"P)R35AA"M;0_
MST9Z;E7X,\%.5H2'*H*#-F!A5*0Z./IV2EM@'(RDAPH2A220BN:V0I;%[,:7
M>BP8YO+S>9*Z%3(]T#7+R/38R#3EA$49*"*<CQI$)*".8F 4TT 9A:-SQJTS
M_EY3U),I0F8K<U(%AH+@1F/@'"DG*5;YXPY)+ZB"0CN9)BDU6]&['I-4]L"S
M!SZ?F>]K^<8[H&.3]%XZ#KK;C;A7.N/#HG\\&HZB+Q[[<@O/_!Z%2FX^XWL!
M\PYNG#RJT9RO:P.GIXN)*%<K2;:.T]&>6V$\:Y0SR'#K0IZWB_GF.>96<PR>
M<804=-YSX8'1,@ :O $&>@D0TXHX;#@RIJ8:,Z,J8P::]>41]<5R#Z/O[ %D
M-'(2P@W0%$?4A(HQQ+G"GD9.@AH2J0:$L^FU\RV)<SM<7J!\^SS?/-!/R?--
MO?!CRJ?1DG/*) *<< 0H#1RH.%L '2T"4RY),**F&I/GFV?0%T=%(!!2H+RR
MT0=F,E6FCX*TV 8$K77,+JU@TN ,-X28S9Q>I/FF=./^.=+QOO%?U_Z^\J_X
M9]*VKA[LM7O5@CF^[I#RIX=W7&[MV/>%MM$AB\\^3=5A>_U1O'LTENB$%>W8
MLKUT-M^1'HR*?BA&^WZ8_+=>N>*OHYT5H=W3/=N./XJF-2H++P^7SR4T/0[C
MAU.\+%ALX%%_V$Z"?3/PG?)DJC]^M-UH?S+W7+IP+#QX<8DVL1%Q&KCQDKJ,
M\5M0L*L#<OEO:G %+R$(R9AB7%B*!#&<,R\%<Q0I&RCZAC!:FERU?QZ8.8HH
M!\S ZT.@0^SD&]WYH4^'2_^\JG]1^:;&?GK8JL%9^9<9Q$NO:>ZSCJRX=F0W
MF\TOK<VU1K'96KM9YR[9'G\6T[N^\6N7K>CSN>TD,UN+]CCP^[XWC"91O+^<
MN;P@G?MMLU=A]6B_?QQOY(:_/Z0+):Q>0$$)Y[$K'7TT]&\F+_YP[>%11Y^^
M:??*!I47_3&^^Q@_DN)/!\;2\ZJOQS8A^3*%))G%."PW?O#88I9+BYF:?*KO
MN%SF"-_X-5Q&-W[WL]LBLLSQS5__[+8__XY3_CB-O=T8_"+T><<(Y^/X2?)6
M;M+UQ.2\3^HV?:JT_7EZ-6/%9:]VO!X,BXV>BPBU[JU/7+H@J'&EGZ]&B)>B
M"'=(?ZRWA%,,;UX=OLVZR4L:.'07,UC\7>!WWD0UEYV?"YRC<N?^USL2F#=1
MW3=^DYY3Q6]@$W_J;FW_?= ZL_':#=C:/F0[VZMTYV#SI/GU4WMW_<_.[L'A
M2?,B?M..UW1:ZV_;S;.-L]V##1BO;V^]:^+FNTVZN_VVO;6]29H'3=Q:FX[?
M;)Z5\9NOFV?-[107^LA:7S?ISMG.CYV#_4[\G#4/[&GS; ?^YVQSIFC?4^VA
M6K!=[QGO,M[E/50O >^F:AX^T1:JO*M_KF40[958655/^4%EM>M2//N5E\A^
MVQ_$M[W"'@\&OF=/B]$@WJU3'O\R%G-9A*I<EM GN83VTYU9E^SN2HBZFJ'&
M$EL;"VP[R:MJWFK/;5](;]4='%=%>^/DMA6V]<F'_J#\8C0:M,UQ&;?=[G_0
M\3:+4I=[(::\CS,4WW.FI#$8( 531A#TP"C# !+$4:.]TL8NK9 &EK,$/]?E
M?C$0,?]C[3)$+"Q$3+%B%"B54-CH]BL!J*<0&(TYT)H%RRV&-!W;31KRFD*[
M"U\,O+[TJ*K)>97\/J#$U<VY,:\VG#'_ :KW?%&/^.XUD\9D"L@X/S^<_S)#
M!9%C1".O0:)^@+K(!S6& AAB.4O[&2,93"<*B@;"<RBI/C^SJODN[ RP&6#K
M%%#. /M4 #M%I+'$S"GE@*+4)2*-@(;,@RA:)9GVP6&ZM")5 \KY5>AZ1GS-
M"=$Y(?K&A&@^GX1H.H^$:,)S-O2S-_XGV="?1WU[N-_O1+@:_L__DQB)/XJ-
M_QZW1Z>+ULG9K.A&]=Z?6'\TJEY7VZ0>E"Y]D^K6.NE:+E,&[Y-T3?@R?93L
M:,KO=^7/&BN7$;M?SO4O,KGQ_#.YV3(7B])6L4RP6I"V(K2,U:(,K%HFB"Q0
M6V^G!-=7M\'P)]5M:I'(+N:;R/[+I;'9C0NW2&FXS4\'_1_3BV\UR?^>'N+K
M\[]78UL3ZXXT_X-N.]#N%6OZJ#W2G9\-^T]Z_:('R]KC[G$G<;N2E93+@^6K
M*]&(\I,J)%'\EO+=9KS>/)8S8[GN0]NV;SZ+[?6.5+E$5H[1-1Y$^?F4%_&3
MLF<X3PSWZ'[]=**J _&*!V"UVS_N_10M?C8 OUA6G_B"O7[/_WS,\B]?^B^S
MJN1?9E7)O\RJDG]91U6I\8;LVS&Y/W5']ZPO].A*;88"PY2?\TM^]SRG_=8J
MD?IV52'N5L_.$JE<L%A8I6E@2FE-//*,(HH55/S;9I+/=+[&9NOM-7D:W7ZO
M]%P7M<[AP<=QHL;1?NML]21><[I[D)(G#F%K>[^[<[!_V#I8/=G=WCG=^OJ1
M-@^^P)W/DT2-/FN]B\_:=NWFV0[=[7Z$NP>MSM;ZSLG6N]V#9O<+VEW?0<WM
M)MQM3R5J'!S&WUK6PIMGK8/][N[ZIVX3Q_8=;,3[-$]WMV,[#[Z<-,\^=?]S
MMC-JMJ\F:BA.(.:8 L4P28D:'A@/.9 L"A9*(HA22RL8-1"7#4SGE?9\.YM9
MU,W/=<IDNYW=SV_C<RV2U!X(=K,I:O=#NMF](I>#<U5 KD:I9HN!8*VUJP@&
M!;+:1O"2Q*F(8,X"0[0&FFIM'</>I\+@. -7!JY7"%S&:,TMB3 5)"7&*84H
M0<H)*WAPDCP$N!8C@79!4&V*EU'E8'!$ *X\3SL4 C 2(1 H$Y+;(+42$=4X
M;T@\>ZI.QK:,;0N*;7?9. "1X!12Z36E-)I+!#LBF6!0,:\=8C>#VPW[!3+*
M/2[*;4UQ-V8$Q9(;0%ED;#22;*!#!#UK4?!,"*;3Z9:T@= L?YM?$9H,;QG>
MZ@AO% L2O&18*4X5U\H$"#V+),YJBI'/\%8S>&MNKUX]%((ZAR5E%$BL4VTM
MA8"DP@-,7; A6"QU9'$(DH;"LP?X9H3+"+=X"'<'@ L>66,4@3B0M.E)4>V]
MA) 1I:.#*K-S6A=<V[R*:T89+!"& #,9O5,$.3 JL,C@'),",5$>3X^8;(AK
M]G?6T3M]HAHJSYD/>5--Z_MT=PXGQUUS;.P"+IB6&;;XCP>=U?2KD5B\4P&S
M;%^5;+-X7]29GEG"6<(+(N&[A%,$(M0)(W2@G :OM<20<*N9<,AJ95]9W?)%
M<#WL;$@%26=Q< &PP!R@E@B@'/(@?DZ]=5XK.(_"Y1D$7B8(Y,,+%A($IN(/
M7 ECK/$@I,I2E$L/I)0!(.\5,I $ILPB@< 3I6\_9_1A4N+>G]A]W=OS5TK<
MZ_,2R,^=S+UXZ'<_DILKE&<I92EE*2VBE.Y ]R1AT$L>O3MM*:3*!!8D1=B;
MR!\4QG,K]I](WZ*5%ET$\K<WDS,4,!6<!PDDU-$!E";E# D"O(SDCUEE(53U
MJ]&?#3O#[PN14AW/6LGP^UCP.^-["\(0XHP#IR$!U'($C(X@;&U FGFA>"#U
MP]]7L+Y?9L%$60R]*\]*B?91>M?/O=Z_> CWH'6C!0T*9REE*3TS6]!26J*"
M(X9PRH4S@6/NA?4,6R=<N#-;N#A9;;C=ORABF6I8;O;&%2S+>@,E:*Y=PLQ/
M_K_'[6%[Y#_[P?>V]1]BW_OND[?]O5YYE[]UY]AGIC$_IG$XLP7.^F!U\ 88
M(1B@ 4='+U$.YC&!3# !/5Y:80U%U4.)1@:%#-U92EE*BRBEYW3'\P2[2!/L
MK"MOD=0<,:"@P8 2(X!$W(+HQ =+&64,F?K-L$]:Z^S\=)PGMNK-X?"XK'C6
M#\F9[_93 Z)_7X#BK^/.:2I\A@I?[G6)/PGQ&>GXINJ$^/;D6ML?5J?*_.-.
MNPZM]JDLE$.86L0D)HY898E$P4*A'P<D4M]2G[V;]'PM-3X#P/P 8./'^ZED
MNO?D4\?_^]/I[E=W9##ENP?[^ZVOK<[N]B&-;3IKK;>Z.WB3M=;_[L;GGT96
M'ON^=]KZ^BDTMU=9[.=),_8I?D9:J]^0HP)QC8 DF )*G0-:40_BAYYHIS71
M;&D%-Y2<C0Q.'3N5@_&/4K"/(4F-U$AP#*ECV$AOH\R<H8I8#G^5 GM-Y;Y+
MAKM^G$"HFLBK*GZQB^57MS3C7,/OMF8\O1V/>.*APL!B; &U#@+%M %(2V@I
MU)(SD<HH, @;41MK%);/-CY?AO]  []A:^VL?9?L_))YYXGXCA;\\:H%!X^5
M%U@#PY$'%$H*-/8&V$B]*0_13>-QZD39<E^LY6(7A&+6<HP,#=Q+ ;7 U =)
M+18&/9;E9GX]3[/>N6K6"@>)E:+ "JX3(\9 (2)!",9[JE(,&\:)&3<@>K"'
MG6U[$:*C64I92EE*#Y@GYQZ>RO/D,\R3&Z?E2N]G>-9:W\/-O6](4,2L<8 *
M&%U81:(+JR$##CL6'/?<>5;-E+A._NL3I975-A:].BJV]WW1U(-#/RH^1RL8
M%JM[ U\>:#Z?>#114G#)D0S)E=5,F_BO\00S2I76_HGCT=G4[V+J)[\*.6]M
M[YRU\ 9K;L?GO_O4CGW\T7JW078.-GYL?8V?GVVDOG?B_Z=#SGAK]5L(/"$'
M!4X[EHZO0$ Q9X%W%B*F.)2>+*U<4R'Y ?'FO-I\ZW@SY$1ZRZER&-(4RU#1
M@!%CVE+,C/J54YOCS36QX:EX,]4&2D4I(,&F:!4,0%D99VS#$/>8LH#]THH@
M#8P?'++*Z22+X##56$H/8V.UD\]=RJ-#YR4.@O@41.8XE4S A K'M<::R[P8
M4!-XG8H:<D2=)X0"J"4!E$:'2&&) )+$&2>,E<)&>,6S(<.\U>/5PUV64I92
M_:>FN3OU>6IZG*EI)E 7Y08M(QY@:6#TN)$&6G$$&&&<1V_<.BNOGYQ>2<;H
M,QA>Y?V6<3;OBG8OV5K/5T;XHSW:+T;[ODC9U[IW^K_#PG>/.OU3[\=1O*/C
M@=W70U\<=?3]-HOFM8O;9^!A@[AE7CK&J+?!4 FII] @1(3F9,X1D8VQJ,L?
M?1@+^D.4<PZ1S!,H3V=") A[B@,T0,!4H4Y !K1W"BCOI748&2_@T@K"#<%F
M#_[(JY6UMO@7MZ;\L*FP=O)YSBW'/^.A-X)QYJ5WAMNID F6S C$297W3!&+
M<.N8 L)8Q:UE'#.?"H+.)V*2T>\EH5^64I92_6>JN>_=S3/5T\Q4,Q$4S1#2
MAFK@#7: *A]G+2T\< QJ#9G7QET_5[V2-*<Z93C=$$NAG]>*0?]4=T:GQ="/
M1ITJW^FWH?=%KS^*/Y@I,I[#Q_,-I'#%,4XG07@;\9! +:GC(2!DD/)(\YQ:
ML@#P>#83-[&,"6Y0 !A[#:CF"J33;X&TW'JE,&;0+JTPB1I(U2G$G"T\+^.]
M$"G=Y0!7Z@.TCB/L'&7*2!6P"!H23 GT^M$R3'(R_CPA>"J60BW$GAL&O),8
M4 D]T"A58'-<6015,$8LK<@&QP\^VC6;=@;@+*4LI464TEU.'C0048B=UII3
M&HDMYYJ$B+'8Q \]S=/D(DR3,X$<Y2 5U!O@D"[3X#U0FBG "(WNBJ/8,%B_
MB7*ASQJ;-DUQK6G^J3ME-$>/BG5O?=?X04%0HRR:]MP+/N/#Y-*039]C?[L3
M[A<<':\-YDBKN'#!(2PI94%I9(BWA#"+C"$T?-N\90QGK0S>E?!8Q6VVCD?#
MD>ZET<N1FSGB(9R)W$":"MAP"(CU$%#% U#!:^ <QCRZ%$&GQ$#,&U&L#8KF
ME?5R.Z-9H%6L5X$"UYS4=2\(N($:[?<[<0R'&V5]S$QU[FS:4]6ID(K2,<(#
M$K $5# !-),$&$H=4X828=#2RNPFVQ=LT8]HQ<_'IJXWXG\\C@#O(+B:(Q=&
MCCC)',&8"FVTU-@)0BCS6@>G'X)<V8.;)ZQ-!3J9X1HQ[('E(?IO*"A@K$L[
M[HPUG"$,*8NPAFD#$Y'!+8/;2P&WW^Z ;AZR$+BR''E!H='*2T4-0M)1KQVW
M-Z/;,'8SOLH$[1&0;&^Z ##V@2$+%)(HXE<JZ:\(!XP@K6P0/M+JZ'NQV9RB
MF3R5#& 9P%X4@,5)/DB/(+:,4^R-PEPSS*T)@HJ(8G,!L,S3YHEN986XRY%V
MXT,YXP 8>"IP#B&07BE L V<&T5Y2N]'BC>DF'5#,\9EC%L\C+M+;KC!T@2*
M'$6:4H&5,8Q8[;27'!IOL@=:&V2;7D,,,D*8$I&O41Z9FV<"&!D,(((P0]->
M42_3/E'10.C!JXA/ F\+?=+R[4RSY4=%IS\</G>.]R5!DB@MUS\V'5],NK]X
MRP4/2GRY_6 L4%I,EG"6<)9PEG"6<)9P/<,K1%KKJ$T>B*<(:Z,<5=Y*Z@3#
MAE?U^/$DMQ'?(<X26=9FS_:[_GVD6MD1F:,C@JX)L02%I#4F $L]!U1##G00
M&DC+A!=*"$K+@C6P0>'L8MCM0RP9!UXF#C"+M>"626,A=<$9S /TB"(&.<;"
M9ARH)PY,!R2$I<Q9#(%7R@/JO0*:40P0MH'H^-8*OU X\*+RG:^WT[?]07S;
M*_R)W=>]/5^,!O%FG?*@]4*?'W?QW*G/BP> N8I*EE*64I;2ZY'2G2H2(2XY
ME @&1R571DE%F=$\NGY&:G4+QG>5Z&V-]OT@E:D=^'W?&[:_^PO>%TG@5MC6
M)YG_S9'_X9E$(@*9QQ8QP(+3@')!@#9< "BQPU":M&EQ:84TL)Q70F2V[(R_
M64KW.NO]X1YWQM_GQM_93<4*$A*\!<Y0""AQ!$@J-8A"-D%$L4*MZX? KV#1
MOTR. 48/?>IB]RA:2.E@/W<2P.)A7*YOD:64I?3D?,%9FHYG9 $30S$E1AMF
MB1;:"6ZD@7?F"[<Z2#?MPB]!<^T29G[R_SUN#]LC_]D/OK>MK\J7?/*VO]<K
M[U)6,LE<8XY<@\S6^?(..P(-@!Z3R#0$!,;Y *CUAECNH#)\:44T5*W.\LFH
MD+$[2RE+J8XS[-P]\CS#+M8,.UOKW3"J$9' (<P #2P K:P *AB'C(M43,/Z
MS;%/O63NVM_K5?9=]USQ8>!!B'V,[OY7/1CH:(-% 8HM.^JG>F+)@(L/FQ\V
MJL7V2F:-HN='Z6[MR9UM?QBOBY_\XPXXPK&R2F)'A9'4.*(,4I)+R:B'PDKT
M.#AR45-P,BYKJ?$9(^:($?3]]NH5%OZ>?.KX?W\ZW?WJC@RF?.?LR]GNP4X<
MC[_;K:^M_=BNDYVSP[/6N^:/UKM6=W>[^6/WW>:/G>Y?H;F]RF(_3YJQ3ZVS
MPQ_-U6_>8B.UQ< 0F$[G3)73(;0@;=^'3C"'65A:H0V(?G(44FF..63_2 =
M$A+I 6%Q!B"4>RJM#L$*!F'LOM6_LNU\;D%-S'BJ^AW348:>!,"U$8 *!8'6
MF -*G:8.0D$Y+6N!*MY@U]1AR,MRBVGCUS@!#S/P?+3U4UGPQYGZE1I['$!
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MOP!'_._$!CFP_03L"N>)N,;E8-V98@BRPSW=#%'CH7":]'MV#&R)/5C@2:?
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MU;;H@J3SAB@*8!2E]N>I[7L!6(K&)3DY:#QB/%L.M2^#L4Q=^Q0Q?*:7W-Y
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MJ4?M3O^&L,U>>#37$CP]\"[<JOO5G)+L-"0*9"*Q#=V<M,! *893#T&@P):
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M&@H<N2MA4%:XP&S':8&+C< ]-Z#5UR4 "-/Q\T4P\[0&A,\A0$RT*S=CS2R
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M.@TB3V&T94V#J?APD>F9X'?5'[@.50YM3_H&=',#K(\BIDO@6LTL6\^2*,S
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M=3>KPW$<IK)@VMORC'SQI34LN?1W\E7O\] FVY>Z(NEAB:\)++Q-CV=Z$\X
MPV;&4WDHNLXF<3V?RQ;F_DE8E:7A5-7OPD[TU]C"6=^NZ#?KPL["UWSWW<HY
M=MN.$ZP]\<:.3/TK^&NBJRJ1Z(^7MD%=$ *]U_7I$0:X6O-XBO7+6OZ.<.==
MMW&\K:1&H'FWX?.S][XOWJ9P9%A< [V]3;>55=*-1],NR;QI.M$86"E;;)==
M4)?-K2H6V?0"EW/6RY!3VVZ?ED613IVUU:Q/FKL6Y'64 E:B G9-<6:53JA!
M><Z)!ZKS-3 :>-4EZ!L?1Z]JSM61>L^_OMSRZD;2KAGUM(VZ>X?]"6O6]WNL
MSOWF34#6#ATCS1<4+5EJM&KPKBYH&4U!L=YO<&%CB*,E&?D->5=GXP>K-3\J
M\B"WV"R\N^ZV>G\P/%D/WF&F]F#8+^1Z ':P'%7:?E;9]V<4Q\8U7X2\Z.3F
M[&@O6T$O$YUA 4H$R" ONM;,2,H1L&(8N?'!QPZ6;2:V,BQ<+]CJ<UBGG=U_
M1MY4J>ZE"5:#'TP.CQQ/SULG3OG@R):OPZ4[#DN!E%.6I^V>E\6/YJ;L:FS!
M8YHVTCSS/W"V2L,[?.^\PM?N&3430C<C&-M!+JW1-(_ *Y()X2)+B52A(:GD
MD8WR)$R-G$='6LD%IYRG:9)PFRH)ZH7IE/,<[N J?[E.U3=7$?"%%'R=*2WJ
M[>FRAO9HA.+[K)QL8 NO7]RA;VV,3],."I>.,1@:;_5@9!GK'?(L)#1<;Y84
MQ:=7=6:G54FWP9 83AH%PM\=23SB@VG!DFEGPJ@!?/Y/T^X% >:9NE&7M'II
M79X4WH>?9C0F?'8H+=#[QD#OZ.D#O5\T</M*N?L6^6L+7OG#Y[DN9[%MD#T_
MR_Q6Y**/50E+T.Q?['C<=68I?+=@ZNZ>]7U.TPS+>>::%L#W!>::$J"6)*Y/
M!P99C:L1VA0G1>YSA_"2'A8>'@]<!C%<9VW/GY-ZV_E\&BMQHZTB)%J.CM;+
M$+-W/=:1_]$W*X_3?#4F%SC&1-:10Z_7@RO/@7O6CI?D1)4@E<G"Y)J^4S6W
M*NK@AED7EYTN%EIDM=->&_!X3SV:T5&%=I_%-,R)8/C$2^'FNE?B;EH:VCFX
M>-:Z9.E<PQU8.[?T#?]YO3RA="> =98.IL'-).ZX9"_GU%>?C(?%X:%U1PHN
M,K)1"^YSTIC,#%64F6D.$-#,2BK/S4$C.>7BCL5+R)'WAYTY[()S0^N<Y6E[
M@6"S/I6MLP,6$IZFHT!IM>1MS1)B1=6!H1'!F<9M7$FQF=8S,D WV1VC#D;+
MR:W:D&M07+6M[HFNB"/&/LO#\RL)QY/)++TN5!2?71%7NJH2%C5*I$K$<ONP
M\L9E+U^8"ZY,R; ^L(E<^F%S\R.NJBL^OE$J^96$4UHNI3=U#>IQ%D9_T(PL
M-6YI0E.6$\0CIY:\ET,$@XP^VJ'+QG_M+HT[[.$'6:)3RQ)!8FX- =5/29;S
ME*11*F@L8Z$PW?ZE^B4[H++P-#OXB)UJD"Q>A(?RIQP!!^'Y*HI/%.M><0.;
M@XY1$U\"NT0K56*I=/A1;F/KN?+D69W[I-4*;E,_M"SP[<<!I"-_@  _;-H*
MU<.=R> ZE*%LJMR9:11YW8D6^+XV V1=_GM&;J(P!&E3AOH+M/_-;68)PGQR
MIW.$Z:VC069P;*X:RZKQ7[(<S5.):3XT%D<'17]._*/\B8Y+,\?@<GGKJ(*Y
ME:F"0^MC4(T#A$H5SYMT'GF&BU7MO3O1T&56HE_K)5O9B+7-6[W3G2F]MLM=
MQZMX[2DP5M/DKS893$(PY$K+;UD21K6BU2':[0A762T=CG6 EM!H$)Q59@NH
M]H),2<\]<%3VBQG]42W^/8<.]9$UDZ[=S3=A--5@OM0K]-ZC(<U?PT'OG>,_
M7PDGGU?/KULQ[[,#RJPV<1R2#(O-P1[D1-DT(W$449%P:858!)YYRJFC)JYM
MMFO-<3JR?U2_O#'%Z+0KS_\H^H["W4UO2IXK0RT86)CKFNV8T'\]C3ELA#[N
M@#VTIWV^RZ\WW%=S/<#]=RG?H(*M_#K<H"N_N^RQ--Q(^:\]]O+O,A;=SV"O
M]UC7H[Q<8]A&Y&17S[B.'?DVZ"$V06\\K[Y4+%Q:=DQ_LQ G6]DL_4[E;38G
M;A?,,T=6*TYA9[K+WW9III>N;#,?+G::?]KKAM)Y9I%N,>'7MG#T)M2EI#[!
M1CA]0\H1:FUMGE\VZZ[-%V3K_<SY:J/&37IWFCYP.AF">S^R,Y;'2DIB5Z_#
MM4DC#)8LE<O'>%)KM3)SSIO&<ZES8$V%5*B09QGGS%B1:?@OX0G\G[,XOJ+T
M>#AO7=W2IKI)7>KGFE^W_^WOT?>]T^/]X[^.=CYLGW_?^G3>@;%\W]H_V]_[
M>O%]SQ3[>Y\+&&,(8SCO5/?\Y^\CU3/=W=Y.T?GV/MP__AO&L_WS^];GDYWC
M/X]V]G:Z.^QO>.;?W=VM3S#?[?/_7&R/.U_"G__LO1]W+C[QG>/M@RBD8#?G
MAI@(\P4$#XGD3!$142V4!.N$96MOH_54T/4DRU94M)YGN3MC,_S6L=OUV>PR
MP7^5^%NI/%K1<87H8"(1(HM25WF)J3RC0D09LR&/=:CCZ(I"]:WH> :BXWQ6
M=*11+G*E$I)PHPA7B2 JBB*2YL;$B64\B7(P4=9IG*[S:0&)IRXZ;FQ"Y>Z_
MFYI0,(%'8NR/OM>N.]+"V-S9/-CE)L)OR>1?I'SC+ 9IEJ1,"<GC3&9YFM+<
M2IDSH'<5MJ;1,Y=OG89IM,]VMTX.(J.23#!+>(B5G:F(B+ J)7$,6LUD)J2I
M6GL;KX<B68]C=EOYMER,W*OU,_?*7[)^7HT $#1DDJM(4L85#864,DPS#<J.
M1RQ\"@9.7ORTAES8X:#E_9OR_ODL[W.3P"XK,&NTD(2G>4ZR3"+O,RMT*&BJ
MK6_K3=F;)\3YMXW_W(L#]/*%PRU[MCV*==#*A2OEPJ<%FT"8)+5YQ(G1%.2"
ML9)D7&<D#Y,XR6D8,QJOO<W6LRQ;9_S>?9X7%RMY^:+BEAW]6E'Q9$7%G F1
M,Z72V,0$MA"1:C0B*J&&A)F-A)*PU:YEY$.%1^[.O/B7.X!?DDOQ *A(8-EI
M;L?'X: _F)3%JT9M&: :)GEV(),D%2(3A%&;$Q[1F,A4)41E:1K)!.2*?K'I
M6WYD!K'<3NC]X<OGP55K;S];[5,;-\W@%%%-C4RA+R44^<5D?2&@RA7T<OV$
MW+3+E*]&684*@%WF#GATEBMN(&=J5!2]4XFI^C.U#_]G=(TJ![?(P+K-@B_+
M*/J5G* KGO-:D\3XZB0Q'+$7NWF>9G$LXB35G*:12I+89J 4.14ZY_2 1F+M
M$5/+5I/#O2_L<GQWM'%IC?2[ #Q.3D^[90G+LC*6*XRU58QT=^":E3T=Y7E2
M*<\0%-YY9^_[T<[QT<G^\6'X_=LV*,23LYVM_9^['_XZ[O3>@]GU]_'NEWGE
M^?GX.QAO.[WW;/?#YV)WZW-W_[C#0?&&.\?O^?ZWSOG^'HRXUXG_<]&ANYL'
M4EM&C1*$QQG8;91E)(LI)T)'622TY4*'\YG22J91ICD'@]UR#;9=Q'28QHR#
MN@U9NJ!J9VJ2!5MV+(ON:%$TSF6;+&8*7OG>)P-3OF&BP\>A/95@N5:M51VL
MV_?[?.?+$P2;+O7O9O)]?K(/!2YV(R\'[L>]AS;T*^8TUMD\2"27-!0:*U3B
M*4MBB!0B)W&$;6(XD\:&"T;JH\#H9ZEQ)3'6C7$'>?";0],/)O!>,_J]AK,_
M'\0SW>"4WSV(F&V$<7H/B&>1B'L9;++ZZQ;Q_+;9YKV%.;<PYY<%<WY4C([3
M.!J^P@$M-E6_-]S4TJC[DP.!_]?]S?^9GC9,1N9..J&0:*812DF)[TI"W.R;
MSYX,WR$5EO;/]8!(T3,U<\N3A&)GJQ/N?GO_<_?;_L^=;_#[A^\GNUM_'G?8
M>_;]^.1B9^_3S^^]]TM.$K;#SL6G>'_O??S]^#V%>?'OO4^\\Z%SL;_WO;>[
MUZ$[6W_U]O>68[1CP;(T8S')+ (MPRPD8";')*8Y?"+"2(H8@4A)^-KPV:W0
M:X7>_/FJ8IG*.36<2LY3)I2*(RV-M!G(/*N<T%LX5FV%WJ,+O3ETN>9I8EF8
M8!:Q)!RVE4B3:$)SI5,5:<UBL?:6\O4LCIZ+U'OQT/)_;^ZYLZ;B!T8L6D#Y
M?5EF583QWUC+:-,8:_;DS\_UPM<"JI5!-Y!!G07#BQHJ,@V2)TH$)SS+,I)1
MIDE.91I;JIG1".$0R1-"@+;8[R=F4+2\>C^\.F<O9 J\(*$I25,3$YY8060J
M!(FU%H9EF8A, KR:BB?$JR\^C-6H/(Z%GN006]MA@2;[PW8'I[X+I?PY[3!X
MF]S]ERV&[B28\[G<!'!HMJ9; /)HN]J UK>Y<UGU:<&N"!,)3DUJ2:@DV!4@
MMXA(#"4B2K+4I%)RZS)GHX3>D6OSA&(V+4O?::BB9>G'8>GY<$7$#()K20ZR
M&<R/$+@Y3C0!AI8F"D,3Z7CM+5W/TJ?$TB\^(.%0&FT<XK[C$&Z9/0:FE39W
M+FV^+IX()4;R% 1-DK"<<,MSDN5Y2,)<I$G$\CB,(I0VC,5/R-UI0Q-/S(!H
MV?>!V'?.6)#:Z,S*F.1AQL#^MY((FN0D3^,<!'&6*TP-H^N4/:6J$B\^6K$W
M&,ON+QX:E:C,"-;6#":(\:S&VYY!W]D"O1C!?5=V5WE.7>*2P05L)?E]2O+]
M!4,LERJ4.J<DTKDE'/:/J,0R$NLH21(J3<+ [1/K7-QQ@N\=L-/SP.ZT@K45
MK ]O$;>"]:$%ZYR)'%J1Q<P8$EN6$<X23&#/<I)&<9;$G"NF,)Z6@8U\:Q?W
MR4C6:Y17>)[I?)M5V]&/\GP&&?0 )2,:+3[*492# *[>]!VL&_U&7WM>'NT<
M'NA0*9X+6%*,*7%.<Z)T'A.1Q$+IV/*$IS<N'O$4:B+,D^&+RM>+-B(:/Y\.
M)?>2KT<W>'J]G,4V7Z_-UVOS]=I\O3MR4=ZU>7IMRLJC0KLJ"G09*J5]\XH\
MU0'=^;8?[1QWNSM[8- >[X??>]_A7M/%^FC[QW\>?]_[&G6.849?YCS5XZ\4
MYL5VOWVEG8N_83XPS][G8H=]C?;W_BHZ'W;@F?I\YUC_7):=QXW($VXDX9D"
M:UDFE@B5AH3)2-A0TCR*M>N@PF\-/6VS\UI1][Q%W9U WEI1]U"B;BXHE\=9
M8L(D(4*$FO HDB23F0"J2BUH*FMB2U'4<98^%U'WXA%P_]C#TBR5$U.,EQNE
M+:3F3FTQM^887L057RJE6D%T T&TF)@G-,O3..6$)ZDA/$PMD38TQ-+<IE;+
M,,D9N*&W[U?7HM^>+JO>B2W1LNI=L^I\7AZG*M4L(W'.+?!KQ,!FX(R(.(]M
MK*R5@J^]35N@V[- Q;^*O)R[0F?-G3<VBX"V8N5&8F4QA<Y$W"9IF)&,64EX
MK 7)0J.( /V?BCA,8 /! N#\"67;M ET3\P":!GU'AAU3O^;&.QQH2,2ZA#U
MO[9$B#@C>9Q$&8VS.#,6&?76-33:M+C[0KJ7L[L4'W6;ED[/.))[ETOS8L3R
M/=E/;8CWSL7U8F:AD"PRN;+$JB@C/(LI46G*2:2$BG1&0YF 7<7767;K/.8[
MY)U'CLFTDK.5G$_9H&TEYWU(SCE#-\["#/;&$,LC33B/!5$AS4@L34JYS15+
MA<<!W%5.]F-*SEFH^O.&IB,$O.XT<[N&,H^$:IZ9P9-#-0NQD<71+X&:V48B
M?@U]? 5..(GNHPE)'-W38*^'E;XFB/=1#8EY!.ERG;E<(+YV]/7SW[@7BG9N
M8>(M3/Q:]3!+5=VV=6DQE(\+42HI<09*^9K<1/;]&XQGZU,(;B*XBSK<V3JD
M^\>?>(=MLYV+[7#_8I/O@_NWZ"9^[W[?>@_7?P(W4<.UG\+=K7\7<#^.%5S+
MS\>=K:/B^X?MI7#Q/),ACU5&3!(I<!,Y)UD"?Z99*--4I\QRN?8V6<_"9X.A
M;.'BK:A[FO&P5M0]J*B;BX@EQH341BG)C9"$*\M(%NF44$$9C7-!XS1&4<?H
M7:$T6KCX75FHW18V_E@VV2(D]85A41Y(("W"QED<9RP.%4ED!@(I2G(BX\@0
MRDP8Y39C492NO:7)4^H1T<+&G[!-T;+JG;'J/&Q<2&73/ 8/R0I@52.)RBD"
MR'B(M9^XL=':VR?5>>GU1*\&/3QIDKC>+8K\0<(TC15O)<RO2)A%!+D%#R2,
M0D$TIK!R&48D4PDGJ54RC:15<4[7WF9W5KCS"45:6B:]EP!#RZ2W9](Y,T!D
M*F2IE21E44YPGXC0*B.:96&>9I19"69 DCZE-(]7$R,8M,U5'JZYRD*ERE;$
M_(J(640\&\4B"=1(8I6"?\&4(ED62Y(HGN06-DY:N_:6LEO; 6U0X.GRZMUV
M4FEY]:YX=3Z9C+(T3FQ.J D-X2G%HK1A3M+," $L:O*4@<U^ZY/3-BK0=DUY
M$H>];7'_^\DK6R6?V^/@NQ+>B[U2(IDD,M(AX7&:$!Z!!,]BEI DB84TF9$Z
MQ4H@ZR*[JUS@QZ_HW_9*:<7I4Q6G=YALUHK3!Q"G\QV'0Z$-SQ-B$AL13L$6
MEMHPDNC(TDB&49SG*$[#.^LX_/CB=$G6V7R;E">2L77#+#3G-P8EWP0-5KI=
M.MK]=E9IUDEI6ZA,6ZCLG!UD,HGCB!N2P[J!K<,X4<"0A%MKHS1,,Q8OME!Y
MC.3!E8179Q&^A#3":(.SZ_4%N6%OE(1&=_Y8ML&27TM.O.RI8H.)I&V-<G_)
M>:\M=:O->6MSWJ[ED31?"@_1I/A)C@H#ELH?S\XL*-LBPOM.XAWV]6SGPWO>
M.7Z/[^*[W[8I7!O!,QBV2@2' $8\WQ;QW\>[>R?1=S =]O<.X;TXK\-X__@K
MF! &3(M];)4(#D&'.4C]N[EF$Y+**)0)H7%LP)H0"1&&I\2FF;6"<ZO3I%WR
M.UWR.).A9"PC*C78K#V6) M#;/&;)N L<YW*!,NLRY$-NDL,]]D?;:Y3F^MT
MSW"!4SN48U@?1Y*517_^LHX@'U <S+?[D:$UW(0DLUH3;A)-%&P4$8I1&<>A
M3A"8'-]UT.6EA*A;B?9Z)-J=@2I:B7:G$FTND,S2.$NTX(3E(:9IYB#,\I 2
M;2-C1<8CP?C:6Q[>NIE&FZ3YZ/7[7P68ZTZ!EU]@]8;G+Q;+]5!B9S$9,U29
M3",3DXC%"1A2848DMXQ0G6:1A \MBAT6M<F8+YA5[Q1WV;+J7;'JG(6@*,MY
MBCX/5<"J,=@*DFM&,A4;:G6>B=RLO:5IB[ML<9=/2Q2U0*&G9D^UXOF6XGE)
M+R1.DP@K3TL9AH2+/"-*2TZ4R7,C,LV2,%I[F]&[RF1]?!Q0"ZMLI>53E99W
M:M*VTO+VTG(>-VFSS(HH(=3&"OQ.IDD6H=RT">X5RS.FUM[&V:VK]#\9:3F+
MFIS#2TY1E$C%17_B\M>?#([R4O!:$"S"(SU/Y'F:Q;&(DU1SFD8J26*;I3'P
MI-# FP>4L[6K097W/JWE8%"^$=PS<O/=H-<KQCW8P-%FW[QS&W]H^QK$S%8Q
MTMW!:#)\,A#.G:WM2M!$G:U_]W8^?.[N;OU]#,P<[EQTCQ&*N7.L+[YOG;#]
MB[^..EN?>[OOYB&<^FSGVW[X_<-7WNEU6.?X4[3[;:?H7("@N=@YV=W[?MSY
M]AZ$T3[_S\57_/X #"9C<B$),YDA/,': R8)B5%AE.E<YM)0+_N!:ZS91)Q[
ME$BAP=RR$44/F69YPK(XD]; UL9I-H_Y;&R$*[8WLQ6+O-HD]CF.]7MT]?OG
MQAOQ-$^CE*5*<9Z'@N96*)B8TE395*X]&4%P4T!U=684>&3&S7#47HH>3T;C
M(C]_.O)N[\@&6&5$]L^#+DYK%&@0_++H!X,\!S\M@%'!OZ"$[#  RB%:]K7M
M.ICNH%X1?^M&@(\K'S.VPU[1EV.XK!_\/>F>(PHR /$18PY' *:(F\/^8'@2
MO"O&Y]7[D&;_GO1M$(5SEW\8_O?_82Q[D]MN#B]=#S[ *W#@_LZ-(&C.!A-%
M[+!;3LO,3@>F-[M]EVJK<L4XVT@15GPZ&!5XS1^NS'KQP[ZIP+O.KFO<6&KH
M<'J+5*",)^/5MRQ #1^),/XB 8WGUJCQ[]%P"E8]M$0-K3PA,H?Q_B&[9_)\
MM/:O69X AIA;QOD5\/-\^__4\%]OE[UXN72Z2MK,2:=0"AG',HM8'/,DRQ6+
M>9S+S(8*]%QJKR&=9CCYD7;G8U?V[>$AZ4@PTOJC86'-E!U.)\/11/;'P7@0
MR* W,$5>N/JK*+7&1W(\Y4V#S+DY.83)5.P9.BX>U7Q<]'5W8FP M'Q4/N,W
MNW&XL1[DQ4^+O0;ZX]\=UZ)T\!=@.;=!WZF@\EKXI =?2Z 3=ZTK]!+T0,Z,
M;1\EBB\'^[L7(4N?!/>"=V-[\$Z8F+*!_6GU9#P8GOM[?6G9(4[1#BVP/U[A
MQFZ"?#CH.1D"TRYZDUXYD5-Y[A7E9.2?:JQ?&O>0X'0(ZP#K^$-V)Q:3%O##
M.:$7#!30@Z?(9NL%9T2304[@T8$<C>S83VU6YOE'G,D1#!46PO@-J7'CC+DM
M84X$ I6AY8YODMV I;"S_?'1"-XXFG3=@%Q*!:P>O*+<['*?<7#&B>)\5A27
M,G/9H(Y@4!)WUY[!ZP:G^)#U0$V >HZ*D1MS?S"NR,/@R\%;T).N7QP<B%L#
M?&>]!FZ)&I!&>/\N$.#_S]Z;-[619.VC7T7!?=][NR-()O>E^Q=$,&UW_Y@8
M0;N-VX/_(7(%V0(Q6HSQI[\GLTI"&[NP!:Z)&#>@4E56YLGG/.?D6<[[G6Y+
M5>*W6;XZ1O$![#6XN;V1OO(0@L@FL6.&6T4=XS1)GI2BW,58>1,QYEC-L]9_
M1QA5G(T&.8!)VT^9-F4K;2;C, >^_A)&_0NPKT R?D@6>WCDP:(E4FLD/>&(
M,\V0MEP@#-@4P12V)LF-[02*L749;7^><];RE46Z ULO65]B;[( 7:?AM[*4
M -;YDU8EN*0(4@U<I-XDTW(#.R6+S=5^J1Y::?^,@'?B$W_-2#\(/0#+"J2^
M9C2=JY>?84ZA5YYQ8C]G_ -L' SRTS>KST]Z77CLZ7F_]SEF\,IC@?_ ; ]:
M<-L*6-VHTPVH!YO5=^VH4+/?1_W\4;6]9I^4-U-F?'YL*@P+JK?R,SKEV==C
MUXF]?7=J0H*/(!R&*R&<B_ 7:31H80GVY0W&9:F%MVR/PL(,_V_V:MC+/^&)
MO=!LT]EM>O#IR)#<")U0A /VB ,L(B.\1";2Y,&JT\'QC>U!YTNE2!:V:1&!
MDVJ2QUO&1>!#9UG2:VU8"8'-6Z/;;165,3SIQUC=<_8>(]#DY4MCW54IO2Q@
MP)\*DSF&77Z9=S.K-!-LMVK/Y4U4;^9!5M2+FVR0?_N?^YQ!>::Y\-0!&>31
M$4.=]$ *F6+:&<N+7!+,*KF$'VZLV+A[YOMY+D!WE__NGLU);![P?GHWB#MY
MM'=+9,<_G.CN?MD_^'31_MB^W,OW?O7ZR'OIL$P>>>USV6:>D](31BYY;X)V
M@8<<2\C$)E#N!0=K@=[[2(4R.+&0>TQ(SZFTAB5&@F$F8>]5,#5:Z1JML&ZD
MXIM+Q<'K(R&H8=PSA'U,B%-MD3-.YZ;BWC"FHR)@RTE.KY&*BMMFXIQA([/,
M##Z%9C^&,V0^4/&4>9*2A64S/_(\^JRLNY=/CW"4"TF5H58YR[4DL%V4<8Y0
ME62DPE:R#*QM6O,VLOP-9?DKC/'(1*5<, YA[@7BFE-DJ4C(<.VH\XE&0C:V
M&;N;+%>&Y)B,+J-LG6D+$]9]ZT5X,JNCM$4:74ALR'[%S)J['=\!=IMM8=B<
MFZT ACULMD)EK/^4)] 69T7L^X[M@JD\L)6S$^X31GXX:YX"A0>Z#+L@7UG*
M&P38S $V9?D.W+GG:FH]OF4+=@]L\ZUJ\V<WQ>PM(\SK:7$A9.NHDS==IOGP
MQ>PK@76NAU_Y0*Y% ]APL+XK";NA,S PN^EWK\;WSUZ_W[N #_Z"X4TV.*(_
MW Y_+?9>M8%^.VD :Q&)"JQD;0E8R8PA&J,%SLD39;G.],)^_M^)O[L'*J S
MT4.5?^M^Z^V4@J=H#=HR^TFY%4#^ U 98YE1BC3KO9+UIGNO/EU6A9H^B;VO
M[2.7A#$AD]2@&.)@AR%'N<Z)U=)[ZK.S>F-[,?OE?Z\Y&IG829L3D!D#_']'
MO>)NA#483+[=[5UDG.B<?8;_Y-5"QWT;LOO45<Z(?-$,G RNP!'0JA^S2Z$%
M#,>>^>GSG=W34Y X7_E+,SY-H=444KFQ:$R0MO9+=,XJ4E"\I9]MIX+6FEM-
M/+YP%U_Y-HK3$@8T]LN.WWJI9W;6I_N2M%H][?_O_Z,I4;\.%GS05_[OS[;?
M*7,Z_4$AF/<AC@^*![B6.$X09.<L_%V/KX#)(/<W:GCB-3SQ:_O5IR.23 !K
M5"!FB <M C]IJA1*6@*)9S& 'M_85E2MQOHES'N+36#6)2ZLML9J6'_ #4\H
M=:'VB=0+?UL7BV;A'[CP!X='W)% $N6(X:#!P(T1.=A\*!E,A$S,6@T++S!;
MOO!C39 =\(#2Y61I3/HK3&%CMWF6D;R8\];IW\N@9%S"Z[P/J]0'O,O@6QWN
MM<KAWL*1WB;@]V#4+W\HJL=^ 7B\..F D9Q/Z\YM)[1<.:(O#D)X@U%FR>5Q
MH%1RC")<<%E#_&#0Z[\D:'_BL*QESO-)NG/;#D=]^.]:E=?[/J=:.T=2)D*(
M$,A:"ALN,(&,Y@H11J4-W!.3^'PT04@FAHB](<IR%XCC6'L@V9P*@X65\[%9
M]83G(Z [G";WBV,]];I YP;Y1_C.-7MXH9K>\C"OI2$4M[[$MZ[*1S#>PE58
MR'W+\FFQQ?##ZN?=_)E@US_TP<7^R):Z8UF^;Y1Z]ET#XO.ISUT*P*TZ)>,'
M2*IXF6D1JTHBNU%'_EF;DZ]&<0^>?' 1NY]CNT3>K$W>Q$-59EUOFA]^W"$?
MX-[M@]>7, 9XU@Z&[WQI?]TE^W_\=;)_\.;KWON_/[5_FZ\W?=(IS_MX^*5]
M\*_3O5=OOL"]0<V^_MK^^(Y_^*.XPLB']V\N_O-U9]CNS'5DQ0D6/6(4L>2@
M<BVH7&$LB@*8+_/!1H/S(<ZCDX"?7RNV[XW$_$%(?$N1@D<7)EB[F;H[$B][
MQ0:)'XC$AV#5'EST&@"^%P"_7@3@&*Q3F"(3K4><.(<<)QI0.($-X +U,I^B
MZW5J5/>#4&'14.&&"J\W .<XOP:"[P7!NPL0C&&IHK48"48IXE+D%E:$ 2(;
MH7VTCG.^L<W$JG*'&PY\9PB6#0=N./!:0_#OO5%_]ABMY&2AK['?D./[(7-[
M 9E9<EI$RY TTN4BIA(Y:R+"RCL;J'61VWR*HV%1?VT(\K=&9]40Y(8@KS<Z
M=S['!IU7@LYO%ET7FB4*0HR<H0+QB!509B^04!+;Y'#4/*P,G1ON?+\ZDCFR
MN10#:!ATPZ#7%J-WLH0V0+U2H'ZW -26"4(-<\AJZA%GDB"GC$)!4)E<<M%%
MT]#H[UCP=RYN^GO0ZFOKU;UH,+_?RS<P_T"8?QX]PY\'O!\NP#OE47!N(U(D
M!ZB3))#+W<-)(%(2C[WW:6.;;$I-G[K92\//[[A9\\[YY2K_Y[S7S\O1</6&
MJZ\7B+\["YV!ASD=QO#Z2ZZ#LW.:?VM ^UZ@[1= FR1,0J ),:X+)S?(&2E0
M2H[34F]#8@#MQP?>-7S\7AOPS_FTQOFD@.](SI=7FVZH^Z.GIM$)=VO.V/#X
MU:F$XP65("7G*3J*>+(*<1$"TE9Q9'$0.!FL93*9QPOV3:K8?PN6/UV_?K;V
M[]WR"M>S3/6X<&5.HMR?*([!_5(FOW-^)*'P(CLW)+S-EDPY*;5(9TI3^ZE9
MN%*?@[J.];C$M3WNQUA5@!W7;1WV2EV#$#_';N_\M"Z#>-RWISD;M?6Y$WJI
M.PJ=T]&@5'[LC$XW6YVO.=&N=YR+[N8<U]WV.Z2%A)OE53L[;MESN,F74BFA
M>WF_*G4/ U6Q6)]_,B%74G$W2)7/%%(?D8+- 3*/L)<:4Z*14MP +C*&#',L
M]ZA+UFK@SCCFU@J+@-B"[= MY3ILMYNEN$IW[N0ROSG#>E+"N"0_@UB5BH?/
M):OYOG7S2^6/^;8$4]#T,BKI[Y[5M2N)G"OH5/PL>9E+/>[S4=^?E**98_!I
M_90OSR<@%/^Z,_YK^9W\^G/KHC,\:?&WO[5V_M@$08)[U<GPDUJW_K^C3G["
M!-9*M;C-NDKM3%W:4EKN'&!HO [5SQF@8#6K]8#AYVHQ,/F?JFL^G?4NT$GO
M(M>L AF&3\\&-7)EZ'4QYK3]VE"OBN@-2KGJJOAM'EY5_KZ&WYWJVCRPMT-X
M@.V'0>O=>2GV O.G$"8MU/KG: "3/!CD]W1U%>M!ZZ>#WGG'MS06/__2^JUK
M8:TNQV_X*J;.6?6@4L=K?(>J>NUD9J^J]T[J?_]TD L4G( T[.[N5A#^]\]5
MK?12/&6J,NZDBFG/E]H$N:Y!KH%0SSWHC?'4]F.]+M.+5:;_LM7O7=IN202'
MBT!'P9_O5]J)@+"D8%VD,?+DJ Z<.A&3MSP&&D6N#0 :4Y3: /F'604Q6ZBC
M%.S[LQ;,R3S]-1[CSN#/V,\5@?;3SC%\>IPUY5X<O@7U,/B1*S^UX;YOCH@1
M2H&.1DQIB7AT 5FA,=*1$,U9 /9<] 1?4N^I+@-@)]-:"D$.\L16&VDB6.>E
MSG'>62&+>55[>C@CUV,ISD+\<R6H5W7G.E_M>&>4)XY!HP*+K=;KE*K:'W4Y
M=E)JSQ-3@=EY+L^;:Y#EAQ7M!=\: M&://+O7*.C,QB,\FZ\5I8')[:?969&
MEH,,5 6G!/.".QUMM#!G7@G%J%"NE"DC!G-"IT5X=^_W94V(>F=OASW_Z6UY
MT"Z,)X:FTLPUXDOW#W:/C%.$<H41#](BCCD%[JH]PB*H1((51N56O!1O8K6D
MTDRUHF.QJF%N4JFJ+@TSR$L""@F$,70J$ES5M1A#]\&53MG,TE7IN\R;0,8^
MQ7B>+YP2[RS\L4CL%LCK0\GUPP1O&;F>R-W?V777\.IK!(ZWO[:/,,@4M@;4
M/!?9^TPBLDX&Y%BNDABIBSGEA=S JZLZI^?QK&Z>T8\^NPO"?"W44N9ND)NA
M^'&5N%S0MY;8LSFDVWH91'32*J$VEN'?<=F^S" M;"K8>I>H=Y&5R&#D!AW8
MD_W+N2V\63A,O0_G..S;@OU%YTRTS^9,WYG*X+EZ;JTNJJ*!_9BK1)4J\E?E
M;NJGWX\%29F[?0@/$B5YE-P8YYU,7)*$M:)B7,.=+:_AWK"@5>SJ-U_:!V^.
MK(Q14 W*@Y$$NL0D!/8QA:W-/2$JP>*PZUA0Q88O\Y:<I3_W ?-'R@+B,\)0
M+?OEE:1/!**L]]Y="US_>"#_)C_S*$@I0X3U%S9JQ)-P"'B&0"90$8%H .-0
M /)JBU[G3QYC?=.H[=9&;7)NCM:P4=L+:;PV;6*-5=8$&>KN9;57H3"3TUQV
M]WXZS1)J)+92,J,X(*<+&OXB##;>>,]LU>UY'KZFK*%;\.LW.SBIP^-JA?9C
M*Z_]@^.CY"2QTH#A'BA#W&B&C(X>16YI-);3D/O=BT7SYW^K#E"#DP=4YW[J
MA:Y,X&:I)TM]V3YH'T4O0\ \H20"\!1F/<"A-,@*$DWP##-ZPU)?6;OS-9FG
M+=T9CVZU#&-W[E;KSRF:/ ,?LV[CU.F6QG?P79N++Y[$;H)?CCN#8;_"U<$0
M&&A!&OCE=^ BK;>(P3@^7U4'K[]< U4UDJW6^^Q1SG^H.BA.L>^IL9SU6JEJ
M&38!M.F#M(K#MUP<7F3W[Q33OS(;7NJ)QK^!^W=;?_9[/L;L7K_GX>J:VHW3
MS7,[57/'RL$][%[F<PO;'Q;W=6D5#"2IDH0L*/U\?6?8LA>Y9FEVO><NI'47
MDE*(&%C',&9S<_J+Q;T.7W.QVXFY?=U%;]0-K>S'Z5>]-VSQ\!2;T=6^_,VI
MDJF5H3_8'!>J+V6#ST)] M"O<#GEZJE;K?_;NX!G]#?KKAH!9K]?WA.LO;S#
MX9%?JSK#*?OML[C[KNV<#NKF?>-A3QVJ#&#SU-5<IU^K_EHV$/OENO$1RU05
M_&'L=F-U.GW>SR\$4UN?S^3+ZEMD"ZAN.S)I'WBYU=JY<G)LCIW :30<S7<2
M.;67^8RQ<_:YU_U<^8MS>?C>",9;)/C\2H+K#JD@3P66X+];=^'==0'9I+00
M1DCE.5',22FB5B)P8GSBY(APL7'[YGARL5^^F<76C=T+5U"#^7?;Z1>WX*O.
MP'=[ UBHP?I46WXWUL*7AU]??]T_>"W:!Y] ([?QWJM_GNZ_ZIY\>/_AI/W^
M4+3??SC=H[M\[^V\%O[71]"L^7M IOQ%^RN,"33N_OO?NQ].7W_Y\/'3ESRF
MPX_'Y#]?CUG[S1%F@@:O.3*>&<1E3@JS1 /?,E19K+DC:;[8LM'8*2!JVDO%
MJ: 6DZ0)D#,M>%!$SQ=;SM/>*O/>>D#;^UN?MOW$4O,6K(PPZL;]-)&?XJ :
M[)R%?U_U$FU'FP4J[)_]E>$H:_Y_VD%GL&8UO;^YE-']G:.0V]\H&E&(+-<7
MI01I%P4B0@#G=@8++>:EYCEK[ZLCE91EOXHB/NF NNS[$]#==1^K*L9XIA6+
MRZUBH_4GH#0^%LTYC,>]!9_PA.Q>*=RZ,]U\A]O36BQS;Y>IP>1G96]]):BY
M[#]HX(7BY2LB4[RX+[YY^7)CMA16#ZE>SN&;RJR^SCC>D@\L7WY;4?2'E5IO
M!OO=!DM746[^NDR"R:64+%R[)/Z_<IM^FVAW?1L7+-[-*<I0Z]5B]P*&31HF
MCB-09Z*='SM?4]D;UX4]+XE\7O^YK!SY94+ODKEREW?_H>;PWSD*N9I$TDS@
MXR:0-A/XN ED]X&\5:7CP11^I\2GRMAZ3,+=RJ3IOAE]S2"?QR!75&N@RJTT
MZ[R9VKVSF!V2_4\1[$%XH^LW%KW?^R_-+'W6:90Y YL[AAT+CJN(M51&"^X2
M]4H[K.^:1ED!V!+GXW-)I'R8SZA.I+S<?_^ALP?//SS8Z[;I+OYP^OOIX6F;
M[+WZQ/=.7^/]]V_XX<&_/GYX.Y](N2L^G.Z2_?=[)VWZ#L;WU^DAW.OPZSN\
M?W!,#P_>B ^O3D[:IWO=4C;V[5R]*X(]+!I&6"N/.(6?3(Z(<@(;P[#0++=4
MTV)34+)&Z?4K*OC1;./Q-DX)2\P52 %.7&EJ'1;*&^>)BD(9TVSC]=K&EW/Y
MT%$YH@)&0<<<&I\XTH)*%&VP1,F$846;;?SRMW%,U$K8M]R)D*O,:B6<X29A
MCKW$)JUX&Z]EX<GGL8/WYA0Q=M03GRL:8,7A'RR0-DPC&8%-V8 EUWP="T\V
M6WC%6YA&0G+$%W.*\*2LE<9AJ:7QB88@<;.%UV8+SRGAS)=,LA;IH!+B5@*-
M3M@AQAT7&#N%G5['+?PCU*JJ:L>.CW^G3WF?J #JBRXA]<,4B>),JP2;VCO)
MN7?)FD2-\<QS*AUCO#&+U@B1WRQX-T24TD4AD8(%0SP%APS!' D;F*562\WQ
MJLRB;U+OM:EPW6#<JC&.>:IH(I$XX[D5UM&@3 Q<"-@AVML&X]8+X^98IW8\
M&JX32E3G4G@$^*<Q#!DN@\(>N*C4#<8U&/=#8QQH>NIT<CE@FP=&#!&4,@5V
MM2(VK1SC&J/ZP? V[Q?C1D9G4T"8"HRX8@99#CQ.8FZ3XI)+L3JCNL&W!M_6
MYZWO57=3"RXXM2($X'#,66F,X;D<DM5XY<=W#;X]'-_F3^Z4LEA9@8PS ?$0
M OP4<P%/G7 0"A;//R]\J]V)<U4N2)W<L.+C@CO<8^IMY\HV/SH>JQGE2QGE
M8WW@=TDN>(@C??UB;.^>=4 >%X+[- +QS".<'Y"G\*A):6;](9D-S91_\UR(
M9LJ;[(DF>Z(9Y+H.LLF>>%A0RTMS4+WH/HLF*FLLYH$DP94P6@0;J!+2,LF2
ME%6-N.8H<2U\49\6PB4"YR08Z5!2@2$NG4,.:X6<2)A@KAFU9&,;K#O)%@O.
M/?L0U :57B@J*4=$2,Q1HQD7@5II=0A",< BCYEK4&F]4&D^K#;'0 LA$'<6
M_DE4(QV(0$E3$A(QPD3=H%*#2NOP;O<)+14.2QM#8"QQ2XR1Q@?M?/+*1FK]
MBE&I.;)[,"#-AR180C!)/B(C<^^ 9#@R-BH4'2@5PBWGFJYCG'^#2 TBW6B]
MT9@89@%>&X-4*P>:-WD?E+0X1FD:1%H;1)JG2$($T!H,"9LI$C<:N1 4TI&#
MCN$^8MQD'KV4S*/E+:CS2S0A7RN8G1<#YS@H+PCU.MC C=2:&^ F. 9C-;>T
M<<:M$Z:_OBAX7IAF&^^_.KP$NU?$4HN%: :@3CQ#EH(9#%23,)%(<!JORNY=
M[1YZ'I&Q#8XV.'H7'+5<1&>$D4QX+HFV.AKI2;#&X6B%:'!TS7"T/8NC7B>J
M62*(!OB'LUQ770N%+,&).JN4TJK!T09'&QQ]8AS-32ZM8M00DL\2G?>6$$>T
M!)I#:>/P7",(?3<+H8S%(!7V"-N<8YJP058YBV 5*=%<AD#3$R4I-!C:8&B#
MH9.C["@,9EK[$"/71#BC#"=41))X\H(V&+H^&.KG,-0K)X1QB',+&$H-18X)
M^$?X7'R!VNC="\/0XM[]1VE-LSW5F&VZM=7R%L6S77.7]>Y]OGV/^K%UD?\Y
MZ[6&?;A5BOW!I#'E=*+!YO1O-'<(G [0'GN4PVC2/O,<QM0+@W'/I!BV6JT7
M,6N_EZZ,BWV=3A<B35L7)QU_TLJ-':O.A[FG4VY Z.&K<'5N"YJN.N"6'^)_
M1YW/@&UG,)N]JC\A8&[9"G:8FRS:KCWSI:=I'&ZV^A%F*3=?/+:=L[J55 _6
M8C#[U,Y9:9P(2Y&;5\'C8^NG^.4\G@WBSTL?,^F/6OJUUFTCX8*ME[&&^Z/^
MXGJUK/< 6\/<V?(D=LNL]>!"9\\^C7M%OMMZNU5F.3>HCK9_EL5],K5VF%MT
MP<SE2;M?0^- 1)0QN\.YXH820X4RF!L9C(N4B.4YTPNJ=/?L,PPD+]QN/:B_
M8#CKU+GX6W>SVX5K/EVT/[8O]PX\O-/.D8N@W*0SR&DC$2><()-$0)+"(BC&
M(X%)WN9;;'D;8UL)P1^Y5_!9R39<D*1GT[SWSDUM3T#<"S[5^)/[P):-47Z(
M7^ O@W'#NU/[I7,Z.FW9TVHWG57=[-QE^?3W5[N_S?5S[9\5<,D'D\?QS.<>
M>+;<;:%S5-4D?GI0N=7N26<P[/6SXN]>MC*L]3MPFPRV<)&'9W>&8U2\R.V;
MI]_A:NAE8-W.:6<X>#GKYVV_?YDQJEJ,"LW+Q-?]B:>;$(*J/K= N6K-,-@<
M(^(@M['.Q*G\I3^*,]=,UG)\R^EFAO;\O-\#><B@"!=U^E-'SIDOQ+J5-_QM
M<-+K#Q&(PRF 6F[)6ZWV5 O$_"C7ZWT:=T2LY6U1\4Y(QQBWJS:&UL&F+9HQ
M_VT R FD9*S/\T0,!J>U5A[./AG^<MSKA8M.MUM&434([Q9=V0%I[/3'7YQ<
M=A%;HT%I0][-3 G4[,PS:N4R!(@NK9ZOO@EC>AMC:Z\'4T8W)PKWB42HW'%9
M_^[E0O5V= HS79I;#D#J.PFV79:B2E!*RV8@$64/;_Q1O]#&2OLAY_:Q:]H/
M63YY/^2WPY[_=-+K@ITT> U4<7B9Q>3*8EZ?KK7'M9X_/VT?'%X>PO/:K_XZ
MW7OE05>_$X<?/WTMSSW]UZ?VQT]P3_B],Z?G3P^_['W\5^?#'X<7>W\<XKVO
M;RX^''0[^P=@('\,G</3-Y<P%@&_T_]\/?[2_OCZR(<H@^8:X2#!KN5,(N=2
M0)1+FK@@D6DUWQPY1445239%3'ET5A/GH_.!VF18C'R^S2VH'X"<5EF*F[LC
MKZ_BN';7+Q?LY7V>;Y^XV8EVSD:KO?,Y*E5JK*T6U 0'!I35(/: +L"[4^NO
M> P:O;(X8)K'EL@2W+ANMNO!<UK:V/YZWAN4QO:_%,CN?(Z_CMMZEI>;^F+M
MG,!77[$.K*+1\/JO+&11?R^[%+6(F@/:J7]/)C5PSH%E(0>6XR=D$XSW%]N]
ML)>#C7_,"BQ(Z]PTSL_ ]0Z1&YJ#WRH$<T(#U\)>IEY&RGB@7AOM!+&2:\4,
M=WACG;?9C0NV>P8Z_G-%< 'O\69K]_04K$3?2IUN(0Z#LAWZT]MA8IAGLQVH
MRVGK+6(54<KW:-VT@[)/)M/;PEYZ*<7LK-D$<W<P*CZ%3&P&8"=FY3XZS\3L
M?^Y3U=!0)BV5.L3 /=,NNMS.B9L R\M,U7L+$\+PC#=8C%4<V Q??FE7ML/.
M\3&\-0Q[OQ[EGP"N\,O;W/ZZ$,MWL(#]\K+3[WJWX 7YPRG'UQ=P#](^>$WW
M#MZ T;USQ$ F== .26$9X@IG(]A[9"5S/#'-".<;VU3@K>O"$&!'=+-(9!=6
MI1$'62-N9O(-B]8O7J3RAPLP0H D@JT0HANV!I-%+,;#/X!_9[$JYE@FR;WL
MF^E?26AEG&3+.YMSO5/7J>S%"4V'BX][<"$0YYW*E(NN/\HLE:AB-[+-?&%V
MB WN)=+$8)9B;GL!VBS_QTK!!"')J,@29D6D<^*>ND&D%X1TLA]WBDWV5SRU
MG>Q':H3W#L(+GQ^#$2"H-XHC:CU&7%N*K%8:"9&\!1GS*KB-;25NE=W^>.XK
M)RB(QXV0>RW?N(^:N>4 8<TUUL0E4VFL*4?X1&O]V>\-SJ,?C@:MMZ/S\VXU
M=ZDVL^^D=^R5$VFL"29?!'P!79"OO<]6YLP:[("M F_@!@B$DQP8:^2!41*#
MJ+73_%EEHYV^]09G>Q_?'%%F>0@,HQ@(;'#/,3+ *9 T$@N-O138;VS?7SF!
M!-HAR-9ER\4B?\5)&/)18P#I@46#7UMVB$!24>U1RI()*@B6O!+DGS9F]D!K
MYZ"]\7/E6'S[]S];_XY9)#Z5@YYCN'[199F]0INU3AO&[*X"B1^3WOPS7%"V
MRAD\_;S?\S'"-:G?.YW90//?*D<8Y8*SH@U;'C9P=HJ"/'^.W=[YV$.552W<
M-HS\L.5A&.7(IU*R>9-6OCP8>NS#=WVO?]XK1QKG(_BI>/RJ8Z7\B/S,_-_X
MI5.YL8H;L0=O->S E\\ =B:C@$<>]^WIV-4X__QJGA:FME5\:=DIF+5^!'RH
MCZNB[7<[<"&\T$^=G\N?E@**A:_71&%P8OLQL]]^;W0\NUKU3?-SJ@$.1NXC
M8%CMG<P3'8H]"!HB%C"#Y:Y]BXMCAEG\J9,'50][BJPL7IQ=W7G*+SJ#6#/T
M[%4LA,5=7C<MM0Q/)B:4PR>0L"$ ?O:UQTY9QW/;'UY6LW8M6BY@)2<^&<V<
MDXY33USRS&:=R['GK,[56#B+VMW[_6;><W U&P"8O?[[?G[3L[W>$-!S!AM!
M/_F,CQ>]?AC$LPDTXA\:&M\1>/Z1T-G$HKFY9A*( T-%3A.+(J%<:V%RO=Z-
M;9C7!61L!;#RZ^/JK$1!2L_*W&]F@061F8&O*6D".?>Q/[3YOYV^'YT"(\KG
M)]-(4(#'5R< E7;..AS$,^. #9]C'Z0[ G3YX7BSU9BX]30.;GHG1M-Z:O?Z
MC4^_UEJY#[.1RGD6@N B*J#"R0C,0$MZZ9.TH3XYOM5(@?T%!";KR(D]\IL]
MM[XSO&QHRQWV)FM_;!]QQI5/02$>,VW!/B%+)$-:L8BM)-0JMK&MM_@MK"5O
MM'KR:Q-E4+.3I2ID37;0#VP5M4$;9YWXC PB:Z@U-DIB#.<:@"-*:1VP;FTE
MH[P*WJ18D,9=]WV11<#8CJ*QRC!&LAFD$5=4(!>XR"$L-A@>#+,2D.5I#*+*
M(KC-*AKO@?L91%,FT ]L]DS/W3.P>&:&>X.Q,W/=7>R<F2\\I8D#;(C1A*GD
M#/,HDJ.:$1UD\-2IZ%UCXGP7L#O,@'>D'+8$)A_E3L4YP4?GDD8>!68CCC9:
MY<3S,G%N.)BXC\XV3 ;MF1="&DXBSV>C6#+)B(S1U$EK#=5_8AGE[:\[1P 3
M@0;AD PARVA4R&#G4#ZDEEXX2K"]DT*^F>M/ ^++B$JLWK[Z=]XS6NA$R!KH
MW,[MU<):0-WE*8O_'<&.@ZON%V+]H/"K);'6RZ%_9TR%?IL,],_8SQ$A^^D/
M,  &?]:49O^LVH%5&%'9A^L4G_U=MY;8>_7F"&SG@$7$*'$.6POV$[)&8L2,
M")9P(S#-)3:7[*S_'1./XSSA2TADQ5JG.'#%CX#C91Y5N(\#DI)WV_]7L:(Y
ML>SW/G="G!'-0G0];+->"8S,>^RTBHLL,EDR.T ,^QTW*G\HJ4HO),1X'#M[
M"=RT!3P>9FGLG:@S@^K [5G#N&\[.3)V;I7N:< JF9V?4F/C%'=":N8I8PIS
M4(W!*W[+=K[2BC.QE;O%!GI5\IC^+"E,)2<1YJM\,F@TY.W;V#.X]L@8$RE+
M'DFK8M:0"5DM)9+"RT"Y232DC6V.M\PM&G)Z=RX_0AG;-^,M?F/Z3;7G5RM,
M4X;!+=+TMCS]GN+T8QL%69R.CZPF7 30"EA*"EI!>01&@D&*.$-I9![, A"G
M38KY)B&+N3MCK)]W@)2<K0KDLH4)+-X>QSNZU/[,/BV;\Y17*4QTCFCD85>"
M]+X>YDXURO)1<;5=#:21F"(Q^Z]VCSC6FL#,HZ0 >S@&%')8281M--&;Y$P$
M #);BBX*RWGL5P)3^266NZ26'%;G(+/OJ\7&-/-W&.5N[1Z:(YN-!KN+ !T>
M84P<R XP3R$=XI$SY"AS2 OG&*R.Q$D $35;\A8-5L*L8=6R[R][$HI]=]'O
MY+]>V37?GP']:2]+I#W0NBLKIJ$\=Q.8@YTC&J*($GLDK ?*8RU#1GN%8%D
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M8BV9B!>)6-R"2+O$1&Z+8KRRDJ@DF.')..8U:Q#K.2!6>PJQX#T^OCN*02;
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M+RNTG\!JD<8BZ9VZT_S]D79ULK<RR+U>#!O4O8-L7K8_OCM2(1!I7$"&I(C
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MC_2$R'BXX$?RSG"!&48Z80X,2V'D=&((4Z%X$E(I05;H1[KW'FQ.5)L3U1_
MD70[&#;^I56BX!P_#-SPW+P"$1L8XC989)V$7[FRPMJH#%4K\B^]C)/4YT2,
MUM6_=,V>KW=V+H!X1[?3\M+6C=OISG P[W8*1COCP4BD@B?$02:0]=$@XIE,
MSFKC<\/3E;F=&@[R@W"0]70[W<X])O7B&K?4XW!F/H!+&Y:L3$@)K!'7PB.C
M*$,:3++$->.$I96XI59(.EY^N%+MEHI7>OB)PY8:-]1W=$--T:W&W[1JR/,+
M_B8@VR#^TB*BA<DG>@%9X2V2C'IF%98)S-EMLLF,WN3F"0H#?F=_4W/$^(,<
M,:ZWO^EZ([-Q+#T*[N:33JU03EN,=. ><>PL,CACGF*:*DQX\J[4]VL"EQK'
MTJH<2XT'Z9OO^WD/4M0VYR :Q!R&?:_!O-->!A2L\@K^"0#[&]MJ2^ F<*EA
M%6OA05H-X,QZB&9QY9?4^1(#^AK[O898W!=@YH@%]9I*S"(2(-]@1W&%--<,
M.8D5)5%(X_4&4 @-J__K&E&+VGTT?M98\*N&;M_A0.MNEN%:)@XV]UAM(N43
MT=?U:_]R]UY+S9P]47>F9F*_1S^G9M:_40>H9Q>*?$L'*+*B@.,?,$&=2V6(
M4]@Q0[A)Q@@P5:()DFBN$JM,%-PDJ#]O ^7U13%.BA>DC?=?'5X>:25=)&"<
M.)HPXL8Y9*@WR"5,DS8N!(_S20\A:I,\O@74?3?;F@<6_[ MH.[]_L\4+*\_
M(GH88C:Y[<\&*-NS0"DIPS)XCA+.*1@.,V2YL4@+K[%AGAF3@X_IEI$_&$@^
MT)&SXAY0WW60+S[<ZC$]H)YO6?W[<6C%F)84.\D8YD)S;9*/28**B%(Y(<N9
M(AF?*7Z+=JI-#ZBGU1)?%NBTTSHR@R.*.)="\#PA:RU#7D?AF'(2.$.ATX9M
M@MI8(Y=_<XC9'&+>A?<^$N6:)E#/"M[F2'!R\#_!(PI8!\1M(KD?E(25-H);
M@8$*2X WOH575<MNC:#MQ=SCQ3N*']<&ZJX)6\\(SK\57WU %Z@F\F054'VY
MZ-CEDA G)7*46L29<T@'*G/K/I^(X2I&L[+0D_5+EV[2,1L>^FUYZ#W[1#6X
MMR+<FZ.HVAMJ9%(H%0N< SNUB8H<R^]L2)@Q:U\P[KV8>[QXE^K*>D@]7__J
M/7M(K9^#M>DA]2W!_NL"R8V)I9B<04H2A;C7&!D5)<*4)1&4BD+ZC6TBV*98
MXFQM^J"N$Q@T?M;ORV^;)E)KA71SM%9HZ77D$BGN .DL5<@EXY%F01H3*,>)
MEA15L:IL_#4"NQ=SCQ?O>;V]BU03I/OP:BR8$VZMBXQX+GQRF$7/! ! -G,)
M*R%GWX+V-D&Z3PG^>('F6IJ4L-PASBC+404..<8"DL83J;$6CH:-;;I)A-KD
M39!NX^I]CI!W0S66!^%>$VK[;.!NCNLR'V3T8- K12GB.'"D*?PC@Z?14.P=
MK\JQ"-XX<%]$.98'&;M-'ZEGO_'?S6Y\%1U@NV6(4 5D)Q?9=,(3%&.DW!MB
MA2X5?15O*OHVO.+A]5@>Q">^92.IQII:)<KX.901BNGD1,[D28AK*9!)0"]P
M(D X;$Q .#:V&<[V5%/3]ULZCQ[<:NIA3J6FQN]:>96:5E/? 1[)@K,)>\JT
M"1X%F1,=B53(.4F19\0%[ZU,D:_0V=34_OW><-$<O*ZCMZGI-?6-87#>"24,
M%2HI)+ !6]2#0:J3E4C&H"CE!@NG5N2$>AD'KL^)&JVK$ZII-K4^>##GFP*J
MPYRB"FEJ&%B-2B"-M4?462J(D5S(5?JF&A;R@["0]?1-/:+;5&.<K1*%YGQ7
MQ%L129*Y U5"7&GX*3?#3-YY#.+"++8K\UTU;=*?HA_5J@*@&E_5=_15-?VH
MGA+WZ()3BF@G#-$!4:X ]X+4R'+F40C8&J4T6&1R8UL)NFE6%A2P/BZIYJ#R
M!SFH7&^75-..ZJG0;L[WQ)T63F&,I *,XX)H9+2RB!A/J:&)ZDB*[XD_NLQ*
M$P#5^)Z:?E3?;>//.9FP,5&2?/;&O$3<,86T319A*X3C"C.=^\7H+=*T-&]X
MQ7HXF;Y!0ZK&FGHLS,QYD61&&:L-\IXSL*881H:'B$#="*D-,<%G:\IL<D;6
MB&"LI"O5"D^^GK KU7-(9GQ)]RBB]8]AAJ+M1=4:.I^W_P_\,[[WJ>T?=\ZJ
MS"@ZJ_(^C@;#3KJL_M0Y"P!YOU"Z5<GH$ZF%<L=?.D,8@;]94="L*-K1#D;]
M M"37;SF;WCC^QR<Q-;%N#^1K2AKRPX&H]/:)SL"]=/JG+6&<.$_W[9;O?+W
MUCDL;LY3/>V%V,T!AB$.@=7"_<N5R7;ZK<]9'64O;OY+/#WO]BYC+)&)("!H
M\H=!KFTWON]Q*4C:ZL<NZ$.X/]PY?YMB8EI_=F%^+F*_.(=3K]OM70Q^N=\J
MK*=0_=49?$*_]V$N=G,7I1RJ^5=N7/12!*R?WR_E]^O#:TV)5ZLS:!6"TX*?
MWVV]W6H=],L&NP21&PS[HU([K'71&9ZT@-&,^IUA!X8VZ,! ;7\L'%=QKB"!
M8WF;EJK!UDN0DO%I8NM5YW,'!AA:AYW8#2]"2EI93#(1MF>7K1/8WF>](0A'
M+H;9RG\*]2L/"GR$7JRNJ%8^RT&Y=NJR'D!9D8-N)TTP:"P-K1VX#V#,8-0=
M;I9/IA\-VP^8<I&GDZM;MB[S9.='N=BZUEPXJ\\S9BP&X:E5T@OM/.8A!4=E
MPI%P(K"D5/FE_;*?Y@3F=\#E8B7L7$'\6*[&8I6AY\66V/OPGQ/L3_\^L^_-
M:/_C+E#Z-Q=MH/M@#G0_'/S5:;\ZYNWW,$K:%NT__O[8/OAT^>'CWQ]S6Y/]
M@T^D??":[KW:^;+_ZM.1UUQB&CGRS&/$9;1(@W&(=!+&$2FHPVYC.T_;@AWP
ML@#I[U[6UMW.\'+\6M\%0UX$$KX"&*OU6@U*I=RB^G4 4'9:E;P[C_V*'9UT
M0,V!LLR@:%M=FS5> O"IP&P R]-)'5]?EDW#<F4'F%<'[O-YLFRM8(=V%@G'
M*#BX4J]3UT^4=O[*U.VG+H&!=$!W]R[.:ET,PW+PNJ%2Y[:5#8SSR7C[Y=2_
M&GK6\<,3.VP!A+7.P3#L^.YE:]BW(8:MHBJ6/S*_1>L"(#S?9I2'/!H4$IEQ
MW,):M7RW5_Z2Z6O,)+)2$H/8K5YQ\OQZTEO527HKE(K,%=OX[Z@#S!8$I75>
M:C>-M0L,QH^Z17%<STA0-7,V@_$\+<D@D15'YVQ4\/QAN+!=.EP^'E]NN4\M
MM)QN*?C.K^<PKWG,OU3,_7/\]:(3AB=C]]K4%RNWQ"_XZBO6#7I=6*YKO[+0
M9_0[[<W?46LJ J5:LZE_3R;>E7.PHI #*OL)V03C_<5V+^SE8.,?LTL!ZS W
MC?,S</U25/_.24REDQWF.GF3HN614Y5<),):+[Q7A#G*-IZ]PLD'*"\#[@^6
MV2\U3\W6T149A74> #^;X%#.Z"M05H$0H&7^:[&?,Q#&S6OH;U$!^=>QM0]0
M=@R G"^"-YL85[4E?@*7 57.AU@9\:=*5-5.@7,[&-Z3SJSQ6BSX0JXF=,ZI
M,6-@5I=EA0/OT9]S64PICWR^!XL*%X5);%OE$ZX#W&A9GGR"4!39_SP@X$%(
M2BSWQB;,N!#4P(^2$; Z/"9:Z5O,C95'/MS88Z9\^ IF=V*9_, FQAN\]ZI]
M1)W 1&J-&/84<6X3 O.1(>:I8)%%+ZW<V)9;>O%XH0C/0V0F2*52BM)$[SA+
MV%@34U":)*EI"NQ;%\QL9.:N,K/[!<S2B_;']N7>UQV\]_7=D?8N*2TBXB$R
MQ*D&BU1;X".<)(J!$1!L-K8)WA)T08 VLU<D:R-@<-W+K=9-81</<FO,B8D_
MB6'4C?MIN31,MSW)"UU)T97KXB ;#0<PHG]VX<(?;NT/O[0!+XR30O 4$&:$
M(RZ5A:4.!&&@@<)I;[RHS["!)L(FRDX=:0.SEB3AA.:Y#:\2QA)EJ7(,*"/?
M .+A[7GFWGW87D4U5A[W4IRR7WGYB[+K7E;U*J\Y,LA&*8)U[G7C +5C?PB
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M-HCA'@>FV.V[Z,5;UZ\70VA64=CH)<+((Y4Q^R8@<A7PUL#(_6&DO:",292
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M75 L:8%57M%3$!;OMB,K#%(RPK3/"TM8'J3*K7$Y"=13,&PP$$@/3/$L@C0
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M!_HH8!XLB?_%$'K14,6<-9E.8-5FP]-= 8='QRPX@YT,B,OHOX2_D&9!(>Y
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M+GAS9.U=2W/;.!*^SZ_ ZK*S5:M8DA/'=L69DE]93]F6R_9,9DXIB 0E5"A
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MW72?7%AIYC'0]:K<;J[FMN.?_'R$ JEF01SLXSJS\7K,C @7,H4K"&<05;6
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M)#N6:T5.[9RN35HR$RJ@0"]UUF$K<=\W4I_\S]8R;SK++5OA7.;R<EA@H+0
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MHT=N>&G=-KH5[7TZ">H18)N+_:"@762@7GPU_OB2IKU61J_5>@:+4XOD$]/
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MW9 ];_;UH)V['+(]<6C.[VL@=9:TAT?F;*B^:@H,1"&'52-J3%DJ[7=#H9O
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M-J%79)"*U(Y>.V92K'U4O&9>*,.$XU8F^C_I>^A>TP#Y043&UF'2/9UM=JW
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MMPC;BW??B9 /-Z17A98AJD4#5C&-DC-O2NV@JT(""YFG9SFFHX5B.PWE6$?
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M;P>\M_)Z@[+*:&-4$*!]4B&H#,J5S 5]Z=+@T4_O(Y?7NSH-1B66'7F9VN3
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M_\K_A/\M_P?^*?ZMW<*[U7:?W.V^.VSW@]WYN]_O'MZ]+B @H"3PBX"K0*C
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MF?3(?O;]:OOM]T?OS]W_:?^&C*R,N<Q5F:<R+3++LN*RO\CZR3Z6;91=@(G
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M.$^>AY^/.=_E(N6"<GGGRN/JY/K*=</-U"W-;=9=U_V.^Z"'LD>D1Z>GE&>
M9P-2$'D167Z!ZX+SA<(+](NV%W,N;ERRO/3\$MGKI%>&U]+E7RX_OKS@;>R=
MXCWO8^R3XO/#U]@WU7?A"N)*^I5EU$G4,Q3%S\(/Y[?I;^N?[\\*< [ !^X*
MO!!8$R0<Y!_4BI9%1Z)[KZI?O7-U\IK!M;1KY&#KX%<A;"$>(>]"1:%BZE.8
M2EA<V%2X27AF.!CA%%$>*109%/DI2BWJ7M3\=;/K>=&<T5[1S9@#F!N8J9CC
M,2]BV6(OQ39CY;&WL;._FO_Z^@;?#?\;W3</WTRY^?.6\ZW:VS*W?[T]$V<>
M5W1GSYW@.T/QAO&XNYQW47<_W].^]_0>,^%RPL?$PXGIB?3[7O<_)AU)>I+$
M>N#SX'.R7G+V0^Z'00\''R$>O4X12KF>,I-JDUKU6.YQPN.?:<BTSG2==%P&
M7T98QN23TT_>/55X^O I_=F59P.9)S+QS_<_O_=\,^MR5E_V+]DE.!E<(F[[
M-]1OWUZ8OZC*4<I)S^7.#<^=>^GTLB/O:%[!*ZE7B:\8^4'YDZ_M7[<6Z!<4
M%.XO3"YB+PHK6GCC_N9+\:GB=R4:)2_PXOC$M\#;L+>+I1=*!\NLRYK+CY:7
M5"A6/*\4J4RH8JN*JB)77ZF>?.?RKK?&JJ:YUK"VLDZS+K_^0'UF@UA#<B-?
MX^U&%N$Z8>/]U??+3;Y-,\W(YM&6\RW]K7:MG]NLVSZTF[6W=!SO('PP_E#?
M:=!9\_'HQ^HNO:ZJ3[J?*KMUNRL_ZWVNZM'O>??EV)?:7J/>QCY$7]/74U_;
M^RW[NP;.#/0..@Y^&W(?FOQV^=N/X8!ARDCX"&WTUS&NL83QO>/I$_LG<HBJ
M1/RDWF3#U*FI3]/GID=GO&:6OH=\I\_>GA.82Y^'S1?\T/I1OV"V\&71;7%V
MZ>H2;?D.28CT?$5EI6+UE]5/Y//D64HPA;5V?UUR/?^GSL_FC;,;$]1 *FTS
M 90$7V\=W>K8=MZ>IT70>>A/&*J,6J8U<XP5R&*Q1H&3 #O;SMC9LN\,3HZ=
M+1<G)P<G-Q>4S'8F#^\N:/)P<T,IBI=O9T#4;GZ^W3M_[%SD#R@[%P<'%Q\/
M-P_?/SU8[P&A7>P/>+YPL!T$V(78.(386*T #*IIN'YG[\_2AHV=@Y.+FP=B
M@Q\ZH7(OQ#X'!\0T%\0Q=#0&.@YP"G$)'SARG%O$[B+/P6NB6C<>O=@E?Z*T
M2<R^EZR@?2GX)B^?N,0^22E%)645534=73W]H\<,3IXR-3.WL+0ZY^#HY P5
M6EZ7O7U\KZ#\0D+#PB,BHZ[?NAUW)_[NO824U,=IZ1E/GC[+R7V9]RK_=4%A
M67E%957UNYK:YI;6MO:.#YT?^[[V#PP.?1L>F9J>^3X[-_]C89&RMOYS@[H)
M;FWOR,4&<+#]S_$/Y1*"Y&+?60.>';G8V"-V3A#BY#IPA%OXN!W/Q6LB![5N
M[!(]\>A%:1.OO+8]6>Q2<"^?N(+.E")E1[3?)?NO"7;SOR79GX+]3:X18#<'
M&[1X'$(  F \9=0CKB DF!]90!GA7NPQD*?E>E#1FP5MU!?4H%1]F6)%BH>?
M^*#7IRO,"[D]XQV;_NVXF1ZZV,-0\"+-&$=[&D9@FI54,_FY6(#*)B6?$4?7
M9P'Y#(-: U+SV7Q7C0^3;4,%IB5.41%T.!Y4AS.$6<#P*@O@\PAA 8]>LX"X
M#1; Y<T"<I T8Q8P95V"7=.]GB0VO"$E0Q!)70JC,7DRL,W;+.!F&0OHA3.R
M60 Y;PBQ)94,(I%D)^2V(@LH)S)%:^=9@+SSZU[S_BOA])-_X?[?Q>U:HU"6
MF'P?KM,/[Z $A9>P]"1W^/(6+1K;=!J+L@7<,69DB6;XC:HJ/>:! 1W?1 ?*
MGK=E6U2)E.%/1(7=>I(7?3Q#JB4!"M+4^1.1;(G>T@UT9GXD)A$V#A(*(@WV
M=[I1O ]YRF=@W__\1^S8L0!^B(,N%G"*0(UF <T9[BS@N]^&E%IC[LGJ:=O!
MI4VZH.8_MGT8N9$P^8;PTYH%^!+HJF$]3#.\74[RZR\D,/XOW/_#.(U_AS/!
M_@&[9D.+9 %--D/4).1P/%,,]AY/HI(-(_-)2/(C?Y@W;5^=FT=F8P^A>V*T
MM#J(.-TC]M,8,ZI,?\4.H^G58#?D'J0VG77Z2O$Z_W%[G+GK)^R?L6=5AED\
MNA7IAB>2C>J8$D-TL0SF/>SR)L2J9@T+^-#_#SVXP2S!9,</8'_A_L_CS/]%
MHO1?N/\$]WE"F=& F'SE*0I"L0$Q/'0.1)!U*PF25PQ*BO+&3:=EO)9[3UX8
M;/9^7/DN+(3ZCCIEL92B7OUOX<$'"@\7_PP/44/MA"TKW'LL34D6*LQZ:S5B
MX/9O0V5^TL]/:#:DX<YTU<P2_]?(D_L/;&]@4<<QYB]W_POW%^X?X:K_AMOZ
MTV5:,1:,>A8P^0K'WZB",09MIP5OL0 .GWZFHK_^,Y\X#?S=RCL)O(%O?!H?
MO5(:$SLGNCOW CI3\OU<XSW\,VP ;,L8-XQ@=JP*8Q>U7_=%&O &@J4=$G>#
MNJ%,C?PK4_^%^POW_U^EU8/=APC"@ZK53>I$[F]@^93R^P)<AZQ6%?GS(ZJ@
MD+_ K*>M:%]N=^-88&* \.7[5=?:P@GD!B@>%,-^6A-\\735RIW')_Q,/A'(
M=^$[=_<5R6$!"WM>(,WLSQL9HFW;H.)_+1_;).OQCST;,16#;7+!_LA@]F!!
M^R4</<DSUQ3QK]?=_%_&"?T358_=SJ.HO=OCL2S@QE^P?U$8X>]@/7_ 2N2I
M-WZOM*'\F7%CF2D7.30E^'ZTR'I5!.6Z_PBJ\<# ,//K:\\67_XLLLHWO%9Y
M2%;->^6$;:5&?R@T%+* SFHP@MFE?X.P<?!M0;K@GG1BXOYK:5LI:++YB^H.
M/*BNC+X#^R\\%4KGBT>W)?Y+=2E_X?ZE<;O65O^9ZE%E.VD/\6Y,$ '[_E\'
M^,_E3)C=BU&*8/'0*O@7["_87[#_BS"W/V#=$*R%BOD3-LIXBO!'C!#;8)7?
M&$\)*!R ,?C:MS35-I^@0S)_7YOW<_ZPGWAZ]FF<7X() >4SB14(WY@E[&8!
MLYI2%E IZ&L,Y6G;$9N+=YM[\RP_JI\+,%%[LZ32^2,,BI/G!;?,JY.PR_ I
M L-"9_''TG,HC+['?C2NAT 7L0(L8/%XOK.Y+9PIO<6-B*0W)ZC@3ZU#V]_8
M$[:D9Q"D>%J0!W-\>WX915.A(\ P3"B6;V0)Z4>Y7]9*VO^P?2UVPWV/E"G;
MM;Y\$$N+C.TE[D:@>@287;#J^2;$GLA@6@=2^2;=:W+<,N]KR?QXZ:7'VH=G
MF2?>%]AWUE@<*]E,GXX234T,,AJK=IZ=H/XT6B49&62>65 -GO@\1,*>6U)3
M"RVMO^SDIGJUN]3$=II),E?0.EG=S80_18R6"+C\</<6\Z*9L(!N&F(8UCU<
M]Y$%I&?&9ODU2-]$Q8GYTK3M?-?2>S=)X]6^W=4+I_VE/\RYH33&O=&U=29^
MSORO3IK:4*4_)W%@ZC+6:,0TH>&Q"O7#-J7E)$NW62<TU?*5Q"D=AU2W[@"F
MPX]>PB9L-C_+A#;;]IR@M8I,!;$-3!);Z'%3*XV2B':<3[@6IC=PJSH&T7 J
MO:^Y\?*]-?0H 8P0G&(!U[.>> C9F8K>$;4S!<36]>G";DP;-T<64%8]@V98
MX)<6GFUE,GDU6(!2,51T#;M1JIDOG3?@TTBMC)9U9,'/;E$[!POH H"=*1R;
MJ0,\=OZ,W$>'C)'K(GDU$6-30%< H\B>2TW/HL?&KH0L77_3O.VVKQ<7^J&8
M6>U79:;>2?"!C;  )M\ S9-^,'[&MXD8A^5D :4E\)5#T\S!VNP1I)Y,W>:!
MC/SN#EWB_L:0G,7"A[-.A/H*]&7ZYE'?)^?BPBR;W3^3KFQ8OAQ9&X"%V#D:
MP7B27I&#4J,IW'V?90(K1K&DGN5Y=&D>M6T]70)=?V,S<#6!H%L_B"^+G-"C
MC;J^DRHW%$UUEL]Y1>.:#O2Y\5@+[8Q-"X<4%%=>G^Y3_8#'UW'LQSTZ8N*W
MB%,ZCG%]E9(B&+T4+180XQS<?[7ET/JAL_(6)#I?YK-?:^5S\OQ1*;"*?4R;
MT0CE3W6$NC2FVEK/ T(E++Z1#>,!NI"C/<EF!04>=.<AQ:^A133UQP_4)9R2
M,)UB6X\B+.IW7ZLM$5UTR#CD.$&X64?GS7(-G>E6]F8&$9\N]#M4ZU6+)WT?
M>T^IIJ'L'#QG5W;6[H_U"\"M/=F%71Z990']-PVVK1H#4YGGV 09F>Z$[8?F
MYS2S<Y.1)Q?45')>'S<5/<OV^Q3#S1@'H_E!97>*8W&9C5[J"T]BFVA=59>"
M^)J%6.GGOJY;)!NE\8=YBF(A)Q) ?ZH? X^=+&8!E1%-1<@'A%V- AB)^MZ5
MDI(+-P>9V_[63V=_G9IQB(JN9JN./=A H HSJDB$ (0@F&I.0;;48"1FB.R+
MN.$)'?+S<NTW>UP>6TNB<3[@]Q/XCV4;Q[CK2B5CY?>\'$V<#4][AFDL"KEY
MQSL>KY(7]@DO_:JDN'<YNE+LV%>\? P^:&E-'0I9<&3=9D'IJ'L]B=VMW& ^
M.(#VCKEQU7VU]F#.RQ3>W#CO2*;9EKWC5AIATN$D6O?KEM./-=A*,0>T3F\4
MGW\D=^H25KYG!*U.H:DA2 WF>^(^$R6Z%>,U 67+B[&@,(O?7)D0!6_)X.(/
MP34C7J4%>&>YJH@1!I(*"7":;H.!2,&9$%N+E\2)=%Q4TNE3JI^/1']<P*1M
M;,DO?%3OPOK>9E3-4(:2DTD>OE.1=+V1#U"?Y#<!&YZKS-Y"#'IE-3JG,LLW
M,ZO#\2YZ$I?,7.2\1S*)UP-'"!-HJI_:R>&>] 52881K"0O /7585'LT5^YI
M:W;<U%)'Q*WVS8>N&GVH#Y]&KCJG@5:(44>L/TS4<B81P8]OXNZ38 KQDL*Q
M5RKGOC&91%SXJB'4D&5(Z_5*83YZKCDY#ZQ^KR/(%3BGC.A'!!I$$>3[50J\
MJM(OHW*3OR,;B<T$LIKE;^D#]+J[(]J;5=6;_H9:*W=_%,&&AVB#XA78(ZG!
M;?33A.4'E4W,KR9R0_4PFA[F% 49MV'YDV%K37;*"\M'CC0.!^9;1TG*")+?
MHI\X?KU?Z'#6(Y3V(<WBZZOOVS)Y8M-01CB#O2NK"^;3=M/UP3B*<EO$L[F&
MHBM?K5\OUM[O/K2IQ5_S1;LN^).8 _:]_XCJ8+Z:KKMBO1LRY.V"8Y+?M>?A
M*$0#EZB=2_K_= 5,+P7/M,\GPYB=\4DLX&=0(M)ZJ!LF!>4G-2P;"UA^$DED
M 68_*G\VG([ #EUD/-F.?:.2D_ "NLHO?TXQW9='QCS-17%A68Y%4_#A4>H7
M*%'E,P=']._6>Y&5IQ!-KWKIB&FWK ,9;E"@BJ%@FJYZ;S7:U&\/G8'Q&IU2
MU.FSJQS+JOXVVWII86KQA(#>;+0"OFI^[*=S#PMXBR,UX9F]+$"XWI%FB(D"
MS1IYP+S)8RV1MX[?G,JKK*^:>/UU-%VA1#)#_A#?AS?%#YX3Z<+FTZMMQ <X
MOE@E?Z0X4\ZO4:FVEZE&/(^J=JWL>388[I=8I>!#*^7^8<!7,^G_]?[8<LTQ
MS&IWN4U0X^5S'5^*5%XO]42'5E;;&)\S>9GS\MF$?TR13E!=1C +J"!,B):.
MC'7RNZOIIQ-BD;5%3,J">T2YH69QL)J:9?%<]2CU[G"$TNPXW9ID+5-1=I(:
M9SN^,EK#=!QGC&WW^DB<<G!([=!]4RQ*J0\B1,GH51H':(Z8)ET(7-/\D0IF
M8>MYG'*OUIX2M3O/ H28!T#]*5@+PW\ZH]7&BX8X3F8^WZRMG$_IJS@+=W(X
MG7[ITV]L_94ZF2EN5:J6)S1MO0DO2DTQME#> E4))(Z9U5'G*=MF#3@U$LV-
MT0-37]>[>J\F+O=0/Y?ZO"B_?K>$*T<<F79U6*8[IM1M^G#EVQ*U/+QBF _.
MJ;(JH_88^5OMT4:T+S9L>%RW.'6IK^=J3H+Z\T4^E9Q?_YQ;^=0F%I ZS$B%
MC":6HLS,-4B*T4#J,+\AUJ(195A&\H0"%&Q][0HRMF*]'D!Y,D;#5-1Q%V1+
MP-]F_MMJZ[H? =^EG5!V,-^:-H&\=P$?5/!W&KF8(T3R.18P4N=,:>A8WB+C
M)U>IMK>-7$R2X'0%B9!1ZQH7:AAVPELB=<FSG"89.S:A XY2XMN097B2*ODF
M'* [D0-.3&]:E]6C C;4/;J>7CC46B)N05S5J@@..C?2P#<<I)2L':@O^CP%
M59%5Z1_MAQ\MF.O[1!YP#PQ].6+S*M4_)[S:1C-&TA330=N+<07+*>K4?L8K
MIFQD3\?UJM+<2.LV\2^12(N&&I1<7X[6I[R+MEL^=8XAR2M#_<)NW7SJG;!.
MY3'L%'K3M<;_2[8L)F5@&-&@1.# "]Z]<W!_[P@IYG,/Y52H Q2CN_FM'C5^
M8-()S;A5V<<IHUUL3D]EG$Z-)=$/-0XDK02&10OUVG?X'WJDLP1;&7C;1_BH
MCXW021GM#F*>WBET9/2^2$!7ZD(%=^['^4[;;K@U>A!76$ T^?7WI*EP2_DP
M[ZE'KP>*XKZ,J!NVUVZP@-OU(L61U9;DAKF&J+R%D'&7*P81=,QB</O]SD )
M9+;9EOF:+H4%),?J8IL"C1"3_*O)I?1=H.W+'P;>B7[.GNSI3G4#TV5)$1]+
M(F:?*Q]Z<4L@GS];O4@P+EMQ0:7#>U6G,D8"V=RAI"RY6VM0*\-#)-QC/+GB
M"EZ=D< "_)(%F<.$\NQ$RNIQ,@VEY>ENXU6TH*'_I"KB2^#Z(QC3]52$>H'1
MU-LHL<6T.->07+MFO\^:W5'%W0M.<=?M"G@B.Y5PJ9 E_M;_]Q:UU?,/'UL[
M?\:2S^*V)+&^!-K1+ D68!'&MZWURI"P],)U#8Z;@R*CW8$_$__OR9^2U4-*
M@ZHU;K"8AL0X,C*QWCUWB/PEAQJE_$[PX-HRM(\?>GOD6XH$\<ZE\:O<ZOF0
MW,J9:2]S2D;#+3W@W<^_/7<T@JNE!'8.*Y2,5K( A9YR%7P&P3=YM&C&B%@I
M03]B2ZHD>YTF(Y/A%7,$<F/Q5!<UX_3@-%]/I;XVILW))F\/;]+CPDI8F7Z[
M8&(V HJP2<P^!"_&;J;;V8&\&F?2Q@)VM=^ZIFTDY3/OP;3"<CN7J%O.;BP4
M''/MM7)N^&KS\IG?PN*G T\O%A[-B^Y\-]*MTU=G8UQAWJ_CD'+\D$IY)^P#
M,8P05[IJC0X,":E;IJXJ]8_11%;P-,>V:.W&Q:&#.7G1+KEQ05*(<?WQ-!-O
M+"BF$+Y^NECA&@7VJ8>NOJ'C$C=08OY[SB6MYX:-/;5A :U0M)PM?^?M8M20
M8S8J0NBJ:2 TF#[Q."BENBK=2MI=6E9++TG:+,QN*'#_T2C;K]NEL6?)(;N]
MV3\Q1K.+$?/S4:[!<1@M6&M9EO2+_J5NL37!>XT*V";_$B.>&$JN*6A.CF^I
MTG,2?)W?DDF-;D N_\B<T'^$DPUO0Z<&9W_C2:#"O_E2R_H(@>CA%DMPR6L*
MO^S6"?=].Z1S.T0A?.@AB3A[;#8GS#NL1SY<\/20A[N8JT,#7L=;='GY:[D_
M'M^]/_3:S\(AAQKWRP,#7YTMARL70J_/BMJYQU_YHZ3_8SIW8\F.R"T]%K '
M:@%\R/K,ETYB/_,P0Y#=0*U"*IJ\RDA'<V 732^>,WXRU-K@/!>C"@5!C=N;
M_RZ6_J<3G]UH&#N(%&[<%TLD<!.\\8(+UW6RI<'X?/>>$MNP*]T1(KD?)3K3
MSN\:$H+O.S97F6OVZF#@R=#,+<4(4'ZWV<%]5U2[?/JVJE+H+C\UQ-;1I"2:
M+]T:Q%)N-1-*5Y=O3<7(M^(DC*S5W)$EY?S6^6#(F=%W/>&O6_S%MK80AS /
MK5_C7U:,>EA96T<;UARL:7 +=2L(F/*V5.2E#0OML7H1V*KZ?4_%XMDLM6O/
M?\X-1%1'A]KF7[-O[2NV/WNG_IG)4"4I=NFUG7UE1:=$MM=61. 83FN%N>(,
MODX9F=OG-&T=X9"Z4J[\<2#I:2TJ1TWM?&"0[]@@9(<#78&V=79G#^<T2C"*
M"9.%N/T('_2HA"=HZTTFM+AFM/3LZLJMOH>?O8,F[2J&&[U=5X]O?HLR06;
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M;KG6LY^ZQ@*:+=]HO7GM%=@8@-77W9AX*M]9U*;0%^3S."@"[ZO=9G]'J<'
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M&1G82[@1[!3DC1=Z1@J18I$GVTT.VO!,PUN(H#7L7-S!M!F+57D7X$CUJK1
MIX#4Y-0'_$4&?@,.8PX0R6>[!9F\W;D8FT&,XJ2-8'-^*W;O2OVQR"^>?BP
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MQCM9OH3 _#G&P:6*26&4FGC)LZ[(9 _]=_URGAZ=U>SVA5#R3G!G2!T75DK
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M0DGTJ_9^H!&2ZRPGFSSZPEZ[='$%$75K)8L0?N"Q9!]E1]$+/GUQ+U:>G7G
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MQ>1!F@P1V/:<5S65IRXW0]=ED[N_5V*<C6(#]?MA<N"UA-COO[UMX>S/%G(
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MHY?1XPIW;P-&A$\-)$8R8V'++R3AH:)B3ZO2YKGAQ#\DQ;#><4?5 3%V/.0
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M9V8+0MH?#TZ=C<CE:@+YX)WY@^[#&&<^%7@;B6:,)/9UHU60U0#,=J@F1\G
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MMB%KM<L_)DI>0UUB3!2#2G8BWI1Z#QL,@"&MYMV-0(75LK^9'29,XE>+8 _
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M5=Y^FX7-BJ]![X+B?T2ES]$FG=RW&H/J3A? >E44C-?02SW<@9[2U2EU8"D
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MWES_YN<?0LMF?2@>N:Z-_%,Z^N%ML'MOKA2WK]<Y?3NFN/=]%.0+\"F4;3Z
MYO#U\[4YJ0&=Y7 /QKU6Q;X#*J73/O\8]#99F<PO_)!@+!'<,5';F)I$W*JM
M5MHCE)O;7$.S$C*<,;Z1<3=]3:<HN>=;?Y?-W^M=CRXZKC[6QDI"3DZ@W*K9
MN>NZWM[@A"T!@?X*6R"B9W-AF/+&.?QIEU:LM'5%Q ?!-S02XS%@3RNEX#H$
M$M GAN1BG( <C$LH97*Q*=2E(7UH$.$LG^!W2E#U:%*+=_OJ7L%50B5_P=98
MZN'D>37@AIIF\,@:1!C\XBJ6=<8D9."G1LP=X5!E/A;'C#V&>29E/9IJ+"(_
M='OY0VGZPU^'[M&V8UDZE%4A4H>3\#AU2P^RJDTD+8TKZ I7^#5(\UJ)_];8
M]S,,235B:MEQ>JRXBIU12EM3@9,+*IYK!-(XU7[GF*LB"_M>U;]IL3]6M5_:
MUO)5Y+X*83(/2ZB(80\8T7G:2<*JM<@7$ T"#85'1JIPSK ,1[;ZH,<A_9'&
M.MYO,D]ER_7B:KB,AI<G<^<A-S)%-]4ZP<!Y 6H>'4:!ON"<[8$FL;102+]%
MUC5NCHF$G%D.TTJCO FB>JJM(F1OI<V@K=V(\)R.%*,=K[A#X3)JM";&<78&
MYVC(@6YN"H"(L+3BVSE20,:Y?HH)V.C-VSK+]"Z=P\8!=U6J_ES\L%_7/WW%
M$G(6TPHA/.0*X.KMI[N@ARW!U\<0 6K1WVT,Y_0,]>F:,]%%>3WNWHS;LI$;
MO/><Y:/>\)Z+GMD\X+1H&\21IXV.O_#5/>]-X1/7M+\M1%DW3EKE[Q#4N6 D
MH[MN\: \^BR/9_<=GJ!0 >HH<Q]J/_LURK^8Y<2]+!YE-I_HSHV075 W%U.<
MPW%>J_>36Y2'PAM.=8(P60\.];3ZK)YJ!=K_M6*>!5%&.8Q"=#QVQI,YX!!"
MAZ A.+9V( I[HI9_OXFK@5;7N)&W8K?Z!\ZEK!:;.>LAT6Y ;A[>-A KHT5W
M;\<="!D:OS>NR_?ANANE_RHI^$WA@(:2KAG^&ECC;OG&XN9;U6_V<T54=RY(
M[0?TRUG\--CSBO4 L*B#XS10C#(IG_':7/%W:/LXW1.H^2/%2/N-1(GHM^F
M_<UV,.",'%4=0Q9'BX>4#%,$7C2+\>?T$V*:#U"@L<3RG['D]2LRT$M=8[9Q
M-\]YGPWU#7Z=_/7U??Z(* =2/$2%I4R3J70FKTNQC&F<^ ]>B?5W/X[6OE I
M:O:9%SR7)&&*:>3?WZ2;/^_.$J[FLJ)%Y[GALFF T-XXWKX*9LJU.:G0#!/7
M:R+LVGI2SH5 AA%GQ,V:7VR<$^C]<3_548"+]Y*HX^R7 :L!*+G*T8I I"B\
M.YQ"$@&P3@VC@1&/*1J34AG6P:I#1I6\1QN.-B6!>@;*K2\6L^  [!TP1")_
MJZ0;M]>ASS1W3VI(EOO.J,D-F/RC_B<1ZWP-# 52.;SB3)59H-V6CFS'G63]
M#02+Q0;*$>C@&(XXRGPT0$_-K-&?.9D[1'1+%-\%Q??Q8HO[PW&?UR.AQS /
MUZ/LH*VP9SL'EM"2WQ^$U$PI('\V!)"4;E,W3=?/)0S=_F8[D6+7I/BS^3S=
MG>R>O*6T*O89*M0,+9_U1-:;50]IOE9UJ_9]G7;VL0O+[]HI4HTA=9&&9)0!
M9A]0HL#*W*? _OV<VS]2>&5#"NIS)%'F[1INKI$>4\>J3A_3>V02XH.A&8(G
MQJVLFH%\<!+ZM+>QW_T=3!SD-+ +^GM,4^^2DLZG"G+DM_!8V.292VT%'=?O
MYBLN1$7 (D*]"XD]X1%^4A=N12VD6Q^M_/"C6OCS_LIF/CJ,C.WD"X\G1!,$
M ]1.W/343@M4C2J[&?21L.W0T>T=+K&?H=O$R& _P1] CT @@^@+(86;G7AQ
M.B&F[-SP;ZP4"TH/G(TOZ70Y*Q9^4Z\Z^9+0UVZ79Y']]9))MDQ-3*L.Q@T^
MJ421+:##YY(CUZDHP_)?9IYAG/*(BAFX@Q?9]UR#MO9C!YWF;17E\D;W\W7/
MG41%!(+>/9W)Y2GGYLBK&/=^&.-5!J-PL!8F\>LJ([_$=MGI[!#JXGS\*M20
M?FCA@V5]+J=+_*"UZE/K]6-:I-=:IGYH%4RK,L:-:T2XZ-8N*(&W&&"VV64D
MI&O2%[#MZR\RTV/<*4]B*]&D0^^_I-3U?W% /!"O,CHW/C3RMYC[:W0?J4KM
M,WABN.WJP!.H.W1?)[E%P)XN0IP92_56JA%T-#YV@I"2 'N5I3+_1RSAQY9L
M$U("4&\C"#;+%0,"W6BIZM'?)EYM]M+6=T94TFW45 INI.B?T3Z64&917)XI
M+[@A\X:+%F;L6)4SU;3"2KD.!/)S(V(Z6 +91CK!]<5UE)K/X-7FBXE7[9])
M=DJJ"?:TZ)PP%%TG2&+<H5'0&H'G&A@0Z\[W@JP[WU&&A=Z9B/+$OJDC:U35
MDY0IMA-$/V3\QR]#4=+@?Y[EC2K'[8)Z$2BN7'M8B<,L&^6/CVK^YSGCU[X3
M_D^;_G'IT+D:[$823!PS@6DC[*0L!6Y=C1B\%G#1OAO-"]\[G^8$RK$0@P@-
MWP5504A@8AUBIJEGAB 9^NVJ5=3J0@76^_S"0L>C]J-BZ;8.BEUO72OEHD#!
MN%XXH*(:&\$\O5?P%;+W-M8-E*:'?MGV1V)(5#Y'NS;PN"2[V.=G2#?;#_>.
M,-< K\G%THHXO -E^N0<)_5@NI Q0M@H4VP79(^$KKO[14+,D5+QV!T//>_9
M)$/%Y"-+=Y;KLE J.IKX.E+!0#KJUH>R!^7'K6_:PRDFCM#<[B$\E%V,<1>(
M0@M6 T_I8O.XJ( (@;_Q3.EH7&C%M;IMX2AE%R-MQ,-]-MD!!S+7RM1\MB3E
MUZFJ]VQD$YW$WSWJ.7/BB-O9R/<NAPGRNR O\#-LM0#5C&OG=\#9.0(1-W>\
M>-XHNJ1>?7()<CKU;OJ4>4M]YO(\JD3R<0EGT1>ZD)FK1 5/W>0<!=.,.;S]
MM -M82VD9[Y;QC,/OTG"#@/:)@TVL[<I41!6.595?C3_!O# 6/YH:"M<%M%V
MV5*A]]XK\RJC#RUC]79>:Z=\V'+W;+I/&0@^SVQ"7%&:_)4ZKN\RCH=R1N'5
MV]3Z(L^KW=T#L4%HB=IQ38%*SU0G?27>Q:X@SJJDQX%2J7W3X^_>O_P:U[.Y
M_U(Y/'H71+-<!^1EZYD.@"29\ 0MS_DZJP38SJN(=;J87P6_N!\4MP)+5XG5
MO=0GHDJZT'I8.>SB#X$AY%0[YRB25L\0V 4]1[:*X?G&4)[SR:)=^>VS M\O
MR.48OQC]X2,4-[#QUZW@X"]\K6<=8,<I'[ZW?]!O3)/"21:FQ-L5U9:7!E<F
M"<1]#$DPD#5/L?#<L)TL"E4QA]F3;I5%&/0-W'WP"9H,K8GY3)I,;2VE'YA?
M[VC1;I>XF[%_=G;1[&6U;J=M\Z>7^T+A7I7$.%.1W+0-:"L24$EFQ'3W"S#\
MV3B"*T:$)37&,E.^^$O;;I2<RYOK/BGPYN?- P8)NR!9FA0/N;('+,MURL=[
M1V"<0!FRZSE2*&5Z,G6%4O0=)4#9G[X32+VG[*21Y%E^#/M@'S2TQ9KZQ[%;
M)4E 9&-6LI.B?LJ9SI>N<L518RW#/5PO0O\-W8E/(*U/. HU=,^LVL2VR;<\
ML+!%%1T#6'..TKE>LT#/8604A" 9;P?7U#3C 6J9BEW;QA77W!LE<6;DP[K5
M\M. U!:N<-],8G/2%L %RT/\M.VV)1:2>0YE0Q.C%KC3T+N@3HA\]@I$%':\
MLVBV]8>7EEE']3M]P8=\#1D*V<;P/*@@8>Y]KC2PM]/Q""V9RJO6-C55.B#J
M61RD>[LQY9S5U'S.*"KG.8$57F=*WFXT_WI)OBWMZNO;/9L&OD8UQ+^#PDKE
M-AJN6 N.%%N571R*6WB4X&!NU%!:+DW\@X7]R"U\M8B]\Z>(\0^7&L9Z8*H)
MJZFT/H9^"P /+1Z@_]5U9MQY)$6>JOWM>\4#^;O82S]8?=UWQ_<QN4*DU5D#
M.8EC/*ECI^&/H ?"MCN3P:%F?<6>$M)]!G59PU]M8C*.#1FKI6VFV3!*JA:J
M_]%M%#=PCGUE<1KM^J/6JBH(T31Y[O<(PT]\S3HJ8<8N?2$E?K ^J"+%R/%7
MA*0?TPH]D(ZM.0:N*A_HF)+G_#4]P:XBM2-$\-[M"S59]=2-S4I;QMK,TVS+
M54G&"T"4HA:?0=I7 XMW C?2<S-XL!]"'DI;R>*CM$K=\GB"]C<*_SKE7HZV
MW5O:J!E[QK3#M**X=,#_%LVWGMP732OH3ZHFKPO:AVK;(;;P&?XBM,L<%=SW
M?]YO6^I:?\<>T!R8/(H!5(HZU Z'P!C!([_77^P$Q6C^+)B_TFRP071H_L=.
M_(TRO4[+-<<:O;Z.RM=<IE2=(B-Y_?T5[_B.#<Z.A7LN!86\5I4M3KCCM_ C
M,$=C9LO(4;.04S?!WN_R+'58:C"%%Q1QR7M.0 ;3&H02)\/C<Z'  3)A$M,E
M(T_OCFHVTXHEXP1"@FX&RC9^URW56.Q]4=NHEK%M^=#EDU]K%[B=!%QV(1.2
MFOD#BZ;0?;/J6$J)%^'^,.>4QX?M5/AE*_? -\['\[0N!%SX\V3^:+N?J3QM
MS5_1RRNU+L>JWU&/L3D9K,?K9Z4OD9U4A2]U;PSRU/%BU4,-+_^":>Q[NH7[
MAS"7 Z99XHYP9C-CXG0%2ED*(RB^>2CO=4:B>7OP-L%C!O0R/\CP8L<RO>=Y
M0,A(<>#*MZM@0$Z,)>)_@^MET8!_)Y$13VO<;ELAZSGIR,:M6QAC:\KBOB:G
MW2*BS=,6E[TS\6:OG5N*:J(:5/I+AK-\&TE?J.WN;QZJ388K9C R%@97^@@F
M*HLN2Q\-G;?R3FFBJIE[#RI-FP68-BL8,8T54DP]6J0*,$8-+H>E,=[5\_H=
MK?T2^O'%4<3)KYUHWQ;O[N:]@UH; "S=5&D]%GZ0,)<-YRIL6I_I2.[88B<1
ML5P[?.BL:KHGWWI;5:696A_KKI)^RD/?]^0>7WNGU7,5%;6^_;55T[T.-U]U
M9<N6P',958@F'3VAEM3ET>3O_X#FS,SL[Z9.O5\^<OQMXDQHL7>?7LU:Q=G]
M!H?^CZ6+=EIB#YSY/[U^=TCE_]MK=MH@FA(-RSD>>&YOO1LB[8KI%\W8!9EN
MC*]].=^ :X<!5V#M3K)T.$LDF,S DC''25[FAC0#ZW0ER2NR;O#54(.?1XKB
M=B""*<DGS)!-K.0W\T=Z4=HOC!PW.$6+[@X@I2J@F(N %%P75@ P;(<*U@+(
MLF9>\H]!W8M"=OH"DSZ659759YZ=Q=3]T<1R):0_A82,<MKKCPI740H:LA0&
MXK&_[S0;<4=KG\PY0PA[1?//=E.0G:]>#41 ##?=+KLLF>=<[KISJ78TMR[8
M^D^6&*DFHTO%FA%8S7ZU!1;J])]#0.$17MW&&;"H7"(][5D5K/ZKA4[6Q;6I
M]&]*(\T'N,:U8=>R#LSQJY&_T#DO*?S:-V,??+?ODA&M&O75F&B+$FS7[+C+
MO%'RA/<RW]/.$-S_[%4R8(X5@_Y*"TGEFJL>S-)_/,";.I:L<KNUM+[$OH54
MNOQM^4IT^(T[%@L:0\85?6Z_&J6="IC.G,&PQ54%;Z8CU[""F4R*:!I+.YVX
M.OI<^4Q(JJO71ZJ@C\6?&XA.*%EL]273 ,4+C):BO\/Y\*?["H&L#J%I?)/<
M!"5EREQ,Z$_UN;%OA5=.-/D2#7G2.A]#:4405<R@(EV.P^L+!>*@9%.68Q>4
M;!F2BMV)G,;017V3+"B4$9_Y/H1*'W'*ONJ7NY25OWAQD4Y1?P0RV)54JN?-
M-0'-'#8E1X%&;V$/K(!/4'V:U7$A:!,)+CMLE(M!* <,5!LK]IP]WWSQD-&;
M-'_MG:^HICJZTS#M+*.8+D9=VGLD+H%MQ2:,[? D_]X%$46<6HOL2!WC*9-9
MAPP]$7 (HOKW_5X7WVB\[BXHZ@K=GQ-K'0NE&>_5MKB':<L"Z@E?H4=9ADU,
MTD0&=V9#@>Q2A7(#C;R^4\4*&N6>]L::/Y-AW"P?XC54KGG%J+-3.[QTRI)C
M^ X]#*]?7#5F.H2$F]"073#P9PYXR&V3JJOYSO.1)S%L8!/-SGMJ8:3V=4(M
MVQ?QJ:<B@YS,$C5G# %&<SEBGYTDZ%W/ A'DK/,UM'Y&[=P*W\J,[$'FRU9_
M#0-]/M85.>G2SET0V13EL MZ9TF!L82XLRK"Y8IB,-803@@SESZ_"WI1@2MV
MK7K[X=/--)T"-]>]IZ6FFF_H!R\>K\K^DUD=-CN#=SR>2MY>]61>0UT$*G$H
M?]IBAW$,'1[K@_2I[?<VCU)=:(Y;]8/L@J[<G@Z7*9T2Q<ZI$>4HX^T"SSCJ
M@, <3O"F)QD#[GZ(5Q[.[5*0V*16#!R?=#3NC$;.G=5;4>.(+'8.[)S_?PFJ
M^H"JKEHSIAZ^KQF]6.^2>SF!;/<M#$X@#K+9)N H+)BCB!*G#23H@FDK\.BN
M]NY, 89VW)GPRP5,DUPJU2I05FN +LL?44L[T#G[%UV-);SY&<JW"[I/F *W
M08_J(MZOA*5Q^4NY7(>,F@0_IS+P;(D]3+3CC=#4>\72A4C0'__-HX#Y?W3T
M]B[H,$2Y9QLO#+R,8=KQ[_WF<"6=YT!R7,T(_%)Z3^'0@D//>O[&9)">5)'F
MUTN3FHJ/7X7:V1>F>C9IU#1-,[49OX!QS0RJ9#ZG'UN#6862"0D8L>YD YQS
M*>!O9F+-$6Q1ZB$RAKP4\\-[Y]GWA!,VV\ZCE%S" PN]3BQ;W1--G[5(D>.L
ME/I:L59"T?PLVP->+"6ZK!ZF4O7_BBJ40S<KY;_-75XUK2JLVG[5:1#R<&I2
M"=_CD9&Q[)SE4CE9H:C)3DU6-/*=2>^O+T4_Q'83B,*4\=6+=-_M^9@NN+!J
M$27"X/+)Q7OUU7'C[%O&(O;W1"T<E+V_AX\.$'481< JTSZDMZ^;5".0Y#:^
MA= QBKE;G7M;Z'P<4>LA7R5(,EY='6JEDFH#W@O] &XT_;=38MJR@89=T*W2
M#BQP?J_NA5*A2-67RX\_5-P:"1J$Q%==7K;J+U$HOJ*IE5T_6FX>T2\0!P>C
M%5!NM/IGS:)T,7@TTY0F$\5.)K\6ZI7'][MG4Q_J'S;%Q&YXC^WM'=Q>G<EC
M@6L!M2*4^Y1+D2>R<"FLH]&D>N6DEH_6Z]-X5_6_)C<.\X1(7G.NL8[C@L?_
MZ(_\?\2^5>"%21,/>=,+7JI+.AI9P<C%$6*2CFZ>V3>AS,=&6KB2.SW06P$<
M578Y6B]DA;(=A=<-R>\R]J<D'YI<JIN5'L&W"OT1G,B>0IHT/72>R18B=6;V
MCD$]X/$[ ]W%NR#/8I2G'V(^/A'#=*N=DK\G9K_*9(W<^CM^@.;B>[E+27O/
M&YLQ/?\.H/^/2!<U*TB_T:NHV)=1.%!4]/)5I7BGP73VS$+_.,4>"E<?P:MC
M6@T)WK!D]"5:<@?T!5YSZ/TH2[ "X^.AOL01KZJU),Q(BO^TH>P/@EA@,&<7
MEIPJN6B)9[\]3X>R1,0ZX3+X*ZA;PP$SYAUH7KKT6''9[(Q^4:<*E<;?!%DV
MZ&!_QT:A2B#'68Y2R?^6,F^3>""J5XC<7,HR(&WO^Y>U4_#P-,O6WBB(C9R8
M9*E'5M,?N+U,DMCE;Q[S+B_*^W4TJ.NE=_J*;A*WP( 2>'6QE"6?1=;<[IJI
MV\Z\/XRKG?@=[[$5WW3APE\I[+]-VY%]33I?ED<7P$>X&@H<#SZ@ 3_Y"WQ,
MU^@DEBL)CT-B*!;A\EQLB->RTW2_YX)D#//,5O\K 7W#["6@_TJ2"H ./6 +
ML/Z_)[1%6=7,(.OYV8-937=Z5W5*=]13ZJ"Z'9;FV44!F=;XV%*-%JL8<Z8&
M9P):8TB-+R4M[X+V04[W%!B6MIT>J\DJM:DHTSQWM/==N&=:_LO(:N?*EPT?
M0[EJ*IF+NG]#B1A&*DT9<Q1_&L :UM":@U?"4%?(R?RVGG55#KB9M+$CK[X8
M(CHHS5-[IO^Z"_K?MN=I'8C/YWC^MW-:&O._,CY1^JFSWWYV: =1+-BU^$];
MLX:;)L^P4XN>;D*$I,V8+K24"#R[.>)>W5+98!QO/&7HFLYK5G\V3ZKTL,,S
M."P94-%FB9@$0*GS]'A3Q'4?_LR0-RQPT2[(ZYQ^$(()2VW2P22ONV?_Q(?\
M1W28_8LJ+;*%_AMXBF+STUQ<<\]<S*EKR2',\?'$?7MTU/CXHJC*:B &.)_,
M@WH,M-.XSM !E4:!Z9)6E?175^-)R4+E4T9!VY=.;CH9HOY,;6LMH**/73]H
M7<[:VSKWGD.$UR"?! I$0P4A9R?:WWG?3<81?\E(UPQG6;G]B"BT.:';'GQ>
MO6;'.ND_,.:_8AJ\\;\339H#Q-RNS.O.A<=)_<3E*?OAMTOS_KT:[G>R"U_5
MW]DAA>]L::#E4&B@B/ZL+5> !DO>^H6L6=_W*_%]B-T1*B6&.N:V_>J_D"<$
M=Q?0YW(W;38.?0RE7@5<?Q<R9336K%VPR!0SIL=$(S3=AC&33RO,<D2"[JY*
M1X6> *[0'SV&B/ZW!X+_!TE2=-XH&;%4^/"I*%RC/&B-5-HDK?PP^$9U*8^F
M; K2\9[1^8VZ&"0./8VIY8F#>LR<97RD"W00:H&5]EDX0[98-</GKYK;H^F7
M\^MNG2B[=ILD.XV:7''RI"0+>4,TZ%I%%&Z 3O/%L^TXWE-+=8=LW3,-@A'Y
M47WJCY3^1DD!GP3^+97D_T<^M+^7Y'@=Y]XG>5Y:N<:4\7MCZV*YM7J'?A=.
MW633.V(F%5W17;M7\2&R'#V%/=+,\YZE\9US=JF1RVQ8F+8KNR!>P^AR3:/?
MV8HEY<WC@M5O+2TMQ4\;'HC;Y#=GO&7G:9*2+Z"'PTB=Y7;;W>GC]-FID,PU
M_920@OCG$^)!BO)_;MWW.9#PH'(/"QW_G?4(<%F/X;^QGC(%\B4O\U?D4W)*
M,TOEVX3B8?L+ ]XW+A1?J974J)WQ89M1H6*8N0_@.NTN>,P.KATL%+)X>[@&
M*XC"R^Z"GKNWU=FY[K2Q)NW?E.=;OS1=L_Y+^Y'W5^3_8N^[HYI:WW1C14&,
M@(""D*. J("H-*G1HS0541$0$*(B4B)$FK20J @(4HZ@("!$I8F42 E(2Z1&
M0$2ZA!(2FI3 #B5L2+MAYL[<F3E3?K/6S+IS[SI_[,4*ZUO[_?;[O>5YOO;"
MW=2?2Y-*5_!SM?[T?0YU-AC%T(?]%]B[+LQ^T'1R,)_R7-)F\':-44K_9;C^
M<PX\VM7@LO=6YN43YD:>JH2%V3M(Y]+619^\H^6]Z0NE 14C(45I O,*X-;X
MX78/_NI#2/AA*P:FG2U+F><S]G0/VCWYJ9RD<+%#^=M7RV1,0,@D\7XML;87
ME=.SHC)0Y'4\.\BKR.NPNF+)R3;]4I]OEHJI(W^#'W]LN-KZ*<'G?::T&L/%
MU\!)19=<?Z)H2DD.'PH?7<.=%=@"G*@:N,4&/,G,9ZF!M6.&ZF>[B(J!9A[R
MLGW^*9G1??U.W6G?*VR3;#;#3Q__MJ+T>QR!+K^)^YZHCM8$3<?@CWF[F3)V
M()+,I.0^U^POCC:I<G"E2FU QC!NO<9(R=^CVK\G"_^&IS3ON[D5V9N6X.%U
MRIW2>I6 *WH^KZ<<^RT[,GM'7?.5R\<NK'I[L3#VI)H!;@;6'1%#*J'&%F%^
M0XLS5>V=,D.RAMP% <:MFU[U9.:[)_'NM893)6:Y'AFFVS,!5X8D$T5;J,-+
M<S8#N*B#!  ?YU*:W"2#^GGP8172E;I;T45]MRS[J6NM"[8^':R.P=9_9"K#
M5K;]G["#^B=*MCW_+JDG\66E [HBV'&QFCP__7,B'$UYH[!#]T-^UJME2Q-B
MZ.7GHPL,6^;"*/2Q /3TT]0;CR['RM*WOU8UL'(]L(/J_D@U:K%T\QW/!+/P
M[JWY8G9\R!8C.,>&FU9C^2&P>I1%DDH._>BF8Z\V5V)GK$=(_W+UE.<+,YN#
M&&#\80'U7_+#?ZE.I5V$)6HR%235=COQ(2=B[U,,DGQ6C>26B:RYAZ12:48E
M^Q*&7.(A114D/#[DWD^D<*9M)ZK@8&UQ+>5$ 7 Y)JV<4]V\6[^72G%E<;@?
M^1"DHQ2Y'KN?IY!%V9ZBDY8;B#3IOOVI^_T?7H/*+S8?^SKF>XMH-MP4M/ ?
MDMF[P,#%QA#,#5\^1#N9S?[9ZUSZE88IR(:[#CH$!P?!SJ*M0!RP2H-S)+9\
MP99"'W$0V1XC2@+>'SW%Q,7W7ZB."^AZ'[FJ;6/U$C7<1D WR/IHKY_06NPS
M1&;^R26N8 2(QA C"?Z#>!OA?9<.*-9F#V6-4Q\*LK*=NN)E9P?9U]]%NR>N
M1$>;&XH[I3OA>Z:.%,7_QU2G&E,:R?,+XD.N-_(A"NR4/+81IA,K37+!1[%(
M^XA"X'LU6*--4K=#78A:C([(Q*4TQ>VZ+_X8#XY>E7/@B9P3! 2Q?DUDN] 5
ML/*=+'+VJ&?1-?5-TV8=>S]\G?WLL/E404/TVNR?^G%F ^KL@H9C_O$_-_?%
M'+:(SF>H_"Z>%#W?/CT9''C_85!8YIS;!>]XEQ!D93:PRGH$%@*EM/@8XFX0
MUFCN2EN V0W:@Q_;&8=>%=$KL*>T;/W5Y45\KL2L?L1NYYWB7.3BC)2F$=(\
M:&#1V#FF_'/OR6E*;)6*9RO#Q>_!M?,N]VQ,MIX8C8[\&S@A\KCW&X1:+M.S
M**F?F'I@)L?CC<QDC< D^]8?]EL1NK!>ZI3$!CZD+.F=@&('T G?<4PAFS?E
M>45V#K]'^669[++<WJ'TWLA^0GALPIYAI"$098/U@L9AH0L\*3"3'IJ1\AX)
M6Y0I!8B/W;/+L_^H2Z+?$',R?D ]Y2KT&2_U-P3+HJ!;B^[?-5[^-B&KN-PE
MP!.YSA_WQV&%?9ZZ:F8-(AT=ACGK24:B:"^PD&W .5,"O@,LR?:1D?ZS2BYA
M5[O'ZQ8[1F)[2Q(.SL<)XRZPJ-$PP!8UV$$G/UF!;_(@2<[YI:EY';;P08@$
M/NRVJ.IYF:^BVOWEB46VW<O1F#C10-M_Q7=(TOKH?_1K?V# Y-#'?/L3+Y/:
M!TB'3OP<6MII<MW]@H>Z'YY[B%P'C47LX4-<$=%Z.LVHI_:-]JAG93OO)EZJ
M3>I4OI'RWBWMY%=AG:]SNI(OH#$UEL@Q?S#*-:]&[ULPB95E"S!LHN<N3NU,
M/J BM";P^(W.I(S1_CU]9=P7TD_OI91B'&NUL$'?,IQE/'9>?&5TE]!9C9Q]
M-U+!&&1?UF%8\"&BF4*QA;^!\>'0HG/O[!4M>/$LSW:O0XNO7W]6J\BH17;G
M"+Y80#+J3'*BS<;!VG<\IIT#[XBH @FQYH]/_R>S3?]&Q!O+>_QU9G&I'OI*
ML2BQQ$%I/,#J&Q@1[2&1.NE9C;!91;6_F2O9?]<]B]VEKX&M099S,P3Y O<<
M6T)MDE6/P6U%F^].I*NHN-,(M4GU*J]N3)K$&2].VIA\-7IC@]A0!>F?C$OR
MAL$W]-,0 MV8_UU.<#$?S;_F-Z5([TT-SJGIG.J*,PIWL4]-2 BP<)I>_8F(
MP$EQ@H!$>D8B,_=+</T ^/Q\;T1F+K6VS*<@X&!*Q>NAO5X.[_85\"%R@60$
MF#BFYDP>.57+MLG#>VA09P)V"I,G.S1*6W_>W-:F<[;)Z>^M&;[X[\191> D
M3@^9VD=R0*!^Q[%B\D*TLY%+#@Z^1L1<<Z8$"P^N,<_1XR-Y&F FN=N4'B\\
MW2<E+]^[_%FA-*E9Q1)D#8Q_6$MFDQ.I6C,4*D=*FL7N7;EH&$REEZ=ES5R9
M.>%$]4B%AM^_7^3O?FM2BYAP^G'E\[[#W$'O5Z<E1TG_]HSA/\QJ7J\;)UR_
M3MO^OJ HZ7E%]KK<R](#O)@LFFZN<@!RAKV>#FM 4?!C\?7J>\'N9AR48RT7
M]XXI8DSJJK%]L.XG7CA1.+M6(?:Q2DSLWOBI6W'-5:A',.#*QCV32& +^@@8
M0!>56FI >"%!/[@$>*?C^A,*(UE4$^X6E:IM"'@SG#S_9--_ALGVU^O'5Q*M
MK@80YI,MB/-/N\BNKX-,KKSLMBWG.E)'5NY%DE$4H3$H0YVY>Y:>V[P@.X2L
M&A[Z7;WL>]2!!_75Y6=WF;T[%!6@+78&%NM=N6^ZW>_<Z%139P?GV#^7^FV<
M\X_:FLXVD!3V2-=5DGQ_\7RM6(-3!ES"NN=C]E%#!_?R@>]7'6'_89Y%KKR!
M+V6J?[Q#>L']]K>EL_@"&A^2(M1[$O&5-^G[TM;T;U"/:=\#/N1;V,QK_#C6
M5[=5Y<\I^,^!(W/V-';R[,HEVT5XY9L)R<Z_90;GZL;G_+:>H[(&&_KN$_WK
MSW.E?Z:,Z]]A:W^$6DERXN===8W]L'\VR7_^AE!7*.>K45XTSW15X\W[*OA_
MA+.,!-G_+NQZ$U:0^O^F,8'9"5+<*>A?8_+7F/PU)O\OC(DU= \(:\Z0>*(?
M+QEX[GJW<\K7J(4YI<=VD=;;>KRR9CM3/4XA DVA3J(7KCY<AN?!!G \BX8O
M"-;A:>SZ1<D _WK,GTI@5>,G+YFR&VL1DUB'6Z3AH^OJ+=OV7KV1?A AR3'F
M0UZR.:?YD%*W?O@R$X7PL&W""3#=A!%I-VF.HM7!-7#XH8G&,BNN]&%=L:!*
M/V-CP5$>F*NX!WL*$T-OR4*?CSB:GH 50CK!*LIKG66F?!V&U J_\B%%08I;
M\7W49Z2]-5 !#[A'8"8V5RU+$0_\\-./15SKJ8@X7QIQ.&5<*!/]_,4L0HKW
MG21<LY_9SQ/>N!MK.ZC.W%[GM:PN&;]UVKYF"_@65\^0?<SM$QX0*J[#;P%=
MF @R@@"OHT:0@'/QL!GQH<#!>NR>>;0NLV]4/R^Y#B,;6*10"==>L3"6M2@W
M;?,:U@[\#NE-(HVF.NUAME,YDJ4-.()0LZQL&DH6'<#-6!&@(62?M(3^\31G
MWZ(!TVSW7[GSSS3!PBM3Z=]&I_;C/Y!<H&N7\ P4'W(GLD$ @7L\<,\8A078
M4:*1,*'LL4(<?,#*VFPL]F'X5;S#[3/+.1RION6.<!C@0(V3%V$64FX,<VZ
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MLC32G;K.)^RGN3Z9'SGOV6)PV3K2,3=ZN>/GXEU@@2-UCE4-4&.*)+5JL::
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MHD"U*<9)'[\0[*D!_^WE+][*9I[R.($ZAHT,0/OC:S&2O*_44L$[GQNI@&,
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MK&+;@)O*<QU\R&':J#I;PH_$58JNK@+^]_6JRS?45R]@GB^>-=YKHVQF"_V
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M3+]25]+YN]A2$7;*M<U74R[^)AK1[(TXWWEFOD.6FP._#1M(9%7T:J(D.*Z
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M ]/,P#%:#6\'F @L-4+?HB\ %DV4(>P]Q,<%\X,I#TH'+^$,?'9G*KSQTD4
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M^+RQ+5ZN3UDX&W)0(NM(\@&5S):6G5K?")123CX0S 7S=F<S(*3QX\Z<SI
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M?-Y=+LE27?51>UF:V:OWJ+>09XN=NB:3-@;MPX47"K30X2:*D2XNXUWPYI4
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M08>_O;LW31-A$^W(<Q AWG])L ]UD6U*:B#<O'8SFX3>U3P$[;#8JJTD0/5
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MX)6%H&JG$<)/[;YOJLH"26LA:-]7=B8_EJ<O!+TQRH1?P4VV_]?-3S1DNF"
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MK1$;#_.V2U:U2BK[X3)3/534/[8:>/#R1PVWJX^\MMM7UA(>9OTTXPV*H/Q
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M7CU2,H:W7MTV3KR[\=G]+4=-:MCV<[')XI [AC4UD]]YU/(OY_Y\-\B^3.J
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MI'3_:3(2ZCG]*BGETV^#B>]@NM%GN49NRWG"OXOR=*F7]S.Y:6X*7NBI?7L
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MXZ;BJ''K4D68]AM@-[XB!]*K-@-Q4GN #@V&4+MD4V%#AI=F?HON,ZVL0('
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M##T%I-_=3': )/S!G("/M4#X"=/HJ!9^Y^.1-H_4*K]STP6 !<V.VQS;;HP
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M!2:;V[:-$^?"<>&LS05>_-_R..Z_Z&-F= M*9G0%2!ZE0._E7$ KT<$)0:S
M1KR:.&*JBN;B+JA,PP8$<.Y<4XD:0 _Y<ZYQD\'SN05,\9$V11:F>P\@UA)
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MW;4?NAI,E$>V&XD\+[HY56JLWFC'T-A)\C%QM94X3%F\^#N,Q)8AT@EM2GN
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MJ9T1.A8[O5[Y1=1YUE%DB=@&!10G7S/E,9V;3V5BW6-'BFQIRJ HL<HL[<(
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M"CXY^AC=KJIPI_JZL-KUW<H]^8I%:5AGKS%""UY83Q7 ,6X 8TP--Z)@PQ$
M2U"BZ"*:D!FRY5\]*MB'LX]&YRL-WWF:Z5%2[6LI<3YE,38)<1,W%LSA5Z+
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M/2*BW*1;YOP@IO](145Z?_-R2S$B:6QTW^>K)H+U0@G/H/?Q3D5A6&D=!Y#
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MY^'=BO80,9\X)]F;#[%D(';*E_>"V:J+(:U@J#'DT(2-QC+KM,,7C5@Y)">
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M$O?X>HFT2XT,KS$UAMJ ZH46-YPXG!0<X9'_O3W+;OO41AE<NKHPC8"B&>
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M'W]0;/A3^S&+=T\52\R!HOY(6(2=6J_SCFCGQ*G#/4#0+F"'U1C>0'(NZR:
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M#S@[1!%K0CQ.58A<D5A@Q]K0./DBT^^'YTNO7,EWP.L@$]%W 0?0#0" I6?
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MNA;SY7"\G(+@UJ[?M=7%4)&43SQ(#:<@%G/:CGUAT!NCZ)FVF1A74O53=6I
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M%C"?"-CL&W*>UMJH$"T:[L<H<*JP=Z&CB9\<S\0RE<!CC$.BTNQS0!QW/W&
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M\6+,XG:=7;!.QWG#+0_]^"%3;PN5&$L47>.'1['3F@.K4'$/:1U70O[7KN(
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MIHL(6'1CZ;(>#]]W%Z&*[1FOTZ-.1WHX33XC=^IT*HTE)-8<*,\2=FV,DA=
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MR5]]$@Q751]']\AMFR:+0?T6MRH@;N6ZI0NWVT&Y60]O4A@\O"%/3!7]39E
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MT_7?,"K *P#;YMCCS]YI]$BVAZ 4I^&=AO]ZLC=0JOH",A8JM0 Y,2[HOPU
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M!7("?,^\I:8?*[(]:R"82'%.[IWW^4.<24JI<G_=[J'TM5(?VEZ* &7T]5.
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MT\B'B])&AJ@?LI@Q7)-)(?TRPZBA0^J!4CI?ID6HLU$E8T":MZUCHEC_ L)
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M(!K2<&?6([.][^W"L2*>-BJL]B6=C/*?2'V_^[?TR/S"31!")ND4F*E4(.@
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MH<ZG!FDFSXU'IAFF'Y[3$_]H]8Y/Y3SD^U:J]LUD%+\LP9,Y-Q-_# FE$;O
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MR%A>>\>Z2W\;:UQ\K2&JWVK /\!VOXY<H=/L8X/#P@\=Y%^"TW5).>KX.'0
MYB%\)_[&BA!J&(S;G<*"#C7 _#R($Q5MNJ^U2GJ'M8XY@2O..61=+].JW%8Y
M+T6'LV3P5S$4#%6'J<?IIJ8/_5J1S.\L",#KO9B?GG0\T,54"S! 2X5A:+=M
M&L)X0NK%_A8M?F(&2"N(MG$&\2<R)(4VD4<N11=9\0MES)6H3,)L))=3%DJQ
M[I2@VCG]-.=02__;7RY9Z.3YNU2M#^@,;V)GPJDK3%5.'UH$>9R.IO!B5(TV
M7A3H5)NE36V..U\8^TC7?+\@?ZDB>GS1XL:^KZ]6_4H!0>8YI#R[  4^2W<B
MP9+\#<U>PPR?*/]Z7R>59LP*2%%O"#AF;,L7(_!::L.)%RC#8UJ7&#KLQ!*<
MADEM5:I5F0,)7:_I!1M:/[P9_Y,(*'F609=Y)L._#=@JP?YM[(>LUC%_BU\K
M.Y7B>YY=+)6Z*YW2YQ=NA!\@5!6U 38I;-^7644K!CY>^WK2&JOM8*@Y>Y1J
MI^$O-S\3=5A:L-9P_IX;D?Z>0^9,. /#;H)Z<$'C%.;Y(;PW/J%JDW\.*]%=
M,*$5W3&\>JY@I_43T^7"^MFOMP3E0W2P6,X8N@+/2PL]!YBN?E Q"CPVQ8?F
MVD79=7/^Z?ECG\K,'CW=79_PL; ZX/3B3A&4$6IR/8$9C+1G%T+]BNI#\31L
MJ[]06QM*Y!D7]%Y"-U^DYH4<4(X/R.!,JOINGJ44L(H.W^""KE<]Y8(*/FHX
MOCSY,#^VS360<"'HX9C)Y]3RH9#,C1>7*2_]G2\<-CWZ+?KDA3U]J[-A]6.>
M0U!3SEZ6*W"7/D-^^Y2.)IL]VEE(9H?U4_5YF=>$1T)OLF9]E?G[I4]/HU[1
MG3%MX$DHXQ;03>_J@%9DM&$>N5^B)T>M\XB@R1O> IW;M<+,RXR54X[*9[FD
M7>@,L+X%I9GOYH+:<,;BZ/%R]$\D;E6/)<XYE\ 1]F=>,*@: 1-FG_-TZ2JT
MFI?VY1G]:3W[$[(I+,61E>P:T:?R>_.GGG5JL/?/AL"WC5P0WR^=K"8!H]M^
MS5 ?+@@XC%FV88(1:89B]+89D\:D6B4K#>^ZR&?K8Y<.[2XR3__.N6 WI^@Y
MU?8TD^$'5D1H7*EU$H%TZMOTMC]8OW7ZW;D?Q%-[K%&&J#8N:"_:$[(=W7()
M[6WMSA$2N_O*8>FVWYUX;SWCD]6))7D=RSG7BRQW^W:"E<R6%$DOY:529V]U
MJE>4OMD01Y8!^6'I&3"3L3,57^=*^0<*3G?H)Y;Z((^6-U7=;8J?7\0OSS#M
M4/T8'/X^G**WO$X_TM.N[]_ L5XZDRPY6CYCH!)CXW#0OR'QT[&3^Z5F7(UX
M'GH<W:+#D0/J8#N6X)4>,AFZJ\]+O0:TG7J6O)_+@XFG)7C9<K.P70>19IZ\
M'ZFVU6"LFN4#A#(-?$?7H;L;;%[!ORZD,]3H3L>Z0ODZ9O/NV;@S3=K]NJ8"
M3G3PN">_ #L/34H!\Z.]DA^ARU1;>/M-&&!YY7?K)M[X!EPS4\[)DW^NE_S.
MFCEA6+5_JC;S_$WF8_-?>6WCYG-%N\F7+2VU'+L[K,(U"HI=LXU@XDA84CKL
M5TW?RQLRRAI3A2>6<U,G\GYRP(3CI/RQYEJ\3R*4(I4X=M__IT^HA:&)9Z_V
M]D%ESZ>T>V4:N/OG W;G!^5H-,MQA MX!MM\=0U*?O-(+C@9,-&Q)F9,%/&V
MZ$;_?6,M0([WM1"0^ HH<"X;#OBUP@\DVU<_,!\6WY0S?XN[82YM[C#P/.+N
M^($#KJ8*I[&9T.L80C5G%Y.V1!)]T+0?-4HLU^GM2G"K?J&S(@,'Q(6S(B8*
MG@["?K>:_YBK\CA(&N7*O^]F[#8=%YQ^0VJ0<WIC2B,!E2W405>Y(1!K,530
M;VWIO%X>;ME=4KV(>HXB$&D7\7NV?B<8&+-5$5F$I=U('XO689_I4%RQQCM=
M\?<*E[ 2F59^G"ZR^NZ,S-S3TQJN=!)\/^!'@3[0QCQ2%!L^5#^(Z]47IAHO
MZ%OM^(B5$WW_ ?L2'0@70AX&)GCK+:"/Q+9N5!;AA9)CJ.\1KDZ@MR/^RQ2G
M(G=IX\7H^Z=^+CAS0:R]&114 5V/(X@G?0]-2-7IBCVR$@(_6I$J>;RBM8$+
M"CM\Z/1R;L.=&GF#[AP5P<(S>8^QC9EU==]',HWJ]B<I>Q4)GSQ\)F0XSZ,X
M,RSL;N60M3-3_?&V+Y=,$ 6#_/L4G_V]=U7ST_M_.XR>'X'W<''+#_,$[S<,
MP4.KXR!+2SN5=L?_M9S&3Y&;=_18DG;-KA @G\G'\@+\:<Q3&-NQT)48V3E,
MGD]889U3_8MB3_/7I]ESGC9@QPTF@\Y^V70">9D'[#W.G%YC/L#GW:*K 2^.
M.I']P( ):8*!J23T%!C2V-3Z$;?4QUR0Z'YLW?=79MU- KQ)3UGFH[_8<JTR
M<)H5EF!G[=13[W<XU-JLM>ZRX\3*C;/:Q3KBMDK=GM<$";5=OILQT-T(?U69
MH]^ESUR<'+6IM)[$-[X,+9%5X^-9AA^>4-V!V?9#BZ5 )HXO4>;;\=3L@^&<
M02 XUV'*R0'Z.4&R-RA<T YZ=U9@=I[0(,'953"SDH@1Y'G%P%APF4!GX'@>
M9>S!KT AQ&VJ#D0&\<"LW%HD7^;8YW>IRI.?/O>HSQS=<Y7MMZ*OIO"S;#60
M.DD+IW11W9@6+&EVEDQS=2\MU7(,EH0ZC+@_')FR43EWY>WW+N@2<K+*X0UL
M8QYDN 9WN&2RW7BK;GX%TH]NUPH?[W&D9;1.E,WTQVTF%MQ#@4V3<9,V(V^8
MQSZ6L%34''W6N*#S?A-HKY6H)C'V2^.="#.2ZCWJYSO0!PU&/F]\OF$_TUO$
MN^:,]>O]I[OJC^K84>R6Z;3JK=\I;V==IO](-/I11)NQJ1MN4(_A7(T2KJ42
M)@H09W>\&%6]%MVRVI-2HT.\R!]Y034+EG,BX\@7_?>;*1JS4$!)8)D+FH''
M@&F6Z%AP!9ZZGT:(U+CZH&TS.S8.J5/<7I]^>*5TO.M@E.E8O,G,0-&2I1K?
M6@]9=%F47D%984E *&"6A-[,WA%#HW=((WKHZ L:NHL0%6#5:#RX:, 6OFAV
MP>$Z>ZK^W7YA05?K,)0P3RDIJ#$N: _RJ#])E)# $;Q!QUX$[KOMJL8/HV06
M;&7QL3B'V$_5OT]EU; >S3)GE9S;Y7RZI1@CDGN6-Z ,!79VD[$?N!*<!"6]
M!E?)Q&@VZ,ST*WB/YBC2NN[=#%5J@N]"W!XA7*U,63!V^*&2G1D1AEK6G6IL
MQ3/X 2C]+!E#/<F\@L!V-0DT#OXD[D,Z5 TW0- A]\P*'1./3:ND&Z-NB&M
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MYF"TO*ZP6%ZV]%!2;]$4U-J!KG,;:8)TA8I4:JC5?!JS(/1"C<0V;O"D0.Q
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MUZ&WS8";L<!AN_N&IVEP2L8C0ZV[D31=J[L]6-'%<H(A+?$&L2<L,6;VT[Q
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MCF/6"788J]KXOG!O<MW=,/M\M_4T<,"H&U$RQRFMHVCP#]0.GDSWTZ8ZWHG
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M4 Y\2]"M+73NEL3X. 0XL15WY88Z*SH\?!G9YH11P-]8F9#I I<USE/SF!)
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M7X"$T^#WT3BD0IYW28%/=9BL!\I](^AL8!7T1.G*5_!S;$^UO%TQ:E!1"GA
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MTKZX[SGWWG//_IYO?S_NCPD\>5;6F&O,,=[Q#M:88SJOW5F.!;_P0-\O3A:
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M)*87#^+O]Y*85SK9IVD(#7V/"OR96U7[6"'V2Z<:RQ4Y]>UL*AT[EC(^KM]
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ME3BD[^_"4 _9W('8-LF5H>?JKK9_7]_7 )[<O7U\28GKEZ$N?$QGS!!E#]J
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M[:&-G:. ^D5F3V#)UW=//&NT=$W]KX_Z_& 4FYPZ[/1Z0C=XC?%VG 0<*Q.
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M AX'RR[4M"BXGJ WW;%+><(_CKX.A/K<]V)R:![/_/?[DL;G-!4</Y7%.PE
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M;[7NHF5Y5X"B+SO44<JMI/S3I^!#%=:#1@XR3<&^0K_4_IOZUT6>^>JR2A6
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M'RT#GS$R\,?.3!&-@1 *BXB/$L6M5Z3O$( L90,FX*("T*V.07WVKTKK,OY
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MSO&'N]4G1D+YNP,*4"G-Q(,EO!?8V_@H[/Y: ZJB2QBDR46'64#V*<KH_^.
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M\!@M881E-3[RU=B3CF#-#[E[7LZ:O4DWU]PYNQ;: !6'4=X0RE=G_7+1Q/6
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MB87YSM1VTY<R>VS,'D]3N[^PRXDE1GJ#/$A(4DU5$U "JR-(HSN?H]M(I\!
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MH1XN*\L>'(TR+#]T6Q<RVE>,^,Q5X(-S"+A)B(+NUCO+$+"GAT<L,\:4.\O
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M-N2^/7&L2>UU[;$#1Q>G]LN4=2*\* ,VO%#AT]M+%#FL?E=%F!BB@'F9@U8
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MM<=94'"?5-.!^W;;G$:UJ+,K']Q<#(O:K">^K!X:UG)5^*Q6=M^0N]PB36R
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MX+TIB*>>7WWLJXB6[C<D,#XD*7KRQ[9NG#M6/,DSV<H 3I'6/SZ?+LRZN;E
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MH#[7,GT6YSX6+3S7)TX_6>^BLDD*B_P\$>I=)(#OB@FW7OJ2L4&S!X5;)+U
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MW>3C9<V0L[<R$$U?PE?3I,/_ 5!+ P04    "  4.%=6)'C9XR_,  !>A@@
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M&XU)DB(E!$F18Y#ON;ZF1KFM6;X3MO>121?(=I3J";J!6;(W:GV";B_AX2_
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M3R*F_34,?<#1*IB]5].\736;/8.3A;4-"B:TH\1!_Z7]4358@!J,5F+7%AS
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M!IDKZJ!V-C]R-50;58]KHEJ]=65EU%\D76V**BG,]H?_G<M"-WG_7%\JC51
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MC$?&]CKM,;'#:^Y)*F^5TK:X"2RN#ESJKYCP((ZC3,$P#<O;D$PSKXI@*,.
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MY1QF699 )A.& Y(2E%@90ZX=3XWE&FEO2A? NLH+WTA<7U2R=+PXCX$EF0V
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M9YXG4@+@1F7^4I4!XDQ<[((!D:3JG]I6I?F63I9/^MMJO9W35&=9D2E@L"D
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MJ$I5M7WYPOD#WBU?\6_EEB^:V@$L$TJD* 5*4@2PUNYS-0@PF0JFL-*:!)T
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M\(81=/R#O$$!/WN>-^R(/8-=5YO-JU552%HO9:DWOY9+_6ZK'S9S3(GD)-,
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M"1EY5%NF!R3/[9L^C^C'9N^6<O6@/V_MA^^<P[^Z";?#O%X]V('FF#),,E0
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M[6/"W%T)/\I((U;-CXG,<87]J$_NZ60(3#2U%[Q?+=='>:>_[GKR($P4QDR
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MP=/O_.*5_3[M#]M[O7:E^-;Z7B\WY7==A].X>#R[/?M@7*BI0IIB4Q# ,R,
M%A0!EB$-"JTY2IF UH((^=A]!IW:Y]^&I.H?\M[5*DRV+H"Q:=3 U7\_UM,2
MQ@=>Z/LQ1&Q,!^:,2MSD2-ZD";!K0WN=MV=EXH;VAJ 4B5R\AAR5;D) >$Y
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M=<<%[^RG\;U4CWSQSW)[_TG7K>DW]^6W+ZO:^_=Z]<#+Y1P2CDF6&T!SU[
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MN,9 6&,@BDP#"B%)96:0(%XIP=W#3(TW#PHL[N1,_G"2]JU*>8RJ'P7<CM7
M%- 'IO[U)\^B$+OPY/$@+U-Q\JRB%TM-GK^ZATOT\[U>F$_Z:^F\J\X2^Z+7
M#^6R^O'CNERM_VE'V>KE^]76G9Y+QJ7=!1) !++,P L(J";VKP3EUJ2B7&G_
M8@%A8T^-+BKI[89P+_XLV>X5F"7?G K)G[4.R;)2(L A%3@S'AZ^X? >/ K!
M0?WI".HOAU!7TB>-^,G[@:$.\ ,.!_E(/L&XT(=Y"/N!U^DM#'SD>)[#?KH>
M>1%[/J+/HL$7?/WD6AEL?ELMM_>+)Q?74/]VGJDT+Y2U&TWJBA/C@ECC,:6
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M[Q]=L;</IJT&MYESS!'&,@4$RQQ@*J7=X @%(,PD)03G>>85(]$QQM06NEI
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ML9CN\-'CTM$9I4XXX]PU?</UFLY+U3/K(B^8*\(H50!+9JPE6A# ..2 Y+E
MG&<F#6NF>F:,J7WF.Q'K+WV6_+_TW],TA<DWOJXK]/PM0>G,_LK]E_ Z+>'_
MFJ(LRU4;M=$PQ&I]&+^1\&WR6LLJ(/I?_P62]&\9G"7NG:ONMC_ T(BSTTGS
MXX<;IV)@FMC/0M,(HNE_'9LX.E"(%C]V.L+($6,753R-$;M\:>\88+NUVCY]
MM+.[=95:_O>Q_.86PU_+I7ZWU0^;>0YS9:32@+B8"9PY&\) "83)698;0K(B
M-!+URI#3HYQ:XEE2R5Q7=VJE3OYP<B>5X('Y>A[@^W)%3$@'IXZ;T>P3E.H)
M4+RHU&L#CAV6Z@G F;A4WSO[4=#?]=)N@A;VT7?JH5PVU7"_Z^:0N,E?DT1
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M(AF* 0./:@J& _+<V.OQA-N*OGY:+19O5VMW!#E/J3)&2@JD@03@S$ @*->
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M]>%KL\1C'"F!A(0TM;F@>4X@0SJ',F$1BRB+M7)R0!S[FZ&/4>7-JD4N#S!
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M+F("FF9U);5G0(@+ZFZ<$QC+D3FG"\8[4(H,_JK^/TJ0G@=FX;($=O8X=3)
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M$?TJBPB^" 96B&!EUBEETP @]RR]7<B*]8Z.0YG:*3+$!)W+Z(P%05 &)5&
M]\&!YY+9(&70.@Z"#+$=,CJ.9K9A:D_(>$5_?;?\M/AS/LF$9.DX@M;%@-+&
M@ ^$]<R3E3I':4U#C7&U\':HZ#C"V8*A/6%B8S6]6[Y?+KY-YPDGJI0@G%-T
M 1+ 58D67&95ZX5B+.V+"]4.&+=6WPX='<<\F[&V)XB\7ZS68?;_3K]NK&I$
MS(H<<_!9T2Z"(V=,T9<J<6:5,R%>'=_# 7)C[>W@T7'\LQ%;QXZ+USTL,6SH
MEDYK%$6#3L[37<@M>!L0G"W!(Y:D\;"WD>NK;0> CD.=>[-N9)'7W(G9^R^+
M^45P+@>>DU,99$@$TH &@M("BN'2.U=\]OD@L=]><3O1=QS?/(B%(XO_(Z:3
M)4&7B_AINI[A)%AFA#,%;)82E! * LI$9K"RG.<2BN0'B?_VBMN)O^/ YD$L
M'%G\GY:A9J=]/#V.B]DDU@P.YP0H\I!!6>3@2F8@M2\J^Z!L/"PEYL9RVPF^
MXTCE_LSKY-"_^9Z^A/EGW(3BK><FI* ALQA!1>G ,8)N<4@V;#0NFL.LO_M6
MW0X#'8<@#V9E%^[ O^-L]C_FY.Q^Q+"B>RR_7:U.Z")3.F>K.0>C,@';"@.1
M\0 LF,"%C"SFPS*E'EU^NY2I[B.0+9C;!4K^;3$[(0$L-T^YR]6$RYRYC0)\
M8@1SP360-T.772G)6Y&5%[X!.FXMNQTJNH\^'L+,+M!PGO%SEM!1KT$2PLEJ
MHH+A*KL(09I /J[CX$TN9 $I8:-.(<46X<?[5]\.&]W'(!NPM@N(O)W3IQ$[
MIM_P=5B'\VU-LD1+BL^"TJ7N0[NZ(PXL)L5R,.0ZL080N7_U[2#2?2"R 6N[
M@,A&^[T*:_R\6)Y.7(F$:N; $*#)<68:/'<> HN%[*ED16D1@;RQZ': Z#[T
MN#\CN\#!Q^,PF_UTLIK.<;4B& M-UZ $S+0'0BX#5Y.*!::DK(S9R<,<T7L6
MW0X''4<@#V5D%SAX<XS+SW3E_;)<_+G^\FIQ_#7,3R=8=.1)%?"BYHKQ+"'8
MG, FS*EPARA;&!7W+KX=+CH.3[9B[,CX>)O*\N@D3^DWCM9K7)W)X.=9^#R1
MQ2H5? 23(EU]65>;R!4H045"?R9SZ3!X/+SV=NCH.'K9B*U=*(^/7\C5OH"V
M#-Z2&^7!E^Q)]6E#JD\R"-ES+"(RABVLS.MK;@>&CB.:![*Q"Q"\/XFS:?IY
MM@CKB<P\U@=XT%H3'Z+VX.C^ TDV,6F^7'(Z["WKSI+;0:#C@.9A3.P" 03=
MXYHTO$C_^/B%V+9Z=[*N1>,U6#_14DNEM 7OD3RD("5$3YZTX=I9RWS!<MC[
MUM,T;%?^UWU<LQF;.RG[6EWEG&/^Z?1#I03G"3_A]_5/],O_F!3IDM5:@K;>
M$+\2Z4+-"G CBF'<*\D/R];>FI3M(-1Q$'08IO>A?FA;RS![.\_X_7_@Z22@
M,1F+@VAJV$YZ1_I3TY>1E^3)&R<UVD+CW%QV.X3T'PH]@)F=Z)6KFMB?Z3NK
M22 O7%II(45-/A<K'D*('%"GI)/4&EV;]@.W%MX.$1U'/ELPM"M,G-7/GVT"
MHZUM-7@MAZPY!/7]1[L 43EOI>!.NL,JSQ]<>CM<=!P ;</4D9%Q1#O(FUU4
MUSLY(W0FY48NM@:E/=%<6$THBUK4^GF?#LN]O+'<=@CH./2Y/_.:2?V??[S#
MO%_I&[LVCMJ$8M[.RV)YO/F,FW1NUS_JSF<<U$;J<8H.["95EYK<7N$2#MF1
MYE;& .-!UU<,A"AC+?/4Q:'4]>'S*68\NL)!!_8L:+9)^$G.(>J0H0@D0IGA
M$'7A8',27F>M$ ][M[JVV#BMI-H)ZL:YW9.'8^OJ,[)_/6\[-RF>6\,R@H[U
MZ96I @Z5!,>BBU+I0'=."_%?+#A.+ZE!(; 7+_N P<_3Y?';/!'1:N:(7!N%
M!.6UAFB= VLB9T'R0.YJ"Q"<+3=."ZE!(; ''WN[O5\MYJO%;)HWP8PPJWTJ
M/WY!7*_VN<8?_K #VT)N1>.!%_O)"CZ'\'6RJ92KEMF[\O-T3HM-R4)?G/4"
MN@1."<C)0&=@.!U\E6O!;2 #4'B>(SID[-%$PA)6<2/?\T7/S@_.UJN+[UP=
MI%WHVE<W7*QQM%H16R]WR5E$%H2%(+ Z(^26>)LUL)",RE%HYQ_S\/;9Y4T*
MQK$<!D/"A0IIP.X1+Y*;U)_G<5UN0AJ?M D1O)8U1S@(<(8S0)>542)QY5N?
MC'L)&1<ZATCV7I <PN8.L/(JK+X<S7/]SYO_=3+]%F8UDGZT?A66R]/I_/._
MA=D)3DQ,3N1L(*!0H+!(B-D*8-;'J(.2V3^61+4/=K8BK <L'02 Q=#2Z !B
M[]9?</GQRV*Y_H1DELV_X6J]>:^9T/EB@KPQD+HD4&93UBH2))YM(4//>O%8
MWY%]8/4@,>,X0L-!J0W7.X#/^R5^#=/\YOM7G*^03L=F9S<8-LD^:,9<!B>B
MJ'7Q"+YH"5P*%6KG-V)68R!M0=8XCM5PD&HMB0[ =9/XX%%*7P<9,(NUV(Z3
M8M41K/88;<DNX6-^]\$FTCB=>X<#S/[<W1\:BW68-=([BZ^X7)^^)[]V36"O
M%_+7JD%_Q_7$&FYD8AEB,I(V)#2XE.G+7$3P/JAH'TO]V4_A/$Q/#Y=7$YNZ
M&=,[T"V_+!;YS^EL-F'&H2[2@U2)@2I>U\H\HMMX7@(O7#\Z)& ?L%RLW<,5
MU 08>S%S;Q!\PV5<M#)_"="AEM[]BF&%'^K,G7?E#[H_*W,F"KG#1)P@=4C&
M6"'-Z'TB;<MBE!(MR_A8O'\O$_@Q@GJX@IH IAW;.U EUPRMWQ?S='ZA1F5$
MK'5Y.1JLK<(<;:*>C**YI^/ C'@L+7UO]^DV(>.TEA\",P>SN0.LG-$_R<D9
M9-& R;& DK* (^L-,,C(DPC%R<?RU?>W9<=I,3]8?&\G1G9@MOXZ#7$ZFZZG
MN"+[:9-2_64Q(Z:OJBVU/KUD#=G<AB[+"+'(FB!CJ@JD?7&%7D3%-7MT:-4^
M -F6MG'-V<%?%P8140>:Y]J^;GN1G+-BB&,@9&U7*$, 9W6F^]8E95%@L:W-
MG(>I&3=J/(ST'X;8(:+H %1'*=5N_:OWX33$&5X$$Z(W=4 <AV!K8S166V0)
M(< YY\EV*R(W=\#OIZ0;,!TDY]M7W^%,[P,ZRQ-:]0Z/)M'R8((PD*3U=+20
M@5=U;*D2#K&8I., Z+F?F'$ON^$ U(#U'6!HXQ+<LPTL43C'!42DJU]I4L[!
M!5YYY7P*Y$4^VLYL;]]K3_P,%N(9"#\MV-X!>N[9@=,E,A4S<.,)_]%HPK_A
M0,ZDU(D;3*8U</;$S&!1GH$P<R"S^_+=KN(/E[S17F6;,@..57/*3*> 60XQ
MUA&IP=9NP,,AYRY!W5Q<SV)&'RB0#I31S8CHQ=9.KT6Z<IV5EER @+XV&Z6]
MN#JHHB!7/F:5M7AL&-WAP>A[B.K&OCX4 (_&IP^51@?PNI=5$^5E+,HR0%%D
M#;37 JIH !TFSTL6T3V+TNI&636&T>%<[^O>FZ!U+)F,4"PG=>T*X9\7 =9J
MIV,62:8![:-NC.EGN=-V8G8'.*EM0J9G66PU2W(QK_H3YZENA=,ADD%J8#9S
M\@P">0:&' 5/BM/DG&T,K=\['B&G&P-[.!RU$D8'5]=C'"K<.FT+\)AK(5+M
M6)1X@2BMHCW23QX=@;9?/<E![R*#/;0^"ZH:B:(#4+V_6'>SI;/,;>;(OPW>
M@72&W%M.?WBSZ83EE3+*D!706DG=0\;8Q3MM)'PW.?4@=G> F&M=L,[HEU&X
M4AB"9K$F^@L+T>4$DGDN2S"H;>O\^-LTC/T4.PA6#F)T!T YRGGS&AUF[\,T
MOYV_"E^G9&--'!H5;/+5XC=0%2UX:21(I-T8*45YM&'^7L\:]Y,RKAT]$&Q:
ML+T']*1T<GPRJT6[FS![;<^YQ"\X7TV_8>VA=HR_+E:KWW']KGP*WR<^^9#1
M\?K@1[H3:8\A*PXYZ11UD85^WOZQ;!<2Q[6VAT+;@&+J (4?<!VF<\QOPG).
MCL/JVG9?8YFFZ7IBBN&YCL<-SB>ZM#%!1 S@A:G1+YU0MPX%/$W5N#;X0%AK
M+(P.X'6741/C@@[%&;K:-P<D*'"..]!D"7JO6,EZ>%=NW.S(@>!S(+,[B"P]
MY=M.)!$M);FSGGM+^U$)7&0%:KFD]\;%PEMW7'B*IG&A]-RQRL/%T@QF0W=X
M>;\1P!=<3Q-9TC>H/[#=R\U/'J;WRR/4/V<CF.3H>N)6@RU6@#*EE@AQ#XBJ
M1)%3M*&U[_P<C6!NACF(U^^6FV7SQI%]7TN^B?\3RZP,-;>*.]IX?2Z$.@@0
MF*G;ES&A?:R+W.&!IH<H&SOVU!@YCT>AFHBG V/JYJ[..K0?G:R_+);3_\0\
M828RA>3_:A-("=?";V^,@)*95U87$?1CO<P/!]MMBL8.6CTKR X21Z?@VHPU
MS1.NK4T)Z[1;5VK!+YFC9*62SZ&\BW1^E&YM=#U,S=@AK1% M8<8NBBYO6\O
MUR=*>.4%BS%"RI;4;VWZ'K1PP(2IW[>^/#KDJ16N=IWC,6 $:P1P[2N0+A!V
M[07AP4O>>">8+AIR0MJ4,@QBD*Y6D%K4R=F06J<^;4'6V/&K@9'66C =7)!W
MAN-<N^L5>;A1YTAGIFXE)-H*<@2=L1AF74;]6'/W S&VE]TU8'#K^;!UD"!Z
MQ-3Y59]+8.2$<#"^LB<FLAUKJ#>;(F3Q$D7S5B4/D+(5EIH/0QP/2WL(H+>;
M\.Z]'H06OB@-S+-XUL8Y%*U)TV+DF(KF=G#UM*N5U7RFXGB8VE<4/??"ON3B
M:E'.<^CIIX=&21_XU&81TFVH;A0=/7L:OESP$EE!(.=1")"$,5!)!@BNM@XM
M06<693*^=4CP 5*:%;*<=R*\:O<A',N%10')U YAR=,>3;V*HTB:>1,>'_I^
M4 '+;6+&C72V0,&#)2L'\;T#Z^<#R8((J*UV7^,WG"TV+>;.=S41*43R 11H
M*6O18+(0L.IAF7VH.8-,J,8@>I2@<8'42.AW$@Y:2: #./V"<^+1C/9RE(^G
M\VGESWKZ#2^VXV+F3/("155&"6,@U!GIP03%O2EH?&LKZ F2Q@V0#P.IEE+H
M 53G#0_?'G\-TV4]'37;:Y)K0BJYE*!]360FRFME5ZY9.4ZZ:L>)QR: 'M)+
M\B8EXX;#!X+0X3P?$3F;B3H?%J=AMC[]B.OU[.SF_[S$S5\^AAG6;,%)1).Y
MX.13\EKT5<L$(\L64.9LO'?<E_*4[;SE6N.&M=N"9 CV=J!G[C!I$K3)0A/%
M(?+:,X^,Q9"-!N)*LM%)EDQK^^<.$>-&J8?1+H=QNH,DN<L-7&4?3XQ03IL2
MP%N3R53C#AQ3M2.>M6B22@Y;/]'>0\:X]LR@OM:>O.X +K\OYHN;N[B8''#%
MH"!I9<)_[9^HR :#Z 2O^E)YRX*GW38&SY-$C6O7# &EMG+HX,JZ&F9RMIVW
M<_IL^DYMI)!\S7PA,X775JVD3W6J8]V9DP:-;M\0^2%:QG7:&XM\,0#_.\#1
MIJSF059-E&1HI#" JO9]=F3(!5ZSESG=]C5[K^C6Q;J/4S3N+3<LIAK*H@-D
M/;R1PKP+2B7@FZ8^20N(GNYPEAP9D]Z1==FZ\^1A>!KLJAL63VTDT(,5A>MK
M)B O)1<=(Q"EHB:L)(BUR"^RXK4R67+5'#[7"1C7H1_$.MJ;OQV XZ)>[R*U
MZ:>PFJ:)P%@82@E"V5+G ]()TE(#NOH&;(*4J74;MWL)&=>)'P(LA_.[@\OI
M]B9>3V<G:\P3J7@LZ!ADJ0PH1M9;E/4H6)F-*R'PW+IBY@%2QLTC>P[@[,/S
M#J#S[UCGZ& ^^D97ZV?\_>0XXO)=N9-M<G8NH@E&\5I-NNEK)U(A7J$%8X2A
M_Z?KMWE+KIT('#?%; B8#2>??L%W?I3N9CRA+]$Z2^YG<F0^9IG!A3J]1;-,
MC+1:-6\]N2.)X^:C/2, F\CHI62EW6C4L3&:&R:GW?WP07+4GMA#^T+>,S!N
M&@G>:7-RE1R9"2V:ZQKVKOV\R,9RBELHQ+I@HV.R^="/'4ELZ^UIPY"\#P3M
MDZWO0PR"182DE&=<!VF:=][9W=M[CF+=YNAXW O<A>\=7(S;M =ZOUANY+9>
M+Z?Q9%VGNGQ:G)7J7S(P*I&%D@9L-.3\ZD)J60N$[.J<WZPE=\UG4;8AO9N"
MW\&!.H:L.X;XSXLE61SSLWD/Z?33,LQ7M+VZ^WG>?#4[@T'^_T[.GBRV8-*$
MV9B9, FDK1:0(@YY7NT3$U0TQ;K<O KF63<X<D;I&!#>\AB-CZ<.#ML]?+GL
M,B>$UDK(!*[D.H G"0B"%)BT @5SVCG;NG3Z$7)&SF/M ,BM9-5S<Z3KCLD]
M;; :>E</-=EJ[5X]M8OV_M4C#;I*YB3-:HX4(<ZM7;)00)"=8H15&)O7$&]%
MV.$M ,\7^51/W42BL5'4;$S%:Q>+PL!A[4A6LE5%,JM\ZVCD30JZ\:8:8>%N
M%\"]^=W!I7=)_1E'JEY=S.MI/?H^74U"2M'*(@$MDLE>E:H/:"$+PVT)6;/F
MF6J/$M0)EO:0]$.@.9CM'6#HUAY>+X[#=#ZANSQ82<<IT7:(*4I K(UTN.#$
M((V!V]9QZ'L)Z00SAPOZ]MO:P5SO #K7:K=_PQHTGQ3/O'0Y@\D^@TK&@F,U
MWUQ&G7,0W#4/=MXA8ES(-!#LPQ7R>W"Y Y@\T(+^?#-<Y6!B2<!<-* DB[2/
MDNO8N!!I,RXTCUL\2M"X[EE[^+3C?@]0>KJ__,49B9(C=Q(L9[[&*Q.$*.I0
M59<XL]Z:,L"T[.V(&S>'<0"(#2*5#N!VN\7\^2Z8(&[(VKLY\1H0J[T%HS-@
MHL.2 CJO6J?LWT_)N)F-[8'4@-\=H.;C25Q-\S0L3VM]Y;GKNK$8N4-MI;60
ME":+L1BR&*V.P+33I&M+L*%UDN.#Q'3R_-3 &VO"[AYP<T7^[^&8_GHMDG]^
MN!BI3^5Y!ID]@@I&0S1)@]8QUV8 I30O<WV:JI%]M#;BOPVJMK(8N\+^OY_,
M3DFR_/U)G$W3F>)^5X@.TK+G2C8'%T16&I*LY9F,>_ I1/!(IF ABIR^=:D]
M4&'_]%HC Z:Q:!?#\7ELV!RM/WW!W\+R'WC6*N"R<<"%.9>R3@D9L)!]'<4;
MR1&MD\2\)Q:F++P.6V'FB85&OJL&!$Q+#H^.%O7QU9U>$^?[<#EQD6V-D#&L
MLRR)09YS8#$9+5#%8O1V2'EXD9&;G0^)DD:<'1LA[])Z0317J;Y_^_[--0Y=
M6/JVE&P,)SN0]J%\D."DS^ C$\S(8D-^\IUTJY5&[ET^(%::\K@'J_C"4_B5
M/,.W]-?5A.RV;#AY"R;6#MB6_O!1># 9E?(FH&>M'R?N4M'):(6&KUG[,;@#
MB+R=IR6&%;[&L_^^G=]]+?ZPF,U^7BS_#,L\R3E+C\%!L3*!DJY <":"YI)L
M-Q&=%JUGO^Q(8B?/7GLBXD[KA>'$TP'Z'NU@G(QRH@@)QC@ZCE8(B 'ILD84
MT@8>1!CP06R_XITA^[L.!X1=^DKO(I6]$?:5O+Y%S:!:KAM=A'<F"9;@?+7O
M #G=YRID R&$!$@7/(:"GL?6K8/W'.DX9!^K9\/4@1+H!DDW"T>L8L;ZD,'9
M^B9C+ =7)-F<W HNK:<CTCJ5;O>"G2&;5ST;?O;G>P?7W%;SO(.6(90<P'NA
MZ#AP"?2E ,FU-[9HQ.9I0_W/6G].B#674@?(NZI;6'U:/)#.L+GC(S%W4\1$
M.]](]P,2<U?3-7[$Y;=IJM.42)%^P+3X/-]\RF;&TH3Q*#VW$B22A4OFK(2(
M68/7P0?!B$FR]:O*T'L:O8W)LR&^*W1T<%HVG#X;S//ZI+X[G&WKS C^'?_<
M_&@U*5$3KTN!@ID,EZ1JATZ=0&O+F%:H-&^?0+\-9:/W47E><[*MI/K%W^8L
M7=N4RH+NF@C6^!I/2!X"+PZ\0E28LI"J=0O>K0@;O;W*V.@[0$[]@N_L2+TY
M_CI;G"*>#5H\6:8OQ.+WLS!?3;BQ#KW3D$V-G]*A(O6.'GQ.14>#*MC6&5U[
MDCIZ^Y6Q =I4EOU"=G,.']SE)!0AA(X6'#=DE"0ZH4&H MRJR"TRKNP@D9]=
M"=T*KOXO#->&<NP K(]&59GTUFF3 *4VY%:&.G*[&$!>A$%A=;&MW:C#8]WL
MKX"]9F(Y,$3Y9IZ'"G4S[4BMJP@L^?K"R3)$:P)9P2F4('Q!;%\)NU>HF_\E
MWD\.%$%3(#U[>?Y9KX,ON)ZF,+NYI=:U^C>7>J;"_4?V]ZQ5_#J8B"7%VG\V
M@"J";C\>>&TB(5$&=$8U3V<>H8I?"V:]$!*23)GVZAPXJVM 2;* D:LD_T\5
M_RY8>***?Q=^=V!4/9S!+A0O4AD'5M3)34$@>&L+H%'1$,.4[JQ>Y+FJ]W>2
M\-;U(KNPNP?</)U%R),J1J"A4Y1$31\FVX^,0=J;]SK6Y^KFK?=?;KW(3N+?
MO5YD%UF,G:B[11T#_53Z36:ZK8V840@Z@A@A:1^<"LK9VP6V?]UZD9U$NV.]
MR"Y\'ALV3U4S:%9BXD*#X"E4#X+7G@421)$U6<9ZQ\U6F'GI]2)[ Z8EA\=&
MRY.9ZK2'R#)GH UYK:20'<3,%#!7I,]&6"&W&_K:I!I@S,J1O?'2E,<]V#QW
M4Y-E$)KY$('7X9(J%@E>1%X+/GGV7 AB7!_5 ,]537V0=7P8@SN R%8)(5?!
M^OIGF"=\M5BM5_6@<4,&'Z!*C Y:)B^T?AD#(RXX&[1O[7$=0F\G3MF>6-DG
MDZ>%X%[,4(:P^O+S;/%GVV$,EQ\ZS!"&^VEN'U:\7.@R@F0B9B5, 2L]6<J:
M)? U5T$7E2765D9YP&CB'7H:!Q$QTG7LZ7JF+=8_R 5PM<NE4CEYG4BGE\&N
MN;Z"B(=)_HG8X2YL[N"R>SB:89EGR=L"#$,M\S0"(F,%#,:"]#UNDFR-EQ<1
M.]Q)PEO'#G=A=P^X>=KGP.(D%A\ABH3$)RO!(2)$98QQ/G,N_D^OF;W$OWOL
M<!=9C.W6G\6R;D6Q9.0A9ZE Q/JZ8TN"*&5].R9?A3D5@TU/630/?GKW\<&=
MQ+=HR<NQP?!D_"&7HJW5=%<')FKM$X=0$CD,D5P%9BW;MC%(DQC/F#'!O4'2
ME,=C V:+B#CF6 =:,7"A*-*UW(*+*D%V 9G&R$1ZUDY58P8&]P9-8S[W8-+<
MT[7 ZE0;:@'9?+0#YPGXBF7(=5ADD,B%;?Y^WG=H\"#C]S &=P"1WW%=G<?W
MR\6W:<;\T^D?*\QOY^^^XI($,O]\1$?KVW0]Q=6KQ9R^<4+?.__A8G[E;J8B
ME%7%@$ZQUNLZ!:X.1..6&9'H_X0;H&*Z >6=^&%[XN=N-?5S"[,/"%^K(??%
M<E.;#F0?$ZA<-#C! Y3Z-*QUUK%Y)Z2.AFV.@8!'2_IW$4<'6+H6</]],4_$
MRLVI_+2H-;#S-)WAC>U]6FS)[6M#(X/)*16@@^SKH(( KJ $Q5*2,F.TOO4$
MFJ'W-.YMW@'BNP)-!X?H-=+*:;KA,/U]AN>#%X^.ZQ2]_]Q\?U+3XS,GERN3
ML5[WA! T77M!22&MY-9A:T-T&[K&5=]](6DQL%@[@.HOBT7^<SJ;O3W^&J;+
MC256;RV,23M4 K1+M L5$CAM-/CL25'0WV)S<-Y/R;BZM6LX-A!=!P#<%*?]
M=+L/QT0[8TOB=49$#N24TGZ(,;05AB@R'25V.SA\N)M^+R7CAGNZ!F #T74
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M.LHUP#;&!7UC=VQL,7>@C _:[-G0KKLOUVEV4H<I76?K&:LG.F7!E(_@!*D
M90,":9]"7R9?5$JDA%KG^CWO#L=-SVY\/CH&1P>7Q&%Z(A@,.FH/M@1?/1:$
M()4"F20/*DF5FM<1#J_X!YLTW!.P=Q+=@:.]:-_+=0=HU49ECHP<"Q4R*&[(
MNQ Z ^=:E*"MC*5U8L/P:!UL,G%7:-U%=)U,-+SH67M18G3YBC//]S@7KZ>K
M-%NL3I9XZ=7$('*Q3D'4C$YHY'1"F;-TIT036(Y%^=:V]J$TCSNJ> #$/IL
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M5)),:L/"H+%\^V_<06/_Y@89-\_K<4+K04Q;GD3!#ERY!X+9I1C)ZC@GF44
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MQ*ZT:Y=C/&,Q:Z-D@J(C^5U6$06,D2!5)FH@_3G)MA!^?E$]%A&,C]G&S.K
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MZ[<+.G;GRS2SPI+;Q!PHP\B\U63HAN 59-I4Q.R]R=WX%@?N;6(/Y$P%:4P
M=2!8KRZVG\GI80*]^;O^F&>)&Q]\YN!\S5XJM7>"$@PPH^6)H1&F=8Q\V,H&
M@7JTX8(3@WH$YDT=DSR:HC<%CO>'0%PY5%(EY)@#,&<E*"P)'%.17CPR:5R6
M:5CR]GAK'(1F\X.AN2>^=Z"13S;Y'J?(+*%&J6."B):L/FXY^,JH1$PSJ(VT
MLGEIZ'C;&20M]@>3EMY@THO$?%?V_CTIPGU2_(+SU7:@RZOU^O*OG3E7#\U(
M1^K'O/J+SZ*.BL[( -DE.CI=*A#J_*"BR<1S7A6)K6.OX^UFD+RX'UE>I@=)
M+^)RU%%;7_XSKS?SQ:>=M\-G#DLQS--FR48"E4,=I.X,<*4Y>M(4[O[M\'0G
MR@/K'R02_D<6B2F <,Y"\)0ZN!II^:&&HGU4R;FB@)/_0%H!!?A$!J@UFCNA
M1>"B^32;L3<U[%*/_5M>7@ SYRQ$#X;._IGGGSX315Y]S2O\M&LN7B]UKJDW
M4T8$S;4"B:DV6-$:Z#V1!WWT.4N-NO68T!?>XC !^U&OS7O&4P?B=IT#EE=?
MYS$_3*T_EHNO=#+GW2&]_KC<U%2#F[_7)D9_+#?_E3<?<EQ^6FP=/N&2,,YG
M"$XY4%(:<$$R4$$(D9UQ2C8?*S?69H:)T(]ZN]X'1GYD8=DIEU^6J_VOZN?X
M#$,D.B0!+J5Z<A-U,'B$*#+FF%/.I?4%R<ON<)A8_:CW\!VCZ8R:;/YY^==?
MN/JV++>RF%_%#5G FV_C]-H<\L2Q6FX>O-L^.F\R&Y.+@0-J77L.%%U'!8GZ
MDH1T5I;F17H_2N?-F$F]6%['N E;FSY;P&@8N!*T5(:;U+R#\;\[;QZ*V?$Z
M;Q["_@XLI+LE>RBRY4$ZB#:K6D:R'64OP0<M.'J1>6Z-W3Z'Z;XD")ZLS3V$
M(QW :93:J: B]]%(0!EJ(:GFY'0H3R:<3#$:[EAX\72\,Z_-/0A6+U&;>PB/
M.\#YXY5X*7J1DHV0 M:F'#D"^1RU/[[GAELTDO][].X+X63PZ-U#F-8!^NXT
M]:73Q3A%%/&ZJ+U'FPJ"T*HP&8IPO+5V[')NY81']M'\Z A+>_G*(C,;9('B
M:EBOI"IIVV;1D2,JIO'^G-T?MUWV09Q\NEWV(62=.OOVF(%6"6-!;3T($3.H
MD +I3A=!2^3%HF/,#AO//-88L9=JIGT0HT\=(W8(U3M0-0W"M]%IY0MW4)-V
M044ZJ .7"6RTC'')@^;=Y%/\UMV L@F/R!?F_3FC?7^/_>YRL]Z0-I@O/GU8
M7ES\LES5/\Z2M$H5$4"GN.U!3<=3T1&*+ZBBY^3&-0\OCK*3SIV3QGALG.30
M !P_EHCL$MIGT@@ODQ409<V=,BX#:GK)5EDFB[ RQGZE8[>),Q6,AL@<3UB.
M@,G1<O)E>ZO[YP97FRZDY6YBU*^KY9IT6%99:J<A.I- V:@ >3:0%#/%9F&9
M89W)RP/;.--6&OU*S*E0Z>%LJ4&^.K TI]>7J^L<]5V9TZT(X/K-WWD5YT2'
M69%)9K2T);)R:Q20=KAE@'3>8$+IY:!^U(<(P\&K/--.&"-B?5Q&'PYEOX/R
M(G_"7750)]82$;OD>9WCNWZU2&_^_C)?;;_AIFV!9!JE$@Y,B;X&O'0M^?-$
M%Z99\2PQT5MJ];.;.M.&%_V>#6UA=*IX=2%9WQN82JNBC-*ULXZHQ;,!?,P<
M#'-8HC4AV^9'R21^2']=-?J5G--@<J(?\F;1AZS\YRXY=JLY=N6SR_JK[VE3
M@O$LDX')L6H1FQ0X5XA 7-L<8\F:]Q;H&KJW,_57^@A]C0*@'AR6$^FR-V]K
MI'Y/ )ND,$D@J3ET=3Y, 6^B V>4=#PIH6PW9=F/;>),W9T^1.4T2/P ,G%+
M*=PK!+QR!K?=0ZN!4/8&@DA):E^K+J(B?DGR#4,@4\$[1(5:12Y;YV^]_"[/
MU"GJ0ZI&!M7_'K&;R8!)22^!F5KA)&, QZ0'=,6G%(-2IC<3;^#6?I@[G%$0
M/HU '@2W\[GU>31I8T@]_%T"Y<1"+DZ#%[9:!P').>8))%<UQ2-Q%"_>,+K=
M]L[4Z^I4)B>"W3F<CL^1YFKWPZCCDTE&)O);P[:Q6&5@\0B!<:=C9CR;%_?B
MFN[P3%V\,Y7+\<!W#J)YZMW&D\02D0P,IQT4;Q,H(0/Q=>NC))M=SEDV;Z R
MZ8;/U(OL5'"[@>8/(,=#/0+AI6<E&;"RU&X@9'2$&!7XG&V0RJ841NGLVHD#
M>@Z7=^<@FV/ [7_-==^3%$O"VHQ"@RN,**:*)M/#&-#)Q9*%+VAZB\:>MN,S
ME=L^(K,O"+8?X)"\=3OT)%F82ME$#, ,PWT_TN #6#(= MHBI'OQT>AMMG;V
MDS8ZN5QL!I\?0*IN)BK<M#.ZZ5%DF2!CA"/D)&JC@:  K>9UCBYZ'YG*NK=\
M^R<W=/;3-Z:4H'90Z45NPO/$" ?;T!]RK:RFWV^'Y1)I+O&BSEP0,RS2A$S,
M2Z46Z O#P4D52=/X*)U7*8V39?FRVSSON\2&(&\US..%$/<#".4C!O7C1_]C
ME..S6&)$1LXN&=(1%.,:?$G$;L'()[9"Y'$J,[O8_7E?/?8KPA/A\P>0[&-(
MQ'APJ!$A1DNV4LXUB$R>LC N!:]9-+QT)L)CR6JWUY']RNK8B.M%*-O$D=\2
M)>:+]3SNAE28)&4),9%.,D0(:S6X7"QHIY(2#C/&;B92/[>9\[XV'%G )D?/
M#R!&SX>!7WWZM-K6#]XCE#=6^\04,%(OH+CW$ J]"..3<LQISGL+SQR]V3.]
M:>A>#%\&?;V(:1N#X"XA^$P$H:S  A&S!&5JOU>7#+TPDY,SV8TSXVN4W9SI
M+<,Y&92GX.>,1J=\J)19+\L_%H29BV]5E=S,$OP'_8_YXJ<_?]^1IUZ^T =^
M7R;"_?)UIM7^-5_<S#V[,Y%DEZV;TV9YU2-YVX=RN<A7;\>9S-+!AL8:_-+!
MUN[PJH^Y,C$4U"%FL+61KG*UA:0-!5A$)[D2W)G6_3M_E+DR23O/DLR@@XZ@
M, MP/&40VF8A'>DXT?P:_M]S90[$['AS90YA?P?&X9U&VLA%B58%4$)I4"67
MVEY?UJA.S"P:4\I83<5_I*DR!T'@J1;UA_"C(RSM6VPC\IB-MF ]T4(YC>"C
M4J"%9TH*98(8:^!!=RWJ#^+DTRWJ#R'KU"WJ7PG&_;/MT;UR,<3"(.?:KSJF
M6E=F.4A=LD*5% ;QG/$Z_'%]H.(89BY'I6P'"J1!GI"4"9F7!5(L)&V,U2Q1
MY4D!&YFD1*%E-TF0OQW4>/X,9K.<<O"],._/&>W7_N8M3_7#?/W?OZQRC;!D
MPL_F UG,,QT*2Y8K**D21'D!(3,#(8K 7"R&]R,,0S=UIEE61Z*TE9", ID?
M38:N+@)>S[_.4UZD+4&2TMGRXJ#HVH*<I4"TX F$DRR8G'Q1W72J'[JI,TUS
MZE"&3H;,CRI#_[F\H*^Y(+MT2Y)HM2&29$C>D/_C4X%@D0-&'5#8(DSLIH/0
M\&V=:0I2QW)T FQZD:1C;LJ>(LD^PRJAS];)6I)*CB(G1]&AER!DC%J1,X>L
MF[3<9W=SIIE%#>5F>I"<T77JE8.ZOU[[[D.5"(MU+LO5]N];8JT_Y+C\M)C_
M/SJ;1[D2;;2HL:XUQZ!9'U>3!.-L=?8@BR^@;+" @@X&XV5 C<YF;!U6[N5J
M\GHP<EY]G<?\B"*[V'XE_?2NW#!TUWMDN])=K,;GX*/4#A!5 J5)F?D0-4C#
MDU*!6V.;9ZJ.L9&SOK(\!,N/7UE.!8L)+:[U:C/[.-_4W;]=I.I\7>+%]J8E
M:<Z<2@BH/-(&BH3 A(>0?%!.H5!V4"<*>L(M3-.[&SP_^O!>+C G \2R)7=Z
M@]<_YYO/6[FNAM?G^9>/RS>+#7DJ^ZL<P6WB+$3R]1T12AD.M6P>DDPA)!E3
M88.J;@X%WM/+F@:2C0#P%)P:<F/J6](K<=U?VA45=%$NDG-1*]P4:@@^!6"!
M:55B0B&>-5P?^-Z.D-"2=\LVA.P@>O!V089]_I-XLG4#?]MKYZW8&%UL$26!
M5=R1PZG)U]1,D5+V5DB4QI;6)7U/+*>7^\JIS[G6G.L7A'O)S,KIY&P$[;,"
MQ179JR%4V?*Q6K).-D_I>7)!TQI<S=@^#$Y'\* #0'T@GM "/K]:I-?Y:[Y8
M?JE[VH<?KM)4F(M*&@T)T8!"VARBXR!B%(5III&WSC8>L*PNP74,");C<J0#
MD/V:%WE%%N8BO4I_S1?SZE[75*B[FV+9:QVX@L!+K"H^@!/10]2\&.^+SR@;
MPVS0PJ8]3L<#6GNN= "U-C;'S56"XW021"N@J$K@>I] YFFU?3.7R )/N74I
M:^,M3'P+VITU."5".A"0A_<[,]&5S(H#DY4$9;T Y$BR'@H:&9QG_F4R *8]
MUB<%QZ ;_(,XU=LMXNXP^XA_Y_4?F<ZR]3K4.ZY\_?OM=I>+_[A<S==I'K<1
MB!,N"$]ZWDEW?^UVVNA:[_K!-W<B-^7')1==1(8H"5>*_!_PD@Q+6K)7A@ED
M:AR_\<'EM/&1Z:MK'YSYXE->Q&^[8X,I*P+C 7AQ)(U!(#@>)(@0)2-AC#JT
M=F0>74P/[LOI:'C8-SZ5]AT<D]<;>76Y^;Q<S3??MG$#)R-C(G&PKG92JKF#
M&!4I=6=31+*3>6P]1>CAE70"G]/8_!AXCJ=YE\C9^VJEF)PL'?[6QTH:\M5<
M\@PR5UK4W!\GQL=./X&YT_C\+'2.('H'X*%5Y_5F'G]>7BXVJV]['YR\&F&5
M0F"^WI0$<G><][+6B7D3/$_8?+[*@POI#3;'\'C9FN =H.87,BSGGQ9W]T"K
M=!Y5K$6LY".S.J8S"0]:V^R$M#ZDUA[=0^OH(7K6&#,GD[L#R'Q/F.MB:*N5
M]IE;8)E,/X7U7M9Q#RBCDL+SD+$U<!Y?32?P&=G..8KVW:)H+V+<15.D<<!]
M]B01TH%/#B%JAX[)R#EK/73HJ?7T=G@=Q_-!4#J" 5V B;YK@1<?\M>\N+P*
MP;W]\.=>P[J0L"C2T<K6.UN;,HD<V8?DI6ICO2B:M[X?>F9)/4+J&-Y_!ZIV
MC.@ 5[_D5.^Y?M]=<7U[5WZ9+W 1\Z]Y]1<N;L[O;+1B#EAR9/())L'5CGSD
M=J3"-&>F>:_$00OKY !LC;'V3)DZ37!O%;[Y.UY<UO:D=W<2BE0NQ0)%:PZ*
M2PXAY5+;/!:1A3(B\[OP>B1K\,G'3'O7UQPLC>G:@2YZR*"\N2U*OC"IN*I]
M/VN]@:^15^=J'J[CKL[YTGPLB^FA!74"IW&,[Y,YT V<ZNW2J\UF-0^7FTJ?
MC\OW6P+/I$HY"9X BY&UY5Z!>FT.Q8OD1%8EEG$L\,=6U(G!=#KK'P15$SYT
M?&5[_6,M_JX7WXLXOYCOTI&:W-$.>$"K2]E#]_("M[#(E$PQQAIT%*"*$."%
M=1!E8L'5;'G?V@(=\1;V32DYUG2R)RC]:K,W VMZVR5]W[<['YY%%DH6.8-D
M1=8LW0ATWC.P"0VF1,:A"JV3KTY?=B=*[D2$?9<V]<+\[.!T';+EO75ZYQ.O
MY_0?*Z_F>#%CEIMLN('H8B":TT]!2@4^6 PI68>F==2BQ;H[<3LG '%3CIX)
MBO]8UK/MDCY&9LL^__?A]+.:WS930GDT)H&+9,JH&'UM^<*A(.V=K/&B9>O[
MR/:[Z,2YF0#A(W+[3/#^\^?:S>7MXLT"M^U9]N<31J^D$PY8X1Y4"@R\+1F<
M5;:VR,S,M?:7CE_MM%UZIL1O ^Z="4X?DM2W?WW!^6I7"[)>Y_6,Q^0Q1]IH
MPEH#4@H$I$/)2)]19Y9$\V$0K=8^[?"LWG3P29P]$T2_VWS.J^M?+3YM8R_O
M\RINXR3")$2MP&E1TVZ4(LN**&]-9#P4DFXYA?Y]:LW33J6:$L'-.'DFR+TZ
M=5[OEUCO.4A*-^O:].VZ+N1?]1)KAKZ48CTY!CQ:4#I@/848%&N=*#X'IUJG
M>C;>PB!<VQ\1UV/QN5N8[Z+AER3"[[[DU:[KQPQ%S?3W%KPL#!32T>.,0,C1
M2\9<Y.VOPX>O;A XW8\!SI.Y<SSNEAN\&/5"X68HXMM%6:[^:GB5\.17M[I$
M&+[^%[@^"":Y$K& 9=+6 G -P88(V5@;DV'9#VMPU<?UP1[LBT_5%/X95ZMO
M1.!M%\S=%; V(B5;'+AL:B]5@T"6<:*W(2033(RY=</=9Y;4;]C_$&3<5THM
M^=#!"?A(Z4DN-B%G&DBM.E!.DMK&0HZ655QZ9YD;J7]37V5=39D]K+CK$,IW
MB9]]>E.2@05C(W@3):@H9#WXZ271R:]\46R\U)US*.XZB,]#B[L.(7H'X'FP
M;B22L<93J*TLA*J]RB-@(@U-YEU":5,HI?40H*/+=%Z^M.L@#@\ITSF$W!U
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MJ::GQLUUELI5VG4J3(7 )7FQDIPD3F+C4@Y0(@K/,Z_=XE\&9<^L=-IDXXE
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M&N#JZ55T!*.6C%^.PH4.+I\?T?!;$=2I1FM%!L8T@F(&P<M@P"2A<T#E_#!
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MJT]%8X]VW]I^[-<\$&6XP$_VX7V9G$31%+BUSO_GBZ,O>O/XS;XZX*O".S[
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M9J5QS#8H ]GM.[_+]SW&TTJ/T_:]Z,SM )(\NH0\I/R8ZY'-BPP1MK=8(MQ
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M2"#6P-_&D0V%GC@ MM6!=H"J+W"XN!?7EKH@UG6+QI2+$LUYG6\KIH.CTLP
MAN9VQ"H+OW-YU@7R-%</1._\;--E*4X7EN"D6?E40C\(+ 9D6-=Z(,5R>SR1
M (@T+BX=/]DQ)2TZE8:DVD\D2/GSF-XI]=-(\R0!2F^O4?TITY8%:^AK;#7-
MY916R? [+_6B/*Z#[=?0D*0DY*OF?=<>W'FE:N3O?:QDW])28">K%E8*1=).
M69F91.4&_ 87)OM[I(- $O ODRO",&>G4K!+^:=^2OL()/@ ,&PF2II#1Q+V
MVG=E&7=F4T0RB16U3O7<#.,6V[(Q;G7<E'=SD;UR%H^-@FUI-R_M["KR[$9O
M_176W.BF;]A<?%EERSD8J@;'].+G4I:V [AF9\-$_)?LBA5?$;V@ZX#I^K+@
MK&&7QX090#R[GHHEB^WR4Q TH_/B"NMS7*"4!&"TS;WF6RP-V]O1K"5[.]"T
M-<CI;JIQDUO<4M>X0F89:%DO4-9&</6(2[@4+N%HQ"6,N(11T_GX)XMH.B^$
M:-Z$.).H(?1'$U1K!\\X*!X)#UH!*W<1\!'*C\27NK0L!FXX'P.KLTK(?2]X
M#K,F /R :.6L1:3VN["6Z9GZ@72J*K>NAPUO^(83YA #,OVD;(I7<D&T-#VO
M)2<W8"XV>+I)78.Z2/ICU' ,?%<R"S%B["79CC[*Q,$X_MNQ8<K12=^<RMN:
MZ'C#A(>R!"#IGR%BM>*G7S0HW8YJ4*_2<06N?^,Y)N+L=8=.P BHRRD:Z(4#
MH&?4LGK!H7[00+R(L(/O1 GIQ3('&[S@$>(L0YDQ";?_T+EJ:)9/;>!PR(.V
MS,WI<DHTJ[0I@!"'>%27;X)0&^;H&7+<[N92"$4U$71[2W(JND<'4;L74+&Q
MUGX1XA=<%3/04YAR;IVOKV>%Y0*\"S$&=I(7F]0DRQC7Z[3<?Y>:)0<'9[0$
MX.(P4HZOB47-@0PR+2SQCH!35\N7 ![<]>A>F]RN11[GG=DM9S/_P'(B1)<&
MQGS%X;0+QPB3&$((?>H0TN8RZUH#!\(*+I :>EQDZ]1<. ;<1%]B%8DB56O2
MNGVF2Y!,RA,CDSLPEU)5H4EAZ898I)6+@DQZF5\):OI^Z/3S3A<94Q(^;DJ"
M*%^F]'ZMD+ R7]75.>L2YCH>DN,2>)^L%']*V?Q4"MA(7@H6A*M*!H.4@(I4
M_K1SHUMG=.M<QJUS9W3KC&Z=T:WS\2T@<>L\:QWR70>!X,PE!;Y"*-LZ-JLY
M8: HEV0%.%T!1,)?_P:Z(!1V@?V.8H[SE3>MEV:0$P!?!(CU4JHI<=B<R\HW
M#4(. _M0&K>',)UQED795E).BTP=WIV2<'UX]S[[6P(W4:E>:O%%H=X2J=^2
MNU)]]>7=!X_4TP[7DKBR>DD96QK11"U*8T$.T%62FI%2&T9J=\?IXF':KCR5
MF33Q3]YJ$^)]J+)(3[!&>B<)+1,/1?!DI"<Q=Z?.MW]XD6O4IZJIV9H&E$[Y
MF355\+CT*D3B(?T;$#9WD.T>+MY+.MGRS@1W5\QO>DE]] 4Z(ZDFO[SSI% [
M\Q7TSTFH?"")!O C_1:+>G'V! ;G.,_\H_'RMOH*2"5U9(\']KAV*<T\V7<#
M94_CE+=3C_[B=D"VEK/([@V ^%] V&N9QJ^T[&BS2Y^*P/LNE&OKH5(Z.37#
M5=@LBHO)-*D(>-_J4^:+4H2P<:ST>6GBL*VL P2_7>576&*72L^69EEPS@@H
ML'NCS+LH;[:1\)>U/,E-Z3;N+)T#)Y47!9( T1N;D7WL9AUCP9$7S90A?THH
M-2D;%U4Q"U*RZR4XVODFQ+ME$Y^SEX:NL!EJCQFI*M9@?4@;K\P@OPBC@SI8
M2RG-%IUSQZC!1FN=21Z-4:U&TQ6'=]5_ZI1,!#J\)D#1_XF:;=Y?UM"4-8^5
MPVNK2!NG -(1:A( [^F!<$XMNN7DZ'5_%K,]-K6X,Z$A?*QM67W-L.%3;YSZ
MP]@:-[E\L9!<BJQ?+@]7F[?SM'9D[DU(I-!6!UP2!U7X4(,J]TWK)BYRZIUG
MXJA#O;B.Q\R[&JF3W'64/HW \EA0K\&C"W88*&-?6G:"AI9F";K4DHENTY3F
MHMXV>K$,@FG'\/=96>C$>PJ-H',963HXVI)@T5F3.\>V/[3B?PR%_!B4)@@V
M-*6#>UM(&D??GI=Q:_R/86!:6!&;1*!(O08DU\-)0LK(7ZB+LI5&,S!6W15X
MD0.>F]@'^4%@R(;$66'(<-..\T]R\2Y??SSM:+U$^%U;<X\&0CO"V->+AA3F
M2>1[GZ@89&;UFS.4<V#U_,>^_JQ^(IT2*IZHDK]Q>GT58ZZF4=4X=N[UN:C\
M9NK7<F6XJ!FL'%1GI^<U!,[(;.\4!W!<0CU'+,-G_ Y6N=U!&.M$?=TJ"M:^
MVM<D\&S2#)@N."?-%0MD[CHPP!F$?TG3<I+4G;0?&'CSZX74MO4YW!QO;A !
M;!,,O O%$5 U12P 7+TO4ZIC%;!:AHP'V+_L7;-09PO2J2MI1%"J@=L.X'"L
M"5H9PH.+:49LN36]T-/S"]ITV0;8W-$2XI"W\2%XMK)276-6?14W*5X0\M9_
MI$V2GT,CA^VJ<\_'L*O",4Q(J6V,Q9Y$X#FO8&3#AO)XG/J.P>#,7;\08\)[
M8L34,H&%;^="S"?];BT:2XT__:1)U+M<4*P32<GM=1+?_5$O0_T,-+:IK>S4
M[X9$^:#D'E7ZSTZV-U#6@6.?@^X=C26JD$$I(RV"U$96R,Q;TK51V8 UB4:M
MM))()JHYJ4$DWM8 _>,>3N*$AL6:$[)"B_+$>=BKC]Z2'D9Z&RNH[%Z2]JS/
M)#(-19]]21$IV^D(W8R*:.]!C1RNQ(]H#?]-JBYR=$/>'-2^E!-6"[[.E\5H
MVC= N$P;OT =#8<2R_3VK>?[\#52AQ>F%2WW/44&TX5C+F^P.<U0PM1FI&R>
MK4V\7BB;ZQRXA;R3#B:!=Y[9@239X7:]HRVQ&0)0IEU=DQ6A0I4DDF5!7Z89
M0F5I2;]-2*6<D_SR!-2=$MH#1;+IE27=2X87'3.GOM.2U>S;Y\T@7E:3X:K=
MVDE_ZVK%,[S58%EH]*1<8_6"4I*;FB&!A2Q3M)ZSOOV+1MCU&)^[5'SN[AB?
M&^-SHX7[\;4@7PZD0,GF=UJ!EZ@6<HV,OXF/ZX#%!V[;?MX;#(9;A[?;%K^&
MK8S@RF2G'Z!5AJ[G%/ ,8IFG5&K9/8ANO(?I\Q(>)Q]6BF86D.9,WV=R;PU*
M:)5![=)RHYX:,,V,%L[-V-LA:$';2C-53-O$>"][ =MC0+'W5^+7 7NA>6_/
M;FB5T[N\W;#UDHDP6,"CKE/2CI(S3]WAU?5R.'X2T<22+Z%ED^_T_T;EOQ=5
M8!J;MJ+MHJK=4Z-+C>IZY8F$*5A#3Y@Q:%ZUK,D6'4R("1@NR+=KOXXG[37;
MC4TJ=XS'-V'Z=DR>?74VCS[B2,=:AC,C #5^\TXX]FOYWQKZ/%R^-*D@$]*T
MSA9MO]=?B<H+%]X[0O.M2+R<E$Z4"_BA?95 A!C9]R<.Z7 >2F,%P;-$W4'Q
M$4Z[T!G.:HHP#",HC8V!Q>T/>]=@,-SEO-P#F)AM_E-6/@SSM0[6%>&L^LS8
M"*79XD;-&'H"H\1K,+]F"RV^2J!,,-#M:HPRLENUUWQQ$O;GYLMAX FUA&N5
M.(]BJ,XQCJ_#3+2&4Z!7+VV%-'_XDL/ MK S[VQ4ATASLIM&=8"J%?D/&5,1
M8(+P,%; HO("OS5SJ3")(U,>T*!O3$1(!7I5F91^=Q@-QH6093F.JL^-$+:-
M<W<@>(USG!V\#6N?:PYBKM1KQ*W&/C__0U!5D+L5T!%<* :A:W @GII6HDTO
MBCU0;TZ>-QB_[E.6U3G36K'RL+'.HSX27T>7WHCJO8"%G4G650N^,> Z!#V4
M0!#8LR>X#8_7B!Y#'^8O$3)?LU,%S(+&8T.\5WIV=C%N(7 ,)J3ZG?4TJ GI
M.7!AFKRZH,+.1.:C4*Y>@YVPHX/Y!^8&?DADQ-&ZY_'B)"W/KGF9W#C6V8I9
MY4FR+NH3C:?/+>-WJ6'R.J&$<VU-%P6E"Z&]-"WFSTNV[UU$BCDP0=32$F@<
M4B-H5REY4Z-7@BC29C-2G4U8FHR0DU+1\%?/Z](OX16=54(KB0%9E$6FA'DR
M$G=^WKEA-[R4T'/2NVP&1$*(G+X* 5X.#T/A8!)Z$%+3&?P"?_,A?E+DI#^<
MM'*WKL4).V9MO4?6UA.:8VBY(-]%>6B(:%*,ZY)%6%+,:X8S,G<QE$D)EEE9
M(]48(AI#1)<)$=T;0T1CB&AT7'U\6VH !-GVO[ #JQ4/$0PB+'+2(5\A>2</
MCIFN_\57/T4 @Q%ID2MG:5*=^VKORW:%'N\U@3[B:_6$2%#.]5Q-ON(4H>W8
M2ZC,PCZS&4PON!M:=71H8$N3+UT%ZB# 1>A&C)'X4F9FHQ&[XOHL?60G0\=>
M,'[3[?*/B#LCD90=Q@*>(D"5)VG+BY%(Q0L/$MSQI/-Z"2>=(6/1++><8UL3
MH^#QH5=9>8=#/@ 9C1GK\/#QL$>N0Q')O0XY1XG'/9I0?8@K+YT">I@'1Q=/
M.!VL\.+]M?G"KR#NXT=VBS+54<T<GM7D@CGE>WTM)1Y3+O:3,LB2K_N+S6WH
ME_I^5HXMKB1>V?AY.]&[;O<DBO?85YY:LMXM+DE9,CRVW2G##4\YN0TNW!@H
ME252[V@R;EKVJEV=%YCH3/V0%YN]5;&9]$.4W??V=GA@&35O$:W(8_I?(%GR
M/%:=[K[_%))AWBDD%6"C_66R]@F$N7C'NS_2WJ;Q6EI?+FOA]_(O9 _3!!22
MN5F>5,UU_)!?$!$[J?8F?A.&0DCAGF=YM;'SDY2]IB2R_%9>&GP@%:;5#U\1
MS<B->Z>19BP$J_V]O0GH=D,RSF3^3:5#U:#MM,#754GMKE'_S L>:[K%R%XD
M)G;2YN=VS6.S,;R'?3SZ=6\T0@_[(FC2"('.@IGXG$%,*74X;Z\+&@WXL>A?
M[)' BL5<6SX*XJ22CXB53F-X")O6>-F%*668 >18VP4_E+@H3=NUYKS@&\H.
MW(%ZV.D53S3GD=*:XQ>UCDD!)B-\0;.2F/F)_(4%9<2'OBG*F:39UI C^')I
M*K"P^:,3AR2+X5C.:?1PWQBM; =\F;W*PH1;%0JT__!J"HT4G3%SK!^P%)9F
M?B8!\=(L<3]HQ9'O%"KT<+0Z./MT2H]"@?'M,CBX+*7MOUC8M%^#AYVC]#%&
M_?&,O%U=>(Y(O@D0 ]0-.K7L+D666G!W3SRF-J 2/'3:78!D#E[\W"R+RH9*
M0WD+^]"'_0X^!C75D-<UX$5?T*9<=0<<4 3J*%#!_#S;2$-)K$.3-WDH]((^
M!@;D^-5"NNV"W_O$F'5W8J)_96@J>!3#5#C!7'A$L4.,\9W3*U&)M)@+7N'$
MG&U5*FG&/889)N]^L#BL0>O60TCT[F6\A*Q0'XW!?>VA9' 5RHNT>S=O^:3B
M.[D^H7]X3(P\B=I.[\&3[CCC$/=ELL/9XR:"V4[H:.6_L5J*TJ< MJ[CVP10
M@W*$?ET5.%5.35JLI8X)OZ#="8DKA')26&,XQ%M5L]XUX1-^:,Z;D.9*(@!-
M43#>5O!L%$ZGKM??A5VB6S*\7KTH0D66;KXHJ1?S*E[,2X.TB+E=(Z$Y,3KT
MG[]+ \PG/4.W>!GV1PHC,1F<;!$A.O<UJ?0L]1R%:PE!<0XME[\"46'OV<#8
MQUGD)X'ACU%"DOF)+-S2T"'-?]'(^"C>)$P4_B1M!*YM).SB\.748<[ WDIK
MG?3WG]\X'<%QZ72,$?7S&1S3#>JG$U-QIVTB$4%:@+_#6S>=RI<)5,QJ!T:D
MK75&T 4;D)PG+TP8W@LC3IBMJKN7PYUTF8*EVDR]\.:$YWT)*G2P0WK^'F;2
M]1AAS@8<8-_P6B_7".7Z%'"X@)HGC_#@1#,"QG;@0\SITTJ:%=L I8T/#AYU
M#? >H G1]XDZN*]^_?WYI -T>G!XU $"HURPG?XVS:9#UTHYX=IS#B4PT%M
M)-_(%L@IM*VQT(9Z .9E1DY1H[OHY]]-5<T,U]FF'VC+;B.U#NYMP[.@!9X
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M:P1SC;K"QQ;^/LA6>AB)T $5915!-Z^E7G WVC:!N&<>2\F^BH":UU49H3S
M(0'R)?BMH(=<^-Q1X[@1BTXTCE^8!:3@L#XL%09A6''7.*.K7@AMXFE#Z-L_
MZ]*ZQ$I$:\$YU&[-1>(]#*2ORNQXY&CK7/NE)/+K-9WKI%1P^>S',<RT[9P9
M8M)C^*0#/1W[7 *O'>,B([ANIDNA!^!?Q0$-1@!/Y0P8H1>@;1RC!TV6OGA
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MET.BEN8]"$SRO$I2Y1)& 5W_E; G/'J),W/5M#W]*;W^ZR'DL6=%);BDYKU
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M;C6H2_*".I.4%8HQPKWMU=8B5NN=M-P08DIODO,!7T,A:.*U3E(4A:03A&(
M^TQ8,D?PMFX>SAIK9E4+2M-J3L*WM&3FS"P VFH_(LT% (YXDN#/.<,1BD0L
M-2PZ>(CJ%AA?/.N/8Z+H%P$&G14N-L8(TBKK-*JS35J<:_LWUVH_/%3/[56F
MA>X;CFD76W$2,1K(NW:24\$2U<'FX%&CNXNUO=;[$[IXG,O$16:U8XHXF=3V
M//"[_#S$B+CU^&L_BM8Z#R#$HP_(0\5/N"#<O,@0(W^/[<(=+'C!'-H^%[1Y
M],R0BDK"=F Y1H#3C;E[=N9^ N!6A]$R]4NV3/).),MD+7GK/)$)M!J -4AJ
M>A%^4BVW.O!^/;,N*2]01KKQ&_5&&Z=/"P[;>-F\XCI.@OI&S(8&YSA^E92E
M]N*7-KCA= ;$S)B"[!VL3M85&H3.@HMVI,! 26@&R$Q <K/Z(.*9M9>+RL>'
MG.,0T),:CZZ%2FV30*4 W>ULI:'"Y;K\C"AUQC/TJ;)C&[YMD\TJ>+>Y&F7>
MBK7X8$D0M"!>SEU-<1PC$H$>J!.$F=*1\3\D=?I,IW4+H<ATX_7)*D%&D3*E
MSLR%L$L*HCI!>($KI]'^R3%4T$076P@_D9\)X[19.Z$N(7S!#&8S!D*7::B#
MG5;91CD2QHT*3:G)? 2F(?HW"'ZX1I$GB",A*OH<<XG&8_%O8&>;YI@'=S3X
M+SD2#Y,7*4,B:MH2ID5PV:G>W+BZ!2+PQCAS6NS_!+^^:UGF0YFZZOY!3#EJ
M%8Y^5Y!E"LM-4FLZ+_F%C;H/M_Y@1^LO<U*'S<*$*@+RIMA>KF87VZF "+C4
M7AG2<=F.;'H[<';*1M&]@6K6L"W? (2 A <IZ>2Q--6**_FQF5\RCH)?8V"C
MCL+K%IW2DY+S+A;&S1%<[]J6N.W9%M)]HV,HMW1'.+OB7+1$6>-.22@LFP;6
MIB!]ZUP-9<WBC(;D(?^]/O-HX85.O.GF&^<2S\ OE5=L_,$EC1N7<+U IMP,
M, :!.!CG,TC:[Q!QVF4A148DBTB2_R'G2*92X ESD]AS/IC^;])G1REX@\[7
M2V#>7J;BN1TL,5-?[X#$67U:MJ2+2$WV,)(Y)E)#D'*!'_K>@9JI9V_+%[4#
MN9=GBM2GDK^($B/:*FQ(!6-&9 R;07@L)J?D)!K* 2!?2\2/DN,V[>SFG<F0
MK^;U*)5$!VYBYU,T8&Y,1%[T?C1/P$DN94G%$!K(#?3W?H M\2GPS,TOQ<_U
MC@P+9FS&X1@$9D6;A6P0CVAJ>R&#L37B T9\P!7P =^.^( 1'S#*H4_K9Y@9
M4K3+5FB7-9578J0SK1;S>B"F_TZ;5+2Q))CXKP59[$X1KYD(*;LK?78OD@/D
M&ZE](8]TBOLAPFWT+'B_4S0 J558CJGO/3GY]8X8^NC"#JVP:_SGBAYC(>95
ML-\KE\!>!P%XG3E3>_,-N\-I?(&%Y 5GEF#^0ZHQ/.\7%76*_>[AS9=UWEW0
M6Y&"DFV9;MZKCZW)WJ&G'JN]PSMD_953E=Q1C=R9<CC)VK./(8$%>2"_&7LJ
MY":9>J+I*'U<AQM "S(9,S\]->"#II>)9SPZ8:5]!HB]*"?XO>=%@=)<>@HW
M7H&58 ":G6 5VK\] $RI"1JQ9^B_J*+N_;+I//*.KB?<!0=%AU&*I*K':BXG
M6+R*_V@F0:$+'H @.(C^?((H+DT]AJ1U,'[M39;)O,$ ;YVV*9I'/4[9\P!J
M(!BC0ZY*.UF&?V,K3&F*@P*,?J%2/1.2F^9"=!/G96]B>+YE>O%H5-RBR_Q=
ML]C)<DD;<R!O!20@FTUA:<? 0U,6G@O&;*1\GDI"=HA:TC% B@C_G/]JEI6<
M^S>%7R,#CF[@SX&E9:]UH?A+K>!S^I?64AONS42QR"HD:8CL-S;?6@9?$$YB
M85&+M*4'LE]@VM&W.%^\:O"V0<YYJCGO+Q,D@@ K>JN$0J-&*EB(SZU/6L#I
M1GH8*[&IK*L2 :0,2J9&^$Y2@\@63#QY40#4>$\BI^5HVJ=D92YMD7G/'H23
M3W:ZK/N*:<["=+"A*V%"I@+</TO22G=^WFTL)#GUO8]_<\W)E$-RWJ1:&)@V
MXYIC%F9!'JAG&NRQ +NY@?3!D:H<]<E7/!P8*IW*[;H X,0&\J:8<E599MZ9
M%XA5ANZ1D9,'@A^R^]T&-#^H[]4>%%=8R9WT7U8.?!1G>C391Y/]*B;[@]%D
M'TWV4<O[M"8[DN6-%G.Q; ?,6_8LS(7,F_%TZ^-I^LW^#]2&Q_ZW8B=[3[_Y
M^OCAXW_>:3?)L8MD-E2W>LN8,[$K#8!KSD= 8JEEVZF# '$/I!RLR=>Q#ZFG
M$<#=@J<R]=37U&/KJ =51R5HF&Q-Z+M5C7'YZ+Q Z#;6G"4EA^^][?HR9].^
M'J>8MX/3Q0,+=A9]SL!TSR7>@A"T4.HPPWD)WNITQB#^4+NN#8" 7?H*F]R5
M,)7=+F_ H^.8,ZWV%EP:O%1_:+ YH)."BS@\^"]N,'PXB9RQ"100X!L.T>##
M1X]IS\Y]PL20,P&LQ>"[4'L=<MM&8H+D,-R9JA\+!+N$%RW3B*C1!,6.!:X'
MF4E9730]\?5<38] M_>.>IV0(3#0M+KPSAU9DC#GS+V^H5WK/0)8%!K^HV\?
M(Q9RB?&O]MC=U/\]-FA_1>[0AJ0KC]0>QYG]DGW?.BE,QZ&MWYZZ%-K:EG&?
MM]_%CC&3M0>#U?6GM)W+4^-\:!'.D!\2G DT.(Z8\TER,F69S]HQP]ZQ#AZU
M3?X!QI/91<4<OV#><QX@PW2XK8LCR2^J+8\,?[7&P50>GBF?!U7?!:XL/+7)
M8&!_]&7<4"G7]&5P!G:T:"4XRI05C+Q<+LU<XZ_4!-A)+R;:D&4#J1DUC+01
MCH4%1[^ K<4XEC:PYQ1%(U&5DHYD@(<.-INH%*8OC%D04CMFP^5QP!( <>J2
M/J)7B+E7UM#5#FD? XTJ%(D)3=2I&/7(41'=L />1WA%VH&5=3L LID)20>=
M.6:R@#[>0_MPJHC).55$K.JF$R!$D/W]]X$BP(T:P&K/AZ33<Y94_LE%DL&'
MNH%)B]F5[!4P860%XZBHV2*7-/1$T>U!CYE,NUU6.1IBTMD]SY4<LEX872MQ
M;82TF7P#N7'T$UXQW@M<=@2OJSG^AYJ1I!6A<X'D[31 2SL#84F-&VY,MXO2
M8LZI,LD"=T&]#2*LBK8;5RL-7X3!YE46>$GVQ#^P\['.8O$ZB'3J[5WJ%Z=,
M>?2UM=Q&."AMKT*HHNH=1OW-%&14?2[KF@L))QN01/(.,M[!"\WSV.!<Z4*[
MV=NRBK285B^A9\QEI6IT7=T5<1?)0BT82;'V/_8[[\P4PFD\DJF,3!I_'9/&
M+P@(S;Y$569<YH]8YA](\5@DYR,6]:8HI+W\@.@%0'Q7/ 92GZ7B$\[&X?&!
MS]*GQT )WOQ+",K9A UY\OPQ](F3R@F> 8V\33)Y?*+>%GG._U0==T>NGFLC
M#>3(O']KRHN>HV0*Z@$A+(@V-I><>=*L9,)N"2=Q&'&X['.P61 %]&=KE+7-
MV*R#UBUQ5J,51B/N%IV9#X'ZF_50YC$-@@X-"H(P$#8Y=U/U6^,OJ7%"NF%,
MT>9/]?NYWI3@%JTL/J"C0B>$?T\'95,A%*S6<B?'FF"D0!H'G$:P(GM9@B^7
M/A^>554^$QRPXV#=HK*!U+ =?1-CH3LR$P&TC;IA,=TP!%VO7B!L#,6-H;A&
M*.[A&(H;0W&C?+OV4)S8<XXC,/!C?X@/JETU+@T:GWC(%P(:[#(:(;457O8Q
MQ_3V[3'H4%YQ@3/3%(L:8S4OA.48B@.CJ1C=QWB@C!6NR![P[+V>5Q#^HH_M
MIM^950[EC5U-2WRSW6'3PX=#[HOA[=[<"?]I'T93/E^?YZ19<0'Q3>:+0Y70
M23!5J]P'5M<^9,\FX;MB$;?%%W']C,ZKCW!>/8GIU0AJ=",*9+'@AD =R7FR
M2>:(.\'ASE4<"RO)Y:/CZZ8(H)<^7UGP.Y%'9&T""F+O8OID2IMA6:0K5-<]
MQ1U"7]R)<?T^260'_- IZ\=@;8-B,PL]0$U9 ?(;[BWFFXJ9U@+?8.^8IS\9
M[O-%Q1VVF6&-"[^'&X_>NX!1[TFL%+!(G)>QT.C@*D$E8VH%2 ;C!/%0 8W-
M?"O]UZ2A_ CPWJD3#!!77YE$CI'^Y)C6C-<3B@]\MI2]$,R&4R=ER?Q&&&C[
M05=0=SBI9*!GW!.:3]HFH2QBNZ@+3<5%!;Y0%/SA>LIU'HU,,F?4[! 2OHPB
M3^Z95&,V 7#E5\87AA;02'\22D"^8B;7'UPY1[A!M=H+F!_-=&C[=T[:65D=
M3)45KASV4UKUAL:4!O3. .TI)QWIB#:C72"?\%ZL>4J3?( :=R9 'K/.A("M
MWI<!P288N<;4=;:E)*SMFI0!W-"'#T<'Y8.LN1="<8!R.-XN00X(=NF'IC8O
M2H!X>%N=Y'(@8F$=O^QK.E01^E,_(,F *;NHZ9$X-P)-&HV:VR13NB %7,%T
M'=-&9D"9XU#^GIZNI@'MXK6..P-I,6VL@MSKXL==)X:!*-X*ZA?_Z=3F@1&%
MXM1TO:%HM4Y1ZR84>TE<(36-V:5LBQD[S=H$/CIVGO,#;;*5#W'VY5>Y+VKM
M3IW')'B@#_6^HBL1@)B8,1(:HR-"ER!H5CF%RV-@4,YFJ$8.JGFZ:L; %#($
M%]CA:HZM#HZ<4N_2Z!3CE;;^IFH6O.F!2I!AQG9FK0-.&) 4/.*-Z1(>OJ@J
M,OZ11M.;P0%\$FCSD$ $&LD\ DSJ.J?G:J^9PW)',$-N&,0425HSU- 1M D3
M92QTER_6,!]2 ??T7 ?3VK@:7H5GMVO<KFO=BFIP;6RW04Z3,#IY#%D#M\7S
M09U>F)"' \UYF +)TQ;+S@[0F.Z.Y7B(;'M9KES/:3F1$L;;E:Y7RPO#I::&
M9XPARY>\0LHCA687Q;R2N1PX,2,!TXVYIY]XW#IX\VT4V*N04W\:O 5NIO%P
M5)IJU9/5D0:3_"Z%L5-36X+-.PJ(#X/B\=^#Q^ULQ!AWUEY?_5W>M5MQG1G&
M3'MCAQ75NF[B*R2\0R&.>GVK+( \"^<O*SRL60VS+VY]!<S A5\;$;OZU;4D
MJIP=S3,KI1R/?=\4\OYV%P+=57)=JECF[(V^]T$7=FU9[>IMS7[,.9$7;&6-
M&MXMNCEZ&IX/:$-Z--0-42+R(M^?5^DF$<QH5!6\:!0=9\9XUU;MPRMF(T<*
M0J]O@:*J$;SW7G6O)?1?KZJ-(+;K'Z*8(&<SNTD $Z!"HH1_3"HJGB]3>"FY
M8]3T!E[;5_JDLJ*\.$I>ICBVU:;FG_Q@C<OA<O0#2L])GNOW="-P$K>H=/R<
M*%:[HPA=I;@_NE%)N#%'O582%A ,K!E<4<Q#C2C;/CHFD)&(:*:>P?&&'_X?
MU.(DN3>14LP92[/PNIUO6]*)7($#"+6%MUP:&2Z441#=HMW9%40;!@P)JT+O
MRAVH]#MI5$61A(6ZSBR3![6JA^"?H6XLLS; 1/1"9O=KMXFK"6XO*^;Z96R^
M:]UG+UW9SJWL:LI-U;U1*%VNH,F.O&0HQ,AJ7.N=^C02E3EW.:1"B\<V-8TL
MZ"M<B)6E'2+P81@:<!TGE:LALZE831><YJQ^E"(?/:\O^KO2P5&[+'U&\L],
M/-OFK&)>,^PT5=JBO% 7-+T9UD\&*+F>K.ISU[JQ&95SE;AM(V>WV3QFW(]:
M)?TQ"^%9\S4(J+ 7N2Y7SP$2AA '6K*99^JB&:*?,$Y&PC,<<_HL+ LY.S?G
M6 U0UAB8G8E/IIHGEM1+5D#KS$2XF^H\O::6O%LO)6G.SJ=0]YQ)D;3/>DPN
MOSBE!+;1VT T1'9X6=B0+SE?%]"V?</>GP5N'RGV,4S,LTQ0O8[>D&GMM5GI
M(>DA&R MRVW!R6@:ZKEW'/:&-N"7C;"=!>3'HAY9>EZ/C7U](9H><MO\NV(#
M[+),O.I_AB-' PX>X1$P/ *&KP(8?C0"AD? \,W3!Y\!V' R6QHNF<81\UDT
M4)N>V:Y;UH78O-?9=GLW10.J@0&C^O$?7\43GXS/' Z>>D_$'Z@ @@CLAB5[
M+K<=AIL/Q%VF6GSQ1MCH 0@>@+>EL;..F=(+#(681B]6,Q$4VXY0% =.!EW/
M.2)"+0*<MXC7:"9-9L!9JU@7K# 49(21)T8-'O%6*UTUB!1]'C?-N&^ORW,U
M8)PL!$<08Q=<='=G=&&RBQ5%_/S<R*61$UH1L3A"Q=N YV"SKEU)*GQ%NS<M
MMMPV&4IB_WWQM^FU;D"X2)X4N=EUN\SNA"JO+5[V&+_]W2R74WI@AP-'O.*I
M7LDUE$A=P6=K#9Q*S@6C<1<Q=O.YQK43P(X<&&:NO%;]NQ\9O]@A5=\#BQ^2
M:]DE]$*[)"M7WC=7S>!MNN.Q @Q%?69G3'$F$?'/X)J[80H5' FS(J^ 1K@\
M;$J["SG6M3]ZIX_CLHCASP5V("/E&G6WW::H4!:BI[A)V7./=HL\0AN6@J6:
MKTVZP'8<\,^K/1]]A<L]<>J/PN )JQ>F+"S3;N-NQ LNNX;&5*8O/97I;8%;
M*)2,\*!^^;!18@'<%GQU2;H3M6I)7FE+%^ILS&BZL1E-;S=Z3JV3L&$52?".
MSG_(4]>U'WN0U_F_*B->3OPYEYWSI>LUH[8=M.U(6RNY(MI*NL(%BM7D#2C?
MK\%;Y%&"6><201+.6T-2D+]U)!#!@N/D2XY@,2LN:T7WP=#;" ">G&)[^22<
M29OU&( ZDY,6I=92.VBAU6O4GLD;F2KBY=H:6TI<D/,_8+)RS9U9 AGZSM+,
M):="&,BI6S2D4]B=4.#:Z>F^CH:KRS7!2^80LY#('"HD(>#'N32B;G:28B:Q
M>?RF]?"3F@;9K1J/# 0XN17Z9Z93IH;VG$L^9=[)6N4:M:;;+VS/-=< PDOU
M< C5K^@W7S\\.CIZ_%2G4I_CFZ^/[ST>Z),NY],[+&>8QD7RH[I)03M8=25A
M"R-EF.1S3IZ3E*1FZ2V>4^1B:0- ;=Q^-+Y44IRX0FE)*YMC[,4Z[R3@R-;:
M"H23_B7)6WZ7\IK[^_K;HV_5DQ=/L(\X(LN5ATC?][S*'0_*1>7SBH2!"D_Q
M]VW_2.4IKG+U4Q3,=8Z4 &8SVI+4>ZZ@1*/<5/EI&3.A)I*I%AVZ$D!N9W?5
MWEZQA]@]R^4M*YKNL&YD?W1IG0<\.I.=&%G);?H9.6NUDG%'!M.:F3"JDUDJ
MIXK7.0C% ]:T%YJZ#,(N9.>QZZD+:O9[QJ^W$KL+P7(_ZR6IT=Z+9768>OZI
MN*?CGB%%AV%66,Z<J21"!SVZ"@AG7J*3K!0>B[A[:MS45#T/&^KWK9Z?RH-/
MV S, S"X7H@ZX0[S@$PR'K:O2H9MSB"'50M T=SX?^BM7"U(:!':<C:*JSXG
M>K1[]U8KLGM[#$K]\89#A/7!@%%0C0W/ !*+$SOE>F(UD[M!XL@B7&'J)]]
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M")[B@9E?LVO\4EP6EC(X/[O9R:319<8U)BZ4[HPC+K)-JB^= ^ZB+]0#J*K
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M5SV?7V]A%!Q9]"HC[W!(2B*3.&,+!:XK=C2V2&=YU"'O<>%QFCI45>**4F>
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M#   $               @ $     97AH:6)I=#(S,3$Q+FAT;5!+ 0(4 Q0
M   ( !0X5U9K@IKN2A   +!$   1              "  7@#  !E>&AI8FET
M-#(R,#(R+FAT;5!+ 0(4 Q0    ( !0X5U8-KXA>6@,  &T-   :
M      "  ?$3  !I;75X+3$R,S$R,GAE>&AI8FET,C$Q+FAT;5!+ 0(4 Q0
M   ( !0X5U:9)7\CR <  %XA   :              "  8,7  !I;75X+3$R
M,S$R,GAE>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    ( !0X5U9Q.NKGN@<  %,A
M   :              "  8,?  !I;75X+3$R,S$R,GAE>&AI8FET,S$R+FAT
M;5!+ 0(4 Q0    ( !0X5U:C\>+[KP0  +@2   :              "  74G
M  !I;75X+3$R,S$R,GAE>&AI8FET,S(Q+FAT;5!+ 0(4 Q0    ( !0X5U9%
MF*#0J00  *,2   :              "  5PL  !I;75X+3$R,S$R,GAE>&AI
M8FET,S(R+FAT;5!+ 0(4 Q0    ( !0X5U:]"^C"5V0# $?)&@ 1
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M &EM=7@M,C R,C$R,S%?9S$N:G!G4$L! A0#%     @ %#A75B1XV>,OS
M7H8( !4              ( !H7D' &EM=7@M,C R,C$R,S%?;&%B+GAM;%!+
M 0(4 Q0    ( !0X5U8@$HYM'H$  $W'!0 5              "  0-&" !I
M;75X+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    "  4.%=6MF+4?BU9  #]
M:0( '@              @ %4QP@ :6UU>"UE>#$P-61I96YS='9E<G1R86=A
M;F0N:'1M4$L! A0#%     @ %#A75M9^$=;85   Q48" !X
M ( !O2 ) &EM=7@M97@Q,#9D:65N<W1V97)T<F%G9&%N+FAT;5!+!08
..$  0 $D$  #1=0D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
